<SEC-DOCUMENT>0001274737-21-000115.txt : 20211110
<SEC-HEADER>0001274737-21-000115.hdr.sgml : 20211110
<ACCEPTANCE-DATETIME>20211110171839
ACCESSION NUMBER:		0001274737-21-000115
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		70
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211110
DATE AS OF CHANGE:		20211110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXAGEN INC.
		CENTRAL INDEX KEY:			0001274737
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39049
		FILM NUMBER:		211397864

	BUSINESS ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
		BUSINESS PHONE:		(760) 560-1501

	MAIL ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXAGEN DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20031230
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exdx-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:c5a0a3fb-3fff-4206-b83d-31088152a01e,g:78c7fea5-b4e3-40b0-a9a0-b197701560e9,d:774bc25129df4ef1954bdef4e9d46c8a--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:exdx="http://www.exagen.com/20210930" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exdx-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80L2ZyYWc6ODI1NTYwM2E4MmQ3NGI5OTkzYmViNTVjNzAwMmMxYmEvdGFibGU6NTQwYzEzYmVmZmJkNDJmYWJjNjkwZGRkNTYzMmE4NjIvdGFibGVyYW5nZTo1NDBjMTNiZWZmYmQ0MmZhYmM2OTBkZGQ1NjMyYTg2Ml8zLTEtMS0xLTE0MjUx_25f8d014-14f2-4390-8de7-40b968eea65a">0001274737</ix:nonNumeric><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" format="ixt:date-month-day" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80L2ZyYWc6ODI1NTYwM2E4MmQ3NGI5OTkzYmViNTVjNzAwMmMxYmEvdGFibGU6NTQwYzEzYmVmZmJkNDJmYWJjNjkwZGRkNTYzMmE4NjIvdGFibGVyYW5nZTo1NDBjMTNiZWZmYmQ0MmZhYmM2OTBkZGQ1NjMyYTg2Ml80LTEtMS0xLTE0MjUx_e9488f16-d60d-4c3b-bec0-95d3e17c83b6">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80L2ZyYWc6ODI1NTYwM2E4MmQ3NGI5OTkzYmViNTVjNzAwMmMxYmEvdGFibGU6NTQwYzEzYmVmZmJkNDJmYWJjNjkwZGRkNTYzMmE4NjIvdGFibGVyYW5nZTo1NDBjMTNiZWZmYmQ0MmZhYmM2OTBkZGQ1NjMyYTg2Ml81LTEtMS0xLTE0MjUx_1dcc752f-9c2f-465b-bcd7-b8dde51c57d3">2021</ix:nonNumeric><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80L2ZyYWc6ODI1NTYwM2E4MmQ3NGI5OTkzYmViNTVjNzAwMmMxYmEvdGFibGU6NTQwYzEzYmVmZmJkNDJmYWJjNjkwZGRkNTYzMmE4NjIvdGFibGVyYW5nZTo1NDBjMTNiZWZmYmQ0MmZhYmM2OTBkZGQ1NjMyYTg2Ml82LTEtMS0xLTE0MjUx_61ee5c6c-9f95-4b8d-bdd5-6548f4dba3c6">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80L2ZyYWc6ODI1NTYwM2E4MmQ3NGI5OTkzYmViNTVjNzAwMmMxYmEvdGFibGU6NTQwYzEzYmVmZmJkNDJmYWJjNjkwZGRkNTYzMmE4NjIvdGFibGVyYW5nZTo1NDBjMTNiZWZmYmQ0MmZhYmM2OTBkZGQ1NjMyYTg2Ml83LTEtMS0xLTE0MjUx_eaef068a-aa5c-46a0-84e6-633f7d7dad97">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i42432a2bad8448ddbefe4f6e51452afb_D20191101-20191130" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTExOQ_3937bf68-a790-4703-a448-0929f254939d">P24M</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exdx-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i69bdb0e5056143559edb4f8abb0e6740_I20211105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie450365559dd46d89f2259410ea12471_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ic947e90b872445479ee484e60712b752_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i865bea50ee1b455a84dfb11e33cf1313_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if523e9aa9c344c3aaa54d52f9293169d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48d05d3781344ed6a035b262079c317a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i756e9691fbec4232a2a72550fe8827ce_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icddde24d5cf540848e569816d215bdc0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i927670c99ebc4fbaa921ca365127a3f9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e0649178e5d45f48148b103ef4c2322_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee067a33f24240b1b6a20b3e1806aff9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9320aadf1dce47e1bed19914403ec55e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1bfa77cf666454cbdeda15eeedec294_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11196ddd025a40529a27602303c8e198_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ed996c7387441b79438aa8ee8022cbe_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15af72fdfd9b40338bca87d9c7bc45b0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i145dd851fc06416792a8abd9ca0753ca_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e86c5941f4241c8af84064215a7e2f5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b6ff882bf31482d857ec6f5683bb78c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbabc350d04d47b6b9d32913973c1fe7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib539fa002ab647c5846c0e3443ff5e82_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf76918b1cb142d5a91a6c2666125f62_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f30bb32e1574d1a9d2b765357dbe0bb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c81cecd619e41fc8c3d99db6c936c40_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7323a0eecec4c4ea71dc4cce1203339_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9a730a0e88a4555abc24b44790a742b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b0855316b0749f19d0440817fc74aba_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38cae9d0228d4b1f8bfa2f60e4501c49_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e627efdf666421e923aa8ef9d7b1607_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0083052ba474d728b64eb6f8a434e04_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1613835ee0c640bca59673be80f4f805_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i926f7d0db6594babacd270a64a40aa1c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e5abb84f7e7474bb50314ab8d17a743_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c3746cf4a004a759993958c2357d3f8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4389a97a55544668bcf3bf8164728b95_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3af59f4ffa848f3b05b4d67819e988c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id832ab757594443da2a42bdc495255a8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee14b6a111af4fb7b7d7e961b7df5732_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie69e6ffa9ddd45f28e8ec1e038f2bb90_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcbd85df5b8d470087005bf4782dd47b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b61faa063d54a29ac1703f1598a4fe4_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia15f05a146964743a0c788d2aded9cd2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i151e4ee09dca43adb7ec755e1cbaea6a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d3b0ea347dd4649be1e8b2d457be919_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i891b142b8c174aee9f36273d0c239eda_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cf656e94ec9450e9b8db4d75b446d2a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icff8ea4afd2e46bca741e9b8f9cd26d0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id38324ce009649c99841caeaeeee19c9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic20ea53b78964d2eb61a34f2189b8a76_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i737254d4d9d1414da6159fa82388a520_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67c6964d373248dabdf6084b560f6710_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia257328b72b043bdad0caeccbdd70e27_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb83497be17d4a9bbbde5ed69cb45bc3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i597e2d4f562748d496c7e6c7f253459c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c6b787c0885415b85652bbc5e484066_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i3af039dd0a6148ce8a2372743552eacf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1482dea3ca984bc698a8c00feba5b0fa_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2256d5cb9fa4792ae30bcc04579ae40_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i532b378bfbdf4cd2ac330f10eff25f42_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i471234789a8b480e9e42bf570277a680_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06dd18b2d2b343c5a26465304ea780b8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53c032eb6d0b41fb85a0f9de89ed5b66_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1391ad143fa64151bce6d46f029b004f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e3015ebd247430c8146f56ddd283df1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f9ec400fb2f4a7c83cf5e1252a8e58a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a4923ef3b1c4f67843da57220a877ba_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i382b42bc67f14a9790ebce32e9cde082_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1b6e104b9dc4b7b9d1a57af719a5906_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc633231ef254f659288a9bd53f5fed1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e7b412022ff4e3881bf05b1500b0b9c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e464ebc33994daf93b13d1aacd0c6b1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib10bc762d1904afc912369ca9320983f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7da4f398eb84cc8b9c54e850f5e3930_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1641e7630f2d462fa941ca0b1795bd39_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if553089e6f8e49f48b85aaa4c21bacc6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05c71c56629c42628c1e160c2c7fab30_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i902bd1d2194847388e05b8182f07579d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac2947a35f6742c3829e243519fdfaff_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabaa81a5a2494069ab337806bdab2015_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d91998ff2db475f802cdcc0275405f9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b61d7a18e7e4264848ef8479c9fd3dc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c77f758beca4e84a48c2c0f4e371cde_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ba9e492d61a4b95bb9150e34f4662f5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c3ac17784114e34ab6fe76435aa264d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bb26b0130c94f85a59a9057df4cadf4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c0ae534cbe04b29aefafcd8deda24a7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eaf63e0a6474648a8bbe8a5cf999092_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ca0f5525e5e4b3685ab76f896c7eb7b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac1adb571402442b9b60c2ec86d410e8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89043fe0d8d347c681da5ba35f7a67d0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic59266bd338a4b6aaf33bc9b4f62065e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idab63119e003452c826621bb5adad62e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i712be5f8ad6d44689ef58bcfe6a5f73d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaba8282bb0c74750a2f12b06a4d5062d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if283cd72fcc34fcbb5110f8be286419a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c61873a8b5e47a0bc7654ef13e90434_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52d956d84424450187b7bff38697c856_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b978a372f504f7b8ec73f8e9f98c5af_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i607600e57bc24ec88574eed626560514_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb722c1180814c33b2ae495db1c4747d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2d2aea57de8408b815a41b955b60d80_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i477e8dec7f57476099590b6983065827_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic49699145b6345228d52c3faecb8df97_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bd2168bca1e4040a9da3b4ab26b86cf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie23ea36541924557943e2430c72ae778_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94231fb385924cf282805bc752ae2a94_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbf4e5e1265e49b0b09d773e4c783692_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82e30d87f5d0467ebb7ed83b6b3c099f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0b1bd5bd7b9482894c0d0ddb344acf9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3d980d0bd964d458411201e56f11d8c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f0d37e10e73443eb87f20a4a6c4f420_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f41e1bfc70949dc928fce12adebe052_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:JanssenPromotionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfc7b19c5d514b50b41cc32aa3d11d39_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic01c383878c04180a2854e8bd4bd7dbb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7580dedc91584d4f98d22c663e83c737_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fbce269e861429686eecad63a7ac8d9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id46550cb6dd04983b799689bf77cb356_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34ca585728074c7dbf14fb4257e9689b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if963174f2eb741b98f44a7603f0a3e37_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc8a6c3b9a71449e81982ff6c411d4e5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>exdx:installment</xbrli:measure></xbrli:unit><xbrli:context id="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c552639d72a4d1586237a5c1c0e6160_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8d669ae291047919c778bbafa987721_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf6b4d792a8b4d7aba9272a67325b8b7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica1cd48a7054411c9b4601c8284a7b57_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90cc78dc6aae4cdcaf1d24b138a2cb0b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e8e3ebf57ba4b84974afb49d0bb404e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf4fcbdc1b4745a5b33f78a2ba491dc3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1367b76ff734867a343920922f694fd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia703865d1c1e42238e72cf40c966acff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic41c409fd996414ca1c565c3fb9e700a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a41951c3b0c4a48a5ed985502dfd9de_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36ed70cc5c794512b4fad8285454fe80_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bdcbd2fc6414ea79b1193e5620bf1a9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i489e0e440e7f4dcc98e8fdbfdd3625bb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f11a04ba9ab4c488c85cd2feab5f19c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9aeb5900bd34680b034242eb67e265a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exdx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i7fe2dbff76584751aa65bc9192aca7f8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91495a4d15cc42a9a43bf2c45f36cb29_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i062b3ce256a24e639baceecc90b79e9d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i009c796a34f14a8489e678bd5e7ba7e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i638a2a722ce94f7fbd4ee6222f3fec82_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3c67b740ab54e61a5a9b343990c65fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfa5972febc9459da204c8686e539242_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4d4d2d813904871b8dc03c5d28b5913_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26a156c330594b2b9417a57e1bc8ad88_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05e6cdd6406045d0a32cecdb01802bcc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i603ccc7a3961470db626807866947b63_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55f4a3829c4446e58090abccb942038c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i597de8f2704546a48516c3951933870b_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie56e06d7b68849928e2fe39a26f73f85_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:CapitalRoyaltyPartnersIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i467bcd314d89428f837631f14432ed8c_D20181207-20181207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-07</xbrli:startDate><xbrli:endDate>2018-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05b9273e32ae45169280d1693bd07c66_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42432a2bad8448ddbefe4f6e51452afb_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44af8d7a747943749fac22ffa3dd323f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f4b404a7a746b88f1807dade1827bc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab6affb37170402fbe076933203ab105_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ec99d0d3d254c33997d3054789d8af4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4f3d87cb19a49f193d7d0107a085292_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d48a5110ed4d4291de9e8ecd5f4fe6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4718b3285d4a899f40931cbfe678bf_I20210823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8bc25f7d63f44cea35854b4039d0885_D20210823-20210823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43b31315848e4d43901c9f3183cbebb4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05fc542a715f42e3aab293e27727085f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f14904a63b24632b074d2bdb5d4c936_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i408f9d848a9e4b6884930325c910b9b3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia55722d9277e48b09ba4ff1dd33c2c09_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29c2b0bce9e84c2a8890706b191065b5_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8141bfc43efa4a6592ea1148f7f0529b_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:AlleghenyHealthNetworkResearchInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21dbc0462f534175819f4c79dddf82df_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0c459a6186e4f998b57dfa0fd36cc51_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9675b9781d014000845af2a6c5ce6ab4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic20a022810a34a0e8c547ff3a27e2eff_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e41083069624d7b86843d65bcb1e246_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1907a197b9bf4ca081846376298c2dbc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id889a74f3c604c9e974adc011ac55e21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b2aebd9d89a4273b23eaddb67c7187b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0afac1488f04780915c25495618223b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40bda80a1b244e9fb44a8c2c934a4459_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1d65917be864b4284e3dcea0b13a340_D20201110-20201110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-10</xbrli:startDate><xbrli:endDate>2020-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba7d0acdfc0f4df5a66f2bb747bb7643_D20210325-20210325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad7af241ac04bb0b5bca5f52f3c3186_I20210325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1381f17c84bb46b99f0deedd39dd8927_D20210622-20210622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:ExchangingStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-22</xbrli:startDate><xbrli:endDate>2021-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08bfaba48e6842479e60870fdf457e2f_I20210622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:ExchangingStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i383d4094819b45efbea334edd4261fee_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i055f44b2d2d645aaa59585abcbde2ce0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8744c39e0b4d471aa0dd059af498b3e8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51655d8dd5cf4160a3e3c43d9ca5e140_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationSep72024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ab1059999b0438cb0af5e2cefc99c04_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1e027871f3d476fb7a00e85ba9c297c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:NoExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied9309b5ec844d98aad6b3f0e1ae47bb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f87200751b54837b785f6f119eae03a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i813af130085e4bcfa2cc8e3c96aa96f8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff8e60ce9c594c9aa9741f476323c52a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa5c746fe4b94017ad86dcc26492fd0a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81f9417379b2400e818961f451bb1226_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48504c2aaa3340f78e4733690a2c664b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd19ac6d04c2437dabe28931d0bda370_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76d674daf6484d4dba8d57a883f437de_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibef4b05e619f40db9ce589f18c223874_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d30161937ff49a0b250f9c9743eaad5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic949c32127e144a882f03102ba80d592_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec9349a3150a4ff99322fb97e4697704_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia972fa811fe848438cbbf17df4213386_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f5390aa51834b0b9c48b6a1ebb975d1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7535719e17e343dd934c82c15efb6c7a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35982159cf8245aea8b27f18c2b7c347_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64d9f93ee0074786a89f1f8599054033_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i812dfaa6798b45bf98314f6d3cb3caf2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf397bbee62e4358a29c8fe357195adc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c1776b0ca2349ccb5b02fae30a4d766_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i985d2c00754740a1a75159006860f2f5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i438f8b50be854314a57a86231478aeae_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d8ea92229ac4b40bb2809f46bc58d7d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68fba0d065ad49d59ebd33550ccf06b8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia119e096fc994ad881c098574fb63096_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e7d648e35d44b77b7fd4855916a6275_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f6449b025d641e0b0375cfa207f3273_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63ee66c9d6104d338fa41906c77c9c58_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c3796eb660a4650801221b114877277_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefa8fc581abf42a49cbe113470783f21_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if68e692cf8c24949bdf0c1127a4fb582_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dfd57d894e647a88470632fbe75162c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i035f9bfef7cb4a9193e6fb924522482a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i402a6e16113b408c83b914eaf5ca9d14_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24ee58a4f9ca4e738b4bacc7d0c3ecff_D20200416-20200416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-16</xbrli:startDate><xbrli:endDate>2020-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70e8b6ad8e4146a199fe29ee3340804a_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9f93b64bd374d91a76b68cea11d1efa_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id84bcf56412d40cbb17dc4a699c488f4_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:HeadquartersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19fdfc2580cb4c58ba25b4bf22f281cb_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie47ef4f6de5046f08313d4c7118cd8d2_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGV4dHJlZ2lvbjo5OTFjZDhmMDg4ZDU0YTQyYmU2ODQzZTQzNjFiZTZiMF84NA_a1d09263-10ae-4d1b-b739-47a7535e9471">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Mark One) </span></div><div><span style="font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:115%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:2.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.026%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6N2Y1NDkxZjNkMTlhNGM2MmJmNjkyNDUxMWY2YWZlNzEvdGFibGVyYW5nZTo3ZjU0OTFmM2QxOWE0YzYyYmY2OTI0NTExZjZhZmU3MV8wLTAtMS0xLTE0MjUx_17f99463-2e61-4876-adcc-4aa5ef3a2340">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the quarterly period ended <ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6N2Y1NDkxZjNkMTlhNGM2MmJmNjkyNDUxMWY2YWZlNzEvdGFibGVyYW5nZTo3ZjU0OTFmM2QxOWE0YzYyYmY2OTI0NTExZjZhZmU3MV8xLTAtMS0xLTE0MjUxL3RleHRyZWdpb246MzE2YmUxMGJkYjdlNGFlM2JiMDQ0ZmYxMjg4MjM4MjBfMzY_be29d40f-906d-4dbf-96df-df0f00795702">September&#160;30, 2021</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6N2Y1NDkxZjNkMTlhNGM2MmJmNjkyNDUxMWY2YWZlNzEvdGFibGVyYW5nZTo3ZjU0OTFmM2QxOWE0YzYyYmY2OTI0NTExZjZhZmU3MV8yLTAtMS0xLTE0MjUx_873698aa-0762-4a13-bae4-6f2407f987df">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Commission File Number: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGV4dHJlZ2lvbjo5OTFjZDhmMDg4ZDU0YTQyYmU2ODQzZTQzNjFiZTZiMF8xMjk_2867e8a4-288a-4f28-a6ea-5e675f24bfca">001-39049</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGV4dHJlZ2lvbjo5OTFjZDhmMDg4ZDU0YTQyYmU2ODQzZTQzNjFiZTZiMF8xMzM_4b665b00-1d30-489f-bb75-f117fdee8477">EXAGEN INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:0.1%"></td><td style="width:1.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NTZhODdmZjBiMjQ0NGQzODk2MzZmODIxYTc0NjU3YWEvdGFibGVyYW5nZTo1NmE4N2ZmMGIyNDQ0ZDM4OTYzNmY4MjFhNzQ2NTdhYV8wLTAtMS0xLTE0MjUx_5b173a8d-d74b-4dc4-9777-b7c05b452620">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NTZhODdmZjBiMjQ0NGQzODk2MzZmODIxYTc0NjU3YWEvdGFibGVyYW5nZTo1NmE4N2ZmMGIyNDQ0ZDM4OTYzNmY4MjFhNzQ2NTdhYV8wLTYtMS0xLTE0MjUx_75cd37b1-0eb0-4165-bcfe-48869341709c">20-0434866</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NTZhODdmZjBiMjQ0NGQzODk2MzZmODIxYTc0NjU3YWEvdGFibGVyYW5nZTo1NmE4N2ZmMGIyNDQ0ZDM4OTYzNmY4MjFhNzQ2NTdhYV8zLTEtMS0xLTE0MjUx_f1c7dd45-9a7a-494c-8df5-aaf0969c4435">1261 Liberty Way</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NTZhODdmZjBiMjQ0NGQzODk2MzZmODIxYTc0NjU3YWEvdGFibGVyYW5nZTo1NmE4N2ZmMGIyNDQ0ZDM4OTYzNmY4MjFhNzQ2NTdhYV80LTEtMS0xLTE0MjUx_103fc9d7-7163-48cc-83fc-7aa44f09bb87">Vista,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NTZhODdmZjBiMjQ0NGQzODk2MzZmODIxYTc0NjU3YWEvdGFibGVyYW5nZTo1NmE4N2ZmMGIyNDQ0ZDM4OTYzNmY4MjFhNzQ2NTdhYV80LTItMS0xLTE0MjUx_774708e7-93df-40ce-b92d-a1f21e6134df">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NTZhODdmZjBiMjQ0NGQzODk2MzZmODIxYTc0NjU3YWEvdGFibGVyYW5nZTo1NmE4N2ZmMGIyNDQ0ZDM4OTYzNmY4MjFhNzQ2NTdhYV80LTYtMS0xLTE0MjUx_b30ae0bf-bdcd-452c-ae9a-575c1eda254e">92081</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.766%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6MDQ2YjZmZGQ0OWQ1NDllNzlkMTdhNGM2ODUzY2JlYWMvdGFibGVyYW5nZTowNDZiNmZkZDQ5ZDU0OWU3OWQxN2E0YzY4NTNjYmVhY18wLTAtMS0xLTE0MjUx_7ad1754a-45e8-4b02-b22d-202b56359842">(760)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6MDQ2YjZmZGQ0OWQ1NDllNzlkMTdhNGM2ODUzY2JlYWMvdGFibGVyYW5nZTowNDZiNmZkZDQ5ZDU0OWU3OWQxN2E0YzY4NTNjYmVhY18wLTEtMS0xLTE0MjUx_427ba533-c13d-4f22-8729-fe1f30d9fbcd">560-1501</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant's Telephone Number, Including Area Code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6M2NkNDIzNDczOTc5NDEwYmEzMjdiYjg3NTFkZDdkNmEvdGFibGVyYW5nZTozY2Q0MjM0NzM5Nzk0MTBiYTMyN2JiODc1MWRkN2Q2YV8xLTAtMS0xLTE0MjUx_529e5a03-0f1a-46c3-85cb-1fad35eafe62">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6M2NkNDIzNDczOTc5NDEwYmEzMjdiYjg3NTFkZDdkNmEvdGFibGVyYW5nZTozY2Q0MjM0NzM5Nzk0MTBiYTMyN2JiODc1MWRkN2Q2YV8xLTItMS0xLTE0MjUx_8efb176f-8d1f-4603-b335-0fd653a4980e">XGN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6M2NkNDIzNDczOTc5NDEwYmEzMjdiYjg3NTFkZDdkNmEvdGFibGVyYW5nZTozY2Q0MjM0NzM5Nzk0MTBiYTMyN2JiODc1MWRkN2Q2YV8xLTQtMS0xLTE0MjUx_8fe96600-7103-4393-8b60-ff413ed410a6">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGV4dHJlZ2lvbjo5OTFjZDhmMDg4ZDU0YTQyYmU2ODQzZTQzNjFiZTZiMF81OTk_1099dfa8-3204-4d1d-b0af-2daeca360181">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGV4dHJlZ2lvbjo5OTFjZDhmMDg4ZDU0YTQyYmU2ODQzZTQzNjFiZTZiMF85MDE_0da9ccd5-5e72-4a38-a1e0-e06f7481cd03">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Securities Exchange Act of 1934. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NDlkZjQwNTFmNGE0NDM4OGI1ZTU2NTk3MjI5MDgxOGQvdGFibGVyYW5nZTo0OWRmNDA1MWY0YTQ0Mzg4YjVlNTY1OTcyMjkwODE4ZF8yLTAtMS0xLTE0MjUx_973b95bd-19fc-4ab8-8869-ac8344da4334">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NDlkZjQwNTFmNGE0NDM4OGI1ZTU2NTk3MjI5MDgxOGQvdGFibGVyYW5nZTo0OWRmNDA1MWY0YTQ0Mzg4YjVlNTY1OTcyMjkwODE4ZF8yLTQtMS0xLTE0MjUx_11dcadcc-bb3e-42f5-baff-ce1402b431dc">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NDlkZjQwNTFmNGE0NDM4OGI1ZTU2NTk3MjI5MDgxOGQvdGFibGVyYW5nZTo0OWRmNDA1MWY0YTQ0Mzg4YjVlNTY1OTcyMjkwODE4ZF80LTQtMS0xLTE0MjUx_6a7edb18-d237-4fa7-8173-f7220c842e7c">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Securities Act&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGV4dHJlZ2lvbjo5OTFjZDhmMDg4ZDU0YTQyYmU2ODQzZTQzNjFiZTZiMF8xNTM0_2addd619-a4df-4522-afd3-e98a2597cc43">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGV4dHJlZ2lvbjo5OTFjZDhmMDg4ZDU0YTQyYmU2ODQzZTQzNjFiZTZiMF8xNjU0_d3c75589-16f8-4064-aab2-cb4ae8e089b1">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total shares of common stock outstanding as of the close of business on November&#160;5, 2021 was <ix:nonFraction unitRef="shares" contextRef="i69bdb0e5056143559edb4f8abb0e6740_I20211105" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGV4dHJlZ2lvbjo5OTFjZDhmMDg4ZDU0YTQyYmU2ODQzZTQzNjFiZTZiMF8xNzQx_77362cf3-a0ca-4346-9aca-ff8190d37a22">16,164,232</ix:nonFraction>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_13">Condensed Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_16">Condensed Balance Sheets as of September 30, 2021 and December 31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_19">Condensed Statements of Operations for the Three and Nine Months ended September 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_22">Condensed Statements of Stockholders' Equity for the Nine Months ended September 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_25">Condensed Statements of Cash Flows for the Nine Months ended September 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_28">Notes to Unaudited Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_58">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_58">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_73">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_73">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_76">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_76">33</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_82">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_82">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_85">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_85">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_88">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_88">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_91">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_91">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_94">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_94">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_97">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_97">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_100">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_100">39</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_103">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i774bc25129df4ef1954bdef4e9d46c8a_103">41</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_13"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I. Financial Information</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Condensed Financial Statements</span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfNC00LTEtMS0xNDI1MQ_ac085751-2424-4b87-8e14-64a81aff0f9a">106,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfNC02LTEtMS0xNDI1MQ_26c75d73-e19b-496d-bc0d-7c77ad24f057">57,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfNS00LTEtMS0xNDI1MQ_a963d561-0190-43ba-a4c8-6958e729a074">9,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfNS02LTEtMS0xNDI1MQ_eefa8969-a96d-4900-b12d-19be55e2c06f">8,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfNi00LTEtMS0xNDI1MQ_1ebcb142-2449-438c-a67d-33b140f12dcd">2,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfNi02LTEtMS0xNDI1MQ_4ef10902-b20b-4076-ad68-408718aa1dfa">4,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfNy00LTEtMS0xNDI1MQ_d388ad6a-8c1d-4561-880d-00984c7a5d91">118,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfNy02LTEtMS0xNDI1MQ_b62a8cea-99b1-4fc3-a30d-6a8a3792c92c">70,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfOC00LTEtMS0xNDI1MQ_64d907fb-6fc4-4f01-92d4-c46ee8b80853">3,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfOC02LTEtMS0xNDI1MQ_7b467475-5cc4-4b29-9113-ee056ad9ec73">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfOS00LTEtMS0xNDI1MQ_44d36bf3-dde5-4745-8287-32a56228e61a">5,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfOS02LTEtMS0xNDI1MQ_300deb7b-fe76-40e1-a19e-c1586ae19194">5,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTAtNC0xLTEtMTQyNTE_cfc9eaf4-2ed9-499d-8733-a22ed5101a49">439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTAtNi0xLTEtMTQyNTE_c6bf5ce9-5cd5-4bfd-a4f1-d42a4b55c2d8">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTEtNC0xLTEtMTQyNTE_c6f0d374-8717-441d-ae5d-c18343a9468a">127,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTEtNi0xLTEtMTQyNTE_083dd182-58d7-42e8-bca0-2e94e64d8f6c">78,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTQtNC0xLTEtMTQyNTE_829c5753-6c7a-40ad-a50a-357b90e0933f">1,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTQtNi0xLTEtMTQyNTE_98b3ba33-9d30-4dae-93b8-68c66e159580">3,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTUtNC0xLTEtMTQyNTE_06f0efc4-a09e-4d20-8102-c537be3ec374">6,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTUtNi0xLTEtMTQyNTE_3c5beacb-c7f2-42c2-ac85-46b362e419c9">5,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTctNC0xLTEtMTQyNTE_24d4b065-03db-434b-b8e2-9df4e5270def">8,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTctNi0xLTEtMTQyNTE_eb89c13d-2371-43a7-82ec-b6a31f27c6ad">8,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTgtNC0xLTEtMTQyNTE_afd81ef4-7b51-4036-8589-3721b49c01d0">27,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTgtNi0xLTEtMTQyNTE_ab3f38a3-1a70-4e8f-a447-8b074e02296f">26,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjAtNC0xLTEtMTQyNTE_50ed72f4-c00a-4b8a-9976-0e5ea6f77689">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjAtNi0xLTEtMTQyNTE_d0da781a-d755-413a-9ead-b4b30e4b60be">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjEtNC0xLTEtMTQyNTE_b86c5100-0b10-4b58-87f9-d4bb951b29b4">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjEtNi0xLTEtMTQyNTE_455a39de-cfe6-40d6-84bb-5caf581dca87">948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjItNC0xLTEtMTQyNTE_1f157c7c-c3f1-4213-905e-fad52f01ce77">36,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjItNi0xLTEtMTQyNTE_8063524c-a1ad-4e2d-8bc3-3f50ad5213ad">36,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjMtNC0xLTEtMTQyNTE_dacd07a3-80dd-4075-8a9c-e378119bdf11"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjMtNi0xLTEtMTQyNTE_ee2ca786-6e03-4561-8dbc-3cbab1059764"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjo2Yjc1YjhmMzg5OTQ0NThiOGQ3ODNkOTE4MTg2ZGFiM18yMQ_336e6dc8-e9c2-434f-9b88-54d17ee8ab2e"><ix:nonFraction unitRef="usdPerShare" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjo2Yjc1YjhmMzg5OTQ0NThiOGQ3ODNkOTE4MTg2ZGFiM18yMQ_7243d33f-efea-404b-8094-47f3999b2fe4">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjo2Yjc1YjhmMzg5OTQ0NThiOGQ3ODNkOTE4MTg2ZGFiM18zNQ_6b7e2d29-1f84-46e9-9fd1-ca5bdab8ca11"><ix:nonFraction unitRef="shares" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjo2Yjc1YjhmMzg5OTQ0NThiOGQ3ODNkOTE4MTg2ZGFiM18zNQ_ec57eac6-1430-46a6-8561-2cd887de69a5">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjo2Yjc1YjhmMzg5OTQ0NThiOGQ3ODNkOTE4MTg2ZGFiM181Nw_5cad7353-6400-4379-b45e-90587725d342"><ix:nonFraction unitRef="shares" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjo2Yjc1YjhmMzg5OTQ0NThiOGQ3ODNkOTE4MTg2ZGFiM181Nw_6665e0aa-9b58-48c9-b091-cdb5b47117c2"><ix:nonFraction unitRef="shares" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjo2Yjc1YjhmMzg5OTQ0NThiOGQ3ODNkOTE4MTg2ZGFiM181Nw_b9843b48-b0ca-44df-af29-31b20e0cf9d0"><ix:nonFraction unitRef="shares" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjo2Yjc1YjhmMzg5OTQ0NThiOGQ3ODNkOTE4MTg2ZGFiM181Nw_cdf33025-e623-4a8f-924a-090d7bf26124">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at September&#160;30, 2021 and December 31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtNC0xLTEtMTQyNTE_15dc11bb-0c17-4a05-9c7e-71ee3bc2c7c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtNi0xLTEtMTQyNTE_f0e6d436-a270-4647-b958-306fc4f83b98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjowYmJkZmRhMjhmMzA0YmY0YTllYjE5ZjVjNWI3MGUwMV8xOA_ca48c59c-db86-47d0-93b1-57a6b0e04e28"><ix:nonFraction unitRef="usdPerShare" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjowYmJkZmRhMjhmMzA0YmY0YTllYjE5ZjVjNWI3MGUwMV8xOA_f07a1fd5-1d39-4ef7-8acd-b1233825a8f5">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjowYmJkZmRhMjhmMzA0YmY0YTllYjE5ZjVjNWI3MGUwMV8zMg_6b5c49e9-f083-4f28-908c-030da3d909ee"><ix:nonFraction unitRef="shares" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjowYmJkZmRhMjhmMzA0YmY0YTllYjE5ZjVjNWI3MGUwMV8zMg_ffdfcc19-32ce-41bb-939b-edcc34ea201f">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at September&#160;30, 2021 and December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjowYmJkZmRhMjhmMzA0YmY0YTllYjE5ZjVjNWI3MGUwMV84Mg_22068120-c675-46ed-ac8c-b24ef4d94528"><ix:nonFraction unitRef="shares" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjowYmJkZmRhMjhmMzA0YmY0YTllYjE5ZjVjNWI3MGUwMV84Mg_85cce2f7-1951-496a-908e-1d0bf47f4938">16,164,232</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjowYmJkZmRhMjhmMzA0YmY0YTllYjE5ZjVjNWI3MGUwMV84OQ_0447ca96-00ef-4016-a0dc-8e43ad833a79"><ix:nonFraction unitRef="shares" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjowYmJkZmRhMjhmMzA0YmY0YTllYjE5ZjVjNWI3MGUwMV84OQ_453c5299-5c4a-45d2-aabd-817fd498f70a">12,652,308</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2021 and December 31, 2020, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctNC0xLTEtMTQyNTE_36792049-ca3a-40cd-bce8-544e8fe1fb34">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctNi0xLTEtMTQyNTE_2ab0f817-82a0-4a91-b9b4-699285a05f81">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional paid-in capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjgtNC0xLTEtMTQyNTE_cf009e95-3930-480a-8e09-aaa99018fc71">291,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjgtNi0xLTEtMTQyNTE_d424eb58-4542-4cc5-b890-75be80e6570e">223,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjktNC0xLTEtMTQyNTE_9f7c9d97-1442-43ed-96b0-7217a008c7c5">201,087</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjktNi0xLTEtMTQyNTE_347b9115-e212-4063-8c31-f3ffd7966a23">181,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMzAtNC0xLTEtMTQyNTE_ea37a680-908a-46e9-97ef-d097a85c8fbc">90,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMzAtNi0xLTEtMTQyNTE_8aaa8d9d-39e1-4d4e-924b-1fbadf512810">41,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMzEtNC0xLTEtMTQyNTE_7a2410b9-5863-437e-b6f0-fd453a601196">127,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMzEtNi0xLTEtMTQyNTE_42d5c2bd-21d7-4618-b016-80db174efcb3">78,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Condensed Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMy0yLTEtMS0xNDI1MQ_8fe5fbe7-ebd4-423f-8191-6d752fcb727f">12,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMy00LTEtMS0xNDI1MQ_fb2f9796-28ab-4969-a7d4-46fab763672b">10,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMy02LTEtMS0xNDI1MQ_3a081dfc-61fb-40c3-a57d-8f2d24b178ef">35,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMy04LTEtMS0xNDI1MQ_5471217e-40e5-4702-9f48-b2b39554a8f9">29,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNS0yLTEtMS0xNDI1MQ_127e2033-e116-4af5-b3c9-48b77f5b5393">5,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNS00LTEtMS0xNDI1MQ_1377edc3-3a92-473b-95b5-059fef67b415">4,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNS02LTEtMS0xNDI1MQ_d1963c8e-cb96-4bf7-84cd-36e728df9a78">15,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNS04LTEtMS0xNDI1MQ_0fe37ca7-2a17-4def-aaa7-38bd4706495e">12,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNi0yLTEtMS0xNDI1MQ_f3810b3c-8be9-4140-8eed-8a764f9ebc7c">11,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNi00LTEtMS0xNDI1MQ_c0bb1d31-c77b-4a33-bd3c-4f385af0100c">9,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNi02LTEtMS0xNDI1MQ_7f1c08a6-e3f3-408f-a5d2-c53e7289f091">32,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNi04LTEtMS0xNDI1MQ_1fb1dc3a-3437-4a4c-839f-a299add75729">27,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNy0yLTEtMS0xNDI1MQ_ff20fa1a-725b-461a-8fd9-ad2086706e3f">1,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNy00LTEtMS0xNDI1MQ_b5c6e1d2-2d34-4c5b-b748-956062014d0f">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNy02LTEtMS0xNDI1MQ_da5cdda6-9d1e-4c94-a087-5fca024fc594">5,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNy04LTEtMS0xNDI1MQ_e0410178-0f59-4e77-a94c-8a428592ac55">2,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTAtMi0xLTEtMTQyNTE_ddb13e5f-7593-4910-9f29-1063d4629d74">18,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTAtNC0xLTEtMTQyNTE_e7a18f87-2f57-467c-bf50-543e16a93ff6">14,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTAtNi0xLTEtMTQyNTE_c1798386-a3b4-4b15-b06c-d0e9e7248fe5">53,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTAtOC0xLTEtMTQyNTE_dc57ea97-def7-43e4-85c8-cf90bed9d832">41,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTEtMi0xLTEtMTQyNTE_789ca620-896d-413f-93ed-5aa5ab296c63">6,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTEtNC0xLTEtMTQyNTE_76fa0cac-b5ac-499a-ae75-dc29345b1390">3,786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTEtNi0xLTEtMTQyNTE_9a342ccd-7598-4791-a668-2b630083cbc6">17,813</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTEtOC0xLTEtMTQyNTE_0688b7ff-933b-4cde-94c1-846394d3af78">12,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTItMi0xLTEtMTQyNTE_2eea7cf1-ccfa-4198-b11b-85befdbcd005">678</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTItNC0xLTEtMTQyNTE_27c45d37-dead-4d67-b41e-1b9029fab080">647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTItNi0xLTEtMTQyNTE_502fec30-7a2f-44c2-8a8f-67d44aeac9ed">1,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTItOC0xLTEtMTQyNTE_afb52eea-499d-46d3-86d6-e880b3dd8979">1,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTQtMi0xLTEtMTQyNTE_8a3264c2-5684-40d9-8b07-f7a8ac906742">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTQtNC0xLTEtMTQyNTE_52a536cf-5c3e-4185-9294-6606a4dca0d0">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTQtNi0xLTEtMTQyNTE_2fcfea87-b3c7-4c3f-9536-74affd90d134">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTQtOC0xLTEtMTQyNTE_0e87ee3d-d43b-4a5a-ac0a-2adb8a85dcf8">985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTUtMi0xLTEtMTQyNTE_8526f81c-8239-4ca3-8129-1e79a6cf5dd9">7,179</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTUtNC0xLTEtMTQyNTE_49e597f0-03b4-44d6-8ca8-2cef02dd64b6">4,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTUtNi0xLTEtMTQyNTE_10b5fb89-ccc4-47c6-a17c-db6dc970a418">19,798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTUtOC0xLTEtMTQyNTE_b5869b8f-5c86-45b1-a310-4f46e277b737">13,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTYtMi0xLTEtMTQyNTE_a642e2ef-dd47-4625-bbca-28782dc367ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTYtNC0xLTEtMTQyNTE_13f78f47-101a-458e-b82c-056aa517a63f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTYtNi0xLTEtMTQyNTE_3ab50c09-c042-4315-866f-1211b74bcadc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTYtOC0xLTEtMTQyNTE_cb44d30c-bebc-4d1c-9cf4-8b4f9c26c3f5">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTctMi0xLTEtMTQyNTE_301dd0a6-1a03-44f7-a37b-7680d3dd67f6">7,179</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTctNC0xLTEtMTQyNTE_27f1bb15-0920-4ec0-b567-79d200d04426">4,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTctNi0xLTEtMTQyNTE_c22402f3-f817-4b2d-910c-dd59e56576fa">19,798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTctOC0xLTEtMTQyNTE_c40e6c1c-0b15-41a1-ba1e-41636b7baaa5">13,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted (Note 2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjEtMi0xLTEtMTQyNTE_7839615b-d747-4a19-bf24-0749929815e1"><ix:nonFraction unitRef="usdPerShare" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjEtMi0xLTEtMTQyNTE_e48160ae-8289-4e95-9a2b-a496b48652d2">0.42</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjEtNC0xLTEtMTQyNTE_0102caae-a913-4636-ba79-2f8f0014a1be"><ix:nonFraction unitRef="usdPerShare" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjEtNC0xLTEtMTQyNTE_dc9a916f-dbc4-481e-9b49-09b2dfe0a018">0.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjEtNi0xLTEtMTQyNTE_02487e91-5599-4ffc-9f1f-2ae255007a80"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjEtNi0xLTEtMTQyNTE_34d3fbed-e0b6-4b3a-a4d4-fd6ad8bddc04">1.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjEtOC0xLTEtMTQyNTE_3dfd6b21-7330-4266-8dc2-145bfbf12c72"><ix:nonFraction unitRef="usdPerShare" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjEtOC0xLTEtMTQyNTE_b248c5a5-c0a2-4baa-a687-dd7883e70541">1.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of shares used to compute net loss per share, basic and diluted (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjItMi0xLTEtMTQyNTE_466e4b57-deef-4bc3-a3e4-0cfd6f4ae7e9"><ix:nonFraction unitRef="shares" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjItMi0xLTEtMTQyNTE_efb0d292-a7bd-4c89-ad70-7894cddfbab7">16,945,591</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjItNC0xLTEtMTQyNTE_5d7f854a-1466-4fd0-99fc-ec147da6f046"><ix:nonFraction unitRef="shares" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjItNC0xLTEtMTQyNTE_8b46dd65-7fa0-4a15-8c18-dbaedc460af0">12,644,348</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjItNi0xLTEtMTQyNTE_47192f0a-5193-4ca1-b6ef-2b54a800fce2"><ix:nonFraction unitRef="shares" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjItNi0xLTEtMTQyNTE_ffb24c15-0054-48e3-99e9-e18c4adb8265">15,636,150</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjItOC0xLTEtMTQyNTE_b989d1b9-3d5e-4cdd-9710-298ce8a4df32"><ix:nonFraction unitRef="shares" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjItOC0xLTEtMTQyNTE_bc35c7af-7dc2-4446-be6a-2f47cde3285e">12,626,259</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Unaudited Condensed Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i865bea50ee1b455a84dfb11e33cf1313_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMi0yLTEtMS0xNDI1MQ_1579006c-6b57-4a97-8d80-0440f1407bbf">12,652,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865bea50ee1b455a84dfb11e33cf1313_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMi00LTEtMS0xNDI1MQ_4a0d9897-289f-4c38-887d-a5f3b551979e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if523e9aa9c344c3aaa54d52f9293169d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMi02LTEtMS0xNDI1MQ_792eb3bc-b7bb-40c1-b2e3-fdc80f3263d4">223,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48d05d3781344ed6a035b262079c317a_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMi04LTEtMS0xNDI1MQ_8cbe0182-e7af-42ca-8fdc-4ccb37d0f389">181,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMi0xMC0xLTEtMTQyNTE_94a37217-3827-4295-ac70-9f24c0657bfe">41,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock in public offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i756e9691fbec4232a2a72550fe8827ce_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="exdx:StockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMy0wLTEtMS0xNDI1MS90ZXh0cmVnaW9uOjQ3ZDRhNTIwMTBmODQ2Mjg5Y2M4OGFiMmRjNjkyODBkXzY3_b48ce234-fdac-49f0-b6a2-0086e7e0c833">4,435</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icddde24d5cf540848e569816d215bdc0_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMy0yLTEtMS0xNDI1MQ_7dad7647-8330-4650-89b0-f8a65b5eadfc">4,255,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddde24d5cf540848e569816d215bdc0_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMy00LTEtMS0xNDI1MQ_f8d49838-4ac9-46ce-aa91-5e1999862a64">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927670c99ebc4fbaa921ca365127a3f9_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMy02LTEtMS0xNDI1MQ_fec4fa69-ec16-4688-b893-2bde6ce6efb3">64,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0649178e5d45f48148b103ef4c2322_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMy0xMC0xLTEtMTQyNTE_1f5fb73d-0a0a-42f9-ad12-c5b984e53bfb">64,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icddde24d5cf540848e569816d215bdc0_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNC0yLTEtMS0xNDI1MQ_a9458bfb-7448-416b-a8c1-675c70f331e3">3,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927670c99ebc4fbaa921ca365127a3f9_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNC02LTEtMS0xNDI1MQ_e99e9dde-4288-4ee4-b3c8-d2384de33b2c">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0649178e5d45f48148b103ef4c2322_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNC0xMC0xLTEtMTQyNTE_15ee2884-b253-4bad-8b73-598d7d8c2aba">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icddde24d5cf540848e569816d215bdc0_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNS0yLTEtMS0xNDI1MQ_fc93bf2c-999c-4bcc-b396-c78d315e1fc2">14,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927670c99ebc4fbaa921ca365127a3f9_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNS02LTEtMS0xNDI1MQ_af085094-5fb8-4ba9-be79-22915688a8e9">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0649178e5d45f48148b103ef4c2322_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNS0xMC0xLTEtMTQyNTE_f40c9dcc-dcf0-406d-89d7-dec1a9f74127">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927670c99ebc4fbaa921ca365127a3f9_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNi02LTEtMS0xNDI1MQ_11cf841f-5c2d-46d5-8a5c-b2bdefb61c58">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0649178e5d45f48148b103ef4c2322_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNi0xMC0xLTEtMTQyNTE_8867d37a-e1de-4893-aa61-ff33af013081">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee067a33f24240b1b6a20b3e1806aff9_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNy04LTEtMS0xNDI1MQ_072cb8d0-861c-40e0-856f-3df0aa56a1a9">6,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e0649178e5d45f48148b103ef4c2322_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNy0xMC0xLTEtMTQyNTE_6c6912eb-19d4-4592-80db-19e54e1f5eb5">6,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9320aadf1dce47e1bed19914403ec55e_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOC0yLTEtMS0xNDI1MQ_aefe674a-390e-4489-a7fe-bf26f0c52e1e">16,925,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320aadf1dce47e1bed19914403ec55e_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOC00LTEtMS0xNDI1MQ_a144a6bf-7ece-4ae7-ad80-0e9a7f7b418c">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1bfa77cf666454cbdeda15eeedec294_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOC02LTEtMS0xNDI1MQ_86955ce1-9270-484f-9706-2faf196c2345">288,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11196ddd025a40529a27602303c8e198_I20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOC04LTEtMS0xNDI1MQ_bcd0bd03-b57e-4f2c-8d39-556aa948de2f">187,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i756e9691fbec4232a2a72550fe8827ce_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOC0xMC0xLTEtMTQyNTE_840b1a41-c233-48a1-9e79-72f950ecf73c">101,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock in exchange for common stock warrant</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7ed996c7387441b79438aa8ee8022cbe_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOS0yLTEtMS0xNDI1MQ_ad9fee79-ab1b-47ea-8c21-5e2d057b72a3">804,951</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ed996c7387441b79438aa8ee8022cbe_D20210401-20210630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOS00LTEtMS0xNDI1MQ_3fae5a7c-cbbb-4328-9219-7ab47b9eed64">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15af72fdfd9b40338bca87d9c7bc45b0_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOS02LTEtMS0xNDI1MQ_af0139db-aa23-4f69-8616-0d5670a3160a">12,774</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i145dd851fc06416792a8abd9ca0753ca_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOS0xMC0xLTEtMTQyNTE_2b280ab9-41a5-4004-8f4c-b86f51c7f712">12,775</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock warrant in exchange for retirement of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15af72fdfd9b40338bca87d9c7bc45b0_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTAtNi0xLTEtMTQyNTE_7c7a0880-7a2c-4966-82c4-7ceb8558f833">12,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i145dd851fc06416792a8abd9ca0753ca_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTAtMTAtMS0xLTE0MjUx_454a376e-b861-4ac6-a45e-9e52eef9f037">12,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ed996c7387441b79438aa8ee8022cbe_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTEtMi0xLTEtMTQyNTE_15845c0e-f72a-406d-b771-7b07350ad624">6,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15af72fdfd9b40338bca87d9c7bc45b0_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTEtNi0xLTEtMTQyNTE_7fb74ad3-dbb0-41a5-a37d-8ef32ec87f81">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i145dd851fc06416792a8abd9ca0753ca_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTEtMTAtMS0xLTE0MjUx_4f391600-b0b4-4ab9-847a-8754e03a3bfd">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15af72fdfd9b40338bca87d9c7bc45b0_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTItNi0xLTEtMTQyNTE_caf3ea38-05f4-4a65-8239-506d19b42dd2">1,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i145dd851fc06416792a8abd9ca0753ca_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTItMTAtMS0xLTE0MjUx_cff0fbf3-7fdd-4eb2-aa65-6a57ff917eb1">1,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e86c5941f4241c8af84064215a7e2f5_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTMtOC0xLTEtMTQyNTE_db2e191c-3c07-4e80-ac3a-76577c06f87b">6,410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i145dd851fc06416792a8abd9ca0753ca_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTMtMTAtMS0xLTE0MjUx_216ede40-8691-44ea-a248-9199e5db6293">6,410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b6ff882bf31482d857ec6f5683bb78c_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTQtMi0xLTEtMTQyNTE_335642bf-34aa-4d1a-a3f0-4bb805292d4f">16,126,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b6ff882bf31482d857ec6f5683bb78c_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTQtNC0xLTEtMTQyNTE_742c96e9-c47b-4d74-b46f-53d146deb9b7">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbabc350d04d47b6b9d32913973c1fe7_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTQtNi0xLTEtMTQyNTE_5719242f-617e-464e-80f0-3d985b8dc266">290,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib539fa002ab647c5846c0e3443ff5e82_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTQtOC0xLTEtMTQyNTE_248e0284-0080-4e8d-be36-b18adb97d971">193,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf76918b1cb142d5a91a6c2666125f62_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTQtMTAtMS0xLTE0MjUx_4a96082a-b2e9-4da7-968f-f9ba77d903b3">96,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f30bb32e1574d1a9d2b765357dbe0bb_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTUtMi0xLTEtMTQyNTE_101bce7e-5f8d-429d-aafd-8bee89ecc2be">1,752</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c81cecd619e41fc8c3d99db6c936c40_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTUtNi0xLTEtMTQyNTE_70032bc2-d98a-469c-af7a-551ba150960b">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTUtMTAtMS0xLTE0MjUx_2e5b175c-4bbf-420b-8a61-4e966f6b4bdd">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f30bb32e1574d1a9d2b765357dbe0bb_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTYtMi0xLTEtMTQ2NDU_d2d38cfc-4166-44e6-a4c1-7ef7636a5037">17,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c81cecd619e41fc8c3d99db6c936c40_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTYtNi0xLTEtMTQ2NDU_8e94d0d2-39d8-40c0-ad85-a416a16fe043">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTYtMTAtMS0xLTE0NjQ1_6461dc19-e2d9-456f-b8c9-6f03c0467d22">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c81cecd619e41fc8c3d99db6c936c40_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTYtNi0xLTEtMTQyNTE_5e0112f6-54a5-4a6a-aa4b-13ccc5386ab0">1,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTYtMTAtMS0xLTE0MjUx_75979c66-54b2-4fb9-9c4c-1f7df2cde5e2">1,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f30bb32e1574d1a9d2b765357dbe0bb_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTctMi0xLTEtMTQyNTE_f6b1d6ae-afb5-420c-a01b-b7b08c338424">17,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c81cecd619e41fc8c3d99db6c936c40_D20210701-20210930" decimals="-3" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTctNi0xLTEtMTQyNTE_9aeb957d-b716-451a-af92-bbce4fc4727e">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTctMTAtMS0xLTE0MjUx_46b3f75a-4d6f-4d38-a08c-423c8d1c19eb">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7323a0eecec4c4ea71dc4cce1203339_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTktOC0xLTEtMTQyNTE_c7d2f141-7bce-4ab1-9b02-e55150cb1600">7,179</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTktMTAtMS0xLTE0MjUx_e2fa7fd0-9909-4d30-9e0a-ebdc5103bddb">7,179</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9a730a0e88a4555abc24b44790a742b_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMjAtMi0xLTEtMTQyNTE_567a8a81-4754-4ef0-a137-14d959a43402">16,164,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9a730a0e88a4555abc24b44790a742b_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMjAtNC0xLTEtMTQyNTE_0d6b033b-8e0f-4e73-9baf-2ce3c043bf50">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b0855316b0749f19d0440817fc74aba_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMjAtNi0xLTEtMTQyNTE_5db77590-7486-4ab2-941c-92561f77d4ed">291,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38cae9d0228d4b1f8bfa2f60e4501c49_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMjAtOC0xLTEtMTQyNTE_aa545be4-fbc3-4ee0-a160-f53732d1c982">201,087</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMjAtMTAtMS0xLTE0MjUx_7ec1d4d2-3138-47cc-bace-bf207bc459e9">90,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Unaudited Condensed Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e627efdf666421e923aa8ef9d7b1607_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMi0yLTEtMS0xNDI1MQ_c468c04b-9631-41eb-ab03-314ec0f9a4c3">12,560,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e627efdf666421e923aa8ef9d7b1607_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMi00LTEtMS0xNDI1MQ_8997bed9-dc19-47bc-aba9-83be3bd52958">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0083052ba474d728b64eb6f8a434e04_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMi02LTEtMS0xNDI1MQ_3d6411d3-a79a-4846-af24-d8212ef5b2e6">220,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1613835ee0c640bca59673be80f4f805_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMi04LTEtMS0xNDI1MQ_7b08244d-8055-41b4-8509-ab1f5744ee1a">164,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926f7d0db6594babacd270a64a40aa1c_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMi0xMC0xLTEtMTQyNTE_8ea6f080-1fb5-4061-8a3b-a28aa6eabc1c">55,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e5abb84f7e7474bb50314ab8d17a743_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMy0yLTEtMS0xNDI1MQ_8da6e422-ea9e-48c8-967d-02963008eda3">43,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c3746cf4a004a759993958c2357d3f8_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMy02LTEtMS0xNDI1MQ_5b361b7d-459e-4bcc-97ea-634b37e6912c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4389a97a55544668bcf3bf8164728b95_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMy0xMC0xLTEtMTQyNTE_8955754e-a216-4108-b7c8-5be95b8d1404">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c3746cf4a004a759993958c2357d3f8_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNC02LTEtMS0xNDI1MQ_05a5c9b5-c45f-4702-a439-3d9ba1f93040">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4389a97a55544668bcf3bf8164728b95_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNC0xMC0xLTEtMTQyNTE_0d4b42e8-747a-4d3f-95b2-9f3949779ec6">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net exercise of common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e5abb84f7e7474bb50314ab8d17a743_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNS0yLTEtMS0xNDI1MQ_80302e02-e7f7-440c-99bb-9aab06bee872">22,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4389a97a55544668bcf3bf8164728b95_D20200101-20200331" decimals="-3" format="ixt:fixed-zero" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNS0xMC0xLTEtMTQyNTE_8c4ad7ae-d192-40c9-ab6f-a731f6df60d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3af59f4ffa848f3b05b4d67819e988c_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNi04LTEtMS0xNDI1MQ_9a7a295a-8740-4e0b-a9c1-82655b3a76ab">5,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4389a97a55544668bcf3bf8164728b95_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNi0xMC0xLTEtMTQyNTE_2e44a171-4e2c-46e4-bebd-00faed96b029">5,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March&#160;31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id832ab757594443da2a42bdc495255a8_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNy0yLTEtMS0xNDI1MQ_b25a34aa-3577-495e-bdfc-548121dbc3bf">12,627,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id832ab757594443da2a42bdc495255a8_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNy00LTEtMS0xNDI1MQ_145421c2-317e-40f7-9c31-b2f95c6b5dc0">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee14b6a111af4fb7b7d7e961b7df5732_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNy02LTEtMS0xNDI1MQ_d124d4e5-ee8d-4261-822d-fe1f1cb8a6e7">220,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie69e6ffa9ddd45f28e8ec1e038f2bb90_I20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNy04LTEtMS0xNDI1MQ_f0afd335-5a03-4c51-9144-63f47ebf8fec">170,165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcbd85df5b8d470087005bf4782dd47b_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNy0xMC0xLTEtMTQyNTE_0364f262-4edd-4d4a-bbbc-4c040480c6e9">50,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b61faa063d54a29ac1703f1598a4fe4_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfOC0yLTEtMS0xNDI1MQ_fadcb7a1-60f7-44f0-826a-381424cdc5db">3,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia15f05a146964743a0c788d2aded9cd2_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfOC02LTEtMS0xNDI1MQ_834db91b-2889-4338-887d-4e55bbdacc1a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e4ee09dca43adb7ec755e1cbaea6a_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfOC0xMC0xLTEtMTQyNTE_b8ba1f27-0f0e-48e9-aceb-788643d9c91d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia15f05a146964743a0c788d2aded9cd2_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfOS02LTEtMS0xNDI1MQ_bb6f2e90-cb8e-4c5e-9668-5cf235ee72c5">647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e4ee09dca43adb7ec755e1cbaea6a_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfOS0xMC0xLTEtMTQyNTE_fbca2ae4-e2b3-442b-992a-54e1d41e298f">647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b61faa063d54a29ac1703f1598a4fe4_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTAtMi0xLTEtMTQyNTE_5b27adc8-b8f8-46d9-b568-9e364ea1bdff">9,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia15f05a146964743a0c788d2aded9cd2_D20200401-20200630" decimals="-3" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTAtNi0xLTEtMTQyNTE_84632be8-e765-43a6-b39c-ee5f8837a2d0">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e4ee09dca43adb7ec755e1cbaea6a_D20200401-20200630" decimals="-3" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTAtMTAtMS0xLTE0MjUx_468b8839-605a-4201-95f3-0b6b26de8a10">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d3b0ea347dd4649be1e8b2d457be919_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTEtOC0xLTEtMTQyNTE_baad6397-5417-468b-90a4-4bceea8c3d64">3,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i151e4ee09dca43adb7ec755e1cbaea6a_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTEtMTAtMS0xLTE0MjUx_092bf707-401e-415a-9508-7b83a1d83b43">3,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i891b142b8c174aee9f36273d0c239eda_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTItMi0xLTEtMTQyNTE_64562b6c-a80e-4ef3-9c18-757aa04b77c7">12,640,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891b142b8c174aee9f36273d0c239eda_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTItNC0xLTEtMTQyNTE_a3cfd6ac-fd40-4c9d-ab6b-a23334f37cee">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cf656e94ec9450e9b8db4d75b446d2a_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTItNi0xLTEtMTQyNTE_591c8351-8315-449f-bcbd-6a10c97dd2d4">221,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icff8ea4afd2e46bca741e9b8f9cd26d0_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTItOC0xLTEtMTQyNTE_88511874-7bfb-4e24-a8f7-a5b2482dc75c">173,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38324ce009649c99841caeaeeee19c9_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTItMTAtMS0xLTE0MjUx_ab125a33-f6fe-4dd6-b629-6c7550d03a5a">47,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic20ea53b78964d2eb61a34f2189b8a76_D20200701-20200930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTMtMi0xLTEtMTQyNTE_057db732-ac03-4e47-b630-fff7eaf7712c">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTMtMTAtMS0xLTE0MjUx_07046172-b923-4d47-90ae-760f2ea9df6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic20ea53b78964d2eb61a34f2189b8a76_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTQtMi0xLTEtMTQyNTE_44f19778-7012-4391-abc8-a0be6a24426d">11,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i737254d4d9d1414da6159fa82388a520_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTQtNi0xLTEtMTQyNTE_eec5b7dc-8ec8-4a0f-984e-e87c02069bac">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTQtMTAtMS0xLTE0MjUx_535a348f-5d1f-4f88-bf46-f39d0e50beec">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i737254d4d9d1414da6159fa82388a520_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTUtNi0xLTEtMTQyNTE_5d4a48f5-baf7-4ae5-bb3d-12a60dc9ec8b">799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTUtMTAtMS0xLTE0MjUx_916522af-eebf-461c-8e19-edaaf072eec0">799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67c6964d373248dabdf6084b560f6710_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTYtOC0xLTEtMTQyNTE_850f542b-74c7-4327-a2e8-0d301d6daf5e">4,308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTYtMTAtMS0xLTE0MjUx_8529d478-c0de-4a66-ac5e-0e063166f5c5">4,308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia257328b72b043bdad0caeccbdd70e27_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTctMi0xLTEtMTQyNTE_4e222f1d-d808-4acf-9724-9cb4bb1eaeba">12,652,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia257328b72b043bdad0caeccbdd70e27_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTctNC0xLTEtMTQyNTE_00a69569-73e8-4a19-b4f1-78956497d20a">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb83497be17d4a9bbbde5ed69cb45bc3_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTctNi0xLTEtMTQyNTE_9040d97a-c79f-4705-b490-061734b488df">222,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i597e2d4f562748d496c7e6c7f253459c_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTctOC0xLTEtMTQyNTE_bf7c300d-717c-4564-a0d2-cae7e8ca4494">177,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6b787c0885415b85652bbc5e484066_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTctMTAtMS0xLTE0MjUx_910db57c-ad2a-44b6-9915-e50138302f92">44,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Unaudited Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNC02LTEtMS0xNDI1MQ_7bd1c223-5e7c-4c41-8ed3-5e052a570177">19,798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNC04LTEtMS0xNDI1MQ_8846a210-13b7-4ee7-9592-f78b3933e227">13,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNi02LTEtMS0xNDI1MQ_d598c22d-385c-45a3-9193-52fd43f8465a">656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNi04LTEtMS0xNDI1MQ_0fa28731-8a7e-42cd-aea9-6686ec9973dc">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNy02LTEtMS0xNDI1MQ_11958e31-a506-4a04-85c0-35f9229537f5">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNy04LTEtMS0xNDI1MQ_9c3bb8fc-a7fa-4a5c-aed8-47c0c1a206d0">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfOC02LTEtMS0xNDI1MQ_6c5599cc-077d-4447-a089-616a4c267d6e">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfOC04LTEtMS0xNDI1MQ_8d146e74-f3bb-453b-9d13-c7fd293cce70">397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTAtNi0xLTEtMTQyNTE_df7adbe9-c1ab-41fd-8d80-a795ecac0af5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTAtOC0xLTEtMTQyNTE_0ade7ffd-5df0-46f8-ae36-aad1f42d7ee1">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTItNi0xLTEtMTQyNTE_8cbd4d77-390e-40c7-a161-fc24f17c17e9">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTItOC0xLTEtMTQyNTE_9b647380-8d2f-4c4b-a096-fb4716b8addd">1,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTQtNi0xLTEtMTQyNTE_20882d2b-17fc-4636-b37c-8c251eecf638">300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTQtOC0xLTEtMTQyNTE_478e2d00-842a-47c4-9888-6387d5e75a7e">3,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTUtNi0xLTEtMTQyNTE_9193400a-d3ee-458c-acb3-3b7edd4d248a">1,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTUtOC0xLTEtMTQyNTE_28ba691d-8986-4a2e-9243-877df1b31826">1,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTYtNi0xLTEtMTQyNTE_cf6c12da-3f21-43a0-a705-346c3544a26c">167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTYtOC0xLTEtMTQyNTE_92a8f624-a8a0-4482-a1ab-507eb4919875">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTctNi0xLTEtMTQyNTE_cb5a681d-b29c-4a84-9524-997bff70b844">1,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTctOC0xLTEtMTQyNTE_b89bbd54-145b-461b-a52a-cc5e4c5d887e">781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTgtNi0xLTEtMTQyNTE_b301df98-e66f-4c30-a5db-769a1812b9eb">538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTgtOC0xLTEtMTQyNTE_8bcfd82f-c3e9-4857-960e-53416ab751c5">1,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjAtNi0xLTEtMTQyNTE_3fb871ac-872d-452a-9a3a-5dcee45b6e24">14,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjAtOC0xLTEtMTQyNTE_d75f2909-6ed9-4d95-82cc-5aef97f611a5">10,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjItNi0xLTEtMTQyNTE_851a682d-d9c1-4e1a-8536-38ba5f61692b">1,306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjItOC0xLTEtMTQyNTE_da83b899-87ca-4e99-9dda-507f100cc139">450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjMtNi0xLTEtMTczMTg_61cd6f11-2c5f-4c5b-86a1-a6d7a52bb817">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjMtOC0xLTEtMTczMTg_e2f0ab0f-1ebe-4569-987e-1c5e58b0961e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjYtNi0xLTEtMTQyNTE_c9a012d6-efff-4c33-bff5-9600bea50fd8">1,356</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjYtOC0xLTEtMTQyNTE_d17315d4-ccb0-47b0-81a6-54962babc687">450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjgtNi0xLTEtMTQyNTE_a01603d5-6787-40b1-86b3-a825d022788c">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjgtOC0xLTEtMTQyNTE_b1948f21-7d1d-4f4a-802b-70cd3e9965d5">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from common stock issued under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjktNi0xLTEtMTQyNTE_5b55b8f6-5a0e-4dc8-836b-57446a1a1bd6">390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjktOC0xLTEtMTQyNTE_160e657b-0a69-41b7-bfdd-f43851e524f1">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzAtNi0xLTEtMTQyNTE_e3404931-bb99-4328-9195-a6e849dcbd9d">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzAtOC0xLTEtMTQyNTE_cda80da9-7f90-4ae7-88e2-fa158de42f0f">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payment on capital lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzEtNi0xLTEtMTQyNTE_cf94458c-c746-4dfa-97d3-ab3e7468d9b1">343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzEtOC0xLTEtMTQyNTE_e4b73ae3-a23c-47f9-9264-3a041ce0ecf5">187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from Paycheck Protection Program loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromBankDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzItNi0xLTEtMTQyNTE_12a09497-fdf0-42ac-af2b-5708f7b34290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromBankDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzItOC0xLTEtMTQyNTE_76781f17-599a-4f86-9ec5-c60ac82497ef">2,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of Paycheck Protection Program loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RepaymentsOfBankDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzMtNi0xLTEtMTQyNTE_dd305cbc-e765-48ea-80e4-85ad3b92a854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzMtOC0xLTEtMTQyNTE_10c91063-b2a4-46f7-ae03-6ab337db489c">2,865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock in public offering, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzUtNi0xLTEtMTQyNTE_0e71baec-139e-4cac-9f6e-aacb0ac0d2e0">69,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzUtOC0xLTEtMTQyNTE_d0c30049-d6df-4477-b0f1-4d4ef4e40e95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of issuance costs related to public offering</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzYtNi0xLTEtMTQyNTE_9d16ac9e-7bd1-40e4-947c-435731d77492">4,407</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzYtOC0xLTEtMTQyNTE_dc01a75b-86ed-4e5b-b5f2-ceff2c016fd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDItNi0xLTEtMTQyNTE_bdf97383-dee8-4a25-80be-81131f3d0963">64,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDItOC0xLTEtMTQyNTE_bda14993-b78c-46f8-8a5a-6bd7844e3204">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDMtNi0xLTEtMTQyNTE_b09ba1ae-a2a4-4c3f-9077-393c6048b39f">49,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDMtOC0xLTEtMTQyNTE_0706caf5-4fe0-454e-9e41-eb4edbb79934">10,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDQtNi0xLTEtMTQyNTE_4a4a786d-d97a-436b-bd97-30901a6b8dd5">57,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926f7d0db6594babacd270a64a40aa1c_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDQtOC0xLTEtMTQyNTE_4c57a72b-38a7-4caa-8f7b-642759864645">72,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDUtNi0xLTEtMTQyNTE_52c2c745-b5ee-431b-8f96-bb94a67e46aa">106,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6b787c0885415b85652bbc5e484066_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDUtOC0xLTEtMTQyNTE_241c45db-8c80-4cbd-be37-d42a4be766c4">61,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDctNi0xLTEtMTQyNTE_b3010cd4-1a19-40f2-95fe-9c08f16bfbe7">1,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDctOC0xLTEtMTQyNTE_f3434c9b-fb37-4168-b0bb-27aa8d12e233">1,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment purchased under capital lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="exdx:EquipmentPurchasedUnderCapitalLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNTAtNi0xLTEtMTQyNTE_19fdecce-5826-4f7e-a1a5-8262c06c6ed0">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" name="exdx:EquipmentPurchasedUnderCapitalLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNTAtOC0xLTEtMTQyNTE_b98ce3e8-270f-4566-8528-8dd3d89bec5d">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs incurred, but not paid, in connection with capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNTItNi0xLTEtMTQyNTE_81979997-bc1a-4700-acc8-bbaf13029c4f">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNTItOC0xLTEtMTQyNTE_42f4c3fd-a384-46ff-a12c-ede29ce00daa">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred offering costs reclassified to equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" name="exdx:DeferredOfferingCostsReclassifiedToEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNTYtNi0xLTEtMTQyNTE_f344f28b-d299-4266-bc2a-9f5c9a3c1d7f">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="exdx:DeferredOfferingCostsReclassifiedToEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNTYtOC0xLTEtMTQyNTE_56412c01-cc95-4b7a-bfb6-d2b2847ea901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_31"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Financial Statements</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zMS9mcmFnOmQwYzQ4MTdhYTJkOTQzNzRiY2JlOTg4OWM1ZTA1ZGRmL3RleHRyZWdpb246ZDBjNDgxN2FhMmQ5NDM3NGJjYmU5ODg5YzVlMDVkZGZfMjIwNQ_a95eb388-e70d-4531-a5ff-ebecbc1197b4" continuedAt="i92f3909e29e240988f01f16dc99aea49" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i92f3909e29e240988f01f16dc99aea49"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exagen Inc. (the Company) is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At September&#160;30, 2021, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zMS9mcmFnOmQwYzQ4MTdhYTJkOTQzNzRiY2JlOTg4OWM1ZTA1ZGRmL3RleHRyZWdpb246ZDBjNDgxN2FhMmQ5NDM3NGJjYmU5ODg5YzVlMDVkZGZfNjE4_c9b889b6-0872-4701-ab5f-25c70c2764a9">106.8</ix:nonFraction> million and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zMS9mcmFnOmQwYzQ4MTdhYTJkOTQzNzRiY2JlOTg4OWM1ZTA1ZGRmL3RleHRyZWdpb246ZDBjNDgxN2FhMmQ5NDM3NGJjYmU5ODg5YzVlMDVkZGZfNjU1_57d183ba-c092-4b69-9e3d-8ba2fd897139">201.1</ix:nonFraction> million. Since inception, the Company has financed its operations primarily through a combination of equity financings of common stock and private placements of preferred securities, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div></ix:continuation><div id="i774bc25129df4ef1954bdef4e9d46c8a_34"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjExOTg_adccba18-1def-4505-9e26-8715b922fb95" continuedAt="ic87ad343e288408b8f579c65226e2355" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ic87ad343e288408b8f579c65226e2355" continuedAt="i1bff3d9abb2541068a4bfb12e113b9f2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed balance sheet as of September&#160;30, 2021, the condensed statements of operations and the condensed statements of stockholders' equity for the three and nine months ended September&#160;30, 2021 and 2020 and cash flows for the nine months ended September&#160;30, 2021 and 2020 and the related footnote disclosure are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all normal adjustments, necessary for the fair presentation of the Company's financial position as of September&#160;30, 2021 and its results of operations for the three and nine month periods presented. The results for the nine months ended September&#160;30, 2021 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. These unaudited condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements for the year ended December 31, 2020, included in its Annual Report on Form 10-K filed with the SEC on March 16, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1bff3d9abb2541068a4bfb12e113b9f2" continuedAt="i21dfdb557a6d47079622ba88339f6924"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the fair value of financial instruments measured at fair value, the recoverability of its long-lived assets (including goodwill) and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDg_60f2d053-4a82-4f52-a2fa-97fc2f0a0f1b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. <ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjExOTU_d93a2d9e-f09b-4d04-97e7-cd299ce0b9e3" continuedAt="i3ecff12ba1b043db864d23ac950415fb" escape="true">For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</ix:nonNumeric></span></div><ix:continuation id="i3ecff12ba1b043db864d23ac950415fb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3af039dd0a6148ce8a2372743552eacf_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfMy0yLTEtMS0xNDI1MQ_03312126-a202-4ee9-94e3-518bdde0ff33">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1482dea3ca984bc698a8c00feba5b0fa_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfMy00LTEtMS0xNDI1MQ_17d04fc9-7ad1-4c32-8cf4-240c6492be3c">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2256d5cb9fa4792ae30bcc04579ae40_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfMy02LTEtMS0xNDI1MQ_6dbbd7c5-2715-4a2e-a1ab-586921887c78">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i532b378bfbdf4cd2ac330f10eff25f42_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfMy04LTEtMS0xNDI1MQ_635584e9-ca31-4a1d-bc44-4ece38521197">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i471234789a8b480e9e42bf570277a680_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNC0yLTEtMS0xNDI1MQ_ce374ae4-8647-40ab-a0db-fba1836d7509">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06dd18b2d2b343c5a26465304ea780b8_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNC00LTEtMS0xNDI1MQ_7151a08e-6045-4860-ad00-da7e5c7c9d3d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53c032eb6d0b41fb85a0f9de89ed5b66_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNC02LTEtMS0xNDI1MQ_c5895e7e-6b35-46e1-b0f9-b3d662c82af0">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1391ad143fa64151bce6d46f029b004f_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNC04LTEtMS0xNDI1MQ_1682b6c4-fe0d-4a37-af4e-10e7a0a7d6cd">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e3015ebd247430c8146f56ddd283df1_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNS0yLTEtMS0xNDI1MQ_43d3d963-4e79-458e-a6dd-f3f98a6cddaa">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f9ec400fb2f4a7c83cf5e1252a8e58a_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNS00LTEtMS0xNDI1MQ_22045694-cbd0-44bd-b8c2-44b8113c72e5">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a4923ef3b1c4f67843da57220a877ba_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNS02LTEtMS0xNDI1MQ_21a3d045-35f0-4c6d-9fd2-c00307d9aac1">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i382b42bc67f14a9790ebce32e9cde082_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNS04LTEtMS0xNDI1MQ_42df5b98-6e2c-4b7a-95d8-7ae2ec9429f6">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1b6e104b9dc4b7b9d1a57af719a5906_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNy00LTEtMS0xNDI1MQ_72fd32c1-9efd-4d1f-ba7c-0b79c4d7c792">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc633231ef254f659288a9bd53f5fed1_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNy04LTEtMS0xNDI1MQ_0e295459-7a30-46fb-99f6-133411136c55">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e7b412022ff4e3881bf05b1500b0b9c_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjNlZmJiOTk1ZDExMjQ2YzlhNDAwMWYzYjYzN2IxMjdjL3RhYmxlcmFuZ2U6M2VmYmI5OTVkMTEyNDZjOWE0MDAxZjNiNjM3YjEyN2NfMy00LTEtMS0xNDI1MQ_3e65c265-636a-4640-884c-7514958d5d5a">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8e464ebc33994daf93b13d1aacd0c6b1_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjNlZmJiOTk1ZDExMjQ2YzlhNDAwMWYzYjYzN2IxMjdjL3RhYmxlcmFuZ2U6M2VmYmI5OTVkMTEyNDZjOWE0MDAxZjNiNjM3YjEyN2NfMy02LTEtMS0xNDI1MQ_c1d9b4f1-9bfb-4530-86d1-d7484a22c8e6">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib10bc762d1904afc912369ca9320983f_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjNlZmJiOTk1ZDExMjQ2YzlhNDAwMWYzYjYzN2IxMjdjL3RhYmxlcmFuZ2U6M2VmYmI5OTVkMTEyNDZjOWE0MDAxZjNiNjM3YjEyN2NfNC00LTEtMS0xNDI1MQ_d3d1ada0-cf88-4a78-939d-b3f6d4f104ee">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7da4f398eb84cc8b9c54e850f5e3930_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjNlZmJiOTk1ZDExMjQ2YzlhNDAwMWYzYjYzN2IxMjdjL3RhYmxlcmFuZ2U6M2VmYmI5OTVkMTEyNDZjOWE0MDAxZjNiNjM3YjEyN2NfNS00LTEtMS0xNDI1MQ_a8bb28ee-b45a-4dbd-a3c7-fb34d5b757b4">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1641e7630f2d462fa941ca0b1795bd39_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjNlZmJiOTk1ZDExMjQ2YzlhNDAwMWYzYjYzN2IxMjdjL3RhYmxlcmFuZ2U6M2VmYmI5OTVkMTEyNDZjOWE0MDAxZjNiNjM3YjEyN2NfNS02LTEtMS0xNDI1MQ_ed08041b-361a-427d-a48d-9d7aef90f566">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2021 and 2020, approximately <ix:nonFraction unitRef="number" contextRef="if553089e6f8e49f48b85aaa4c21bacc6_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMzM3Mg_58b81fb4-091d-48c2-9042-50c13fa87361">81</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i05c71c56629c42628c1e160c2c7fab30_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMzM3OQ_e31bf86f-85f6-4dd6-a357-9b02b4d29ab8">68</ix:nonFraction>%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test. For the nine months ended September&#160;30, 2021 and 2020, approximately <ix:nonFraction unitRef="number" contextRef="i902bd1d2194847388e05b8182f07579d_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMzUxMA_eeedf216-a2c5-4c38-a750-20f98ba9bd12">81</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="iac2947a35f6742c3829e243519fdfaff_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMzUxNw_070f9503-3f5d-4214-b279-c61e9ee8b25d">71</ix:nonFraction>%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on key suppliers for certain laboratory materials. For the three months ended September&#160;30, 2021 and 2020, approximately <ix:nonFraction unitRef="number" contextRef="iabaa81a5a2494069ab337806bdab2015_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTA5OTUxMTY0OTExMQ_47aa9b6d-aa89-415c-8953-7134b15a6892">95</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2d91998ff2db475f802cdcc0275405f9_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTA5OTUxMTY0OTExOQ_60c64fec-562d-4630-8b71-40c5e9793033">98</ix:nonFraction>%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. For the nine months ended September&#160;30, 2021 and 2020, approximately <ix:nonFraction unitRef="number" contextRef="i5b61d7a18e7e4264848ef8479c9fd3dc_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTA5OTUxMTY0OTIzMQ_4656bedd-589c-4665-89e1-076eb5d9b691">96</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i6c77f758beca4e84a48c2c0f4e371cde_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTA5OTUxMTY0OTIzOQ_cba1d6b7-8a83-47bb-9bf6-059029cb6634">97</ix:nonFraction>%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDk_71a17f84-fb93-422c-9542-31231b933b2a" continuedAt="i6198ab98807e45ddbc8f8d3033e23013" escape="true">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i21dfdb557a6d47079622ba88339f6924" continuedAt="ic5f31fb019074c68bc160c96fc1a38cd"><ix:continuation id="i6198ab98807e45ddbc8f8d3033e23013"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ba9e492d61a4b95bb9150e34f4662f5_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfMy0yLTEtMS0xNDI1MQ_c7e7f378-7148-4a8d-850f-18eaf2d96618">6,910</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3ac17784114e34ab6fe76435aa264d_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfMy00LTEtMS0xNDI1MQ_07aba1a3-ebb1-48b3-8550-f3b7ed6071e9">5,749</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb26b0130c94f85a59a9057df4cadf4_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfMy02LTEtMS0xNDI1MQ_04ddefa0-5b63-4662-bcb1-f2a7d3f37187">20,318</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0ae534cbe04b29aefafcd8deda24a7_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfMy04LTEtMS0xNDI1MQ_ab8ed310-7f6b-4c7e-ad7a-3cab07405f45">15,949</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eaf63e0a6474648a8bbe8a5cf999092_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNC0yLTEtMS0xNDI1MQ_b4a99878-f32b-4cb8-a2b8-ced5f10f509b">2,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca0f5525e5e4b3685ab76f896c7eb7b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNC00LTEtMS0xNDI1MQ_4163a0bc-eeb8-46db-8043-fae8b1217d5b">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac1adb571402442b9b60c2ec86d410e8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNC02LTEtMS0xNDI1MQ_c32e06b4-8254-4df7-b39d-36b77a6b491d">6,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89043fe0d8d347c681da5ba35f7a67d0_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNC04LTEtMS0xNDI1MQ_7096f9bc-b3a2-4a9b-8a99-3ee5b665e8dd">6,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic59266bd338a4b6aaf33bc9b4f62065e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNS0yLTEtMS0xNDI1MQ_2196b742-38aa-41da-a829-bef14bd9a6f3">2,346</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idab63119e003452c826621bb5adad62e_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNS00LTEtMS0xNDI1MQ_3ecc2ee9-1cce-4ba9-b200-e67c918f2f66">1,260</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i712be5f8ad6d44689ef58bcfe6a5f73d_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNS02LTEtMS0xNDI1MQ_7c67c75e-525e-4bd7-8709-121b247e506e">6,738</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba8282bb0c74750a2f12b06a4d5062d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNS04LTEtMS0xNDI1MQ_8897f53d-84fc-4a01-82ed-42038de0817b">3,088</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if283cd72fcc34fcbb5110f8be286419a_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNi0yLTEtMS0xNDI1MQ_0b81fe71-b5ed-4ce8-aa86-0462ffdc7176">265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c61873a8b5e47a0bc7654ef13e90434_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNi00LTEtMS0xNDI1MQ_cd4f7120-3253-4d65-b2a7-52792aae04fa">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d956d84424450187b7bff38697c856_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNi02LTEtMS0xNDI1MQ_092321fd-10a5-49bd-a03b-2a142101ae9f">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b978a372f504f7b8ec73f8e9f98c5af_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNi04LTEtMS0xNDI1MQ_ca84699e-e59a-4742-8037-80ed0a26381e">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607600e57bc24ec88574eed626560514_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNy0yLTEtMS0xNDI1MQ_f1ae569f-ca2c-4f75-8d00-4bf2f6d5d3ac">400</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb722c1180814c33b2ae495db1c4747d_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNy00LTEtMS0xNDI1MQ_c54589d0-0b39-465c-b637-65a51f5a9ec5">1,347</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d2aea57de8408b815a41b955b60d80_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNy02LTEtMS0xNDI1MQ_4fb2d6f4-239c-4aa4-af2d-c467676495de">1,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i477e8dec7f57476099590b6983065827_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNy04LTEtMS0xNDI1MQ_44fa22bf-ddc9-4e84-9e63-bf8c474df304">3,398</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfOC0yLTEtMS0xNDI1MQ_0b60576e-0686-4446-ac36-b5d96d892e07">12,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfOC00LTEtMS0xNDI1MQ_864fb3cb-732b-4c93-822f-11790607035d">10,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfOC02LTEtMS0xNDI1MQ_fb70b857-8880-49c4-8cad-eb123170f802">35,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfOC04LTEtMS0xNDI1MQ_8d7c63c3-b59a-4572-bb8d-1af4c1483b06">29,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMTA_368043e7-3b0d-4afa-9a60-9102a06d8f7e" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDA_f554cae1-5724-412f-ae95-5d9c141bbc49" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into an arrangement with a financial institution with which it has an existing banking relationship whereby, in exchange for the issuance of corporate credit cards, the Company agreed to obtain a $<ix:nonFraction unitRef="usd" contextRef="ic49699145b6345228d52c3faecb8df97_I20161231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfNjI4Mw_d3fe8da0-0c75-4e21-9dc2-9d67fb57433d">0.1</ix:nonFraction> million certificate of deposit with this financial institution as collateral for the balances borrowed on these credit cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDE_0f8642a6-7f38-4d28-8b0b-b657794e6ae6" continuedAt="i383db9c558a94a85971be9f43747610c" escape="true"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDE_f50178ea-0327-440a-8da5-d899c141e530" continuedAt="ica3f43b3a384478d9cb488c0b9b22759" escape="true">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic5f31fb019074c68bc160c96fc1a38cd" continuedAt="i57236c31d9404e96b4708dc9fdcaf9da"><div><ix:continuation id="i383db9c558a94a85971be9f43747610c"><ix:continuation id="ica3f43b3a384478d9cb488c0b9b22759"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjQ0ZGNlM2E4YzU1ZTRmZGE5ZmIyNGFjNjdmNjg4NzdjL3RhYmxlcmFuZ2U6NDRkY2UzYThjNTVlNGZkYTlmYjI0YWM2N2Y2ODg3N2NfMi00LTEtMS0xNDI1MQ_efa728ff-7c3d-44eb-a2e5-2d8e2358f763">106,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjQ0ZGNlM2E4YzU1ZTRmZGE5ZmIyNGFjNjdmNjg4NzdjL3RhYmxlcmFuZ2U6NDRkY2UzYThjNTVlNGZkYTlmYjI0YWM2N2Y2ODg3N2NfMi02LTEtMS0xNDI1MQ_475649e3-5e9e-453b-b1ef-13788e9ccaf8">57,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjQ0ZGNlM2E4YzU1ZTRmZGE5ZmIyNGFjNjdmNjg4NzdjL3RhYmxlcmFuZ2U6NDRkY2UzYThjNTVlNGZkYTlmYjI0YWM2N2Y2ODg3N2NfMy00LTEtMS0xNDI1MQ_cb68c9eb-51df-4d00-a8bd-206b092677e3">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjQ0ZGNlM2E4YzU1ZTRmZGE5ZmIyNGFjNjdmNjg4NzdjL3RhYmxlcmFuZ2U6NDRkY2UzYThjNTVlNGZkYTlmYjI0YWM2N2Y2ODg3N2NfMy02LTEtMS0xNDI1MQ_87f68823-b2ee-495a-ae71-2dd994076c73">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjQ0ZGNlM2E4YzU1ZTRmZGE5ZmIyNGFjNjdmNjg4NzdjL3RhYmxlcmFuZ2U6NDRkY2UzYThjNTVlNGZkYTlmYjI0YWM2N2Y2ODg3N2NfNC00LTEtMS0xNDI1MQ_a5a6292b-d57e-4fdd-b672-a13345d94584">106,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjQ0ZGNlM2E4YzU1ZTRmZGE5ZmIyNGFjNjdmNjg4NzdjL3RhYmxlcmFuZ2U6NDRkY2UzYThjNTVlNGZkYTlmYjI0YWM2N2Y2ODg3N2NfNC02LTEtMS0xNDI1MQ_d4525aa7-5896-4493-a54b-e47e83a0876f">57,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjExOTY_cd725306-5a97-4992-84a5-f3c478d4dd1f" escape="true"><div style="margin-top:16pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janssen Promotion Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into a co-promotion agreement (as amended from time to time, the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. In August 2021, the Company and Janssen mutually agreed to terminate the Janssen Agreement effective on August 31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Janssen Agreement, the Company was responsible for the costs associated with its sales force over the course of such co-promotion. Janssen was responsible for all other aspects of the commercialization of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company was entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for that quarter over a predetermined baseline. For the first and second quarters of 2020, the tiered promotion fee ranged from $<ix:nonFraction unitRef="usd" contextRef="i2bd2168bca1e4040a9da3b4ab26b86cf_I20200630" decimals="0" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTAxNzE_cd53d6c6-882d-4118-849f-6c2fd9f1f7e6"><ix:nonFraction unitRef="usd" contextRef="ie23ea36541924557943e2430c72ae778_I20200331" decimals="0" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTAxNzE_f315b38f-2c10-46d0-9de3-565f781bcb36">750</ix:nonFraction></ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i94231fb385924cf282805bc752ae2a94_I20200331" decimals="0" format="ixt:num-dot-decimal" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTAxNzc_4bbea50f-e7f8-4912-90de-888642a79742"><ix:nonFraction unitRef="usd" contextRef="idbf4e5e1265e49b0b09d773e4c783692_I20200630" decimals="0" format="ixt:num-dot-decimal" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTAxNzc_92b78a90-829d-4b99-a6c1-877997778c33">1,250</ix:nonFraction></ix:nonFraction> per prescription over a predetermined baseline. Due in part to COVID-19, in June 2020, the Janssen Agreement was amended to adjust the predetermined average baseline for the third and fourth quarters of 2020. The Janssen Agreement was further amended in June 2020 and December 2020 to adjust the predetermined average baseline for prescribed units for the quarters ending December 31, 2020 and March 31, 2021 and was subject to further adjustment under certain circumstances. In June 2021, the Janssen Agreement was again amended to proportionally increase the baseline for prescribed units for the quarter ended June 30, 2021 to reflect the addition of certain geographies to the sales territories covered by the Janssen Agreement. For the first and second quarters of 2021, the Company was entitled to an amended tiered promotion fee ranging from $<ix:nonFraction unitRef="usd" contextRef="i82e30d87f5d0467ebb7ed83b6b3c099f_I20210630" decimals="-2" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTEwMjg_940e4fff-0a0e-4edf-8989-3d57c13cf045"><ix:nonFraction unitRef="usd" contextRef="id0b1bd5bd7b9482894c0d0ddb344acf9_I20210331" decimals="-2" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTEwMjg_e9b2d36b-3d41-4884-b5ef-0833f53129c3">500</ix:nonFraction></ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="ib3d980d0bd964d458411201e56f11d8c_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTEwMzQ_1aa491bd-877d-4c5a-a4c9-145ffd65c2d9"><ix:nonFraction unitRef="usd" contextRef="i4f0d37e10e73443eb87f20a4a6c4f420_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTEwMzQ_539e30b3-7301-4c9d-9783-9170aa278921">1,000</ix:nonFraction></ix:nonFraction> per prescription based on the incremental increase in total prescribed units, and the Company was entitled to receive a promotion fee of at least $<ix:nonFraction unitRef="usd" contextRef="i82e30d87f5d0467ebb7ed83b6b3c099f_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="exdx:JointVentureQuarterlyPromotionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTExODI_40fdf31b-ec47-4c32-b484-e07d6ef45c47"><ix:nonFraction unitRef="usd" contextRef="id0b1bd5bd7b9482894c0d0ddb344acf9_I20210331" decimals="-5" format="ixt:num-dot-decimal" name="exdx:JointVentureQuarterlyPromotionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTExODI_69b38540-654c-4db2-a808-fa46285f2ebc">0.3</ix:nonFraction></ix:nonFraction>&#160;million, but capped at <ix:nonFraction unitRef="number" contextRef="idf76918b1cb142d5a91a6c2666125f62_I20210630" decimals="INF" name="exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTEyMDA_213e44a3-3072-4841-952b-cc4ba7bafb71"><ix:nonFraction unitRef="number" contextRef="i756e9691fbec4232a2a72550fe8827ce_I20210331" decimals="INF" name="exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTEyMDA_ba931e00-371f-4401-a77f-5809673bede8">10</ix:nonFraction></ix:nonFraction>% above the adjusted predetermined baseline. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i57236c31d9404e96b4708dc9fdcaf9da" continuedAt="ia44387aa0a3e489d9a0cf9ccd4b62e13"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the termination of the Janssen Agreement on August 31, 2021, the Company became entitled to receive an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i6f41e1bfc70949dc928fce12adebe052_I20210930" decimals="-5" name="exdx:JointVentureTerminationConsiderationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTEzNTQ_5515ce57-6f2c-4943-8bf8-763906e98594">0.6</ix:nonFraction> million in consideration. Pursuant to the terms of the termination, the Company is restricted from promoting any other biologic or Janus kinase inhibitor used for treatment of indications covered by the Janssen Agreement without first obtaining Janssen's written consent until May 31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's obligations relating to sales and co-promotion services for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were a series of single performance obligations since Janssen simultaneously received and consumed benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations was based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit since the Amended Janssen Agreement is cancelable. The Company recognized co-promotion revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="icfc7b19c5d514b50b41cc32aa3d11d39_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTIyODM_4a970ad4-5de5-4df0-9785-6d5fdbb54a56">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic01c383878c04180a2854e8bd4bd7dbb_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTIyOTg_6ee9f2ca-56d7-4a4d-bc21-bb64de53c1a2">1.3</ix:nonFraction> million during the three months ended September&#160;30, 2021 and 2020, respectively. The Company recognized co-promotion revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="i7580dedc91584d4f98d22c663e83c737_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTI0Mjc_49ac68d4-5860-4c0f-960f-e5111acc8e28">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3fbce269e861429686eecad63a7ac8d9_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTI0NDI_026a87f4-101a-4dc9-b4a3-498feffc1083">3.4</ix:nonFraction> million during the nine months ended September&#160;30, 2021 and 2020, respectively. The related expenses for marketing SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are included in selling, general and administrative expenses and are expensed as incurred.</span></div><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjExOTc_d9c74aa3-f513-4557-9126-c10b9ee90f86" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMTE_e4190ced-b479-4275-9204-ed9d955a2ae5" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $<ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTMyMDI_5a22a67d-c918-40af-8d7e-8cff837bb5eb">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTMyMTc_fbb6e342-d0c1-424f-9e92-35c33310e82f">0.3</ix:nonFraction> million for the three months ended September&#160;30, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTMyODY_d82ad4a5-6657-405b-9c64-958a024a480f">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTMzMDE_35652ef2-9f10-4584-92e3-077f5fe6900f">0.9</ix:nonFraction> million for the nine months ended September&#160;30, 2021 and 2020, respectively, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDQ_ca3b34e2-8000-4947-b510-5f68a16c1817" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $<ix:nonFraction unitRef="usd" contextRef="id46550cb6dd04983b799689bf77cb356_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTM2Njg_d993a6ee-8729-4f26-828a-5645addd8eaf">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i34ca585728074c7dbf14fb4257e9689b_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTM2NzU_62cf3242-ce29-4747-84c5-9f7bae9e0861">0.4</ix:nonFraction> million for the three months ended September&#160;30, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="if963174f2eb741b98f44a7603f0a3e37_D20210101-20210930" decimals="-5" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTM3MzY_635969a5-f4a9-4909-aebe-f9886e54e5da">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibc8a6c3b9a71449e81982ff6c411d4e5_D20200101-20200930" decimals="-5" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTM3NTE_7f7cc310-2459-433d-89dd-dd96c3c0616f">1.1</ix:nonFraction> million for the nine months ended September&#160;30, 2021 and 2020, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:EmployeeStockOwnershipPlanESOPPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDU_5c71184d-f35c-4785-8d5f-0426bc6fc750" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was <ix:nonFraction unitRef="number" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTQ4ODE_95fc6255-4bfc-4d8c-a9fc-5f8a33e61e7e">zero</ix:nonFraction>, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on the grant date and generally vest from the grant date in <ix:nonFraction unitRef="installment" contextRef="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjE5OTAyMzI3Nzk1OA_c2003199-26b0-4ece-8414-5746f6b9b911">four</ix:nonFraction> equal annual installments subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's common stock is determined by using the closing price of its common stock on the corresponding date.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia44387aa0a3e489d9a0cf9ccd4b62e13" continuedAt="i6eda70c7384a4a02b30e71c2f0023f59"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjExOTE_0805dfcc-97bb-4e62-bf70-6a4692ab5dfb" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDI_ee9115f3-470d-4916-8c6e-8761231aed7c" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares in 2021 used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three and nine months ended September&#160;30, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDY_807e7a5c-446e-43a5-8f91-90071ed87626" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c552639d72a4d1586237a5c1c0e6160_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNC0yLTEtMS0xNDI1MQ_fb68b698-8e06-4045-861b-c968a51ef425">409,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8d669ae291047919c778bbafa987721_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNC00LTEtMS0xNDI1MQ_9ffff3ae-6a45-4d5e-ace5-bc0badddb63d">426,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf6b4d792a8b4d7aba9272a67325b8b7_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNC02LTEtMS0xNDI1MQ_4c47de2e-a686-4990-a32e-ce1573f1df57">409,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica1cd48a7054411c9b4601c8284a7b57_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNC04LTEtMS0xNDI1MQ_1614a796-a16d-4d27-968b-d4ea4f392c88">426,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90cc78dc6aae4cdcaf1d24b138a2cb0b_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNS0yLTEtMS0xNDI1MQ_27d5eaa9-92dc-4f15-8ce0-b87a03ae24b7">2,067,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e8e3ebf57ba4b84974afb49d0bb404e_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNS00LTEtMS0xNDI1MQ_4a4705da-8f61-4278-a15b-cef454291a62">1,975,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf4fcbdc1b4745a5b33f78a2ba491dc3_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNS02LTEtMS0xNDI1MQ_544bc947-0b96-411d-b272-235fbe1c4285">2,067,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1367b76ff734867a343920922f694fd_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNS04LTEtMS0xNDI1MQ_ba6a4d13-7478-4b67-bbbb-dac6efc870b3">1,975,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia703865d1c1e42238e72cf40c966acff_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNi0yLTEtMS0xNDI1MQ_f162b016-4d82-4e37-8a63-ad5de9bee0e2">403,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic41c409fd996414ca1c565c3fb9e700a_D20200701-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNi00LTEtMS0xNDI1MQ_bfd180c7-c8c1-4737-ab51-ecfa5e453e70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a41951c3b0c4a48a5ed985502dfd9de_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNi02LTEtMS0xNDI1MQ_b627be07-7ca0-4dd5-a702-9bb49932ee7f">403,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36ed70cc5c794512b4fad8285454fe80_D20200101-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNi04LTEtMS0xNDI1MQ_340c1690-69cb-463d-92f0-3d22c7e16ca1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7bdcbd2fc6414ea79b1193e5620bf1a9_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNy0yLTEtMS0xNDI1MQ_b69df5b7-eb69-440c-a185-73dfb6a0efd3">4,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i489e0e440e7f4dcc98e8fdbfdd3625bb_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNy00LTEtMS0xNDI1MQ_09dc0f0f-8e90-4e48-8536-fd98cbc10361">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f11a04ba9ab4c488c85cd2feab5f19c_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNy02LTEtMS0xNDI1MQ_8c63d88d-4308-44ee-aedc-a1883dccb67e">4,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9aeb5900bd34680b034242eb67e265a_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNy04LTEtMS0xNDI1MQ_f8f99982-ff97-4ef8-9f6a-8a2688101de1">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfOC0yLTEtMS0xNDI1MQ_68c3c78d-0fe3-45ff-ae98-0e071f10ed5c">2,883,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfOC00LTEtMS0xNDI1MQ_fe1b672b-5a96-48f2-b131-c3db1b965ce3">2,405,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfOC02LTEtMS0xNDI1MQ_d527e85b-cb40-478f-8b52-b876b3632536">2,883,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfOC04LTEtMS0xNDI1MQ_48edd6c0-d095-4038-824e-f162fdd48236">2,405,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Assistance Grant Income</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance grants which are unconditional when received and intended to compensate for expenses incurred or replace lost revenue are recognized when those expenses are incurred or during the period that lost revenue is experienced, and the net amount is included in other income in the accompanying condensed statements of operations.</span></div><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDc_72608a2b-09a4-4c11-91fc-c0ccccc156bb" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, <ix:nonFraction unitRef="segment" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTc5NDA_602d663c-2c5a-43c5-af42-79a4e9f0c343">one</ix:nonFraction> operating segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjExOTI_fe4d438c-0e6a-4bb2-87ce-9642c5ca1e2c" continuedAt="i4e77470a6e234736aeeda21c2d1f9f6b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6eda70c7384a4a02b30e71c2f0023f59"><ix:continuation id="i4e77470a6e234736aeeda21c2d1f9f6b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Leases&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: Targeted Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to early adopt this ASU as of January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its condensed financial statements.</span></div></ix:continuation></ix:continuation><div id="i774bc25129df4ef1954bdef4e9d46c8a_37"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfNzc1_758713c0-3157-406c-b2fe-11d6d1f3005f" continuedAt="i886446206fca470b9a6bb7b37fcf3a16" escape="true">Other Financial Information</ix:nonNumeric></span></div><ix:continuation id="i886446206fca470b9a6bb7b37fcf3a16" continuedAt="ie141e9dbe1a54907b347e9c8a2da83f7"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfNzc2_cedd683a-dd60-456f-a1f5-aded8f0faf44" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfMS0yLTEtMS0xNDI1MQ_8fbb1f86-a2b4-42c8-b48f-a660ff52f7c9">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfMS00LTEtMS0xNDI1MQ_cb519d08-7fdd-4154-9042-955c244537e2">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" name="us-gaap:PrepaidRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfMi0yLTEtMS0xNDI1MQ_d00a6a5a-dae4-45c4-99cc-27bf6bd6543d">54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" name="us-gaap:PrepaidRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfMi00LTEtMS0xNDI1MQ_e8c8852f-27fc-4bbf-b70f-a8b3190ad857">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="exdx:PrepaidMaintenanceAndInsuranceContracts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfMy0yLTEtMS0xNDI1MQ_68201592-2f8b-4f29-9972-0d30734ede69">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="exdx:PrepaidMaintenanceAndInsuranceContracts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfMy00LTEtMS0xNDI1MQ_04c5e7f1-3c67-466b-995b-8533b888a130">2,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfNC0yLTEtMS0xNDI1MQ_43a283e8-87f4-4694-aff5-04b9b3b341f8">301</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfNC00LTEtMS0xNDI1MQ_e14f963d-4983-4fbc-96fc-0549f05d8229">659</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfNS0yLTEtMS0xNDI1MQ_2ff8a6f5-e777-4e5c-9d2c-3cb61d7099b2">2,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfNS00LTEtMS0xNDI1MQ_8cd36909-601f-492f-b66c-1f3064c938d2">4,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfNzc3_7304438f-e98f-4455-8d1b-3db215a351ed" continuedAt="i1451325c3b0e4d76a4e00cb44cff2980" escape="true">Property and equipment consist of the following (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie141e9dbe1a54907b347e9c8a2da83f7"><div><ix:continuation id="i1451325c3b0e4d76a4e00cb44cff2980"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe2dbff76584751aa65bc9192aca7f8_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfMS0yLTEtMS0xNDI1MQ_74c37015-6562-49fd-b6c5-b83461d89408">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91495a4d15cc42a9a43bf2c45f36cb29_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfMS00LTEtMS0xNDI1MQ_def4c23b-5466-44f4-803c-103e353392c5">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i062b3ce256a24e639baceecc90b79e9d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfMi0yLTEtMS0xNDI1MQ_9e181668-f5d4-497d-9c19-30f6f34b20a3">4,100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009c796a34f14a8489e678bd5e7ba7e7_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfMi00LTEtMS0xNDI1MQ_dd24aaca-2090-4de5-97d2-4d52518205bc">2,679</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i638a2a722ce94f7fbd4ee6222f3fec82_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfMy0yLTEtMS0xNDI1MQ_f4518df4-71cd-40dd-8f20-66e75e4a32ba">1,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3c67b740ab54e61a5a9b343990c65fb_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfMy00LTEtMS0xNDI1MQ_0e844e1e-2bf3-44f7-a9a4-7b93f3ad9c9a">927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa5972febc9459da204c8686e539242_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfNC0yLTEtMS0xNDI1MQ_c2b7f0cb-2fd5-4e9b-8ece-47a1422a11e7">1,141</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4d4d2d813904871b8dc03c5d28b5913_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfNC00LTEtMS0xNDI1MQ_ba312a47-0eb1-4bc8-b049-949581ffdee2">1,072</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a156c330594b2b9417a57e1bc8ad88_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfNS0yLTEtMS0xNDI1MQ_bb99aa83-aff0-42eb-b005-0ea807270b0f">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05e6cdd6406045d0a32cecdb01802bcc_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfNS00LTEtMS0xNDI1MQ_f8af1db8-1bd6-49ac-bcb8-8a043fcdf081">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfNi0yLTEtMS0xNDI1MQ_74493b23-4114-4a73-af2a-8278ebdcfcc2">7,043</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfNi00LTEtMS0xNDI1MQ_e05d3a47-32ad-494b-b97f-f840531d2e3c">5,043</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfNy0yLTEtMS0xNDI1MQ_0e36d12a-7b67-4bc9-af27-55169a751213">3,597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfNy00LTEtMS0xNDI1MQ_fcd1bb9a-ec6f-4598-ba80-3cfc478cba79">2,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfOC0yLTEtMS0xNDI1MQ_cf6b97d1-2c2a-4ad1-b8eb-2cec84f00e0a">3,446</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfOC00LTEtMS0xNDI1MQ_d96575e5-da16-4b89-afe7-4efeb13647bb">2,102</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the three months ended September&#160;30, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfMzY1_a0568bc6-9ce7-4f53-98f3-ad002668ef52">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfMTA5OTUxMTYyODU2OA_918243de-ef59-4587-81db-a54aaa5ab393">0.1</ix:nonFraction> million, and for the nine months ended September&#160;30, 2021 and 2020, was approximately $<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfNDM3_8c164c6a-a216-47ee-b987-44bed9ac1bb6">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfNDUy_d74e07a9-799a-494c-84ef-0bea1328a2ec">0.4</ix:nonFraction> million, respectively. At September&#160;30, 2021 and December 31, 2020, the gross book value of assets under capital lease was $<ix:nonFraction unitRef="usd" contextRef="i603ccc7a3961470db626807866947b63_I20210930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfNTQ3_5ce027d7-c45c-48d3-a4e7-4d87c2e86cc4">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i55f4a3829c4446e58090abccb942038c_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfNTYy_f5d2632b-7eb6-42ea-a563-644208b40e51">1.2</ix:nonFraction> million, respectively, and is classified in "Laboratory equipment" in the table above.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Other Current Liabilities</span></div><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfNzc4_a1a3eba5-c85c-492d-b434-4569c6bd867c" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfMS0yLTEtMS0xNDI1MQ_8ab3e052-f01b-47bc-bd25-842b09d911b6">3,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfMS00LTEtMS0xNDI1MQ_ac7b66db-2217-45d7-bfe5-c43dbcfc4420">3,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfMy0yLTEtMS0xNDI1MQ_3096a76a-b499-4d10-87f0-fa0592792432">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfMy00LTEtMS0xNDI1MQ_0cb34d05-80cd-4e43-8dcd-e116f3189bf4">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" name="exdx:AccruedPurchaseGoodsAndServicesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfNC0yLTEtMS0xNDI1MQ_8938c5c8-ce62-4b43-83b5-3c830ec38e10">765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" name="exdx:AccruedPurchaseGoodsAndServicesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfNC00LTEtMS0xNDI1MQ_6d9b8638-dee5-4882-97aa-ff08a474be05">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfNS0yLTEtMS0xNDI1MQ_84f5086b-95de-4086-9cf6-4e3a9b8bd921">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfNS00LTEtMS0xNDI1MQ_58cc4173-64bf-4746-9212-40b46a91cbb5">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" name="exdx:AccruedLiabilitiesClinicalStudyCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfNi0yLTEtMS0xNDI1MQ_9e9532ca-dfb5-4cb4-bcf7-fc879fe26460">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" name="exdx:AccruedLiabilitiesClinicalStudyCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfNi00LTEtMS0xNDI1MQ_0f173817-788e-44d5-be70-28cae3c60666">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" name="us-gaap:CapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfNy0yLTEtMS0xNDI1MQ_41468c95-87ab-434d-9f91-f66be5797453">586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" name="us-gaap:CapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfNy00LTEtMS0xNDI1MQ_d2e763f6-f4af-41ec-8c1f-e81bb6eb5f06">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfOC0yLTEtMS0xNDI1MQ_5272da8a-ec17-4b2c-8867-5d5cdf99431c">616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfOC00LTEtMS0xNDI1MQ_43f11bcf-319a-4818-8a6c-2b5ef77fe3e4">953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfOS0yLTEtMS0xNDI1MQ_10d7d22d-2732-49f6-b457-4d0d2060d41e">6,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie450365559dd46d89f2259410ea12471_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfOS00LTEtMS0xNDI1MQ_7a5998ff-df77-4b2b-aa57-34241e738c6d">5,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_40"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfNDkyNw_8979e66d-181d-49bc-90e7-94812cdff1dd" continuedAt="ic77ef03fa97b483ab220657c19a31c9d" escape="true">Borrowings</ix:nonNumeric></span></div><ix:continuation id="ic77ef03fa97b483ab220657c19a31c9d" continuedAt="i8837f770b7c64493b0358df19d83d7f7"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Term Loan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus) and borrowed $<ix:nonFraction unitRef="usd" contextRef="i597de8f2704546a48516c3951933870b_D20170901-20170930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTk3_d24e89d5-03cc-4cd7-b90b-5a1a2a8a5fbd">20.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie56e06d7b68849928e2fe39a26f73f85_D20170901-20170930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMjAx_2ba7cb0f-9e15-491f-adf4-e72037d03fdb">17.8</ix:nonFraction> million of which was immediately used to repay the Company's existing loan with Capital Royalty Partners II L.P. and its affiliates. On December&#160;7, 2018, the Company borrowed an additional $<ix:nonFraction unitRef="usd" contextRef="i467bcd314d89428f837631f14432ed8c_D20181207-20181207" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMzg1_014aa446-f9a5-483f-a19b-4a762ceac07e">5.0</ix:nonFraction> million under the 2017 Term Loan. At September&#160;30, 2021, <ix:nonFraction unitRef="usd" contextRef="i05b9273e32ae45169280d1693bd07c66_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfNDIx_4d562fa9-b4bc-4b47-8543-b61355651e28">no</ix:nonFraction> additional amounts remain available to borrow under the 2017 Term Loan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company executed the First Amendment to the Loan and Security Agreement (the 2017 Loan Amendment). The interest rate on all borrowings under the 2017 Loan Amendment is <ix:nonFraction unitRef="number" contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfNjgx_9505889a-4ecd-42f5-be36-976d3f8f05e2">8.5</ix:nonFraction>%, of which <ix:nonFraction unitRef="number" contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130" decimals="INF" name="exdx:DebtInstrumentStatedInterestRatePaidInKind" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfNjk0_9bef45ab-d77f-406e-a9b0-f54f9d225740">2.0</ix:nonFraction>% is paid in-kind in the form of additional term loans (PIK Loans) until December of 2022, after which interest accrues at an annual rate of <ix:nonFraction unitRef="number" contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfODM2_9505889a-4ecd-42f5-be36-976d3f8f05e2">8.5</ix:nonFraction>%. The Company has estimated the effective interest rate of this loan to be approximately <ix:nonFraction unitRef="number" contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130" decimals="2" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfOTI3_b4ff9fb4-3b97-4d46-8f30-fc70caf2adf5">10</ix:nonFraction>%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the 2017 Loan Amendment will be repaid in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTExOQ_3937bf68-a790-4703-a448-0929f254939d">twenty-four</span> equal monthly installments commencing in December 2022. Upon repayment of the final installment under the 2017 Loan Amendment, the Company is required to pay an additional fee of $<ix:nonFraction unitRef="usd" contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFeeAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTI5Ng_92e05323-02ca-4045-a08f-d72b1ad8f169">1.0</ix:nonFraction> million. This obligation is being accreted into interest expense over the term of the 2017 Loan Amendment using the effective interest method. For each of the three months ended September&#160;30, 2021 and 2020, the Company issued PIK Loans totaling $<ix:nonFraction unitRef="usd" contextRef="i44af8d7a747943749fac22ffa3dd323f_D20200701-20200930" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTUxMQ_963dab66-c210-457a-b6be-d82d91c63fe4"><ix:nonFraction unitRef="usd" contextRef="i98f4b404a7a746b88f1807dade1827bc_D20210701-20210930" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTUxMQ_d3f681a0-c8ab-4a1d-8ff6-4539adbf2b74">0.1</ix:nonFraction></ix:nonFraction> million. For each </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8837f770b7c64493b0358df19d83d7f7"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the nine months ended September&#160;30, 2021 and 2020, the Company issued PIK Loans totaling $<ix:nonFraction unitRef="usd" contextRef="iab6affb37170402fbe076933203ab105_D20210101-20210930" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTYwNw_8c9c5dc8-f9d1-47a0-8c3e-ac23da1a9e23"><ix:nonFraction unitRef="usd" contextRef="i1ec99d0d3d254c33997d3054789d8af4_D20200101-20200930" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTYwNw_c5b80f73-9d0e-4930-a908-97fd06c0e7b9">0.4</ix:nonFraction></ix:nonFraction> million. In October 2021, the Company executed the Second Amendment to the Loan and Security Agreement (the Second Loan Amendment), discussed in Note 10 to these financial statements, below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Loan Amendment requires a prepayment premium of <ix:nonFraction unitRef="number" contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130" decimals="INF" name="exdx:DebtInstrumentPrepaymentPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTY3MQ_77082d4e-c071-46cb-84fe-f5ca3b4279a8">2</ix:nonFraction>% of the aggregate outstanding principal. The prepayment premium decreases by <ix:nonFraction unitRef="number" contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130" decimals="INF" name="exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTc1MA_282244c0-1f81-4cf1-a414-657757891a2b">1</ix:nonFraction>% on November 19, 2021 and 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Loan Amendment is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the 2017 Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis. The consequences of failing to achieve the performance covenant may be cured if, within sixty days of failing to achieve the performance covenant, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The 2017 Loan Amendment requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $<ix:nonFraction unitRef="usd" contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130" decimals="-5" name="exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMjk3Mw_04aa74a0-1f2e-4048-a0d8-95af278332f4">2.0</ix:nonFraction> million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021, the Company was in compliance with all covenants of the 2017 Loan Amendment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an event of default in any of the 2017 Loan Amendment covenants, the repayment of the 2017 Loan Amendment may be accelerated, and the applicable interest rate will be increased by <ix:nonFraction unitRef="number" contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130" decimals="INF" name="exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfNDM0NA_3012d540-c5f8-410d-b836-ea7afce0665a">4.0</ix:nonFraction>% until the default is cured. Although repayment of the 2017 Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the 2017 Loan Amendment due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Minimum Payments on the Outstanding Borrowings</span></div><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfNDkyOA_89071401-627c-4980-a712-97c79dbefe8f" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RhYmxlOjIzNzkwMjUzYmYxZjQyMTRhZGVjMDE1NjI2MjBiZGYyL3RhYmxlcmFuZ2U6MjM3OTAyNTNiZjFmNDIxNGFkZWMwMTU2MjYyMGJkZjJfMS0yLTEtMS0xNDI1MQ_ea057c2d-7fd1-425c-9069-c587bcef5cd4">446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RhYmxlOjIzNzkwMjUzYmYxZjQyMTRhZGVjMDE1NjI2MjBiZGYyL3RhYmxlcmFuZ2U6MjM3OTAyNTNiZjFmNDIxNGFkZWMwMTU2MjYyMGJkZjJfMi0yLTEtMS0xNDI1MQ_60a868f5-2906-4264-ab74-18367463b0c7">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RhYmxlOjIzNzkwMjUzYmYxZjQyMTRhZGVjMDE1NjI2MjBiZGYyL3RhYmxlcmFuZ2U6MjM3OTAyNTNiZjFmNDIxNGFkZWMwMTU2MjYyMGJkZjJfMy0yLTEtMS0xNDI1MQ_5acb039d-e772-45cb-9f0e-ce510b39ab3d">15,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RhYmxlOjIzNzkwMjUzYmYxZjQyMTRhZGVjMDE1NjI2MjBiZGYyL3RhYmxlcmFuZ2U6MjM3OTAyNTNiZjFmNDIxNGFkZWMwMTU2MjYyMGJkZjJfNC0yLTEtMS0xNDI1MQ_f1954579-b591-4997-a01a-85e8a4cb6863">14,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="exdx:LongTermDebtIncludingUndiscountedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RhYmxlOjIzNzkwMjUzYmYxZjQyMTRhZGVjMDE1NjI2MjBiZGYyL3RhYmxlcmFuZ2U6MjM3OTAyNTNiZjFmNDIxNGFkZWMwMTU2MjYyMGJkZjJfNi0yLTEtMS0xNDI1MQ_3b55ab89-2dc1-46e5-8623-ea6025b920c4">33,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RhYmxlOjIzNzkwMjUzYmYxZjQyMTRhZGVjMDE1NjI2MjBiZGYyL3RhYmxlcmFuZ2U6MjM3OTAyNTNiZjFmNDIxNGFkZWMwMTU2MjYyMGJkZjJfOC0yLTEtMS0xNDI1MQ_d45f4aa2-79ac-4acd-a6fa-ec614d88890d">224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="exdx:LongTermDebtUndiscountedInterestAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RhYmxlOjIzNzkwMjUzYmYxZjQyMTRhZGVjMDE1NjI2MjBiZGYyL3RhYmxlcmFuZ2U6MjM3OTAyNTNiZjFmNDIxNGFkZWMwMTU2MjYyMGJkZjJfOS0yLTEtMS0xNDI1MQ_5d9fe093-6b78-4523-af71-2b5107f6596d">5,829</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RhYmxlOjIzNzkwMjUzYmYxZjQyMTRhZGVjMDE1NjI2MjBiZGYyL3RhYmxlcmFuZ2U6MjM3OTAyNTNiZjFmNDIxNGFkZWMwMTU2MjYyMGJkZjJfMTAtMi0xLTEtMTQyNTE_830a1547-3ff3-49b2-9270-873c58f63fc9">27,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfNDYxNQ_6242e679-43be-4a46-bfd4-fe5da42edd17" continuedAt="i6266a6e86211421a90d36a0d2905608d" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i6266a6e86211421a90d36a0d2905608d" continuedAt="i54381b45b0534ff6bc630fd085e6ee07"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company leases office and laboratory space in Vista, California, under leases that expire in January 2026, with an option to extend a portion of the lease for an additional <ix:nonNumeric contextRef="id4f3d87cb19a49f193d7d0107a085292_D20210101-20210930" format="ixt-sec:duryear" name="exdx:OperatingLeasesRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMjM5_5279987c-6230-4e16-8048-d939d98af9f1">5</ix:nonNumeric>-year period. In addition, the Company also leases additional office space in Vista, California, under a lease that expires in January 2026 with an option to extend the lease for an additional <ix:nonNumeric contextRef="if4d48a5110ed4d4291de9e8ecd5f4fe6_D20210101-20210930" format="ixt-sec:duryear" name="exdx:OperatingLeasesRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfNDM0_7cf66950-fd63-4e5d-8325-112db591dcba">5</ix:nonNumeric>-year period. The Company's lease payments under each of these leases are subject to escalation clauses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective on August 23, 2021, the Company entered into a sub-lease agreement for an additional office space in Carlsbad, California. The sub-lease commenced in October 2021 and expires in April 2027. The sub-lease agreement provides for monthly base rent of $<ix:nonFraction unitRef="usd" contextRef="icd4718b3285d4a899f40931cbfe678bf_I20210823" decimals="0" format="ixt:num-dot-decimal" name="exdx:OperatingLeaseMonthlyBaseRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTA5OTUxMTYzMzc3Mw_2c8bbca0-a51d-408d-be25-269cef4b8e22">66,021</ix:nonFraction> which began on October 1, 2021, and such amount shall increase by approximately <ix:nonFraction unitRef="number" contextRef="ia8bc25f7d63f44cea35854b4039d0885_D20210823-20210823" decimals="INF" name="exdx:OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTA5OTUxMTYzMzg0OQ_90f82875-c570-4019-b571-3b93c2e53eee">3</ix:nonFraction>% annually beginning October 1, 2022. The Company is entitled to base rent abatement for a specified period of time which began on November 1, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2021 and 2020, rent expense was $<ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-5" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfNTk4_a15b231c-bed8-47ae-b074-b47bde40c0ec">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-5" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfNjEz_1dd8b8b3-e815-4ac7-bb87-5bd80f8a9bc8">0.3</ix:nonFraction> million, respectively. For the nine months ended September&#160;30, 2021 and 2020, rent expense was $<ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-5" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfNjk0_3965e58a-4d6c-4762-a695-90ef5d407b2c"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-5" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfNjk0_877be5f7-b088-42f1-a349-f6c90fc01f02">0.5</ix:nonFraction></ix:nonFraction> million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related liabilities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition. The acquisition also included amounts that may be due under several licensing agreements. One such license agreement, the license agreement, dated September 13, 2007, between the Company and Prometheus Laboratories, Inc. (the Prometheus License), was terminated by mutual agreement on September 28, 2021. In consideration for terminating the Prometheus License, including with respect to the remaining potential milestone payments thereunder, the Company agreed to pay Prometheus Laboratories, Inc. a fee of approximately $<ix:nonFraction unitRef="usd" contextRef="i43b31315848e4d43901c9f3183cbebb4_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTA5OTUxMTYzMzM3Mw_5025d63e-0b93-4da9-9819-33186220918f">0.1</ix:nonFraction> million and acquired the intellectual property previously licensed to the Company pursuant to the Prometheus Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has ongoing royalty payment obligations of <ix:nonFraction unitRef="number" contextRef="i05fc542a715f42e3aab293e27727085f_I20210930" decimals="3" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTQyNQ_27b26041-df54-4a6d-aff7-bed0d18a35ca">2.5</ix:nonFraction>% on net sales of products which incorporate certain acquired technologies. Future royalties payable under these arrangements are limited to the lesser of (i) an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i3f14904a63b24632b074d2bdb5d4c936_I20210930" decimals="-5" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTYwMQ_31909ca4-40cf-45af-9743-4ced30e13eed">1.2</ix:nonFraction> million (including an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i3f14904a63b24632b074d2bdb5d4c936_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="exdx:AdvancePayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTY0NQ_3990d832-16a5-43e3-8c2a-0ec2f2d36ef9">100,000</ix:nonFraction>) and (ii) the total royalties earned through January 1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements as described above, individual license agreements generally provide for ongoing royalty payments ranging from <ix:nonFraction unitRef="number" contextRef="i408f9d848a9e4b6884930325c910b9b3_I20210930" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTk3Nw_d0413e42-b75f-4033-bfc6-b7262dea4567">1.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia55722d9277e48b09ba4ff1dd33c2c09_I20210930" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTk4Mw_205a6c17-4393-48e3-bade-774c8fe18f8b">3.0</ix:nonFraction>% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when earned and recorded in costs of revenue in the accompanying condensed statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into an exclusive license agreement with Allegheny Health Network Research Institute, or AHN, to obtain an exclusive license to AHN's patent rights in certain inventions, pursuant to which the Company paid AHN an initial license fee of $<ix:nonFraction unitRef="usd" contextRef="i29c2b0bce9e84c2a8890706b191065b5_D20210501-20210531" decimals="-5" name="exdx:LicenseAgreementInitialLicenseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMjQ3Mg_18d609e2-09fb-4750-ad61-676d2b12f89d">0.4</ix:nonFraction> million. In addition, under the terms of the exclusive license agreement, the Company is required to pay the greater of royalties in the low single digits on net sales of diagnostic tests using the assigned patents or a flat annual minimum royalty amount, pending approvals and commercialization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supply Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $<ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-5" name="us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMjk0Ng_a54400e5-09c0-435e-a570-c7ca33a9e013">4.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="-5" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMjk2MQ_f348437d-6827-4751-82fc-8ed49c2a0284">6.0</ix:nonFraction> million for the years ended December 31, 2021 and 2022, respectively, with a <ix:nonFraction unitRef="number" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="2" name="exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMzA0MQ_82c9f75b-24ec-40fa-b140-8ac9276c0c3e">15</ix:nonFraction>% annual increase thereafter through the year ended December 31, 2025.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i54381b45b0534ff6bc630fd085e6ee07"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Obligations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a master research collaboration agreement with AHN, pursuant to which the Company is required to pay AHN a collaboration fee of $<ix:nonFraction unitRef="usd" contextRef="i8141bfc43efa4a6592ea1148f7f0529b_D20210501-20210531" decimals="-5" name="exdx:CollaborationAgreementAnnualCollaborationFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMzMwNQ_8cb77c90-8a32-4ab9-91b9-ca7c61d1c49c">0.4</ix:nonFraction> million for each year during the initial term of the agreement. Collaboration expenses under the master research collaboration agreement were $<ix:nonFraction unitRef="usd" contextRef="i21dbc0462f534175819f4c79dddf82df_D20210701-20210930" decimals="-5" name="exdx:CollaborationAgreementCollaborationExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMzQ1MA_6244baff-7623-417e-9276-9ef617d87f65">0.1</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id0c459a6186e4f998b57dfa0fd36cc51_D20210101-20210930" decimals="-5" name="exdx:CollaborationAgreementCollaborationExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTA5OTUxMTYzMjY0NQ_46c185de-1576-402d-a4fb-c15b5ea3cdae">0.2</ix:nonFraction> for the three and nine months ended September&#160;30, 2021, respectively. Collaboration expenses under the AHN collaboration are included in research and development expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payors and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities.</span></div></ix:continuation><div id="i774bc25129df4ef1954bdef4e9d46c8a_46"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RleHRyZWdpb246M2U4NTBkODJjMTI4NGQ4Y2E3ZWViYmFmNTQyZTMwYzlfMjk4_b148f8ce-5c60-4c83-be3f-3c0d18cb2631" continuedAt="icf33936e2f454c32a345d58560071cef" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="icf33936e2f454c32a345d58560071cef" continuedAt="i3ec19eba48324aa0aeb2dfaa3f573d16"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RleHRyZWdpb246M2U4NTBkODJjMTI4NGQ4Y2E3ZWViYmFmNTQyZTMwYzlfMjk5_7fc41366-034d-4fd4-8c0a-6c2a962a9389" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9675b9781d014000845af2a6c5ce6ab4_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RhYmxlOjMwODQ5MTQ0MGNjYjRmNzliOGQ3ZGQ5OTgzYTVmNDkyL3RhYmxlcmFuZ2U6MzA4NDkxNDQwY2NiNGY3OWI4ZDdkZDk5ODNhNWY0OTJfMy0yLTEtMS0xNDI1MQ_3e39a9e2-76e4-412b-af82-500b3aebdacf">105,679</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic20a022810a34a0e8c547ff3a27e2eff_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RhYmxlOjMwODQ5MTQ0MGNjYjRmNzliOGQ3ZGQ5OTgzYTVmNDkyL3RhYmxlcmFuZ2U6MzA4NDkxNDQwY2NiNGY3OWI4ZDdkZDk5ODNhNWY0OTJfMy00LTEtMS0xNDI1MQ_5de7bc5f-090d-4ba8-a309-0690c2e71462">105,679</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e41083069624d7b86843d65bcb1e246_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RhYmxlOjMwODQ5MTQ0MGNjYjRmNzliOGQ3ZGQ5OTgzYTVmNDkyL3RhYmxlcmFuZ2U6MzA4NDkxNDQwY2NiNGY3OWI4ZDdkZDk5ODNhNWY0OTJfMy02LTEtMS0xNDI1MQ_9e709af3-5da1-4491-b55a-0a9091fdc453">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1907a197b9bf4ca081846376298c2dbc_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RhYmxlOjMwODQ5MTQ0MGNjYjRmNzliOGQ3ZGQ5OTgzYTVmNDkyL3RhYmxlcmFuZ2U6MzA4NDkxNDQwY2NiNGY3OWI4ZDdkZDk5ODNhNWY0OTJfMy04LTEtMS0xNDI1MQ_c26d9045-9f08-4a99-8f42-d6412aa6eba5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id889a74f3c604c9e974adc011ac55e21_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RhYmxlOjExZDE3YjFlMjE0ZDQxMjA4Y2Q4MzUyOTA1N2NiMjU1L3RhYmxlcmFuZ2U6MTFkMTdiMWUyMTRkNDEyMDhjZDgzNTI5MDU3Y2IyNTVfMy0yLTEtMS0xNDI1MQ_f5390699-606c-4c91-baf1-76308e36345e">34,507</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b2aebd9d89a4273b23eaddb67c7187b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RhYmxlOjExZDE3YjFlMjE0ZDQxMjA4Y2Q4MzUyOTA1N2NiMjU1L3RhYmxlcmFuZ2U6MTFkMTdiMWUyMTRkNDEyMDhjZDgzNTI5MDU3Y2IyNTVfMy00LTEtMS0xNDI1MQ_623426f3-dd5e-4bae-80f9-a855f41f89ee">34,507</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0afac1488f04780915c25495618223b_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RhYmxlOjExZDE3YjFlMjE0ZDQxMjA4Y2Q4MzUyOTA1N2NiMjU1L3RhYmxlcmFuZ2U6MTFkMTdiMWUyMTRkNDEyMDhjZDgzNTI5MDU3Y2IyNTVfMy02LTEtMS0xNDI1MQ_a0f5bcb7-051f-469f-8627-9b1af579600f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40bda80a1b244e9fb44a8c2c934a4459_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RhYmxlOjExZDE3YjFlMjE0ZDQxMjA4Y2Q4MzUyOTA1N2NiMjU1L3RhYmxlcmFuZ2U6MTFkMTdiMWUyMTRkNDEyMDhjZDgzNTI5MDU3Y2IyNTVfMy04LTEtMS0xNDI1MQ_61d37b55-4c1b-4b30-993f-3253e7bed9ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3ec19eba48324aa0aeb2dfaa3f573d16">The fair value of the Company's money market funds is based on quoted market prices.</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_49"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfMjU5Ng_79ab03e1-e778-4480-9769-b548b61eaa01" continuedAt="i1cec996164db48c2ba27fc63144fddb4" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i1cec996164db48c2ba27fc63144fddb4" continuedAt="ie1ecfa1e68a44da68a4bbfd9e81a92b0"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2020, the Company filed a registration statement on Form S-3 (the Shelf Registration Statement), covering the offering, from time to time, of up to $<ix:nonFraction unitRef="shares" contextRef="id1d65917be864b4284e3dcea0b13a340_D20201110-20201110" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfMjEz_e8e9a09f-a7b2-431b-8e67-71f0f7f5987f">150.0</ix:nonFraction> million of common stock, preferred stock, debt securities, warrants and units, which Shelf Registration Statement became effective on November 19, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="iba7d0acdfc0f4df5a66f2bb747bb7643_D20210325-20210325" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfNDMx_7db56aa9-cef2-471c-8e8b-95b6fca776f7">4,255,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0ad7af241ac04bb0b5bca5f52f3c3186_I20210325" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfNDkx_2c1594cb-7845-4ed4-a9f1-a0da74f63bcd">16.25</ix:nonFraction> per share. Net proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="iba7d0acdfc0f4df5a66f2bb747bb7643_D20210325-20210325" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfNTU1_b3404ed0-fc11-44df-931c-ee38b7fe9d6f">64.7</ix:nonFraction> million, after deducting underwriting discounts and commissions and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i0ad7af241ac04bb0b5bca5f52f3c3186_I20210325" decimals="-5" name="exdx:StockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfNjQ3_bf3a1670-b3c1-4c32-b3b1-2519ed15579e">4.4</ix:nonFraction> million. The shares were registered pursuant to the Company's Shelf Registration Statement discussed above. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie1ecfa1e68a44da68a4bbfd9e81a92b0"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2021, the Company entered into an exchange agreement (the Exchange Agreement) with an Investor and its affiliates (the Exchanging Stockholders), pursuant to which the Company exchanged an aggregate of <ix:nonFraction unitRef="shares" contextRef="i1381f17c84bb46b99f0deedd39dd8927_D20210622-20210622" decimals="INF" format="ixt:num-dot-decimal" name="exdx:ExchangeAgreementNumberOfSharesExchangedForWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfOTkx_33ba4674-d995-45c6-8737-68c9a7629213">804,951</ix:nonFraction> shares of the Company's common stock owned by the Exchanging Stockholders for pre-funded warrants (the Exchange Warrants) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i08bfaba48e6842479e60870fdf457e2f_I20210622" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfMTE0NA_84409b57-0d7a-48f1-9140-599c9a6389bc">804,951</ix:nonFraction> shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i08bfaba48e6842479e60870fdf457e2f_I20210622" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfMTM4NQ_26fe0d63-c44b-4d80-9060-58029effb637">0.001</ix:nonFraction> per share. The Exchange Warrants do not expire and are exercisable at any time except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than <ix:nonFraction unitRef="number" contextRef="i1381f17c84bb46b99f0deedd39dd8927_D20210622-20210622" decimals="4" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfMTY0Ng_cf5ad683-a95a-4ded-b84a-74ac7e33e9a3">4.99</ix:nonFraction>% of the Company's common stock, which percentage may change at the Exchanging Stockholder's election to any other percentage upon 61 days' notice to the Company. The Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants are classified as equity and the fair value of the Exchange Warrants was recorded as an increase to additional paid-in-capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. As of September&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="INF" format="ixt:fixed-zero" name="exdx:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfMjQzMA_c2afe735-67a7-4067-b9b5-d31970743a0b">none</ix:nonFraction> of the Exchange Warrants have been exercised.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Warrants</span></div><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfMjU5Mw_3f18508d-d10c-49ca-b8bb-1f1a8ab14a9a" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following equity classified warrants to purchase common stock were outstanding as of September&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i383d4094819b45efbea334edd4261fee_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfMS0xLTEtMS0xNDI1MQ_1fc1e605-3c6e-4bda-871c-2fd1b390bdc1">237,169</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i383d4094819b45efbea334edd4261fee_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfMS0zLTEtMS0xNDI1MQ_2c379357-8c26-472c-ad50-2b09339295bb">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i055f44b2d2d645aaa59585abcbde2ce0_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfMi0xLTEtMS0xNDI1MQ_d515dca9-12c2-4438-a43a-701db8f7c100">67,086</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i055f44b2d2d645aaa59585abcbde2ce0_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfMi0zLTEtMS0xNDI1MQ_69ecc69a-2f71-4e85-8fea-6c56aa368b1b">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8744c39e0b4d471aa0dd059af498b3e8_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfMy0xLTEtMS0xNDI1MQ_27aef067-43e2-4816-b005-0e2948cffd2d">131</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8744c39e0b4d471aa0dd059af498b3e8_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfMy0zLTEtMS0xNDI1MQ_0ef433ab-bf6b-4389-9a70-af4d88283124">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51655d8dd5cf4160a3e3c43d9ca5e140_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfNC0xLTEtMS0xNDI1MQ_f17928dd-c50c-4a53-99e1-3ca5935f8a4c">83,778</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i51655d8dd5cf4160a3e3c43d9ca5e140_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfNC0zLTEtMS0xNDI1MQ_c221ef6f-9de3-4573-af40-3f6248334850">14.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ab1059999b0438cb0af5e2cefc99c04_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfNS0xLTEtMS0xNDI1MQ_d558fcfb-f57b-4fd0-8b71-e87c6c14287f">20,944</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3ab1059999b0438cb0af5e2cefc99c04_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfNS0zLTEtMS0xNDI1MQ_776e5768-7bef-47ed-b04d-950f23598e6f">14.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants (Exchange Warrants)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1e027871f3d476fb7a00e85ba9c297c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfNi0xLTEtMS0xNDI1MQ_b00409a7-95eb-4810-8091-61f871fe7274">804,951</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if1e027871f3d476fb7a00e85ba9c297c_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfNi0zLTEtMS0xNDI1MQ_e7a99d8a-e038-4a03-880f-d5a470a7837d">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfNy0xLTEtMS0xNDI1MQ_0ca454a3-0f18-4ea7-8ae2-c49b9a18df7b">1,214,059</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, warrants to purchase common stock were exercised resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfMTA5OTUxMTYzMDUwOQ_591d3357-635b-42c8-bf76-9c7daa5216e9">17,719</ix:nonFraction> shares of the Company's common stock and cash proceeds of an immaterial amount.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_52"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMjkwNw_0099e554-5398-4a23-be8e-0884b0cdf9db" continuedAt="i546d7c870edf4c2ba14963064a61158e" escape="true">Stock Option Plan</ix:nonNumeric></span></div><ix:continuation id="i546d7c870edf4c2ba14963064a61158e" continuedAt="if5f84c4c2daf423d897d369075cb55fb"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Incentive Award Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire <ix:nonNumeric contextRef="ied9309b5ec844d98aad6b3f0e1ae47bb_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfNTA0_12dc9aa7-a405-4d94-9978-5b7aaabde7ce">ten years</ix:nonNumeric> after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally <ix:nonNumeric contextRef="ied9309b5ec844d98aad6b3f0e1ae47bb_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfNjM5_684653d4-168d-4ef7-a25c-d7af32f4dcba">four years</ix:nonNumeric> from the date of grant. As of September&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i1f87200751b54837b785f6f119eae03a_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfNjc2_b4b76d72-0c6d-427e-955a-edc5c224120d">1,139,831</ix:nonFraction> shares of common stock remained available for future awards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Board of Directors adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i813af130085e4bcfa2cc8e3c96aa96f8_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMTA2Mg_45dd8e81-1090-4b49-811a-0b4640b83100">20</ix:nonFraction>% of their eligible compensation. As of September&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i813af130085e4bcfa2cc8e3c96aa96f8_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMTEwNw_5153f024-dfa3-4fff-9638-016814697f93">327,516</ix:nonFraction> shares of common stock remained available for issuance under the ESPP.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if5f84c4c2daf423d897d369075cb55fb" continuedAt="i7c7edd356ea744e1a167d7782e4f88cf"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMjkwMg_21c13f99-d92b-4cfc-87e1-3407c00e605c" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company's 2019 Plan is set forth below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff8e60ce9c594c9aa9741f476323c52a_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfMS0yLTEtMS0xNDI1MQ_70309d9c-3123-4a5a-a0e2-e15eaf27bbd1">1,975,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff8e60ce9c594c9aa9741f476323c52a_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfMS00LTEtMS0xNDI1MQ_f749066b-23a8-417b-830f-b4898e52d514">11.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifa5c746fe4b94017ad86dcc26492fd0a_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfMS02LTEtMS0xNDI1MQ_dd8cf806-1814-4bf2-84fb-c6c111b80fc7">8.71</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff8e60ce9c594c9aa9741f476323c52a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfMS04LTEtMS0xNDI1MQ_7b96fa71-3ddf-48c4-ba68-864413ca7155">6,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfMi0yLTEtMS0xNDI1MQ_4cceae43-d878-46d8-adb1-aaffc7aaca5d">229,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfMi00LTEtMS0xNDI1MQ_837cf226-0508-4230-a747-3e320d60fe17">16.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfMy0yLTEtMS0xNDI1MQ_ddc6e94d-5446-4196-b22b-e59b204e23ad">11,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfMy00LTEtMS0xNDI1MQ_a8c6f1cf-f0f3-475e-92a0-14f87ac20092">7.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNC0yLTEtMS0xNDI1MQ_96cd1343-b4e9-4570-9b3e-f269bcfbd7be">122,435</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNC00LTEtMS0xNDI1MQ_f3fa413b-6139-4075-92fe-0dc4d6365cac">14.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNS0yLTEtMS0xNDI1MQ_04d6b431-370d-4c8a-b645-a5477f06bcf1">4,931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNS00LTEtMS0xNDI1MQ_1fdf5fec-350f-4369-80a4-9639fa10cc0b">21.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNi0yLTEtMS0xNDI1MQ_5c94e070-5012-491a-b364-bb5589176151">2,067,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNi00LTEtMS0xNDI1MQ_b269b0c7-51aa-4782-a17a-95d7de03a89d">12.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNi02LTEtMS0xNDI1MQ_aaddd7ec-d8dc-4ab7-9aff-4be862a10f99">8.14</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNi04LTEtMS0xNDI1MQ_32e1cee4-b565-4c96-91d1-d1a78bb445f3">6,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNy0yLTEtMS0xNDI1MQ_e6b2c422-e20f-4886-badd-cebe576c58f2">2,067,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNy00LTEtMS0xNDI1MQ_d944e6c0-fd94-4a34-a967-fe002e077c60">12.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNy02LTEtMS0xNDI1MQ_d20ab1ee-cf4a-47d4-a850-3b3ae447e555">8.14</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNy04LTEtMS0xNDI1MQ_807c25bf-d23d-4e93-88ae-e56d3b3ed117">6,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfOC0yLTEtMS0xNDI1MQ_1abdb0a2-f214-40fc-80f1-b4a24c11ace6">979,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfOC00LTEtMS0xNDI1MQ_866f4aea-b346-4e14-83f9-dc5a64a59fe4">10.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfOC02LTEtMS0xNDI1MQ_abc8be65-c5a3-4fef-859e-dc160c1f3d68">7.77</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfOC04LTEtMS0xNDI1MQ_48a543d6-ddf0-44b1-a869-2a489cb9dbcb">4,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. As of September&#160;30, 2021, total unrecognized compensation cost related to option awards was $<ix:nonFraction unitRef="usd" contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMTQ5Ng_88bb4f31-ae7d-4286-b95d-653bd62f6848">7.7</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMTU5NQ_0f3ab73c-54aa-459a-8b83-d57a2eb98bba">2.2</ix:nonNumeric>&#160;years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMjkwMw_176d046f-a4ef-4ecb-a2a2-705c695568a0" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd19ac6d04c2437dabe28931d0bda370_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfMS0yLTEtMS0xNDI1MQ_ac7a3939-994d-41a8-bca1-9eafa7e061e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd19ac6d04c2437dabe28931d0bda370_I20201231" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfMS00LTEtMS0xNDI1MQ_e9e2f0a3-6cd4-4f76-b7cb-597b1fd53322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd19ac6d04c2437dabe28931d0bda370_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfMS02LTEtMS0xNDI1MQ_ee9baf93-7bce-4d16-bec7-a1a95052ec69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfMi0yLTEtMS0xNDI1MQ_e36c7d5f-297a-47c7-a0f9-abf7b3b25a7f">422,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfMi00LTEtMS0xNDI1MQ_107bf930-d11f-48eb-8b4b-32903a1ef2f4">16.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfMy0yLTEtMS0xNDI1MQ_29876498-9602-4f71-b942-7faf07609f6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfMy00LTEtMS0xNDI1MQ_fa0b0c51-6923-401a-9029-edebca4f14dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfNC0yLTEtMS0xNDI1MQ_9e7266d6-32bf-4a46-8497-e52ce2cbf274">19,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfNC00LTEtMS0xNDI1MQ_acfdb6d0-231d-41c8-9833-f0b00b7dd526">16.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i76d674daf6484d4dba8d57a883f437de_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfNS0yLTEtMS0xNDI1MQ_c3969152-45ec-4e49-9712-83db6137f800">403,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i76d674daf6484d4dba8d57a883f437de_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfNS00LTEtMS0xNDI1MQ_8fb51480-df78-4784-bbd4-fb18fb4a87fe">16.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d674daf6484d4dba8d57a883f437de_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfNS02LTEtMS0xNDI1MQ_58b25c55-b9f5-41b4-abf4-519593ec15a1">5,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, all of the outstanding restricted stock units are unvested. As of September&#160;30, 2021, total unrecognized compensation cost related to restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="i76d674daf6484d4dba8d57a883f437de_I20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMTg2Ng_8ef5a067-740c-4394-ab8e-9e4d9d381fd8">5.9</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMTk2NQ_15579023-a844-4799-a24b-af14f5eae96c">3.5</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMjkwNA_2d8114a0-1954-430d-9ec0-9934c42853c7" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibef4b05e619f40db9ce589f18c223874_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMi0yLTEtMS0xNDI1MS90ZXh0cmVnaW9uOjk2ZjIyZWY5NmMzMjQ5MjNiMTNhYzMyOWY0NzUwM2E4XzQ_d5b2f675-8397-448a-85c1-bdd2a085d8db">86</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3d30161937ff49a0b250f9c9743eaad5_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMi00LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjY1NThjYTMwZDg0MjQ4MjNhYTI2MzIzNjNhMmEwMjIzXzQ_dd0af9ae-6fc7-4edd-a9ed-7fe165d3079a">52</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMi02LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjVhMTdjNWEwMDdhMzQyNDhiN2IxZTZhNWJjZGQyMjI1XzQ_62b46931-8707-499b-831f-4074189d4422">83</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMi02LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjVhMTdjNWEwMDdhMzQyNDhiN2IxZTZhNWJjZGQyMjI1Xzc_8a5313c1-bb13-493c-ac94-73f9a9b31d8a">86</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic949c32127e144a882f03102ba80d592_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMi04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjlmZmQ2ZWRmYmEyODRmZDliZDI4MjBjOTZlZTE0NjQxXzQ_1a8230c2-a400-48a3-bd43-28f7d9d35ba8">47</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ic949c32127e144a882f03102ba80d592_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMi04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjlmZmQ2ZWRmYmEyODRmZDliZDI4MjBjOTZlZTE0NjQxXzc_b1c1958b-9cd0-4a98-97c7-6595e45dd35c">52</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibef4b05e619f40db9ce589f18c223874_D20210701-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMy0yLTEtMS0xNDI1MS90ZXh0cmVnaW9uOjlhOTQwMjFiNTI1YTQyYjU5ZGVkY2QzOWRjOTQ5Nzk3XzQ_f982e5f7-e8ea-4b28-9b32-b1d1667b4d0b">0.9</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3d30161937ff49a0b250f9c9743eaad5_D20200701-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMy00LTEtMS0xNDI1MS90ZXh0cmVnaW9uOmZmMDU3ODFlYjQ3ZjQxMzE4ZTg3Y2NjMDdlNDY2ZTlkXzQ_3cc87f70-ad8c-4577-ab70-237f178917ef">0.4</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMy02LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjUzOGY3NTk0NTMyZjQ1M2U4NTUyN2I2NjU0NWVhNmM3XzQ_bffd7cfd-2632-4b87-b912-0ccc74866f6b">0.8</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMy02LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjUzOGY3NTk0NTMyZjQ1M2U4NTUyN2I2NjU0NWVhNmM3Xzc_db68adff-9eb7-4e3c-bfb0-e47a467222bc">1.1</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic949c32127e144a882f03102ba80d592_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMy04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjk3OWE4YTQ1YzFlYzQwYmU4MTUzYmU2NDNmYzhjMmFhXzQ_cd8df384-c2c7-49aa-a5b2-aa88e2e71968">0.4</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ic949c32127e144a882f03102ba80d592_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMy04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjk3OWE4YTQ1YzFlYzQwYmU4MTUzYmU2NDNmYzhjMmFhXzc_305ad745-136f-48dd-aefd-22b5695a5e52">1.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibef4b05e619f40db9ce589f18c223874_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNC0yLTEtMS0xNDI1MQ_ff5f67b3-2704-4512-969d-d77ec16cbf7d">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3d30161937ff49a0b250f9c9743eaad5_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNC00LTEtMS0xNDI1MQ_94e01da8-888b-4254-9e71-f3c5aff18b85">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNC02LTEtMS0xNDI1MQ_91c3dee3-645e-4f53-8400-877272194423">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic949c32127e144a882f03102ba80d592_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNC04LTEtMS0xNDI1MQ_eb1737ae-736b-4c2a-b1e4-c7891584f98a">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iec9349a3150a4ff99322fb97e4697704_D20210701-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNS0yLTEtMS0xNDI1MS90ZXh0cmVnaW9uOjYwYTk0YTU0NjNmMzQ2YjVhYjM0NThlODk4OTUzMjUyXzQ_4033f021-bf44-4d73-a73c-51e8bd92f646">5.77</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia972fa811fe848438cbbf17df4213386_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNS00LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjU4ZTRlNmFlZWYyZDQ2NzE5MDEzNDNiMjQxNTdmYzkzXzQ_cb46f2a3-b562-484e-86d7-a8e915a64ccf">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5f5390aa51834b0b9c48b6a1ebb975d1_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNS02LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjVmMzE3ODAxYzBlMjRkNDFiN2JlOGZhZDE4MTQyOTE1XzQ_c04915ff-ade3-4ffa-9d13-133d3124fe34">5.50</ix:nonNumeric>-<ix:nonNumeric contextRef="i7535719e17e343dd934c82c15efb6c7a_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNS02LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjVmMzE3ODAxYzBlMjRkNDFiN2JlOGZhZDE4MTQyOTE1Xzc_49592615-5b2a-4ac2-8e24-fbfdf79c2368">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i35982159cf8245aea8b27f18c2b7c347_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNS04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjFlODc4MDUxYjlkMTQ5ODRiYmRlNzYwMWJiYmEzMzBjXzQ_c3e91ab3-e4cc-483f-adb5-75a1f848b9c7">5.50</ix:nonNumeric>-<ix:nonNumeric contextRef="i64d9f93ee0074786a89f1f8599054033_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNS04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjFlODc4MDUxYjlkMTQ5ODRiYmRlNzYwMWJiYmEzMzBjXzc_60818d4c-a65c-4b9d-a318-6f96325a1ef6">6.08</ix:nonNumeric></span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMjkwNQ_f3418029-fa1d-468e-a678-a4874f782a21" continuedAt="i55f9785092464545b04c15371d56b2d8" escape="true">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7c7edd356ea744e1a167d7782e4f88cf"><div style="margin-top:9pt"><ix:continuation id="i55f9785092464545b04c15371d56b2d8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i812dfaa6798b45bf98314f6d3cb3caf2_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMi0yLTEtMS0xNDI1MQ_03a4ee88-149b-45b1-91a8-6103eab1586f">45</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf397bbee62e4358a29c8fe357195adc_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMi00LTEtMS0xNDI1MQ_5b8bab65-6fee-4bed-b4e2-14c50cc76215">83</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMi02LTEtMS0xNDI1MS90ZXh0cmVnaW9uOmFlZWJkMjdhYmI2NTQ4YjJiMDNiZDA0ZTZiM2JhMzg5XzEwOTk1MTE2Mjc3ODM_4634afcc-25de-4829-8fd8-62a658c12d00">45</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMi02LTEtMS0xNDI1MS90ZXh0cmVnaW9uOmFlZWJkMjdhYmI2NTQ4YjJiMDNiZDA0ZTZiM2JhMzg5XzEwOTk1MTE2Mjc3OTA_3fb8c08d-5c2d-4f99-88e0-0dadaa141921">60</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMi04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOmFlZWM5M2ZkZGM2NzRjODE5NGMxOGY5YjVlM2RhZmE5XzEwOTk1MTE2Mjc3ODY_483ba132-1eaa-4d85-8738-af22413408db">58</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMi04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOmFlZWM5M2ZkZGM2NzRjODE5NGMxOGY5YjVlM2RhZmE5XzEwOTk1MTE2Mjc3OTA_41c26cf7-11a7-475c-9a01-53f4cd3d2007">83</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i812dfaa6798b45bf98314f6d3cb3caf2_D20210701-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMy0yLTEtMS0xNDI1MQ_04708e47-e38d-4a8f-9502-3c85d90e7ad8">0.1</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf397bbee62e4358a29c8fe357195adc_D20200701-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMy00LTEtMS0xNDI1MQ_1c13667e-544d-41b3-b4ce-36ca0eb4805f">0.1</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c1776b0ca2349ccb5b02fae30a4d766_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMy02LTEtMS0xNDI1MQ_23368e46-2d23-4760-923c-102ea4678350">0.1</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMy04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOmQ3OGVmNjUxODg5OTQyN2ZhZGU1YTc0MWVlZTE1NWE1XzEwOTk1MTE2Mjc3ODQ_4668de22-c0a6-4d82-aba6-da98d59f9eaf">0.1</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMy04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOmQ3OGVmNjUxODg5OTQyN2ZhZGU1YTc0MWVlZTE1NWE1XzEwOTk1MTE2Mjc3OTI_2cef7aaf-5d70-48ae-9a5b-d1bfcf7990d6">1.1</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i812dfaa6798b45bf98314f6d3cb3caf2_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfNC0yLTEtMS0xNDI1MQ_9096ffb5-cb33-475e-8b4e-4bd05bb05505">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf397bbee62e4358a29c8fe357195adc_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfNC00LTEtMS0xNDI1MQ_e50e0947-3441-4f9b-bbe1-aa1777f348db">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c1776b0ca2349ccb5b02fae30a4d766_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfNC02LTEtMS0xNDI1MQ_4f0b484d-e4e1-40d5-9e84-88707d28e8c4">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i985d2c00754740a1a75159006860f2f5_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfNC04LTEtMS0xNDI1MQ_606907f4-9719-47a1-ba35-cd0fcdf83407">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i812dfaa6798b45bf98314f6d3cb3caf2_D20210701-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfNS0yLTEtMS0xNDI1MQ_1c53efbc-e3a9-4382-aebf-8f33e7872dcd">0.50</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf397bbee62e4358a29c8fe357195adc_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfNS00LTEtMS0xNDI1MQ_5bba8bf1-251a-4fc6-8674-2ba605a9b6ad">0.50</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c1776b0ca2349ccb5b02fae30a4d766_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfNS02LTEtMS0xNDI1MQ_b45660f4-65d8-43f9-b5b3-cf91b8f4179d">0.50</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i985d2c00754740a1a75159006860f2f5_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfNS04LTEtMS0xNDI1MQ_390dbdca-3013-4b6a-831a-99b4031f3f9c">0.50</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for the ESPP was immaterial for the three and nine months ended September&#160;30, 2021 and 2020. As of September&#160;30, 2021, total unrecognized compensation cost related to stock purchase rights granted under the ESPP was an immaterial amount, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="i6c1776b0ca2349ccb5b02fae30a4d766_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMjY1NA_15f1de80-5278-48b2-9bdf-f781f8c2ec7a">0.4</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMjkwNg_dd78a3cb-9aff-4e41-96ee-07a3d5b02ef0" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438f8b50be854314a57a86231478aeae_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfMi0yLTEtMS0xNDI1MQ_f767645a-53ac-47d6-b247-28c54d92bce4">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d8ea92229ac4b40bb2809f46bc58d7d_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfMi00LTEtMS0xNDI1MQ_4cbbe704-b963-46a0-a24a-d26c01c9cf39">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68fba0d065ad49d59ebd33550ccf06b8_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfMi02LTEtMS0xNDI1MQ_f208dc11-464b-47ec-84bc-6b2b0fdbe8c7">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia119e096fc994ad881c098574fb63096_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfMi04LTEtMS0xNDI1MQ_3f57e8d2-c89b-460d-812b-40cae8a39fa1">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7d648e35d44b77b7fd4855916a6275_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfMy0yLTEtMS0xNDI1MQ_7030b12e-f155-486c-b9dc-b7f2060ee2e2">1,115</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f6449b025d641e0b0375cfa207f3273_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfMy00LTEtMS0xNDI1MQ_bc877a8f-91f4-4fca-8722-fe8bfb6c47b6">710</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ee66c9d6104d338fa41906c77c9c58_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfMy02LTEtMS0xNDI1MQ_5ce5feba-1511-42f9-a4fc-3dda10057b5b">2,955</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3796eb660a4650801221b114877277_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfMy04LTEtMS0xNDI1MQ_31bcf64e-6c8a-419e-8347-8e6f123c23f2">1,696</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefa8fc581abf42a49cbe113470783f21_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfNC0yLTEtMS0xNDI1MQ_bb23df56-bb46-41f6-97ea-9685c60b34ea">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68e692cf8c24949bdf0c1127a4fb582_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfNC00LTEtMS0xNDI1MQ_2edcac08-8dcf-43f3-b0d0-523529057eb4">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dfd57d894e647a88470632fbe75162c_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfNC02LTEtMS0xNDI1MQ_6888c2d8-f2c5-4b14-96a4-8b84ea44fee9">460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035f9bfef7cb4a9193e6fb924522482a_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfNC04LTEtMS0xNDI1MQ_77de442c-13ad-4c35-ad38-2caa8b022f13">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfNS0yLTEtMS0xNDI1MQ_69f76d48-3250-426c-a3f9-d5bf32d37be6">1,354</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfNS00LTEtMS0xNDI1MQ_91f35e2e-ea25-4409-ad49-7731b136b744">799</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfNS02LTEtMS0xNDI1MQ_cf942af4-c49b-461a-b216-de99b34f1714">3,551</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfNS04LTEtMS0xNDI1MQ_91236efa-cb27-42f6-b4a1-b81ef6538255">1,877</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_55"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81NS9mcmFnOmExNWU0YWRhYTI2MzQwYjJiZDE4MjI3MjUyNjk3OGYwL3RleHRyZWdpb246YTE1ZTRhZGFhMjYzNDBiMmJkMTgyMjcyNTI2OTc4ZjBfNDE0MA_93400baf-2cc5-4aa1-840d-c860ae8f9bec" continuedAt="i0470ef5d9f1e4c6ebc295252e827c874" escape="true">COVID-19</ix:nonNumeric></span></div><ix:continuation id="i0470ef5d9f1e4c6ebc295252e827c874" continuedAt="ib06d048c3bd04fd3a7545ac0014bba23"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, due to the worldwide COVID-19 pandemic, the Company experienced a reduction in patient test volumes, delays in patient enrollment in ongoing and planned clinical studies, and delays in the procurement of its testing supplies. In response to the pandemic, the Company has curtailed non-essential employee travel, equipped employees with the ability to work remotely with the exception of clinical laboratory employees, and reduced marketing spend and employee headcount. The full extent to which the COVID-19 pandemic will directly or indirectly continue to impact the Company's business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, including, the success of ongoing vaccination efforts, the emergence and prevalence of variant strains of COVID-19, the institution or reinstitution of shutdowns, "stay-at-home-orders" and other public health measures as well as the related economic impact of these matters on local, regional and international markets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits net operating loss (NOL) carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. The CARES Act did not have a material impact on the Company's effective tax rate or income tax provision for the three months ended March 31, 2020. Under the Tax Cuts and Jobs Act (TCJA), NOLs generated post TCJA were allowed to be carried forward indefinitely but were only allowed to offset 80% of taxable income. As a result of the CARES Act and the change to permit NOLs generated in taxable years 2018, 2019 and 2020 to offset 100% of taxable income, the Company released valuation allowance against its deferred tax assets in the amount of $<ix:nonFraction unitRef="usd" contextRef="ibcbd85df5b8d470087005bf4782dd47b_I20200331" decimals="-5" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81NS9mcmFnOmExNWU0YWRhYTI2MzQwYjJiZDE4MjI3MjUyNjk3OGYwL3RleHRyZWdpb246YTE1ZTRhZGFhMjYzNDBiMmJkMTgyMjcyNTI2OTc4ZjBfMjAxNg_e9085e2f-be46-4386-8191-259cdab28cfd">0.1</ix:nonFraction> million. The release of valuation allowance resulted in a discrete tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i4389a97a55544668bcf3bf8164728b95_D20200101-20200331" decimals="-5" format="ixt:num-dot-decimal" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81NS9mcmFnOmExNWU0YWRhYTI2MzQwYjJiZDE4MjI3MjUyNjk3OGYwL3RleHRyZWdpb246YTE1ZTRhZGFhMjYzNDBiMmJkMTgyMjcyNTI2OTc4ZjBfMjEwMQ_3c3d7ae4-e2de-402e-bc4e-3ceff9ac543d">0.1</ix:nonFraction>&#160;million in the first quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, the Company received $<ix:nonFraction unitRef="usd" contextRef="i402a6e16113b408c83b914eaf5ca9d14_D20200401-20200430" decimals="-5" name="exdx:ProceedsFromGovernmentAssistance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81NS9mcmFnOmExNWU0YWRhYTI2MzQwYjJiZDE4MjI3MjUyNjk3OGYwL3RleHRyZWdpb246YTE1ZTRhZGFhMjYzNDBiMmJkMTgyMjcyNTI2OTc4ZjBfMjE3MQ_a8a1e751-19af-4071-8f13-d992ab52da08">0.7</ix:nonFraction> million of funding under the CARES Act Provider Relief Fund, subject to the Company's agreement to comply with the Department of Health &amp; Human Services' standard terms and conditions. The CARES Act Provider Relief Fund is a federal fund allocated for general distributions to Medicare facilities and providers impacted by the COVID-19 pandemic and is intended to support COVID-related expenses or lost revenue attributable to COVID-19. The funding received is considered a government grant, which is recognized when there is reasonable assurance that the grant will be received and that conditions attached to the grant have been met. During the three and nine months ended September&#160;30, 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930" decimals="-5" name="exdx:ProceedsFromGovernmentAssistance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81NS9mcmFnOmExNWU0YWRhYTI2MzQwYjJiZDE4MjI3MjUyNjk3OGYwL3RleHRyZWdpb246YTE1ZTRhZGFhMjYzNDBiMmJkMTgyMjcyNTI2OTc4ZjBfMjg3NA_47441ead-f9ae-4b99-97a1-f0feaecadbdd">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930" decimals="-5" name="exdx:ProceedsFromGovernmentAssistance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81NS9mcmFnOmExNWU0YWRhYTI2MzQwYjJiZDE4MjI3MjUyNjk3OGYwL3RleHRyZWdpb246YTE1ZTRhZGFhMjYzNDBiMmJkMTgyMjcyNTI2OTc4ZjBfMTA5OTUxMTYzMTkzMw_15239885-a41d-4384-b4f0-912c3de12f47">0.7</ix:nonFraction> million, respectively, due to lost revenue attributable to COVID-19, which is reflected in other income, net, on its condensed statements of operations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="ib06d048c3bd04fd3a7545ac0014bba23"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 16, 2020, the Company entered into a promissory note (the Note) with BOKF, NA dba Bank of Oklahoma (BofO), the lender, evidencing an unsecured loan pursuant to the U.S. Small Business Administration (SBA) Paycheck Protection Program (PPP) of the CARES Act of approximately $<ix:nonFraction unitRef="usd" contextRef="i24ee58a4f9ca4e738b4bacc7d0c3ecff_D20200416-20200416" decimals="-5" name="us-gaap:ProceedsFromBankDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81NS9mcmFnOmExNWU0YWRhYTI2MzQwYjJiZDE4MjI3MjUyNjk3OGYwL3RleHRyZWdpb246YTE1ZTRhZGFhMjYzNDBiMmJkMTgyMjcyNTI2OTc4ZjBfMzI5OA_bb2379e1-5786-4455-970c-f4d107adf29f">2.9</ix:nonFraction> million (the PPP Loan). The Company applied for and received the PPP Loan pursuant to the then published PPP qualification and certification requirements. On April 23, 2020, the SBA, in consultation with the Department of Treasury, issued new guidance that created uncertainty regarding the qualification requirements for the PPP Loan (the New Guidance). In light of the New Guidance, on May 11, 2020, the Company paid off in full the principal and interest on the PPP Loan, resulting in the termination of the Note. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law. It provides additional COVID-19 focused relief and extends certain provisions of the CARES Act. At this time, the Company does not believe that the Consolidated Appropriations Act, 2021 has a material impact on its financial statements.</span></div></ix:continuation><div id="i774bc25129df4ef1954bdef4e9d46c8a_582"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzI3NDg3NzkwNjk3Nzc_42f545c8-5d8a-4581-813a-63aadef8b3fa" continuedAt="id9d1b80d93ff4ea1ac7a20790bd5f322" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="id9d1b80d93ff4ea1ac7a20790bd5f322"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into a lease amendment relating to its existing office space located adjacent to the Company's headquarters. The lease amendment extends the term of such lease from January 2026 to April 2027. The lease amendment provides that the base monthly rent for the leased space shall be $<ix:nonFraction unitRef="usd" contextRef="i70e8b6ad8e4146a199fe29ee3340804a_I20211031" decimals="0" format="ixt:num-dot-decimal" name="exdx:OperatingLeaseMonthlyBaseRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzEwOTk1MTE2Mjg3MjA_be4833e3-d29c-450c-846f-0522a01743c2">22,470</ix:nonFraction> for the <ix:nonNumeric contextRef="ie9f93b64bd374d91a76b68cea11d1efa_D20211001-20211031" format="ixt-sec:durmonth" name="exdx:OperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzE1OTQyOTE4NjA0NjY0_2eb9c580-1f89-4bc7-bd65-6861e36f9c2c">12</ix:nonNumeric>-month period beginning February 2026 and $<ix:nonFraction unitRef="usd" contextRef="i70e8b6ad8e4146a199fe29ee3340804a_I20211031" decimals="0" format="ixt:num-dot-decimal" name="exdx:OperatingLeaseMonthlyBaseRentFirstIncrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzEwOTk1MTE2Mjg4MDU_52fc0412-3455-4770-9ae0-2a5513b3bf4c">23,594</ix:nonFraction> for the period beginning February 2027 through April 2027.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into a fifth addendum to the lease relating to its headquarters. The fifth addendum extends to the term of such lease from January 2026 to April 2027. The fifth addendum provides that the base monthly rent for the leased space shall be $<ix:nonFraction unitRef="usd" contextRef="id84bcf56412d40cbb17dc4a699c488f4_I20211031" decimals="0" format="ixt:num-dot-decimal" name="exdx:OperatingLeaseMonthlyBaseRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzEwOTk1MTE2MjkyMDI_49d08647-b387-4674-b3a9-3b81196319ba">20,084</ix:nonFraction> for the period between February 2026 and April 2027.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into a first addendum to the lease related to its office and laboratory space in the building attached to the Company's existing headquarters. The first addendum extends the term of such lease from January 2026 to April 2027. The first addendum provides that the base monthly rent for the leased space shall be $<ix:nonFraction unitRef="usd" contextRef="i19fdfc2580cb4c58ba25b4bf22f281cb_I20211031" decimals="0" format="ixt:num-dot-decimal" name="exdx:OperatingLeaseMonthlyBaseRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzEwOTk1MTE2Mjk0NzE_c7bd93be-0896-4a3e-9a8c-760d044429cc">14,751</ix:nonFraction> for the period between February 2026 and April 2027.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company and Innovatus entered into the Second Loan Amendment to the 2017 Term Loan, which became effective on November 1, 2021. The Second Loan Amendment amends the 2017 Term Loan by, among other things, (i) decreasing the interest rate on all borrowings to <ix:nonFraction unitRef="number" contextRef="ie47ef4f6de5046f08313d4c7118cd8d2_I20211031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzEwOTk1MTE2MzAzMTc_aa544711-78f8-43d4-b9ac-bd25b9f31153">8.0</ix:nonFraction>%, of which <ix:nonFraction unitRef="number" contextRef="ie47ef4f6de5046f08313d4c7118cd8d2_I20211031" decimals="INF" name="exdx:DebtInstrumentStatedInterestRatePaidInKind" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzEwOTk1MTE2MzAzMzE_66ed7b50-9f2b-4de2-9df8-52bf33b69a0f">2.0</ix:nonFraction>% will be paid-in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until December 2024; after which interest will accrue at an annual rate of <ix:nonFraction unitRef="number" contextRef="ie47ef4f6de5046f08313d4c7118cd8d2_I20211031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzEwOTk1MTE2MzA1MTM_aa544711-78f8-43d4-b9ac-bd25b9f31153">8.0</ix:nonFraction>%; (ii) extending the interest-only period through December 2024 and the maturity date to November 19, 2026; and (iii) changing the specified level of revenue, as measured quarterly on a rolling twelve-month basis, commencing with the quarter ending December 31, 2022, the Company must achieve to satisfy the related financial covenant in the 2017 Loan Amendment, subject to exceptions based on achievement of performance milestones and the ability to cure any default thereof with the issuance of equity securities or subordinated indebtedness.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion of our financial condition and results of operations in conjunction with the unaudited condensed financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited financial statements and notes thereto for the year ended December 31, 2020 included in our Annual Report on Form 10-K for the year ended December 31, 2020, as amended.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Looking Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and other parts of this quarterly report contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this quarterly report, including statements regarding our future results of operations and financial position, business strategy, the impact of the COVID-19 pandemic, current and future product offerings, reimbursement and coverage, our ability to implement an integrated testing and therapeutics strategy, the expected benefits from our partnerships or promotion arrangements with third-parties, research and development costs, timing and likelihood of success and plans and objectives of management for future operations, are forward-looking statements. These statements are often identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; or &#8220;continue,&#8221; and similar expressions or variations. The forward-looking statements in this quarterly report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, operating results, business strategy, and short-term and long-term business operations and objectives. These forward-looking statements speak only as of the date of this quarterly report and are subject to a number of risks, uncertainties and assumptions, including those described in Part II, Item 1A, &#8220;Risk Factors.&#8221; The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand, several of which are based on our proprietary CB-CAPs technology. Our goal is to enable healthcare providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including systemic lupus erythematosus, or SLE, and rheumatoid arthritis, or RA. Our strategy includes leveraging our portfolio of testing products to market therapeutics through our sales channel, targeting the approximately 5,000 rheumatologists across the United States. Our business model of integrating testing products and therapeutics positions us to offer targeted solutions to rheumatologists and, ultimately, better serve patients.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently market 10 testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand that allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases. Our lead testing product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD, enables differential diagnosis for patients presenting with symptoms indicative of a wide variety of CTDs and other related diseases with overlapping symptoms. We commercially launched AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD in 2012 and revenue from this product comprised 81% and 71% of our revenue for the nine months ended September&#160;30, 2021 and 2020, respectively. There is an unmet need for rheumatologists to add clarity in their CTD clinical evaluation, and we believe there is a significant opportunity for our tests that enable the differential diagnosis of these diseases, particularly for potentially life-threatening diseases such as SLE. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging our portfolio of testing products to establish partnerships with leading pharmaceutical companies, academic research centers and patient advocacy organizations. We also have agreements with GlaxoSmithKline plc., or GSK, Covance Inc. and Parexel, among others, that leverage our testing products and/or the information generated from such tests. We provide GSK, a leader in lupus therapeutics, our test result data to provide market insight into and help increase awareness of the benefits of early and accurate diagnosis of SLE and lupus nephritis, and monitoring disease activity. We partner with academic research centers and patient advocacy organizations, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as Brigham and Women's Hospital, Hospital for Special Surgery, Duke University and Emory University as well as the Lupus Foundation of America, to help improve the quality of life for people affected by autoimmune diseases through programs of research, education, support and advocacy. We plan to pursue additional strategic partnerships that are synergistic with our evolving portfolio of testing products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform all of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tests in our approximately 10,000 square foot clinical laboratory, which is certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, by the Centers for Medicare and Medicaid Services, or CMS, and accredited by the College of American Pathologists, or CAP, and located in Vista, California. Our laboratory is certified for performance of high-complexity testing by CMS in accordance with CLIA and is licensed by all states requiring out-of-state licensure. Our clinical laboratory reports all AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing product results within five business days. In the second half of 2021, we began the conversion of approximately 8,000 square feet of warehouse space into additional clinical laboratory space and approximately 6,000 square feet of warehouse space into additional research and development facility space, and expect to complete such conversions by the first quarter of 2022 and the second quarter of 2022, respectively. The expansion of our clinical laboratory and research and development facility are expected to allow us to enhance our testing capacity and improve efficiencies as well as allow us to develop molecular and multiomic capabilities and advance our product pipeline, including support of development of tests for fibromyalgia, RA, thrombosis and lupus nephritis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing products using our specialized sales force. As of September&#160;30, 2021, we have a sales force of 62 representatives covering a total of 63 territories. Unlike many diagnostic sales forces that are trained only to understand the comparative benefits of their tests, the specialized backgrounds of our sales force coupled with our comprehensive training enables our sales representatives to interpret results from our de-identified patient test reports and provide unique insights in a highly tailored discussion with rheumatologists. Our integrated testing and therapeutics strategy results in a unique opportunity to promote and sell targeted therapies in patient focused sales calls with rheumatologists, including those with whom we have a longstanding relationship and history using our portfolio of testing products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement for our testing services comes from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare, and patients. Reimbursement rates vary by product and payor. We continue to focus on expanding coverage among existing contracted rheumatologists and to achieve coverage with commercial payors, laboratory benefit managers and evidence review organizations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception we have devoted substantially all of our efforts developing and marketing products for the diagnosis, prognosis and monitoring of autoimmune diseases. Although our revenue has increased sequentially year over year, we have never been profitable and, as of September&#160;30, 2021 we had an accumulated deficit of $201.1&#160;million. We incurred net losses of $19.8&#160;million and $13.2 million for the nine months ended September&#160;30, 2021 and 2020, respectively. We expect to continue to incur operating losses in the near term as our operating expenses will increase to support the growth of our business, as well as additional costs associated with being a public company. We have funded our operations primarily through equity and debt financings and revenue from sales of our products. We completed our initial public offering, or IPO, in September 2019, raising net proceeds from the offering of approximately $50.4 million, net of underwriting discounts, commissions and other offering expenses, for aggregate expenses of approximately $7.5 million. In March 2021, we completed a public offering of 4,255,000 shares of our common stock at a public offering price of $16.25 per share. Net proceeds from the offering were approximately $64.7 million, net of underwriting discounts and commissions and offering costs of $4.4 million. As of September&#160;30, 2021, we had $106.8&#160;million of cash and cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Developments</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we entered into an agreement with Inland Empire Health Plan, or IEHP, to offer AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD and AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lupus tests on an in-network basis to approximately over one million IEHP members.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current COVID-19 worldwide pandemic has presented substantial public health challenges and is affecting our employees, patients, physicians and other healthcare providers, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing varying forms of "stay-at-home" orders, restricting business functions outside of one's home, restricting gatherings, restricting travel, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mandating social distancing and face coverings. While many jurisdictions have fully reopened or have begun a phased re-opening, the potential to return to prior restrictions remains if there are future increases (or, in some jurisdictions, continued increases) in new cases of COVID-19 or any of its viral variants, including the Delta variant. Even in areas that have fully reopened and where the number of COVID-19 cases has declined, many individuals remain cautious about resuming activities such as preventative-care medical visits. As a result of COVID-19 related limitations and reordering of priorities across the U.S. healthcare system, a reduction in patient flow occurred and our test volumes began to decrease in the second half of March 2020 and we experienced an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD volume decrease of approximately 5% in the year ended December 31, 2020 as compared to 2019. In the fourth quarter 2020, our volume of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests delivered substantially recovered to pre-COVID-19 levels. For the three months ended September&#160;30, 2021 as compared to the same period in 2020, we experienced an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test volume increase of approximately 21%. For the nine months ended September&#160;30, 2021 as compared to the same period in 2020, we experienced an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test volume increase of approximately 31%. However, the continued spread of COVID-19 and patient hesitancy in seeking preventative medical care, each of which are dependent on circumstances that are highly uncertain, may adversely affect testing volumes in future periods. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we believe there are several other important factors that have impacted, and that we expect will impact our operating performance and results of operations, including shutdowns of our facilities and operations as well as those of our suppliers and courier services, disruptions to the supply chain of material needed for our tests, our sales and commercialization activities and our ability to receive specimens and perform or deliver the results from our tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, as well as our inability to achieve volume-based pricing discounts with our key suppliers and absorb fixed laboratory expenses. For example, we have experienced delays in patient enrollment for ongoing and planned clinical studies involving our tests, which may delay or prevent launch of future test products. We have also experienced delays in procurement of our testing supplies due in part to suppliers rationing testing supplies and prioritizing COVID-19 testing beginning in the first quarter of 2021, which may continue into the future, and our partners may also experience a disruption in their ability to readily obtain supply. Our sales force has been, and for an extended period of time may continue to be limited, in their in-person interactions with healthcare providers, and therefore, also limited in their ability to engage in various types of healthcare provider education activities. Healthcare providers and patients have canceled or delayed scheduling, and for an extended period of time may continue to cancel or delay scheduling, standard wellness visits and other non-emergency appointments and procedures, contributing to a decline in orders of our testing products. The portion of our workforce which has been working remotely in an effort to reduce the spread of COVID-19, may be infected from the virus or otherwise distracted. We may also face increased competition for laboratory and scientific employees due to the increased demand in the industry for such personnel. We may inaccurately estimate the duration or severity of the COVID-19 pandemic, which could cause us to misalign our staffing, spending, activities and precautionary measures with market current or future market conditions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we initially curtailed non-essential travel and have equipped most of our employees with the ability to work remotely with the exception of our clinical laboratory employees, and implemented measures to protect the health of our employees and to support the functionality of our clinical laboratory, such as providing personal protective equipment (including face masks or shields) and maintaining social distancing. In addition, in the second quarter of 2020, our sales force recommenced certain field-based interactions and scaled marketing spend, although access to healthcare providers remains limited and the use of virtual sales tools has increased. From March 2020 through December 31, 2020, as a result of the COVID-19 pandemic, we terminated our temporary employees and 18 full-time employees, which included three employees at the vice president level. The full extent of which the COVID-19 pandemic will directly or indirectly continue to impact our business, results of operations and financial condition and will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, including the success of ongoing vaccination efforts, the emergence and prevalence of variant strains of COVID-19, the institution or reinstitution of shutdowns, "stay-at-home-orders" and other public health measures, as well as the related economic impact of these matters on local, regional and international markets.</span></div><div style="margin-top:12pt"><span><br/></span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting Our Performance</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the impact of COVID-19, we believe there are several important factors that have impacted, and that we expect will impact, our operating performance and results of operations, including:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Continued Adoption of Our Testing Products.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Since the launch of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD in 2012 and through September&#160;30, 2021, we have delivered over 581,000 of these tests. Through the third quarter of 2021, 94,099 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests were delivered, representing approximately 31% growth over the same period in 2020. The number of ordering healthcare providers in the third quarter of 2021 was a record 1,969, representing an approximate 18% increase over the same period in 2020, and we had a record 714 adopting healthcare providers (defined as those who previously prescribed at least 11 diagnostic tests in the corresponding period) compared to 600 in the same period in 2020. A high percentage of adopting healthcare providers continue to order tests in subsequent quarters, as approximately 99% of adopting healthcare providers from the second quarter of 2021 ordered at least one diagnostic test in the third quarter of 2021. Revenue growth for our testing products will depend on our ability to continue to expand our base of ordering healthcare providers and increase our penetration with existing healthcare providers.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Reimbursement for Our Testing Products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payors, including both commercial and government payors such as Medicare. Payment from third-party payors differs depending on whether we have entered into a contract with the payors as a "participating provider" or do not have a contract and are considered a "non-participating provider." Payors will often reimburse non-participating providers, if at all, at a lower amount than participating providers. We have received a substantial portion of our revenue from a limited number of third-party commercial payors, most of which have not contracted with us to be a participating provider. Historically, we have experienced situations where commercial payors proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payors have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract to serve as a participating provider, reimbursements are made pursuant to a negotiated fee schedule and are limited to only covered indications.&#160;If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payors, we may not be able to effectively increase our testing volume and revenue as expected. Additionally, retrospective reimbursement adjustments can negatively impact our revenue and cause our financial results to fluctuate.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Success of Synergistic Partnerships</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;In August 2021, we mutually agreed to terminate the Janssen Agreement regarding our promotion efforts with SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effective August 31, 2021. Our SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> promotion efforts contributed approximately $1.0 million and $3.4 million in revenue for the nine months ended September&#160;30, 2021 and 2020, respectively. We will continue to rely on our existing testing products to drive revenue growth and intend to leverage our integrated testing and therapeutics strategy to establish partnerships with a focus on the development and commercialization of therapeutics that are synergistic with our testing products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Development of Additional Testing Products.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We rely on sales of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test to generate the significant majority of our revenue. We expect to continue to invest in research and development in order to develop additional testing products and expect these costs to increase. Our success in developing new testing products will be important in our efforts to grow our business by expanding the potential market for our testing products and diversifying our sources of revenue.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Maintain Meaningful Margin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;We believe we are well positioned to maintain meaningful margin through a continued focus on increasing operating leverage through the implementation of certain internal initiatives, such as conducting additional validation and reimbursement oriented clinical studies to facilitate payor coverage of our testing products, capitalizing on our growing reagent purchasing to negotiate improved volume-based pricing and automation in our clinical laboratory to reduce material and labor costs. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Timing of Our Research and Development Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;Our spending on experiments and clinical studies may vary substantially from quarter to quarter. We also expend funds to secure clinical samples that can be used in discovery, product development, clinical validation, utility and outcome studies. The timing of these research and development activities is difficult to predict. If a substantial number of clinical samples are obtained in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses will affect our financial results. We conduct clinical studies to validate our new testing products, as well as ongoing clinical and outcome studies to further expand the published evidence to support our commercialized AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing products. Spending on research and development for both experiments and studies may vary significantly by quarter depending on the timing of these various expenses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">How We Recognize Revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;We record revenue on an accrual basis based on our estimate of the amount that will be ultimately realized for each test upon delivery based on a historical analysis of amounts collected by test and by payor. Changes to such estimates may increase or decrease revenue recognized in future periods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While each of these areas present significant opportunities for us, they also pose significant risks and challenges that we must address. We discuss many of these risks, uncertainties and other factors in the section entitled "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Janssen Promotion Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we entered into the Janssen Agreement, under which we are responsible for the costs associated with our sales force in promoting SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. In August 2021, the Company and Janssen mutually agreed to terminate the Janssen Agreement effective on August 31, 2021. Pursuant to the Janssen Agreement, Janssen was responsible for all other costs associated with our promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the Janssen Agreement. In exchange for our sales and co-promotional services, we were entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for that quarter over a predetermined baseline. For the quarter ended September&#160;30, 2020, the tiered promotion fee ranged from $750 to $1,250 per prescription over a predetermined baseline. Due in part to COVID-19, in June 2020 we amended the Janssen Agreement, to adjust the predetermined average baseline for the third and fourth quarters of 2020. In December 2020, we further amended the Janssen Agreement, to adjust the average baseline for total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the quarters ending December 31, 2020 and March 31, 2021, subject to further adjustment under certain circumstances. In June 2021, the Janssen Agreement was again amended to proportionally increase the baseline for prescribed units for the quarter ending June 30, 2021 to reflect the addition of certain geographies to the sales territories covered by the Janssen Agreement. For the first and second quarters of 2021, we were entitled to an amended quarterly tiered promotion fee ranging from $500 to $1,000 per prescription based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for that quarter over the predetermined baseline, and we were entitled to receive a minimum promotion fee of $0.3 million and the fee was be capped at 10% above the adjusted predetermined baseline. Upon the termination of the Janssen Agreement on August 31, 2021, we became entitled to receive an aggregate of $0.6 million in consideration. Pursuant to the terms of the termination, we are restricted from promoting any other biologic or Janus kinase inhibitor used for treatment of indications covered by the Janssen Agreement without first obtaining Janssen's written consent until May 31, 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized approximately $1.0 million and $3.4 million in revenue for the nine months ended September&#160;30, 2021 and 2020, respectively, for our promotional efforts under the Janssen Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our experience to date, we expect some seasonal variations in our financial results due to a variety of factors, such as the year-end holiday period and other major holidays, vacation patterns of both patients and healthcare providers, including medical conferences, climate and weather conditions in our markets, seasonal conditions that may affect medical practices and provider activity, including for example influenza outbreaks that may reduce the percentage of patients that can be seen, and other factors relating to the timing of patient benefit changes, as well as patient deductibles and co-insurance limits.</span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_67"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have derived nearly all of our revenue from the sale of our testing products, most of which is attributable to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test. We primarily market our testing products to rheumatologists in the United States. The rheumatologists who order our testing products and to whom results are reported are generally not responsible for payment for these products. The parties that pay for these services, or payors, consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (e.g. hospitals, other laboratories, etc.), and patient self-pay. Our service is completed upon the delivery of test results to the prescribing rheumatologists which triggers billing for the service.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with the provisions of ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We record revenue on an accrual basis based on our estimate of the amount that will be ultimately realized for each test upon delivery based on a historical analysis of amounts collected by test and by payor. These assessments require significant judgment by management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase our revenue will depend on our ability to further penetrate the market for our current and future testing products, and increase our reimbursement and collection rates for tests delivered.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, our volume of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests delivered substantially recovered to pre-COVID-19 levels in the fourth quarter 2020. However, the continued spread of COVID-19, including any of its viral variants, may adversely affect testing volumes in future periods, and the extent of any such adverse effects is highly uncertain.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue represents the expenses associated with obtaining and testing patient specimens. The components of our costs of revenue include materials costs, direct labor, equipment and infrastructure expenses associated with testing specimens, shipping charges to transport specimens, blood specimen collections fees, royalties, depreciation and allocated overhead, including rent and utilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each payor, whether a commercial third-party, government, or individual, reimburses us at different amounts. These differences can be significant. As a result, our costs of revenue as a percentage of revenue may vary significantly from period to period due to the composition of payors for each period's billings.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming future testing volumes are not negatively impacted by the continued spread of COVID-19, we expect that our costs of revenue will increase in absolute dollars as the number of tests we perform increases. However, we expect that the cost per test will decrease over time due to volume discounts on materials and shipping costs and other volume efficiencies we may gain as the number of tests we perform increases. As discussed above, the continued spread of COVID-19 may adversely affect testing volumes which may result in an increase in cost per test due to our inability to realize volume efficiencies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist of personnel costs, including stock-based compensation expense, direct marketing expenses, accounting and legal expenses, consulting costs, and allocated overhead including rent, information technology, depreciation and utilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our selling, general and administrative expenses will increase in absolute dollars in 2021 as compared to 2020, as we continue to evaluate the reach and frequency of our sales and sales support functions, expected additions to headcount and increases for personnel costs, including stock-based compensation. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include costs incurred to develop our technology, testing products and product candidates, collect clinical specimens and conduct clinical studies to develop and support our testing products and product candidates. These costs consist of personnel costs, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities. We expense all research and development costs in the periods in which they are incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our research and development expenses will increase in absolute dollars in 2021 as compared to 2020, as we continue to invest in research and development activities related to our existing testing products and product candidates, including the expansion of our clinical research and development facility, expected additions to headcount and increases for personnel costs, including stock-based compensation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of cash and non-cash interest expense associated with our financing arrangements, including the borrowings under our amended loan and security agreement with Innovatus Life Sciences Lending Fund I, LP, or Innovatus. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect interest expense to remain consistent in 2021 as compared to 2020, and remain consistent thereafter until 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, consists primarily of interest income earned on our cash and cash equivalents and amount received under the CARES Act Provider Relief Fund in the second quarter of 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Benefit</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes include federal and state income taxes in the United States.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_70"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended September&#160;30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited, in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,561&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,194&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,504)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,786)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,718)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,179)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,308)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,871)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased $1.5&#160;million, or 13.7%, for the three months ended September&#160;30, 2021 compared to the three months ended September&#160;30, 2020, primarily due to an increase in the number of diagnostic tests delivered resulting in part from volume reductions experienced in late March 2020 as a result of the COVID-19 pandemic. The number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests delivered, which accounted for 81% and 68% of revenue in the three months ended September&#160;30, 2021 and 2020, respectively, increased to 31,742 tests delivered in the three months ended September&#160;30, 2021 compared to 26,201 tests delivered in the same 2020 period. The adoption of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test by healthcare providers for the three months ended September&#160;30, 2021 increased to 1,969 ordering healthcare providers as compared to 1,665 ordering healthcare providers in the same 2020 period. The increase in revenue was partially offset by a decrease in revenue resulting from the Janssen Agreement during the three months ended September&#160;30, 2021 to approximately $0.4 million compared to approximately $1.3 million during the three months ended September&#160;30, 2020. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue increased $1.1 million, or 26.4%, for the three months ended September&#160;30, 2021 compared to the three months ended September&#160;30, 2020. This increase was primarily due to increased direct costs such as materials and supplies, labor and shipping and handling associated with the increase in test volume in 2021 compared to 2020. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased $2.3&#160;million, or 25.3%, for the three months ended September&#160;30, 2021 compared to the three months ended September&#160;30, 2020. This increase was primarily due to an increase of $1.9 million of employee related expenses, including stock-based compensation and recruitment expenses, and increases related to marketing expenses of $0.3 million, audit and professional services of $0.1 million and insurance expenses of $0.1 million. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $0.7 million for the three months ended September&#160;30, 2021 compared to the three months ended September&#160;30, 2020. This increase was primarily due to increases related to employee related expenses, including stock-based compensation, of $0.3 million, clinical trial expenses of $0.2 million and collaboration expenses of $0.1 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense remained substantially consistent for the three months ended September&#160;30, 2021 compared to the three months ended September&#160;30, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, decreased $0.1 million for the three months ended September&#160;30, 2021 compared to the three months ended September&#160;30, 2020. The decrease was primarily due to lower money market interest rates in 2021 compared to 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Nine Months Ended September&#160;30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited, in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,423&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,731&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,692&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,813)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,389)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,986)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(984)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,798)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,352)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,446)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,798)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,234)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,564)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased $6.3&#160;million, or 21.5%, for the nine months ended September&#160;30, 2021 compared to the nine months ended September&#160;30, 2020, primarily due to an increase in the number of diagnostic tests delivered resulting in part from volume reductions experienced in late March 2020 as a result of the COVID-19 pandemic. The number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests delivered, which accounted for 81% and 71% of revenue in the nine months ended September&#160;30, 2021 and 2020, respectively, increased to 94,099 tests delivered in the nine months ended September&#160;30, 2021 compared to 71,849 tests delivered in the same 2020 period. The adoption of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test by healthcare providers for the nine months ended September&#160;30, 2021 increased to 2,595 ordering healthcare providers as compared to 2,273 ordering healthcare providers in the same 2020 period. The increase in revenue was partially offset by a decrease in revenue resulting from the Janssen Agreement during the nine months ended September&#160;30, 2021 to approximately $1.0 million compared to approximately $3.4 million during the nine months ended September&#160;30, 2020. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue increased $3.4 million, or 28.0%, for the nine months ended September&#160;30, 2021 compared to the nine months ended September&#160;30, 2020. This increase was primarily due to increased direct costs such as materials and supplies, labor and shipping and handling associated with the increase in test volume in 2021 compared to 2020, partially offset by decreased royalty costs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased $5.6&#160;million, or 20.8%, for the nine months ended September&#160;30, 2021 compared to the nine months ended September&#160;30, 2020. This increase was primarily due to an increase of $4.4 million of employee related expenses, including stock-based compensation and recruitment expenses, and increases related to insurance expenses of $0.4 million, marketing expenses of $0.3 million and audit and professional services of $0.2 million. The first quarter of 2020 included one-time restructuring charges of approximately $0.2 million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $2.6 million for the nine months ended September&#160;30, 2021 compared to the nine months ended September&#160;30, 2020. This increase was primarily due to increases related to clinical trial expenses of $0.9 million, employee related expenses, including stock-based compensation and recruitment expenses, of $0.9 million, license fees of $0.4 million, laboratory supplies expense of $0.2 million and collaboration expenses of $0.2 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense remained substantially consistent for the nine months ended September&#160;30, 2021 compared to the nine months ended September&#160;30, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, decreased $1.0 million for the nine months ended September&#160;30, 2021 compared to the nine months ended September&#160;30, 2020. The decrease was primarily driven by the $0.7 million we received under the CARES Act Provider Relief Fund due to lost revenues attributable to COVID-19 in the second quarter of 2020 and lower money market interest rates in 2021 compared to 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Benefit</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit decreased $0.1 million for the nine months ended September&#160;30, 2021 compared to the nine months ended September&#160;30, 2020 due to a change in tax law under the CARES Act enacted in 2020 that resulted in an income tax benefit during the nine months ended September&#160;30, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception. For the nine months ended September&#160;30, 2021 and 2020, we incurred a net loss of $19.8 million and $13.2&#160;million, respectively, and we expect to incur additional losses and increased operating expenses in future periods. As of September&#160;30, 2021, we had an accumulated deficit of $201.1&#160;million. To date, we have generated only limited revenue, and we may never achieve revenue sufficient to offset our expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the date of our IPO in September 2019, our operations were financed primarily from sales of our common stock and redeemable convertible preferred stock and borrowings under various debt financings. In September 2019, we completed our IPO and received net proceeds of approximately $50.4 million, net of underwriting discounts, commissions and other offering expenses, for aggregate expenses of approximately $7.5 million. On November 10, 2020, we filed a registration statement on Form S-3, or the Shelf Registration Statement, covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units, which Shelf Registration Statement became effective on November 19, 2020. In March 2021, we completed a public offering of 4,255,000 shares of our common stock at a public offering price of $16.25 per share, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which shares were sold under the Shelf Registration Statement. Net proceeds from the offering were approximately $64.7 million, net of underwriting discounts and commissions and other offering expenses of $4.4 million. As of September&#160;30, 2021, we had $106.8&#160;million of cash and cash equivalents. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our funds are held in cash and money market funds.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we entered into the loan and security agreement with Innovatus under which we immediately drew down $20.0&#160;million. In December 2018, we borrowed an additional $5.0&#160;million under the loan agreement. In each of November 2019 and November 2021, we amended the loan and security agreement with Innovatus, which we collectively refer to as the Amended Loan Agreement. Pursuant to the Amended Loan Agreement, the loan term is for nine years with a final maturity date of November 2026. The Amended Loan Agreement accrues interest at an annual rate of 8.0%, of which 2.0% will be payable in-kind. Paid in-kind interest is added to the principal balance each period. After December 1, 2024, the entire 8.0% will be paid in cash at the end of each period. On or after November 1, 2022, we may, at our option, prepay the term loan borrowings by paying the lender a prepayment premium. The prepayment premium was 3% as of November 2021 and decreases by 1% on each of November 1, 2022, November 1, 2023 and November 1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Amended Loan Agreement are secured by a security interest in substantially all of our assets, including our intellectual property. The Amended Loan Agreement contains customary conditions to borrowing, events of default, and covenants, including covenants requiring us to maintain certain levels of minimum liquidity of $2.0&#160;million, performance covenants to achieve certain minimum amounts of revenue, and covenants limiting our ability to dispose of assets, undergo a change in control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of our capital stock, repurchase stock and make investments, in each case subject to certain exceptions. The consequences of failing to achieve the performance covenant will be cured if, within sixty days of failing to achieve the performance covenant, we issue additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined in the Amended Loan Agreement. At September&#160;30, 2021, we were in compliance with all covenants of the Amended Loan Agreement. In addition, upon the occurrence of an event of default, Innovatus, among other things, can declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working capital needs, capital expenditures and other general corporate purposes. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the loan and security agreement with Innovatus in November 2017, we issued the lender a seven-year warrant to purchase 15,384,615 shares of our Series&#160;F redeemable convertible preferred stock at an exercise price of $0.078&#160;per share, and in December 2018, in connection with the additional $5.0 million borrowed under the loan and security agreement, we issued to the lender a seven-year warrant to purchase 3,846,154 shares of our Series F redeemable convertible preferred stock at an exercise price of $0.078 per share. In connection with the completion of our IPO in September 2019, the warrants were automatically converted into warrants exercisable for an aggregate of 104,722 shares of common stock at an exercise price of $14.32 per share.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, we received $0.7 million of funding under the CARES Act Provider Relief Fund, subject to our agreement to comply with the Department of Health &amp; Human Services', or HHS, standard terms and conditions. The CARES Act Provider Relief Fund is a federal fund allocated for general distributions to Medicare facilities and providers impacted by the COVID-19 pandemic and is intended to support healthcare-related expenses or lost revenue attributable to COVID-19.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash are to fund our operations as we continue to grow our business. We expect to continue to incur operating losses in the near term as our operating expenses will be increased to support the growth of our business. We expect that our costs of revenue, selling, general and administrative expenses, and research and development expenses will continue to increase as we increase our test volume, expand our marketing efforts and increase our internal sales force to drive increased adoption of and reimbursement for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing products, prepare to commercialize new testing products, continue our research and development efforts and further develop our product pipeline. We believe we have sufficient laboratory capacity to support increased test volume. We expect to make significant investments for laboratory equipment and capital expenditures in the near term related to our laboratory facilities and expansion of research capabilities, including an investment to convert approximately 8,000 square feet of warehouse space into additional clinical laboratory space and approximately 6,000 square feet of warehouse space into additional research and development facility space. We began such conversion in the second </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">half of 2021 and expect to complete the conversion for the clinical laboratory space by the first quarter of 2022 and expect to complete the conversion for the additional research and development facility by the second quarter of 2022. The expansion of our clinical laboratory and research development facility are expected to allow us to enhance our testing capacity and improve efficiencies as well as allow us to develop molecular and multiomic capabilities and advance our product pipeline, including support of development of tests for fibromyalgia, RA, thrombosis and lupus nephritis. Cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our near- and longer-term liquidity requirements will continue to consist of working capital and general corporate expenses associated with the growth of our business, including payments we may be required to make upon the achievement of previously negotiated milestones associated with intellectual property we have licensed, payments related to non-cancelable purchase obligations with one supplier for reagents, payments related to our principal and interest under our long term borrowing arrangements, payments for operating leases related to our office and laboratory space in Vista, California and Carlsbad, California and payments for capital leases related to our laboratory equipment. Based on our current business plan, we believe that our existing cash and cash equivalents and our anticipated future revenue, will be sufficient to meet our anticipated cash requirements for at least the next 12&#160;months from the date of this filing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimate of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business, including challenges resulting from social distancing and stay-at home orders through a reduction in testing volumes;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain and grow sales of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our products and support reimbursement efforts;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for our testing products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in working capital;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation, utility and outcome studies as well as the success of our development efforts;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the additional costs we may incur as a result of operating as a public company;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we establish additional partnerships or in-license, acquire or invest in complementary businesses or products as well as the success of our existing partnerships and/or in-licenses; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with our promotion of other therapeutics, including the expansion of our sales capabilities, and the extent and timing of generating revenue from each such promotion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate revenue to support our costs structure, we expect to finance our operations through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. If additional funding is required or desired, there can be no assurance that additional funds will be available to us on acceptable terms on a timely basis, if at all, or that we will generate sufficient cash from operations to adequately fund our operating needs or achieve or sustain profitability. If we are unable to raise additional capital or generate sufficient cash from operations to adequately fund our operations, we will need to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion plans or commercialization efforts. Doing so will likely have an unfavorable effect on our ability to execute on our business plan and could have a negative impact on our relationships with parties such as our commercial and strategic relationships. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition, and results of operations could be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,222)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,185)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,896&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,650)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the nine months ended September&#160;30, 2021 was $14.2 million and primarily resulted from (i) our net loss of $19.8 million adjusted for non-cash charges of $4.8 million related to stock-based compensation, depreciation, amortization and non-cash interest and (ii) changes in our net operating assets of $0.7&#160;million primarily related to net decreases in prepaid expenses and other current assets, partially offset by net decreases in accounts payables. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the nine months ended September&#160;30, 2020 was $10.2&#160;million and primarily resulted from (i) our net loss of $13.2&#160;million adjusted for non-cash charges of $2.8&#160;million related to stock-based compensation, non-cash interest, depreciation, amortization and deferred income taxes and (ii) changes in our net operating assets of $0.3&#160;million primarily related to net increases in accounts receivables, partially offset by net decreases in prepaid expenses and other current assets and net increases in accounts payables and accrued liabilities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the nine months ended September&#160;30, 2021 and 2020 was $1.4&#160;million and $0.5&#160;million, respectively, and was primarily due to net purchases of property and equipment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided in financing activities for the nine months ended September&#160;30, 2021 was $64.9 million primarily resulting from the net proceeds received from our public offering in March 2021 of $64.7 million and proceeds from ESPP purchases, partially offset by principal payments on capital lease obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the nine months ended September&#160;30, 2020 was $15,000 and primarily resulted from principal payments on capital lease obligations, as well as proceeds from our unsecured loan pursuant to the U.S. Small Business Administration Paycheck Protection Program of the CARES Act, which we subsequently repaid in May 2020, partially offset by proceeds from Employee Stock Purchase Plan purchases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Management Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions, and any such differences may be material. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our critical accounting policies, please see the section entitled "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Significant Management </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" contained in our Annual Report on Form 10-K for the year ended December 31, 2020, as amended. There have been no significant changes in our critical accounting policies and estimates during the three months ended September&#160;30, 2021 as compared to the critical accounting policies and estimates disclosed in the Management&#8217;s Discussion and Analysis of Financial Condition and Operations included in our Annual Report on Form 10-K for the year ended December 31, 2020, as amended, other than as set forth in Note 2 to the unaudited condensed financial statements included in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 2 to the unaudited condensed financial statements included in this Quarterly Report on Form 10-Q for a summary of changes in significant accounting policies. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the periods presented we did not have, nor do we currently have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission, or the SEC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, contains provisions that, among other things, reduce certain reporting requirements for an "emerging growth company." The JOBS Act permits an "emerging growth company" such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our audited financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended, or the Securities Act, which such fifth anniversary will occur in 2024. However, if certain events occur prior to the end of such five-year period, including if we become a "large accelerated filer" as defined in Rule&#160;12b-2 under the Exchange Act, our annual gross revenues exceed $1.07&#160;billion or we issue more than $1.0&#160;billion of non-convertible debt in any three-year period, we may cease to be an emerging growth company prior to the end of such five-year period.</span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_73"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_76"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file with or submit to the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this quarterly report, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer have concluded that as of September&#160;30, 2021, our disclosure controls and procedures were effective at the reasonable assurance level. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgement in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting during the three months ended September&#160;30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_79"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div style="text-align:center"><span><br/></span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_82"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently not a party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the risk factors disclosed in Part I, Item 1A, "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2020, as amended, other than changes to the risk factors set forth below:</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Strategy </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business is subject to risks arising from epidemic diseases, such as the continuing global pandemic of the COVID-19 coronavirus.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current COVID-19 worldwide pandemic has presented substantial public health challenges and is affecting our employees, patients, physicians and other healthcare providers, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing varying forms of "stay-at-home" orders, restricting business functions outside of one's home, restricting gatherings, restricting travel, and mandating social distancing and face coverings. While many jurisdictions have fully reopened or have begun a phased re-opening, the potential to return to prior restrictions remains if there are future increases (or, in some jurisdictions, continued increases) in new cases of COVID-19 or any of its viral variants, including the Delta variant. The duration of any restrictions may also vary depending on the ultimate success of ongoing vaccination efforts. Even in areas where "stay-at-home" restrictions, masking and social distancing measures have been lifted and the number of COVID-19 cases have declined, some jurisdictions are considering re-imposing these measures as variant strains emerge. Many individuals remain cautious about resuming activities such as preventative-care medical visits. A pandemic, including COVID-19 or other public health epidemic, poses the risk that we or our employees, contractors, suppliers, third-party shipping carriers, government and third-party payors and other members of our supply chain may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. As a result of COVID-19 related limitations and reordering of priorities across the U.S. healthcare system, a reduction in patient flow occurred and our test volumes began to decrease in the second half of March 2020 and we experienced an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD volume decrease of approximately 5% in the year ended December 31, 2020 as compared to 2019. In the fourth quarter 2020, our volume of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests delivered substantially recovered to pre-COVID-19 levels. For the three months ended September&#160;30, 2021 as compared to the same period in 2020, we experienced an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD volume increase of approximately 21%. For the nine months ended September&#160;30, 2021 as compared to the same period in 2020, we experienced an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test volume increase of approximately 31%. However, the continued spread of COVID-19 and patient hesitancy in seeking preventative medical care, the extent of which are dependent on circumstances that are highly uncertain, may adversely affect testing volumes in future periods. Healthcare providers and patients have canceled or delayed scheduling, and for an extended period of time may continue to cancel or delay scheduling, standard wellness visits and other non-emergency appointments and procedures, contributing to a decline in orders of our testing products. The economic downturn may also result in closures of the practices of our primary customers.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we believe there are several other important factors that have impacted, and that we expect will impact our operating performance and results of operations, including shutdowns of our facilities and operations as well as those of our suppliers and courier services, disruptions to the supply chain of material needed for our tests, our sales and commercialization activities and our ability to receive specimens and perform or deliver the results from our tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, as well as our inability to achieve or re-negotiate volume-based discounts with our key suppliers and to absorb fixed laboratory expenses. For example, we have experienced delays in patient enrollment for ongoing and planned clinical studies involving our tests, which may delay or prevent launch of future test products. Our sales force has been, and for an extended period of time may continue to be, limited to their in-person interactions with healthcare providers, and therefore, also limited their ability to engage in various types of healthcare provider education activities. The portion of our workforce which has been working remotely in an effort to reduce the spread of COVID-19, may be infected from the virus or otherwise impaired. We have also experienced delays in procurement of our testing supplies due in part to suppliers rationing testing supplies and prioritizing COVID-19 testing beginning in the first quarter of 2021, which may continue into the future, and our partners, may also experience a disruption in their ability to readily obtain supply. We may also face increased competition for laboratory and scientific employees due to the increased demand in the industry for such personnel. We may inaccurately estimate the duration or severity of the COVID-19 pandemic, which could cause us to misalign our staffing, spending, activities and precautionary measures with market current or future market conditions.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our laboratory operations, including laboratory employees and medical directors, may be subject to closure or shut down, either due to the spread of the disease within these individuals, or as part of a larger scale government recommendation or mandate. Disruptions in our laboratory operations could have a material adverse effect on our business and could impede our ability to process tests in a timely manner, or at all.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The occurrence of any of the foregoing events could have a material adverse effect on our business, financial condition and results of operations. The COVID-19 pandemic and mitigation measures have had and may continue to have an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital on a timely basis or at all. The extent to which the COVID-19 pandemic impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact. COVID-19 may also have the effect of heightening many of the other risks described in this section and in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2020, as amended.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Developing new testing products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other testing products we are developing. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will continue to devote considerable resources to the research and development of our planned future testing products and enhancements to our current testing products. We may not be able to develop testing products with the clinical utility necessary to be useful and commercially successful. There are certain products for which a commercial launch would trigger additional payment obligations to licensors of the technology. In these cases, if the economic projections of the product do not outweigh the additional obligations, we may not launch these products. In order to develop and commercialize testing products, we need to: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expend significant funds to conduct substantial research and development; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conduct successful validation studies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and scale our laboratory processes to accommodate different tests; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">achieve and maintain required regulatory certifications, including the hiring of appropriately licensed laboratory personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and scale our infrastructure to be able to analyze increasingly large amounts of data; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">build the commercial infrastructure to market and sell new testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our testing product development process involves a high degree of risk and may take several years. Our testing product development efforts may fail for many reasons, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to identify additional biomarkers to incorporate into our testing products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure or sub-optimal performance of the testing product at the research or development stage;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining patient consent inclusive of genetic analysis;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">difficulty in accessing archival patient blood specimens, especially specimens with known clinical results; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure of clinical validation, utility and outcome studies to support the effectiveness of the test. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Typically, few research and development projects result in commercial products, and success in early clinical studies often is not replicated in later studies. At any point, we may abandon development of a testing product candidate or we may be required to expend considerable resources repeating clinical studies, which would adversely affect the timing for generating potential revenue from a new testing product and our ability to invest in other products in our pipeline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the second half of 2021, we began the conversion of approximately 8,000 square feet of warehouse space into additional clinical laboratory space and approximately 6,000 square feet of warehouse space into additional research and development facility space in order to develop molecular and multiomic capabilities. We have not yet developed any molecular or multiomic testing products nor do we have experience developing and integrating molecular biomarkers into new or existing testing products, and we may never be successful doing so in the future. As a result, there is considerable risk that the expansion of our clinical laboratory and research and development facility may not lead to the development of additional testing products that generate meaningful revenue. Further, as we begin to expand our clinical laboratory and research and development facility in order to develop molecular and multiomic capabilities, we expect to need to make significant investments in key personnel and highly trained scientists with relevant experience to handle the increased operations and development of molecular biomarkers.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as we develop testing products, we will have to make significant investments in product development, marketing and selling resources. If a clinical validation study fails to demonstrate the prospectively defined endpoints of the study, we might choose to abandon the development of the testing product or product feature that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">was the subject of the clinical study, which could harm our business. Additionally, competitors may develop and commercialize competing products or technologies faster than us or at a lower cost. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Developing new testing products and enhancements to our existing technologies is expensive and time consuming, and there is no assurance that such activities will result in significant new marketable testing products, enhancements to our current technologies, design improvements, cost savings, revenue or other expected benefits. If we spend significant resources on research and development and are unable to generate an adequate return on our investment or divert resources away from other, more attractive growth opportunities, our business and results of operations may be materially and adversely affected. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our future growth depends, in part, on our ability to execute on our strategy of integrating the promotion of our existing and future proprietary testing products with the promotion of therapeutics through third party collaborations and strategic partnerships, and we may be unsuccessful in our efforts to establish relationships with these third parties or our promotion efforts after any of these relationships are established, which could adversely affect our ability to implement this strategy. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to integrate our historical testing products business with the promotion of therapeutics in an integrated testing and therapeutics strategy. Our integrated testing and therapeutics strategy would leverage our sales and marketing efforts, targeting rheumatologists for the commercialization of our testing products in co-promotion with therapeutics. As a result, our future growth is dependent, in part, on the success of this strategy. The Janssen Agreement was terminated effective as of August 31, 2021. While we remain committed to the strategy of providing an integrated testing and therapeutics model, we may be unsuccessful in our efforts to establish relationships with collaborators in the future. Even if we successfully establish these relationships, our ability to effectively implement this strategy will include creating demand for the applicable therapeutic through our or our collaborator's commercial and sales activities. Moreover, we may encounter difficulties in maintaining an effective salesforce in furtherance of these co-promotion efforts. We have a limited history partnering with pharmaceutical companies for the promotion of therapeutics. Consequently, any predictions made about our future success or viability with respect to our promotion activities may not be as accurate as they could be if we had a history of successfully co-promoting therapeutics.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we fail to successfully establish and maintain relationships with these collaborators and strategic partners, our ability to implement our integrated testing and therapeutics strategy and generate sufficient revenue to grow and sustain our business, and our business, financial condition and results of operations, will be materially adversely affected.</span></div><div><span><br/></span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_88"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Use of Proceeds</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2019, the SEC declared effective our registration statement on Form S-1 (File No. 333-233446), as amended, filed in connection with our IPO. At the closing of the offering on September 23, 2019, we issued and sold 4,140,000 shares of our common stock at the initial public offering price to the public of $14.00 per share, which included the exercise in full of the underwriters&#8217; option to purchase additional shares. We received gross proceeds from the IPO of $58.0 million, before deducting underwriting discounts, commissions and other offering expenses, which resulted in net proceeds of approximately $50.4 million and offering-related transaction costs of approximately $7.5 million. Cowen and Company, LLC, Cantor Fitzgerald &amp; Co and William Blair &amp; Company, L.L.C. acted as joint book-running managers for the offering. No offering expenses were paid or are payable, directly or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September&#160;30, 2021, we have used approximately $32.2 million of the proceeds from our IPO primarily related to selling and marketing activities. There has been no material change in the planned use of such proceeds from that described in the final prospectus filed by us with the SEC on September 20, 2019.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between September 1, 2021 and September 30, 2021, we issued 17,719 shares of common stock pursuant to the exercise of common stock warrants. These warrants had an exercise price of $1.84 per share and were exercised for an aggregate exercise price of $32,538.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These issuances were made in reliance on Section 4(a)(2) of the Securities Act. The recipients of the shares represented their intention to acquire the securities for investment only and not with a view to, or for sale in connection with, any distribution thereof, and appropriate legends were affixed to the securities.</span></div><div style="text-align:center"><span><br/></span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_91"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_94"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_97"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Filing Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519252366/d769261dex31.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/23/2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000017/ex31-amendedandrestatedbyl.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/22/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex41.htm">Specimen stock certificate evidencing the shares of common stock.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex42.htm">Amended and Restated Investors' Rights Agreement, dated July 12, 2019, by and among the Company and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex43.htm">Amended and Restated Stockholders' Agreement, dated July 12, 2019, by and among the Company and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex44.htm">Form of Common Stock Purchase Warrant issued to investors by the Company in connection with private placement financings.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex48.htm">Form of Common Stock Purchase Warrant to purchase common stock issued to investors by the Company in 2016.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000094/ex45-formofprexfundedwarra.htm">Form of Exchange Warrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/9/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-subleaseagreement819.htm">Sublease Agreement, dated August 19, 2021, by and between Plum Healthcare Group, LLC and the Company.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex102-amend2to1221libertyw.htm">Second Amendment to Standard Industrial/Commercial Single-Tenant Lease, dated October 11, 2021, by and between Liberty Vista and the Company.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex103-fifthaddendumtolease.htm">Fifth Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated October 19, 2021, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex104-firstaddendumtolease.htm">First Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated October 19, 2021, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex105-secondamendmentloana.htm">Second Amendment to Loan and Security Agreement dated November 1, 2021, by and among Innovatus Life Sciences Lending I, LP, other lenders and the Company.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex106-letteragreementippur.htm">Letter Agreement, dated September 28, 2021, by and between the Company and Prometheus Laboratories Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn311-93021.htm">Certificate of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn312-93021.htm">Certificate of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn321-93021.htm">Certifications Pursuant to U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, has been formatted in Inline XBRL.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">* &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="margin-top:6pt;padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Certain schedules to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Copies of the omitted schedules will be furnished to the SEC upon request.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i774bc25129df4ef1954bdef4e9d46c8a_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:52.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.198%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXAGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November&#160;10, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Fortunato Ron Rocca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fortunato Ron Rocca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November&#160;10, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kamal Adawi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101-subleaseagreement819.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="margin-bottom:0.08pt;text-align:right"><font><br></font></div><div style="margin-top:0.09pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUBLEASE AGREEMENT</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This SUBLEASE AGREEMENT (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sublease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into as of the date of last signature below, by and between PLUM HEALTHCARE GROUP, LLC, a California limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sublandlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) whose address is 2175 Salk Avenue, Carlsbad, CA 92008 and EXAGEN INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subtenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) whose address is 1261 Liberty Way, Vista, CA 92081.</font></div><div style="margin-top:13.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;BROOKWOOD CB I, LLC, a Delaware limited liability company and BROOKWOOD CB II, LLC, a Delaware limited liability company (collectively, as tenants in common, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Landlord'&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), and Sublandlord entered into that certain Lease dated April 3, 2018, as amended by that certain First Amendment to Lease dated May 7, 2019 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Master Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), for the lease of the Premises (as defined in the Master Lease). </font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;Sublandlord wishes to sublease to Subtenant, and Subtenant wishes to sublease from Sublandlord, the Premises in accordance with the terms and conditions set forth herein.</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, Sublandlord and Subtenant agree as follows&#58;</font></div><div style="margin-top:13.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AGREEMENT</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sublease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Sublandlord hereby subleases to Sublessee, and Sublessee hereby subleases from Sublandlord, the Premises, for the Term upon all of the terms, covenants and conditions set forth in this Sublease. All capitalized terms not defined in this Sublease shall have the meanings given to them in the Master Lease.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Master Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A true copy of the Master Lease (with certain financial provisions redacted for reasons of confidentiality) is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Sublease is and shall be at all times subject and subordinate to the Master Lease. All of the terms and conditions of the Master Lease are hereby incorporated into this Sublease, and Subtenant does hereby expressly assume and agree to perform and comply with, for the benefit of Sublandlord and Landlord, each and every obligation of the Tenant under the Master Lease, except with respect to those provisions of the Master Lease which are expressly excluded from this Sublease or directly contradicted by this Sublease, in which event the terms of this Sublease shall control. The following provisions of the Master Lease shall not be incorporated into this Sublease&#58; Exhibit C, the last sentence of the first paragraph in Paragraph 7, and provisions related to the Guaranty, Landlord&#8217;s Work, Landlord&#8217;s Work Letter, Moving Allowance, Move-In Costs, Tenant Allowance, and Tenant&#8217;s Work, including without limitation Exhibit D, Exhibit E, and Exhibit H, but excepting therefrom Section 7 of Exhibit C, Section 4 of Exhibit D, and Schedule 2 of Exhibit E, which shall be incorporated into this Sublease. In furtherance of and subject to the foregoing, for the purposes of this Sublease, wherever in the Master Lease the word &#8220;Landlord&#8221; is used it shall be deemed to mean the Sublandlord herein and wherever in the Master Lease the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">word &#8220;Tenant&#8221; is used it shall be deemed to mean the Subtenant herein&#59; provided, however, Subtenant agrees to look solely to the Landlord, and not to Sublandlord, for the performance of all services and obligations of the Landlord under the Master Lease with respect to the Premises. Sublandlord does not assume any obligation to perform the terms, covenants and conditions contained in the Master Lease on the part of the Landlord to be performed. In the event Landlord shall fail to perform any of the terms, covenants and conditions contained in the Master Lease on its part to be performed, Sublandlord shall cooperate with Subtenant in seeking to obtain the performance of Landlord under the Master Lease but Sublandlord shall have no obligation to supply such services or incur any cost or expense in connection therewith and shall not be obligated to bring a legal action to enforce Landlord&#8217;s obligations unless such action is requested in writing by Subtenant, who agrees to pay all costs and expenses to institute such legal action against Landlord. Subtenant shall indemnify and hold Sublandlord harmless from and against all liability, judgments, costs, demands, claims, and damages of any kind whatsoever (including, without limitation, attorneys&#8217; fees and court costs) by reason of any failure on the part of Subtenant to perform any of the obligations of Tenant under the Master Lease which Subtenant is obligated hereunder to perform. In order to facilitate the coordination of the provisions of this Sublease with those of the Master Lease, the time periods contained in provisions of the Master Lease that are incorporated by reference into this Sublease and for which the same action must be taken under the Master Lease and this Sublease (such as, for example and without limitation, payment of Rent, any cure time periods or for the response to requests by Subtenant for consent to an action for which consent of the Landlord is also required), are changed for the purpose of incorporation by reference by shortening or lengthening that period in each instance by five (5) days so that in each instance Subtenant shall have much less time to observe or perform hereunder than Sublandlord has as Tenant under the Master Lease and Sublandlord shall have that much more time to observe, perform, consent, approve or otherwise act hereunder than the Landlord has under the Master Lease. In instances in which the same action is not required under both the Master Lease and this Sublease, the time periods contained in provisions of the Master Lease that are incorporated by reference are not changed. With respect to approval required to be obtained by Landlord under the Master Lease, such consent must be obtained from Landlord and Sublandlord and the approval of Sublandlord will be deemed withheld if Landlord&#8217;s consent is not obtained. Sublandlord will duly notice Landlord of requests for consent by Subtenant, but retains the right to make its own independent determination of consent pursuant to the terms of this Sublease.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The term (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of this Sublease will begin on October 1, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and will end on the Expiration Date (April 30, 2027) unless sooner terminated in accordance with the provisions hereof.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subtenant shall occupy and use the Premises only for general office use consistent with the Master Lease.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subtenant will pay Sublandlord as base rent (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the Premises the amounts set forth in the Base Rent schedule below. Sublandlord shall be responsible to pay for any Base Rent amounts under the Master Lease that are greater than the Base Rent amounts hereunder. During and for the Term of this Sublease, Subtenant shall be responsible to pay for all Additional Rent due by Tenant to Landlord under the Master Lease, provided, however, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sublandlord shall be responsible for paying all Operating Expenses and real property taxes to be paid by Tenant to Landlord under the Master Lease except for 100% of any increases in the same over the calendar year 2021 base year, which shall be Subtenant&#8217;s obligation to pay when the same become due under the Master Lease (subject to the timing adjustments set forth in Section 2 above), and shall be deemed &#8220;Additional Rent&#8221; for all purposes hereof. All Rent will be paid to Sublandlord at the following address&#58; 2175 Salk Avenue, Carlsbad, CA 92008 (unless written notice is provided of a change of address)&#59; provided, however, that Subtenant agrees upon written notice from Sublandlord to pay any portion of the Rent directly to Landlord as and when same the same becomes due under the Master Lease.</font></div><div style="margin-top:4.5pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Base Rent Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-top:4.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Months</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Rent&#47;RSF</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Monthly Rate</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1-12</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">$2.35</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">$66,020.90</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">13-24</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">$2.42</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">$68,001.53</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">25-36</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">$2.49</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">$70,041.57</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">37-48</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">$2.57</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">$72,142.82</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">49-60</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">$2.64</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">$74,307.10</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">61-67</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">$2.72</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">$76,536.32</font></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, 100% of the Base Rent shall be abated for months two (2)&#160;through four (4)&#160;of the Term (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Base Rent Abatement Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (subject to the other abatement provisions of the Master Lease).</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Security Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon execution hereof, Subtenant shall deposit with Sublandlord $153,072.64 as the Security Deposit (to be held by Landlord in accordance with Paragraph 11 of the Master Lease). If, as of the date of expiration of the thirtieth (30th) full calendar month of the Term, the Reduction Conditions (defined below) apply, upon written request by Subtenant, Sublandlord shall return to Subtenant a portion of the Security Deposit equal to $76,536.32, which may at Sublandlord&#8217;s option be retained by Sublandlord and applied towards the next payment of Base Rent. As used herein, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reduction Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean that (i) Subtenant is not then in default of its obligations under this Sublease and (ii) Subtenant has not previously been in default of its obligations under this Sublease.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Acceptance of the Premises&#59; Early Access</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Sublandlord shall deliver the Premises to Subtenant on or before the Commencement Date with the following delivery conditions satisfied&#58; (a) all personal items other than the FF&#38;E (as defined in Section&#160;11 below) shall have been removed from the Premises, and (b) the Premises shall otherwise be delivered to Subtenant in a broom clean condition, with commercially cleaned carpets, paint touched up as needed, walls patched if necessary, and any damaged ceiling tiles or light bulbs replaced. Other than as set forth in the previous sentence, Subtenant shall accept the Premises in its present &#8220;as is&#8221; condition when possession of the Premises is delivered to Subtenant, Sublandlord makes no representation or warranty as to its fitness for Subtenant&#8217;s intended use, and Sublandlord shall not be obligated to make any alterations or improvements to the Premises. At Subtenant&#8217;s own </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">risk and expense, and provided Landlord has consented to this Sublease as set forth in Section 12 below, and the early entry of Subtenant and its agents into the Premises, as set forth herein, Sublandlord shall reasonably coordinate and cooperate with Subtenant to provide prior reasonable access to the Premises in advance of the Commencement Date, but no earlier than September 20, 2021 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Early Access Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), for the sole purpose of installation of its IT infrastructure (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IT Installation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) subject to prior coordination with the Sublandlord and, to the extent required under the Master Lease, approval of Landlord and otherwise in compliance with all applicable terms of the Master Lease relating to such IT Installation, it being acknowledged by Subtenant that early access to the data room in the Premises will not be provided until Sublandlord&#8217;s servers are removed therefrom. Any such early access to the Subtenant and its contractors shall not interfere with the normal occupancy and use of the Premises by the Sublandlord and a Sublandlord representative may accompany Subtenant or Subtenant&#8217;s employees, contractors, or representatives during any such early access.  In the event such early access is granted, Subtenant acknowledges and agrees neither Subtenant, nor any third party shall interfere with the continued operations of the Sublandlord.  Subtenant shall not be obligated to pay any Rent or parking fees during the Early Access Period, but shall obtain prior to any Early Access Period, any insurance coverage required under the Master Lease with respect to the IT Installation, naming Sublandlord and Landlord as additional insureds, and providing evidence of such coverage prior to commencement, or Subtenant&#8217;s early access, whichever is earlier.  For the avoidance of doubt, in the event Subtenant is granted early access, all policies of insurance shall cover the Early Access Period. Subtenant shall indemnify and hold harmless Sublandlord from and against any damages, injuries, claims and expenses (including reasonable attorneys&#8217; fees) incurred by Sublandlord and Landlord arising out of, incidental to, or otherwise related to the Early Access Period and or the IT Installation from any cause whatsoever, including without limitation, any damage to the Building, the Premises, and any claims by Sublandlord and or Landlord.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance&#59; Waiver of Subrogation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All policies of insurance required to be carried by Subtenant under the Master Lease shall include as additional insureds Landlord and any additional insureds required by Landlord under the Master Lease. With respect to the waiver of subrogation contained in the Master Lease, such waiver shall be deemed to be modified to constitute an agreement by and among Landlord, Sublandlord and Subtenant (and Landlord&#8217;s consent to this Sublease shall be deemed to constitute its approval of this modification).</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Sublandlord agrees that during the Term of this Sublease, Subtenant shall be entitled to any parking rights of Sublandlord under and subject to any terms, limitations, and conditions in the Master Lease.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Signage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Sublandlord agrees that during the Term of this Sublease, Subtenant shall be entitled to any signage rights of Sublandlord under and subject to any terms, limitations, and conditions in the Master Lease.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Furniture, Fixtures and Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Sublandlord agrees that during the Term of this Sublease, Subtenant shall have the exclusive use of Sublandlord&#8217;s furniture, fixtures and equipment attached hereto as&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;to this Sublease (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FF&#38;E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), provided that Subtenant maintains and repairs the same subject to normal wear and tear. On the Expiration Date, so long </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">as this Sublease has not been terminated earlier, Subtenant shall purchase the FF&#38;E for One and 00&#47;100 Dollar ($1.00) in its current &#8220;as-is&#8221; condition.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Consent of Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Pursuant to the Master Lease, Sublandlord is required to obtain the written consent of Landlord prior to any subletting of the Premises by Sublandlord. Therefore, this Sublease shall not be effective unless Landlord consents to this Sublease in writing, which consent shall be attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Audit Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Sublandlord agrees to reasonably cooperate with Subtenant regarding rights under the Master Lease to review or audit any Landlord statements (i.e. as set forth under Paragraph 8 of the Master Lease).&#160;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event any action or proceeding at law or in equity for an alleged breach of this Sublease, to recover rent, to terminate the tenancy of Subtenant at the Premises, or to enforce, protect, or establish any right or remedy of a party to this Sublease, the prevailing party by judgment or settlement (it being understood that the prevailing party shall be the party receiving substantially the relief requested) in such action or proceeding shall be entitled to recover as part of such action or proceeding all costs and expenses, including reasonable attorneys&#8217; fees, expert witness fees, and court costs, incurred by such party related to such action or proceeding.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Real Estate Brokers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subtenant and Sublandlord each represents that except for Jones Lang LaSalle (Ryan Hawkins) on behalf of Sublandlord and CBRE (Andrew Ewald) on behalf of Subtenant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), it has dealt with no real estate broker, agent, finder or other person acting as such in connection with this Sublease. Sublandlord shall pay the leasing commissions of Brokers in connection with this Sublease pursuant to a separate agreement. Each party shall indemnify and hold the other harmless from and against any and all claims, judgments, suits, costs, reasonable attorney&#8217;s fees and other expenses which the other may incur by reason of claims of any person, firm or corporation for a brokerage commission, finder&#8217;s fee or equivalent compensation alleged to be owing on account of the indemnifying party&#8217;s dealings with any real estate broker or agent other than Brokers in connection with the Premises or this Sublease. Each party&#8217;s obligations under this section shall survive the expiration or sooner termination of this Sublease.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All notices shall be sent to the respective parties at the address provided in the introductory paragraph of this Sublease, provided, however, following the execution of this Sublease, Subtenant shall send a copy of all notices to Gary Sanders at 5316 East Chapman Avenue, Orange, CA 92869. The parties hereto agree to provide each other copies of any notices and statements received from and sent to the Landlord with respect to the Premises.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executed Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Sublease may be executed in one or more counterparts, all of which together shall constitute a single agreement and each of which shall be an original for all purposes.</font></div><div style="margin-top:9pt;text-align:center;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have caused this Sublease to be duly executed as of the day and year last written below.</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.153%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUBLANDLORD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PLUM HEALTHCARE GROUP, LLC &#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a California limited liability company&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">_&#47;s&#47; Naveed Hakim____________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Naveed Hakim&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; CFO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; 8&#47;18&#47;2021</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="display:inline-block;max-width:7.692%;min-width:6.692%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.155%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUBTENANT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXAGEN INC.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">_&#47;s&#47; Mark Hazeltine___________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Mark Hazeltine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; COO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; 8&#47;19&#47;2021</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SCHEDULE 1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FF&#38;E  UPDATED 8.10.2021</font></div><div><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MASTER LEASE</font></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_87"></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">LEASE</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">BY AND BETWEEN</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">BROOKWOOD CB I, LLC and</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">BROOKWOOD CB II, LLC (collectively, as tenants in common, &#34;Landlord&#34;)</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">and</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">PLUM HEALTHCARE GROUP, LLC</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">(&#34;Tenant&#34;)</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_93"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">TABLE OF CONTENTS</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Page</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">TERMS</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">THE PREMISES</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">TERM</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">CONDITION OF THE PREMISES AND BUILDING</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">MONTHLY RENT</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">6.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">TAXES</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">7.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">OPERATING EXPENSES</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">7</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">8.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">RECONCILIATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">9.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">INSURANCE</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">9</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">10.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">WAIVER OF SUBROGATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">11.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SECURITY DEPOSIT</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">12.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">USE</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">12</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">13.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">MAINTENANCE&#59; SERVICES</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">12</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">14.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SUBLEASE&#59; ASSIGNMENT</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">14</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">15.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">INDEMNITY&#59; NON-LIABILITY OF LANDLORD</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">16</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">16.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">UTILITIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">17.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">HOLDING OVER</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">18</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">18.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">NO RENT DEDUCTION OR SET OFF</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">18</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">19.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">CASUALTY</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">18</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">20.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SUBORDINATION&#59; ESTOPPEL LETTERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">19</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">21.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ALTERATIONS&#59; RESTORATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">20</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">22.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">DEFAULT&#59; REMEDIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">21</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">23.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">NOTICES</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">25</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">24.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">EMINENT DOMAIN</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">25</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">25.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">QUIET ENJOYMENT</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">25</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">26.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">RULES AND REGULATIONS</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">25</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">27.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ENVIRONMENTAL</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">26</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">28.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">FINANCIAL STATEMENTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">27</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">29.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">BROKERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">27</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">30.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">MISCELLANEOUS</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">27</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">31.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">PARKING</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">29</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">32.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SIGNAGE</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">30</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">33.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">INTENTIONALLY OMITTED</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">30</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">34.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">CERTAIN RIGHTS RESERVED TO LANDLORD</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">30</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">35.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">LEASE COMMENCEMENT&#47;ACCEPTANCE OF PREMISES</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">30</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">36.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">WAIVER OF RIGHT TO JURY TRIAL</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">31</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">37.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">RECORDING</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">31</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">i</font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_101"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">1.&#160;&#160;&#160;&#160;TERMS. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Each reference in this Lease to any of the following subjects shall be construed to incorporate the data stated for that subject in this Section 1.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Date of this Lease&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">April 3, 2018</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Name of Tenant&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Plum Healthcare Group, LLC,<br>a California limited liability company</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Notice Address of Tenant&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(a) Prior to possession&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">100 E. San Marcos Blvd., Ste. 200 <br>San Marcos, CA 92069 <br>Attn&#58; Naveed Hakim</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(b) Following possession&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">At the Premises.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Name of Guarantor&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Name of Landlord&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">BROOKWOOD CB I, LLC, a Delaware limited<br>liability company, and BROOKWOOD CB II,<br>LLC, a Delaware limited liability company, as<br>tenants in common</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Notice Address of Landlord&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Brookwood CB I, LLC<br>Brookwood CB II, LLC<br>c&#47;o Brookwood Financial Partners, LLC <br>138 Conant Street<br>Beverly, Massachusetts 01915<br>Attention&#58; Kurt Zernich, Director of Asset<br>Management</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Landlord's Remittance Address&#58; </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Lockbox&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Overnight to Lockbox&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Wire&#47;ACH&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Building&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The building located at 2175 Salk Avenue,<br>Carlsbad, California.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Property&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The Building and the real property on which the<br>Building is located and any other buildings and<br>improvements located thereon. For all purposes<br>under this Lease, the Property shall include all<br>related site land, easements, rights of way,<br>property, improvements, parking facilities,<br>common areas, driveways, sidewalks and<br>landscaping which form a part of the project<br>located at 2173, 2175 and 2177 Salk Avenue, <br>Carlsbad, California and commonly known as <br>Ventana Real.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Premises&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Approximately 25,404 rentable square feet of</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">space on the third (3rd) floor of the Building</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">commonly known as Suite 300 as approximately</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">shown by the floor plan attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Exhibit </font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. The Premises shall be measured utilizing the</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">BOMA standard of measurement ANSI Z65.1-1996.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Permitted Use&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">General office, related general office and<br>administrative services, company training center,<br>and&#47;or any other use, each to the extent permitted<br>under Applicable Law and zoning ordinances, and<br>no other use or purpose.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Term&#58; </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The period of time beginning on the<br>Commencement Date and ending at 11&#58;59 P.M.<br>Pacific Time on the Expiration Date.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Commencement Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The date that is the later of (i) August 1, 2018 and<br>(ii) the date that Landlord's Work is Substantially<br>Complete (as such terms are defined in the<br>Landlord's Work Letter attached as Exhibit D to<br>the Lease). Tenant shall confirm the<br>Commencement Date pursuant to the terms of<br>Section 35 hereof.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Rent Commencement Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The date that is ninety (90) days following the<br>Commencement Date. Tenant shall confirm the Rent Commencement Date pursuant to the terms<br>of Section 35 hereof.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Expiration Date&#58; </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">That certain date which is the last day of the</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">eighty-fourth (84</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:125%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">) complete calendar month</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">following the Rent Commencement Date. </font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Tenant's Percentage&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">32.04%, being the ratio of rentable square footage<br>of the Premises to the total rentable square<br>footage of the Building as reasonably determined<br>by Landlord, subject to reasonable prospective<br>adjustment by Landlord from time to time. In the<br>event any item of Additional Rent provided for in<br>this Lease is calculated by Landlord with respect<br>to the Property, then Tenant's Percentage for any <br>such item shall be 11.58%, being the ratio of<br>rentable square footage of the Premises to the<br>total rentable square footage of the Property as<br>determined by Landlord, subject to reasonable<br>adjustment by Landlord from time to time. </font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Base Taxes&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The Taxes for the calendar year 2018, as they<br>may be reduced by the amount of any abatement.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Tax Excess&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Tenant's Percentage of the amount by which<br>Taxes for any calendar year during the Term<br>exceed Base Taxes.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Base Operating Expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The Operating Expenses for the calendar year<br>2018.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Operating Expenses Excess&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Tenant's Percentage of the amount by which<br>Operating Expenses exceed Base Operating<br>Expenses for any calendar year during the Term.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Security Deposit&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibits&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Exhibit A     The Premises<br>Exhibit B     Rules and Regulations      <br>Exhibit C     Additional Stipulations<br>Exhibit D     Landlord's Work Letter<br>Exhibit E     Tenant's Work Letter<br>Exhibit F     Commencement Letter<br>Exhibit G     Form of Estoppel Certificate<br>Exhibit H     Guaranty<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">All of the Exhibits listed above are incorporated<br>into and made part of this Lease. </font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Rent&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Base Rent and all Additional Rent.</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Additional Rent&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">All amounts required to be paid by Tenant to<br>Landlord pursuant to this Lease other than Base<br>Rent, including, without limitation, Operating<br>Expenses and Taxes.</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Base Rent&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The amounts set forth in the table below, plus<br>applicable tax thereon.</font></td></tr></table></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Months of Term</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Base Rent</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(per month)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Base Rent</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(per rentable square foot, per month)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Rent Commencement Date - 12</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">13 - 24</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">25 - 36</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">37 - 48</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">49 - 60</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">61 - 72</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">73 - 84</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Notwithstanding the foregoing, &#91;***&#93; (the &#34;Base Rent Abatement Period&#34;). The Base Rent due for any partial calendar month immediately following the Base Rent Abatement Period shall be prorated based on the number of days in that month. In no event shall the Base Rent Abatement Period be deemed to reduce or eliminate Tenant's obligation to pay Additional Rent or any other amounts due hereunder other than Base Rent. If Tenant defaults under this Lease beyond any applicable notice and cure period, then Tenant's right to abate the Base Rent shall immediately terminate and be of no further force and effect and the unamortized portion (based on straight line amortization across the initial Term) of all Base Rent which had been abated prior to Tenant's default shall immediately become due and payable.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">2.&#160;&#160;&#160;&#160;THE PREMISES.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Landlord leases to Tenant, and Tenant leases from Landlord, upon and subject to the terms and conditions of this Lease, the Premises. The Premises are leased with the right of Tenant to use for its customers, employees and visitors, in common with other parties entitled thereto, such common areas and facilities as Landlord may from time to time designate and provide.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">3. &#160;&#160;&#160;&#160;TERM.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  The Premises are leased for the Term. If for any reason Landlord is unable to Substantially Complete Landlord's Work on or prior to August 1, 2018, then Landlord shall not be liable to Tenant for any resultant loss or damage and this Lease shall not be affected except that Tenant shall receive a day for day credit against Base Rent in accordance with the terms and conditions of the Landlord's Work Letter attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">4.&#160;&#160;&#160;&#160;CONDITION OF THE PREMISES AND BUILDING. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Except as otherwise expressly stated to the contrary in this Lease or in the Landlord's Work Letter attached as Exhibit D to this Lease, the Premises are leased in an &#34;as is&#34; and &#34;where is&#34; condition without any warranty of fitness for use or occupation express or implied, it being agreed that (i) Tenant has had an opportunity to examine the condition of the Premises, (ii) Landlord has made no representations or warranties of any kind with respect to such condition, and (iii) Landlord has no obligation to do or approve any work or make or approve any improvements to or with respect to the Premises to prepare the same for Tenant's occupancy except as specifically provided in this Lease.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Landlord, at Landlord's sole cost, shall ensure that the Building's roof and the HVAC, electrical, lighting, fire sprinkler, and plumbing systems serving and within the Premises are in good working condition as of the Commencement Date and that the same have been recently operated and regularly serviced. If it is determined prior to the end of the sixth (6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:125%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">) month of the Term that, through no fault of Tenant, one or more of such items does not have a remaining useful life that is at least equal to the remainder of the initial Term, then, if such item requires replacement during the initial Term, such item shall be replaced by Landlord at Landlord's sole cost.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Landlord, at Landlord's sole cost (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, not included in Operating Expenses or deducted from the Tenant Allowance), shall be responsible for ensuring that (i) the Premises comply with Applicable Law as of the date of Landlord's execution and delivery of this Lease to Tenant and (ii) the common areas of the Building comply with Applicable Law as of the Commencement Date, and if it is determined thereafter that Landlord failed to deliver the Premises or Building, as applicable, in such a condition, Landlord, as Tenant's sole remedy, shall promptly correct such deficiency at no cost to Tenant.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">5.&#160;&#160;&#160;&#160;MONTHLY RENT.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Commencing on the Commencement Date, Base Rent shall be paid monthly in advance on or before the first day of each calendar month in accordance with the schedule set forth in Section 1. The Base Rent shall not be adjusted or modified if the actual rentable square footage of the Premises varies from the rentable square footage set forth in Section 1. If the Commencement Date shall be on any day other than the first day of a calendar </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">month, Base Rent for the partial month shall be prorated based on the number of days in that month. Unless otherwise provided herein, commencing on the Commencement Date, Additional Rent shall be paid monthly in advance on or before the first day of each calendar month. If the Commencement Date shall be on any day other than the first day of a calendar month, Additional Rent for the partial month shall be prorated based on the number of days in that month. Rent shall be paid to Landlord, without notice or demand, and without deduction or offset, in lawful money of the United States of America, at Landlord's Remittance Address as set forth in Section 1 or to such other address as Landlord may from time to time designate in writing. Tenant acknowledges that the late payment of Rent or other sums due hereunder shall cause Landlord to incur costs not contemplated by this Lease, the exact amount of which shall be extremely difficult to ascertain. Such costs include, but are not limited to, processing and accounting charges, and late charges which may be imposed on Landlord by the terms of any mortgage or trust deed covering the Property. Accordingly, if any installment of Rent or any other sums due from Tenant shall not be received by Landlord when due, Tenant shall pay to Landlord a late charge equal to five percent (5%) of such overdue amount. In addition, any amount due to Landlord, if not paid when due, shall bear interest from the date due until paid at the lesser of&#58; (i) the Prime Rate (as hereinafter defined) plus five percent (5%) per annum, or (ii) the highest rate permitted by law (the &#34;Default Rate&#34;). The term &#34;Prime Rate&#34; shall mean the Prime Rate as published in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> from time to time. The parties agree that such late charges represent a fair and reasonable estimate of the costs Landlord shall incur by reason of late payment by Tenant. Notwithstanding the foregoing, no late charge shall be assessed with respect to any late payment that is delivered to Landlord within five (5) days of Landlord's notice of nonpayment if Tenant has timely made all payments required in connection with this Lease during the twelve (12) month period immediately preceding the due date of such late payment. The acceptance of such late charges by Landlord shall in no event constitute a waiver of Tenant's default with respect to the overdue amount or prevent Landlord from exercising any of the other rights and remedies granted hereunder. Notwithstanding anything to the contrary in this Lease, Tenant shall pay the first full monthly installment of Rent due hereunder (i.e. Rent for the first complete month of the Term, or, if applicable, for the first complete month following any initial abatement period) simultaneously with Tenant's execution and delivery of this Lease.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">6.&#160;&#160;&#160;&#160;TAXES.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Tenant shall pay monthly, as Additional Rent, one-twelfth (1&#47;12) of the Tax Excess based on good faith estimates provided by Landlord from time to time and subject to reconciliation as provided in Section 8 below. The calculation of Base Tax.es shall not take into account any temporary reductions in real property taxes. No credit or payment shall be due to Tenant in the event Taxes for any year are less than Base Taxes. &#34;Taxes&#34; means all taxes, assessments and fees levied upon the Property by any governmental entity based upon the ownership, leasing, renting or operation of the Property. Landlord may allocate Taxes incurred with respect to multiple buildings on the Property among such buildings. Taxes shall not include any federal, state or local net income, capital stock, succession, transfer, replacement, gift, estate or inheritance taxes&#59; provided, however, if at any time during the Term, a tax or excise on income is levied or assessed by any governmental entity in lieu of or as a substitute for, in whole or in part, real estate taxes or other ad valorem taxes, such tax shall constitute and be included in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Taxes. In addition to the foregoing, Tenant shall pay Landlord, as Additional Rent, for any use, rent or sales tax, service tax, value added tax, franchise tax or any other tax on Rent however designated as well as for any tax.es which are reasonably attributable to the cost or value of Tenant's equipment, furniture, fixtures and other personal property located in the Premises or the cost or value of any leasehold improvements made in or to the Premises by or for Tenant. All expenses, including reasonable attorneys' fees and disbursements, experts' and other witnesses' fees, incurred in contesting the validity or amount of any Taxes or in obtaining a refund of Taxes shall be considered as part of the Taxes for the year in which the expenses are incurred.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">7.&#160;&#160;&#160;&#160; OPERATING EXPENSES.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Tenant shall pay monthly, as Additional Rent, one-twelfth (1&#47;12) of the Operating Expenses Excess based on good faith estimates provided by Landlord from time to time and subject to reconciliation as provided in Section 8 below. No credit or payment shall be due to Tenant in the event Operating Expenses for any year are less than Base Operating Expenses. &#34;Operating Expenses&#34; means and includes all expenses, costs, fees and disbursements paid or incurred by or on behalf of Landlord for managing, operating, maintaining, improving, servicing or repairing the Building or Property and all associated plumbing, heating, ventilation, air conditioning, lighting, electrical, mechanical and other systems, including, without limitation, costs of&#58; performing the Landlord's obligations described in Section 13&#59; janitorial services, the repair, maintenance, repaving and re-striping of any parking and dock areas&#59; providing any services or amenities such as conference rooms, parking garage, cafeteria, or gymnasium&#59; exterior maintenance, repair and repainting&#59; landscaping&#59; snow removal&#59; utilities&#59; management fees&#59; supplies and sundries&#59; sales or use taxes on supplies or services&#59; charges or assessments under any easement, license, declaration, restrictive covenant or association&#59; legal and accounting expenses&#59; Insurance Premiums&#59; and compensation and all fringe benefits, worker's compensation insurance premiums and payroll taxes paid to, for or with respect to all persons engaged in the operation, administration, maintenance and repair of the Property. Landlord may allocate any item of Operating Expenses that benefits multiple buildings on the Property among such buildings. Landlord may allocate any item of Operating Expenses among different portions or occupants of the Building or Property based on use or other considerations as determined by Landlord in Landlord's reasonable discretion. If there is less than ninety five percent (95%) occupancy during any period (including the calendar year 2018), Landlord shall adjust those Operating Expenses that are affected by variations in occupancy levels to the amount of Operating Expenses that would have been incurred had there been at least ninety-five percent (95%) occupancy. Operating Expenses accounting shall be consistently applied from year to year. During the first twelve (12) months of the Term, Tenant shall not be responsible for paying any excess over Tenant's Percentage of Operating Expenses Excess.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">If, in any calendar year following the calendar year 2018 (such later year being a &#34;Subsequent Year&#34;), a new expense item is included in Operating Expenses which was not included in Base Operating Expenses, then the cost of such new item shall be added to Base Operating Expenses for purposes of determining the Operating Expenses Excess payable for such Subsequent Year and for each year thereafter, but only for so long as the new expense item is included in Operating Expenses. Conversely, when an expense item that was originally </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">included in Base Operating Expenses is, in any Subsequent Year, no longer included in Operating Expenses, then the cost of such item shall be deleted from Base Operating Expenses for purposes of determining the Operating Expenses Excess payable for such Subsequent Year and for each year thereafter, but only for so long as the expense item is absent from Operating Expenses.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Notwithstanding the foregoing, Operating Expenses shall not include costs of alterations to the premises of other tenants of the Property, depreciation charges, interest and principal payments on mortgages, ground rental payments and real estate brokerage and leasing commissions&#59; costs incurred for Landlord's general overhead and any other expenses not directly attributable to the operation and management of the Building or the Property&#59; costs of selling or financing any of Landlord's interest in the Property&#59; costs incurred by Landlord for the repair of damage to the Property to the extent that Landlord is reimbursed by insurance proceeds or other means or sources&#59; reserves for future capital replacements&#59; maintenance and replacement of structural elements of the Building and the Property (including the structural walls, foundations, concrete subflooring, structural elements of the roof and underground utilities)&#59; amounts paid for services provided by affiliates of Landlord, to the extent that the same exceed the amounts which would otherwise be payable for the same services had such services been performed by unaffiliated third parties&#59; and the costs of services and utilities separately chargeable to individual tenants of the Building.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Notwithstanding the foregoing, the maximum increase in the amount of Controllable Operating Expenses (defined herein below) that may be included in calculating such Operating Expenses for each calendar year during the Term shall be limited to 5% per calendar year on a cumulative, compounded basis. For the purposes hereof, Controllable Operating Expenses means all Operating Expenses other than those expenses the increase in which is beyond the reasonable control of Landlord. By way of illustration and not limitation, examples of increases in Operating Expenses that are beyond the reasonable control of Landlord include Insurance Premiums, utilities, management fees, association charges, governmentally mandated charges, and wages and benefits.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">8.&#160;&#160;&#160;&#160;RECONCILIATION.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Any failure by Landlord to deliver any estimate or statement of Additional Rent required under this Lease shall not operate as a waiver of Landlord's right to collect all or any portion of Additional Rent due hereunder. On an annual basis, Landlord shall provide Tenant with a reasonably detailed statement of all actual Operating Expenses and Taxes for the preceding year. If Tenant has made estimated payments of Operating Expenses or Taxes in excess of the actual amount due, Landlord shall credit Tenant with any overpayment against the next Rent otherwise due, provided, however, if such overpayment occurs within the final year of the Term, then Landlord shall use commercially reasonable efforts to timely reimburse Tenant in the amount of such overpayment in cash as part of Landlord's reconciliation procedure at the end of the Term. If the actual amount due exceeds the estimated payments made by Tenant during the preceding year, Tenant shall pay the difference to Landlord within fifteen (15) business days and such obligation shall survive the expiration or earlier termination of this Lease.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Tenant shall have the right during the Term, by providing written notice to Landlord (the &#34;Review Notice&#34;) within sixty ( 60) days after receiving Landlord's statement of actual Operating Expenses, to review Landlord's records relating to Operating Expenses for such year, but not for any prior year(s) to such period. If Tenant does not timely provide a Review Notice, Tenant's right to audit, contest, object or challenge Operating Expenses shall be waived, with Operating Expenses to be deemed approved by Tenant. Within a reasonable period of time after receipt of a timely Review Notice, Landlord shall make such records available for Tenant's review at either Landlord's home office or at the office of the property manager for the Building. If Tenant fails to give Landlord written notice stating in reasonable detail any objection to Landlord's statement of actual Operating Expenses within thirty (30) days after such records are made available to Tenant for review then Tenant shall be deemed to have approved Landlord's statement of Operating Expenses for such year and Tenant shall have no further right to object or contest such statement. Upon Landlord's receipt of a timely objection notice from Tenant, Landlord and Tenant shall work together in good faith to resolve the discrepancy between Landlord's statement and Tenant's review. If Landlord and Tenant determine that Operating Expenses for the year in question are less than reported in Landlord's statement, Landlord shall provide Tenant with a credit against future Rent then next due in the amount of any overpayment by Tenant. Likewise, if Landlord and Tenant determine that Operating Expenses for the year in question are greater than reported in Landlord's statement, Tenant shall forthwith pay to Landlord the amount of underpayment by Tenant. Any information obtained by Tenant pursuant to the provisions of this section shall be treated as confidential and Landlord may require that Tenant execute a confidentiality agreement as a condition of Tenant's review. If Tenant retains an agent to review Landlord's books and records for any year, such agent must (i) be a CPA firm (ii) not be compensated on a contingency basis, and (iii) execute a confidentiality agreement with respect to such review. Tenant shall be solely responsible for all costs incurred by Tenant in connection with such review. Notwithstanding anything herein to the contrary, Tenant shall not be permitted to review Landlord's records or to dispute any statement of Operating Expenses if Tenant is in default or if Tenant has not first paid to Landlord the amount due as shown on Landlord's statement of actual Operating Expenses.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">9.&#160;&#160;&#160;&#160;INSURANCE.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(A)&#160;&#160;&#160;&#160;Tenant shall maintain the following insurance in force from the date upon which Tenant first enters the Premises and throughout the Term and thereafter for so long as Tenant is in occupancy of any part of the Premises&#58;</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(i)&#160;&#160;&#160;&#160;Commercial General Liability insurance with limits of at least $1,000,000 per occurrence, $2,000,000 general aggregate, and, if the Tenant manufacturers or produces a product, $2,000,000 products completed operations aggregate or such larger amounts as Landlord may reasonably require from time to time, covering bodily injury and property damage arising out of the use of the Premises, as well as products&#47;completed operations, blanket contractual liability, personal injury and advertising liability&#59;</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(ii)&#160;&#160;&#160;&#160;Worker's Compensation insurance as required by the state in which the Premises is located covering occupational injuries or disease to all employees of Tenant and to any contractors, subcontractors or other agents used by Tenant for work or other activities on or about the Premises. Such policy shall include Employer's Liability limits of at least $500,000 each accident, $500,000 each employee, and $500,000 disease&#59;</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(iii)&#160;&#160;&#160;&#160;Business Automobile Liability insurance for all owned (Symbol 1), non-owned (Symbol 9) hired, rented and&#47;or borrowed (Symbol 8) vehicles used by the Tenant, its employees or agents. Such policy shall include a combined single limit of liability of at least $1,000,000 per claim for bodily injury and property damage and shall provide that employees are insureds&#59;</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(iv)&#160;&#160;&#160;&#160;Excess or Umbrella Liability insurance with a limit of at least $3,000,000 providing additional limits of insurance over the primary per occurrence and aggregate limits of the Commercial General Liability (including bodily injury, property damage, products&#47;completed operations, personal&#47;advertising injury and blanket contractual liability), Employer's Liability, and Business Auto Liability insurance required in (i), (ii), and (iii) above&#59; and</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(v)&#160;&#160;&#160;&#160;Property insurance covering &#34;all risk&#34; of physical damage to Tenant's personal property and any property in the care, custody, and control of the Tenant. In addition this policy shall cover any direct or indirect physical damage to all alterations, additions, improvements (including carpeting, floor coverings, paneling, decorations, fixtures and any improvements or betterments to the Premises made by Tenant or by Landlord at Tenant's request or for Tenant's benefit) situated in or about the Premises. Such coverage shall be for the full replacement value of the covered property. </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(B)&#160;&#160;&#160;&#160;Tenant's Commercial General Liability, Property, and Excess Liability&#47;Umbrella Liability policies shall name Landlord, Landlord's managing agent, and Landlord's mortgagee as Additional Insureds and shall be primary insurance as to any insurance carried by the parties designated as Additional Insureds. All policies purchased and maintained by Tenant to satisfy the requirements in this Lease must be purchased from an insurance company with a minimum rating of &#34;A- X&#34; or its equivalent &#58;from one of the major rating agencies (AM Best, Moodys, Standard &#38; Poors, Fitch) that is admitted or eligible to do business in the state where the Premises is located.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(C)&#160;&#160;&#160;&#160;Tenant shall provide Landlord with a certificate of insurance for each policy simultaneously with the delivery of an executed counterpart of this Lease and prior to each renewal of such insurance. Such certificates of insurance shall be on an ACORD Form 27 or ISO Form 2026 or their equivalent, shall certify that such policy has been or shall be issued and that it provides the coverage and limits required above. The policy shall provide thirty (30) days' notice of cancellation for other than non-payment and ten (10) days for non-payment. Such notice is given to Landlord and the first named insured on the policy. In addition to providing the certificates of insurance required herein, Tenant shall also promptly furnish any additional information, including complete copies of Tenant's insurance policies, when received by Tenant, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">and as Landlord may request&#58; from time to time pertaining to Tenant's insurance coverage. Tenant shall notify Landlord in writing at least sixty (60) days in advance if Tenant intends to or receives a notice that its insurance company intends to cancel or non-renew such insurance for any reason, other than non-payment, which in such case of non-payment is ten (10) days advance notice, or if the required coverage or limits are to be materially changed from the initial requirements in this Lease. In the event that the applicable statutory time period is less than sixty (60) days, then Tenant shall notify Landlord within three (3) business days of receipt of any cancellation or non-renew notice. In the event that Tenant fails to obtain or maintain the insurance required above or fails to provide the Certificates of Insurance required, Landlord may, at its option, obtain such insurance on behalf of Tenant. Tenant shall pay, as Additional Rent upon demand, the reasonable cost of such insurance plus a twenty-five percent (25%) surcharge. Landlord's failure to obtain such coverage on behalf of Tenant shall not limit Tenant's liability in the event of an uncovered loss.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(D)&#160;&#160;&#160;&#160;Landlord shall carry or cause to be carried such insurance in amounts and with deductibles as a reasonably prudent landlord would purchase and maintain with respect to the Property. Tenant shall pay Tenant's Percentage of Landlord's insurance premiums (&#34;Insurance Premiums&#34;) during the Term of the Lease as a part of Operating Expenses. Tenant shall not do or permit to be done anything which shall contravene, invalidate, or increase the cost of the Landlord's insurance and shall comply with all rules, orders, regulations, requirements and recommendations of Landlord or its insurance companies relating to or affecting the condition, use, or occupancy of the Premises. If Tenant does conduct any activity within or about the Premises that results in an increase to the cost of Landlord's insurance Tenant shall reimburse Landlord for the entire amount of such additional premiums or surcharges on demand.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">10.&#160;&#160;&#160;&#160;WAIVER OF SUBROGATION.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Notwithstanding any other language of this Lease to the contrary, Landlord and Tenant each waive their respective rights to recover &#58;from the other for any and all loss of or damage to their respective property if such loss or damage is covered, or required by this Lease to be covered, by insurance. Tenant shall obtain an endorsement acknowledging such waiver from its insurance company(s) evidencing compliance with this section.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">11.&#160;&#160;&#160;&#160;SECURITY DEPOSIT.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Upon execution of this Lease, Tenant shall deposit with Landlord the amount of the Security Deposit specified in Section 1 of this Lease. Provided that Tenant has paid all amounts due and has otherwise performed all obligations hereunder, the Security Deposit shall be returned to Tenant without interest within thirty (30) days of the expiration of the Term, further provided that Landlord may deduct from the Security Deposit prior to returning it any amounts owed by Tenant to Landlord. If Tenant defaults under any provision of this Lease, Landlord may, but shall not be obligated to, apply all or any part of the Security Deposit to cure the default. In the event Landlord elects to apply the Security Deposit as provided for above, Tenant shall, within five (5) days after Landlord' s demand, restore the Security Deposit to the original amount. Furthermore, if Tenant defaults under this Lease more than two (2) times during any twelve (12) month period, irrespective of whether such default is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">cured, then, without limiting Landlord's other rights and remedies, Landlord may, in Landlord's sole discretion, modify the amount of the Security Deposit. Within ten (10) days after notice of such modification, Tenant shall submit to Landlord the required additional sums and Tenant's failure to do so shall constitute an Event of Default without further notice or right to cure, and Landlord shall have the right to exercise any remedy provided for in this Lease. Landlord may, at its discretion, commingle the Security Deposit with its other funds. Upon any sale or other conveyance of the Building, Landlord may transfer the Security Deposit (or any amount of the Security Deposit remaining) to a successor owner, and Tenant agrees to look solely to the successor owner for repayment of the same. The Security Deposit shall not operate as a limitation on any recovery to which Landlord may be entitled.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">12.&#160;&#160;&#160;&#160;USE.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  The Premises shall be used for the Permitted Use and for no other purposes whatsoever. Tenant shall not do or permit to be done in or about the Premises, Building or Property anything which is prohibited by any ordinance, order, rule, regulation, certificate of occupancy, or other governmental requirement, now in force or which may hereafter be enacted, including, without limitation, the Americans with Disabilities Act of 1990, as amended (collectively, &#34;Applicable Law&#34;). Tenant shall comply with all Applicable Law in its use of the Premises and common areas of the Property. Tenant use and cause all contractors, agents, employees, invitees and visitors of Tenant to use the Premises and any common area of the Property in such a manner as to prevent waste, nuisance and any disruption of other occupants. Tenant shall not place a load upon any floor in the Premises exceeding the floor load per square foot of area which such floor was designed to carry or which is allowed by law. Tenant shall, at Tenant's sole cost and expense, make any changes necessary to bring the Premises into compliance with any Applicable Law, to the extent that such changes are required (i) in connection with any Alterations performed by or at the request of Tenant, (ii) to accommodate Tenant's employees with disabilities, (iii) as a result of Tenant's use or occupancy of the Premises for any purpose other than general office use, or (iv) as a result of any breach by Tenant of any of Tenant' s covenants or agreements under this Lease. The judgment of any court of competent jurisdiction or the admission by Tenant in any action or proceeding against Tenant, whether Landlord is a party thereto or not, that Tenant has violated any Applicable Law in the use or occupancy of the Premises, Building or Property shall be conclusive of that fact as between Landlord and Tenant.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">13.&#160;&#160;&#160;&#160;MAINTENANCE&#59; SERVICES. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Excepting only those obligations for which Landlord is expressly responsible pursuant to this Lease, Tenant will, throughout the Term and at its sole cost, keep and maintain the Premises and all fixtures and equipment located therein, including, without limitation, carpeting, wall-covering, doors, plumbing and other fixtures, and any alterations performed by Tenant or within the Premises, clean safe and in good working order, condition and repair and make all necessary repairs and replacements thereto, including, without limitation, replacing all interior broken glass with glass of the same size and quality as that broken and repairing or replacing all systems or portions of systems exclusively serving the Premises including, without limitation, electrical, mechanical, plumbing and heating, ventilating and air conditioning systems. By way of example, and not limitation, Tenant shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">responsible, at Tenant's sole expense, for repairing and&#47;or replacing, carpet, marble, tile or other flooring, paint, wall coverings, corridor and interior doors and door hardware, telephone and computer equipment, interior glass, window treatments, ceiling tiles, shelving, cabinets, millwork and other tenant improvements. All repairs and replacements required of Tenant in connection herewith shall be of a quality and class at least equal to the minimum building standards established by Landlord and shall be done in a good and workmanlike manner in compliance with Applicable Law and the terms and conditions of this Lease&#59; provided that Tenant's maintenance and repair obligations shall be subject to normal wear and tear. If Tenant fails to maintain the Premises in compliance with the terms hereof, Landlord shall have the right to do such acts and expend such funds at the expense of Tenant as are reasonably required and Tenant shall reimburse Landlord for the cost thereof as Additional Rent upon demand. If Tenant uses heat generating machines or equipment in the Premises that materially affect the temperature otherwise maintained by the heating, ventilating and air conditioning system, Landlord reserves the right to install supplementary units for the Premises and the cost thereof, including the cost of installation, operation and maintenance, shall be paid by Tenant to Landlord as Additional Rent upon demand. Should Tenant require any additional service not provided by Landlord pursuant to this Lease, including any services furnished outside the Building's normal business hours, Landlord may, but shall not be obligated to, furnish such additional service and Tenant agrees to pay Landlord's charges therefor, including a reasonable administrative fee, any taxes imposed thereon, and, where appropriate, a reasonable allowance for depreciation of any systems being used to provide such service, as Additional Rent upon demand. The current charge for after-hours HVAC usage is Thirty-Five Dollars ($35.00) per hour per zone.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Landlord shall maintain the roof, foundation, exterior walls, structural portions, elevators, if any, any common areas and electrical, plumbing, mechanical and fire protection systems (subject to systems exclusive to the Premises) of the Building, the cost of which shall be included as a part of Operating Expenses unless expressly excluded therefrom pursuant to Section 7 of this Lease, provided that Landlord shall have no obligation to make any repairs unless Landlord has first received written notice of the need for such repairs from Tenant. Notwithstanding the foregoing, any damage to the Property occasioned by the negligence or willful act of Tenant or any person claiming under Tenant, or contractors, agents, employees, invitees or visitors of Tenant or any such person, shall be repaired by and at the sole expense of Tenant, except that Landlord shall have the right, at its sole option, to make such repairs and to charge Tenant for all costs and expenses incurred in connection therewith and Tenant shall pay the cost therefor as Additional Rent upon demand.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">In addition to the foregoing, during normal hours of operation of the Building throughout the Term, Landlord shall provide&#58; (i) reasonable quantities of electricity for the common areas&#59; (ii) electricity for Tenant's normal office use&#59; (iii) heating, ventilation and air conditioning as required in Landlord's reasonable judgment for the comfortable use and occupancy of the Premises during the normal hours of operation of the Building&#59; (iv) building standard window washing and five (5) days per week janitorial services&#59; (v) water for drinking, cleaning and restroom purposes only, and (vi) such other services as Landlord reasonably determines are </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">necessary or appropriate. The normal hours of operation of the Building shall be 7&#58;00 a.m. through 6&#58;00 p.m. Monday through Friday and 9&#58;00 a.m. through 1&#58;00 p.m. on Saturday, (except holidays), subject to adjustment from time to time by Landlord.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">14.&#160;&#160;&#160;&#160;SUBLEASE&#59; ASSIGNMENT.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Tenant shall not mortgage, pledge, hypothecate or otherwise encumber its interest in this Lease. Tenant shall not allow the Premises to be occupied, in whole or in part, by any other party and shall neither sublet the Premises, in whole or in part, nor assign this Lease, nor amend any sublease or assignment to which Landlord has consented, without in each case obtaining the prior written consent of Landlord. Any sublease or assignment, or amendment to any sublease or assignment, without Landlord's prior written consent shall, at Landlord's option, be null, void and of no effect, and shall, at Landlord' s option, constitute an Event of Default. The provisions of this section shall apply to a transfer, by one or more transfers, of all, or substantially all, of the business or assets of Tenant, of a majority of the stock, partnership or membership interests, or other evidences of ownership, of Tenant, and of any shares, voting rights or ownership interests of Tenant which results in a change in the identity of the entity or entities which exercise, or may exercise, effective control of Tenant as if such transfers were an assignment of this Lease. Tenant must request Landlord's consent to any assignment or sublease at least sixty (60) days prior to the proposed effective date of the assignment or sublease. At the time of its request, Tenant shall provide Landlord in writing&#58; (a) the name and address of the proposed assignee or subtenant, (b) a complete copy of the proposed assignment or sublease, (c) reasonably satisfactory information about the nature, business, and business history of the proposed assignee or subtenant and its proposed use of the Premises, and (d) banking, financial or other credit information about the proposed assignee or subtenant sufficient to enable Landlord to determine its financial condition and operating performance. Landlord shall not unreasonably withhold, condition or delay its consent to Tenant's written request to sublease the Premises or assign this Lease which is made in compliance with the terms and conditions of this section. Without limiting the other instances in which it may be reasonable for Landlord to withhold its consent to an assignment or sublease, Landlord's refusal to consent to any proposed assignment or sublease shall not be unreasonable if&#58; (a) the financial condition or operating performance of the proposed subtenant or assignee, determined in Landlord's reasonable discretion, is less than the greater of the financial condition or operating performance of the Tenant on (i) the date of execution of this Lease or (ii) the date of Tenant's request for Landlord's consent to the proposed assignment or sublease, (b) Tenant is in default under any of the terms, covenants or conditions of this Lease, (c) the proposed use of the Premises may result in&#58; (i) increased wear and tear on the Premises, Building or Property or (ii) any adverse effect on other tenants in the Building or adjacent buildings owned by Landlord, ( d) the proposed subtenant or assignee is a governmental agency, (e) Landlord has space available elsewhere in the Building which can accommodate the needs of the proposed subtenant or assignee or the proposed subtenant or assignee is a prospect to whom Landlord has made a proposal for the lease of space within the market area within the prior six (6) months, (f) the proposed assignee or subtenant is a tenant in any building owned by Landlord or any affiliate of Landlord including, without limitation, the Building, (g) the proposed subtenant or assignee would cause Landlord to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">be in violation of any covenant or restriction contained in another lease or other agreement, (h) Landlord's lender, if any, does not consent to the proposed sublease or assignment.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Notwithstanding the foregoing, Landlord's consent shall not be withheld when Tenant is transferring its interest in the Premises pursuant to transactions with an entity into or with which Tenant is merged or consolidated or to which all or substantially all of Tenant's business or assets are transferred or to any entity which controls or is controlled by Tenant or is under common control with Tenant, provided that in any of such events (a) Tenant is not then in default beyond all applicable notice and cure periods under this Lease, and (b) the successor to Tenant has a net worth computed in accordance with generally accepted accounting principles at least equal to the greater of (i) the net worth of Tenant immediately prior to such merger, consolidation or transfer, or (ii) the net worth of Tenant herein named on the date of this Lease. &#34;Control,&#34; as used in this section, shall mean the ownership, directly or indirectly, of at least fifty-one percent (51%) of the voting securities of, or possession of the right to vote, in the ordinary direction of its affairs, of at least fifty-one percent (51%) of the voting interest in, any person or entity. In addition, so long as Tenant remains substantially the same entity and meets the net worth requirement set forth in this paragraph, neither the raising of additional equity capital nor an initial price offering of Tenant's stock shall be deemed a transfer requiring Landlord' s consent hereunder. </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">No subletting or assignment shall release Tenant from Tenant's obligations under this Lease or alter the primary liability of Tenant to pay the Rent and to perform all other obligations to be performed by Tenant hereunder. Any subtenant shall, at Landlord's election, attorn to Landlord following any early termination of this Lease and any assignee shall be jointly and severally liable for the full performance of all of Tenant's obligations hereunder. Landlord may require, as a condition to granting Landlord's consent with respect to the provisions of this section, that the proposed subtenant or assignee enter into a written agreement with Landlord confirming the obligations of such subtenant or assignee under this Lease. Tenant shall pay, as Additional Rent on demand, all legal fees incurred by Landlord in connection with each proposed assignment or sublease whether or not Landlord's consent is obtained. If Tenant receives rent or other payments under any assignment or sublease in excess of the payments made by Tenant to Landlord under this Lease (as such amounts are adjusted on a per square foot basis if less than all of the Premises is transferred, and after deducting Tenant's costs of subletting), then Tenant shall pay Landlord fifty percent (50%) of such excess. Landlord's consent to one assignment or sublease shall not be deemed a waiver of the requirement of Landlord's consent to any subsequent assignment or sublease.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Notwithstanding the foregoing, Landlord's consent shall not be withheld when Tenant is transferring its interest in the Premises pursuant to transactions (A) with an entity into or with which Tenant is merged or consolidated or to which all or substantially all of Tenant's business or assets are transferred or (B) to any entity which controls or is controlled by Tenant or is under common control with Tenant (e.g., a wholly-owned affiliate or subsidiary or parent of Tenant), or (C) which constitute the initial public offering or regular trading of Tenant's securities on a national exchange (any such transfer being a &#34;Permitted Transfer&#34;)&#59; provided that in any of such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">events (a) no uncured Event of Default is then continuing under this Lease, (b) the successor to Tenant has a net worth computed in accordance with generally accepted accounting principles at least equal to the greater of (i) the net worth of Tenant immediately prior to such merger, consolidation or other transfer, and (ii) the net worth of Tenant as of the Date of this Lease, and (c) Tenant provides Landlord with notice of the transfer as soon as is reasonably practicable under the circumstances (which notice shall include proof that the subject transfer meets all of the requirements of this paragraph).</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">15.&#160;&#160;&#160;&#160;INDEMNI1Y&#59; NON-LIABILI1Y OF LANDLORD. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Except to the extent of any gross negligence or willful misconduct of Landlord or its agents, as a material part of the consideration for Landlord's execution of this Lease, Tenant shall neither hold nor attempt to hold Landlord or its employees or Landlord's agents or contractors or their employees liable for, and Tenant covenants and agrees that it shall indemnify and defend Landlord for and against any and all penalties, damages, fines, causes of action, liabilities, judgments, expenses (including, without limitation, reasonable attorneys' fees) or charges incurred in connection with or arising from&#58; (i) the use or occupancy of the Premises by Tenant or any person claiming under Tenant&#59; (ii) any acts, omissions or negligence of Tenant or any person claiming under Tenant, or contractors, agents, employees, invitees or visitors of Tenant or any such person&#59; (iii) any breach, violation or nonperformance by Tenant or any person claiming under Tenant or the employees, agents, contractors, invitees or visitors of Tenant or any such person of any term, covenant or provision of this Lease or any law, ordinance or governmental requirement of any kind, to the extent that Tenant or any such person has any legal or contractual duty relating thereto&#59; (iv) any injury or damage to the person, property or business of Tenant, its employees, agents, contractors, invitees, visitors or any other person entering upon the Property under the express or implied invitation of Tenant&#59; or (v) any matter occurring in the Premises during the Term.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Landlord, to the fullest extent not prohibited by law, shall not be liable for any damage occasioned by failure to keep the Premises, Building or Property in repair, nor for any damage done or occasioned by or from plumbing, gas, electricity, water, sprinkler, or other pipes or sewerage or the bursting, leaking or running of any pipes, tank or plumbing fixtures, in, above, upon or about the Premises or the Building nor from any damage occasioned by water, snow or ice being upon or coming through the roof, skylights, trap door or otherwise, nor for any damages arising from acts, or neglect of co-tenants or other occupants of the Building or of any owners or occupants of adjacent or contiguous property, nor for any loss of or injury to property or business occurring, through, in connection with or incidental to the failure to furnish any such services or the interruption of any services to the Premises. Further, Landlord shall not be liable or responsible to Tenant for any loss or damage to any property or person occasioned by theft or any other criminal act, fire, act of God, public enemy, injunction, riot, strike, insurrection, war, court order, law of requisition or order of any governmental authority.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Landlord shall not be liable in any event for incidental or consequential damages to Tenant by reason of any default by Landlord hereunder, whether or not Landlord is notified that such damages may occur. The term &#34;Landlord&#34;, as used in this Lease, so far as covenants or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">obligations to be performed by Landlord are concerned, means only the owner or owners at the time in question of the Landlord's interest in the Building, and in the event of any transfer or transfers of title to the Landlord's interest in the Building, the Landlord herein named (and in case of any subsequent transfers or conveyances, the then grantor) shall be automatically freed and relieved from and after the date of such transfer or conveyance of all liability as respects the performance of any covenants or obligations on the part of the Landlord contained in this Lease thereafter to be performed. Tenant's sole recourse against Landlord, and any successor to the interest of Landlord in the Premises, is to the interest of Landlord, and any successor, in the Premises and the Building of which the Premises are a part. In no event whatsoever shall Landlord or any beneficiary of any trust of which Landlord is a trustee or any of Landlord's officers, directors, partners, managers, members, shareholders, agents, attorneys and employees ever be personally liable hereunder.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">16.&#160;&#160;&#160;&#160;UTILITIES.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Tenant shall contract directly with public utility providers for all utilities which are separately metered to the Premises and shall pay such utility providers directly and promptly when due. If any utility, including electricity, is not separately metered to the Premises, the cost of such utility consumed on the Premises, as reasonably determined by Landlord, shall be paid by Tenant as Additional Rent. Tenant's obligation to pay for utilities provided to the Premises during the Term shall survive the expiration or earlier termination of the Lease. Tenant shall not utilize an alternative provider for a utility service other than the public utility provider servicing the Property unless Tenant shall first obtain the written consent of Landlord. Except to the extent attributable to any gross negligence or willful misconduct of Landlord or its agents, Landlord shall in no way be liable or responsible for any loss, damage, or expense that Tenant may sustain or incur by reason of any change, failure, interruption, or defect in the supply or character of the electric energy furnished to the Premises or Building. To ensure the proper functioning and protection of all utilities, Tenant agrees to abide by all reasonable regulations and requirements which Landlord may prescribe and to allow Landlord and its utility providers access to all electric lines, feeders, risers, wiring, and any other machinery within the Premises. </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Notwithstanding the foregoing, if any interruption or discontinuance of any service to be provided to the Premises by Landlord pursuant to the terms of the Lease&#58; (i) renders the entire Premises or a material portion thereof unusable for the Permitted Use, (ii) continues for more than five (5) consecutive business days without being cured by Landlord following Landlord's receipt of written notice from Tenant advising Landlord of the same, and (iii) is attributable to the willful neglect or negligence of Landlord, then, provided that Tenant does not use the affected portion of the Premises for the entire period of interruption, as Tenant's sole and exclusive remedy in connection with such interruption or discontinuance, Tenant shall be entitled to an equitable abatement of Base Rent, Operating Expenses Excess, and Tax Excess based on the relationship of the rentable area of the affected &#183;portion to the total rentable area of the Premises, which abatement shall commence on the sixth (6th) business day of the interruption and shall continue until Landlord has restored service&#59; provided that the amount of any such abatement shall be reduced by the amount of any proceeds Tenant receives from its business interruption insurance policy in connection with such interruption.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">17.&#160;&#160;&#160;&#160;HOLDING OVER. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> If Tenant or any party claiming by or under Tenant remains in occupancy of the Premises or any part thereof beyond the expiration or earlier termination of this Lease, such holding over shall be without right and a tenancy at sufferance, and Tenant shall be liable to Landlord for any loss or damage incurred by Landlord as a result thereof, including consequential damages. In addition, for each month or any part thereof that such holding over continues, Tenant shall pay to Landlord a monthly fee for the use and occupancy of the Premises equal to one hundred fifty percent (150%) of the Rent payable for the month immediately preceding such hold over, and there shall be no adjustment or abatement for any partial month. The provisions of this section shall not be deemed to limit or exclude any of Landlord's rights of re-entry or any other right granted to Landlord hereunder, at law or in equity.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">18.&#160;&#160;&#160;&#160;NO RENT DEDUCTION OR SET OFF.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Tenant's covenant to pay Rent is and shall be independent of each and every other covenant of this Lease. Tenant agrees that any claim by Tenant against Landlord shall not be deducted from Rent nor set off against any claim for Rent in any action. No payment by Tenant or receipt by Landlord of a lesser amount than the Rent herein stipulated shall be deemed to be other than on account of the earliest stipulated Rent, nor shall any endorsement or statement on any check or any letter accompanying any check or payment as Rent be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord's right to recover the balance of such Rent or pursue any remedy provided in this Lease or at law. In connection with the foregoing, Landlord shall have the absolute right in its sole discretion to apply any payment received from Tenant to any account or other payment of Tenant then not current and due or delinquent.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">19.&#160;&#160;&#160;&#160;CASUALTY.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  If the Premises or any part thereof are damaged by fire or other casualty, Tenant shall give prompt notice thereof to Landlord. If the Premises or the Building are totally or partially damaged or destroyed by fire or other casualty, thereby rendering the Premises totally or partially inaccessible or unusable, Landlord shall diligently restore and repair the Premises and the Building to substantially the same condition they were in prior to such damage. Provided that such damage was not caused by the act or omission of Tenant or any of its employees, agents, licensees, invitees or subtenants, until the repair and restoration of the Premises is completed Base Rent, Base Operating Expenses and Operating Expenses Excess shall be abated for that part of the Premises that Tenant is unable to use without substantial interference and is not occupied while repairs are being made, based on the ratio that the amount of unusable rentable area bears to the total rentable area of the Premises. Landlord shall bear the costs and expenses of repairing and restoring the Premises and the Building, provided, however, that Landlord shall not be obligated to spend more than the net proceeds of insurance proceeds made available for such repair and restoration nor shall Landlord be obligated to repair or restore, or to pay for the repair or restoration of, any furnishings, equipment or personal property belonging to Tenant or any alterations, additions, or improvements (including carpeting, floor coverings, paneling, decorations, fixtures) made to the Premises or Building by Tenant or by Landlord at Tenant's request or for Tenant's benefit. It shall be Tenant's sole responsibility to repair and restore all such items.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Notwithstanding the foregoing, (a) if there is a destruction of the Building that exceeds twenty-five percent (25%) of the replacement value of the Building from any risk, whether or not the Premises are damaged or destroyed, or (b) if Landlord reasonably believes that the repairs and restoration cannot be completed despite reasonable efforts within ninety (90) days after the occurrence of such damage, or (c) if Landlord reasonably believes that there shall be less than two (2) years remaining in the Term (exclusive of any extension options) upon the substantial completion of such repairs and restoration, or ( d) if any mortgagee or lender fails or refuses to make sufficient insurance proceeds available for repairs and restoration, or ( e) if zoning or other Applicable Law or regulations do not permit such repairs and restoration, Landlord shall have the right, at its sole option, to terminate this Lease by giving written notice of termination to Tenant within one hundred eighty (180) days after the occurrence of such damage. If this Lease is terminated pursuant to the preceding sentence, all Rent payable hereunder shall be apportioned and paid to the date of termination.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Notwithstanding anything to the contrary in this Section 19, in the event that (i) any damage by fire or other casualty for which Landlord is responsible for repairing pursuant to this Section 19 renders the entirety of the Premises unfit for occupancy by Tenant (including damage which renders the Premises inaccessible), (ii) Tenant does not occupy any portion of the Premises following the casualty event, (iii) Landlord does not exercise its right to terminate the Lease pursuant to this Section 19, and (iv) Landlord fails to substantially complete the repairs required of Landlord within two hundred seventy (270) days following the end of the casualty event, Tenant shall have the right to terminate the Lease by providing written notice to Landlord, such termination to be effective thirty (30) days after notice from Tenant is received by Landlord, unless Landlord substantially completes the repairs within such thirty (30) day period (in which case Tenant's termination election shall be deemed rescinded and shall have no force or effect).</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">All time periods provided in this Section for Landlord's performance shall be subject to extension on account of delays in effectuating a satisfactory settlement with any insurance company involved and events beyond Landlord's reasonable control. In the event of any damage or destruction to the Building or Premises, it shall be Tenant's responsibility to secure the Premises and, upon notice from Landlord, to remove forthwith, at its sole cost and expense, property belonging to Tenant or its licensees from such portion of the Premises as Landlord shall request.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">20.&#160;&#160;&#160;&#160;SUBORDINATION&#59; ESTOPPEL LETTERS. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> This Lease is expressly subordinate to any current or future mortgage or mortgages placed on the Property and to all other documents executed in connection with any such mortgage. Tenant agrees not to pay rent more than thirty (30) days in advance and to attorn to any party acquiring rightful possession of the Premises by or through any such mortgage. Tenant agrees that from time to time it shall deliver to Landlord or Landlord's mortgagee or designee within ten (10) business days of the date of Landlord's or Landlord's mortgagees or such other designee's request, a statement, in writing and substantially in the form attached as Exhibit G hereto, certifying the information set forth therein and such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">other true statements as Landlord or Landlord's mortgagee or designee may require. Tenant's failure to execute and deliver such statements within the time required shall, at Landlord's election, be an Event of Default and shall also be conclusive upon Tenant that (a) this Lease is in full force and effect and has not been modified except as represented by Landlord&#59; (b) that Landlord is not in default under any provisions of this Lease and that Tenant has no right of offset, counterclaim or deduction against Rent&#59; and (c) not more than one month's Rent has been paid in advance.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Upon Tenant's request, provided that Tenant is not then in default under this Lease, Landlord shall obtain from any mortgagee of the Property a subordination, nondisturbance agreement in favor of Tenant and in a commercially reasonable form.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">21.&#160;&#160;&#160;&#160; ALTERATIONS&#59; RESTORATION.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(A)&#160;&#160;&#160;&#160;Tenant shall not make or permit to be made any alterations, additions, or improvements in or to the Premises (&#34;Alterations&#34;) without first obtaining the prior written consent of Landlord which consent may be withheld in Landlord's reasonable discretion. Notwithstanding the foregoing, so long as Tenant provides Landlord with at least ten (I 0) business days' prior written notice of the same, Landlord's consent shall not be required with respect to &#34;Cosmetic Work&#34; (as hereinafter defined) costing up to Five Dollars ($5.00) per rentable square foot of the Premises, in the aggregate, in any twelve (12) month period. Cosmetic Work shall include only Alterations which (1) are purely cosmetic in nature (e.g., painting, carpeting) (2) do not require building permits, (3) neither affect the Building's systems nor its structural components, ( 4) do not require work to be performed inside the walls or above the ceiling of the Premises, and ( 5) are not visible from outside the Premises. All Alterations (i) must comply with all Applicable Law, (ii) must be compatible with the Building and its mechanical, electrical, heating, ventilating, air-conditioning and life safety systems&#59; (iii) must not interfere with the use and occupancy of any other portion of the Building by any other tenant or their invitees&#59; and (iv) must not affect the integrity of the structural portions of the Building. In addition, Landlord may impose as a condition to such consent such additional requirements as Landlord in its reasonable discretion deems necessary or desirable, including, without limitation&#58; (a) Tenant's submission to Landlord, for Landlord's prior written approval, of all plans and specifications relating to the Alterations&#59; (b) Landlord's prior written approval of the time or times when the Alterations are to be performed&#59; (c) Landlord's prior written approval of the contractors and subcontractors performing work in connection with the Alterations&#59; (d) Tenant' s receipt of all necessary permits and approvals from all governmental authorities having jurisdiction over the Premises prior to the construction of the Alterations&#59; (e) Tenant's delivery to Landlord of such bonds and insurance as Landlord customarily requires&#59; (f) Tenant's payment to Landlord of a commercially reasonable fee for Landlord's supervision of any Alterations&#59; (g) Tenant's and Tenant's contractor's compliance with such construction rules and regulations and building standards as Landlord promulgates from time to time&#59; and (i) Tenant's delivery to Landlord of &#34;as built&#34; drawings of the Alterations in such form or medium as Landlord may require. All direct and indirect costs relating to any modifications, alterations or improvements of the Building, whether outside or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">inside of the Premises, required by any governmental agency or by law as a condition or as the result of any Alteration requested or effected by Tenant shall be borne by Tenant. Landlord may elect to perform such required modifications, alterations or improvements (at Tenant's sole cost and expense) or require such performance directly by Tenant&#59; provided that if Landlord elects to perform any such required modification, alteration or improvement work, Tenant shall not be deemed in default under this Lease if, in the performance of such work, Landlord fails to meet any requirement of this Section 21. Tenant shall not permit any mechanic's lien or other liens to be placed upon the Premises or the Building as a result of any materials, services or labor ordered by or provided to Tenant or any of Tenant's agents, officers, or employees. Without waiving any other rights or remedies under this Lease, Landlord may bond or insure or otherwise discharge any such lien and Tenant shall reimburse Landlord for any amount paid by Landlord in connection therewith as Additional Rent upon demand.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(B)&#160;&#160;&#160;&#160;Upon the expiration or earlier termination of the Lease, Tenant shall surrender the Premises in good working order and condition. Tenant shall remove any and all Alterations, trade fixtures, equipment, data&#47;telecommunications cabling and wiring installed by or on behalf of Tenant and furniture from the Premises and Tenant shall fully repair any damage, including any structural damage, occasioned by the removal of the same. Notwithstanding the foregoing, Landlord may require that Tenant not remove any or all Alterations and any such Alteration or Alterations shall become a part of the realty and shall belong to Landlord without compensation, and title thereto shall pass to Landlord under this Lease as by a bill of sale&#59; provided that, if requested by Tenant, Landlord shall advise Tenant if an Alteration will need to be removed from the Premises at the time of Landlord's approval of such Alteration. At Landlord's election, all Alterations, trade fixtures, equipment, wire and cable, furniture, fixtures, other personal property not removed shall conclusively be deemed to have been abandoned by Tenant and may be appropriated, sold, stored, destroyed or otherwise disposed of by Landlord without notice to Tenant or to any other person and without obligation to account for them. Tenant shall pay Landlord all reasonable expenses incurred in connection with Landlord's disposition of such property, including without limitation the cost of repairing any damage to the Building or the Premises caused by removal of such property, and shall hold Landlord harmless from loss, liability, or expense arising from the claims of third parties such as Tenant's lenders whose loans are secured by such property. Tenant's obligations under this section shall survive the end of this Lease. Notwithstanding the foregoing, with the exceptions of (i) cabling, (ii) security systems, (iii) cubicles, (iv) audio&#47;visual systems, and any portions of Tenant's Work that would cost more to remove than traditional office improvements, Tenant shall not be required to remove any Tenant's Work that is reflected on Schedule 1 to Exhibit E attached hereto upon the expiration or earlier termination of this Lease.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">22.&#160;&#160;&#160;&#160;DEFAULT&#59; REMEDIES.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(A)&#160;&#160;&#160;&#160;In addition to any other acts or omissions designated in this Lease as Events of Default, each of the following shall constitute an Event of Default by Tenant hereunder&#58; (i) the failure to make any payment of Rent or any installment thereof or to pay any other sum required to be paid </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">by Tenant under this Lease or under the terms of any other agreement between Landlord and Tenant and the continuance of such failure for more than five (5) days following written notice from Landlord to Tenant&#59; provided, however, if, on two (2) occasions during any consecutive twelve (12) month period during the Term, Tenant fails to pay any installment of Rent when due but does pay the same within five (5) days after notice of such failure, then Tenant' s subsequent failure to pay any installment of Rent when due during said twelve (12) month period shall constitute an Event of Default hereunder without the need for notice or grace period&#59; (ii) the use or occupancy of the Premises for any purpose other than the Permitted Use without Landlord's prior written consent or the conduct of any activity in the Premises which constitutes a violation of law&#59; (iii) if the interest of Tenant or any part thereof under this Lease shall be levied on under execution or other legal process and said interest shall not have been cleared by said levy or execution or bonded around within thirty (30) days from the date thereof&#59; (iv) if any voluntary or involuntary petition in bankruptcy or for corporate reorganization or any similar relief shall be filed by or against Tenant or any guarantor of the Lease or if a receiver shall be appointed for Tenant or any guarantor or any of the property of Tenant or guarantor&#59; (v) if Tenant or any guarantor of the Lease shall make an assignment for the benefit of creditors or if Tenant shall admit in writing its inability to meet Tenant's debts as they mature&#59; (vi) if, for more than five (5) days, any insurance required to be maintained by Tenant pursuant to this Lease shall be cancelled or terminated or shall expire or shall be reduced or materially changed, except, in each case, as permitted in this Lease, or mutually agreed to in writing by the parties, and provided that such five (5) day period shall not delay Landlord's right to obtain insurance on behalf of Tenant and to charge Tenant for the cost thereof pursuant to the terms of Section 9(D) of this Lease&#59; (vii) if Tenant shall fail to promptly discharge or bond over any lien placed upon the Premises in violation of this Lease&#59; (viii) if any Letter of Credit required to be maintained by Tenant pursuant to this Lease shall be cancelled or terminated or shall expire or shall be reduced or materially changed, except, in each case, as permitted in this Lease, or mutually agreed to in writing by the parties&#59; (ix) if Tenant shall abandon or vacate the Premises during the Term&#59; (x) if Tenant shall fail to execute and deliver an estoppel certificate or subordination agreement as required hereunder&#59; or (xi) the failure to observe or perform any of the other covenants or conditions in this Lease which Tenant is required to observe and perform and which Tenant has not corrected within thirty (30) days after written notice thereof to Tenant&#59; provided, however, that if said failure involves the creation of a condition which, in Landlord's reasonable judgment, is dangerous or hazardous, Tenant shall be required to cure same within 24 hours after receipt of notice thereof, and if a default which is not dangerous or hazardous cannot reasonably be cured within thirty (30) days then Tenant shall have such additional period of time as is reasonably necessary to effect a cure provided that Tenant promptly commences the cure and diligently pursues the same to completion&#59; provided further that the cure periods set forth above shall not operate to delay any right of Landlord set forth in this Lease to perform on the account of Tenant.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(B)&#160;&#160;&#160;&#160;Upon the occurrence of an Event of Default by Tenant, the cost of all unamortized brokerage commissions, rental abatements, legal fees, Tenant allowances, work performed by Landlord to the Premises, and any other Tenant inducements paid or provided under this Lease plus interest on the foregoing items accruing from the Commencement Date at the Default Rate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">shall immediately become due, and Landlord may, at its option, with or without notice or demand of any kind to Tenant or any other person, exercise any one or more of the following described remedies, in addition to all other rights and remedies provided at law, in equity or elsewhere herein, and such rights and remedies shall be cumulative and none shall exclude any other right allowed by law&#58;</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(i)&#160;&#160;&#160;&#160;Landlord may terminate this Lease, repossess and re-let the Premises, in which case Landlord shall be entitled to recover as damages (in addition to any other sums or damages for which Tenant may be liable to Landlord) a lump sum equal to the amount by which the present value of the excess Rent remaining to be paid by Tenant for the balance of the Term of the Lease exceeds the fair market rental value of the Premises, after deduction of all anticipated expenses of reletting. For the purpose of determining present value, Landlord and Tenant agree that the interest rate shall be the rate applicable to the then-current yield on obligations of the U .S. Treasury having a maturity date on or about the Expiration Date. Should the fair market rental value of the Premises for the balance of the Term (after deduction of all anticipated expenses of reletting) exceed the value of the Rent to be paid by Tenant for the balance of the Term, Landlord shall have no obligation to pay to or otherwise credit Tenant for any such excess amount&#59;</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(ii)&#160;&#160;&#160;&#160;Landlord may, without terminating the Lease, terminate Tenant's right of possession, repossess the Premises including, without limitation, removing all or any part of Tenant's personal property in the Premises and to place such personal property in storage or a public warehouse at the expense and risk of Tenant, and relet the same for the account of Tenant for such rent and upon such terms as shall be satisfactory to Landlord. For the purpose of such reletting, Landlord is authorized to decorate, repair, remodel or alter the Premises. Tenant shall pay to Landlord as damages a sum equal to all Rent under this Lease for the balance of the Term unless and until the Premises are relet. If the Premises are relet, Tenant shall be responsible for payment upon demand to Landlord of any deficiency between the Rent as relet and the Rent for the balance of this Lease, all costs and expenses of reletting, and all reasonable decoration, repairs, remodeling, alterations, additions and collection of the rent accruing therefrom. Tenant shall not be entitled to any rents received by Landlord in excess of the rent provided for in this Lease. No re-entry or taking possession of the Lease Premises by Landlord shall be construed as an election to terminate this Lease unless a written notice of such intention be given to Tenant or unless the termination thereof be decreed by a court of competent jurisdiction. Notwithstanding any reletting without termination, Landlord may at any time thereafter elect to terminate this Lease for any breach, and in addition to the other remedies it may have, recover as damages (in addition to any other sums or damages for which Tenant may be liable to Landlord) a lump sum equal to the amount by which the present value of the excess Rent remaining to be paid by Tenant for the balance of the Term of the Lease exceeds the fair market rental value of the Premises, after deduction of all anticipated expenses of reletting. In the event Landlord repossesses the Premises as provided above, Landlord may remove all persons and property from the Premises and store any such property at the cost of Tenant, without liability for damage&#59; and</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(iii)&#160;&#160;&#160;&#160;Landlord may, but shall not be obligated to, and without waiving or releasing Tenant from any obligations of Tenant hereunder, make any payment or perform such other act on Tenant's part to be made or performed as provided in this Lease. All sums so paid by Landlord and all necessary incidental costs shall be payable to Landlord as Additional Rent on demand and Tenant covenants to pay such sums.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(C)&#160;&#160;&#160;&#160;Tenant agrees that Landlord may file suit to recover any sums falling due under the terms of this section from time to time and that no suit or recovery of any portion due Landlord hereunder shall be any defense to any subsequent action brought for any amount not theretofore reduced to judgment in favor of Landlord.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(D)&#160;&#160;&#160;&#160;Tenant shall promptly pay upon notice, as Additional Rent, all reasonable costs, charges and expenses incurred by Landlord (including, without limitation, reasonable fees and out-of-pocket expenses of legal counsel, collection agents, and other third parties retained by Landlord) together with interest thereon at the rate set forth in Section 5 of this Lease, in collecting any amount due from Tenant, enforcing any obligation of Tenant hereunder, or preserving any rights or remedies of Landlord&#59; and Tenant shall pay all reasonable attorneys' fees and expenses arising out of any litigation, negotiation or transaction in which Tenant causes Landlord, without Landlord's fault, to become involved or concerned.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(E)&#160;&#160;&#160;&#160;No waiver of any provision of this Lease shall be implied by any failure of Landlord to enforce any remedy on account of the violation of such provision, even if such violation be continued or repeated subsequently, and no express waiver by Landlord shall be valid unless in writing and shall not affect any provision other than the one specified in such written waiver and that provision only for the time and in the manner specifically stated in the waiver. No receipt of monies by Landlord from Tenant after the termination of this Lease shall in any way alter the length of the Term or Tenant's right of possession hereunder or after the giving of any notice shall reinstate, continue or extend the Term or affect any notice given Tenant prior to the receipt of such monies, it being agreed that after the service of notice or the commencement of a suit or after final judgment for possession of the Premises, Landlord may receive and collect any Rent due, and the payment of Rent shall not waive or affect said notice, suit or judgment. Landlord shall not be required to serve Tenant with any notices or demands as a prerequisite to its exercise of any of its rights or remedies under this Lease, other than those notices and demands specifically required under this Lease. Tenant expressly waives the service of any statutory demand or notice which is a prerequisite to Landlord's commencement of eviction proceedings against Tenant, including the demands and notices specified in any federal, state or local laws and ordinances.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(F)&#160;&#160;&#160;&#160;Landlord shall not be in default under this Lease unless Landlord fails to perform its obligations hereunder within thirty (30) days after Landlord's receipt of written notice from Tenant specifying how Landlord has failed to perform such obligations and the act required to cure the same&#59; provided, however, that if the nature of Landlord's obligation is such that more than thirty (30) days are required for performance, Landlord shall not be in default if Landlord </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">commences performance within such thirty (30) day period and thereafter diligently prosecutes the same to completion. Tenant shall have no right to terminate this Lease or withhold Rent payments as such amounts become due and payable hereunder.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">23.&#160;&#160;&#160;&#160;NOTICES.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  All notices permitted or required hereunder shall be in writing and (i) delivered personally, (ii) sent by U.S. certified mail, postage prepaid, with return receipt requested, or (iii) sent overnight by nationally recognized overnight courier and sent to the respective parties at the Notice Addresses provided in Section 1 of this Lease. If sent by U.S. certified mail, such notice shall be considered received by the addressee on the second (2nd) business day after posting. If sent by nationally recognized overnight courier, such notice shall be considered received by the addressee on the first (1st) business day after deposit with the courier. Notices may be given by an agent on behalf of Landlord or Tenant. Any notice from Landlord to Tenant shall also be deemed to have been given if delivered to the Premises, addressed to Tenant.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">24.&#160;&#160;&#160;&#160;EMINENT DOMAIN.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  If during the Term (a) the whole of the Premises or the Building shall be taken by any governmental or other authority having powers of eminent domain or conveyed to such entity under threat of the exercise of such power or (b) any part of the Premises or the Building shall be so taken or conveyed and as a result, the remainder of the Premises or the Building has been rendered impractical, in Landlord's sole judgment, for the operation of Landlord's rental activities on the Property, this Lease shall terminate on the date of the taking or conveyance, and Base Rent, Operating Expenses Excess, and Tax Excess shall be apportioned to the date thereof Tenant shall have no right to any apportionment of or any share in any condemnation award or judgment for damages made for the taking or conveyance of any part of the Premises or the Building&#59; provided, however, that so long as Tenant's award does not diminish or otherwise adversely affect any award collectible by Landlord, Tenant shall be entitled to make its own claim for, and receive any separate award that may be made for, Tenant's loss of business, or for the taking of or injury to Tenant's improvements, or on account of any cost or loss Tenant may sustain in the removal of Tenant's trade fixtures, equipment, and furnishings, or as a result of any alterations, modifications or repairs which may be reasonably required by Tenant in order to place the remaining portion of the Premises not so condemned in a suitable condition for the continuance of Tenant's occupancy.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">25.&#160;&#160;&#160;&#160;QUIET ENJOYMENT.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Landlord represents and warrants that it has full right and authority to enter into this Lease and that Tenant, while paying the rental and performing its other covenants and agreements contained in this Lease, shall peaceably and quietly have, hold and enjoy the Premises for the Term without hindrance or molestation from Landlord subject to the terms and provisions of this Lease. Landlord shall not be liable for any interference or disturbance by other tenants or third persons, nor shall Tenant be released from any of the obligations of this Lease because of such interference or disturbance.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">26.&#160;&#160;&#160;&#160;RULES AND REGULATIONS. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Tenant agrees to comply with (and cause its agents, contractors, employees and invitees to comply with) the rules and regulations attached hereto as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Exhibit B and with such reasonable modifications thereof and additions thereto as Landlord may from time to time reasonably make. Provided that Landlord enforces the rules and regulations uniformly against all tenants of the Property, Landlord shall not be liable for any violation of said rules and regulations by other tenants or occupants of the Building or Property.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">27.&#160;&#160;&#160;&#160;ENVIRONMENTAL.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  &#34;Environmental Laws&#34; shall mean all federal, state and local laws (including, without limitation, case and common law), statutes, regulations, rules, ordinances, guidance, permits, licenses, grants, orders, decrees and judgments relating to the environment, human health and safety. &#34;Hazardous Substances&#34; shall mean all explosive materials, radioactive materials, hazardous or toxic materials, wastes, chemicals or substances, petroleum, petroleum byproducts and petroleum products (including, without limitation, crude oil or any fraction thereof), asbestos and asbestos-containing materials, radon, lead, polychlorinated biphenyls, mold, urea-formaldehyde, microorganisms, and all materials, wastes, chemicals and substances that are regulated by any Environmental Law. Tenant shall not (i) manufacture, generate, utilize, store, handle, treat, process, or release any Hazardous Substances at, in, under, from or on the Premises or Property or (ii) suffer or permit to occur any violation of Environmental Laws with respect to the Premises or Property. Tenant shall indemnify, defend (with counsel reasonably acceptable to Landlord and at Tenant's sole cost) and hold harmless Landlord and its partners, managers, members, officers, directors, employees, agents, successors, grantees, assigns and mortgagees from any and all claims, demands, liabilities, damages, expenses, fees, costs, fines, penalties, suits, proceedings, actions, causes of action and losses of any and every kind and nature, including, without limitation, diminution in value of the Property, damages for the loss or restriction on use of the rentable or usable space or of any amenity, natural resource damages, damages arising from any adverse impact on leasing space on the Premises or Property, and sums paid in settlement of claims and for attorney's fees, consultant's fees and expert's fees that may arise during or after the Term or any extension of the Term in connection with any breach by Tenant of the covenants contained in this section, the presence, release or threatened release of Hazardous Substances at, in, under, from, to or on the Premises or Property, or any violation or alleged violation of any Environmental Laws. For purposes of this section, the term &#34;costs&#34; includes, without limitation, costs, expenses and consultant's fees, expert's fees and attorney's fees incurred in connection with any investigation of site conditions or any cleanup, remedial, removal, restoration, monitoring or maintenance work. This covenant of indemnity shall survive the termination of this Lease. Notwithstanding the foregoing, the prohibition contained herein shall not apply to ordinary office products that may contain de minimis quantities of Hazardous Substances, provided such products are used in compliance with Environmental Laws&#59; however, Tenant's indemnification obligations are not diminished with respect to the presence of such products. Tenant shall immediately notify Landlord of any release or threatened release at, in, under, from, to or on the Premises or Property.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Except with respect to hazardous conditions caused or contributed to by Tenant, Landlord shall indemnify, defend and hold harmless Tenant from and against any and all claims to the extent that the same arise out of the presence of Hazardous Substances on or below the Premises, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Building or Property, including Hazardous Substances located within existing Building mechanical, electrical, plumbing, and fire life safety systems.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">28.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  From time to time, but not more often than twice each year, Tenant shall furnish Landlord within ten (10) business days of such request copies of financial statements showing Tenant's current financial condition and the results of the previous year's operations which shall be certified as true and correct by the chief financial officer, or other responsible officer, of Tenant.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">29.&#160;&#160;&#160;&#160;BROKERS.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Landlord utilized the services of Cushman &#38; Wakefield (the &#34;Listing Broker&#34;) and Tenant utilized the services of Hughes Marino Inc. (the &#34;Non-Listing Broker&#34;) in connection with this Lease. Tenant represents to Landlord that Tenant did not involve any other brokers in procuring this Lease. Landlord shall pay a commission to the Non-Listing Broker and the Listing Broker as is agreed to by the parties per a separate agreement. Tenant agrees to forever indemnify, defend and hold Landlord harmless from and against any commissions, liability, loss, cost, damage or expense (including reasonable attorneys' fees) that may be asserted against or incurred by Landlord by any broker other than the Listing Broker and Non-Listing Broker as a result of any misrepresentation by Tenant hereunder.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">30.&#160;&#160;&#160;&#160;MISCELLANEOUS.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(A)&#160;&#160;&#160;&#160;Time is of the essence of this Lease and each of its provisions.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(B)&#160;&#160;&#160;&#160;This Lease and all covenants and agreements herein contained shall be binding upon, apply, and inure to the respective heirs, executors, successors, administrators and assigns of all parties to this Lease&#59; provided, however, that this Lease shall not inure to the benefit of any assignee, heir, administrator, devisee, legal representative, successor, transferee or successor of Tenant except upon the prior written consent of Landlord.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(C)&#160;&#160;&#160;&#160;This Lease contains the entire agreement of the parties, all other and prior representations, negotiations and agreements having been merged herein and extinguished hereby. No modification, waiver or amendment of this Lease or of any of its conditions or provisions shall be binding upon either party hereto unless in writing signed by both parties.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(D)&#160;&#160;&#160;&#160;The captions of sections and subsections of this Lease are for convenience only and shall not be deemed to limit, construe, affect or alter the meaning of such sections or subsections.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(E)&#160;&#160;&#160;&#160;Interpretation of this Lease shall be governed by the laws of the state or commonwealth in which the Premises is located, without regard to conflict of laws. Tenant irrevocably submits to the nonexclusive jurisdiction of the courts of said state or commonwealth and agrees that all suits, actions, claims or proceedings may be heard and determined in such courts. Tenant waives any objection which it may have at any time to the laying of venue of any suit, action, claim or proceeding arising out of or relating to this Lease. The foregoing shall not be deemed to preclude </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Landlord from bringing any suit, action, claim or proceeding in connection with this Lease in any other jurisdiction.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(F)&#160;&#160;&#160;&#160;This Lease is and shall be deemed and construed to be the joint and collective work product of Landlord and Tenant and, as such, this Lease shall not be construed against either party, as the otherwise purported drafter of same, by any court of competent jurisdiction in order to resolve any inconsistency, ambiguity, vagueness or conflict, if any, in the terms or provisions contained herein.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(G)&#160;&#160;&#160;&#160;In the event that either party thereto shall be delayed or hindered in or prevented from the performance of any act required hereunder by reason of strikes, lock-outs, labor troubles, inability to procure labor, inability to procure materials or equipment or reasonable substitutes therefore, failure of power, fire or other casualty, restrictive government laws or regulations, judicial orders, enemy or hostile government actions, riots, insurrection or other civil commotions, war or other reason of a like nature not at the fault of the party delayed in performing any act as required under the terms of this Lease (&#34;Force Majeure&#34;), then performance of such act shall be excused for the period of delay and the period for the performance of any such act shall be extended for a period equivalent to the period of such delay. Force Majeure shall not operate to excuse Tenant from the prompt payment of Rent or any other payments required under the terms of this Lease.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(H)&#160;&#160;&#160;&#160;Tenant shall reimburse Landlord as Additional Rent on demand for all reasonable out-of-pocket expenses, including without limitation legal, engineering or other professional services or expenses incurred by Landlord in connection with any requests by Tenant for consents or approvals hereunder to the extent that such consents or approvals are required hereunder&#59; provided that the foregoing shall not create any right of Landlord to be reimbursed for the same expense more than one (1) time, and provided further that the foregoing reimbursement obligation of Tenant shall be subject to any applicable dollar maximums expressly set forth in this Lease. </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(I)&#160;&#160;&#160;&#160;A final determination by a court of competent jurisdiction that any provision of this Lease is invalid shall not affect the validity of any other provision, and any provision so determined to be invalid shall, to the extent possible, be construed to accomplish its intended effect.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(J)&#160;&#160;&#160;&#160;If more than one person or entity shall ever be Tenant, the liability of each such person and entity shall be joint and several.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(K)&#160;&#160;&#160;&#160;If Tenant is a corporation, a limited liability company, an association or a partnership, it shall, concurrently with the signing of this Lease, at Landlord's option, furnish to Landlord certified copies of the resolutions of its board of directors (or of the executive committee of its board of directors) or consent of its members or partners authorizing Tenant to enter into this Lease. Moreover, each individual executing this Lease on behalf of Tenant represents and warrants that he or she is duly authorized to execute and deliver this Lease and that Tenant is a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">duly organized corporation, limited liability company, association or partnership under the laws of the state of its incorporation or formation, is qualified to do business in the jurisdiction in which the Building is located, is in good standing under the laws of the state of its incorporation or formation and the laws of the jurisdiction in which the Building is located, has the power and authority to enter into this Lease, and that all corporate or partnership action requisite to authorize Tenant to enter into this Lease has been duly taken.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(L)&#160;&#160;&#160;&#160;The submission of this Lease to Tenant is not an offer to lease the Premises, or an agreement by Landlord to reserve the Premises for Tenant. Landlord shall not be bound to Tenant until Tenant has duly executed and delivered an original Lease to Landlord and Landlord has duly executed and delivered an original Lease to Tenant. Notwithstanding the Commencement Date or Commencement Date contemplated in Section 1 hereof, this Lease shall take effect and be binding upon the parties hereto as of its execution and delivery.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(M)&#160;&#160;&#160;&#160;This Lease may be executed in any number of counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Any signature to this Lease transmitted via facsimile (or other electronic means) shall be deemed an original signature and be binding upon the parties hereto.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(N)&#160;&#160;&#160;&#160;Tenant represents and warrants to Landlord that neither Tenant nor any of Tenant's members, shareholders or other equity owners, is a person or entity with whom U.S. persons or entities are restricted from doing business under regulations of the Office of Foreign Asset Control (&#34;OFAC&#34;) of the Department of the Treasury (including those named on OFAC's Specially Designated and Blocked Persons List) or under any statute, executive order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism), or other governmental action.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">31.&#160;&#160;&#160;&#160;PARKING.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  At no additional cost, Tenant shall be entitled to the use of no more than four (4) parking spaces per one thousand (1,000) rentable square feet of the Premises. Tenant shall have the right to designate up to fifteen (15) of such spaces for use exclusively by Tenant and Tenant's invitees in covered parking areas approved by Landlord. With the exception of such designated exclusive covered spaces, all spaces to which Tenant shall be entitled shall be located in areas designated by Landlord and shall be provided on a non-excusive, first-come-first-served basis in common with other occupants and visitors of the Property. Landlord shall not be obligated to enforce parking limits. Tenant shall not use any parking space designated by Landlord as visitor parking or as exclusive to other parties. If Tenant uses parking in excess of that provided for herein, and if such excess use occurs on a regular basis, and if Tenant fails, after written notice from Landlord of any one violation, to reduce its excess use of the parking areas, then such excess use shall constitute an Event of Default under this Lease without further notice or opportunity to cure such Event of Default.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">32.&#160;&#160;&#160;&#160;SIGNAGE.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Landlord, at Tenant's expense, shall furnish Tenant with Building standard suite entry, elevator lobby, and directory signage. Landlord may specify that the design of such signage be similar to, or consistent with, the design and location of other signs identifying tenants in the Building. Such signage shall be subject to all Applicable Law and ordinances. Upon termination of this Lease, Tenant shall remove such signage and repair any damage caused thereby.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">33.&#160;&#160;&#160;&#160;INTENTIONALLY OMITTED.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">34.&#160;&#160;&#160;&#160;CERTAIN RIGHTS RESERVED TO LANDLORD.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Landlord reserves the following rights, each of which Landlord may exercise without notice or liability to Tenant, and the exercise of any such rights shall not be deemed to constitute an eviction or disturbance of Tenant's use or possession of the Premises and shall not give rise to any claim for set-off or abatement of Rent or any other claim&#58; (a) to enter the Premises upon not less than twenty-four (24) hours prior written or verbal notice (except in the event of an emergency, in which case no prior notice shall be required) for the purposes of examining the same or to make repairs or alterations or to provide any service&#59; (b) to change the arrangement and&#47;or locations of entrances, or passageways, doors and doorways, and corridors, windows, elevators, stairs, parking areas and any other common areas, (c) to change the name or street address of the Building or the suite number of the Premises&#59; (d) to install, affix and maintain any and all signs on the exterior or interior of the Building&#59; (e) to make repairs, decorations, alterations, additions or improvements, whether structural or otherwise, in, about and to the Building or common areas and for such purposes temporarily close doors, corridors and other areas of the Building and interrupt or temporarily suspend services or use of common areas&#59; (f) to retain at all times, and to use in appropriate instances, keys to all doors within and into the Premises&#59; (g) to grant to any person or to reserve unto itself the exclusive right to conduct any business or render any service in the Building&#59; (h) to show the Premises at reasonable times and, if vacated or abandoned, to prepare the Premises for reoccupancy&#59; provided that Landlord may only show the Premises to prospective tenants during the final twelve (12) months of the Term and during any time when Tenant is in default&#59; (i) to install, use and maintain in and through the Premises pipes, conduits, wires and ducts serving the Building&#59; (j) to approve the weight, size and location of safes or other heavy equipment or other articles which may be located in the Premises and to determine the time and manner in which such articles may be moved in, about or out of the Building or Premises&#59; and (k) to take any other action which Landlord deems reasonable in connection with the operation, maintenance, marketing or preservation of the Premises or Building. The reduction or elimination of Tenant's light, air or view shall not affect Tenant's liability under this Lease, nor shall it create any liability of Landlord to Tenant. Except in the event of an emergency, Landlord shall endeavor to minimize any unreasonable interference with Tenant's ongoing business operations and use and occupancy of the Premises in connection with the exercise of any of the foregoing rights under this Section 34.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">35.&#160;&#160;&#160;&#160;LEASE COMMENCEMENT&#47;ACCEPTANCE OF PREMISES. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> At Landlord' s request, Landlord and Tenant shall enter into a commencement letter agreement (the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#34;Commencement Letter&#34;) in form substantially similar to that attached hereto as Exhibit F. Tenant's failure to execute and return the Commencement Letter, or to provide written objection to the statements contained in the Commencement Letter, within fifteen (15) days shall be deemed an approval by Tenant of the statements contained therein.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">36.&#160;&#160;&#160;&#160;WAIVER OF RIGHT TO JURY TRIAL.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  TO THE EXTENT PERMITTED BY APPLICABLE LAW, LANDLORD AND TENANT WAIVE THEIR RESPECTIVE RIGHTS TO A TRIAL BY JURY OF ANY CLAIM, ACTION, PROCEEDING OR COUNTERCLAIM BY EITHER PARTY AGAINST THE OTHER ON ANY MATTERS ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS LEASE, THE RELATIONSHIP OF LANDLORD AND TENANT, AND&#47;OR TENANT'S USE OR OCCUPANCY OF THE PREMISES OR BUILDING (INCLUDING ANY CLAIM OF INJURY OR DAMAGE OR THE ENFORCEMENT OF ANY REMEDY UNDER ANY CURRENT OR FUTURE LAWS, STATUTES, REGULATIONS, CODES OR ORDINANCES).</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">37.&#160;&#160;&#160;&#160;RECORDING.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Tenant shall not record this Lease without the prior written consent of Landlord. Tenant, upon the request of Landlord, shall execute and acknowledge a short form memorandum of this Lease for recording purposes.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;signatures on following page&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">IN WITNESS WHEREOF, the parties hereto have executed this Lease.</font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.955%"><tr><td style="width:1.0%"></td><td style="width:36.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.505%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">TENANT&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">LANDLORD&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">PLUM HEALTHCARE GROUP, LLC, a California limited liability company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">BROOKWOOD CB I, LLC, a Delaware limited liability company</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline"> &#47;s&#47; Naveed Hakim     </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58; Brookwood CB Investors, LLC<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;a Delaware limited liability company,<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;its Sole Member</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Naveed Hakim</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;  Brookwood CB Co., LLC,<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a Delaware limited liability company,<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;its Managing Member</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58; CFO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline"> &#47;s&#47; Kurt Zernich              </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Kurt Zernich</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58; Authorized Signatory</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline"> 4-3-18                          </font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">BROOKWOOD CB II, LLC,<br>a Delaware limited liability company</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58; Brookwood U.S. Real Estate Aggregator, L.P.<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;a Delaware limited partnership,<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;its Sole Member</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58; Brookwood U.S. Real Estate Fund GP,<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;LLC, a Delaware limited liability<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;company, its General Partner </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline"> &#47;s&#47; Kurt Zernich              </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Kurt Zernich</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58; Authorized Signatory</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline"> 4-3-18                          </font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">32</font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_113"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">EXHIBIT A</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">THE PREMISES</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_123"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">EXHIBIT B</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">RULES AND REGULATIONS</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Tenant shall faithfully observe and comply with the following Rules and Regulations and Tenant shall cause all of its agents, contractors, subcontractors, employees, licensees, servants, invitees, and subtenants any persons or entities claiming through any of these persons or entities to faithfully observe and comply the following Rules and Regulations. Landlord shall enforce the rules and regulations uniformly against all tenants of the Property. Landlord shall not be responsible to Tenant for the nonperformance of any of said Rules and Regulations by or otherwise with respect to the acts or omissions of any other tenants or occupants of the Building or the Real Property. In the event of any conflict between the terms of the Lease and the following Rules and Regulations (as the same may be amended by Landlord), the terms of the Lease shall control.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1.&#160;&#160;&#160;&#160;Tenant shall not alter any lock or install any new or additional locks or bolts on any doors or windows of the Premises without obtaining Landlord's prior written consent. Tenant shall bear the cost of any lock changes or repairs required by Tenant. Two (2) keys will be furnished by Landlord for the Premises, and any additional keys required by Tenant must be obtained from Landlord at a reasonable cost to be established by Landlord.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">2.&#160;&#160;&#160;&#160;All keys to the Building, the Premises, rooms, mailbox, and toilet rooms, if any, shall be obtained from Landlord. The Tenant, upon termination of the tenancy, shall deliver to the Landlord the keys to the Building, the Premises, rooms, mailbox, and toilet rooms, if any, which shall have been furnished and shall pay the Landlord the cost of replacing any lost key or of changing the lock(s) opened by such lost key if Landlord deems it necessary to make such change. Tenant shall not alter any lock or install any new or additional locks or bolts on any doors or windows of the Premises, without prior written, consent of Landlord and subsequent delivery of a duplicate key to Landlord. Landlord shall retain a master key to the Premises and be allowed admittance thereto at all times to enable its representatives to examine the Premises.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">3.&#160;&#160;&#160;&#160;All doors opening to public corridors shall be kept closed at all times except for normal ingress and egress to the Premises.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">4.&#160;&#160;&#160;&#160;Landlord reserves the right to close and keep locked all entrance and exit doors of the Building during such hours as are customary for comparable buildings. Tenant, its employees and agents must be sure that the doors to the Building are securely closed and locked when leaving the Premises if it is after the normal hours of business for the Building. Any tenant, its employees, agents or any other persons entering or leaving the Building at any time when it is so locked, or any time when it is considered to be after normal business hours for the Building, may be required to sign a Building register when so doing. Access to the Building may be refused unless the person seeking access has proper identification or has a previously arranged a pass for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">access to the Building. The Landlord and its agents shall in no case be liable for damages for any error with regard to the admission to or exclusion from the Building of any person. In case of invasion, mob, riot, public excitement, or other commotion, Landlord reserves the right to prevent access to the Building during the continuance of same by any means it deems appropriate for the safety and protection of life and property.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">5.&#160;&#160;&#160;&#160;Landlord shall have the right to prescribe the weight, size and position of all safes and other heavy property, furniture, fixtures, and equipment (&#34;FF&#38;E&#34;) brought into the Building. If such safe or heavy property is requested by Tenant, Landlord shall require structural review of the proposed Tenant FF&#38;E at Tenant's sole cost. Safes and other heavy objects shall, if considered necessary by Landlord, stand on supports of such thickness as is necessary to properly distribute the weight. Landlord will not be responsible for loss of or damage to any such safe or property in any case. All damage done to any part of the Premises, Building, its contents, occupants or visitors by moving or maintaining any such FF&#38;E shall be the sole responsibility of Tenant and any expense of said damage or injury shall be borne by Tenant.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">6.&#160;&#160;&#160;&#160;No bulky furniture, freight, packages, supplies, equipment or merchandise will be brought into or removed from the Building or carried up or down in the elevators, except upon prior notice to Landlord, and in such manner, in such specific elevator, and between such hours as shall be reasonably designated by Landlord. Tenant shall provide Landlord with not less than 24 hours prior written notice of the need to utilize an elevator for any such purpose, so as to provide Landlord with a reasonable period to schedule such use and to install such padding or take such other actions or prescribe such procedures as are appropriate to protect against damage to the elevators or other parts of the Building.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Notwithstanding the foregoing, all damage or injury to the Building or to the Premises, fixtures, appurtenances and&#47;or equipment caused by the Tenant moving property in or out of the Building or the Premises or by Tenant's installation or removal of furniture, fixtures, or other property, or from any other cause of any kind or nature whatsoever due to carelessness, omission, neglect, or improper conduct, or other cause of the Tenant, its agents, employees, invitees, contractors or subcontractors shall be repaired, restored, or replaced promptly by the Landlord at Tenant' s sole cost and expense. Landlord shall have the right to control and operate the common areas of the Building, the heating and air conditioning, and any other facilities furnished for the common use of tenants, in such manner as is customary for comparable buildings.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The sidewalks, halls, passages, exits, entrances, elevators and stairways, driveways, and parking areas shall not be obstructed by tenants or used by them for any purpose other than for ingress and egress from their respective Premises. The halls, corridors, passages, stairways, elevators, exits, entrances and roof are not for the use of the general public and Landlord shall in all cases retain the right to the control thereof and prevent access thereto by all persons whose presence in the judgment of Landlord shall be prejudicial to the safety, character, reputation, and interests of the Building, the Property or its tenants, provided, however, that nothing herein </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">contained shall be construed to prevent access by persons with whom Tenant normally deals in the ordinary course of Tenant's business, unless such persons are engaged in activities which are illegal or in contravention to these Rules and Regulations. Tenant and employees or invitees of Tenant shall NOT go upon the roof of the Building.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">7.&#160;&#160;&#160;&#160;The requirements of Tenant will be attended to only upon application at the office location designated by Landlord. Employees or agents of Landlord shall not perform any work or do anything outside their regular duties unless under special instructions from Landlord.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">8.&#160;&#160;&#160;&#160;Tenant shall not disturb, solicit, or canvass any occupant of the Building or Property and shall reasonably cooperate with Landlord or Landlord' s agents to prevent same.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">9.&#160;&#160;&#160;&#160;Without the written consent of Landlord, Tenant shall not use the name of the Property in connection with or in promoting or advertising the business of Tenant except to identify Tenant's address.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">10.&#160;&#160;&#160;&#160;The toilet rooms, showers, urinals, wash bowls and other apparatus shall not be used for any purpose other than that for which they were constructed, and no foreign substance of any kind whatsoever shall be thrown therein. The expense of any breakage, stoppage or damage resulting from the violation of this rule shall be borne by the Tenant who, or whose employees or agents, shall have caused it.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11.&#160;&#160;&#160;&#160;Tenant shall not overload the floor of the Premises, nor mark, drive nails or screws, or drill into the partitions, woodwork or plaster or in any way deface the Premises or any part thereof without Landlord's prior written consent first had and obtained. The floor load of the Premises is designed for up to 80 pounds live load.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">12.&#160;&#160;&#160;&#160;Except for vending machines intended for the sole use of Tenant's employees and invitees, no vending machine or machines of any description other than normal office machines shall be installed, maintained or operated upon the Premises without the prior written consent of Landlord.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">13.&#160;&#160;&#160;&#160;Tenant shall not use or keep in or on the Premises or the Building any kerosene, gasoline or other inflammable or combustible fluid or material, or use any method of heating or air conditioning other than that supplied or approved in writing by the Landlord.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">14.&#160;&#160;&#160;&#160;Tenant shall not use any method of heating or air conditioning other than that which may be supplied by Landlord, without the prior written consent of Landlord, which shall not be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">15.&#160;&#160;&#160;&#160;Tenant shall not use, keep or permit to be used or kept, any foul or noxious gas or substance in or on the Premises, or permit or allow the Premises to be occupied or used in a manner unreasonably offensive or objectionable to Landlord or other occupants of the Building </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">or Real Property by reason of noise, odors, or vibrations, or unreasonably interfere in any way with other tenants or those having business therein.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">16.&#160;&#160;&#160;&#160;No loud speakers, televisions, phonographs, radios or other devises shall be used in a manner so as to be heard or seen outside of the Premises or in neighboring space without the prior written consent of Landlord.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">17.&#160;&#160;&#160;&#160;Bicycles, motor scooters or any other type of vehicle shall not be brought into the lobby or elevators of the Building or into the Premises except for those vehicles which are used by a physically disabled person in the Premises. Bicycles must be stored only at designated bicycle racks.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">18.&#160;&#160;&#160;&#160;No cooking shall be done or permitted by any Tenant on the Premises, nor shall the Premises be used for the storage of merchandise, for lodging or for any improper, objectionable or immoral purposes. Notwithstanding the foregoing, Underwriters' laboratory-approved equipment and microwave ovens may be used in the Premises for heating food and brewing coffee, tea, hot chocolate and similar beverages, provided that such use is in accordance with all applicable federal, state and city laws, codes, ordinances, rules and regulations, and does not cause odors which are reasonably objectionable to Landlord and other tenants.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">19.&#160;&#160;&#160;&#160;No Tenant shall occupy or permit any portion of the Premises to be occupied for the manufacture, sale, or use of liquor or narcotics in any form.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">20.&#160;&#160;&#160;&#160;Landlord will approve where and how wires and cables are to be introduced to the Premises. No boring or cutting for wires shall be allowed without the prior written consent of Landlord. The location of telephone, call boxes and other office equipment affixed to the Premises shall be subject to the prior written approval of Landlord.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">21.&#160;&#160;&#160;&#160;Landlord reserves the right to exclude or expel from the Building or Property any person who, in the judgment of Landlord, is intoxicated or under the influence of liquor or drugs, or who shall in any manner do any act in violation of any of these Rules and Regulations.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">22.&#160;&#160;&#160;&#160;Tenant, its employees and agents shall not loiter in the common areas including but not limited to the following&#58; entrances or corridors, nor in any way obstruct the sidewalks, lobby, halls, stairways or elevators, and shall use the same only as a means of ingress and egress for the Premises.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">23.&#160;&#160;&#160;&#160;Tenant shall not waste electricity, water or air conditioning and agrees to use commercially reasonably efforts to cooperate fully with Landlord to ensure the most effective operation of the Building's heating and air conditioning system. This includes the closing of exterior blinds, preventing the sun rays to shine directly into areas adjacent to exterior windows.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">24.&#160;&#160;&#160;&#160;Tenant shall store all its trash and garbage within the interior of the Premises. No material shall be placed in the trash boxes or Landlord approved receptacles if such material is of such nature that it may not be disposed of in the ordinary and customary manner of removing and disposing of trash and garbage in the Carlsbad area without violation of any law or ordinance governing such disposal. All trash, garbage and refuse disposal shall be made only through entry-ways and elevators provided for such purposes at such times as Landlord shall designate. All garbage and refuse shall be placed by Tenant in the containers at the location prepared by Landlord for refuse collection, in the manner and at the times and places specified by Landlord. Tenant shall not burn any trash or garbage of any kind in or about the Premises or the Project. All cardboard boxed must be &#34;broken down&#34; prior to being placed in the trash container. All styrofoam chips must be bagged or otherwise contained prior to placement in the trash container, so as not to constitute a nuisance. Pallets may not be disposed of in the trash bins or enclosures. It is the Tenant's responsibility to dispose of pallets by alternative means. Should any garbage or refuse not be deposited in the manner specified by Landlord, Landlord may after three (3) hours verbal notice to Tenant, take whatever action necessary to correct the infraction at Tenant's expense.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">25.&#160;&#160;&#160;&#160;Tenant shall comply with all safety, fire protection and evacuation procedures and regulations established by Landlord or any governmental agency. Tenant assumes full responsibility for protecting the Premises from theft, robbery and pilferage, including keeping doors and other means of entry into the Premises closed during normal business hours and securely locked before leaving the Premises, and that all water faucets, water apparatus, and electricity are entirely shut off before Tenant or Tenant's employees leave the Premises. Tenant shall be responsible for any damage to the Premises, the Building, the Project or other tenants or their property caused by a failure to comply with this rule.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">26.&#160;&#160;&#160;&#160;No contractors or vendors shall be allowed into the Building to perform services for Tenant without first providing Landlord evidence of required insurance.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">27.&#160;&#160;&#160;&#160;Landlord may waive any one or more of these Rules and Regulations for the benefit of any particular Tenant or tenants, but no such waiver by Landlord shall be construed as a waiver of such Rules and Regulations in favor of any other Tenant or tenants, nor prevent Landlord from thereafter enforcing any such Rules or Regulations against any or all tenants of the Building or Real Property. Notwithstanding the foregoing, Landlord agrees to enforce the Rules and Regulations in a non-discriminatory manner.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">28.&#160;&#160;&#160;&#160;No awnings, rooftop equipment, or other projection shall be attached to the outside walls of the Building without the prior written consent of Landlord. No aerial antenna shall be erected on the roof or exterior walls of the Premises, or on the grounds, without in each instance, the written consent of Landlord first being obtained. Any aerial or antenna so installed without such written consent shall be subject to removal by Landlord at any time without notice at Tenant's sole cost.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">29.&#160;&#160;&#160;&#160;No curtains, blinds, shades or screens shall be attached to or hung in, or used in connection with, any window or door of the Premises without the prior written consent of Landlord. Such window coverings must be of a quality, type, design and color in form with building standards in order to maintain an attractive exterior appearance for the Building. No sign, placard, picture, advertisement, name or notice shall be inscribed, displayed or printed or affixed on or to any part of the outside or inside of the Building without the written consent of Landlord first had and obtained and Landlord shall have the right to remove and destroy any such sign, placard, picture, advertisement, name or notice to and at the expense of Tenant. All approved signs or lettering on doors shall be printed, painted, affixed or inscribed at the expense of Tenant by a person approved by the Landlord. Tenant shall not place anything or allow anything to be placed near the glass of any window, door, partition or wall which may appear unsightly from outside the Premises&#58; provided, however, that the Landlord may furnish and install a building standard window covering at all exterior windows. Tenant shall not without prior written consent of Landlord cause or otherwise install sunscreen on any window.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">30.&#160;&#160;&#160;&#160;The sashes, sash doors, skylights, windows, and doors that reflect or admit light and air into the halls, passageways or other public places in the Building shall not be covered or obstructed by Tenant, nor shall any bottles, parcels or other articles be placed on the windowsills.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">31.&#160;&#160;&#160;&#160;The outside areas immediately adjoining the Premises shall be kept clean and free from dirt and rubbish by the Tenant, to the satisfaction of the Landlord, and Tenant shall not place or permit any obstruction or materials in such areas. No exterior storage shall be allowed.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">32.&#160;&#160;&#160;&#160;Tenant shall use at Tenant' s cost such pest extermination contractors as Landlord may direct and at such intervals as Landlord may require.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">33.&#160;&#160;&#160;&#160;The washing and&#47;or detailing of or, the installation of windshields, radios, telephones in or general work on, automobiles shall not be allowed on the Real Property.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">34.&#160;&#160;&#160;&#160;Food vendors shall be allowed in the Building upon receipt of a written request from the Tenant and proof of Landlord required insurance. The food vendor shall service only the tenants that have a written request on file with Landlord. Under no circumstance shall any food vendor providing service to Tenant display their products in a public or common area including corridors and elevator lobbies. Any failure to comply with this rule shall result in immediate permanent withdrawal of the vendor from the Building.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">35.&#160;&#160;&#160;&#160;Tenant must comply with requests by the Landlord concerning the informing of their employees of items of importance to the Landlord.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">36.&#160;&#160;&#160;&#160;Tenant shall comply with any non-smoking ordinance adopted by Landlord and&#47;or any applicable governmental authority. If Tenant is required under the ordinance to adopt a written smoking policy, a copy of said policy shall be on file in the office of the Building. In addition, no smoking of any substance shall be permitted within the Project except in specifically </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">designated outdoor areas. Within such designated outdoor areas, all remnants of consumed cigarettes and related paraphernalia shall be deposited in ash trays and&#47;or waste receptacles. No cigarettes shall be extinguished and&#47;or left on the ground or any other surface of the Project. Cigarettes shall be extinguished only in ash trays. Furthermore, in no event shall Tenant, its employees or agents smoke tobacco products or other substances (x) within any interior areas of the Project, or (y) within two hundred feet (200') of the main entrance of the Building or the main entrance of any of the adjacent buildings, or (z) within seventy-five feet (75') of any other entryways into the Building.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">37.&#160;&#160;&#160;&#160;Tenant and Tenant's employees, agents, contractors and other invitees shall not be permitted to bring firearms or weapons of any other type into the Building or surrounding areas at any time unless such person carrying the firearm or weapon has a required State or Federal CCW (Carry a Concealed Weapon) Permit.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">38.&#160;&#160;&#160;&#160;Tenant hereby acknowledges that Landlord shall have no obligation to provide guard service or other security measures for the benefit of the Premises, the Building or the Project. Tenant hereby assumes all responsibility for the protection of Tenant and its agents, employees, contractors, invitees and guests, and the property thereof, from acts of third parties, including keeping doors locked and other means of entry to the Premises closed, whether or not Landlord, at its option, elects to provide security protection for the Project or any portion thereof. Tenant further assumes the risk that any safety and security devices, services and programs which Landlord elects, in its sole discretion, to provide may not be effective, or may malfunction or be circumvented by an unauthorized third party, and Tenant shall, in addition to its other insurance obligations under this Lease, obtain its own insurance coverage to the extent Tenant desires protection against losses related to such occurrences. Tenant shall cooperate in any reasonable safety security program developed by Landlord or required by law.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">39.&#160;&#160;&#160;&#160;Parking.</font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(a)&#160;&#160;&#160;&#160;Automobiles must be parked entirely within the stall lines on the ground.</font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(b)&#160;&#160;&#160;&#160;All directional signs and arrows must be observed.</font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(c)&#160;&#160;&#160;&#160;The speed limit shall be 5 miles per hour.</font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(d)&#160;&#160;&#160;&#160;Parking is prohibited in areas not striped for parking.</font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(e)&#160;&#160;&#160;&#160;Parking cards and&#47;or access cards or and&#47;or any other device or form of identification supplied by Landlord (or its operator) shall remain the property of Landlord (or its operator). Such parking identification and&#47;or access card devices must be displayed as requested and may not be mutilated in any manner. The serial number of the parking identification and&#47;or access card devices may not be obliterated. Devices are not transferable or assignable and any device in the possession of an unauthorized holder will be void. There will be a replacement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">charge to the Tenant or person designated by Tenant of $50.00 for loss of any parking card and&#47;or access card, as the case may be. There shall be an initial cost of $25.00 due at issuance for each parking card key and access card issued to Tenant. Tenant shall immediately notify Landlord of any missing or lost parking or access cards and of the need to deactivate any parking or access card upon termination of any employee. </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(f)&#160;&#160;&#160;&#160;Landlord (and its operator) may refuse to permit any person who violates the rules to park in the Building parking facility, and any violation of the rules shall subject the automobile to removal from the Building parking facility at the parker's expense.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(g)&#160;&#160;&#160;&#160;All responsibility for any loss or damage to automobiles or any personal property therein is assumed by the parker.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(h)&#160;&#160;&#160;&#160;Loss or theft of parking identification devices from automobiles must be reported to the Building parking facility manager immediately, and a lost or stolen report must be filed by the parker at that time. </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(i)&#160;&#160;&#160;&#160;The parking facilities are for the sole purpose of parking one automobile per space. Washing, waxing, cleaning or servicing of any vehicles by the parker or his agents is prohibited.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(j)&#160;&#160;&#160;&#160;Landlord (and its operator) reserves the right to refuse the issuance of monthly stickers or other parking identification devices to any Tenant and&#47;or its employees who refuse to comply with the above Rules and Regulations and all City, State or Federal Laws.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(k)&#160;&#160;&#160;&#160;Tenant agrees to acquaint all employees with these Rules and Regulations.</font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(l)&#160;&#160;&#160;&#160;No vehicle shall be stored in the Building parking facility for a period of more than one (1) day.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">40.&#160;&#160;&#160;&#160;Tenant shall be responsible for the compliance of these Rules and Regulations by Tenant's employees, agents, clients, customers, invitees and guests.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">41.&#160;&#160;&#160;&#160;Without limiting the other terms and provisions of the Lease, these common types of damages will be charged back to the Tenant if they are not corrected prior to vacating the Premises&#58;</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Keys not returned to Landlord for ALL locks, requiring the service of a &#160;&#160;&#160;&#160;locksmith and rekeying.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Removal of all decorator painting, wallpapering and paneling, or Landlord's prior consent to remain.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Electrical conduit and receptacles on the surface of walls.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Phone outlets, wiring, or phone equipment added on wall surfaces.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Security tape&#47;magnetic tape switches for burglar alarm systems added to windows and door surfaces.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Penetration of roof membrane in any manner.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Holes in walls, doors, and ceiling surfaces.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Addition or change of building standard door hardware.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Painting or gluing of carpet or tile on floors.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Glass damage.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Damage to ceiling insulation.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Stains or damage to carpeting beyond normal wear and tear.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Damaged, inoperative, or missing electrical, plumbing, or HVAC equipment.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Debris and furniture requiring disposal.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Damaged or missing mini blinds, draperies, and baseboards.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Installation of additional improvements without Landlord's prior written approval and obtainment of required City building permits.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_131"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">EXHIBIT C</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ADDITIONAL STIPULATIONS</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The Additional Stipulation(s) listed below are hereby incorporated and made a part of the Lease to which this Exhibit C is attached hereto. The rights granted to Tenant in this Exhibit C are personal to Tenant and may not be assigned or transferred in any manner and shall automatically terminate in the event of any assignment or subletting.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">1.&#160;&#160;&#160;&#160;EXTENSION OPTION.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  So long as there exists no default beyond any applicable notice and cure period either at the time of exercise or on the first day of the Extension Term (as hereinafter defined) and Tenant has not assigned this Lease in whole or in part ( other than pursuant to a Permitted Transfer) nor sublet the Premises in whole or in part, Tenant shall have the option to extend the Term for up to two (2) consecutive periods of five (5) years apiece (each period being an &#34;Extension Term&#34;) upon written notice to Landlord given not less than nine (9) months and not more than twelve (12) months prior to the scheduled expiration of the Term. If Tenant fails to exercise either option to extend the Term strictly within the time period set forth in this section, then Tenant's options to extend the Term shall automatically lapse and be of no further force or effect. In the event that Tenant exercises an option granted hereunder, the Extension Term shall be upon the same terms and conditions as are in effect under this Lease immediately preceding the commencement of such Extension Term except that the Base Rent due from the Tenant shall be increased to Landlord's determination of Base Rent as provided herein, and Tenant shall have no further right or option to extend the Term or to any abatements, improvement allowance or other inducements. If Tenant timely exercises its option to extend the Term, then no later than thirty (30) days following receipt of Tenant's notice, Landlord shall notify Tenant in writing of Landlord's determination of the Base Rent for the Extension Term (&#34;Landlord's Rental Notice&#34;). If Tenant does not object to Landlord's determination of the Base Rent by written notice to Landlord within ten (10) days after the date of Landlord's Rental Notice, then Tenant shall be deemed to have accepted the Base Rent set forth in Landlord's Rental Notice. </font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">If Tenant timely objects to Landlord's Rental Notice, and the parties cannot agree on Base Rent for the Extension Term within thirty (30) days after Landlord receives Tenant's notice of objection, then the Term shall automatically be extended and Base Rent for the Extension Term shall be submitted to arbitration as follows&#58; Base Rent shall be determined by impartial arbitrators (who shall be qualified real estate appraisers or brokers with at least ten (10) years of experience dealing with like types of properties in the market area), one to be chosen by the Landlord, one to be chosen by Tenant, and a third to be selected, if necessary, as below provided, and shall reflect the greater of (i) the rate that would be agreed upon between a landlord and a tenant on or about the date on which the Extension Term is to begin for a comparable term and for space comparable to the Premises in the Building and buildings comparable to the Building in the market area, taking into account any material economic differences between the terms of this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">ease and any comparison lease, such as the manner, if any, in which the landlord under any such lease is reimbursed for operating expenses and taxes and (ii) the Base Rent payable during the last month of the current Term. The unanimous written decision of the two first chosen (without selection and participation of a third arbitrator), or otherwise the written decision of a majority of three arbitrators chosen and selected as aforesaid, shall be conclusive and binding upon Landlord and Tenant. Landlord and Tenant shall each notify the other of its chosen arbitrator within ten (10) days following the call for arbitration and, unless such two arbitrators shall have reached a unanimous decision within thirty (30) days after their designation, they shall select an impartial third arbitrator to determine the market value as herein defined. Such third arbitrator and the first two chosen shall render their decision within thirty (30) days following the date of appointment of the third arbitrator and shall notify Landlord and Tenant thereof, which decision shall be final and binding on the parties. Landlord and Tenant shall each pay the expenses of its own arbitrator and shall share the payment of expenses of the third arbitrator equally, regardless of the outcome of arbitration. If the dispute between the parties as to the Base Rent for the Extension Term has not been resolved before the commencement of the Extension Term, Tenant shall pay Base Rent for the Extension Term based upon the Base Rent designated by Landlord in the Landlord' s Rental Notice until either (i) agreement of the parties as to the fair market rent, or (ii) decision of the arbitrators, as the case may be, at which time Tenant shall promptly pay any underpayment of Base Rent to Landlord, or Landlord shall credit the overpayment of Base Rent against the next installment of rental or other charges due to Landlord.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">2.&#160;&#160;&#160;&#160;FACADE SIGNAGE. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Upon Landlord's written approval of the location, material, size, design and content thereof, Tenant may, at its sole cost and expense (but at no fee or profit to Landlord), install one (1) &#34;building top&#34; sign on the exterior of the Building in a location approved by Landlord (collectively, &#34;Tenant's Exterior Building Signage&#34;). Tenant's Exterior Building Signage shall contain only Tenant's name and no advertising material, shall be in accordance with all Applicable Law, and shall be installed by a contractor or other party which meets with Landlord's prior approval. Tenant shall be solely responsible for obtaining any necessary permits or governmental approvals required for Tenant's Exterior Building Signage, shall remove Tenant's Exterior Building Signage upon the expiration or earlier termination of this Lease, and shall reimburse Landlord for the cost of repairing any damage caused thereby. Tenant acknowledges and agrees that Landlord shall have the right, from time to time, to adopt new sign criteria governing the Building, and that, in connection therewith, Tenant, at Tenant's sole cost and expense, shall cause Tenant's Exterior Building Signage to be aesthetically compatible to any such newly adopted sign criteria. At its expense, Tenant will maintain Tenant's Exterior Building Signage in good condition and repair and if Tenant fails to do so, Landlord may remove Tenant's Exterior Building Signage at Tenant's expense upon five (5) days prior notice.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">3.&#160;&#160;&#160;&#160;MONUMENT SIGNAGE. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Tenant, at Tenant's sole cost and expense (but at no fee or profit to Landlord), shall be entitled to Building standard monument signage (&#34;Monument Signage&#34;) in a location designated by Landlord&#59; provided, however, that the precise design of such Monument Signage shall be subject to Landlord' s prior written approval. Tenant's </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Monument Signage shall be subject to all Applicable Law. Landlord shall not unreasonably withhold its approval of the plans for Tenant's Monument Signage, provided, however, that Landlord may specify that the design of Monument Signage be similar to, or consistent with, the design of other monument signage of other tenants in the Building. </font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">4.&#160;&#160;&#160;&#160;TERMINATION OPTION. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> During the initial Term only, so long as there exists no default either at the time of exercise or on the Early Termination Date (as hereinafter defined), the Tenant named herein has not assigned any portion of this Lease ( other than pursuant to a Permitted Transfer) nor sublet any portion of the Premises, Tenant shall have a one (1) time right to terminate this Lease (the &#34;Termination Right&#34;) effective at any time after the end of the sixtieth (60th) complete calendar month following the Rent Commencement Date (the &#34;Early Termination Date&#34;) upon not less than nine (9) months and not more than twelve (12) months prior written notice to Landlord. Following such notice, Tenant shall deliver to Landlord, prior to the scheduled Early Termination Date, a termination payment equal to the sum of (i) the unamortized balance of Landlord's &#34;Lease Costs&#34; (as hereinafter defined) plus (ii) three (3) full months of Base Rent at the rate payable as of the final month of the Term. If Tenant fails to exercise the Termination Right strictly in accordance with this section, time being of the essence, then the Termination Right shall automatically lapse and Tenant shall have no right to terminate this Lease. Upon timely exercise of the Termination Right in compliance with the terms hereof, the Early Termination Date shall be deemed the Expiration Date and Tenant shall surrender the Premises on or before the Early Termination Date in accordance with the terms of this Lease. Notwithstanding the foregoing, any failure of Tenant to timely deliver the termination payment or to timely surrender the Premises in strict accordance with the terms of this section shall be an incurable default not requiring the delivery of any further notice to Tenant, and in such event, Landlord, in Landlord's sole and absolute discretion, may elect to either (a) treat such failure as a failure of a necessary condition to the effectiveness of Tenant's exercise of the Termination Right, in which case Tenant's notice electing to terminate the Lease shall be deemed revoked and this Lease shall continue in effect without any further right of Tenant to terminate the Lease, or (b) Landlord may elect to treat Tenant's exercise of the Termination Right as effective notwithstanding such failure, in which case such failure shall be deemed a holdover of Tenant for each day that such failure continues beyond the Early Termination Date. For the purposes hereof, &#34;Lease Costs&#34; shall be the cost of all brokerage commissions, rental abatements, legal fees, Tenant allowances, work performed by Landlord to the Premises, and any other Tenant inducements paid or provided under this Lease plus interest on the foregoing items accruing from the Rent Commencement Date at the rate of eight percent (8%) per annum. For purposes of determining the unamortized balance of Lease Costs, Lease Costs shall be amortized on a straight line basis over the initial Term.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">5.&#160;&#160;&#160;&#160;RIGHT OF FIRST REFUSAL. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Provided that (i) Tenant is not then in default under this Lease beyond any applicable notice and cure period and no condition exists which, with the giving of notice or passage of time or both, would constitute an Event of Default hereunder, (ii) this Lease is then in full force and effect, (iii) the Tenant named herein has not assigned this Lease (other than pursuant to a Permitted Transfer) or sublet any part of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Premises and is then in actual occupancy of the entire Premises demised hereunder, and (iv) Tenant's financial condition meets the financial criteria Landlord requires for the lease of such space, if, during the initial Term, Landlord receives a proposal or expression of intent to lease from a third party which Landlord is willing to accept ( an &#34;Offer&#34;) for the lease of all or any portion of any adjacent space on the third (3rd) floor of the Building, then Landlord shall notify Tenant of the Offer and shall provide Tenant with a redacted copy of the Offer, for verification purposes. Tenant shall thereupon have the one time right and option to lease the space described in the Offer (the &#34;Offered Space&#34;) upon such terms and conditions as are set forth in the Offer by delivering final and irrevocable notice to Landlord within five (5) days after receipt of Landlord's notice, time being of the essence. Promptly following Tenant's election to the lease the Offered Space, the parties shall enter into an amendment to this Lease on a form prepared by Landlord incorporating the Offered Space as part of the Premises&#59; provided, however, that the execution of such amendment shall not be a condition to the effectiveness of Tenant's election to lease the Offered Space. If Tenant fails to lease the Offered Space in compliance with the terms and conditions of this section then Tenant shall have no further rights under this section. Tenant's rights under this section will be subject to the rights of expansion, renewal, first refusal, first offer, or similar rights contained in any then existing lease or leases of the Offered Space, as the same may be amended from time to time. Landlord shall not be liable for any damages for any holdover tenant or other occupant of any Offered Space.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">6.&#160;&#160;&#160;&#160;SATELLITE DISH.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  At no additional cost, Tenant shall have the right, at its sole cost and expense, to install a satellite transmission and receiving dish on the roof of the Building (&#34;Roof Equipment&#34;) for its own use provided (a) Tenant complies with all local, state and federal laws pertaining to the installation, maintenance, operation, removal and replacement of any of Tenant's Roof Equipment&#59; (b) Tenant does not do any act which would invalidate any roof warranty or guaranty which now or hereafter relates to the roof of the Building&#59; (c) the area required for Tenant's Roof Equipment shall not exceed 1.5 meters and Tenant shall obtain Landlord's prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed, as to the location and general aesthetics of Tenant's Roof Equipment (provided that Landlord may require adequate screening)&#59; (d) Tenant obtains all required operating permits and approvals from any governmental entity with jurisdiction over such activities&#59; (e) Tenant, at its sole cost and expense, shall maintain the Tenant's Roof Equipment and adequate insurance thereon&#59; (f) in the event of any damage caused to the Building (including, without limitation, the roof or any exterior portions thereof) by reason of the installation, maintenance, operation, removal or replacement of any of Tenant's Roof Equipment, Tenant shall, at Landlord's option (1) promptly repair such damage&#59; or (2) promptly reimburse Landlord for reasonable out-of-pocket costs and expenses incurred by Landlord in repairing such damage&#59; (g) Tenant shall use such contractors and observe such requirements as reasonably required by Landlord&#59; (h) Tenant shall remove Tenant's Roof Equipment upon the expiration or sooner termination of the Term of this Lease&#59; and (i) the installation and operation of Tenant's Roof Equipment does not adversely affect the operation of any equipment on the roof of the Building pre-dating the installation of Tenant's Roof Equipment. If any transmissions from the Roof Equipment interfere with transmissions sent or received by satellite dishes of other tenants of the Building or adjacent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">buildings, Tenant will take all measures necessary to eliminate such interference. All maintenance, repair, and removal work performed in connection with the Tenant's Roof Equipment shall be performed using contractors approved by Landlord and observing such requirements as reasonably required by Landlord. The provisions of this section shall survive the termination of this Lease.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">7.&#160;&#160;&#160;&#160;CALIFORNIA LAW. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Notwithstanding anything to the contrary contained elsewhere in the Lease, the following provisions concerning California law are incorporated herein&#58; </font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Repairs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Tenant hereby waives the benefits of the provisions of California Civil Code Sections 1932 (1), 1941, and 1942 and any other similar laws, statues or ordinances now or hereafter in effect regarding Landlord's obligations for Tenant habitability of the Premises and Tenant's right to make repairs and deduct the cost of such repairs from Rent and or terminate the Lease as a result of any failure by Landlord to maintain or repair. </font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Liens.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  In the event that Tenant shall cause any liens to be placed on the Premises, Landlord may, within five (5) business days of notice to Tenant, and without waiving its rights based on such breach, in addition to any other remedies, record a bond pursuant to California Civil Code Section 3143 and all amounts incurred by Landlord in so doing shall become immediately due and payable by Tenant to Landlord as Additional Rent.</font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Damage or Destruction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Landlord and Tenant acknowledge that the Lease constitutes the entire agreement of the parties regarding events of damage or destruction, and Tenant waives the provisions of California Civil Code Sections 1932(2) and 1933(4) and any similar statute now or hereafter in force. </font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Remedies Upon Default.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  If Landlord chooses to repossess the Premises as result of an Event of Default, then this Lease will automatically terminate in accordance with the provisions of California Civil Code Section 1951.2. In addition, Tenant waives redemption or relief from forfeiture under California Code of Civil Procedure Sections 1174 and 1179, California Civil Code Section 3275 or under any other present or future law, if Tenant is evicted or Landlord takes possession of the Premises by reason of any Event of Default by Tenant.</font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(e)&#160;&#160;&#160;&#160;Intentionally Omitted.</font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Continuation After Default.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  In event that Tenant's right to possession is not terminated after an Event of Default, Landlord may, without limitation of any other remedies allowed under this Lease, exercise all of the rights and remedies of a Landlord under Section 1951.4 of the California Civil Code, or any successor statute. </font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Eminent Domain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Tenant hereby waives and releases any right to terminate this Lease under Sections 1265.120 and 1265.130 of the California Code of Civil Procedure, or under any similar law, statute or ordinance now or hereafter in effect.</font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Notice.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Tenant hereby agrees that service of notice in accordance with the terms of the Lease shall be in lieu of the methods of service specified in Section 1161 of the California Code of Civil Procedure. The provisions of subdivision (a) of Section 1013 of the California Code of Civil Procedure, extending the time within which a right may be exercised or an act may be done, shall not apply to a notice given pursuant to this Lease.</font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Hazardous Substances.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Landlord hereby notifies Tenant, and Tenant hereby acknowledges that, prior to the leasing of the Premises pursuant to this Lease, Tenant has been notified, pursuant to California Health and Safety Code Section 25359.7 (or any successor statute), that Landlord knows, or has reasonable cause to believe, that certain hazardous substances (as such term is used in such Section 25359.7), such as common cleaning supplies, office supplies, spillage of petroleum from motor vehicles, and other consumer products, may have come to be located on or beneath the Premises.</font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Warranties.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Tenant, for itself and its agents, affiliates, successors and assigns, hereby releases and forever discharges Landlord and its officers, directors, members, managers, authorized persons, partners, agents, affiliates, successors and assigns from, and waives any right to proceed against Landlord and such related persons and entities for, any and all costs, expenses, claims, liabilities and demands (including attorney's fees and costs) at law or in equity, whether known or unknown, arising out of the physical, environmental, economic, legal, or other condition of the Premises, including any claims for contribution pursuant to the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended, or any other hazardous material laws which Tenant, or any of its agents, affiliates, successors or assigns, has or may have in the future. Without limiting the foregoing, Tenant hereby specifically waives the provisions of Section 1542 of the California Civil Code which provide&#58; &#34;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HA VE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.&#34;</font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(k)&#160;&#160;&#160;&#160;In accordance with California Civil Code Section 1938, Landlord hereby informs Tenant that as of the Date of this Lease, the Premises have not been inspected by a Certified Access Specialist (as defined in California Civil Code section 55.52(3)) (&#34;CASp&#34;). Civil Code Section 1938(e) provides&#58;</font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#34;A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.&#34;</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Accordingly, Landlord and Tenant hereby mutually agree that if Tenant desires to obtain a CASp inspection, (i) the CASp inspection shall be at Tenant's sole cost and expense, (ii) the inspection shall be performed by a CASp that is currently certified in California and has been reasonably approved by Landlord, (iii) the CASp inspection shall take place during regular business hours with at least five (5) business day's prior written notice to Landlord and shall not materially disrupt any of the other tenants within the Building, (iv) Tenant shall promptly provide Landlord with a copy of the final report prepared in connection with the CASp inspection (the &#34;CASp Report&#34;), and (v) Tenant shall be solely responsible for promptly making any repair or modifications necessary to correct violations of construction-related accessibility standards that are noted in the CASp Report and shall defend with competent counsel, indemnify and hold Landlord harmless from any claims, damages or liability resulting from Tenant' s failure to promptly make such repairs. Tenant hereby acknowledges and agrees that the CASp Report is to be kept strictly confidential, except as necessary for Tenant to complete repairs and correct violations of construction-related accessibility standards as noted in the CASp Report. Accordingly, except as provided above or as may be required by law or court order, Tenant shall not release, publish or otherwise distribute (and shall not authorize or permit any other person or entity to release, publish or otherwise distribute) any information contained in the CASp Report. Tenant's obligations hereunder shall survive the expiration or sooner termination of this Lease.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Energy Use Disclosure Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Throughout the Term, and within ten (10) business days following Landlord' s written request, Tenant shall deliver to Landlord such information and&#47;or documentation as Landlord requires and otherwise cooperate with Landlord (including, but not limited to, the execution of any documentation) to assist Landlord in its compliance with the Nonresidential Building Energy Use Disclosure Program set forth in California Code of Regulations, Title 20, Division 2, Chapter 4, Article 9, Sections 1680 et. seq. (and pursuant to Public Resources Code Section 25402.10), any successor or related statute(s) and&#47;or code(s), and any other energy use disclosure requirements or programs required by law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_139"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">EXHIBIT D</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">LANDLORD'S WORK LETTER</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Landlord's Work.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Landlord, at Landlord's sole cost, will make certain improvements to (i) the common areas of the third (3rd) floor of the Building and (ii) the existing fitness center located on the first (1st) floor of the building commonly known as 2173 Salk Avenue in Carlsbad, California (collectively, &#34;Landlord's Work&#34;), as set forth on the space plans (collectively, &#34;Landlord's Plans&#34;) attached hereto as Schedule A. Landlord shall be responsible for making any alterations or repairs to the Building, the common areas located therein, or the Premises that are required as a result of Landlord's Work in order to comply with Applicable Laws. Tenant shall have no right to request that Landlord's Plans be revised to reflect any work which is not contemplated on Schedule A attached hereto. Except as may be otherwise shown on Landlord's Plans, Landlord shall perform Landlord's Work using building standard materials, quantities and procedures then in use by Landlord.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">A portion of Landlord's Work is to be performed in close proximity to the Premises during  Tenant's performance of Tenant's Work (as defined in the Tenant's Work Letter attached as Exhibit E to this Lease), and Landlord agrees to work in harmony with Tenant's contractors and use commercially reasonable efforts to perform Landlord's Work in a manner that minimizes disruption to Tenant's Work. Notwithstanding the foregoing, Tenant agrees to cooperate with Landlord and Landlord's contractor and to follow all reasonable directions given by Landlord in connection with the performance of Landlord's Work. Tenant agrees to remove equipment and other personal property from any Landlord's Work area promptly upon receiving a request to do so from Landlord or Landlord's agents. Tenant shall determine what measures are necessary to protect Tenant's Work and the personal property of Tenant and Tenant's agents from dirt, dust or paint resulting from Landlord's Work, and Tenant shall be fully responsible for taking such measures. Except with for Landlord's negligence or willful misconduct, Landlord shall not be liable to Tenant for injury or damage which may be sustained by the person or property of Tenant, its employees, agents, invitees or customers, or any other person arising out of or during construction of Landlord's Work.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Substantial Completion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  &#34;Substantial Completion&#34; or &#34;Substantially Complete&#34; means that Landlord's Work has been completed subject to any minor or insubstantial details of construction, decoration or mechanical adjustment that remain to be performed (i.e., punch-list items). Landlord shall use commercially reasonable efforts to Substantially Complete Landlord's Work on or before August 1, 2018. If Landlord is unable to Substantially Complete Landlord's Work on or before August 1, 2018 (the &#34;Scheduled Completion Date&#34;), subject to delays caused by Force Majeure (as defined in Section 30G of the Lease), permitting delays not caused by Landlord, and&#47;or Tenant Delay (as defined in Section 3 of this Work Letter), then Tenant shall be entitled to a day for day credit against Base Rent for each day following the Scheduled Completion Date until Landlord Substantially Completes Landlord's Work. Notwithstanding the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">foregoing or any language of the Lease to the contrary, if Landlord's Work is delayed by a Tenant Delay (as defined below) then Tenant shall begin paying Rent as required under the Lease as of the date the Rent Commencement Date would have occurred but for such Tenant Delay.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Tenant Delay.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  In addition to any other occurrence defined in the Lease or in this Landlord's Work Letter as Tenant Delay, &#34;Tenant Delay&#34; means the occurrence of any one or more of the following which cause a delay in the completion of Landlord's Work&#58; (i) Tenant is Delinquent (as hereafter defined) in submitting to Landlord any information, authorization or approvals requested by Landlord in connection with the performance of Landlord's Work&#59; (ii) the performance or completion of any work or activity by a party employed by Tenant, including any of Tenant's employees, agents, contractors, subcontractors and materialmen that continues for more than one (1) day after notice thereof from Landlord&#59; (iii) any postponements or delays requested by Tenant and agreed to by Landlord regarding the completion of Landlord's Work&#59; (iv) any error in Landlord's Work caused or related to any act or omission by Tenant or its employees or agents&#59; (v) the performance of any Changes (as defined below)&#59; or (vi) any other act or omission of Tenant (including any contractors selected by Tenant) which causes a delay in the completion of Landlord's Work that continued for more than one (1) day after notice thereof from Landlord. For the purposes of this Section, the term &#34;Delinquent&#34; shall mean that the action or communication required of Tenant is not taken within three (3) business days following request by Landlord.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Changes to Landlord's Work.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Tenant will have no right to make any changes (&#34;Changes&#34;) to Landlord' s Plans or Landlord' s Work without the prior written consent of Landlord (which may be withheld in Landlord's sole and absolute discretion) and the execution by Landlord of a written change order which specifies (i) the nature of the Changes and (ii) an estimate of the cost to Tenant as a result of such Changes. Tenant shall be solely responsible for the costs of all Changes, and Tenant shall pay such costs as Additional Rent upon demand.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SCHEDULE A</font></div><div style="margin-bottom:0.08pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">FITNESS CENTER PLAN</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_147"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">EXHIBIT E</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">TENANT'S WORK LETTER</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Tenant's Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Tenant shall perform all work (&#34;Tenant's Work&#34;) necessary to prepare the Premises for Tenant's occupancy in accordance with the plans and specifications (collectively, &#34;Tenant's Plans&#34;) attached hereto as Schedule 1. Any Tenant's Work not reflected in Schedule 1 shall be set forth in detailed plans prepared by a licensed architect and shall be subject to Landlord's prior written approval, not to be unreasonably withheld.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Tenant's Performance of Tenant's Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Tenant shall promptly, and with all due diligence, perform Tenant's Work in accordance with (i) Tenant's Plans as set forth on Schedule 1 and (ii) those construction rules and regulations of the Property attached hereto as Schedule 2 (the &#34;Construction Rules&#34;). Tenant shall obtain all necessary governmental permits and approvals for Tenant's Work, and Tenant shall have Tenant's Work performed by contractors reasonably approved by Landlord, which contractors shall maintain such insurance as the Landlord may reasonably require. Upon notice to Tenant, Landlord shall have the right to reasonably modify the Construction Rules and&#47;or to prescribe such additional reasonable rules and regulations relative to the performance of Tenant's Work and any other work which Tenant may perform under this Lease, and Tenant shall abide by all such rules and regulations and shall use its best efforts to cause all of its contractors to so abide including, without limitation, payment for the costs of using Building services. All of Tenant's Work shall be done in accordance with Tenant's Plans and in a good and workmanlike manner and in compliance with Applicable Law and all insurance requirements set forth in the Lease. Notwithstanding the foregoing, Landlord shall be responsible for making any alterations to the Building and common areas located therein that are required as a result of Tenant's Work in order to comply with Applicable Laws and Tenant shall be responsible for any modifications to the Premises that are required as a result of Tenant's Work. Except as may be otherwise shown on Tenant's Plans, Tenant shall perform Tenant's Work using building standard materials, quantities and procedures then in use by Landlord unless otherwise agreed to. It shall be Tenant's obligation to obtain a certificate of occupancy or other like governmental approval for the use and occupancy of the Premises to the extent required by Applicable Law, and Tenant shall submit to Landlord a copy of the same together with waivers of liens from all of Tenant's contractors in recordable form. Tenant shall also prepare and submit to Landlord promptly after Tenant's Work is substantially complete a set of as-built plans in both print and electronic forms showing the work performed by Tenant to the Premises including, without limitation, any wiring or cabling installed by Tenant or Tenant's contractor for Tenant's computer, telephone and other communication systems.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Tenant Allowance&#58; Moving Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. Subject to the terms and conditions </font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">hereof, Landlord agrees to provide to Tenant an allowance equal to &#91;***&#93; (the &#34;Tenant Allowance&#34;). The Tenant Allowance shall be used and applied by Tenant solely on account of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">the cost of Tenant's Work in accordance with this paragraph and not the cost of Landlord's Work or any other work. The Tenant Allowance shall be paid by Landlord to Tenant upon submission of paid invoices (together with such supporting documentation as Landlord may reasonably request) by Tenant or evidence that the invoiced costs will be paid for with Landlord's disbursement, together with a certification from Tenant's architect on the American Institute of Architects (AIA) standard form or such form as may be mutually agreed to by the parties that all of the work or supplies so invoiced have in fact been provided to the Premises. Each request for payment must be accompanied by partial releases (or, in the case of final payment, final releases) of lien rights from all contractors and subcontractors. Each request for payment shall also be deemed to be a certification by Tenant that all of the invoices, paid or unpaid, for which payment is requested from the Tenant Allowance relate to the Tenant Work and have been incurred by Tenant. Until Tenant's Work is seventy-five percent (75%) complete, disbursement of the Tenant Allowance for the foregoing purposes shall be made not more frequently than once per month in an amount equal to eighty-five percent (85%) of the amount requested by Tenant within fifteen (15) days. At such time as Tenant's Work is seventy-five percent (75%) complete and thereafter, remaining disbursements of the Tenant Allowance shall be in an amount equal to ninety percent (90%) of the amount requested by Tenant. The remaining ten percent (10%) (the &#34;Retention Amount&#34;) shall be paid to Tenant forty (40) days after the receipt of final unconditional lien releases from all Tenant's contractors, subcontractors, suppliers and materialmen, provided, however, that (i) no Retention Amount shall be withheld where the request is for the payment of an invoice from a supplier who has no lien rights and (ii) the Retention Amount for any given trade shall be paid by Landlord upon the satisfactory completion of all of the work to be performed by that trade and Landlord's receipt of all lien releases and any other supporting documentation reasonably requested by Landlord with respect thereto. Except as provided in the previous sentence, Landlord shall not be obligated to make any payments if there are any liens, suits, actions or proceedings pending which may affect the Building or the Property with respect to any Tenant Work or if an Event of Default exists at the time a disbursement is requested or is otherwise to be made. Tenant may bond or otherwise discharge any lien and, as long as there is no effect on the Building or the Property from the underlying dispute, Landlord shall disburse the unused Tenant Allowance in accordance with the foregoing provisions </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">For the purposes hereof&#58; the costs to be paid from the Tenant Allowance include the hard costs of Tenant's Work, a construction management fee payable to Hughes Marino, Inc., acting as Tenant's construction manager, in an amount equal to four percent (4%) of the lesser of (y) the Tenant Allowance and (z) the hard costs of Tenant's Work (which construction management fee shall be in lieu of any construction management fee collectible by Landlord), together with Tenant' s actual out-of-pocket engineering, architectural and permitting costs. Except as </font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">expressly stated in this Tenant's Work Letter to the contrary, Landlord shall have no obligation to pay any portion of the Tenant Allowance for the cost of any of Tenant's personal property, trade fixtures, trade equipment, furniture, Move-In Costs (as defined below), security systems, signage, or cabling&#47;wiring. Landlord shall be under no obligation to apply any portion of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Tenant Allowance for any purposes other than as provided herein, nor shall Landlord be deemed to have assumed any obligations, in whole or in part, of Tenant to any contractors, subcontractors, suppliers, workers or materialmen. Further, with the sole exception of the aforementioned construction management fee, in no event shall Landlord be required to pay any portion of the Tenant Allowance on account of any supervisory fees, overhead, management fees or other payments to Tenant, or any partner or affiliate of Tenant. Landlord shall be entitled to deduct from the Tenant Allowance an amount equal to the sum of all third party expenses, not to exceed $5,000.00, incurred by Landlord to review Tenant's Plans and Tenant's Work.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">To the extent that the Tenant Allowance remains unused following Landlord's payment of Tenant Allowance funds to Tenant for the cost of Tenant's Work in accordance with the foregoing paragraph, Tenant shall have the option to elect to apply such unused Tenant Allowance funds toward (i) reimbursement for Move-In Costs and&#47;or (ii) as a credit against Tenant's next required payments of Base Rent under the Lease until all such credit is fully used even if it takes more than one (1) month to absorb all of such credit&#59; provided that in order to be entitled to any such reimbursement or credit, Tenant must deliver a written notice to Landlord requesting the same no later than sixty (60) days following the Rent Commencement Date. In order to be effective, any request for reimbursement of Move-In Costs must also meet the requirements applicable to requests for distribution of Moving Allowance funds (as set forth below). Any portion of the Tenant's Allowance which is not requested in compliance with the strict terms and conditions of this paragraph shall be retained by Landlord and forfeited by Tenant.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">In addition to the Tenant Allowance, Landlord shall reimburse Tenant in a single payment not to exceed &#91;***&#93; (the &#34;Moving Allowance&#34;) for Tenant's actual, reasonable, out-of-pocket &#34;Move-In Costs&#34; (as hereinafter defined). For purposes of this Tenant's Work Letter, &#34;Move-In Costs&#34; shall include only (a) costs of moving Tenant's existing furniture, fixtures and equipment from 100 E. San Marcos Blvd., Ste. 200, San Marcos, California 92069 to the Premises and (b) hard costs of installing Tenant's cabling, security, audio&#47;visual systems, signage, and telecommunications systems at the Premises. Tenant shall have no right to any application of the Moving Allowance toward other Tenant' s Work or toward Tenant's rent obligations under the Lease. Provided that Tenant (i) has opened for business in the Premises, (ii) has completed all of Tenant's Work in accordance with the terms of this Work Letter and has paid for all Move-In Costs in full and has delivered to Landlord lien waivers (in recordable form) from all persons who might have a lien as a result of any work for which reimbursement is requested, (iii) has delivered to Landlord its certificate specifying the total Move-In Costs and all </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">contractors, subcontractors and suppliers involved with the work for which reimbursement is requested, together with evidence of all Move-In Costs in the form of paid invoices, receipts and the like, (iv) has made written request for such payment on or before the Rent Commencement Date, (v) is not otherwise in material default under this Lease, and (vi) there are no liens against Tenant's interest in the Lease or against the Building or arising out of the work for which </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">reimbursement is requested or any litigation in which Tenant is a party, then within thirty (30) days after the satisfaction of the foregoing conditions, Landlord shall pay to Tenant the lesser of (a) the amount of such costs so certified and (b) the amount of the Moving Allowance. Landlord shall be under no obligation to apply any portion of the Moving Allowance for any purposes other than as provided herein, nor shall Landlord be deemed to have assumed any obligations, in whole or in part, of Tenant to any contractors, subcontractors, suppliers, workers or materialmen. Further, in no event shall Landlord be required to pay any portion of the Moving Allowance on account of any supervisory fees, overhead, management fees or other payments to Tenant, Tenant's construction manager, or any partner or affiliate of Tenant. Any portion of the Moving Allowance which not requested or applied in compliance with the terms and conditions hereof on or before the Rent Commencement Date shall be retained by Landlord and forfeited by Tenant.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Tenant's Use of Premises Prior to Commencement Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Promptly following Landlord's execution and delivery of this Lease to Tenant and Tenant's timely payment of all amounts required to be paid concurrently with Tenant's execution hereof, Landlord shall permit Tenant to enter the Premises for the sole purpose of performing Tenant's Work (as defined in the Tenant's Work Letter attached as Exhibit E to this Lease) in preparation for Tenant's occupancy of the Premises. In connection with such entry, Tenant agrees (a) to cease promptly upon notice from Landlord any Tenant's Work which has not been approved by Landlord or is not in compliance with the provisions of this Lease or which shall interfere with or delay the performance of Landlord's Work, and (b) to comply promptly with all reasonable procedures and regulations prescribed by Landlord from time to time for coordinating Landlord's Work and Tenant's Work, each with the other and with any other activity or work in the Building. Such entry shall be deemed to be subject to all of the applicable provisions of this Lease, including without limitation the insurance and indemnity requirements thereof, except that, so long as Tenant does not use the Premises for any purpose other than the performance of Tenant's Work, there shall be no obligation on the part of Tenant to pay Base Rent or Additional Rent with respect to the Premises until otherwise required by the terms of this Lease.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">As a condition precedent to Landlord's obligation to permit such entry, prior to accessing the Premises, Tenant shall provide to Landlord, in form and substance reasonably acceptable to Landlord&#58; (i) a detailed description of and schedule for Tenant's Work&#59; (ii) the names and addresses of all contractors, subcontractors and material suppliers and all other representatives of Tenant who or which will be entering the Premises on behalf of Tenant to perform Tenant's Work or will be supplying materials for such work, and the approximate number of individuals, itemized by trade, who will be present in the Premises&#59; (iii) copies of all contracts, subcontracts and material purchase orders pertaining to Tenant's Work&#59; (iv) copies of all plans and specifications pertaining to Tenant's Work&#59; (v) copies of all licenses and permits required in connection with the performance of Tenant's Work&#59; and (vi) certificates of insurance (in amounts satisfactory to Landlord and with the parties identified in, or required by, the Lease named as additional insureds).</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">If Tenant fails or refuses to comply or cause its contractors to comply with any of the obligations described or referred to above, then immediately upon notice to Tenant, Landlord may revoke Tenant's right to access the Premises prior to the date of Substantial Completion of Landlord's Work, and such revocation shall not affect the Commencement Date of the Lease. Landlord shall assume no responsibility for the quality or completion of Tenant' s Work under this Section, and shall not be responsible for equipment or supplies left or stored in the Premises by Tenant or Tenant's contractors. Tenant's access to the Premises pursuant to this Section shall be at the sole risk of Tenant.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Hold Harmless.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">  Tenant shall indemnify and hold Landlord harmless from and against any and all liability and claims of any kind for loss or damage to any person or property arising out of or occurring during construction of Tenant's Work except in the event caused by Landlord or its agents' negligence or willful misconduct. In addition, Landlord shall not be liable for injury or damage which may be sustained by the person or property of Tenant, its employees, agents, invitees or contractors, or any other person in or about the Premises, arising out of or during performance of Tenant's Work except in the event caused by Landlord or its agents' negligence or willful misconduct.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Schedule 1</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Schedule 2</font></div><div style="margin-bottom:0.08pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">CONSTRUCTION RULES AND REGULATIONS</font></div><div style="margin-bottom:0.08pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">VENTANA CARLSBAD</font></div><div style="margin-bottom:0.08pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Insurance</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">All contractors are required to have insurance coverage as indicated in the Construction Agreement. An approved insurance certificate must be on file in the management office before commencing any work. Contractor and all subcontractors shall hold valid licenses for the type of work to be done and evidence of such shall be provided to management upon request.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">General Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">All workers are expected to behave in a manner fitting a professional work environment. Shirts identifying the company the employee works for are to be worn at all times. Music will be allowed to be played only at low levels which cannot be heard in common areas or adjacent tenant space. Yelling is prohibited at all times. Contractors are to limit their activities to the construction site, the designated path of travel and the designated exterior contractor staging&#47;lunch&#47;portable restroom areas. Trespassing in other areas of the building&#47;property is prohibited. Contractor is responsible for keeping the staging&#47;lunch&#47;portable restroom area neat and clean at all times.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Smoking is not allowed anywhere in the building. The designated exterior location to smoke is at the north side of the building where the ash urns are located. Smoking is not allowed in any other location on the property. Consumption of non-prescription drugs or alcohol at the property is strictly prohibited.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">General Safety</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Contractor is responsible for ensuring all workers follow appropriate safety precautions for the work being performed. The contractor is responsible for adhering to all Jaws, ordinances and codes. The contractor is responsible for taking normal and customary safety precautions to minimize the chance of fire or other damages. Management must be informed when contractor is using any open flames so appropriate notices and precautions can be made. Contractor is responsible for providing fire extinguishers and first aid kits which must be easily accessible to all construction personnel.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Proper lock out - tag out procedures must be used when working on projects involving electrical distribution. Electrical panels must be closed up when not actively being worked on. </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">When coring an elevated deck the contractor must have someone stationed below the suite under construction to catch the core when it drops. Contractor is responsible for protecting all finishes in the suite below and will be responsible for any damages to the suite below caused during any coring work.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Building Hours and Access</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The current building hours are Monday through Friday from 7&#58;00 a.m. to 6&#58;00 p.m. and Saturday 7&#58;00 a.m. to 1&#58;00 p.m. All contractors will be required to use only the designated path of travel for all access to the building. Any contractor found using any other path of travel or trespassing in other areas of the building&#47;property may be removed from the job at management's discretion. Contractor is required to check out an access card from management for all after-hours access to the building. Access to any part of the building other than the construction site, such as adjacent tenant space, is to be scheduled through management and contractor shall be responsible for any and all costs related to security or escorts for accessing adjacent tenant spaces.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Deliveries</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">All delivery of construction material must be made via the designated path of travel. All large items including but not limited to sheetrock, cabinetry, doors and other large items should be scheduled after hours. If any materials cannot be brought in through the designated path due to size, coordination of an alternate delivery path must be made with management at least 24 hours in advance. No items are to be brought up the elevators without management approval.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Protection of Finishes &#38; Cleaning</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Contractor is responsible to protect all finishes along the designated path of travel including flooring, walls, handrails, ceiling tiles, etc. Contractor is required to submit protective coverings for management approval prior to installation. Contractor is responsible for keeping all protection and the path of travel neat and clean at all times. A pre-construction walk will be held with management prior to job start to note any pre-existing damage to the building and&#47;or property. A final walk will be held upon completion of the job and contractor will be held responsible for repair and&#47;or replacement of any damaged building finishes or property.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Signage</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Contractor shall not post any signage at the building&#47;property. All notices posted pursuant to the requirements of a governmental agency shall be posted within the suite under construction.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Parking</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">All contractors and subcontractors must park in areas designated by management. At no time will any contractor be allowed to park in the covered parking area. Any contractor found parking in an unapproved area will be subject to towing and removal from the job at management's discretion.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Trash</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">All contractors are responsible for keeping their construction areas clean including all work areas, staging areas, lunch areas etc. Trash carts must be used to remove trash daily to a construction dumpster, provided by contractor. The building trash containers are not to be used for construction debris at any time. All trash must be hauled from the property by the contractor. Combustible material is not to be mixed with other materials. Contractor is to empty their trash </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">dumpster immediately upon filling. The location of the construction dumpster must be approved by management prior to delivery to the site and must have protective boards&#47;risers to prevent damage to the parking surface.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Equipment</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Contractors are to provide their own equipment including ladders, wheel dollies, vacuum cleaners, etc. Carts and dollies are to be fitted with rubber wheels.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Restrooms</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Upon commencement of construction, common area restrooms are not to be used by construction personnel. Any contractor found in violation of this rule is subject to immediate and permanent removal from the job. Contractor is responsible for providing portable restrooms to be installed in a location approved by management. Contractor is responsible for making sure the portable restroom area is kept neat and clean at all times.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Excessive Noise&#47;Disruption</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The utmost consideration must be given to the building tenants. Any work which will result in noise, odors or other conditions which will be disruptive to normal business activity as determined by the building manager is to be performed after hours. This work may include but is not limited to coring, shooting track to the deck, attaching ceiling wires to the deck, installation of tack strip, painting, staining, etc. Dragging items across floors and dropping of tools&#47;materials is to be avoided at all times.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Pre-stock</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Pre-stock material is inventoried by the property manager. Pre-stock can only be used as provided in the construction agreement, or as agreed by the manager.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Building Systems</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Contractor is required to coordinate access or usage of any building system through management. This includes but is not limited to the MPOE, HVAC system, FLS system, switchgear etc. Contractor is responsible for requesting any building system be put in test for any work that may create an alarm on a building system. A minimum 1 hour notice is requested whenever possible. Contractor is responsible for monitoring and silencing the fire panel during any period of work affecting the FLS system. Contractor is responsible for installing management approved covers on smoke detectors to prevent damage to the detector from dust and to prevent the system from going into alarm. Contractor will be held liable for any damage to any building systems or components.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">A written request is to be submitted to management by contractor for any of the following, preferably at least a week in advance to allow proper tenant notification and scheduling&#58;</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">- FLS system shut down or testing</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">- HVAC shut down</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">- Power shut off</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">- Permit inspections requiring usage or testing of any building systems</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Toxic Materials</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The contractor is responsible for adhering to all laws and ordinances regarding toxic and hazardous materials. Management must be informed about the use of said materials. If special ventilation is required, advance notification is required. If application of these materials impacts other tenants then said application will have to be done during non-business hours as directed by manager. Contractor must provide MSDS sheets as required by management. </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Agreed to and accepted by Contractor&#58;</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.871%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Company Name</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Authorized Representative Signature</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Print Name</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Date</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_155"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">EXHIBIT F</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">COMMENCEMENT LETTER</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">_____________, 20____</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">__________________</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">__________________</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">__________________</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">RE&#58;&#160;&#160;&#160;&#160;Lease dated ____________, between BROOKWOOD CB I, LLC, a Delaware limited liability company, and BROOKWOOD CB II, LLC, a Delaware limited liability company (&#34;Landlord&#34;) and Plum Healthcare Group, LLC, a California limited liability company (&#34;Tenant&#34;) concerning premises located at 2175 Salk Avenue in Carlsbad, California.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">In accordance with the above-referenced Lease, we request that you and&#47; or the proper </font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">authority, please confirm the following statements&#58;</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1.&#160;&#160;&#160;&#160;The Commencement Date is deemed to be ______________, and the Rent Commencement Date is __________________ and the Expiration Date is ________________.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">2.&#160;&#160;&#160;&#160;Tenant acknowledges and agrees that as of the date of this letter (i) all improvements required by the Lease to be performed by Landlord prior to the Commencement Date have been completed&#59; and (ii) Tenant has accepted the Premises in its current condition.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Please confirm your agreement with the above terms of this letter by signing below and returning a copy to Landlord. Failure to execute this letter and deliver the same to Landlord shall be conclusive evidence against Tenant that the above statements are accurate and true. </font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Sincerely,</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Its&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">AGREED TO &#38; ACCEPTED BY&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Its&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_163"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">EXHIBIT G</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">FORM OF ESTOPPEL CERTIFICATE</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">TENANT ESTOPPEL CERTIFICATE</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">To&#58;&#160;&#160;&#160;&#160;__________________________, its successors and&#47;or assigns </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:125%">(&#34;Lender&#34;)</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Re&#58;&#160;&#160;&#160;&#160;Plum Healthcare Group, LLC </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:125%">(&#34;Tenant&#34;)</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Lease between BROOKWOOD CB I, LLC and BROOKWOOD CB II, LLC, as Landlord or its assignees (individually and collectively, &#34;Landlord&#34;, and Tenant, dated _____________, 2018 for approximately 25,404 rentable square feet of space (the &#34;Premises') in 2175 Salk Avenue, Carlsbad, California (the &#34;Properly'&#47;, as amended by ______________________________________________________________________</font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1.&#160;&#160;&#160;&#160;The Lease is in full force and effect and has not been modified, supplemented, or amended, except&#58;_____________________________________. The Lease represents the entire agreement between the parties as to the Property, and Tenant claims no rights with respect to the Property other than as set forth in the Lease.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">2.&#160;&#160;&#160;&#160;The Lease has been duly executed and delivered by, and is a binding obligation of, Tenant, and the Lease is in full force and effect.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">3.&#160;&#160;&#160;&#160;Tenant has paid rent for the Premises up to and including ___________________ The current amount of fixed monthly rent is $_____________&#59; the current monthly common area or other charges are $__________________. The base year for operating expenses and real estate taxes, as defined in the Lease, is ________. No rent has been or will be paid more than one (1) month in advance of its due date, except&#58;_____________________________.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">4.&#160;&#160;&#160;&#160;Tenant has paid a security deposit of $________________. Tenant waives collection of the deposit against Lender or any purchaser at a foreclosure sale, unless Lender or such purchaser actually receives the deposit from Landlord.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">5.&#160;&#160;&#160;&#160;The commencement date of the Lease was _____________________. The current expiration date for the Lease is ___________________, and Tenant has no option or right to terminate the Lease prior to the expiration date except&#58;____________________. Tenant has no option(s) to renew or extend the Lease, except&#58;_______________________________.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">6.&#160;&#160;&#160;&#160;All work to be performed to the Premises for Tenant under the Lease has been performed in all material respects. All payments, free rent, or other credits, allowances or abatements required to be given under the Lease to Tenant with respect to work to be performed to the Premises have been received by Tenant, except&#58;________________________________. Tenant has unconditionally accepted the Premises, is in physical occupancy of the Premises and is operating its business in the Premises.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">7.&#160;&#160;&#160;&#160;As of the date hereof (i) there exists no breach, default, or event or condition which, with the giving of notice or the passage of time or both, would constitute a breach or default by Tenant or Landlord under the Lease&#59; and (ii) Tenant has no existing claims, defenses or offsets against rental due or to become due under the Lease.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">8.&#160;&#160;&#160;&#160;Tenant has not assigned any of its rights under the Lease or sublet all or any portion of the Premises. Tenant does not hold the Premises under assignment or sublease.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">9.&#160;&#160;&#160;&#160;Tenant has no right or option to purchase all or any part of the Premises or the building of which the Premises is a part. Tenant has no right to expand or occupy any additional space at the Property.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">10.&#160;&#160;&#160;&#160;Lender shall not be liable for or bound by any modification or amendment of the Lease, or any waiver of any terms of the Lease, that (i) materially modifies the economic terms of the Lease, or (ii) materially and adversely affects Landlord's obligations under the Lease or Lender's rights, duties or obligations, unless such modification, amendment, or waiver was consented to in writing by Lender.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11.&#160;&#160;&#160;&#160;No actions, whether voluntary or otherwise, are pending against Tenant under the bankruptcy laws of the United States or any state.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">12.&#160;&#160;&#160;&#160;The Lease, as the same may hereafter be modified, amended or extended, and all of Tenant's right, title and interest in and to the Premises and the Property, including all rights, remedies and options of Tenant under the Lease, are and shall be unconditionally subject and subordinate to the Lender's loan documents and the lien thereof, and to all renewals, modifications, consolidations, replacements, substitutions and extensions thereof&#59; provided that Lender agrees that so long as no event exists on Tenant's part that constitutes a default under the Lease, Tenant's leasehold estate in the Premises under the Lease shall not be terminated by Lender and Tenant's possession of the Premises shall not be disturbed by Lender.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">13.&#160;&#160;&#160;&#160;Tenant shall attorn to Lender upon any foreclosure of the Lender's lien on the Property or Lender's acceptance of a deed-in-lieu of foreclosure, and shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">recognize Lender as the landlord or lessor under the Lease, and shall be bound to Lender in accordance with all of the provisions of the Lease for the balance of the term thereof, and Lender will accept the attornment of Tenant. Such attornment will be effective and self-operative without the execution of any further instrument.</font></div><div style="margin-bottom:0.08pt;padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The person executing this certificate on behalf of Tenant is duly authorized to execute this certificate.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Executed by Tenant on _______________________________</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">TENANT&#58;</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">PLUM HEALTHCARE GROUP, LLC,</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">a California limited liability company</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;_____________________________</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58;</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_171"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">EXHIBIT H</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">GUARANTY</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">THIS GUARANTY (this &#34;Guaranty&#34;) dated as of &#91;____________________&#93;, 2018, is made by &#91;***&#93; (&#34;Guarantor&#34;) in favor of BROOKWOOD CB I, LLC, a Delaware limited liability company, and BROOKWOOD CB II, LLC, a Delaware limited liability company (&#34;Landlord&#34;).</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">WHEREAS, PLUM HEALTHCARE GROUP, LLC, a California limited liability company, as tenant (&#34;Tenant&#34;), and Landlord, will be entering into that certain Lease dated ______________________, 2018 (the &#34;Lease&#34;)&#59; and</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">WHEREAS, as a condition to Landlord entering into said Lease, Guarantor agrees to execute and deliver this Guaranty.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">NOW THEREFORE, in consideration of the foregoing, and of Ten Dollars ($10.00) and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Guarantor agrees with Landlord as follows&#58;</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1.&#160;&#160;&#160;&#160;Guarantor unconditionally and irrevocably guarantees that Tenant shall faithfully perform each and every one of its obligations and duties, and pay all amounts (of whatever nature, and including without limitation rent, additional rent, late charges, fees, costs of collection and the like), due under the Lease promptly and in accordance with the provisions of the Lease. This Guaranty is irrevocable, unconditional and absolute, and if for any reason any such payments or obligations shall not be paid or performed, as the case may be, by Tenant when due, Guarantor will pay or perform same or cause the same promptly to be paid or performed, regardless of any defenses or rights of set-off or counterclaims which Tenant may have or assert and regardless of whether Landlord shall have taken any steps to enforce any rights against Tenant or any other remedy thereunder, provided Landlord gives written notice to Guarantor that such payment or obligation is due. Without limiting the foregoing obligations, Guarantor agrees to pay all of Landlord's reasonable legal and other fees, expenses and costs reasonably incurred in enforcing the Lease and this Guaranty.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">2.&#160;&#160;&#160;&#160;The obligations, covenants, agreements and duties of Guarantor under this Guaranty shall in no way be affected or impaired by reason of the happening from time to time of any of the following, although without notice to or with the further consent of Guarantor&#58;</font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(a)&#160;&#160;&#160;&#160;the waiver by Landlord of the performance or observance by Tenant of any of the agreements, covenants, terms or conditions contained in the Lease&#59; or</font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(b)&#160;&#160;&#160;&#160;the extension, in whole or in part, of the time for payment by Tenant or Guarantor of any sums owing or payable under the Lease or this Guaranty&#59; or</font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(c)&#160;&#160;&#160;&#160;the modification or amendment (whether material or otherwise) of any of the obligations of Tenant under the Lease&#59; or</font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(d)&#160;&#160;&#160;&#160;any assignment of the Lease or any subletting of the Premises&#59;</font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(e)&#160;&#160;&#160;&#160;any failure, omission or delay on the part of Landlord to enforce, assert or exercise any right, power or remedy conferred on or available to Landlord in or by the Lease or this Guaranty, or any action on the part of Landlord granting indulgence or extension in any form&#59; or</font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(f)&#160;&#160;&#160;&#160;the voluntary or involuntary liquidation, dissolution, sale of all or substantially all of the assets, marshalling of assets and liabilities, receivership, conservatorship, insolvency, bankruptcy, assignment for the benefit of creditors, reorganization, arrangement, composition or readjustment of, or other similar proceeding affecting Tenant or Guarantor or any of their assets&#59; or</font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(g)&#160;&#160;&#160;&#160;the release of Tenant or Guarantor from the performance or observance of any of the agreements, covenants, terms or conditions contained in the Lease or this Guaranty by operation of law.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">3.&#160;&#160;&#160;&#160;If, for any reason, any payment to Landlord of any of the obligations to which this Guaranty is applicable is required to be refunded to Tenant or required to be paid over to any other party including, without limitation, by reason of the operation of any bankruptcy law or other law affecting creditors' rights now or hereafter enacted, Guarantor will pay the amount so required to be paid by Landlord upon demand, and such obligations of Guarantor hereunder shall not be treated as having been discharged by reason of the payment by Tenant to Landlord giving rise to the obligation of Landlord to repay the same&#59; and this Guaranty shall be treated as having remained in full force and effect for any such repayment so made by Landlord as well as any amount not theretofore paid to Landlord on account of such obligations. Guarantor hereby agrees, for itself and its successors and assigns, that it will consent to and not contest or otherwise oppose any action or motion by or on behalf of Landlord for relief from the automatic stay provided in 11 U.S.C. &#167;362 (including without limitation any stay against actions against non-debtor parties).</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">4.&#160;&#160;&#160;&#160;Notice of acceptance of this Guaranty and notice of any obligations or liabilities contracted or incurred by Tenant, together with notice of presentment, notice of dishonor, protest and notice of non-payment, non-performance or non-observance and notice of acceptance, are hereby waived by Guarantor.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">5.&#160;&#160;&#160;&#160;The liabilities and obligations of Guarantor hereunder are direct and primary, and not secondary, and shall be joint and several with Tenant. Such liabilities and obligations of Guarantor shall be enforceable either before, simultaneously with, or after proceeding against Tenant or against any property or security available to Landlord. Notwithstanding anything in the Lease or this Guaranty to the contrary, Landlord shall have the right to apply or not apply any credit in favor of Tenant as Landlord shall determine in its commercially reasonable discretion, and Guarantor's liability under this Guaranty shall not be affected in any manner thereby. Landlord may proceed against Guarantor under this Guaranty without initiating or exhausting any remedy against Tenant (including, without limitation, the application of any security deposit or other credit in favor of Tenant) and may proceed against Tenant and Guarantor separately or concurrently.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">6.&#160;&#160;&#160;&#160;Guarantor is fully aware of the financial condition of Tenant, and is executing and delivering this Guaranty based solely upon its own independent investigation of all matters pertinent thereto, and is not relying in any manner upon any representation or statement to Landlord. Guarantor shall have no right to require Landlord to obtain or disclose any information with respect to such obligations, the financial condition or character of Tenant or any other matter, fact or occurrence whatsoever.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">7.&#160;&#160;&#160;&#160;Guarantor hereby agrees that all actions to enforce the terms and provisions of this Guaranty may be brought and maintained within the State of California, and Guarantor hereby consents to the jurisdiction of any court within the State of California.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">8.&#160;&#160;&#160;&#160;This Guaranty shall be construed in accordance with the laws of the State of California. Guarantor agrees that any action or proceeding brought hereunder shall be tried before a judge sitting without a jury, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:125%">TO THE EXTENT PERMITTED BY APPLICABLE LAW, GUARANTOR HEREBY WAIVES ITS RIGHT TO A JURY TRIAL IN ANY SUCH ACTION OR PROCEEDING. GUARANTOR MAKES 'I'HE FOREGOING WAIVER KNOWINGLY AND VOLUNTARILY, AND ACKNOWLEDGES THAT GUARANTOR HAS HAD THE BENEFIT OF LEGAL COUNSEL OF GUARANTOR'S CHOOSING</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">9.&#160;&#160;&#160;&#160;This Guaranty may not be modified or amended except by a written agreement duly executed by Guarantor with the consent in writing of Landlord.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">10.&#160;&#160;&#160;&#160;Guarantor represents and warrants that Landlord's execution of the Lease is an economic benefit to Guarantor and constitutes good, valuable and sufficient consideration for Guarantor's execution of this Guaranty, notwithstanding any future rejection or other termination of all of any part of the Lease.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11.&#160;&#160;&#160;&#160;This Guaranty shall be binding upon, and inure to the benefit of, the parties hereto and their respective successors and assigns.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;signature appears on the following page&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">IN WITNESS WHEREOF, Guarantor has caused to be executed under seal as of the date first set forth above.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Witness&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">GUARANTOR&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_180"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">FIRST AMENDMENT TO LEASE</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">This FIRST AMENDMENT TO LEASE (this &#34;Amendment'') is dated as of May 7, 2019 (the &#34;Effective Date&#34;) by and between BROOKWOOD CB I, LLC, a Delaware limited liability company and BROOKWOOD CB II, LLC, a Delaware limited liability company (collectively, as tenants in common, &#34;Landlord'') and PLUM HEALTHCARE GROUP, LLC, a California limited liability company (&#34;Tenant&#34;).</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">WHEREAS, Landlord and Tenant are parties to that certain Lease dated April 3, 2018 (the &#34;Lease''), for the lease of certain premises (the &#34;Existing Premises&#34;) known as Suite 300 and consisting of approximately 25,404 rentable square feet on the third (3rd) floor of the building located at 2175 Salk Avenue, Carlsbad, California (the &#34;Building&#34;), as more particularly described in the Lease&#59; and</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">WHEREAS, Landlord and Tenant desire to amend the Lease as provided herein&#59;</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">NOW, TIIEREFORE, for good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">AGREEMENT</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Capitalized terms used in this Amendment shall have the same meaning ascribed to such capitalized terms in the Lease, unless otherwise provided for herein.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  The Term is extended such that the Expiration Date shall be April 30, 2027.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Expansion Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  The &#34;Expansion Premises&#34; shall mean the approximately 2,690 rentable square feet of space commonly known as Suite 315 of the Building, as approximately shown on Exhibit A attached hereto. Promptly within one (1) business day following the Effective Date, Landlord shall deliver possession of the Expansion Premises to Tenant On the date of such delivery (the &#34;Expansion Date''), the Expansion Premises shall be added to the Existing Premises and the term ''Premises&#34;, as used in the Lease, shall mean and collectively refer to both the Existing Premises and the Expansion Premises. The Expansion Premises shall be subject to all the terms and provisions of the Lease, as modified by this Amendment.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Temporary Space License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Commencing promptly following Tenant's request therefor, and expiring on the date that is the earlier of (i) substantial completion of all portions of Tenant's Work (as defined in Exhibit B to this Amendment) to be completed in the Expansion Premises and (ii) September 1, 2019, so long as no Event of Default occurs, Landlord shall permit Tenant to use vacant, unleased space at the Property to be designated by Landlord (the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#34;Temporary Space'')&#59; provided that Landlord shall not be required to deliver possession of the Temporary Space to Tenant until Tenant has delivered to Landlord (i) the amount of the Security Deposit increase set forth in Section 7 hereof and (ii) certificates of insurance demonstrating that the insurance coverage required to be maintained by Tenant under the Lease is in effect with respect to the Temporary Space. Tenant's occupation of the Temporary Space shall be subject to all of the terms and conditions of the Lease (including, without limitation, the insurance and indemnity provisions thereof, and the right of Landlord to show the Temporary Space to prospective tenants following verbal or written notice provided at least 24 hours in advance), except that&#58;</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">A.&#160;&#160;&#160;&#160;Tenant shall accept the Temporary Space in its &#34;as is&#34; condition and shall have no right to alter or improve the Temporary Space in any way without Landlord's prior written consent, which may be withheld in Landlord's sole but reasonable discretion, it being agreed that Landlord shall have the right to condition such consent upon the requirement that, prior to surrendering the Temporary Space to Landlord, Tenant shall remove any such improvements or alterations (including any Cosmetic Work) and restore the Temporary Space to the condition which existed immediately prior to the installation thereof&#59;</font></div><div style="margin-bottom:0.08pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">B.&#160;&#160;&#160;&#160;Tenant shall not be responsible for the payment of Operating Expenses Excess or Tax Excess with respect to the Temporary Space (provided that the foregoing shall not affect Tenant's obligation to pay any other costs relating to the Temporary Space, including, without limitation, costs of utilities and janitorial services which are provided to the Temporary Space), and, provided that Tenant timely vacates and surrenders the Temporary Space in accordance with the terms of this section, Tenant shall not be responsible for the payment of Base Rent for the Temporary Space&#59;</font></div><div style="margin-bottom:0.08pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">C.&#160;&#160;&#160;&#160;If Tenant fails to timely vacate and surrender the Temporary Space in accordance with the applicable requirements of the Lease (including, without limitation, Section 21(B) thereof), such failure shall constitute an Event of Default, and Tenant's occupancy following such failure shall be deemed a holdover with respect to the Temporary Space. For purposes of calculating the fee payable by Tenant for such holdover period pursuant to Section 17 of the Lease, Tenant shall be deemed to have been paying Base Rent for the Temporary Space immediately prior to such holdover period at the same rate per square foot as was then applicable to the Existing Premises&#59;</font></div><div style="margin-bottom:0.08pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">D.&#160;&#160;&#160;&#160;Tenant shall have no right to transfer its right to occupy the Temporary Space (whether by assignment or sublease or otherwise) without the prior written consent of Landlord, which may be withheld in Landlord's sole and absolute discretion&#59;</font></div><div style="margin-bottom:0.08pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">E.&#160;&#160;&#160;&#160;Tenant shall not be entitled to any signage or parking spaces with respect to the Temporary Space&#59; and</font></div><div style="margin-bottom:0.08pt;padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">F.&#160;&#160;&#160;&#160;Tenant shall be responsible for all costs of moving to and from the Temporary Space.</font></div><div style="margin-bottom:0.08pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  From and after the Effective Date, Tenant shall pay Base Rent according to the following schedule&#58;</font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Period</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Base Rent</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(per month)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Base Rent</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(per rentable square foot, per month)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Effective Date - 8&#47;31&#47;19</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">9&#47;1&#47;19 - 10&#47;31&#47;19</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11&#47;1&#47;19 - 10&#47;31&#47;20</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11&#47;1&#47;20 - 10&#47;31&#47;21</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11&#47;1&#47;21 - 10&#47;31&#47;22</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11&#47;1&#47;22 - 10&#47;31&#47;23</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11&#47;1&#47;23 - 10&#47;31&#47;24</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11&#47;1&#47;24 - 10&#47;31&#47;25</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11&#47;1&#47;25 - 10&#47;31&#47;26</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11&#47;1&#47;26 - 10&#47;31&#47;26</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11&#47;1&#47;26 - 4&#47;30&#47;27</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">*Base Rent shall be net of Additional Rent, which shall be payable in accordance with the Lease.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;. In no event shall either Base Rent Abatement Period be deemed to reduce or eliminate Tenant's obligation to pay Additional Rent or any other amounts due under the Lease other than Base Rent. If an Event of Default occurs under this Lease, then Tenant's right to abate Base Rent pursuant to this section shall immediately terminate and any and all Base Rent which had been abated prior to Tenant's default shall immediately become due and payable.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Tenant's Percentage&#59; Base Taxes&#59; Base Operating Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Effective as of the Expansion Date, (i) Tenant's Percentage of the Building shall be 35.31%, (ii) Tenant's Percentage of the Property shall be 12.81%, (iii) Base Taxes for the Expansion Premises shall be the Taxes for the calendar year 2019, and (iv) Base Operating Expenses for the Expansion Premises shall be the Operating Expenses for the calendar year 2019.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Security Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Landlord is currently in possession of a Security Deposit equal to &#91;***&#93;. The Security Deposit amount is hereby increased to &#91;***&#93;. Accordingly, concurrent with Tenant's delivery of this Amendment to Landlord, Tenant shall deposit with Landlord &#91;***&#93; to be held by Landlord in accordance with Section 11 of the Lease.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Restoration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  With the exceptions of(i) cabling, (ii) security systems, (iii) cubicles, (iv) audio&#47;visual systems, and any portions of Tenant's Work (as defined in Exhibit B attached to this Amendment) that would cost more to remove than traditional office improvements, Tenant shall not be required to remove any of Tenant's Work performed in accordance with Exhibit B upon the expiration or earlier termination of the Lease.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">New Notice Addresses for Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  All notices under the Lease shall be sent to </font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Landlord at the following address&#58;</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Brookwood CB I, LLC and Brookwood CB II, LLC</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">c&#47;o Brookwood Financial Partners, LLC</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">138 Conant Street</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Beverly, Massachusetts 01915</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Attention&#58; Kurt Zernich, Director of Asset Management</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Brokerage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Landlord utilized the services of Cushman &#38; Wakefield (the &#34;Listing Broker&#34;) in connection with this Amendment. Tenant represents to Landlord that Tenant did not involve any other brokers in procuring this Amendment other than Hughes Marino, Inc. (the &#34;Tenant Broker''). Landlord shall pay a commission to the Listing Broker and the Tenant Broker as is agreed to by the parties per a separate agreement. Tenant agrees to forever indemnify, defend and hold Landlord harmless from and against any commissions, liability, loss, cost, damage or expense (including reasonable attorneys' fees) that may be asserted against or incurred by Landlord by any broker as a result of any misrepresentation by Tenant hereunder.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  This Amendment shall be governed by and construed in accordance with the laws of the State of California (without regard to conflicts of law).</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Ratification of Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Except as modified hereby, all other terms and conditions of the Lease remain unchanged and in full force and effect and are hereby ratified and confirmed by the parties hereto. Tenant accepts the Premises (i.e., the Existing Premises and the Expansion Premises) in its &#34;as is&#34; and ''where is&#34; condition. Tenant represents and warrants to Landlord that as of the date of Tenant's execution of this Amendment&#58; (a) Tenant is not in default under any of the terms and provisions of the Lease&#59; (b) Landlord is not in default in the performance of any of its obligations under the Lease and Tenant is unaware of any condition or circumstance which, with the giving of notice or the passage of time or both, would constitute a default by Landlord&#59; (c) Landlord has completed, to Tenant's satisfaction, any and all improvements to the Premises and has paid any and all allowances required of it under the Lease ( other than the Tenant Allowance, as such term is defined in Exhibit B to this Amendment)&#59; and (d) Tenant has no defenses, liens, claims, counterclaims or right to offset against Landlord or against the obligations of Tenant under the Lease. Other than the Extension Option set forth in Section 1 of Exhibit C to the Lease, Tenant acknowledges, confirms, and agrees that Tenant has no right or option to expand the Premises or to extend, renew- or terminate the Lease except as may be provided in this Amendment. In furtherance of the foregoing, Sections 4 and 5 of Exhibit C to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">the Lease (&#34;Termination Option&#34; and &#34;Right of First Refusal,&#34; respectively) are hereby deleted and of no further force or effect.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Neither Landlord nor any officer, director, member or employee of Landlord nor any owner of the Building, whether disclosed or undisclosed, shall have any personal liability with respect to any of the provisions of the Lease, as hereby amended, or the Premises, and if Landlord is in breach or default with respect to Landlord's obligations under the Lease, as hereby amended, or otherwise, Tenant shall look solely to the interest of Landlord in the Building for the satisfaction of Tenant's remedies or judgments.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  This Amendment, in conjunction with the Lease, constitutes the entire agreement of Landlord and Tenant with respect to the subject matter hereof and supersedes all oral and written agreements and understandings made and entered into by the parties prior to the date hereof.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Multiple Counterparts&#58; Facsimile Signature</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  This Amendment may be executed in multiple counterparts, all of which, when taken together, shall constitute one and the same instrument. Any signature to this Amendment transmitted via facsimile or electronic mail shall be deemed an original signature and be binding upon the parties hereto with the same force and effect as an original signature.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">16.&#160;&#160;&#160;&#160;Certified Access Specialist Inspection. In accordance with California Civil Code Section 1938, Landlord hereby informs Tenant that as of the Effective Date of this Amendment, the Premises and Building have not been inspected by a Certified Access Specialist (as defined in California Civil Code section 55.52(3)) (&#34;CASp''). Civil Code Section 1938(e) provides&#58;</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#34;A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.&#34;</font></div><div style="margin-bottom:0.08pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Accordingly, Landlord and Tenant hereby mutually agree that if Tenant desires to obtain a CASp inspection, (i) the CASp inspection shall be at Tenant's sole cost and expense, (ii) the inspection shall be performed by a CASp that is then currently certified in California and has been reasonably approved by Landlord, (iii) the CASp inspection shall take place during regular business hours with at least five (5) business day's prior written notice to Landlord and shall not materially disrupt any of the other tenants at the Building, (iv) Tenant shall promptly provide </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Landlord with a copy of the final report prepared in connection with the CASp inspection (the &#34;CASp Report''), and (v) Tenant shall be solely responsible for promptly making any repair or modifications necessary to correct violations of construction-related accessibility standards that are noted in the CASp Report and shall defend with competent counsel, indemnify and hold Landlord harmless from any claims, damages or liability resulting from Tenant's failure to promptly make such repairs. Tenant hereby acknowledges and agrees that the CASp Report is to be kept strictly confidential, except as necessary for Tenant to complete repairs and correct violations of construction-related accessibility standards as noted in the CASp Report. Accordingly, except as provided above or as may be required by law or court order, Tenant shall not release, publish or otherwise distribute (and shall not authorize or permit any other person or entity to release, publish or otherwise distribute) any information contained in the CASp Report. Tenant's obligations hereunder shall survive the expiration or sooner termination of the Lease.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;Signature on the Following Page&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the Effective Date set forth above.</font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.619%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">TENANT&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">LANDLORD&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">PLUM HEALTHCARE GROUP, LLC, a California limited liability company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">BROOKWOOD CB I, LLC, a Delaware limited liability company</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;  Brookwood CB Investors, LLC<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a Delaware limited liability company,<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;its Sole Member</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58; Brookwood CB Co., LLC, a Delaware<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;limited liability company, its Sole<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;Member</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline"> &#47;s&#47; Naveed Hakim       </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline"> &#47;s&#47; Thomas W. Brown       </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Naveed Hakim</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Thomas W. Brown</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58; Manager</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58; Authorized Signatory</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">BROOKWOOD CB II, LLC,<br>a Delaware limited liability company</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58; Brookwood U.S. Real Estate Aggregator, L.P.<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;a Delaware limited partnership, its Sole<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;Member</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58; Brookwood U.S. Real Estate Fund GP,<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;LLC, a Delaware limited liability<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;company, its General Partner</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline"> &#47;s&#47; Thomas W. Brown       </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Thomas W. Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58; Authorized Signatory</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">RATIFICATION OF GUARANTY</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The undersigned Guarantor of Tenant's obligations under the Lease pursuant to the terms of the Guaranty attached as Exhibit H to the original Lease (the &#34;Guaranty&#34;) hereby consents to the foregoing First Amendment to Lease and confirms the applicability of said Guaranty to the Lease as amended thereby.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.314%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">GUARANTOR&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">a Delaware limited liability company</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">8</font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_220"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">EXHIBIT A</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">EXPANSION PREMISES</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">9</font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_228"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">EXHIBIT B</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">WORK LETTER</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Preparation of Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Tenant shall perform all work (&#34;Tenant's Work&#34;) necessary to prepare the Expansion Premises for Tenant's occupancy in accordance with plans and specifications prepared by a licensed architect and approved by Landlord. Tenant shall submit to Landlord a detailed floor plan layout together with working drawings (collectively, the &#34;Plans'') for all Tenant's Work and all Tenant's Work and the Plans therefor shall be subject to Landlord's prior written approval.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Tenant's Performance of Tenant's Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Once the Plans have been approved by Landlord, Tenant shall promptly, and with all due diligence, perform Tenant's Work as set forth on the Plans, and, in connection therewith, the Tenant shall obtain all necessary governmental permits and approvals for Tenant's Work. Tenant shall have Tenant's Work performed by contractors approved by Landlord, which contractors shall maintain such insurance as the Landlord may reasonably require. Landlord shall have the right to prescribe such rules and regulations relative to the performance of Tenant's Work and any other work which the Tenant may perform under this Lease and Tenant shall abide by all such rules and regulations and shall cause all of its contractors to so abide including, without limitation, payment for the costs of using Building services. All of Tenant's Work shall be done strictly in accordance with the Plans and in a good and workmanlike manner and in compliance with all applicable laws, ordinances, rules, regulations, statutes, by-laws, court decisions, and orders and requirements of all public authorities and all insurance requirements set forth in the Lease. Except as may be otherwise shown on the Plans, Tenant shall perform Tenant's Work using building standard materials, quantities and procedures then in use by Landlord. It shall be Tenant's obligation to obtain a certificate of occupancy or other like governmental approval for the use and occupancy of the Expansion Premises to the extent required by law and Tenant shall submit to Landlord a copy of the same together with waivers of lien from all of Tenant's contractors in form adequate for recording purposes. Tenant shall also prepare and submit to Landlord promptly after Tenant's Work is substantially complete a set of as-built plans in both print and electronic forms showing the work performed by Tenant to the Expansion Premises including, without limitation, any wiring or cabling installed by Tenant or Tenant's contractor for Tenant's computer, telephone and other communication systems.</font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Tenant Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Subject to the terms and conditions hereof, Landlord agrees to provide to Tenant an allowance equal to &#91;***&#93; (the &#34;Tenant Allowance&#34;). The Tenant Allowance shall be used and applied by Tenant solely on account of the cost of Tenant's Work. Tenant may request that Landlord disburse the Tenant Allowance up to once per month with minimum draws of $5,000 for each such disbursement request for payment of completed portions of Tenant Work, provided that together with each such disbursement request, Tenant (i) provides copies of paid invoices and&#47;or receipts for such completed portions of Tenant's Work, (ii) provides </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">certification from Tenant's architect on a form reasonably acceptable to Landlord that all such completed portions of Tenant's Work have been completed in accordance with the Plans and with this Work Letter, (iii) has paid for all of the completed portions of Tenant's Work for which such disbursement request is made and has delivered to Landlord lien waivers from all persons who might have a lien arising out of such completed portions of Tenant's Work in recordable form, (iv) has delivered to Landlord its certificate specifying the total cost of such completed portions of Tenant's Work and all contractors, subcontractors and suppliers involved with the completed portions of Tenant's Work, together with evidence of such cost in the form of paid invoices, receipts and the like, (v) has made written request to Landlord for such payment, (vi) is not otherwise in default under this Lease beyond applicable cure and notice periods, and (vii) there are no liens against Tenant's interest in the Lease or against the Building or arising out of such completed portions of Tenant's Work or any litigation in which Tenant is a party. Within thirty (30) days after each such monthly disbursement is requested, provided that the foregoing conditions (i) through (vi) have been satisfied, Landlord shall pay to Tenant the lesser of the amount of such costs so certified in such monthly disbursement request and the remaining amount of the Tenant Allowance. For the purposes hereof, the cost to be so reimbursed by Landlord shall include the hard costs of Tenant's Work, together with Tenant's actual out-of-pocket engineering, architectural and permitting costs, but not the cost of any of Tenant's personal property, trade fixtures, trade equipment, or wiring. Landlord shall be under no obligation to apply any portion of the Tenant Allowance for any purposes other than as provided herein, nor shall Landlord be deemed to have assumed any obligations, in whole or in part, of Tenant to any contractors, subcontractors, suppliers, workers or materialmen. Further, in no event shall Landlord be required to pay any portion of the Tenant Allowance on account of any supervisory fees, overhead, management fees or other payments to Tenant, or any partner or affiliate of Tenant. Any portion of the Allowance which not requested or applied in compliance with the terms and conditions hereof on or before December 31, 2019 shall be retained by Landlord and forfeited by Tenant. Landlord shall be entitled to deduct from the Tenant Allowance an amount equal to the sum of&#58; (i) five percent (5%) of the total cost of Tenant's Work for Landlord's out-of-pocket costs for supervision of Tenant's Work by Landlord's property management company, plus (ii) third party expenses incurred by Landlord to review Tenant's Plans and Tenant's Work.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Hold Harmless</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Tenant shall indemnify and hold Landlord harmless from and against any and all liability and claims of any kind for loss or damage to any person or property arising out of or occurring during construction of Tenant's Work. In addition, Landlord shall not be liable for injury or damage which may be sustained by the person or property of Tenant, its employees, agents, invitees or contractors, or any other person in or about the Premises, arising out of or during performance of Tenant's Work.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">11</font></div></div></div><div id="i1ce24029fd1345bc91e0fd3afa3d0d9d_13"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LANDLORD&#8217;S CONSENT TO SUBLEASE</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consent to Sublease Agreement</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Definitions&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As appears in the Lease. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Landlord&#58; &#160;&#160;&#160;&#160;            Brookwood CB I, LLC, a Delaware limited liability company and </font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Brookwood CB II, LLC, a Delaware limited liability company, as tenants </font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in common.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Tenant&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Plum Healthcare Group, LLC, a California limited liability company</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Lease&#58; &#160;&#160;&#160;&#160;Lease dated April 3, 2018, as amended by that certain First Amendment to Lease dated May 7, 2019.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Premises&#58;&#160;&#160;&#160;&#160;Approximately 28,094 rentable square feet of office space designated as Suites 300 and 315, as more particularly described in the Lease.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Subtenant&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exagen Inc., a Delaware corporation</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Sublease&#58;&#160;&#160;&#160;&#160;The Sublease between Tenant and Subtenant, dated as of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">August 19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, 2021, covering the Subleased Premises.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Building&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The building located at 2175 Salk Ave., Carlsbad, CA.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Subleased Premises&#58;&#160;&#160;&#160;&#160;The Premises.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Landlord, Tenant, and Subtenant hereby agree as follows&#58;</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Subordination&#47;Future Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Pursuant to the terms of the Lease, Tenant has requested Landlord's consent to the Sublease, a fully executed copy of which is annexed hereto as Exhibit A and made a part hereof. Landlord hereby consents to the Sublease subject to, and in reliance upon, the following representations, warranties, covenants, and conditions and the following agreements of Tenant and Subtenant. The Sublease shall be subject and subordinate at all times to the Lease and to all of the provisions, covenants, agreements, terms, and conditions of the Lease, and this Consent to Sublease Agreement, and neither Tenant nor Subtenant shall do or permit anything to be done in connection with Subtenant's occupancy of the Subleased Premises that would violate any of said provisions, covenants, agreements, terms, and conditions. Tenant and Subtenant will not change, modify, amend, cancel, or terminate the Sublease or enter into any additional agreements relating to or affecting the use or occupancy of the Subleased Premises or the Building or the use, sale, or rental of Tenant's fixtures, leasehold improvements, equipment, furniture, or other personal property outside the ordinary course of business without first obtaining Landlord's prior written consent thereto, which consent shall not be unreasonably withheld, conditioned, or delayed.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Estoppel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Tenant and Subtenant each hereby represents and warrants that the Sublease and this Consent to Sublease Agreement constitute the complete agreement between the parties and that they are not a party to or a beneficiary of any oral agreements, representations or </font></div><div style="height:48.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">warranties of any kind or nature referring or relating to the Lease, the Sublease, or the use and occupancy of the Subleased Premises or the Building except as set forth therein and that no rent or other consideration is being paid to Tenant by Subtenant for the Sublease, or for the right to use or occupy the Subleased Premises, except as set forth in the Sublease.  Tenant represents and warrants that (i) the Lease has not been assigned, modified, supplemented or amended in any manner, (ii) as of this date,  Tenant has no knowledge that there are any existing defenses or offsets that Tenant has against the enforcement of the Lease by Landlord, and Tenant has no knowledge of any event that with the giving of notice, the passage of time or both would constitute a defense under the Lease, and (iii) as of this date, Tenant is not entitled to any offsets, abatements, deductions or otherwise against the rent payable under the Lease to and including the date hereof.  All provisions, covenants, agreements, terms, and conditions of the Lease are hereby declared by Tenant to be in full force and effect.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Neither this Consent to Sublease Agreement, the Sublease nor any acceptance of rent or other consideration from Subtenant by Landlord or Landlord's agent paid pursuant to the Sublease shall operate or be construed so as (i) to waive, modify, impair, release or in any manner affect any of the provisions, covenants, agreements, terms or conditions contained in the Lease, other than to satisfy the Landlord&#8217;s consent to the Sublease pursuant to the provisions of this Consent to Sublease Agreement (ii) to waive, modify, impair, release or in any manner affect Tenant's liability under the Lease or Tenant's and Subtenant's liability under the Sublease, (iii) to waive any breach or violation of the Lease or any rights of Landlord against any person, firm, associate, corporation or other entity liable or responsible for the performance of any of the provisions, covenants, agreements, terms or conditions contained in the Lease, and (iv) to enlarge or increase Landlord's obligations or Tenant's rights under the Lease or otherwise.  The consent by Landlord to the Sublease shall not be deemed an approval of any future assignment of the Lease or the Sublease or any subsequent subletting of the Premises or the Subleased Premises or any portion thereof.  No assignment of the Lease or Sublease or further sublease or assignment of all or any part of the Premises or the Subleased Premises shall be made without the prior written approval of Landlord pursuant to, and in accordance with, the provisions of the Lease and this Consent to Sublease Agreement, which consent shall not be unreasonably withheld, conditioned, or delayed. The term &#8220;Sublease&#8221; is deemed to include sub-subleases (regardless of tier), concessions, licenses, and any other arrangement where occupancy or possessory rights are granted or made available to third parties.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Sublease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Nothing herein contained shall be construed as a consent to or approval or ratification by Landlord of any of the particular provisions of the Sublease or as a representation or warranty by Landlord.  Landlord has not, and will not, review or approve of or express a view on any of the provisions of the Sublease and shall not be bound or estopped in any way by the provisions of the Sublease.  Landlord shall have no liability to the Subtenant under the terms of the Sublease and neither this Consent to Sublease Agreement nor the Sublease shall give Subtenant any rights under the Lease or Sublease against Landlord, all of such rights being personal to Tenant.  Landlord shall be under no obligation to make any changes, improvements, or alterations to the Subleased Premises to prepare the same for occupancy by Subtenant.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Permitted Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Subject to all of the provisions, covenants, agreements, terms, and conditions of the Lease and this Consent to Sublease Agreement (and notwithstanding anything </font></div><div style="height:48.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">to the contrary in the Sublease), the Subleased Premises and each part thereof shall be used by Subtenant solely for general office use in connection with Subtenant's business and for no other purpose.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Tenant and Subtenant Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Tenant and Subtenant hereby acknowledge and agree that none of Landlord&#8217;s agents, managers, partners, trustees, stockholders, officers, members of a governing board, directors, employees, or beneficiaries of Landlord shall be personally liable under the Lease or the Sublease nor shall any of their assets be subject to levy, execution, or other enforcement procedure for the satisfaction of the Tenant&#8217;s or Subtenant&#8217;s remedies arising under this Lease or the Sublease.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  In the event of any default by Tenant or Subtenant in the full performance and observance of any of their respective obligations hereunder or in the event any representation or warranty of Tenant or Subtenant contained herein should prove to be untrue, such event may, at Landlord's option, be deemed a default under the Lease and each of the parties hereto shall have all of the rights, powers and remedies provided for in the Lease or at law or in equity or by statute or otherwise with respect to defaults.  In addition, any breach or violation of any provision of the Lease by Subtenant shall be deemed to be and shall constitute a default by Tenant in fulfilling such provision unless Tenant timely cures such default, if such cure is provided for in the Lease.  If any default occurs under the Lease, Landlord may, at its option, and in addition to any other available rights and remedies, collect directly from Subtenant all rents due under the Sublease, and no such collection shall constitute an acceptance of Subtenant as a tenant or a novation or release of Tenant from its obligations under the Lease except to the extent of the rent collected.  </font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Termination of Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  If at any time prior to the expiration of the term of the Sublease, the term of the Lease shall terminate or be terminated for any reason including, but not limited to, by operation of any provisions of the Lease or of law, Subtenant agrees, at the election and upon demand of Landlord or any other owner of the Land (as defined in the Lease) or the Building, or of the holder of any mortgage in possession of the Land or the Building, or of any lessee under any lease to which the Sublease shall be subject and subordinate, to attorn, from time to time, to Landlord or any such owner, holder or lessee, upon the then executory terms and conditions set forth in the Sublease for the remainder of the term demised in the Sublease.  In such event, Subtenant agrees that Landlord or any such owner, holder or lessee (i) shall not be bound by any payment of rent or additional rent made by Subtenant to Tenant for more than one month in advance&#59; (ii) shall have no obligation to perform any work under any work letter or otherwise to prepare any space for occupancy pursuant to the provisions of the Sublease&#59; (iii) shall not be liable for any previous act, omission or negligence of Tenant or for the payment of any money owing by, or on deposit with, Tenant for the credit of Subtenant, including, without limitation, any security deposit held by Tenant&#59; (iv) shall not be bound by any amendment or modification of the Sublease made without the written consent of Landlord&#59; (v) shall not be liable for the return of any security deposit except to the extent actually received by Landlord&#59; (vi)  shall not be bound by any other provision of the Sublease which in any way increases Landlord&#8217;s duties, obligations or liabilities to Subtenant beyond those owed to Tenant under the Lease&#59; (vii) shall be entitled to the full benefits of the limitation of liability set forth in Section 6 of this Consent to Sublease Agreement&#59; and (viii) shall not be subject to any defenses or offsets that  Subtenant may have against Tenant.  The foregoing provisions of this Section shall inure to </font></div><div style="height:48.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">the benefit of any such owner, holder or lessee and shall apply notwithstanding that, as a matter of law, the Sublease may terminate upon the termination of the Lease, shall be self-operative upon any such demand, and no further instrument shall be required to give effect to said provisions.  Upon demand of Landlord or any such owner, holder or lessee, Subtenant agrees, however, to execute, from time to time, instruments in confirmation of the foregoing provisions of this Section, satisfactory to Landlord or any such owner, holder or lessee, in which Subtenant shall acknowledge such attornment and shall set forth the terms and conditions of its tenancy as set forth above.  Nothing contained in this Section shall be construed to impair any right otherwise exercisable by Landlord or any such owner, holder or lessee.  Upon request of Landlord or any such owner, holder or lessee, whether or not made prior to such termination, Tenant and Subtenant shall deliver an executed counterpart of the Sublease to Landlord.  Landlord or any such owner, holder or lessee shall have the right, in each&#8217; s sole discretion, to elect not to have Subtenant attorn, and, in such event, the Sublease Agreement shall be deemed terminated on the date the Lease is terminated and Landlord shall have no obligation to permit Subtenant to continue to occupy the Subleased Premises.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Indemnity and Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1.&#160;&#160;&#160;&#160;Subtenant agrees to fully indemnify Landlord to the same extent and in the </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">same manner as the indemnification for Tenant to Landlord set forth in the Lease, and that Landlord can seek indemnification directly from Subtenant without first seeking indemnification from Tenant, and that if Landlord first seeks indemnification from Tenant, it will not preclude or limit Landlord&#8217;s ability and right later to seek indemnification from Subtenant.  The covenants and agreements set forth in this Section 9 shall continue in full force and effect for the longest period of time permitted by law, notwithstanding the expiration or termination of the Lease or Sublease.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2.&#160;&#160;&#160;&#160;Subtenant shall comply with all insurance requirements under the Lease and shall provide certificates of such insurance to Landlord and Tenant prior to taking possession of the Subleased Premises and thereafter in accordance with the terms of the Lease.  All such insurance policies shall name Landlord, Landlord&#8217;s management company, and Tenant as additional insureds.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.   Any notices given or required to be given under this Consent to Sublease Agreement shall be effective only if rendered or given in writing (and signed by the party (or the party&#8217;s attorney) giving such notice) and delivered personally with receipt acknowledged or sent by a nationally recognized overnight courier or by mail (registered or certified, return receipt requested), postage prepaid, addressed to the respective party at the address hereinabove set forth or at such other address as such party may designate as its new address for such purpose by notice in accordance with the provisions hereof, or, if addressed to Subtenant, at the Subleased Premises.  The same shall be deemed to have been rendered or given on the date delivered, if delivered personally, or three business days after the date mailed, if mailed.  Notwithstanding anything in the Lease to the contrary, Tenant hereby acknowledges, by its signature hereto, that its address for all notices under the Lease shall be the address for Tenant set forth above. </font></div><div style="height:48.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Tenant&#8217;s Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  Tenant shall pay to Landlord as additional rent under the Lease, all costs incurred by Landlord in connection with this Consent to Sublease Agreement, including reasonable attorney&#8217;s fees.  </font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Inconsistencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.  In the event that there shall be any conflict or inconsistency between the terms, covenants and conditions of this Consent to Sublease Agreement or the Lease and the terms, covenants, and conditions of the Sublease, then the terms, covenants, and conditions of this Consent to Sublease Agreement and the Lease shall prevail.  In the event that there shall be any conflict or inconsistency between this Consent to Sublease Agreement and the Lease, such conflict or inconsistency shall be determined to the benefit of Landlord.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1.&#160;&#160;&#160;&#160;Each of Tenant and Subtenant hereby represents and warrants that it has full right, power, and authority to enter into this Consent to Sublease Agreement and that the person or persons executing this Consent to Sublease Agreement on behalf of Tenant and Subtenant, as the case may be, are duly authorized to do so.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.&#160;&#160;&#160;&#160;To facilitate execution, this Consent to Sublease Agreement may be executed in counterparts, and it shall not be necessary that the signatures of all parties appear on each counterpart.  It shall be sufficient that the signature of each party appears on one or more of the counterparts.  All counterparts shall collectively constitute a single agreement.  It shall not be necessary in making proof of this Consent to Sublease Agreement to produce or account for more than a number of counterparts containing the respective signatures of all the parties to this Consent to Sublease Agreement.  A facsimile, pdf,  or photocopy of a counterpart shall be considered the same as an original.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3.&#160;&#160;&#160;&#160;Each right and remedy of Landlord provided for in this Consent to Sublease Agreement or in the Lease shall be cumulative and shall be in addition to every other right and remedy provided for therein or now or hereafter existing at law or in equity or by statute or otherwise, and the exercise or beginning of the exercise by Landlord of any one or more of the rights or remedies so provided for or existing shall not preclude the simultaneous or later exercise by Landlord of any or all other rights or remedies so provided for or so existing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4.&#160;&#160;&#160;&#160;The terms and provisions of this Consent to Sublease Agreement bind and inure to the benefit of the parties hereto and their respective successors and assigns except that no violation of the provisions of Section 3 hereof shall operate to vest any rights in any successor or assignee of Tenant or Subtenant.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.5.&#160;&#160;&#160;&#160;This Consent to Sublease Agreement contains the entire agreement of the </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">parties with respect to the matters contained herein and may not be modified, amended or otherwise changed except by a written instrument signed by the party sought to be bound.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.6.&#160;&#160;&#160;&#160;All provisions, covenants, agreements, terms, rights, and conditions of the </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Lease are hereby ratified and affirmed by Landlord and Tenant and shall continue to be in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.7.&#160;&#160;&#160;&#160;This Consent to Sublease Agreement shall take effect as an instrument </font></div><div style="height:48.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">under seal and shall be governed by the internal laws of The Commonwealth of Massachusetts in all respects, without regard to principles of conflict of laws.  To the extent permitted by law, the parties hereto consent to the jurisdiction of the courts of the competent jurisdiction of the State of California in any dispute arising out of this Consent to Sublease Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Tenant agrees that it shall pay or cause to be paid any brokerage </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">commissions that may be payable in connection with the Sublease and that Landlord shall have no responsibility with respect thereto.  Tenant and Subtenant, jointly and severally, further agree to indemnify and hold Landlord harmless against and from all costs, liabilities, damages, and expenses, including attorneys' fees and disbursements, arising from any claims for brokerage commissions, finder's fees or other compensation from any broker, finder or other entity or person in connection with or relating to the Sublease.  The provisions of this Section shall survive the expiration or sooner termination of the Lease.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="height:48.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">IN WITNESS WHEREOF, the parties have executed this Consent to Sublease Agreement as of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:125%;position:relative;text-decoration:underline;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> day of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">August</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, 2021.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BROOKWOOD CB I, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware limited liability company</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;  Brookwood CB Investors, LLC</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        a Delaware limited liability company,</font></div><div style="margin-bottom:8pt;padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">        its Sole Member</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;  Brookwood CB Co., LLC,</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        a Delaware limited liability company,</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        its Managing Member</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:8pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">_&#47;s&#47;Kurt M. Zernich________________</font></div><div style="margin-bottom:8pt;padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">      Kurt M. Zernich, Authorized Signatory </font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BROOKWOOD CB II, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware limited liability company</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; Brookwood U.S. Real Estate Aggregator, L.P.</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">       a Delaware limited partnership,</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">       its Sole Member</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;  Brookwood U.S. Real Estate Fund GP, LLC,</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        a Delaware limited liability company,</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        its General Partner</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:8pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">        By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">_&#47;s&#47; Kurt M. Zernich______________</font></div><div style="margin-bottom:8pt;padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">              Kurt M. Zernich, Authorized Signatory</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;Signatures continue on following page&#93;</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="height:48.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Accepted and Agreed by&#58;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">TENANT&#58;  </font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Plum Healthcare Group, LLC, a California limited liability company </font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">_&#47;s&#47; Naveed Hakim____________</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">_Naveed Hakim____________</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Its&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">_CFO_______________________</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">SUBTENANT&#58;  </font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Exagen Inc., a Delaware corporation</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">_&#47;s&#47; Mark Hazeltine____________</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Mark Hazeltine </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Its&#58; COO</font></div><div style="height:48.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex102-amend2to1221libertyw.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i85a83d806cba4db9a9ff746bd05dbc34_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div><div style="margin-top:3.35pt;padding-left:159.32pt;padding-right:159.32pt;text-align:center;text-indent:-166.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECOND AMENDMENT OF LEASE</font></div><div style="margin-top:0.9pt"><font><br></font></div><div style="padding-left:50.8pt;padding-right:34pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This Second Amendment of Lease is made on October 11, 2021, between Liberty Vista, a California limited partnership, (&#34;Lessor&#34;), whose address is 1000 Pioneer Way, El Cajon, CA 92020, and Exagen Diagnostics, Inc., (&#34;Lessee&#34;), with reference to 1221 Liberty Way, San Diego, CA 92083 who agree as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:12pt;padding-left:87.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:11.34pt;text-decoration:underline">Recitals.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> This Second Amendment of Lease is made with reference to the following facts and objectives&#58;</font></div><div style="margin-top:12pt;padding-left:123.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">Lessor and Lessee entered into a written Lease dated August 15, 2014, as extended February 1, 2018, February 25, 2020, as amended December30, 2020 (&#34;the Lease&#34;) in which Lessor leased to Lessee, and Lessee leased from Lessor, premises located in the City of Vista, County of San Diego, California, commonly known as 1221 Liberty Way, Vista, CA 92083, consisting of approximately 19,504 square feet (&#8220;Premises&#8221;).</font></div><div style="margin-top:12pt;padding-left:123.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">The term of the Lease expires on January 31, 2026.</font></div><div style="margin-top:12pt;padding-left:123.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.78pt">The parties desire to amend the Lease in the following respect&#58;</font></div><div style="margin-top:12pt;padding-left:87.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:11.34pt;text-decoration:underline">Extension of Term.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The term of the Lease shall be extended for an additional period of one (1) year and three (3) months from and after February 1, 2026, so that the term of the Lease shall extend to and include April 30, 2027.</font></div><div style="margin-top:12pt;padding-left:87.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:11.34pt;text-decoration:underline">Base Monthly Rent Schedule.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  Base monthly rent for the current and extended term shall be as follows&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.878%"><tr><td style="width:1.0%"></td><td style="width:38.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rent</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Base Rent </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Amortized TIA)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Base Rent</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 1, 2021 through January 31, 2022</font></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,000.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">990.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,990.00&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 1, 2022 through January 31, 2023</font></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,600.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">990.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,590.00&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 1, 2023 through January 31, 2024</font></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,200.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">990.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,190.00&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 1, 2024 through January 31, 2025</font></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,800.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">990.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,790.00&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 1, 2025 through January 31, 2026</font></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,400.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">990.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,390.00&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 1, 2026 through January 31, 2027</font></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,470.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.00&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,470.00&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 1, 2027 through April 30, 2027</font></td><td style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,594.00&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.00&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,594.00&#160;</font></td><td style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:87.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:11.34pt;text-decoration:underline">Lessor Ownership Correction.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Lessor of the premises erroneously appeared as &#8220;Liberty Vista, a California limited partnership&#8221;. The correct Lessor name is &#34;Liberty Vista, LP, a California limited partnership&#34;. The Lessor name is hereby corrected throughout the Lease.</font></div><div style="margin-top:12pt;padding-left:87.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:11.34pt;text-decoration:underline">Lessee Name Change.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  The Lessee's name shall change from Exagen Diagnostics, Inc., a California corporation to Exagen Inc. a California corporation.</font></div><div style="margin-top:12pt;padding-left:87.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:11.34pt;text-decoration:underline">Counterparts.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  The Amendment may be signed by the parties in different counterparts and the signature pages combined shall create a single document binding on all parties. This Amendment may be executed and delivered by the exchange of .pdf or using electronic signature technology (e.g., via DocuSign or similar electronic signature technology), and such signed electronic record shall be valid and bind the party so signing as a such party's hand-written signature for all purposes.</font></div><div style="margin-top:12pt;padding-left:87.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:11.34pt;text-decoration:underline">Effectiveness of Lease.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  Except as set forth in this Second Amendment of Lease, all the provisions of the Lease shall remain unchanged and in full force and effect.</font></div><div style="padding-left:51.5pt"><font><br></font></div><div style="padding-left:51.5pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:51.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"></td><td style="width:44.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LESSOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LESSEE&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liberty Vista, LP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exagen Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A California Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A Delaware Corporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">By&#58; Hamann Property Management, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Its Authorized Agent</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Brendan Thiessen</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brendan Thiessen - President</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fortunato Ron Rocca, President &#38; CEO</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date&#58; 10&#47;13&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date&#58; 10&#47;12&#47;2021</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Mark Hazeltine</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mark Hazeltine, COO</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date&#58; 10&#47;12&#47;2021</font></td></tr></table></div><div style="padding-left:51.5pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ex103-fifthaddendumtolease.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie71c9224fca34aa8a09896e627191ad4_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FIFTH ADDENDUM TO STANDARD INDUSTRIAL&#47;COMMERCIAL MULTI-TENANT LEASE - NET DATED JANUARY 13, 2012 BY AND BETWEEN RGS PROPERTIES, AS LESSOR AND EXAGEN DIAGNOSTICS, INC., AS LESSEE, FOR THE PREMISES LOCATED AT 1261 LIBERTY WAY, SUITES B &#38; C, CALIFORNIA.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lessor and Lessee mutually agree to amend the lease as follows&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Parties (1.1)&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lessee has changed their name and shall here for be referred to as Exagen Inc., a Delaware Corporation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Paragraph 1.3 (Term)&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Lease Term will be extended to the new Expiration Date of April 30, 2027</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Paragraph 50 (Rent Schedule)&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Base Rent shall be as follows&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Dates</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Base Rent</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">February 1, 2026 - April 30, 2027</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$20,084.42 per month</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">All other terms and conditions of the existing Lease shall remain in full force and effect.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">This addendum shall automatically expire is not executed by Lessee on or before Friday October 15, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AGREED AND ACCEPTED&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LESSOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LESSEE&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RGS Properties</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exagen Inc., a Delaware Corporation</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Scott Smith</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Ron Rocca</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Greg Smith</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ron Rocca</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; 10&#47;19&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; CEO</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; 10&#47;12&#47;2021</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>ex104-firstaddendumtolease.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ia8eaa421db444f2586b1186863c9961c_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.4</font></div><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FIRST ADDENDUM TO STANDARD INDUSTRIAL&#47;COMMERCIAL MULTI-TENANT LEASE - NET DATED FEBRUARY 27, 2020 BY AND BETWEEN RGS PROPERTIES, AS LESSOR AND EXAGEN DIAGNOSTICS, INC., AS LESSEE, FOR THE PREMISES LOCATED AT 1261 LIBERTY WAY, SUITE A, CALIFORNIA.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lessor and Lessee mutually agree to amend the lease as follows&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Parties (1.1)&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lessee has changed their name and shall be referred to as Exagen Inc., a Delaware Corporation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Paragraph 1.3 (Term)&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Lease Term will be extended to the new Expiration Date of April 30, 2027</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Paragraph 50 (Rent Schedule)&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Base Rent shall be as follows&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Dates</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Base Rent</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">February 1, 2026 - April 30, 2027</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$14,750.63 per month</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">All other terms and conditions of the existing Lease shall remain in full force and effect.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">This addendum shall automatically expire if not executed by Lessee on or before Friday October 15, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AGREED AND ACCEPTED&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LESSOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LESSEE&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RGS Properties</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exagen Inc., a Delaware Corporation</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Scott Smith</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Ron Rocca</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Greg Smith</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ron Rocca</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; 10&#47;19&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; CEO</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; 10&#47;12&#47;2021</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>ex105-secondamendmentloana.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i0b0bf75a2d4a487b83140f1ae87784d5_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.5</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is entered into effective as of November 1, 2021, by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership (together with its successors and assigns, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Innovatus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), as collateral agent (in such capacity, together with its successors and assigns in such capacity, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Lenders listed on Schedule 1.1 thereof or otherwise a party thereto from time to time (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and EXAGEN INC., a Delaware corporation (f&#47;k&#47;a EXAGEN DIAGNOSTICS, INC.) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collateral Agent, Lenders, and Borrower have entered into that certain Loan and Security Agreement dated as of September 7, 2017 (as the same may from time to time be amended, modified, supplemented or restated, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loan Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lenders have extended credit to Borrower for the purposes permitted in the Loan Agreement.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrower has requested that Collateral Agent and Lenders amend the Loan Agreement as more fully set forth herein.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Collateral Agent and Lenders have agreed to amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 1, 2021, the outstanding principal balance of the Term Loans, including payable in-kind interest which has been capitalized, is $27,203,341.00 (See </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annex X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Definitions.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized terms used but not defined in this Agreement shall have the meanings given to them in the Loan Agreement.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Amendments.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;Section 2.3 (Payment of Interest on the Term Loan).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Section 2.3(a) of the Loan Agreement is amended and restated as follows&#58;</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Interest Rate.  Subject to Section 2.3(b), the principal amount outstanding under the Term Loan shall accrue interest at a fixed per annum rate equal to percent (8.00%) prior to , which interest shall be payable monthly in arrears in accordance with Sections 2.2(b) and 2.3(e)&#59; provided that two percent (2.00%) of such eight percent (8.00%) interest rate shall be payable in-kind through December 1, 2024 by adding an amount equal to such two percent (2.00%) interest to the then outstanding principal balance on a monthly basis so as to increase the outstanding principal balance of such Term Loan on each Payment Date and which amount shall be payable when the principal amount of the Term Loan is payable in accordance with Sections 2.2(b) and 2.3(e) and on which principal amount interest shall be owed pursuant to Section 2.3(a).</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.2&#160;&#160;&#160;&#160;Section 6.15 (Performance to Plan).  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A new Section 6.15 is added to the Loan Agreement as follows&#58;</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.15&#160;&#160;&#160;&#160;Performance to Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  So long as the Performance Period is not in effect, Borrower shall achieve minimum trailing twelve (12) month revenue under GAAP, measured at the end of each calendar quarter commencing with the quarter ending December 31, 2022, greater than sixty-five percent (65%) of projected revenue under GAAP (such projections attached hereto as Annex Q, the &#8220;Management Plan&#8221;) (the &#8220;Performance Covenant&#8221;). Borrower&#8217;s failure to maintain the Performance Covenant may be cured by the Equity Cure. Upon the Equity Cure, the Performance Covenant shall be based on the New Management Plan.</font></div><div style="padding-left:36pt;text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.7&#160;&#160;&#160;&#160;Section 13 (Definitions).  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following terms and their definition are added to or amended and restated in Section 13 of the Loan Agreement as follows&#58;</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Amortization Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is January 1, 2025.</font></div><div style="padding-left:72pt;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Maturity Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is November 19, 2026.</font></div><div style="padding-left:72pt;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Second Amendment Effective Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is November 1, 2021.</font></div><div style="padding-left:72pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Prepayment Fee&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is, with respect to any Term Loan subject to prepayment prior to the Maturity Date, whether by mandatory or voluntary prepayment, acceleration or otherwise, as indicated, an additional fee payable to the Lenders in amount equal to&#58;</font></div><div style="padding-left:36pt;text-indent:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;for any prepayment made after the Second Amendment Effective Date through and including the first anniversary of the Second Amendment Effective Date, which, pursuant to Section 2.2(d), may not be a voluntary prepayment, three percent (3.00%) of the principal amount of the Term Loan prepaid&#59;</font></div><div style="padding-left:72pt;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;for any prepayment made after the first anniversary of the Second Amendment Effective Date through and including the second anniversary of the Second Amendment Effective Date, two percent (2.00%) of the principal amount of the Term Loan prepaid&#59;</font></div><div style="padding-left:72pt;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;for any prepayment made after the second anniversary of the Second Amendment Effective Date through and including the third anniversary of the Second Amendment Effective Date, one percent (1.00%) of the principal amount of the Term Loan prepaid&#59; and</font></div><div style="padding-left:72pt;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;for any prepayment made after the third anniversary of the Second Amendment Effective Date, zero percent (0%) of the principal amount of the Term Loan prepaid.</font></div><div style="padding-left:72pt;text-indent:36pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annex Q</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Management Plan) to the Loan Agreement is replaced with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annex Q</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attached hereto.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annex X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Loan Interest Rate and Payment of Principal Schedule) to the Loan Agreement is replaced with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annex X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attached hereto.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Limitation of Agreement.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Agreement is effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Collateral Agent and Lenders may now have or may have in the future under or in connection with any Loan Document.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Agreement shall be construed in connection with and as part of the Loan Documents, and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents are hereby ratified and confirmed and shall remain in full force and effect.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;Representations and Warranties.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Borrower represents and warrants to Collateral Agent and Lenders as follows&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing immediately before and after giving effect to this Agreement&#59;</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrower has the power and authority to execute and deliver this Agreement and to perform its obligations under the Loan Agreement&#59;</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The organizational documents of Borrower delivered to Collateral Agent and Lenders on the Effective Date or subsequent thereto remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect&#59;</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The execution and delivery by Borrower of this Agreement and the performance by Borrower of its obligations under the Loan Agreement have been duly authorized by all necessary action on the part of Borrower&#59;</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The execution and delivery by Borrower of this Agreement and the performance by Borrower of its obligations under the Loan Agreement do not and will not contravene (a) any law or regulation binding on or affecting Borrower, (b) any contractual restriction with a Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower&#59;</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The execution and delivery by Borrower of this Agreement and the performance by Borrower of its obligations under the Loan Agreement do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on either Borrower, except as already has been obtained or made&#59; and</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Agreement has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&#8217; rights.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;Prior Agreement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Documents are hereby ratified and reaffirmed and shall remain in full force and effect. This Agreement is not a novation and the terms and conditions of this Agreement shall be in addition to and supplemental to all terms and conditions set forth in the Loan Documents. In the event of any conflict or inconsistency between this Agreement and the terms of such documents, the terms of this Agreement shall be controlling, but such document shall not otherwise be affected or the rights therein impaired.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;Integration.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;Counterparts.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Agreement may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;Conditions to Effectiveness.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Agreement shall be deemed effective upon the due execution and delivery to Collateral Agent and Lenders, in form and substance reasonably satisfactory to Collateral Agent and each Lender, such documents, and completion of such other matters, as Collateral Agent and each Lender may reasonably deem necessary or appropriate (and requested in writing at least three Business Days prior to the date hereof), including, without limitation&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) this Agreement duly executed by each party hereto&#59; and</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) a duly executed corporate borrowing certificate dated as of the date hereof.</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;Miscellaneous.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Agreement shall constitute a Loan Document under the Loan Agreement&#59; the failure to comply with the covenants contained herein shall constitute an Event of Default under the Loan Agreement&#59; and all obligations included in this Agreement (including, without limitation, all obligations for the payment of principal, interest, fees, and other amounts and expenses) shall constitute obligations under the Loan Agreement and secured by the Collateral.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each provision of this Agreement is severable from every other provision in determining the enforceability of any provision.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;Governing Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  This Agreement and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of New York.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature pages follow&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the parties hereto have caused this Agreement to be executed as of the date first written above.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BORROWER&#58;</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXAGEN INC.</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47;Kamal Adawi</font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Kamal Adawi</font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; CFO</font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the parties hereto have caused this Agreement to be executed as of the date first written above.</font></div><div style="text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COLLATERAL AGENT AND LENDER&#58;</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INNOVATUS LIFE SCIENCES LENDING FUND I, LP</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; Innovatus Life Sciences GP, LP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Its&#58; General Partner</font></div><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Andrew Dym&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Andrew Dym</font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; Authorized Signatory</font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i0b0bf75a2d4a487b83140f1ae87784d5_59"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNEX Q</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(Management Plan)</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i0b0bf75a2d4a487b83140f1ae87784d5_65"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNEX X</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>7
<FILENAME>ex106-letteragreementippur.htm
<DESCRIPTION>EX-10.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id21029b59c9b47ffba36f04421eb9d13_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Exhibit 10.6</font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:63px;margin-bottom:5pt;vertical-align:text-bottom;width:171px"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">September 28, 2021</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mr. Mike Walther</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prometheus Laboratories Inc. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9410 Carroll Park Dr., Suite A</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">San Diego, CA 92121</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dear Mr. Walther, </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Letter Agreement represents the agreement between Prometheus Laboratories Inc. (&#8220;Prometheus&#8221;) and Exagen Inc. (&#8220;Exagen&#8221;) regarding the sale of certain intellectual property of Prometheus relating to methotrexate metabolites and pharmacogenetics as further described in Exhibit A (the &#8220;MTX Portfolio&#8221;) and to terminate the license agreement entered into by the parties on September 13, 2007, as amended (the &#8220;Methotrexate License Agreement&#8221;) and is effective as of the date of last signature below (the &#8220;Effective Date&#8221;).</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prometheus represents and warrants that they are the owner of all right, title, and interest, free and clear of all claims thereto, to sell, market, use, license, sublicense or further develop, the source materials, including texts, notes, diagrams, lists, charts, text files, together with preexisting works solely relating to these materials (collectively the &#8220;Licensed Assets&#8221;), that are listed as MTX Patents in Exhibit A licensed to Exagen under the Methotrexate License Agreement and the patents issues based on those Licensed Assets (collectively the &#8220;MTX Patents&#8221;). Prometheus further represents and warrants that, except for the license granted to Exagen under the Methotrexate License Agreement between Prometheus and Exagen, Prometheus has not previously granted and will not grant any rights in the MTX Patents to any third party.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exagen has the right to rely on such representations and warranties in entering into this Letter Agreement.  Prometheus agrees to indemnify Exagen against any losses, damages or claims arising out of a breach of any of Prometheus&#8217; representations and warranties in this Letter Agreement.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prometheus agrees to sell, transfer, assign, convey and set over to Exagen, and Exagen agrees to purchase from Prometheus, Prometheus&#8217; rights in and to the MTX Portfolio free and clear of all liens, claims and encumbrances in consideration of Fifty Thousand U.S. Dollars ($50,000) and subject to the terms and conditions of this Letter Agreement. In addition, Exagen will pay to Prometheus Thirty-Five Thousand, Three Hundred and Seven U.S. Dollars ($35,307) in disputed royalty payments attributable to freight reductions. Prometheus acknowledges that in offering this additional payment, Exagen in no way admits that any such royalty payments are owed to Prometheus and that in any event, the right to such payments is unsettled. Exagen will remit payment to Prometheus within five (5) business days of the Effective Date of this Agreement.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In connection with the sale and purchase of the MTX Portfolio, Prometheus shall execute and deliver an Assignment, in the form that is attached as Exhibit B, in favor of Exagen.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prometheus shall be solely responsible for the payment of, and shall pay when due, any federal, state, local, foreign or other tax, duty, levy, impost, fee, assessment or other governmental charge, including without limitation income, gross receipts, business, occupation, sales, stamp, value-added, excise (or similar transfer taxes), use, or other tax of any kind whatsoever and any premium, together with any interest, penalties, surcharges, fines and additional attributable to or imposed with respect to the foregoing (collectively &#8220;Taxes&#8221;) that may be payable in connection with the sale or purchase of the MTX Portfolio as contemplated in this Letter Agreement and Prometheus shall indemnify Exagen against any such Taxes.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Letter Agreement supersedes and immediately terminates the Methotrexate License Agreement in its entirety by mutual consent and replaces any and all other agreements that may exist, whether written or verbal, between Prometheus and Exagen relating to the MTX Portfolio. This Letter Agreement, including the attached exhibits, constitutes the entire agreement of the parties with respect to this subject matter. This Letter Agreement shall be governed in accordance with the laws of the State of California.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have carefully reviewed this Letter Agreement and agree to and accept all of its terms and conditions.  We are executing this Letter Agreement as of the Effective Date. Please sign below to indicate your agreement with the foregoing and return the partially executed Letter Agreement together with the executed Assignment to Exagen at your earliest convenience. We look forward to your response.</font></div><div style="text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prometheus Laboratories Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exagen Inc.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Mike Walther               </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Kamal Adawi                   </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> Mike Walther              </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> Kamal Adawi                   </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> President                        </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> CFO                                      </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> 9&#47;29&#47;2021                     </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> 9&#47;28&#47;2021                         </font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="id21029b59c9b47ffba36f04421eb9d13_39"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MTX Portfolio</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Licensed Assets</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Please see Exhibit 1.9 of the Methotrexate License Agreement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MTX Patents</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">US Patent No. 6,921,667 - expiration&#58; May 22, 2023</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">US Patent No. 7,563,590 - expiration&#58; August 28, 2023</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">US Patent No. 7,582,282 - expiration&#58; March 24, 2026</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">US Patent No. 7,695,908 - expiration&#58; October 15, 2027</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="id21029b59c9b47ffba36f04421eb9d13_46"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit B</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PATENT ASSIGNMENT</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This PATENT ASSIGNMENT (&#8220;Assignment&#8221;), effective as of September 28, 2021, is made by and between Prometheus Laboratories Inc., a California corporation with its principal place of business located at 9410 Carroll Park Drive, Suite A, San Diego, California 92121 (hereinafter &#8220;Assignor&#8221;), and Exagen Inc., a Delaware corporation having its principal place of business at 1261 Liberty Way, Vista, California 92081 (hereinafter &#8220;Exagen&#8221;).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;Assignor is the sole owner of the intellectual property listed in the attached Exhibit A (hereinafter &#8220;Methotrexate Portfolio&#8221;)&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;Exagen is desirous of acquiring all of Assignor&#8217;s right, title and interest in and to the Methotrexate Portfolio.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, for good and valuable consideration, receipt of which is hereby acknowledged, Assignor has sold, assigned and transferred, and does hereby sell, assign and transfer to Exagen all right, title and interest in and to&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;the Methotrexate Portfolio, including any and all inventions, invention disclosures and discoveries disclosed or claimed therein&#59; and</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;all United States, foreign and international patents and patent applications, certificates of invention, utility models and any other grants by any governmental entity for the protection of inventions resulting from the Patents, including any and all patents and patent applications disclosing said invention(s) and any patents issuing from such applications, including provisionals, non-provisionals, divisionals, continuations, continuations-in-part, reissues, extensions, and reexaminations of the Patents, along with the rights of priority created by such patents and patent applications under any treaty relating thereto&#59; and</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">iii.&#160;&#160;&#160;&#160;all past, present and future causes of action and enforcement rights, whether currently pending, filed or otherwise, in connection with the Patents, the patents and patent applications resulting from the Patents and any of the inventions or discoveries described or claimed therein, including without limitation, all rights to sue for any past, present or future infringement of the Patents, including the rights to license and to collect and receive any damages, royalties, injunctive relief, and&#47;or any other settlements or remedies for such infringements, the same to be held and enjoyed by Exagen for its own use and enjoyment, and for the use and enjoyment of its successors, assigns and other legal representatives, to the end of the term or terms thereof as fully and entirely as the same would have been held and enjoyed by Assignor, if this assignment and sale had not been made.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature page to follow&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Assignor has caused these presents to be signed by its duly appointed officer having full authority in the circumstances.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Prometheus Laboratories Inc.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> &#47;s&#47; Mike Walther                      </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> Mike Walther                      </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> President                                </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> 9&#47;29&#47;2021                             </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>xgn311-93021.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i246f620a8b4948f0ba06f53de8671714_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I, Fortunato Ron Rocca, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I have reviewed this Quarterly Report on Form 10-Q of Exagen Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:21pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;10, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>xgn312-93021.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i464173d9017e4f8082fdfccde295b2e3_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I, Kamal Adawi, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I have reviewed this Quarterly Report on Form 10-Q of Exagen Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:21pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;10, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>xgn321-93021.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i46c7d9bfbdd044d08332dcd892ad7aba_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:201%">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the &#34;Company&#34;) hereby certifies, to such officer's knowledge, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The accompanying quarterly report on Form 10-Q of the Company for the quarterly period ended September&#160;30, 2021 (the &#34;Report&#34;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; November&#160;10, 2021</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:20pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the &#34;Company&#34;) hereby certifies, to such officer's knowledge, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The accompanying quarterly report on Form 10-Q of the Company for the quarterly period ended September&#160;30, 2021 (the &#34;Report&#34;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; November&#160;10, 2021</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:20pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>exdx-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:c5a0a3fb-3fff-4206-b83d-31088152a01e,g:78c7fea5-b4e3-40b0-a9a0-b197701560e9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exdx="http://www.exagen.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exagen.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.exagen.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://www.exagen.com/role/CondensedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedStatementsofOperations" roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations">
        <link:definition>1003004 - Statement - Unaudited Condensed Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedStatementsofStockholdersEquity" roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Unaudited Condensed Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedStatementsofStockholdersEquityParenthetical" roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical">
        <link:definition>1005006 - Statement - Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedStatementsofCashFlows" roleURI="http://www.exagen.com/role/UnauditedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Unaudited Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.exagen.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.exagen.com/role/OrganizationDetails">
        <link:definition>2402401 - Disclosure - Organization - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies - (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSecuritiesDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformation" roleURI="http://www.exagen.com/role/OtherFinancialInformation">
        <link:definition>2111103 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.exagen.com/role/OtherFinancialInformationTables">
        <link:definition>2312302 - Disclosure - Other Financial Information - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPrepaidexpensesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails">
        <link:definition>2413407 - Disclosure - Other Financial Information - Prepaid expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPropertyandequipmentDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails">
        <link:definition>2414408 - Disclosure - Other Financial Information - Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationNarrativeDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails">
        <link:definition>2415409 - Disclosure - Other Financial Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails">
        <link:definition>2416410 - Disclosure - Other Financial Information - Accrued and other current liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.exagen.com/role/Borrowings">
        <link:definition>2117104 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.exagen.com/role/BorrowingsTables">
        <link:definition>2318303 - Disclosure - Borrowings - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails">
        <link:definition>2419411 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsFutureminimumpaymentsDetails" roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails">
        <link:definition>2420412 - Disclosure - Borrowings - Future minimum payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.exagen.com/role/CommitmentandContingencies">
        <link:definition>2121105 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesNarrativeDetails" roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails">
        <link:definition>2422413 - Disclosure - Commitment and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exagen.com/role/FairValueMeasurements">
        <link:definition>2123106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exagen.com/role/FairValueMeasurementsTables">
        <link:definition>2324304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails">
        <link:definition>2425414 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.exagen.com/role/StockholdersEquity">
        <link:definition>2126107 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.exagen.com/role/StockholdersEquityTables">
        <link:definition>2327305 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2428415 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.exagen.com/role/StockholdersEquityDetails">
        <link:definition>2429416 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlan" roleURI="http://www.exagen.com/role/StockOptionPlan">
        <link:definition>2130108 - Disclosure - Stock Option Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanTables" roleURI="http://www.exagen.com/role/StockOptionPlanTables">
        <link:definition>2331306 - Disclosure - Stock Option Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanNarrativeDetails" roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails">
        <link:definition>2432417 - Disclosure - Stock Option Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockOptionActivityDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails">
        <link:definition>2433418 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanRestrictedStockUnitsDetails" roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails">
        <link:definition>2434419 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanFairValueAssumptionsDetails" roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails">
        <link:definition>2435420 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockBasedCompensationExpenseDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails">
        <link:definition>2436421 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Covid19" roleURI="http://www.exagen.com/role/Covid19">
        <link:definition>2137109 - Disclosure - Covid-19</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Covid19Details" roleURI="http://www.exagen.com/role/Covid19Details">
        <link:definition>2438422 - Disclosure - Covid-19 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.exagen.com/role/SubsequentEvents">
        <link:definition>2139110 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsNarrativeDetails" roleURI="http://www.exagen.com/role/SubsequentEventsNarrativeDetails">
        <link:definition>2440423 - Disclosure - Subsequent Events - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exdx_AHNCollaborationMember" abstract="true" name="AHNCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ReceivableBenchmarkMember" abstract="true" name="ReceivableBenchmarkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_CollaborationAgreementCollaborationExpenses" abstract="false" name="CollaborationAgreementCollaborationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExpirationSep72024Member" abstract="true" name="ExpirationSep72024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentPaidInKindLoansIssued" abstract="false" name="DebtInstrumentPaidInKindLoansIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_OperatingLeaseMonthlyBaseRent" abstract="false" name="OperatingLeaseMonthlyBaseRent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentPrepaymentPremiumPercentage" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exdx_OfficeMember" abstract="true" name="OfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_RentalPropertyByTypeAxis" abstract="true" name="RentalPropertyByTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exdx_BlueShieldMember" abstract="true" name="BlueShieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_JointVentureTerminationConsiderationReceivable" abstract="false" name="JointVentureTerminationConsiderationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_UnitedHealthcareMember" abstract="true" name="UnitedHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_LongTermDebtUndiscountedInterestAmount" abstract="false" name="LongTermDebtUndiscountedInterestAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_LicenseAgreementInitialLicenseFee" abstract="false" name="LicenseAgreementInitialLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_JanssenSIMPONIMember" abstract="true" name="JanssenSIMPONIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_OperatingLeasesRenewalTerm" abstract="false" name="OperatingLeasesRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_PaycheckProtectionProgramCARESActMember" abstract="true" name="PaycheckProtectionProgramCARESActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_JointVentureQuarterlyPromotionFee" abstract="false" name="JointVentureQuarterlyPromotionFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_HealthcareInsurersMember" abstract="true" name="HealthcareInsurersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_RentalPropertyByTypeDomain" abstract="true" name="RentalPropertyByTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentStatedInterestRatePaidInKind" abstract="false" name="DebtInstrumentStatedInterestRatePaidInKind" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" abstract="false" name="CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_JointVentureQuarterlyPromotionFeePerPrescription" abstract="false" name="JointVentureQuarterlyPromotionFeePerPrescription" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExchangingStockholdersMember" abstract="true" name="ExchangingStockholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_CollaborationAgreementAnnualCollaborationFee" abstract="false" name="CollaborationAgreementAnnualCollaborationFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" abstract="false" name="DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_Government1Member" abstract="true" name="Government1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ExpirationApr12026Member" abstract="true" name="ExpirationApr12026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_OfficeSpaceMember" abstract="true" name="OfficeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exdx_IncentiveAwardPlan2019Member" abstract="true" name="IncentiveAwardPlan2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_Term2017Member" abstract="true" name="Term2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ProceedsFromGovernmentAssistance" abstract="false" name="ProceedsFromGovernmentAssistance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_InnovatusLifeSciencesLendingFundMember" abstract="true" name="InnovatusLifeSciencesLendingFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_HeadquartersMember" abstract="true" name="HeadquartersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_RoyaltyObligationPercentageOfSales" abstract="false" name="RoyaltyObligationPercentageOfSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_LongTermDebtIncludingUndiscountedInterest" abstract="false" name="LongTermDebtIncludingUndiscountedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_OfficeAndLaboratoryMember" abstract="true" name="OfficeAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" abstract="false" name="PurchaseObligationAnnualIncreaseInCommitmentPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_MedicareAdvantageMember" abstract="true" name="MedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_AssetsUnderCapitalLeaseMember" abstract="true" name="AssetsUnderCapitalLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_EquipmentPurchasedUnderCapitalLease" abstract="false" name="EquipmentPurchasedUnderCapitalLease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_PrometheusLaboratoriesIncMember" abstract="true" name="PrometheusLaboratoriesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_PrepaidMaintenanceAndInsuranceContracts" abstract="false" name="PrepaidMaintenanceAndInsuranceContracts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_CapitalRoyaltyPartnersIILPMember" abstract="true" name="CapitalRoyaltyPartnersIILPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" abstract="false" name="CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_OperatingLeaseMonthlyBaseRentFirstIncrease" abstract="false" name="OperatingLeaseMonthlyBaseRentFirstIncrease" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExpirationDec72025Member" abstract="true" name="ExpirationDec72025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" abstract="false" name="ClassOfWarrantOrRightNumberOfWarrantsExercised" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercisedNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercisedNet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_OperatingLeaseTermOfContract" abstract="false" name="OperatingLeaseTermOfContract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" abstract="false" name="DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" abstract="false" name="OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_AdvancePayment" abstract="false" name="AdvancePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" abstract="false" name="ExchangeAgreementNumberOfSharesExchangedForWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_AccruedPurchaseGoodsAndServicesCurrent" abstract="false" name="AccruedPurchaseGoodsAndServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExpirationMar312026Member" abstract="true" name="ExpirationMar312026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_StockIssuanceCosts" abstract="false" name="StockIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AlleghenyHealthNetworkResearchInstituteMember" abstract="true" name="AlleghenyHealthNetworkResearchInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_JanssenPromotionAgreementMember" abstract="true" name="JanssenPromotionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DeferredOfferingCostsReclassifiedToEquity" abstract="false" name="DeferredOfferingCostsReclassifiedToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" abstract="false" name="CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exdx_ClientMember" abstract="true" name="ClientMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" abstract="false" name="JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_TwoMajorSuppliersMember" abstract="true" name="TwoMajorSuppliersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_AVISECTDTestMember" abstract="true" name="AVISECTDTestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_AccruedLiabilitiesClinicalStudyCurrent" abstract="false" name="AccruedLiabilitiesClinicalStudyCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExpirationJan192026Member" abstract="true" name="ExpirationJan192026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_NoExpirationMember" abstract="true" name="NoExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>exdx-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:c5a0a3fb-3fff-4206-b83d-31088152a01e,g:78c7fea5-b4e3-40b0-a9a0-b197701560e9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="exdx-20210930.xsd#CondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_99780df2-a0b2-4954-8ace-d973088bd226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5b7e1bf0-586e-4e8b-b3f9-4876d0cfac17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_99780df2-a0b2-4954-8ace-d973088bd226" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5b7e1bf0-586e-4e8b-b3f9-4876d0cfac17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c49f5035-791b-40bd-bd5f-bd7bd12e11b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_99780df2-a0b2-4954-8ace-d973088bd226" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c49f5035-791b-40bd-bd5f-bd7bd12e11b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_3c13b308-8ca2-49ab-bced-cd335b192d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_99780df2-a0b2-4954-8ace-d973088bd226" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_3c13b308-8ca2-49ab-bced-cd335b192d01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cecf6f86-0ea4-495c-b87c-e3930f2a48ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6351a56d-67c6-476d-8a32-42b294a65587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cecf6f86-0ea4-495c-b87c-e3930f2a48ef" xlink:to="loc_us-gaap_StockholdersEquity_6351a56d-67c6-476d-8a32-42b294a65587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_00d3ca18-da83-495f-8fd8-c80938e973d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cecf6f86-0ea4-495c-b87c-e3930f2a48ef" xlink:to="loc_us-gaap_Liabilities_00d3ca18-da83-495f-8fd8-c80938e973d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c84910bd-287b-492c-994a-7b8bf1d22c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cecf6f86-0ea4-495c-b87c-e3930f2a48ef" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c84910bd-287b-492c-994a-7b8bf1d22c29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c1fceca1-b304-4764-b4b4-c1277313ac0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_34125573-546e-40b0-a88d-1c085bf1c45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c1fceca1-b304-4764-b4b4-c1277313ac0a" xlink:to="loc_us-gaap_PreferredStockValue_34125573-546e-40b0-a88d-1c085bf1c45c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_23b603a7-6498-4e0a-975d-cbc1e798d97a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c1fceca1-b304-4764-b4b4-c1277313ac0a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_23b603a7-6498-4e0a-975d-cbc1e798d97a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a57a1120-9a5a-4fa8-a532-3f25d046b5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c1fceca1-b304-4764-b4b4-c1277313ac0a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a57a1120-9a5a-4fa8-a532-3f25d046b5c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_04cc53b5-738e-4b8f-8ccb-6b45a8952d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c1fceca1-b304-4764-b4b4-c1277313ac0a" xlink:to="loc_us-gaap_CommonStockValue_04cc53b5-738e-4b8f-8ccb-6b45a8952d81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_bec578ad-3247-4642-a03f-ee9aea02648b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f5adda87-b057-4e9c-8f29-b22959a4be15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bec578ad-3247-4642-a03f-ee9aea02648b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f5adda87-b057-4e9c-8f29-b22959a4be15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a5de40fb-5404-4614-a75d-7fadedabef62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bec578ad-3247-4642-a03f-ee9aea02648b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a5de40fb-5404-4614-a75d-7fadedabef62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_81762c39-5abf-4f85-89b8-ebee14a09a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bec578ad-3247-4642-a03f-ee9aea02648b" xlink:to="loc_us-gaap_AssetsCurrent_81762c39-5abf-4f85-89b8-ebee14a09a29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3d88cdcc-6ed4-479b-91f6-f18960d781be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bec578ad-3247-4642-a03f-ee9aea02648b" xlink:to="loc_us-gaap_Goodwill_3d88cdcc-6ed4-479b-91f6-f18960d781be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_70956c80-8963-45fe-8026-0089b357ae38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_605b655b-35ad-4ca9-9150-ede79325ccb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_70956c80-8963-45fe-8026-0089b357ae38" xlink:to="loc_us-gaap_AccountsPayableCurrent_605b655b-35ad-4ca9-9150-ede79325ccb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_46b2439d-cf9f-47ae-856d-f8b83b412772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_70956c80-8963-45fe-8026-0089b357ae38" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_46b2439d-cf9f-47ae-856d-f8b83b412772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2cd57b2c-33e8-4a3d-a62d-75c2bdf00c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f2cf4065-7afc-4077-821b-3e15f01556a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2cd57b2c-33e8-4a3d-a62d-75c2bdf00c56" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f2cf4065-7afc-4077-821b-3e15f01556a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_971ac43a-ce75-410e-9bf0-5a7fc6e48fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2cd57b2c-33e8-4a3d-a62d-75c2bdf00c56" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_971ac43a-ce75-410e-9bf0-5a7fc6e48fd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e81a48a9-46ea-48b4-af13-30a8ebc36086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2cd57b2c-33e8-4a3d-a62d-75c2bdf00c56" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e81a48a9-46ea-48b4-af13-30a8ebc36086" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_667fe4e1-a303-4065-99cb-19d396994163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2cd57b2c-33e8-4a3d-a62d-75c2bdf00c56" xlink:to="loc_us-gaap_LiabilitiesCurrent_667fe4e1-a303-4065-99cb-19d396994163" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="simple" xlink:href="exdx-20210930.xsd#UnauditedCondensedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_35907189-2969-43df-9dbc-0350704993a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_680e178a-2ab8-441b-b6bc-7048a33b2bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_35907189-2969-43df-9dbc-0350704993a6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_680e178a-2ab8-441b-b6bc-7048a33b2bdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_be6dd5c3-a212-43bf-9bed-5f4251527d36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_35907189-2969-43df-9dbc-0350704993a6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_be6dd5c3-a212-43bf-9bed-5f4251527d36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8b2b9372-533b-461e-9372-8f772060bdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_35907189-2969-43df-9dbc-0350704993a6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8b2b9372-533b-461e-9372-8f772060bdfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_00fb28a7-4d15-4e02-b122-67b058f48f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_9b25ecb1-7ceb-454f-8ab8-0b7a6c8dbfff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_00fb28a7-4d15-4e02-b122-67b058f48f12" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_9b25ecb1-7ceb-454f-8ab8-0b7a6c8dbfff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4d85ea19-275a-4d13-bd50-a4b63e072a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_00fb28a7-4d15-4e02-b122-67b058f48f12" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4d85ea19-275a-4d13-bd50-a4b63e072a31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_bb0fec61-e444-459d-adcb-f7375d99cf06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_01710fa4-bd3d-4f1a-8eab-39682b01cd60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_bb0fec61-e444-459d-adcb-f7375d99cf06" xlink:to="loc_us-gaap_InterestExpense_01710fa4-bd3d-4f1a-8eab-39682b01cd60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ec6fd9e8-7c3a-4df6-90d6-6606e7f6824e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_bb0fec61-e444-459d-adcb-f7375d99cf06" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ec6fd9e8-7c3a-4df6-90d6-6606e7f6824e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_92d0d5ec-c4ea-450a-a07f-1048a9fadefc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_bb0fec61-e444-459d-adcb-f7375d99cf06" xlink:to="loc_us-gaap_OperatingIncomeLoss_92d0d5ec-c4ea-450a-a07f-1048a9fadefc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_23a0ad63-5b01-44c8-a630-5cd0e4931ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a11fc915-7173-4eda-a3a8-fd347975cf54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_23a0ad63-5b01-44c8-a630-5cd0e4931ea6" xlink:to="loc_us-gaap_CostsAndExpenses_a11fc915-7173-4eda-a3a8-fd347975cf54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f5d2648d-f99d-4a61-b9b1-ab980e3aea89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_23a0ad63-5b01-44c8-a630-5cd0e4931ea6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f5d2648d-f99d-4a61-b9b1-ab980e3aea89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_195498ed-92d7-406d-a183-c3c91c35ff5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20210930.xsd#UnauditedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d07b345e-6af9-48f4-9b8c-0db2c1b4fa53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_ba7e906d-2161-4291-bd38-c4183610d24b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d07b345e-6af9-48f4-9b8c-0db2c1b4fa53" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_ba7e906d-2161-4291-bd38-c4183610d24b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_76244412-b304-4232-8eb6-a966893e9924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d07b345e-6af9-48f4-9b8c-0db2c1b4fa53" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_76244412-b304-4232-8eb6-a966893e9924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e48ae2cf-27be-42c2-b2f1-c594b661d9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3c026028-a675-4490-84ee-f5d3026c67bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e48ae2cf-27be-42c2-b2f1-c594b661d9ff" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3c026028-a675-4490-84ee-f5d3026c67bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_ec885db8-bd37-4aa3-bfb2-2297c93c4400" xlink:href="exdx-20210930.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e48ae2cf-27be-42c2-b2f1-c594b661d9ff" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_ec885db8-bd37-4aa3-bfb2-2297c93c4400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_18cc1a11-8cac-4bdf-bb14-7aee9c504a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e48ae2cf-27be-42c2-b2f1-c594b661d9ff" xlink:to="loc_us-gaap_NetIncomeLoss_18cc1a11-8cac-4bdf-bb14-7aee9c504a39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_d24e60b2-2b3c-470b-87a1-a477638d73b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e48ae2cf-27be-42c2-b2f1-c594b661d9ff" xlink:to="loc_us-gaap_PaidInKindInterest_d24e60b2-2b3c-470b-87a1-a477638d73b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a0a2c6d2-eaa8-420f-9152-630a78351113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e48ae2cf-27be-42c2-b2f1-c594b661d9ff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a0a2c6d2-eaa8-420f-9152-630a78351113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fdd3e4f5-83f7-4ee0-8753-0465adf8b812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e48ae2cf-27be-42c2-b2f1-c594b661d9ff" xlink:to="loc_us-gaap_ShareBasedCompensation_fdd3e4f5-83f7-4ee0-8753-0465adf8b812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_cf3dfed3-86ec-467f-835d-0ae9b391dc12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e48ae2cf-27be-42c2-b2f1-c594b661d9ff" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_cf3dfed3-86ec-467f-835d-0ae9b391dc12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d4027158-df55-4d61-9074-fccf536dfedc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e48ae2cf-27be-42c2-b2f1-c594b661d9ff" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d4027158-df55-4d61-9074-fccf536dfedc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_8633dbb2-1e59-4fac-b8b3-ea586b3bc060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e48ae2cf-27be-42c2-b2f1-c594b661d9ff" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_8633dbb2-1e59-4fac-b8b3-ea586b3bc060" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_f1d14377-2676-4f5d-8fbf-c94dbc9f3150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e48ae2cf-27be-42c2-b2f1-c594b661d9ff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_f1d14377-2676-4f5d-8fbf-c94dbc9f3150" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7088af3f-69af-4ad9-8b18-4bbd7eeb04f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e48ae2cf-27be-42c2-b2f1-c594b661d9ff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7088af3f-69af-4ad9-8b18-4bbd7eeb04f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d56cd3a-c3b8-48ff-9e48-7e6bf097358e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3f3dda26-3877-41ab-98ec-e92756148074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d56cd3a-c3b8-48ff-9e48-7e6bf097358e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3f3dda26-3877-41ab-98ec-e92756148074" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfBankDebt_8d66ebb9-efb2-471c-b794-d6796fbc9853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d56cd3a-c3b8-48ff-9e48-7e6bf097358e" xlink:to="loc_us-gaap_RepaymentsOfBankDebt_8d66ebb9-efb2-471c-b794-d6796fbc9853" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_0167f8bd-7c50-41e6-8621-02f2d27e6268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d56cd3a-c3b8-48ff-9e48-7e6bf097358e" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_0167f8bd-7c50-41e6-8621-02f2d27e6268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_c06bcba7-5332-4774-869d-6998568041bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d56cd3a-c3b8-48ff-9e48-7e6bf097358e" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_c06bcba7-5332-4774-869d-6998568041bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9938a9d0-b315-4be0-b323-416d2e596e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d56cd3a-c3b8-48ff-9e48-7e6bf097358e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9938a9d0-b315-4be0-b323-416d2e596e4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_d80efd3f-b546-4c88-b9a2-2d742e9412ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d56cd3a-c3b8-48ff-9e48-7e6bf097358e" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_d80efd3f-b546-4c88-b9a2-2d742e9412ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_d40c3de1-1780-4e38-80b7-495b55645303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d56cd3a-c3b8-48ff-9e48-7e6bf097358e" xlink:to="loc_us-gaap_ProceedsFromStockPlans_d40c3de1-1780-4e38-80b7-495b55645303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromBankDebt_4209280f-0879-450a-bd16-16014ff02de1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromBankDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d56cd3a-c3b8-48ff-9e48-7e6bf097358e" xlink:to="loc_us-gaap_ProceedsFromBankDebt_4209280f-0879-450a-bd16-16014ff02de1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_66e43113-20b5-43ce-ad9b-8ccd54cde472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2f619b9-c9dc-49a1-9132-4d615f9b1098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_66e43113-20b5-43ce-ad9b-8ccd54cde472" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2f619b9-c9dc-49a1-9132-4d615f9b1098" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8a7fa62-ced7-484d-812d-206c664cfa8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_66e43113-20b5-43ce-ad9b-8ccd54cde472" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8a7fa62-ced7-484d-812d-206c664cfa8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_72b0258c-e3d2-417b-b655-91c59bd270cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_66e43113-20b5-43ce-ad9b-8ccd54cde472" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_72b0258c-e3d2-417b-b655-91c59bd270cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_83675c58-e395-4b16-aaf6-98c78ea24982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_c49ea256-a070-4696-a986-989a8ce455a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_83675c58-e395-4b16-aaf6-98c78ea24982" xlink:to="loc_us-gaap_RestrictedCash_c49ea256-a070-4696-a986-989a8ce455a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_10458288-2663-4188-b063-b5005d7be1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_83675c58-e395-4b16-aaf6-98c78ea24982" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_10458288-2663-4188-b063-b5005d7be1d0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#OtherFinancialInformationPrepaidexpensesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33a483ea-de2d-44ae-94a3-e190bda3fe81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_1db5b154-3454-464e-8f8a-c9091b2cd7bd" xlink:href="exdx-20210930.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33a483ea-de2d-44ae-94a3-e190bda3fe81" xlink:to="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_1db5b154-3454-464e-8f8a-c9091b2cd7bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties_f2c21c8f-4ed2-4597-a104-2e1150673767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidRoyalties"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33a483ea-de2d-44ae-94a3-e190bda3fe81" xlink:to="loc_us-gaap_PrepaidRoyalties_f2c21c8f-4ed2-4597-a104-2e1150673767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_66a35cc5-5453-4ae9-8680-be10d5471345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33a483ea-de2d-44ae-94a3-e190bda3fe81" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_66a35cc5-5453-4ae9-8680-be10d5471345" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_3716267a-3bfb-486c-9ec6-75c088273cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33a483ea-de2d-44ae-94a3-e190bda3fe81" xlink:to="loc_us-gaap_OtherAssetsCurrent_3716267a-3bfb-486c-9ec6-75c088273cba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#OtherFinancialInformationPropertyandequipmentDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e6f77137-2164-4675-a6f7-5d8066e686a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a3bb2d4a-f147-4f4a-92a7-33c264a6fe25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e6f77137-2164-4675-a6f7-5d8066e686a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a3bb2d4a-f147-4f4a-92a7-33c264a6fe25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d8f91246-64d1-4cfd-bbaf-49cd26d1875e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e6f77137-2164-4675-a6f7-5d8066e686a8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d8f91246-64d1-4cfd-bbaf-49cd26d1875e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2380ff5e-1be1-4c80-8d70-37e525e453b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_bf97300d-dd89-4d80-bc3b-3e50bd7eb4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2380ff5e-1be1-4c80-8d70-37e525e453b7" xlink:to="loc_us-gaap_AccruedSalariesCurrent_bf97300d-dd89-4d80-bc3b-3e50bd7eb4ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_e7cb9bd3-813f-40a6-b707-1545c09b0792" xlink:href="exdx-20210930.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2380ff5e-1be1-4c80-8d70-37e525e453b7" xlink:to="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_e7cb9bd3-813f-40a6-b707-1545c09b0792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_f754ea14-cde6-45b2-9898-3cc11871cd80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2380ff5e-1be1-4c80-8d70-37e525e453b7" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_f754ea14-cde6-45b2-9898-3cc11871cd80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_69bc4676-ca30-443f-b7b3-08867dd2347b" xlink:href="exdx-20210930.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2380ff5e-1be1-4c80-8d70-37e525e453b7" xlink:to="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_69bc4676-ca30-443f-b7b3-08867dd2347b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_155f450d-5f3e-42a8-a08e-43fa7500ba45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2380ff5e-1be1-4c80-8d70-37e525e453b7" xlink:to="loc_us-gaap_InterestPayableCurrent_155f450d-5f3e-42a8-a08e-43fa7500ba45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_e29ae941-de71-4e1f-92e6-5838779e21d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2380ff5e-1be1-4c80-8d70-37e525e453b7" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_e29ae941-de71-4e1f-92e6-5838779e21d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_afd162b3-d515-4076-a8d4-7531b50fa882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2380ff5e-1be1-4c80-8d70-37e525e453b7" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_afd162b3-d515-4076-a8d4-7531b50fa882" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#BorrowingsFutureminimumpaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_b794c745-8a46-4a0d-9b34-4778dcba4707" xlink:href="exdx-20210930.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_9d7c779c-d65e-4bea-9090-c411f5acab03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_b794c745-8a46-4a0d-9b34-4778dcba4707" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_9d7c779c-d65e-4bea-9090-c411f5acab03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b356640e-efc8-49fb-aa7a-4cba40eeffc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_b794c745-8a46-4a0d-9b34-4778dcba4707" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b356640e-efc8-49fb-aa7a-4cba40eeffc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_01289438-01a1-457a-8fa8-d033f6d3415e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_b794c745-8a46-4a0d-9b34-4778dcba4707" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_01289438-01a1-457a-8fa8-d033f6d3415e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9c565ee9-77ae-408d-bd2e-87a12f22268f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_b794c745-8a46-4a0d-9b34-4778dcba4707" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9c565ee9-77ae-408d-bd2e-87a12f22268f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b8d72601-f893-434a-ae16-b6b07e633bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2c2ff8f1-fa09-416f-a994-017f60fd40fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b8d72601-f893-434a-ae16-b6b07e633bb3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2c2ff8f1-fa09-416f-a994-017f60fd40fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_f99f5962-6b15-43d2-bfaa-b1d02b092bf4" xlink:href="exdx-20210930.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b8d72601-f893-434a-ae16-b6b07e633bb3" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_f99f5962-6b15-43d2-bfaa-b1d02b092bf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_14c5cc47-65a3-429b-81e1-c8e8ca4605bd" xlink:href="exdx-20210930.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b8d72601-f893-434a-ae16-b6b07e633bb3" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_14c5cc47-65a3-429b-81e1-c8e8ca4605bd" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>exdx-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:c5a0a3fb-3fff-4206-b83d-31088152a01e,g:78c7fea5-b4e3-40b0-a9a0-b197701560e9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exdx-20210930.xsd#UnauditedCondensedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="extended" id="i554f39a3e8f84410a0cada6e408fbf37_UnauditedCondensedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bafd2280-2a7f-4eb3-b590-bdc0a898b0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bafd2280-2a7f-4eb3-b590-bdc0a898b0fa" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_39d3be9a-d0ae-47fe-a451-234c2c14d51c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_39d3be9a-d0ae-47fe-a451-234c2c14d51c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_38af790a-bd90-47d2-bed8-597e3ed86a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockholdersEquity_38af790a-bd90-47d2-bed8-597e3ed86a67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_257c1a43-020f-4fa0-8975-2e97069a63e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_257c1a43-020f-4fa0-8975-2e97069a63e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_389b84ad-0226-4134-9a19-f2f55d0fd301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_389b84ad-0226-4134-9a19-f2f55d0fd301" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_cf6c631c-8b69-47a5-9b28-911e5af79da0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_cf6c631c-8b69-47a5-9b28-911e5af79da0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_6a55f856-507b-4d7b-a0cd-9b51887fcb44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_6a55f856-507b-4d7b-a0cd-9b51887fcb44" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c906a8c5-2238-4411-9c4c-deca0590d9da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c906a8c5-2238-4411-9c4c-deca0590d9da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_67ceda77-90fe-4584-84eb-aa26592d65b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_67ceda77-90fe-4584-84eb-aa26592d65b6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9579bef4-2d1f-4771-beb7-f9c48674c2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9579bef4-2d1f-4771-beb7-f9c48674c2c3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1060ab03-d500-481f-9b54-8115c13c360a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1060ab03-d500-481f-9b54-8115c13c360a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_f87aa881-fd75-4bec-8a17-d0a166aefa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_f87aa881-fd75-4bec-8a17-d0a166aefa8d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9d127b99-4555-45ca-a0a0-4110340534b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9d127b99-4555-45ca-a0a0-4110340534b8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_61deed17-7998-4292-bb97-16f4dca719b3" xlink:href="exdx-20210930.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_61deed17-7998-4292-bb97-16f4dca719b3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_86e6cc81-a0b3-46de-9e02-5bcb186ab5c2" xlink:href="exdx-20210930.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_86e6cc81-a0b3-46de-9e02-5bcb186ab5c2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fb06233a-3a9b-47b2-9c7f-de9a77671574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_NetIncomeLoss_fb06233a-3a9b-47b2-9c7f-de9a77671574" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_982fdaa1-0e5c-43cf-b140-30ba7d9c95b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f95a8360-5c0a-441b-ae13-a59a1e6a3632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f9dd8afe-5236-4c76-9b13-dd031a4ccb52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bafd2280-2a7f-4eb3-b590-bdc0a898b0fa" xlink:to="loc_us-gaap_StatementTable_f9dd8afe-5236-4c76-9b13-dd031a4ccb52" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6e830ec5-d1f1-49e5-ac03-b517b2d1c3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f9dd8afe-5236-4c76-9b13-dd031a4ccb52" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6e830ec5-d1f1-49e5-ac03-b517b2d1c3ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6e830ec5-d1f1-49e5-ac03-b517b2d1c3ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6e830ec5-d1f1-49e5-ac03-b517b2d1c3ec" xlink:to="loc_us-gaap_EquityComponentDomain_6e830ec5-d1f1-49e5-ac03-b517b2d1c3ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_57c8cbb5-9ea4-459f-9b45-38f4e83d45b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6e830ec5-d1f1-49e5-ac03-b517b2d1c3ec" xlink:to="loc_us-gaap_EquityComponentDomain_57c8cbb5-9ea4-459f-9b45-38f4e83d45b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6b95ea29-ac03-41d7-8f1d-2db603ae63cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57c8cbb5-9ea4-459f-9b45-38f4e83d45b7" xlink:to="loc_us-gaap_CommonStockMember_6b95ea29-ac03-41d7-8f1d-2db603ae63cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_54bed112-5bc4-4e5e-ae7c-e1bfc95110d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57c8cbb5-9ea4-459f-9b45-38f4e83d45b7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_54bed112-5bc4-4e5e-ae7c-e1bfc95110d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_44ab31d0-09b3-435d-8aae-9023dbb271dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57c8cbb5-9ea4-459f-9b45-38f4e83d45b7" xlink:to="loc_us-gaap_RetainedEarningsMember_44ab31d0-09b3-435d-8aae-9023dbb271dd" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended" id="ief6530dadc1c45df803e47df49d1e78a_SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_90836f4d-d1a0-4f64-bf7e-1727e8c36a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_42c08e0a-a8d3-484d-b7e1-c19e3bf316f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_90836f4d-d1a0-4f64-bf7e-1727e8c36a0d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_42c08e0a-a8d3-484d-b7e1-c19e3bf316f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7734d9c0-736c-459e-b8c9-097346eba6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_90836f4d-d1a0-4f64-bf7e-1727e8c36a0d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7734d9c0-736c-459e-b8c9-097346eba6ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_82cab900-786f-466a-b1bb-e19c300ead2d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7734d9c0-736c-459e-b8c9-097346eba6ac" xlink:to="loc_srt_MajorCustomersAxis_82cab900-786f-466a-b1bb-e19c300ead2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_82cab900-786f-466a-b1bb-e19c300ead2d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_82cab900-786f-466a-b1bb-e19c300ead2d" xlink:to="loc_srt_NameOfMajorCustomerDomain_82cab900-786f-466a-b1bb-e19c300ead2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cccfb6fe-1b38-494f-bd78-aba3cdcd049e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_82cab900-786f-466a-b1bb-e19c300ead2d" xlink:to="loc_srt_NameOfMajorCustomerDomain_cccfb6fe-1b38-494f-bd78-aba3cdcd049e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_d13c8e6b-829b-43b2-9ed5-c5827ffa5626" xlink:href="exdx-20210930.xsd#exdx_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cccfb6fe-1b38-494f-bd78-aba3cdcd049e" xlink:to="loc_exdx_MedicareMember_d13c8e6b-829b-43b2-9ed5-c5827ffa5626" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_4816073b-f73b-4f7b-b474-72b544778faa" xlink:href="exdx-20210930.xsd#exdx_MedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cccfb6fe-1b38-494f-bd78-aba3cdcd049e" xlink:to="loc_exdx_MedicareAdvantageMember_4816073b-f73b-4f7b-b474-72b544778faa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember_4e5c1f02-8a43-41ac-ae4e-e32f0ee391c5" xlink:href="exdx-20210930.xsd#exdx_BlueShieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cccfb6fe-1b38-494f-bd78-aba3cdcd049e" xlink:to="loc_exdx_BlueShieldMember_4e5c1f02-8a43-41ac-ae4e-e32f0ee391c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember_e747bdbf-ec30-43af-a4d4-83d3eea4f812" xlink:href="exdx-20210930.xsd#exdx_UnitedHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cccfb6fe-1b38-494f-bd78-aba3cdcd049e" xlink:to="loc_exdx_UnitedHealthcareMember_e747bdbf-ec30-43af-a4d4-83d3eea4f812" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_891439f5-a942-4b7f-8e3e-bb44a1017db5" xlink:href="exdx-20210930.xsd#exdx_JanssenSIMPONIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cccfb6fe-1b38-494f-bd78-aba3cdcd049e" xlink:to="loc_exdx_JanssenSIMPONIMember_891439f5-a942-4b7f-8e3e-bb44a1017db5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6827423f-d61e-405a-b8de-7d34b2c85ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7734d9c0-736c-459e-b8c9-097346eba6ac" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6827423f-d61e-405a-b8de-7d34b2c85ed6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6827423f-d61e-405a-b8de-7d34b2c85ed6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6827423f-d61e-405a-b8de-7d34b2c85ed6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6827423f-d61e-405a-b8de-7d34b2c85ed6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4072e005-91bb-4c3b-be4e-efd3c1f50c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6827423f-d61e-405a-b8de-7d34b2c85ed6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4072e005-91bb-4c3b-be4e-efd3c1f50c11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_b390e7ee-d78f-468d-b06f-3da3761176e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4072e005-91bb-4c3b-be4e-efd3c1f50c11" xlink:to="loc_us-gaap_SalesRevenueNetMember_b390e7ee-d78f-468d-b06f-3da3761176e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember_d7f689d4-260d-4955-a158-463e189d7268" xlink:href="exdx-20210930.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4072e005-91bb-4c3b-be4e-efd3c1f50c11" xlink:to="loc_exdx_ReceivableBenchmarkMember_d7f689d4-260d-4955-a158-463e189d7268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b405a57e-826d-4323-ac88-c5b69495fae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7734d9c0-736c-459e-b8c9-097346eba6ac" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b405a57e-826d-4323-ac88-c5b69495fae8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b405a57e-826d-4323-ac88-c5b69495fae8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b405a57e-826d-4323-ac88-c5b69495fae8" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b405a57e-826d-4323-ac88-c5b69495fae8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_40149e33-f655-4d89-ac1a-48192a5f7153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b405a57e-826d-4323-ac88-c5b69495fae8" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_40149e33-f655-4d89-ac1a-48192a5f7153" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_00835638-c7b8-42d0-bbe8-e1672493a157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_40149e33-f655-4d89-ac1a-48192a5f7153" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_00835638-c7b8-42d0-bbe8-e1672493a157" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="ia0a73f54c831411085a8d9774e3714f2_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ae19ec31-dc9b-4a7b-83f0-0e4dec2d76c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ae19ec31-dc9b-4a7b-83f0-0e4dec2d76c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_b112478b-9c28-4034-88a9-a5ea7bf6d2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_RestrictedCash_b112478b-9c28-4034-88a9-a5ea7bf6d2e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription_bd289c6b-6899-4345-b87b-83822c87c7fa" xlink:href="exdx-20210930.xsd#exdx_JointVentureQuarterlyPromotionFeePerPrescription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription_bd289c6b-6899-4345-b87b-83822c87c7fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFee_77637d54-8dd9-4d56-84eb-f2cb40a9982a" xlink:href="exdx-20210930.xsd#exdx_JointVentureQuarterlyPromotionFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFee_77637d54-8dd9-4d56-84eb-f2cb40a9982a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_cf5419dc-ba97-43e8-959d-03565973c6de" xlink:href="exdx-20210930.xsd#exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_cf5419dc-ba97-43e8-959d-03565973c6de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureTerminationConsiderationReceivable_0f7f2d65-ee48-4124-980e-c04b0dc2ffd8" xlink:href="exdx-20210930.xsd#exdx_JointVentureTerminationConsiderationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_exdx_JointVentureTerminationConsiderationReceivable_0f7f2d65-ee48-4124-980e-c04b0dc2ffd8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_16cdbe67-4072-4b9e-b354-a6d03edad9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_16cdbe67-4072-4b9e-b354-a6d03edad9bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_821105cc-8d7a-431c-8cd1-b6b01af13d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_AdvertisingExpense_821105cc-8d7a-431c-8cd1-b6b01af13d4b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_2994a203-235f-43cc-b1f3-6e9395982a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_CostOfRevenue_2994a203-235f-43cc-b1f3-6e9395982a18" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_673b369b-0f5a-44f5-933d-7a18b916665d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_673b369b-0f5a-44f5-933d-7a18b916665d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_82d2bece-1cf4-42ef-ae7a-c25fc4b68a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_82d2bece-1cf4-42ef-ae7a-c25fc4b68a0a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_98399e2e-a3c3-44c5-a319-8d70c367f939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_NumberOfOperatingSegments_98399e2e-a3c3-44c5-a319-8d70c367f939" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments_9b70b05b-53b8-4595-bb1f-55daea8399bf" xlink:href="exdx-20210930.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments_9b70b05b-53b8-4595-bb1f-55daea8399bf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cf32e51f-f244-4c39-8b1e-6619449b150a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cf32e51f-f244-4c39-8b1e-6619449b150a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cf32e51f-f244-4c39-8b1e-6619449b150a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cf32e51f-f244-4c39-8b1e-6619449b150a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cf32e51f-f244-4c39-8b1e-6619449b150a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7e083b20-ecca-474d-9fb7-45c5583a0f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cf32e51f-f244-4c39-8b1e-6619449b150a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7e083b20-ecca-474d-9fb7-45c5583a0f8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_f4b5850b-7d44-4bcb-8e55-7beddfb74bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7e083b20-ecca-474d-9fb7-45c5583a0f8a" xlink:to="loc_us-gaap_SalesRevenueNetMember_f4b5850b-7d44-4bcb-8e55-7beddfb74bca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f2e771f7-bb2d-4be7-9b29-87d1da190ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f2e771f7-bb2d-4be7-9b29-87d1da190ae7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f2e771f7-bb2d-4be7-9b29-87d1da190ae7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f2e771f7-bb2d-4be7-9b29-87d1da190ae7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f2e771f7-bb2d-4be7-9b29-87d1da190ae7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_be0043bb-6a12-48cb-85b5-6f0399beb121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f2e771f7-bb2d-4be7-9b29-87d1da190ae7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_be0043bb-6a12-48cb-85b5-6f0399beb121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_edca614d-ab35-4297-b2bb-19014ad4d3de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_be0043bb-6a12-48cb-85b5-6f0399beb121" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_edca614d-ab35-4297-b2bb-19014ad4d3de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_bcd9c764-cb01-4b4c-9878-248afd4ab7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_be0043bb-6a12-48cb-85b5-6f0399beb121" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_bcd9c764-cb01-4b4c-9878-248afd4ab7f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_96796673-7238-4549-9a17-2b50082837c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_srt_ProductOrServiceAxis_96796673-7238-4549-9a17-2b50082837c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_96796673-7238-4549-9a17-2b50082837c9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_96796673-7238-4549-9a17-2b50082837c9" xlink:to="loc_srt_ProductsAndServicesDomain_96796673-7238-4549-9a17-2b50082837c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cf80bffe-21c2-4eae-a3be-b2c9b9f57dd6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_96796673-7238-4549-9a17-2b50082837c9" xlink:to="loc_srt_ProductsAndServicesDomain_cf80bffe-21c2-4eae-a3be-b2c9b9f57dd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_6e1772dc-928c-47a9-af03-8c4a3e24a67b" xlink:href="exdx-20210930.xsd#exdx_AVISECTDTestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cf80bffe-21c2-4eae-a3be-b2c9b9f57dd6" xlink:to="loc_exdx_AVISECTDTestMember_6e1772dc-928c-47a9-af03-8c4a3e24a67b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_f0b84e06-2bf7-48ec-a0d8-0e70f9ff337d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cf80bffe-21c2-4eae-a3be-b2c9b9f57dd6" xlink:to="loc_us-gaap_ShippingAndHandlingMember_f0b84e06-2bf7-48ec-a0d8-0e70f9ff337d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ff963b38-8cd0-46f9-80c0-f4513be91c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ff963b38-8cd0-46f9-80c0-f4513be91c22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ff963b38-8cd0-46f9-80c0-f4513be91c22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ff963b38-8cd0-46f9-80c0-f4513be91c22" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ff963b38-8cd0-46f9-80c0-f4513be91c22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fe24cf0a-31f7-491b-98e9-6d6d051be5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ff963b38-8cd0-46f9-80c0-f4513be91c22" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fe24cf0a-31f7-491b-98e9-6d6d051be5b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_e1cfaf2f-8f15-4dd6-9fe2-c0adb6aa165a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fe24cf0a-31f7-491b-98e9-6d6d051be5b6" xlink:to="loc_us-gaap_OtherAssetsMember_e1cfaf2f-8f15-4dd6-9fe2-c0adb6aa165a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_79f883ef-3d8a-42f2-843a-c9eb6c9584dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_srt_RangeAxis_79f883ef-3d8a-42f2-843a-c9eb6c9584dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_79f883ef-3d8a-42f2-843a-c9eb6c9584dd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_79f883ef-3d8a-42f2-843a-c9eb6c9584dd" xlink:to="loc_srt_RangeMember_79f883ef-3d8a-42f2-843a-c9eb6c9584dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_853649fa-dd5f-4966-a4c5-48bd567ceaad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_79f883ef-3d8a-42f2-843a-c9eb6c9584dd" xlink:to="loc_srt_RangeMember_853649fa-dd5f-4966-a4c5-48bd567ceaad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f7db2829-8f1e-49c8-b92d-05205a6cf23d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_853649fa-dd5f-4966-a4c5-48bd567ceaad" xlink:to="loc_srt_MinimumMember_f7db2829-8f1e-49c8-b92d-05205a6cf23d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_535722f0-b8ff-4633-9323-57b6376d92c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_853649fa-dd5f-4966-a4c5-48bd567ceaad" xlink:to="loc_srt_MaximumMember_535722f0-b8ff-4633-9323-57b6376d92c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_19bf6004-d3f5-463b-9e7d-848f19421572" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_srt_CounterpartyNameAxis_19bf6004-d3f5-463b-9e7d-848f19421572" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19bf6004-d3f5-463b-9e7d-848f19421572_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_19bf6004-d3f5-463b-9e7d-848f19421572" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19bf6004-d3f5-463b-9e7d-848f19421572_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31fed9da-58f0-46a9-b9bb-0d96a8b7e514" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_19bf6004-d3f5-463b-9e7d-848f19421572" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31fed9da-58f0-46a9-b9bb-0d96a8b7e514" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_f7b203bf-5c14-4922-a907-87df2b98f006" xlink:href="exdx-20210930.xsd#exdx_JanssenSIMPONIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31fed9da-58f0-46a9-b9bb-0d96a8b7e514" xlink:to="loc_exdx_JanssenSIMPONIMember_f7b203bf-5c14-4922-a907-87df2b98f006" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_07b9848b-b209-4f8e-9bea-ec481dc40297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_us-gaap_AwardTypeAxis_07b9848b-b209-4f8e-9bea-ec481dc40297" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07b9848b-b209-4f8e-9bea-ec481dc40297_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_07b9848b-b209-4f8e-9bea-ec481dc40297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07b9848b-b209-4f8e-9bea-ec481dc40297_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70373a10-6655-46a6-8a11-83c45cce468d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_07b9848b-b209-4f8e-9bea-ec481dc40297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70373a10-6655-46a6-8a11-83c45cce468d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7dc9dc85-e3b3-45d0-a955-99375b5a963f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70373a10-6655-46a6-8a11-83c45cce468d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7dc9dc85-e3b3-45d0-a955-99375b5a963f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c133e8d9-16fe-44e3-9100-431502c1adc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c133e8d9-16fe-44e3-9100-431502c1adc4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c133e8d9-16fe-44e3-9100-431502c1adc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c133e8d9-16fe-44e3-9100-431502c1adc4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c133e8d9-16fe-44e3-9100-431502c1adc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e447815c-24c6-492a-b9bc-2f591bb94d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c133e8d9-16fe-44e3-9100-431502c1adc4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e447815c-24c6-492a-b9bc-2f591bb94d4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenPromotionAgreementMember_e0d2fd04-7900-4923-8edf-e232fa8f1e36" xlink:href="exdx-20210930.xsd#exdx_JanssenPromotionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e447815c-24c6-492a-b9bc-2f591bb94d4a" xlink:to="loc_exdx_JanssenPromotionAgreementMember_e0d2fd04-7900-4923-8edf-e232fa8f1e36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_3b9530a5-aa76-4d20-92fb-532c34f10d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_3b9530a5-aa76-4d20-92fb-532c34f10d40" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_3b9530a5-aa76-4d20-92fb-532c34f10d40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_3b9530a5-aa76-4d20-92fb-532c34f10d40" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_3b9530a5-aa76-4d20-92fb-532c34f10d40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_ea804dce-ec03-4ec1-b57d-7e546da3ec8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_3b9530a5-aa76-4d20-92fb-532c34f10d40" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_ea804dce-ec03-4ec1-b57d-7e546da3ec8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TwoMajorSuppliersMember_c8d2951e-449a-41d6-aa7c-97ddba377c3a" xlink:href="exdx-20210930.xsd#exdx_TwoMajorSuppliersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_ea804dce-ec03-4ec1-b57d-7e546da3ec8d" xlink:to="loc_exdx_TwoMajorSuppliersMember_c8d2951e-449a-41d6-aa7c-97ddba377c3a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended" id="ia37b2ff0f70f40449a9b0c7a6a9a58f4_SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_1f4cbf1b-956d-48f4-8ff2-906978153e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e91038c4-d430-49b2-9c2e-88ba03a5c135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1f4cbf1b-956d-48f4-8ff2-906978153e73" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e91038c4-d430-49b2-9c2e-88ba03a5c135" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2234f24a-99b8-4cfd-95c1-2317c329d5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1f4cbf1b-956d-48f4-8ff2-906978153e73" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2234f24a-99b8-4cfd-95c1-2317c329d5e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ea17c1a9-41f6-421a-b081-a5b45bac2f2b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2234f24a-99b8-4cfd-95c1-2317c329d5e6" xlink:to="loc_srt_MajorCustomersAxis_ea17c1a9-41f6-421a-b081-a5b45bac2f2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ea17c1a9-41f6-421a-b081-a5b45bac2f2b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ea17c1a9-41f6-421a-b081-a5b45bac2f2b" xlink:to="loc_srt_NameOfMajorCustomerDomain_ea17c1a9-41f6-421a-b081-a5b45bac2f2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2e7947a7-d841-4221-b969-0b03904ae830" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ea17c1a9-41f6-421a-b081-a5b45bac2f2b" xlink:to="loc_srt_NameOfMajorCustomerDomain_2e7947a7-d841-4221-b969-0b03904ae830" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember_6f1c81b2-1d6a-4123-80be-4265205e1021" xlink:href="exdx-20210930.xsd#exdx_HealthcareInsurersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2e7947a7-d841-4221-b969-0b03904ae830" xlink:to="loc_exdx_HealthcareInsurersMember_6f1c81b2-1d6a-4123-80be-4265205e1021" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member_d19e10e3-b72c-46c1-9234-02dc3dfdd1ab" xlink:href="exdx-20210930.xsd#exdx_Government1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2e7947a7-d841-4221-b969-0b03904ae830" xlink:to="loc_exdx_Government1Member_d19e10e3-b72c-46c1-9234-02dc3dfdd1ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_e2f1bef1-2759-47de-a2e4-e0137e6c3642" xlink:href="exdx-20210930.xsd#exdx_ClientMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2e7947a7-d841-4221-b969-0b03904ae830" xlink:to="loc_exdx_ClientMember_e2f1bef1-2759-47de-a2e4-e0137e6c3642" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember_9270e737-d0cc-4e8f-9b86-e55792fc7144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2e7947a7-d841-4221-b969-0b03904ae830" xlink:to="loc_us-gaap_OtherCustomerMember_9270e737-d0cc-4e8f-9b86-e55792fc7144" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_1899c6e1-7c62-4ee5-835c-29d405e8449f" xlink:href="exdx-20210930.xsd#exdx_JanssenSIMPONIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2e7947a7-d841-4221-b969-0b03904ae830" xlink:to="loc_exdx_JanssenSIMPONIMember_1899c6e1-7c62-4ee5-835c-29d405e8449f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended" id="if90c7d062614499c83343bb389dcda67_SummaryofSignificantAccountingPoliciesSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f95ef240-bf84-447f-9031-e8004bcb1ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_53de83a2-e5af-45d9-9f7c-566377404490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f95ef240-bf84-447f-9031-e8004bcb1ef0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_53de83a2-e5af-45d9-9f7c-566377404490" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_98ba5668-3cad-4f51-952c-dc7b8b47c1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f95ef240-bf84-447f-9031-e8004bcb1ef0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_98ba5668-3cad-4f51-952c-dc7b8b47c1b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d95047c9-8591-4510-a273-7be5082402f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_98ba5668-3cad-4f51-952c-dc7b8b47c1b9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d95047c9-8591-4510-a273-7be5082402f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d95047c9-8591-4510-a273-7be5082402f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d95047c9-8591-4510-a273-7be5082402f4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d95047c9-8591-4510-a273-7be5082402f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5e7b78-7f44-42e6-b739-c6ef36701a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d95047c9-8591-4510-a273-7be5082402f4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5e7b78-7f44-42e6-b739-c6ef36701a4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1e6ac931-9226-4784-88c4-792a06faaa5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5e7b78-7f44-42e6-b739-c6ef36701a4e" xlink:to="loc_us-gaap_WarrantMember_1e6ac931-9226-4784-88c4-792a06faaa5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_c1234dfd-b62b-406e-8f0f-29cb1f94b35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5e7b78-7f44-42e6-b739-c6ef36701a4e" xlink:to="loc_us-gaap_StockOptionMember_c1234dfd-b62b-406e-8f0f-29cb1f94b35a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_eb835ada-ec82-426d-a179-ec24ceb430c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5e7b78-7f44-42e6-b739-c6ef36701a4e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_eb835ada-ec82-426d-a179-ec24ceb430c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4c5d70cc-973f-4bb4-af5f-27067ab6e31b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5e7b78-7f44-42e6-b739-c6ef36701a4e" xlink:to="loc_us-gaap_EmployeeStockMember_4c5d70cc-973f-4bb4-af5f-27067ab6e31b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#OtherFinancialInformationPropertyandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="extended" id="i24690cdf100e4c7ba7ddcdc6b3ea88ec_OtherFinancialInformationPropertyandequipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ccef2d2-3366-418a-8557-347f0efbe385" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6a85c685-a934-48d8-8d57-47a31dd0caca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ccef2d2-3366-418a-8557-347f0efbe385" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6a85c685-a934-48d8-8d57-47a31dd0caca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9db5be3d-3ee4-4991-bdc5-4ba3fbce88ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ccef2d2-3366-418a-8557-347f0efbe385" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9db5be3d-3ee4-4991-bdc5-4ba3fbce88ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_466751b9-7745-4ce9-a154-75d0adaf64a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ccef2d2-3366-418a-8557-347f0efbe385" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_466751b9-7745-4ce9-a154-75d0adaf64a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb68c779-504a-4a16-8ca2-a91c3d98e76f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ccef2d2-3366-418a-8557-347f0efbe385" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb68c779-504a-4a16-8ca2-a91c3d98e76f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5cacb97-df16-425a-a077-1316a0a3617d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb68c779-504a-4a16-8ca2-a91c3d98e76f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5cacb97-df16-425a-a077-1316a0a3617d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a5cacb97-df16-425a-a077-1316a0a3617d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5cacb97-df16-425a-a077-1316a0a3617d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a5cacb97-df16-425a-a077-1316a0a3617d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31b38fd5-b894-451b-b1ed-707307b8ffde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5cacb97-df16-425a-a077-1316a0a3617d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31b38fd5-b894-451b-b1ed-707307b8ffde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2b82a6e8-5c50-4602-8761-d30eba36523f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31b38fd5-b894-451b-b1ed-707307b8ffde" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2b82a6e8-5c50-4602-8761-d30eba36523f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_4de4199b-aa88-4242-8eb5-e3dfd92e8dff" xlink:href="exdx-20210930.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31b38fd5-b894-451b-b1ed-707307b8ffde" xlink:to="loc_exdx_LaboratoryEquipmentMember_4de4199b-aa88-4242-8eb5-e3dfd92e8dff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_ffc6cca4-0769-48d1-9b76-2ebe2263cc1a" xlink:href="exdx-20210930.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31b38fd5-b894-451b-b1ed-707307b8ffde" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_ffc6cca4-0769-48d1-9b76-2ebe2263cc1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_b11c91a6-7466-4a92-9207-8658823e030b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31b38fd5-b894-451b-b1ed-707307b8ffde" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_b11c91a6-7466-4a92-9207-8658823e030b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_299d228b-2009-4c0c-b2da-5403d792622f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31b38fd5-b894-451b-b1ed-707307b8ffde" xlink:to="loc_us-gaap_ConstructionInProgressMember_299d228b-2009-4c0c-b2da-5403d792622f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended" id="iba4667423ac34a9e9d2dcafafb4b470e_OtherFinancialInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fded27f4-9a8b-4beb-b902-60c7d9a79747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1d540dcb-c768-48e3-bc8c-02c0297cd368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fded27f4-9a8b-4beb-b902-60c7d9a79747" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1d540dcb-c768-48e3-bc8c-02c0297cd368" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_66a79c33-9e8e-4bcc-a34b-9e252638eb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fded27f4-9a8b-4beb-b902-60c7d9a79747" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_66a79c33-9e8e-4bcc-a34b-9e252638eb6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e60628fd-9200-44b1-95dc-7a97cf91c7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fded27f4-9a8b-4beb-b902-60c7d9a79747" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e60628fd-9200-44b1-95dc-7a97cf91c7f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4845b1e9-1385-4141-89f2-933136c3c77b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e60628fd-9200-44b1-95dc-7a97cf91c7f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4845b1e9-1385-4141-89f2-933136c3c77b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4845b1e9-1385-4141-89f2-933136c3c77b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4845b1e9-1385-4141-89f2-933136c3c77b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4845b1e9-1385-4141-89f2-933136c3c77b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab0fa7bb-c7a0-4dbb-b1a1-49063f568255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4845b1e9-1385-4141-89f2-933136c3c77b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab0fa7bb-c7a0-4dbb-b1a1-49063f568255" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AssetsUnderCapitalLeaseMember_95120de8-5861-449d-932f-a866a7c106bd" xlink:href="exdx-20210930.xsd#exdx_AssetsUnderCapitalLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab0fa7bb-c7a0-4dbb-b1a1-49063f568255" xlink:to="loc_exdx_AssetsUnderCapitalLeaseMember_95120de8-5861-449d-932f-a866a7c106bd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="ie8efe5f31c87434e86c089fd3341a410_BorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_88b4b019-7603-4cd1-8fa7-6436acea052f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_88b4b019-7603-4cd1-8fa7-6436acea052f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d40d176d-129e-40c5-bac7-d4b12676892f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d40d176d-129e-40c5-bac7-d4b12676892f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_03e48cb1-be9f-4e36-9d38-d2b26d29d96e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_03e48cb1-be9f-4e36-9d38-d2b26d29d96e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_ceee34a4-78bd-49d6-94ed-0c3b93b6ebb1" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_ceee34a4-78bd-49d6-94ed-0c3b93b6ebb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_afbb76bf-7d6f-42ba-80b9-75faa90ebd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_afbb76bf-7d6f-42ba-80b9-75faa90ebd7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c8944b30-0c32-46ef-bc71-7f475594ecca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_us-gaap_DebtInstrumentTerm_c8944b30-0c32-46ef-bc71-7f475594ecca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_c58bf897-0826-436e-8643-dd3b8a5f6d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_c58bf897-0826-436e-8643-dd3b8a5f6d3c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_515c2c46-d79d-4304-9489-88a5917436cb" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_515c2c46-d79d-4304-9489-88a5917436cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_379ce648-5c25-47a1-b4e8-13068b84642e" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_379ce648-5c25-47a1-b4e8-13068b84642e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_ab896484-c0a4-411f-9ce9-28f97cd5a96b" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_ab896484-c0a4-411f-9ce9-28f97cd5a96b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_d75640f9-6fd3-4fcc-9c1f-818bf5bc279c" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_d75640f9-6fd3-4fcc-9c1f-818bf5bc279c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_c925f783-17db-4886-8f02-fa07d0e99045" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_c925f783-17db-4886-8f02-fa07d0e99045" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ccd63bcc-15a1-43c5-a777-f2d256e7374e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_us-gaap_DebtInstrumentTable_ccd63bcc-15a1-43c5-a777-f2d256e7374e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_86457941-c8b3-415b-a603-6430ef8f4711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ccd63bcc-15a1-43c5-a777-f2d256e7374e" xlink:to="loc_us-gaap_DebtInstrumentAxis_86457941-c8b3-415b-a603-6430ef8f4711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_86457941-c8b3-415b-a603-6430ef8f4711_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_86457941-c8b3-415b-a603-6430ef8f4711" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_86457941-c8b3-415b-a603-6430ef8f4711_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_60e45613-46f1-4080-8e0d-1416da09a031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_86457941-c8b3-415b-a603-6430ef8f4711" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_60e45613-46f1-4080-8e0d-1416da09a031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_eabe977c-f713-4913-b103-332811fe940d" xlink:href="exdx-20210930.xsd#exdx_Term2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_60e45613-46f1-4080-8e0d-1416da09a031" xlink:to="loc_exdx_Term2017Member_eabe977c-f713-4913-b103-332811fe940d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ebf31c6c-ac1a-4288-975b-b997c592bfae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ccd63bcc-15a1-43c5-a777-f2d256e7374e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ebf31c6c-ac1a-4288-975b-b997c592bfae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ebf31c6c-ac1a-4288-975b-b997c592bfae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ebf31c6c-ac1a-4288-975b-b997c592bfae" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ebf31c6c-ac1a-4288-975b-b997c592bfae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f891fed8-9fef-4775-9f72-af5e3e45e6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ebf31c6c-ac1a-4288-975b-b997c592bfae" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f891fed8-9fef-4775-9f72-af5e3e45e6b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_29ff0ffe-152e-4936-a9f8-0c24eebe9b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f891fed8-9fef-4775-9f72-af5e3e45e6b3" xlink:to="loc_us-gaap_LoansPayableMember_29ff0ffe-152e-4936-a9f8-0c24eebe9b1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_0a1bbbeb-3abe-4506-9d39-ab74bd3ead68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f891fed8-9fef-4775-9f72-af5e3e45e6b3" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_0a1bbbeb-3abe-4506-9d39-ab74bd3ead68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_da2b25f1-d51b-489d-9740-190e529f6dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ccd63bcc-15a1-43c5-a777-f2d256e7374e" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_da2b25f1-d51b-489d-9740-190e529f6dff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_da2b25f1-d51b-489d-9740-190e529f6dff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_da2b25f1-d51b-489d-9740-190e529f6dff" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_da2b25f1-d51b-489d-9740-190e529f6dff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_9fec9f25-a753-4e68-97ea-8406f02180e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_da2b25f1-d51b-489d-9740-190e529f6dff" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_9fec9f25-a753-4e68-97ea-8406f02180e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_bd3eae22-e20d-462d-ae05-9c8df48272ea" xlink:href="exdx-20210930.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_9fec9f25-a753-4e68-97ea-8406f02180e9" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_bd3eae22-e20d-462d-ae05-9c8df48272ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CapitalRoyaltyPartnersIILPMember_2d8c084e-f36a-4031-b42b-aba019b900b3" xlink:href="exdx-20210930.xsd#exdx_CapitalRoyaltyPartnersIILPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_9fec9f25-a753-4e68-97ea-8406f02180e9" xlink:to="loc_exdx_CapitalRoyaltyPartnersIILPMember_2d8c084e-f36a-4031-b42b-aba019b900b3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended" id="iac78433d37e14dd190aa478b08984cef_CommitmentandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeasesRenewalTerm_1c5bbcb0-3559-4868-b011-ee90c086a791" xlink:href="exdx-20210930.xsd#exdx_OperatingLeasesRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_OperatingLeasesRenewalTerm_1c5bbcb0-3559-4868-b011-ee90c086a791" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRent_125c0b1d-9a2f-4d88-a684-d74b8398e74d" xlink:href="exdx-20210930.xsd#exdx_OperatingLeaseMonthlyBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_OperatingLeaseMonthlyBaseRent_125c0b1d-9a2f-4d88-a684-d74b8398e74d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_b9051362-eea6-444b-809e-ed04b456a632" xlink:href="exdx-20210930.xsd#exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_b9051362-eea6-444b-809e-ed04b456a632" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_373c1341-410c-4a70-acee-bebbd4d30ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_us-gaap_LeaseAndRentalExpense_373c1341-410c-4a70-acee-bebbd4d30ce0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_127f9e1a-5648-4ca3-a463-8fb1727dae30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_127f9e1a-5648-4ca3-a463-8fb1727dae30" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_2b38ab45-f0e4-40e1-8188-7bba4841ac7d" xlink:href="exdx-20210930.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_2b38ab45-f0e4-40e1-8188-7bba4841ac7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_3bff6fcd-0504-4073-86a2-27e9ed55e8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_3bff6fcd-0504-4073-86a2-27e9ed55e8ca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment_687e611d-2496-47a2-8622-9565531176b0" xlink:href="exdx-20210930.xsd#exdx_AdvancePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_AdvancePayment_687e611d-2496-47a2-8622-9565531176b0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementInitialLicenseFee_92f69d5f-1f60-405e-8d1c-7993c85e7ad6" xlink:href="exdx-20210930.xsd#exdx_LicenseAgreementInitialLicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_LicenseAgreementInitialLicenseFee_92f69d5f-1f60-405e-8d1c-7993c85e7ad6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_a9a9feb6-a47e-4de6-b8b9-ba71234dc1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_a9a9feb6-a47e-4de6-b8b9-ba71234dc1f8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_0af9f3f9-8277-451d-bc01-43d00061110a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_0af9f3f9-8277-451d-bc01-43d00061110a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_03f12c43-5097-4351-8a25-7cd3c12b6d3e" xlink:href="exdx-20210930.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_03f12c43-5097-4351-8a25-7cd3c12b6d3e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee_a3b17320-0365-4c88-aa4e-26eb187db921" xlink:href="exdx-20210930.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_CollaborationAgreementAnnualCollaborationFee_a3b17320-0365-4c88-aa4e-26eb187db921" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses_e1f7ed15-3cab-4456-852d-b5d031436c59" xlink:href="exdx-20210930.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_CollaborationAgreementCollaborationExpenses_e1f7ed15-3cab-4456-852d-b5d031436c59" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b423ba9b-0a1c-465d-95d2-1612e37b0283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_us-gaap_LossContingenciesTable_b423ba9b-0a1c-465d-95d2-1612e37b0283" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_8ec7b515-c756-4989-9549-b88cbbcb9eee" xlink:href="exdx-20210930.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b423ba9b-0a1c-465d-95d2-1612e37b0283" xlink:to="loc_exdx_RentalPropertyByTypeAxis_8ec7b515-c756-4989-9549-b88cbbcb9eee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_8ec7b515-c756-4989-9549-b88cbbcb9eee_default" xlink:href="exdx-20210930.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exdx_RentalPropertyByTypeAxis_8ec7b515-c756-4989-9549-b88cbbcb9eee" xlink:to="loc_exdx_RentalPropertyByTypeDomain_8ec7b515-c756-4989-9549-b88cbbcb9eee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_b3d3e129-c9aa-4722-9baf-75977abc6bf9" xlink:href="exdx-20210930.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exdx_RentalPropertyByTypeAxis_8ec7b515-c756-4989-9549-b88cbbcb9eee" xlink:to="loc_exdx_RentalPropertyByTypeDomain_b3d3e129-c9aa-4722-9baf-75977abc6bf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_4e302a89-5eb7-4e11-a8e5-06a309cb0897" xlink:href="exdx-20210930.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_b3d3e129-c9aa-4722-9baf-75977abc6bf9" xlink:to="loc_exdx_OfficeAndLaboratoryMember_4e302a89-5eb7-4e11-a8e5-06a309cb0897" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_1cfba06f-2b20-4310-b9c5-fd6fe6e4fc5b" xlink:href="exdx-20210930.xsd#exdx_OfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_b3d3e129-c9aa-4722-9baf-75977abc6bf9" xlink:to="loc_exdx_OfficeMember_1cfba06f-2b20-4310-b9c5-fd6fe6e4fc5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_05121020-43f2-42ad-b418-bfc607c6af48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b423ba9b-0a1c-465d-95d2-1612e37b0283" xlink:to="loc_srt_CounterpartyNameAxis_05121020-43f2-42ad-b418-bfc607c6af48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05121020-43f2-42ad-b418-bfc607c6af48_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_05121020-43f2-42ad-b418-bfc607c6af48" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05121020-43f2-42ad-b418-bfc607c6af48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e9718fa-022f-4511-843f-5d1fcd4e8c61" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_05121020-43f2-42ad-b418-bfc607c6af48" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e9718fa-022f-4511-843f-5d1fcd4e8c61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember_37ba91a0-760a-4ef7-8800-954f65946914" xlink:href="exdx-20210930.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e9718fa-022f-4511-843f-5d1fcd4e8c61" xlink:to="loc_exdx_PrometheusLaboratoriesIncMember_37ba91a0-760a-4ef7-8800-954f65946914" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_88b6e59b-d5da-4b15-9521-8aa180be37e2" xlink:href="exdx-20210930.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e9718fa-022f-4511-843f-5d1fcd4e8c61" xlink:to="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_88b6e59b-d5da-4b15-9521-8aa180be37e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a4987be7-8169-481c-aa02-0652599fe7d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b423ba9b-0a1c-465d-95d2-1612e37b0283" xlink:to="loc_srt_RangeAxis_a4987be7-8169-481c-aa02-0652599fe7d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a4987be7-8169-481c-aa02-0652599fe7d2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a4987be7-8169-481c-aa02-0652599fe7d2" xlink:to="loc_srt_RangeMember_a4987be7-8169-481c-aa02-0652599fe7d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dff8b943-f9a0-433f-b222-258e01802245" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a4987be7-8169-481c-aa02-0652599fe7d2" xlink:to="loc_srt_RangeMember_dff8b943-f9a0-433f-b222-258e01802245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7b659172-1db6-403e-b8b3-9e2382134fc4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dff8b943-f9a0-433f-b222-258e01802245" xlink:to="loc_srt_MinimumMember_7b659172-1db6-403e-b8b3-9e2382134fc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8d9ba9f5-2d66-41a9-a175-5b2d51aa3076" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dff8b943-f9a0-433f-b222-258e01802245" xlink:to="loc_srt_MaximumMember_8d9ba9f5-2d66-41a9-a175-5b2d51aa3076" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_27c6e949-2b4b-4e45-9f1f-2c9c76918ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b423ba9b-0a1c-465d-95d2-1612e37b0283" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_27c6e949-2b4b-4e45-9f1f-2c9c76918ea7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_27c6e949-2b4b-4e45-9f1f-2c9c76918ea7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_27c6e949-2b4b-4e45-9f1f-2c9c76918ea7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_27c6e949-2b4b-4e45-9f1f-2c9c76918ea7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_acbf0c2a-0da4-424e-a695-dc159740e693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_27c6e949-2b4b-4e45-9f1f-2c9c76918ea7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_acbf0c2a-0da4-424e-a695-dc159740e693" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_77d43753-2f7b-4260-bd1d-779503e268c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_acbf0c2a-0da4-424e-a695-dc159740e693" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_77d43753-2f7b-4260-bd1d-779503e268c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_eae13816-9713-4905-881a-b82773a884c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b423ba9b-0a1c-465d-95d2-1612e37b0283" xlink:to="loc_us-gaap_TypeOfArrangementAxis_eae13816-9713-4905-881a-b82773a884c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eae13816-9713-4905-881a-b82773a884c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_eae13816-9713-4905-881a-b82773a884c5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eae13816-9713-4905-881a-b82773a884c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_56afb8d8-e9c0-4d5e-bd97-6200b896617c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_eae13816-9713-4905-881a-b82773a884c5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_56afb8d8-e9c0-4d5e-bd97-6200b896617c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember_6df78149-ecae-4e06-bdaa-aa18c860c0ef" xlink:href="exdx-20210930.xsd#exdx_AHNCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_56afb8d8-e9c0-4d5e-bd97-6200b896617c" xlink:to="loc_exdx_AHNCollaborationMember_6df78149-ecae-4e06-bdaa-aa18c860c0ef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i7eb7e892102649f4a4d53ddf6a3f23d5_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ea308942-d3c9-43fc-9709-b99ef2a3fa43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_6f37e406-6b8e-4a75-8df7-3a250a1507d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ea308942-d3c9-43fc-9709-b99ef2a3fa43" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_6f37e406-6b8e-4a75-8df7-3a250a1507d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_31e6d7bf-6854-4eea-a084-2df152671dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6f37e406-6b8e-4a75-8df7-3a250a1507d5" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_31e6d7bf-6854-4eea-a084-2df152671dbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_588d7eed-9809-4cd2-a05d-11134c049196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ea308942-d3c9-43fc-9709-b99ef2a3fa43" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_588d7eed-9809-4cd2-a05d-11134c049196" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2d820ec6-9377-4761-86b4-2a8d883ece10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_588d7eed-9809-4cd2-a05d-11134c049196" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2d820ec6-9377-4761-86b4-2a8d883ece10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2d820ec6-9377-4761-86b4-2a8d883ece10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2d820ec6-9377-4761-86b4-2a8d883ece10" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2d820ec6-9377-4761-86b4-2a8d883ece10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e634d8d-9a4a-41c5-90d4-5976178504c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2d820ec6-9377-4761-86b4-2a8d883ece10" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e634d8d-9a4a-41c5-90d4-5976178504c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a20f4128-4cd1-4c3b-8460-0a41d9d7ad11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e634d8d-9a4a-41c5-90d4-5976178504c2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a20f4128-4cd1-4c3b-8460-0a41d9d7ad11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c590bc2-835a-4faa-b69f-da5b0aea1eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_588d7eed-9809-4cd2-a05d-11134c049196" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c590bc2-835a-4faa-b69f-da5b0aea1eb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c590bc2-835a-4faa-b69f-da5b0aea1eb5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c590bc2-835a-4faa-b69f-da5b0aea1eb5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c590bc2-835a-4faa-b69f-da5b0aea1eb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3ac55c0-2326-43c9-b32f-5078e274371d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c590bc2-835a-4faa-b69f-da5b0aea1eb5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3ac55c0-2326-43c9-b32f-5078e274371d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6f55780f-fd79-4eef-bd98-08fa150a9b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3ac55c0-2326-43c9-b32f-5078e274371d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6f55780f-fd79-4eef-bd98-08fa150a9b65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_01079582-6810-447a-a502-ed1463dbc2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3ac55c0-2326-43c9-b32f-5078e274371d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_01079582-6810-447a-a502-ed1463dbc2ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_030c220b-e2a6-416d-aaf0-fb06320eee37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3ac55c0-2326-43c9-b32f-5078e274371d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_030c220b-e2a6-416d-aaf0-fb06320eee37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e84ef1d0-f776-4ddb-a3cb-7e23b61f04aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_588d7eed-9809-4cd2-a05d-11134c049196" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e84ef1d0-f776-4ddb-a3cb-7e23b61f04aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e84ef1d0-f776-4ddb-a3cb-7e23b61f04aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e84ef1d0-f776-4ddb-a3cb-7e23b61f04aa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e84ef1d0-f776-4ddb-a3cb-7e23b61f04aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6797349b-f323-43d4-a4c0-4873374551c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e84ef1d0-f776-4ddb-a3cb-7e23b61f04aa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6797349b-f323-43d4-a4c0-4873374551c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_49de0eae-c91d-4286-aeb9-3442854e04d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6797349b-f323-43d4-a4c0-4873374551c9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_49de0eae-c91d-4286-aeb9-3442854e04d2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i542e0af2168c443e86c1405df33673d4_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_849c6fed-e744-4812-ac73-6cb85eaeacca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_849c6fed-e744-4812-ac73-6cb85eaeacca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_388c07be-2439-4e9a-8d1e-b32fc415aee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_388c07be-2439-4e9a-8d1e-b32fc415aee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_db9a993b-a908-4bb7-87db-2ea5098891d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_db9a993b-a908-4bb7-87db-2ea5098891d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts_afa71229-b7a1-4c26-9699-5bdbc15cbf83" xlink:href="exdx-20210930.xsd#exdx_StockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_exdx_StockIssuanceCosts_afa71229-b7a1-4c26-9699-5bdbc15cbf83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_c24408e9-2c15-4a23-89cd-91b2b84f741a" xlink:href="exdx-20210930.xsd#exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_c24408e9-2c15-4a23-89cd-91b2b84f741a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f3b4a907-df23-434b-92b8-e7f626ad8951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f3b4a907-df23-434b-92b8-e7f626ad8951" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a4dd2f8b-0e49-417a-a86b-6ed7501960a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a4dd2f8b-0e49-417a-a86b-6ed7501960a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_c1a75656-0e9a-466c-bf7b-7cf85da4d2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_c1a75656-0e9a-466c-bf7b-7cf85da4d2b5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_e4c41378-6b18-4164-ad94-057013541851" xlink:href="exdx-20210930.xsd#exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_e4c41378-6b18-4164-ad94-057013541851" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_18f86550-20c6-4882-af9e-2ca59df99674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_18f86550-20c6-4882-af9e-2ca59df99674" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c52c8558-015f-41f3-9751-8b2e11e1b027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_18f86550-20c6-4882-af9e-2ca59df99674" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c52c8558-015f-41f3-9751-8b2e11e1b027" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c52c8558-015f-41f3-9751-8b2e11e1b027_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c52c8558-015f-41f3-9751-8b2e11e1b027" xlink:to="loc_us-gaap_EquityComponentDomain_c52c8558-015f-41f3-9751-8b2e11e1b027_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5f6e57f1-9949-4392-9b1c-8371c287c2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c52c8558-015f-41f3-9751-8b2e11e1b027" xlink:to="loc_us-gaap_EquityComponentDomain_5f6e57f1-9949-4392-9b1c-8371c287c2c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bf04410c-eb0d-47d6-8bba-690b0c50bfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5f6e57f1-9949-4392-9b1c-8371c287c2c6" xlink:to="loc_us-gaap_CommonStockMember_bf04410c-eb0d-47d6-8bba-690b0c50bfb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d0ad0c00-81e9-4676-ad49-4cbf08e90c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_18f86550-20c6-4882-af9e-2ca59df99674" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d0ad0c00-81e9-4676-ad49-4cbf08e90c5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d0ad0c00-81e9-4676-ad49-4cbf08e90c5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d0ad0c00-81e9-4676-ad49-4cbf08e90c5b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d0ad0c00-81e9-4676-ad49-4cbf08e90c5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f117f18d-56cf-4f5f-bc0d-0e6bac3ccf97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d0ad0c00-81e9-4676-ad49-4cbf08e90c5b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f117f18d-56cf-4f5f-bc0d-0e6bac3ccf97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_045f0f4e-7ab6-4a80-aedd-85677c99cac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f117f18d-56cf-4f5f-bc0d-0e6bac3ccf97" xlink:to="loc_us-gaap_IPOMember_045f0f4e-7ab6-4a80-aedd-85677c99cac5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a173bc5c-64ab-4ce2-8271-641b58348637" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_18f86550-20c6-4882-af9e-2ca59df99674" xlink:to="loc_srt_CounterpartyNameAxis_a173bc5c-64ab-4ce2-8271-641b58348637" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a173bc5c-64ab-4ce2-8271-641b58348637_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a173bc5c-64ab-4ce2-8271-641b58348637" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a173bc5c-64ab-4ce2-8271-641b58348637_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_789072d0-ec92-4b49-8e3e-091298a875dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a173bc5c-64ab-4ce2-8271-641b58348637" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_789072d0-ec92-4b49-8e3e-091298a875dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangingStockholdersMember_9debaeff-1104-428e-99cf-b75a8fe33ad2" xlink:href="exdx-20210930.xsd#exdx_ExchangingStockholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_789072d0-ec92-4b49-8e3e-091298a875dc" xlink:to="loc_exdx_ExchangingStockholdersMember_9debaeff-1104-428e-99cf-b75a8fe33ad2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="extended" id="i8e2a68ff21564c41b33c7ce79f1c5de9_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3ccb8c04-a38d-490c-bd2e-36452fece7be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_11163fbf-c609-4122-b842-3e49c81dac4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ccb8c04-a38d-490c-bd2e-36452fece7be" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_11163fbf-c609-4122-b842-3e49c81dac4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_396d5107-ef28-4261-b94c-f0c4c4f1a970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ccb8c04-a38d-490c-bd2e-36452fece7be" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_396d5107-ef28-4261-b94c-f0c4c4f1a970" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_2939531d-cec0-4c4c-9220-776bb8cbaae4" xlink:href="exdx-20210930.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ccb8c04-a38d-490c-bd2e-36452fece7be" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_2939531d-cec0-4c4c-9220-776bb8cbaae4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_04173147-209d-42b0-a6b4-32393bea607b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ccb8c04-a38d-490c-bd2e-36452fece7be" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_04173147-209d-42b0-a6b4-32393bea607b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_72faed2f-3677-41c8-8211-f8616272aad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_04173147-209d-42b0-a6b4-32393bea607b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_72faed2f-3677-41c8-8211-f8616272aad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_72faed2f-3677-41c8-8211-f8616272aad4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_72faed2f-3677-41c8-8211-f8616272aad4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_72faed2f-3677-41c8-8211-f8616272aad4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d6c5d9d1-0ad4-40f9-98ec-158ea8a91bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_72faed2f-3677-41c8-8211-f8616272aad4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d6c5d9d1-0ad4-40f9-98ec-158ea8a91bd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_83b089ae-cb03-41c7-b5be-9e1dff117bf6" xlink:href="exdx-20210930.xsd#exdx_ExpirationJan192026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d6c5d9d1-0ad4-40f9-98ec-158ea8a91bd4" xlink:to="loc_exdx_ExpirationJan192026Member_83b089ae-cb03-41c7-b5be-9e1dff117bf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_bc3be0e1-b61a-4f82-be35-838066c37d45" xlink:href="exdx-20210930.xsd#exdx_ExpirationMar312026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d6c5d9d1-0ad4-40f9-98ec-158ea8a91bd4" xlink:to="loc_exdx_ExpirationMar312026Member_bc3be0e1-b61a-4f82-be35-838066c37d45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_514b20a7-6f8a-414d-a614-781aea88e301" xlink:href="exdx-20210930.xsd#exdx_ExpirationApr12026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d6c5d9d1-0ad4-40f9-98ec-158ea8a91bd4" xlink:to="loc_exdx_ExpirationApr12026Member_514b20a7-6f8a-414d-a614-781aea88e301" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member_0a854a94-0239-4fdb-950a-766840a3af00" xlink:href="exdx-20210930.xsd#exdx_ExpirationSep72024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d6c5d9d1-0ad4-40f9-98ec-158ea8a91bd4" xlink:to="loc_exdx_ExpirationSep72024Member_0a854a94-0239-4fdb-950a-766840a3af00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_78780efe-9957-46d9-8b86-7dad39113719" xlink:href="exdx-20210930.xsd#exdx_ExpirationDec72025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d6c5d9d1-0ad4-40f9-98ec-158ea8a91bd4" xlink:to="loc_exdx_ExpirationDec72025Member_78780efe-9957-46d9-8b86-7dad39113719" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember_83ac126f-92ca-4e9f-8460-a96bdb6195f8" xlink:href="exdx-20210930.xsd#exdx_NoExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d6c5d9d1-0ad4-40f9-98ec-158ea8a91bd4" xlink:to="loc_exdx_NoExpirationMember_83ac126f-92ca-4e9f-8460-a96bdb6195f8" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockOptionPlanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended" id="i1cf3f2799649495aa3304c44d2970ddd_StockOptionPlanNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32064ecf-95a1-4a12-9ec8-c211f95f3df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3ac3d834-006c-4fd2-93c0-5a3679b0cc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32064ecf-95a1-4a12-9ec8-c211f95f3df3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3ac3d834-006c-4fd2-93c0-5a3679b0cc8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eb44b018-bc38-4160-a9ff-c87238b0323a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32064ecf-95a1-4a12-9ec8-c211f95f3df3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eb44b018-bc38-4160-a9ff-c87238b0323a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7693cae0-aada-4c45-a20d-72c336ff4180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32064ecf-95a1-4a12-9ec8-c211f95f3df3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7693cae0-aada-4c45-a20d-72c336ff4180" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_614ac0e4-eb77-452c-b302-6498ba5b92da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32064ecf-95a1-4a12-9ec8-c211f95f3df3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_614ac0e4-eb77-452c-b302-6498ba5b92da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_99f7208c-626d-4f41-8a6d-aa8c70ab8208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32064ecf-95a1-4a12-9ec8-c211f95f3df3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_99f7208c-626d-4f41-8a6d-aa8c70ab8208" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7cd924b7-01d7-47e8-9ebb-61914e04126e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32064ecf-95a1-4a12-9ec8-c211f95f3df3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7cd924b7-01d7-47e8-9ebb-61914e04126e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae6d39c7-0e62-4728-9fec-2c7505ebbdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32064ecf-95a1-4a12-9ec8-c211f95f3df3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae6d39c7-0e62-4728-9fec-2c7505ebbdc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_237b8002-ca0e-4f86-bf0a-68223295b7db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae6d39c7-0e62-4728-9fec-2c7505ebbdc3" xlink:to="loc_us-gaap_PlanNameAxis_237b8002-ca0e-4f86-bf0a-68223295b7db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_237b8002-ca0e-4f86-bf0a-68223295b7db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_237b8002-ca0e-4f86-bf0a-68223295b7db" xlink:to="loc_us-gaap_PlanNameDomain_237b8002-ca0e-4f86-bf0a-68223295b7db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_71e4d9be-2be7-402b-b95c-f1ad92448fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_237b8002-ca0e-4f86-bf0a-68223295b7db" xlink:to="loc_us-gaap_PlanNameDomain_71e4d9be-2be7-402b-b95c-f1ad92448fb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_bd60e7de-dcd7-45c7-bfbc-a43eda3b9019" xlink:href="exdx-20210930.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_71e4d9be-2be7-402b-b95c-f1ad92448fb6" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_bd60e7de-dcd7-45c7-bfbc-a43eda3b9019" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_98f5579f-a20c-4302-9307-2236f065f199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae6d39c7-0e62-4728-9fec-2c7505ebbdc3" xlink:to="loc_us-gaap_AwardTypeAxis_98f5579f-a20c-4302-9307-2236f065f199" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98f5579f-a20c-4302-9307-2236f065f199_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_98f5579f-a20c-4302-9307-2236f065f199" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98f5579f-a20c-4302-9307-2236f065f199_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_058a0fe5-3781-47e6-9282-4c06f845ba73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_98f5579f-a20c-4302-9307-2236f065f199" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_058a0fe5-3781-47e6-9282-4c06f845ba73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7a0ec08d-498f-415a-83a2-0325d6049067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_058a0fe5-3781-47e6-9282-4c06f845ba73" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7a0ec08d-498f-415a-83a2-0325d6049067" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_734dafa1-7b76-4779-a125-97fe87203dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_058a0fe5-3781-47e6-9282-4c06f845ba73" xlink:to="loc_us-gaap_EmployeeStockMember_734dafa1-7b76-4779-a125-97fe87203dff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_365af2f0-cfe4-4b9b-ac7e-5cf9244a7c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_058a0fe5-3781-47e6-9282-4c06f845ba73" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_365af2f0-cfe4-4b9b-ac7e-5cf9244a7c8e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended" id="ie7e15dbab23844418b1a625e32bd9981_StockOptionPlanStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98f81a77-68bc-4f4f-8980-44283d45cef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98f81a77-68bc-4f4f-8980-44283d45cef8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_38edc834-5fe9-4ed0-bf24-1c336f2810d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98f81a77-68bc-4f4f-8980-44283d45cef8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_38edc834-5fe9-4ed0-bf24-1c336f2810d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0136e218-28e7-455e-b5cd-bb341c07a622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98f81a77-68bc-4f4f-8980-44283d45cef8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0136e218-28e7-455e-b5cd-bb341c07a622" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3e42f98-c2ad-4ac1-9087-13b60b16c6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98f81a77-68bc-4f4f-8980-44283d45cef8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3e42f98-c2ad-4ac1-9087-13b60b16c6f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9e53eac0-cbc2-469a-a6a1-08363016d27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98f81a77-68bc-4f4f-8980-44283d45cef8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9e53eac0-cbc2-469a-a6a1-08363016d27a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0a566a7e-b82d-4458-ac20-517340e3ee05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98f81a77-68bc-4f4f-8980-44283d45cef8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0a566a7e-b82d-4458-ac20-517340e3ee05" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b1c2ff2d-117b-404e-9289-edc1f5592d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ba02b0ac-91a8-44d5-844e-afefa3dd1dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ba02b0ac-91a8-44d5-844e-afefa3dd1dbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_78f39dd1-f396-4291-8921-a984695e2f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_78f39dd1-f396-4291-8921-a984695e2f17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c70a5032-05ed-48dc-b072-26ab916b4d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c70a5032-05ed-48dc-b072-26ab916b4d1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10c1b9cc-12ac-4296-b72a-e2305b7ccded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c70a5032-05ed-48dc-b072-26ab916b4d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10c1b9cc-12ac-4296-b72a-e2305b7ccded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_67908d07-c187-4865-9f1c-386a87a0df17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c70a5032-05ed-48dc-b072-26ab916b4d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_67908d07-c187-4865-9f1c-386a87a0df17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_51de9182-27c5-41de-9977-1db7b0519530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c70a5032-05ed-48dc-b072-26ab916b4d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_51de9182-27c5-41de-9977-1db7b0519530" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1351f6a8-0173-466b-bcd3-67688cb8d165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c70a5032-05ed-48dc-b072-26ab916b4d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1351f6a8-0173-466b-bcd3-67688cb8d165" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_7dfca1cf-0ec9-4759-a07d-c3cf4a3dcd14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c70a5032-05ed-48dc-b072-26ab916b4d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_7dfca1cf-0ec9-4759-a07d-c3cf4a3dcd14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9eb46a26-de34-41ad-bba6-4903a21db6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ec1d03ea-fcf8-4c89-9f5a-8b32a3052a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ec1d03ea-fcf8-4c89-9f5a-8b32a3052a80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_816d8bf3-95b0-43f2-948a-437062b994dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_816d8bf3-95b0-43f2-948a-437062b994dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62ab11df-9096-4fa9-99f8-5a9f12c35546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62ab11df-9096-4fa9-99f8-5a9f12c35546" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5273fa25-7103-4779-952a-927ea2a8c628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62ab11df-9096-4fa9-99f8-5a9f12c35546" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5273fa25-7103-4779-952a-927ea2a8c628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ea8ef93a-b84c-45d8-8795-c63321e4a76d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62ab11df-9096-4fa9-99f8-5a9f12c35546" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ea8ef93a-b84c-45d8-8795-c63321e4a76d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_381dc009-c466-42a0-98ec-8dce2cd29cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62ab11df-9096-4fa9-99f8-5a9f12c35546" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_381dc009-c466-42a0-98ec-8dce2cd29cba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_688e8e9c-bf68-4fc8-8f53-35c006f445e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62ab11df-9096-4fa9-99f8-5a9f12c35546" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_688e8e9c-bf68-4fc8-8f53-35c006f445e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_021cf214-82eb-4434-8344-e4e94d5e1b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62ab11df-9096-4fa9-99f8-5a9f12c35546" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_021cf214-82eb-4434-8344-e4e94d5e1b17" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e8c4eb48-6d5d-4664-a748-ee436f3c695c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62ab11df-9096-4fa9-99f8-5a9f12c35546" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e8c4eb48-6d5d-4664-a748-ee436f3c695c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa5ec25a-c580-4e7e-be9e-228d00a8599b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa5ec25a-c580-4e7e-be9e-228d00a8599b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_daeb9b0d-2536-418b-a035-39a748961abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa5ec25a-c580-4e7e-be9e-228d00a8599b" xlink:to="loc_us-gaap_AwardTypeAxis_daeb9b0d-2536-418b-a035-39a748961abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_daeb9b0d-2536-418b-a035-39a748961abe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_daeb9b0d-2536-418b-a035-39a748961abe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_daeb9b0d-2536-418b-a035-39a748961abe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d3cbed0-63c8-49ae-9731-7d5cdc1b992f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_daeb9b0d-2536-418b-a035-39a748961abe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d3cbed0-63c8-49ae-9731-7d5cdc1b992f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c591f449-203e-4472-9dd3-1dcf38dd4ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d3cbed0-63c8-49ae-9731-7d5cdc1b992f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c591f449-203e-4472-9dd3-1dcf38dd4ef3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockOptionPlanRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="extended" id="i383e2b056b464e0cafb377677d05c6dd_StockOptionPlanRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988630cf-ec74-40b7-b0c9-5c2d0011311d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30b6cba9-1dbf-4099-87d1-37be8513483c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988630cf-ec74-40b7-b0c9-5c2d0011311d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30b6cba9-1dbf-4099-87d1-37be8513483c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b6a63dc5-38ea-4758-89f1-d2476778374a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30b6cba9-1dbf-4099-87d1-37be8513483c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b6a63dc5-38ea-4758-89f1-d2476778374a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_755d31b7-1851-43af-afc5-5a07178b0339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30b6cba9-1dbf-4099-87d1-37be8513483c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_755d31b7-1851-43af-afc5-5a07178b0339" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cec6c454-b70c-4da7-9d38-b010d86e9848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30b6cba9-1dbf-4099-87d1-37be8513483c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cec6c454-b70c-4da7-9d38-b010d86e9848" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e0aac164-605f-4cfa-808b-4217d4277692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30b6cba9-1dbf-4099-87d1-37be8513483c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e0aac164-605f-4cfa-808b-4217d4277692" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16cb0902-48c8-4035-9af1-5893209d14e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77a036a7-4ce1-4649-a57d-572b22b9ee98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988630cf-ec74-40b7-b0c9-5c2d0011311d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77a036a7-4ce1-4649-a57d-572b22b9ee98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2a1cac45-4e21-479d-8cad-3569bbbad09d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77a036a7-4ce1-4649-a57d-572b22b9ee98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2a1cac45-4e21-479d-8cad-3569bbbad09d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_caa49e16-9741-45e8-8144-2fee5205bf82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77a036a7-4ce1-4649-a57d-572b22b9ee98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_caa49e16-9741-45e8-8144-2fee5205bf82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2e302711-6098-4758-b987-c3a53c4390c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77a036a7-4ce1-4649-a57d-572b22b9ee98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2e302711-6098-4758-b987-c3a53c4390c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e0190633-24dd-444c-99f5-b70dd3ef841c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77a036a7-4ce1-4649-a57d-572b22b9ee98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e0190633-24dd-444c-99f5-b70dd3ef841c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8fd009cd-46af-43c5-bd5e-e299b7873c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_e2c148f2-b722-44e8-a1be-51bcb3a30809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988630cf-ec74-40b7-b0c9-5c2d0011311d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_e2c148f2-b722-44e8-a1be-51bcb3a30809" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_41e7bd35-ab1c-4459-877a-4a0b9beb39c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_e2c148f2-b722-44e8-a1be-51bcb3a30809" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_41e7bd35-ab1c-4459-877a-4a0b9beb39c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c657893a-8b8c-4280-af26-95009bb10a36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988630cf-ec74-40b7-b0c9-5c2d0011311d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c657893a-8b8c-4280-af26-95009bb10a36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac3e48b7-74b6-41d1-bb8f-bb5553cdb112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c657893a-8b8c-4280-af26-95009bb10a36" xlink:to="loc_us-gaap_AwardTypeAxis_ac3e48b7-74b6-41d1-bb8f-bb5553cdb112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac3e48b7-74b6-41d1-bb8f-bb5553cdb112_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ac3e48b7-74b6-41d1-bb8f-bb5553cdb112" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac3e48b7-74b6-41d1-bb8f-bb5553cdb112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b1b0d90-3a55-4041-abfb-b578975e3f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ac3e48b7-74b6-41d1-bb8f-bb5553cdb112" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b1b0d90-3a55-4041-abfb-b578975e3f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dccf5935-b5ea-4524-830f-b6662c006893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b1b0d90-3a55-4041-abfb-b578975e3f37" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dccf5935-b5ea-4524-830f-b6662c006893" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockOptionPlanFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="extended" id="i0cf8c9d556f04d0fa61d66b692cbf29b_StockOptionPlanFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9d51814b-44f5-423c-91af-1df0f973bfca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9d51814b-44f5-423c-91af-1df0f973bfca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_559883e5-95ff-4232-b0f6-b7d96fbf63bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_559883e5-95ff-4232-b0f6-b7d96fbf63bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c6e2089b-d473-4e7e-9794-34a41b1528d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c6e2089b-d473-4e7e-9794-34a41b1528d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9eb090f4-1fad-4f8b-94ed-1489b824d66d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9eb090f4-1fad-4f8b-94ed-1489b824d66d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_36bc0d8c-a960-475c-bbe6-92545c9e97ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_36bc0d8c-a960-475c-bbe6-92545c9e97ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_94539eaf-02b6-483a-b13e-4ed982143ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_94539eaf-02b6-483a-b13e-4ed982143ff8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2b585fbd-fff1-4f04-a542-0f3b12c2500e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2b585fbd-fff1-4f04-a542-0f3b12c2500e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_06a6ea7a-c03b-4255-af7f-b4745031748a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_06a6ea7a-c03b-4255-af7f-b4745031748a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd7b555a-9773-42ac-8db9-d69059449b44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd7b555a-9773-42ac-8db9-d69059449b44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f865953e-c90c-4705-9474-9e35ad6b89af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd7b555a-9773-42ac-8db9-d69059449b44" xlink:to="loc_us-gaap_AwardTypeAxis_f865953e-c90c-4705-9474-9e35ad6b89af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f865953e-c90c-4705-9474-9e35ad6b89af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f865953e-c90c-4705-9474-9e35ad6b89af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f865953e-c90c-4705-9474-9e35ad6b89af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc69128a-69d8-4584-ace5-83185bfe2ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f865953e-c90c-4705-9474-9e35ad6b89af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc69128a-69d8-4584-ace5-83185bfe2ef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1b43555e-62b5-4948-9620-7d82e973980f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc69128a-69d8-4584-ace5-83185bfe2ef7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1b43555e-62b5-4948-9620-7d82e973980f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_ca4a58df-cba5-4ad2-838f-614c634e98d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc69128a-69d8-4584-ace5-83185bfe2ef7" xlink:to="loc_us-gaap_EmployeeStockMember_ca4a58df-cba5-4ad2-838f-614c634e98d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f3220c5-62c3-4ffc-abd7-983b82c869cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd7b555a-9773-42ac-8db9-d69059449b44" xlink:to="loc_srt_RangeAxis_2f3220c5-62c3-4ffc-abd7-983b82c869cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2f3220c5-62c3-4ffc-abd7-983b82c869cb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2f3220c5-62c3-4ffc-abd7-983b82c869cb" xlink:to="loc_srt_RangeMember_2f3220c5-62c3-4ffc-abd7-983b82c869cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1cce5a0b-1320-4c60-9b86-fc9edf3d106d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2f3220c5-62c3-4ffc-abd7-983b82c869cb" xlink:to="loc_srt_RangeMember_1cce5a0b-1320-4c60-9b86-fc9edf3d106d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5c9a6ffc-8400-430e-954f-5b74b2335d77" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1cce5a0b-1320-4c60-9b86-fc9edf3d106d" xlink:to="loc_srt_MinimumMember_5c9a6ffc-8400-430e-954f-5b74b2335d77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c7a7be88-191c-4c6d-82b8-c10bfd019dbd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1cce5a0b-1320-4c60-9b86-fc9edf3d106d" xlink:to="loc_srt_MaximumMember_c7a7be88-191c-4c6d-82b8-c10bfd019dbd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended" id="icf79d4f66b3e476881bf96df794c681b_StockOptionPlanStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aaaf9a17-fe6a-4b72-8270-932744dfdabe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6dcb39e0-cbbd-4f17-b267-1823eb0c3423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aaaf9a17-fe6a-4b72-8270-932744dfdabe" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6dcb39e0-cbbd-4f17-b267-1823eb0c3423" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22b58aa8-0f76-4529-9e26-5c121cf5f6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aaaf9a17-fe6a-4b72-8270-932744dfdabe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22b58aa8-0f76-4529-9e26-5c121cf5f6dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6eb6fc6e-fa32-494f-be3c-55fae283def7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22b58aa8-0f76-4529-9e26-5c121cf5f6dc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6eb6fc6e-fa32-494f-be3c-55fae283def7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6eb6fc6e-fa32-494f-be3c-55fae283def7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6eb6fc6e-fa32-494f-be3c-55fae283def7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6eb6fc6e-fa32-494f-be3c-55fae283def7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4d7fe41d-c77d-4151-90a6-968dc75849cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6eb6fc6e-fa32-494f-be3c-55fae283def7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4d7fe41d-c77d-4151-90a6-968dc75849cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_b8eea58a-c7ca-4bf6-a812-dbf3815b88fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d7fe41d-c77d-4151-90a6-968dc75849cc" xlink:to="loc_us-gaap_CostOfSalesMember_b8eea58a-c7ca-4bf6-a812-dbf3815b88fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b0639086-3778-4668-a3bb-0d94d468428a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d7fe41d-c77d-4151-90a6-968dc75849cc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b0639086-3778-4668-a3bb-0d94d468428a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ff519cb1-ec7f-405a-bdda-f3324a58e4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d7fe41d-c77d-4151-90a6-968dc75849cc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ff519cb1-ec7f-405a-bdda-f3324a58e4a7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19Details" xlink:type="simple" xlink:href="exdx-20210930.xsd#Covid19Details"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/Covid19Details" xlink:type="extended" id="i8cff2162130443059546424483c46a0d_Covid19Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0dcbc47e-7584-4b1e-90ae-52dd9a1db7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_4f409665-f7fc-4f27-b89d-aa43a6400a7f" xlink:href="exdx-20210930.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0dcbc47e-7584-4b1e-90ae-52dd9a1db7a0" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_4f409665-f7fc-4f27-b89d-aa43a6400a7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_73a996a0-1634-4035-88e4-82a3f5249111" xlink:href="exdx-20210930.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0dcbc47e-7584-4b1e-90ae-52dd9a1db7a0" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_73a996a0-1634-4035-88e4-82a3f5249111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ProceedsFromGovernmentAssistance_6a268d4f-34c5-4172-8aff-5c0b262839b4" xlink:href="exdx-20210930.xsd#exdx_ProceedsFromGovernmentAssistance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0dcbc47e-7584-4b1e-90ae-52dd9a1db7a0" xlink:to="loc_exdx_ProceedsFromGovernmentAssistance_6a268d4f-34c5-4172-8aff-5c0b262839b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromBankDebt_2e031e13-9dbc-4928-a652-0c3735acd403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromBankDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0dcbc47e-7584-4b1e-90ae-52dd9a1db7a0" xlink:to="loc_us-gaap_ProceedsFromBankDebt_2e031e13-9dbc-4928-a652-0c3735acd403" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a97ea2a-1625-44c6-8a08-5e4fd455ee69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0dcbc47e-7584-4b1e-90ae-52dd9a1db7a0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a97ea2a-1625-44c6-8a08-5e4fd455ee69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d64a2ea9-3beb-4b40-91b3-98cf690db326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a97ea2a-1625-44c6-8a08-5e4fd455ee69" xlink:to="loc_us-gaap_DebtInstrumentAxis_d64a2ea9-3beb-4b40-91b3-98cf690db326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d64a2ea9-3beb-4b40-91b3-98cf690db326_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d64a2ea9-3beb-4b40-91b3-98cf690db326" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d64a2ea9-3beb-4b40-91b3-98cf690db326_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c982ac70-1780-4213-bef8-b454fb3b2aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d64a2ea9-3beb-4b40-91b3-98cf690db326" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c982ac70-1780-4213-bef8-b454fb3b2aa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PaycheckProtectionProgramCARESActMember_2aa02972-a29c-4d82-8ac5-f0b99cc06c68" xlink:href="exdx-20210930.xsd#exdx_PaycheckProtectionProgramCARESActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c982ac70-1780-4213-bef8-b454fb3b2aa5" xlink:to="loc_exdx_PaycheckProtectionProgramCARESActMember_2aa02972-a29c-4d82-8ac5-f0b99cc06c68" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SubsequentEventsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#SubsequentEventsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended" id="i520025d939694cd39e5b5f95ff06337d_SubsequentEventsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_9a452613-7b45-4193-9b36-5e68691b16d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRent_7e013e33-8eef-4867-a17c-8635895681be" xlink:href="exdx-20210930.xsd#exdx_OperatingLeaseMonthlyBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9a452613-7b45-4193-9b36-5e68691b16d0" xlink:to="loc_exdx_OperatingLeaseMonthlyBaseRent_7e013e33-8eef-4867-a17c-8635895681be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseTermOfContract_3fe8983a-70af-46f6-824d-e5fe36ff3dcc" xlink:href="exdx-20210930.xsd#exdx_OperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9a452613-7b45-4193-9b36-5e68691b16d0" xlink:to="loc_exdx_OperatingLeaseTermOfContract_3fe8983a-70af-46f6-824d-e5fe36ff3dcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRentFirstIncrease_88337e7d-6f6a-4187-b4eb-bd904c5a8316" xlink:href="exdx-20210930.xsd#exdx_OperatingLeaseMonthlyBaseRentFirstIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9a452613-7b45-4193-9b36-5e68691b16d0" xlink:to="loc_exdx_OperatingLeaseMonthlyBaseRentFirstIncrease_88337e7d-6f6a-4187-b4eb-bd904c5a8316" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a15dedc0-1785-44db-9ea4-fa93faf9ea3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9a452613-7b45-4193-9b36-5e68691b16d0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a15dedc0-1785-44db-9ea4-fa93faf9ea3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_03c3967a-007d-4a81-896b-93c268f7b870" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9a452613-7b45-4193-9b36-5e68691b16d0" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_03c3967a-007d-4a81-896b-93c268f7b870" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_7ea06a22-a19e-4c84-b1d1-3070d813325b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_9a452613-7b45-4193-9b36-5e68691b16d0" xlink:to="loc_us-gaap_SubsequentEventTable_7ea06a22-a19e-4c84-b1d1-3070d813325b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fafc7d6f-8552-4843-b01d-5c4e8055d9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_7ea06a22-a19e-4c84-b1d1-3070d813325b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fafc7d6f-8552-4843-b01d-5c4e8055d9d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fafc7d6f-8552-4843-b01d-5c4e8055d9d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fafc7d6f-8552-4843-b01d-5c4e8055d9d3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fafc7d6f-8552-4843-b01d-5c4e8055d9d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c0bcb11d-8cde-40c2-b549-b6232764d24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fafc7d6f-8552-4843-b01d-5c4e8055d9d3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c0bcb11d-8cde-40c2-b549-b6232764d24f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_eaf9a632-3161-45c4-a50e-9f3508e90b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c0bcb11d-8cde-40c2-b549-b6232764d24f" xlink:to="loc_us-gaap_SubsequentEventMember_eaf9a632-3161-45c4-a50e-9f3508e90b17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_164aca2b-1861-4857-8fc0-6b6f99c696bf" xlink:href="exdx-20210930.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_7ea06a22-a19e-4c84-b1d1-3070d813325b" xlink:to="loc_exdx_RentalPropertyByTypeAxis_164aca2b-1861-4857-8fc0-6b6f99c696bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_164aca2b-1861-4857-8fc0-6b6f99c696bf_default" xlink:href="exdx-20210930.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exdx_RentalPropertyByTypeAxis_164aca2b-1861-4857-8fc0-6b6f99c696bf" xlink:to="loc_exdx_RentalPropertyByTypeDomain_164aca2b-1861-4857-8fc0-6b6f99c696bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_a6ef0905-64cc-49c7-91f9-c9e5113856ad" xlink:href="exdx-20210930.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exdx_RentalPropertyByTypeAxis_164aca2b-1861-4857-8fc0-6b6f99c696bf" xlink:to="loc_exdx_RentalPropertyByTypeDomain_a6ef0905-64cc-49c7-91f9-c9e5113856ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeSpaceMember_73fb365a-7292-47bb-bbbc-65eae71ea8fe" xlink:href="exdx-20210930.xsd#exdx_OfficeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_a6ef0905-64cc-49c7-91f9-c9e5113856ad" xlink:to="loc_exdx_OfficeSpaceMember_73fb365a-7292-47bb-bbbc-65eae71ea8fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HeadquartersMember_e2e7e8dc-e71b-4c63-ba4b-1bfe70935506" xlink:href="exdx-20210930.xsd#exdx_HeadquartersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_a6ef0905-64cc-49c7-91f9-c9e5113856ad" xlink:to="loc_exdx_HeadquartersMember_e2e7e8dc-e71b-4c63-ba4b-1bfe70935506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_36246533-c897-480e-8a05-34a5c4aa1cc9" xlink:href="exdx-20210930.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_a6ef0905-64cc-49c7-91f9-c9e5113856ad" xlink:to="loc_exdx_OfficeAndLaboratoryMember_36246533-c897-480e-8a05-34a5c4aa1cc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_096e0d5a-d42c-47aa-871d-7a24f90de274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_7ea06a22-a19e-4c84-b1d1-3070d813325b" xlink:to="loc_us-gaap_DebtInstrumentAxis_096e0d5a-d42c-47aa-871d-7a24f90de274" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_096e0d5a-d42c-47aa-871d-7a24f90de274_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_096e0d5a-d42c-47aa-871d-7a24f90de274" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_096e0d5a-d42c-47aa-871d-7a24f90de274_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5e8c09c9-6c7b-402f-b35b-baaf2195d125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_096e0d5a-d42c-47aa-871d-7a24f90de274" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5e8c09c9-6c7b-402f-b35b-baaf2195d125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_65ae085e-2293-4289-af26-b665c727c5fd" xlink:href="exdx-20210930.xsd#exdx_Term2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5e8c09c9-6c7b-402f-b35b-baaf2195d125" xlink:to="loc_exdx_Term2017Member_65ae085e-2293-4289-af26-b665c727c5fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_c47e073c-137c-41c2-b462-72e123121994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_7ea06a22-a19e-4c84-b1d1-3070d813325b" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_c47e073c-137c-41c2-b462-72e123121994" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_c47e073c-137c-41c2-b462-72e123121994_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_c47e073c-137c-41c2-b462-72e123121994" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_c47e073c-137c-41c2-b462-72e123121994_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_58e0a72a-c748-433a-b666-5777b8b8b337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_c47e073c-137c-41c2-b462-72e123121994" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_58e0a72a-c748-433a-b666-5777b8b8b337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_50f446b8-d00c-485d-9973-f90ae57299fb" xlink:href="exdx-20210930.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_58e0a72a-c748-433a-b666-5777b8b8b337" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_50f446b8-d00c-485d-9973-f90ae57299fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_65fb7bb0-a093-4e3a-bca7-729f62eb8d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_7ea06a22-a19e-4c84-b1d1-3070d813325b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_65fb7bb0-a093-4e3a-bca7-729f62eb8d90" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_65fb7bb0-a093-4e3a-bca7-729f62eb8d90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_65fb7bb0-a093-4e3a-bca7-729f62eb8d90" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_65fb7bb0-a093-4e3a-bca7-729f62eb8d90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8aa27766-6991-499b-996a-e4ca30fcb105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_65fb7bb0-a093-4e3a-bca7-729f62eb8d90" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8aa27766-6991-499b-996a-e4ca30fcb105" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_ac3bec8a-b2a6-4a25-9e35-8fe64938d6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8aa27766-6991-499b-996a-e4ca30fcb105" xlink:to="loc_us-gaap_LoansPayableMember_ac3bec8a-b2a6-4a25-9e35-8fe64938d6e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>exdx-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:c5a0a3fb-3fff-4206-b83d-31088152a01e,g:78c7fea5-b4e3-40b0-a9a0-b197701560e9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_e7e40116-9284-4e30-a515-228811722272_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of common stock warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_b6909ef8-3f93-4aa6-8c24-6a4787335d4f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_767cc549-ea13-48c2-a9bc-ec40323781ab_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_757a946b-8454-4b55-acda-cf19aaf57f24_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ef294ee2-fb8e-4718-831a-7299b355b922_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a245b96-b537-4508-9559-17f786598ee8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_1cd4c394-2733-45ef-9c2e-9b922e2d7a52_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_dfd21a2f-6a2e-4dc6-8b94-b831b7b2b03c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fdeb9f49-6ef0-491c-b431-418d14d19918_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_cd28395f-b5ca-426e-b949-d381514ea339_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d1415142-9b73-4d80-87cd-f376129bd940_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OperatingLeaseMonthlyBaseRentFirstIncrease_a67da9ce-b1ba-4b5e-9080-2c7906664ad9_terseLabel_en-US" xlink:label="lab_exdx_OperatingLeaseMonthlyBaseRentFirstIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, monthly base rent after first increase</link:label>
    <link:label id="lab_exdx_OperatingLeaseMonthlyBaseRentFirstIncrease_label_en-US" xlink:label="lab_exdx_OperatingLeaseMonthlyBaseRentFirstIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Base Rent, First Increase</link:label>
    <link:label id="lab_exdx_OperatingLeaseMonthlyBaseRentFirstIncrease_documentation_en-US" xlink:label="lab_exdx_OperatingLeaseMonthlyBaseRentFirstIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Base Rent, First Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRentFirstIncrease" xlink:href="exdx-20210930.xsd#exdx_OperatingLeaseMonthlyBaseRentFirstIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OperatingLeaseMonthlyBaseRentFirstIncrease" xlink:to="lab_exdx_OperatingLeaseMonthlyBaseRentFirstIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_304a27e6-93c9-4221-8450-135bd05ac78c_terseLabel_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_label_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund [Member]</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_documentation_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:href="exdx-20210930.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:to="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_352b9020-0d0a-4510-b375-80c112dee1f1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a0254e58-e2a3-49e9-b08d-292ae4c77bd9_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b7a8ece7-9607-426c-a1da-496876568a6b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_420d2305-2388-4712-8304-e3712c669282_terseLabel_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Axis]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_label_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Axis]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_documentation_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis" xlink:href="exdx-20210930.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RentalPropertyByTypeAxis" xlink:to="lab_exdx_RentalPropertyByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_aaa2d451-cd1f-4bdb-8628-f68caed4217f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_c18a9c6e-f1de-4caf-bba4-d01c063cc042_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_608d80c3-161f-495e-aeb9-ae09672b3f1e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e6a1892c-6522-41c2-8f88-ce1d99e6c962_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards canceled, Weighted-Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b72d5baf-19fa-4edd-af99-c7474e9ddcc5_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6981f0af-356e-4328-b608-b15f75459670_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f0f9d7e9-f5af-466a-8518-47e1a207b4a9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41274264-ff1a-4772-91bb-29787ecc08fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_57b264fc-6826-4e28-8442-9237220785b8_terseLabel_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covid-19</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_label_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure [Text Block]</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_documentation_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:href="exdx-20210930.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:to="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fa115408-7b70-4110-a627-e245cdf102ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares that remain available for future awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9d4f8868-f127-4c11-b1a5-968c655d99c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f4f79da5-c06e-4925-9829-184702ebb058_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_07ac6113-dcfd-4e8f-8c56-f130b3f91caf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_BlueShieldMember_a17c6ac5-e346-4066-aa9a-17bba2032175_verboseLabel_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield</link:label>
    <link:label id="lab_exdx_BlueShieldMember_label_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield [Member]</link:label>
    <link:label id="lab_exdx_BlueShieldMember_documentation_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember" xlink:href="exdx-20210930.xsd#exdx_BlueShieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_BlueShieldMember" xlink:to="lab_exdx_BlueShieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_10ac79b4-2724-420e-9b4a-66262ab49ea4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_73100ef0-c083-4dd9-8077-7fba9bf889c4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4925be22-590d-4132-ad99-af71a1c35d6e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_167ed5a7-0e9a-47fa-84d6-76ce1c5062c2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remaining)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b07bbe9d-8343-4507-b147-0554e8289a9a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfBankDebt_72dfdca3-bce7-43da-8bfe-011611a8a1cf_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfBankDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Paycheck Protection Program loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfBankDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfBankDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Bank Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfBankDebt" xlink:to="lab_us-gaap_RepaymentsOfBankDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_cb7e670a-5143-4a2d-a147-831837af7afe_terseLabel_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty obligation, percent of net sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_label_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_documentation_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:href="exdx-20210930.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:to="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_03389bf3-d0e4-4e0d-92f8-3487c6360bd2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_008b07d6-2e31-4ce6-813d-1bd7d3c2919a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_85955f4b-aa9b-4821-a98e-3555e6c75649_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_119bb6ee-5378-4c3c-8e1f-9760b7edced9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_4469ce03-0037-451c-926e-fe4c2b908b40_terseLabel_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, valuation allowance</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_documentation_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:href="exdx-20210930.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:to="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_04461ccb-67f1-4937-9ef5-286e1b7d93ca_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_21bc2238-8742-4905-8809-fd68aaba9fa6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b14f20d2-c974-4720-aca4-3b3e3b445371_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted, Weighted-Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JanssenPromotionAgreementMember_5e803e3f-5c73-42f2-ba8b-19cd17dae8be_terseLabel_en-US" xlink:label="lab_exdx_JanssenPromotionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Promotion Agreement</link:label>
    <link:label id="lab_exdx_JanssenPromotionAgreementMember_label_en-US" xlink:label="lab_exdx_JanssenPromotionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Promotion Agreement [Member]</link:label>
    <link:label id="lab_exdx_JanssenPromotionAgreementMember_documentation_en-US" xlink:label="lab_exdx_JanssenPromotionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Promotion Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenPromotionAgreementMember" xlink:href="exdx-20210930.xsd#exdx_JanssenPromotionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JanssenPromotionAgreementMember" xlink:to="lab_exdx_JanssenPromotionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2207d43a-a1de-4e8e-a3aa-9e13e9d0d103_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7dd013c5-bb47-4843-a304-e5c476a782bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_c1c166d6-68fd-4f31-9e50-3a2f2fbdc433_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b42498a1-43d3-4f32-86bc-6139a44ad2a9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1cfc8b89-d1a9-41a9-ada9-7ca151af3107_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_804a4051-d0fd-4721-9e8c-e773d3942d21_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OperatingLeasesRenewalTerm_5f4a1e7c-cd81-4495-9980-85326d33acc6_terseLabel_en-US" xlink:label="lab_exdx_OperatingLeasesRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_exdx_OperatingLeasesRenewalTerm_label_en-US" xlink:label="lab_exdx_OperatingLeasesRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Renewal Term</link:label>
    <link:label id="lab_exdx_OperatingLeasesRenewalTerm_documentation_en-US" xlink:label="lab_exdx_OperatingLeasesRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeasesRenewalTerm" xlink:href="exdx-20210930.xsd#exdx_OperatingLeasesRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OperatingLeasesRenewalTerm" xlink:to="lab_exdx_OperatingLeasesRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f3f031f3-bb3d-4109-832d-17060601cf38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, June 30, 2021, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_3327dbed-0ff9-48e6-bc23-40860714e2ee_terseLabel_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued purchases of goods and services</link:label>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_label_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase, Goods and Services, Current</link:label>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase, Goods and Services, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:href="exdx-20210930.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:to="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_54e98950-547d-4b58-8714-ebe21218b96f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5327110d-beca-4ae0-bbc4-23ba3d1bc1ad_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_a664bdb0-5564-4d72-a627-7d9edf83bb67_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_7721957c-36e5-4faf-af3b-37bd092ce0e2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at September&#160;30, 2021 and December 31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9a74f762-2422-4ea0-9edb-35138b279916_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ae1ed811-247c-4b7b-b460-280aa35260c5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e67c44d6-4aee-47c8-9778-a959b9125eac_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, June 30, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_374c9be0-7b78-4eff-ad6e-9b34fcb7a07d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7b14c22f-30b8-4302-99f8-71db26694e52_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_8a7980d2-572d-49e8-b4ee-f72fffc64e35_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_ae204792-4681-4e61-b701-f26c23731e73_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_1631d66c-235a-4292-b2cd-e96bfd560a5b_terseLabel_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Domain]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_label_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Domain]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_documentation_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain" xlink:href="exdx-20210930.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RentalPropertyByTypeDomain" xlink:to="lab_exdx_RentalPropertyByTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_ca6f9af1-7efa-4113-b14c-85f8e30e9a2b_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising and Marketing Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_aa3edc6a-ffc8-4803-9463-1ceec571d7ae_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_25c1edd1-1c22-4507-bc04-862b062a1aa6_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, paid in-kind loans issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_label_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:to="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationSep72024Member_a3b27d68-5f4c-464d-b600-6b06ed395e27_terseLabel_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration September 7, 2024</link:label>
    <link:label id="lab_exdx_ExpirationSep72024Member_label_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Sep 7, 2024 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationSep72024Member_documentation_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Sep 7, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member" xlink:href="exdx-20210930.xsd#exdx_ExpirationSep72024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationSep72024Member" xlink:to="lab_exdx_ExpirationSep72024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_aa038eff-72bb-41ce-949c-f6a9ab2b5788_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock in exchange for common stock warrant</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFee_e0e2b6e9-4c0a-4b09-b396-ef439ded8277_terseLabel_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture, quarterly promotion fee</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFee_label_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFee_documentation_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFee" xlink:href="exdx-20210930.xsd#exdx_JointVentureQuarterlyPromotionFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JointVentureQuarterlyPromotionFee" xlink:to="lab_exdx_JointVentureQuarterlyPromotionFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7c0c33ff-8ed1-40d4-b9cd-9ba87dbf8099_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5a009d9e-5c09-4f87-87ca-75de72229ca1_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred, but not paid, in connection with capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_16b11757-07bb-4f73-be75-ebf393597566_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee payroll deduction percentage</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeMember_83670d32-3a08-45d6-891b-490d78bc696f_terseLabel_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office</link:label>
    <link:label id="lab_exdx_OfficeMember_label_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office [Member]</link:label>
    <link:label id="lab_exdx_OfficeMember_documentation_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember" xlink:href="exdx-20210930.xsd#exdx_OfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeMember" xlink:to="lab_exdx_OfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6dc14935-e2fe-4732-b673-1aa4b5d3eaea_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_714dfb13-fa7f-43ed-8195-9bf78faf717c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationMar312026Member_8bc2a662-7a55-43a0-816d-149351b43b8e_terseLabel_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration March 31, 2026</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_label_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Mar 31, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Mar 31, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member" xlink:href="exdx-20210930.xsd#exdx_ExpirationMar312026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationMar312026Member" xlink:to="lab_exdx_ExpirationMar312026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LicenseAgreementInitialLicenseFee_b67a3bb6-90b3-4778-b5a8-15c8c6f1cbae_terseLabel_en-US" xlink:label="lab_exdx_LicenseAgreementInitialLicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial license fee</link:label>
    <link:label id="lab_exdx_LicenseAgreementInitialLicenseFee_label_en-US" xlink:label="lab_exdx_LicenseAgreementInitialLicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial License Fee</link:label>
    <link:label id="lab_exdx_LicenseAgreementInitialLicenseFee_documentation_en-US" xlink:label="lab_exdx_LicenseAgreementInitialLicenseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial License Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementInitialLicenseFee" xlink:href="exdx-20210930.xsd#exdx_LicenseAgreementInitialLicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LicenseAgreementInitialLicenseFee" xlink:to="lab_exdx_LicenseAgreementInitialLicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4db7021c-55f1-4e38-aad1-6d22976ae3c8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_5d4fe34e-8c3d-4af4-a4e0-f01d3b1e8acd_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_fbe99911-740f-486c-8ce1-b6e53a36fa1e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_640f89fc-cad2-4e85-8b93-6c549a4c23a0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2c25cbfa-35e6-43a1-8ed6-269f8ed300fd_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, September &#160;30, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_73aab068-983b-487f-ba43-2b0932e7e17d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7601225c-ac49-4b3b-8451-42b2d57268b5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_0497d8c6-e8fa-420a-8490-6f2f6e67272d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareMember_f8aa7f4b-a2e1-491c-aa80-2d9b7a9c7fc3_terseLabel_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_exdx_MedicareMember_label_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_exdx_MedicareMember_documentation_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember" xlink:href="exdx-20210930.xsd#exdx_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareMember" xlink:to="lab_exdx_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_989206bf-1451-497a-b708-4d656b284443_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3cdcb56c-9038-45a5-a305-094168f0cc51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_3d74b343-4dbf-432c-b5cf-2f0dc78538e8_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_f947df58-f021-44ca-aa66-c3bfdd27e751_terseLabel_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture quarterly promotion fee cap</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_label_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_documentation_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:href="exdx-20210930.xsd#exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:to="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_87714260-72b7-4700-9f1a-0526460d63c1_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid in-kind note</link:label>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_label_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment in Kind (PIK) Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:to="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_40c86967-2fbc-401c-90c6-c276d41447dd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationDec72025Member_909ad1c2-0cf5-4307-8428-281164effd95_terseLabel_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration December 7, 2025</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_label_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Dec 7, 2025 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_documentation_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Dec 7, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member" xlink:href="exdx-20210930.xsd#exdx_ExpirationDec72025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationDec72025Member" xlink:to="lab_exdx_ExpirationDec72025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_7cf48c20-c447-4b81-af32-6d77e0ab7322_negatedLabel_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_label_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_documentation_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:href="exdx-20210930.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:to="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_bbb1475c-409d-431b-8425-05af96bc7f55_terseLabel_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_label_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Benchmark [Member]</link:label>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_documentation_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Benchmark</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember" xlink:href="exdx-20210930.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ReceivableBenchmarkMember" xlink:to="lab_exdx_ReceivableBenchmarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_7cc2a9d4-5547-425b-8207-aadab44991c0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_c0907685-06c1-49aa-8ba4-bffca7f2d8eb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_bf96adbc-8bc8-4552-85f5-0280d3505b72_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total borrowings, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_3b189f28-0eb9-4592-bb81-3b06ef8d4514_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_cf9f2187-d57c-42cb-9bc7-c34a95daeefd_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_UnitedHealthcareMember_f29d67f9-357d-4186-97f1-7331a8aeba0f_terseLabel_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare</link:label>
    <link:label id="lab_exdx_UnitedHealthcareMember_label_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare [Member]</link:label>
    <link:label id="lab_exdx_UnitedHealthcareMember_documentation_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember" xlink:href="exdx-20210930.xsd#exdx_UnitedHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_UnitedHealthcareMember" xlink:to="lab_exdx_UnitedHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_5b87a358-eaf1-4c27-ada4-0a0470566134_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7a39c3cb-65f9-4bd0-ac3f-a3f4e9aec6c8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_EquipmentPurchasedUnderCapitalLease_9ea78f5f-231b-4089-b79f-8f170b679b8a_terseLabel_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment purchased under capital lease obligations</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderCapitalLease_label_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Purchased Under Capital Lease</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderCapitalLease_documentation_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Purchased Under Capital Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderCapitalLease" xlink:href="exdx-20210930.xsd#exdx_EquipmentPurchasedUnderCapitalLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_EquipmentPurchasedUnderCapitalLease" xlink:to="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_b3b52f01-b09e-4901-944c-292774e29379_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of other assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b0add01c-a0c6-4af3-9053-c5d34e3b1427_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_c4e56e82-319b-4982-9587-e76de9e7370d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_e9297db6-47c9-461a-8f57-be5af660a344_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_ebc41680-5fc5-45e2-8aae-6c474da281fc_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash items:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35c60288-1571-4daf-a4db-aba4865d0e79_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_8f22f08e-4d79-4aca-93f1-7b7b90d314c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JointVentureTerminationConsiderationReceivable_34670cfc-83cc-4035-9836-5895fa294c20_terseLabel_en-US" xlink:label="lab_exdx_JointVentureTerminationConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination of agreement</link:label>
    <link:label id="lab_exdx_JointVentureTerminationConsiderationReceivable_label_en-US" xlink:label="lab_exdx_JointVentureTerminationConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Termination, Consideration Receivable</link:label>
    <link:label id="lab_exdx_JointVentureTerminationConsiderationReceivable_documentation_en-US" xlink:label="lab_exdx_JointVentureTerminationConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Termination, Consideration Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureTerminationConsiderationReceivable" xlink:href="exdx-20210930.xsd#exdx_JointVentureTerminationConsiderationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JointVentureTerminationConsiderationReceivable" xlink:to="lab_exdx_JointVentureTerminationConsiderationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_59d661e4-3aa8-42fb-8462-8f7649fe6378_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_79cc0e1e-6f2a-4776-9eec-bbd0ce1d85a0_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d78876fa-cb5c-469e-ae22-cfa86ad7cacb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ae4cbc5c-2409-4ada-a8c3-deb10266e37b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_43446586-cf79-4786-a340-6b689f6e4db0_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum royalty commitment</link:label>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_label_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_7b96f8a7-4e06-436a-b62d-3731646a16f9_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_753198fe-f137-4e05-8270-2413ab5cb67f_terseLabel_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories</link:label>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_label_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories, Inc. [Member]</link:label>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_documentation_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember" xlink:href="exdx-20210930.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrometheusLaboratoriesIncMember" xlink:to="lab_exdx_PrometheusLaboratoriesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_479dc967-dc99-4eb8-adc9-a6c04e038daf_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_419f6f8f-56fb-4ced-8165-551e7b974f3c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_45b5456d-e60f-489f-8581-5f39b392791a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_6bbb2544-23b5-4ffc-9170-5ea8e27766c8_terseLabel_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Award Plan</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_label_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Award Plan, 2019 [Member]</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_documentation_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Award Plan, 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member" xlink:href="exdx-20210930.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncentiveAwardPlan2019Member" xlink:to="lab_exdx_IncentiveAwardPlan2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_541245a5-21c6-4d01-80a0-b154f284ed08_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_c843a058-6b88-4df2-862e-35e7a7e4a2cb_negatedLabel_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_label_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_documentation_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:href="exdx-20210930.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:to="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_acd0980e-456b-461b-a0f6-2825dba2a778_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0604054f-4e75-475a-8b4b-26b2207f3441_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock in public offering, net of issuance costs of $4,435</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_2f39093d-1de9-4c74-af55-77ceebef9336_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_ab5ec09c-874a-4334-bed5-73435b4f7629_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a19fb84d-e854-4e9b-9dc7-987559131451_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidRoyalties_1d707641-7f1d-4947-bc62-c8f7b84020f4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid product royalties</link:label>
    <link:label id="lab_us-gaap_PrepaidRoyalties_label_en-US" xlink:label="lab_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRoyalties" xlink:to="lab_us-gaap_PrepaidRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_0dc31194-ac95-49ec-8ea8-93fe146e5086_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_458f4725-e17f-4ed0-9bb2-6b69a6d9e134_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments_f40979d2-2869-4286-a61d-7b6353a049f4_terseLabel_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Period, Number Of Annual Installments</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments_label_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Period, Number Of Annual Installments</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments_documentation_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Period, Number Of Annual Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments" xlink:href="exdx-20210930.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments" xlink:to="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9ee19a93-0d54-4ded-aa09-83572c27f558_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_b7425fd7-39d3-488a-ba1e-ddc690d3dd1a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of issuance costs related to public offering</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5a0ce1fd-c12e-4d73-9320-444d269f15ca_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock in public offering, net of issuance costs of $4,435 (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_0be169a4-0ec0-4bac-a176-778b5ef1e7dc_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, paid in-kind, interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_label_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:to="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_dd9ad39e-534d-46fa-9ee1-bc64188170ea_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 200,000,000 shares authorized at September&#160;30, 2021 and December 31, 2020; 16,164,232 and 12,652,308 shares issued and outstanding at September&#160;30, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_f6f36a32-cdc9-4345-93cf-466ead66e136_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_169a7288-90c8-428f-b2c3-4a46116fe369_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, cost not yet recognized, remaining weighted average vesting period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39a79da6-8a6d-40e4-8654-f1e7b496a08c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December&#160;31, 2020 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ea37ac39-ea10-4207-90c5-1d81079364d5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, September 30, 2021 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_a7c77ee2-6f4d-47e2-9593-24c8297c7319_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_55a64cc3-0c37-4e69-8a79-37fcef4f3446_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 5)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PaycheckProtectionProgramCARESActMember_5bacdfb9-21af-42b4-81c6-efbbc334c65a_terseLabel_en-US" xlink:label="lab_exdx_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:label id="lab_exdx_PaycheckProtectionProgramCARESActMember_label_en-US" xlink:label="lab_exdx_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act [Member]</link:label>
    <link:label id="lab_exdx_PaycheckProtectionProgramCARESActMember_documentation_en-US" xlink:label="lab_exdx_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PaycheckProtectionProgramCARESActMember" xlink:href="exdx-20210930.xsd#exdx_PaycheckProtectionProgramCARESActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PaycheckProtectionProgramCARESActMember" xlink:to="lab_exdx_PaycheckProtectionProgramCARESActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_9bdb613c-fa5d-4de8-8feb-95cf32160e13_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1cf39029-1920-4587-9de8-58d0b34cca1f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions, Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_ac809978-be8b-4116-8abd-02f2079b021d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_92001301-10bb-4738-a2d3-2e04b1384d33_terseLabel_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid maintenance and insurance contracts</link:label>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_label_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Maintenance and Insurance Contracts</link:label>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_documentation_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Maintenance and Insurance Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:href="exdx-20210930.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:to="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_b185fe42-2711-4980-97e0-75414c1264b4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b4267ed3-30d8-4491-9b34-50609b2d5e4e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_a90ae875-40cb-4826-978f-c99df0b33200_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5d4394ec-942c-4374-bfff-9d17b518cfaf_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ef3ef586-d6b6-41cf-90d4-4108e0e9b50f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c314c80a-6a18-49fc-8ca0-d8df6c753bfb_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_56d37b5a-e132-4993-8e90-b0c6c29611db_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued to purchase redeemable convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ed3e44c9-9b37-4547-b2c4-f285ae6dbf08_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering, net</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_28ad70f7-a59b-4af7-98ba-2ad75009a143_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire intellectual property</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_36b80e34-6820-4aaa-88cf-4e86b992141b_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_80fb733e-6223-4288-ac2b-fdf6330208d3_terseLabel_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, collaboration expenses</link:label>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_label_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Collaboration Expenses</link:label>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_documentation_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Collaboration Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses" xlink:href="exdx-20210930.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CollaborationAgreementCollaborationExpenses" xlink:to="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_444d3e2f-5f51-4766-9c13-edc0920b379f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8d347832-4a38-4747-913e-8e6ed758d9a3_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3a74bfed-ddba-46cb-914b-98584f5e2e93_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_17d84cf8-041f-4d52-8ddd-0476324b635b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_69af2ec7-d274-45aa-ab1d-d610883b6a17_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_HealthcareInsurersMember_39020d2c-910f-4538-82d2-ff553aaceb15_terseLabel_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare insurers</link:label>
    <link:label id="lab_exdx_HealthcareInsurersMember_label_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Insurers [Member]</link:label>
    <link:label id="lab_exdx_HealthcareInsurersMember_documentation_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Insurers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember" xlink:href="exdx-20210930.xsd#exdx_HealthcareInsurersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_HealthcareInsurersMember" xlink:to="lab_exdx_HealthcareInsurersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3b073c9c-8d67-45c9-adf6-00787ee84405_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_6af0ddd5-12fb-49a5-80e3-f65a02426933_terseLabel_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory</link:label>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_label_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory [Member]</link:label>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_documentation_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember" xlink:href="exdx-20210930.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeAndLaboratoryMember" xlink:to="lab_exdx_OfficeAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_05b70562-ceb4-424b-a01b-16aa3c2b01d7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_b2500dfe-3f20-4f01-98c1-642daeec64f7_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReorganizationsAbstract_label_en-US" xlink:label="lab_us-gaap_ReorganizationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reorganizations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReorganizationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReorganizationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReorganizationsAbstract" xlink:to="lab_us-gaap_ReorganizationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_173a7391-41b2-4989-80c0-5f6377f89243_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_650323c6-e5b0-4cc5-90ea-93cd88f595cc_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d7beabb-8a68-4d61-8095-3991c0017d21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_d6287bc4-849d-41f7-b91b-0409437b853f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a33baa66-cfca-4db4-81e6-c4b4e47f3e97_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5f2e458f-7bb8-4a09-aed9-7879a4800cef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6efcdde7-a034-4c5c-9ff2-27722b838669_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ff134e30-81a2-42ec-ac0d-edb940ef95ab_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8ff65aac-1970-4f18-8073-d28a4612015c_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_a92e343b-c947-4a03-9368-fc4c12e2e15d_terseLabel_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of common stock warrants (in shares)</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_label_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_documentation_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:href="exdx-20210930.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:to="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_eea369ca-4d55-417e-ab73-a64c1f713a79_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_90f7b784-2c1a-4c0e-a88d-2fe3f46f5ab7_terseLabel_en-US" xlink:label="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease annual increase in base rent payment percent</link:label>
    <link:label id="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_label_en-US" xlink:label="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Annual Increase In Base Rent Payment, Percent</link:label>
    <link:label id="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_documentation_en-US" xlink:label="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Annual Increase In Base Rent Payment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:href="exdx-20210930.xsd#exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:to="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromBankDebt_9115986f-a807-44c2-b1d5-e177031c7d25_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromBankDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Paycheck Protection Program loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromBankDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromBankDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Bank Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromBankDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromBankDebt" xlink:to="lab_us-gaap_ProceedsFromBankDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7d1038d8-6e44-4184-9c1a-526f2be0ba18_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ca370c71-e1e0-4964-9d9a-94b214bbc737_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2206b1a7-8480-4f1f-a70c-a07b3ac5f8c4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares to be called upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_cadb920a-a1cc-412e-94bc-801f4e67b304_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_83b383c3-0307-48be-8d0c-fef65a67b854_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_50df1650-dce8-4d98-8543-a8e75c71227e_terseLabel_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:href="exdx-20210930.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:to="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription_0280bd23-f988-43ed-808c-ac74add2237e_terseLabel_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture, quarterly promotion fee per prescription</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription_label_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee Per Prescription</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription_documentation_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee Per Prescription</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:href="exdx-20210930.xsd#exdx_JointVentureQuarterlyPromotionFeePerPrescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:to="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_420f9bdc-2db1-4b68-b9dc-4e47ec1da954_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock in exchange for common stock warrant (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_36e4a696-91ae-4cbd-b12f-6338d97a3968_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b7982b41-3c47-4c31-88f0-200db3752d22_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_36cc2b8a-adf4-4222-9684-2315a0a2f9b4_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_af8ca1ce-c230-4f06-8d9e-6ac06acc438b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_554fe07f-3c96-4cc6-aac7-ff9f5e26686d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ea76d7db-ad85-4dea-85d1-b058336b916f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_642ffae3-50c4-4905-88ef-742fcbde0808_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_5abe2971-cdec-4214-8b0d-02dec7e52473_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised, June 30, 2021, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_13d1e000-81b1-4183-9f2a-c3d8833e73d7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6d02d8a3-d9f1-48e2-adf5-5232a325323f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_10d7b656-d2fe-43ef-8efa-752b090d29e1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_454f6fce-2e2b-4aa1-99a6-baf26c66dcfb_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_91ee3e4e-c326-49bf-a085-4a0d0041694c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_2fc1787a-4474-49a9-a7a9-43817b3ada30_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0fc6dc52-2a0f-43f5-8b4c-7d08f37f53ad_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_a5c1c3d6-ac09-4a07-bdec-9af1630b12e1_terseLabel_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegheny Health Network Research Institute</link:label>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_label_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegheny Health Network Research Institute [Member]</link:label>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_documentation_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegheny Health Network Research Institute</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:href="exdx-20210930.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:to="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7e782992-7b43-43b8-913b-4eff1599967d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e316c128-31c7-47d1-86ce-98fbe4caab70_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_35f6bfc4-e66f-460a-81f0-55b9ebb498cc_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risk and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_232a1ae4-b20b-47c1-9f79-2c88978cba63_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_e86617dd-efdb-40e6-b16a-0ea8f93e56d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_c04d26d2-588b-41ce-b348-804578170900_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Term2017Member_4984eb0d-521f-4426-87c8-cf313eaaa6c8_terseLabel_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Term loan</link:label>
    <link:label id="lab_exdx_Term2017Member_label_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term 2017 [Member]</link:label>
    <link:label id="lab_exdx_Term2017Member_documentation_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member" xlink:href="exdx-20210930.xsd#exdx_Term2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Term2017Member" xlink:to="lab_exdx_Term2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_366248dc-d066-4ae4-9ec4-706cbc1c90c8_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7369b9a7-5e8d-4e52-81ea-610781a9a8b5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_be11fea6-75fd-47f9-aa81-64f8b6ce1473_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e61908ab-a6ed-4041-9257-fd473e88f4e0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0e4a564f-2dc7-43e3-af08-3a6c21f4787a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c53ef080-f329-48ef-b988-ae68b7625fe9_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeSpaceMember_5d67cf31-8bf6-46db-bb4a-bc2ce7681936_terseLabel_en-US" xlink:label="lab_exdx_OfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space</link:label>
    <link:label id="lab_exdx_OfficeSpaceMember_label_en-US" xlink:label="lab_exdx_OfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space [Member]</link:label>
    <link:label id="lab_exdx_OfficeSpaceMember_documentation_en-US" xlink:label="lab_exdx_OfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeSpaceMember" xlink:href="exdx-20210930.xsd#exdx_OfficeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeSpaceMember" xlink:to="lab_exdx_OfficeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3899e6b3-2b14-44b4-92b9-2a5b15f952f4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1b293480-7157-4523-a644-738375cc5637_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_09476d29-b181-48ca-9c25-49973fb6d065_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_1f44bcfa-316e-456d-bb4b-85644df5ca1c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_997d5f82-b0cf-4f3e-9a48-70ce3fcd19bc_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AssetsUnderCapitalLeaseMember_bdddca54-f716-4232-b37f-8c080230fbde_terseLabel_en-US" xlink:label="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets under capital lease</link:label>
    <link:label id="lab_exdx_AssetsUnderCapitalLeaseMember_label_en-US" xlink:label="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Under Capital Lease [Member]</link:label>
    <link:label id="lab_exdx_AssetsUnderCapitalLeaseMember_documentation_en-US" xlink:label="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Under Capital Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AssetsUnderCapitalLeaseMember" xlink:href="exdx-20210930.xsd#exdx_AssetsUnderCapitalLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AssetsUnderCapitalLeaseMember" xlink:to="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bcc93b78-6918-483e-85ad-330a779021ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_18234f54-2f15-4eed-b8c0-67f3aa75e047_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_bd5215e5-e479-43e7-bdd4-af40bf2ff893_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0bb86b67-443e-4cdc-82f0-97e46ce9208f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_50f36634-5daf-4304-bc34-be0da713bad3_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_36508696-0a5a-4b53-9acb-cd1ad793348f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_05d5acb9-b663-48df-bc0f-b553a7ca2135_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9c91181e-7b59-4f3f-b5e5-6a81ac228541_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3d8a5dcf-3ba4-40c2-8275-d08dc5e4299d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_68f22fd2-663f-432b-8cf6-3b488c7a9330_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2614e81d-c455-4694-b406-a5916bd1e632_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_21385b15-ead0-4fbb-bff7-2a43bf96eb35_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ab0e8bce-1a19-48cd-ace5-bf7ad3d48f83_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_65088bff-b825-48b5-a8ff-3f5a0ddf9e30_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_ce770962-44c7-44fa-9809-ffd17f7e3c2b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_955d5e9e-45b7-4978-ab6f-f3d51582aec0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3180cea8-d19a-40ad-b7e2-d6ac3b980bff_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_e93f66d9-418e-4d52-8387-642dcc6e1337_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, to be paid remainder of fiscal year</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_5c5f2882-599a-48b3-96db-5d4993aa06d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e27a3ed9-6961-4423-9b24-35cdf12e53a3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_4ca46e47-8f87-49fd-91e1-6ff5e98320fd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock warrant in exchange for retirement of common stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_8c5fb23a-2f58-4c2c-a47f-ac0589aedbf6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_242de2e3-252f-4c31-b812-323471475b2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_b5145445-ce0c-4709-a873-8e5ab87a18da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_5413098e-5fea-4f94-84e3-219bbe315f4a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0cb9b67d-2039-46d2-a3a4-20e83a1e0944_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_23ee5186-c5fb-4f59-b30d-14a818635f3d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5ad9df4c-d2e1-4219-8a4b-79da9a1b2fce_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d7fe5ce8-1ab4-4744-849d-bdae6fc2c644_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_96ff20d4-5a09-4000-b432-54f2b280cf7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_9fd0b7de-1ebd-4cf1-93cb-f907dac20dd3_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6c46b346-1d16-48d0-9015-f46ba9c9c5ce_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AHNCollaborationMember_61c638fb-d321-43ea-9db1-94b3508f2e7b_terseLabel_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHN Collaboration</link:label>
    <link:label id="lab_exdx_AHNCollaborationMember_label_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHN Collaboration [Member]</link:label>
    <link:label id="lab_exdx_AHNCollaborationMember_documentation_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHN Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember" xlink:href="exdx-20210930.xsd#exdx_AHNCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AHNCollaborationMember" xlink:to="lab_exdx_AHNCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_2620009d-839c-4e4f-b179-3e1c78d0e5fa_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_814389e0-9af9-4a2b-b7f0-691ef2e981f6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5aff21b1-6325-4019-a50a-a701bb55b3ed_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_ee4f231e-09fa-4f64-b63e-2839f76d5d57_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_7d39f401-fea4-455a-b8a0-6bc995956860_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsCurrent_f50541af-e713-4bb5-8185-d0af912fe9a2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital lease obligations, current portion</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Lease Obligations, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_CapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e8d760d4-36bb-44f0-bd3a-3a393195a9d8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f6794373-bf39-4124-a36b-e802b953fb53_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CapitalRoyaltyPartnersIILPMember_460fe882-bf35-4e6a-b977-bffed904cdb5_terseLabel_en-US" xlink:label="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Royalty Partners II LP</link:label>
    <link:label id="lab_exdx_CapitalRoyaltyPartnersIILPMember_label_en-US" xlink:label="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Royalty Partners II LP [Member]</link:label>
    <link:label id="lab_exdx_CapitalRoyaltyPartnersIILPMember_documentation_en-US" xlink:label="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Royalty Partners II LP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CapitalRoyaltyPartnersIILPMember" xlink:href="exdx-20210930.xsd#exdx_CapitalRoyaltyPartnersIILPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CapitalRoyaltyPartnersIILPMember" xlink:to="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_7912d420-7581-4db5-b160-5599178bc9b6_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan covenant, minimum unrestricted cash balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:to="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_c6a9d74f-4e33-4ec5-b04a-13f3a0cf29d7_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b8b6ab26-78bc-4899-a797-983042eb4b09_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_84362375-99ce-4cc0-ac3a-bb8de0e66913_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6a47233b-317a-4544-9537-6abe7c04e1c0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_HeadquartersMember_49c4c36b-6a4c-40a3-b0c8-e706994ba709_terseLabel_en-US" xlink:label="lab_exdx_HeadquartersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters</link:label>
    <link:label id="lab_exdx_HeadquartersMember_label_en-US" xlink:label="lab_exdx_HeadquartersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters [Member]</link:label>
    <link:label id="lab_exdx_HeadquartersMember_documentation_en-US" xlink:label="lab_exdx_HeadquartersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HeadquartersMember" xlink:href="exdx-20210930.xsd#exdx_HeadquartersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_HeadquartersMember" xlink:to="lab_exdx_HeadquartersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TwoMajorSuppliersMember_4cc81735-5dd4-40d4-a7ad-4a97f18c9886_terseLabel_en-US" xlink:label="lab_exdx_TwoMajorSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Major Suppliers</link:label>
    <link:label id="lab_exdx_TwoMajorSuppliersMember_label_en-US" xlink:label="lab_exdx_TwoMajorSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Major Suppliers [Member]</link:label>
    <link:label id="lab_exdx_TwoMajorSuppliersMember_documentation_en-US" xlink:label="lab_exdx_TwoMajorSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Major Suppliers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TwoMajorSuppliersMember" xlink:href="exdx-20210930.xsd#exdx_TwoMajorSuppliersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TwoMajorSuppliersMember" xlink:to="lab_exdx_TwoMajorSuppliersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_701242d5-c5f7-46c5-9314-b09f77da3e4c_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_1df8f3e3-196b-4da4-9f5a-4f462154647f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Government1Member_7717d326-35f7-4531-81b1-f076ce8828db_terseLabel_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government</link:label>
    <link:label id="lab_exdx_Government1Member_label_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government1 [Member]</link:label>
    <link:label id="lab_exdx_Government1Member_documentation_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member" xlink:href="exdx-20210930.xsd#exdx_Government1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Government1Member" xlink:to="lab_exdx_Government1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80affa59-0fd4-4c53-bacf-c2f0d3dc3dcb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d1b1c264-44bb-4507-893b-9ffa705d2ff5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8a5d6ffe-7010-4f24-85da-11d62b515b28_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_127aa10b-9021-420b-a654-5d50e51f6e2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-cash Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_77fc70f0-c400-40b5-a258-a4c4e49ac508_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of common stock in public offering, gross</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c27039c2-a888-4713-b505-9a45ba50adae_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_94af659c-5262-4140-824d-d95b84887fa2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_881af24c-2051-447c-8c1f-f859feceb859_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_4693d358-de5e-447d-94a8-20977a322188_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_3a1b2609-b107-4479-b3bc-56460360daa4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest expense</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ee3023d3-507d-46e4-8ef5-1f6795859999_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_fd6350b7-1cdc-4d7e-b634-31f59a3b91bd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_79a0c1be-0dda-41c7-9001-9b4613f28c75_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_75240bda-0465-4b53-a36a-16c84fa6f6e4_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_d775b8d5-64fc-4602-b165-2c7e76ce44a0_terseLabel_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_label_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:href="exdx-20210930.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:to="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb96bcc9-229b-441e-9b30-998591570c29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_167084f6-9fb5-4860-912e-5bce249d23d6_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a92ba64c-bd79-457f-823b-a7fdbbc960c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d05f779f-89dc-4223-8d24-9e2235819d3d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_4cfe94b9-2b10-4611-b23e-5d60a526d67d_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture&#160;and&#160;fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_90111827-bfa2-4eeb-9ca0-3dc22b7ff038_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_54f3f2a8-388f-460e-9656-7cc16a74bd70_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_4dbf4f0c-dcaa-46cc-b8b6-d937b740a94b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_5c8eeec1-f648-4b82-af26-d5264a7796d8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, fee incurred upon payment of final installment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a4923e02-8ad8-46c5-b992-92fc1272a6b6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used to compute net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1553d8ef-86e9-41db-a51b-0e81047a2665_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8f9856f6-6676-4cdf-a2f3-2fa6bd4ef7dc_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_464a8282-2f1b-4f3d-86bc-fb3d34e18869_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in public offering, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareAdvantageMember_427f8820-cec7-4a04-88dc-b82cd36125b1_verboseLabel_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_label_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_documentation_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember" xlink:href="exdx-20210930.xsd#exdx_MedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareAdvantageMember" xlink:to="lab_exdx_MedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_3da606fe-8f39-4c1f-9831-c25d13a4abfb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_a1e35397-020b-41cf-867f-dff38f720598_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bdec7271-a41f-41c5-8178-df4e1e181a98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_3d87c0d9-b0b1-467f-be0a-cef9b5a3ca2a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_4407982c-8212-403d-b83f-a4940f8a054d_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, prepayment premium percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_label_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:to="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3bca5d0-82eb-49e8-8c1f-66e73fcef6c3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_b672e803-0fae-4018-bb56-324a1b805a88_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_916ddf8e-1175-4322-aad6-c381ef8c3f24_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a23fa2c9-c8cd-4b6e-abb5-f839125919d4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ade691fb-a1d4-4af6-8727-fb1c0c62466c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ProceedsFromGovernmentAssistance_87c3d9d8-cf8d-4114-8079-50e7a43f1c93_terseLabel_en-US" xlink:label="lab_exdx_ProceedsFromGovernmentAssistance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from government assistance</link:label>
    <link:label id="lab_exdx_ProceedsFromGovernmentAssistance_label_en-US" xlink:label="lab_exdx_ProceedsFromGovernmentAssistance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Government Assistance</link:label>
    <link:label id="lab_exdx_ProceedsFromGovernmentAssistance_documentation_en-US" xlink:label="lab_exdx_ProceedsFromGovernmentAssistance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Government Assistance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ProceedsFromGovernmentAssistance" xlink:href="exdx-20210930.xsd#exdx_ProceedsFromGovernmentAssistance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ProceedsFromGovernmentAssistance" xlink:to="lab_exdx_ProceedsFromGovernmentAssistance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ebc0488d-28c4-4190-bd7e-19f4b3ee5d8a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_08a61f8a-502f-4367-8be7-ae18e18679d0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a0dd19b3-ad5b-43b6-8df0-29f052ad4839_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_852ab745-36c6-4d86-a8b2-bbc9a0c56b9c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_03efe321-6ed5-40eb-a3f9-017213148f4a_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdvancePayment_93cedd28-3485-482c-9ebf-f750f4f1b5b5_terseLabel_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance royalties payment</link:label>
    <link:label id="lab_exdx_AdvancePayment_label_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payment</link:label>
    <link:label id="lab_exdx_AdvancePayment_documentation_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment" xlink:href="exdx-20210930.xsd#exdx_AdvancePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdvancePayment" xlink:to="lab_exdx_AdvancePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_5a6a8f5f-8e86-4938-a6b1-b787c00c588e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5b00273b-2645-46f2-a500-a84694c2861b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_97bc1c3a-2d9e-456d-bdbb-67f70fb1f202_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_08b15dbd-d550-4075-8dc2-a4eaf441ac83_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f9969564-3a8c-4ff6-8086-4a9796c68f89_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4513cd1d-784c-4ab2-8fbc-c20594f42e46_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d82247a2-bded-47e1-9b91-14eabe69b399_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_cd2ff88b-c8ef-4225-b251-2a0c534fa432_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk</link:label>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_f1631f57-12ad-4905-8906-74ec20a35a14_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, percentage of ownership after transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_09d15ac0-e393-45b9-a2ca-b072722cfdc2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JanssenSIMPONIMember_8b01df2b-9818-40d4-aedb-88da83a82c1d_terseLabel_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI)</link:label>
    <link:label id="lab_exdx_JanssenSIMPONIMember_label_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI) [Member]</link:label>
    <link:label id="lab_exdx_JanssenSIMPONIMember_documentation_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember" xlink:href="exdx-20210930.xsd#exdx_JanssenSIMPONIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JanssenSIMPONIMember" xlink:to="lab_exdx_JanssenSIMPONIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_c5de54d5-9cf4-4189-a473-6d9366d15f5b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_82bc89da-91aa-43f7-a55a-29921a4d5b6c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_b7c1484b-0f96-4141-ba96-2d067d6fab2a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AVISECTDTestMember_25483281-faa1-4224-8faf-f4cecea9c319_terseLabel_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_label_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test [Member]</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_documentation_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember" xlink:href="exdx-20210930.xsd#exdx_AVISECTDTestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AVISECTDTestMember" xlink:to="lab_exdx_AVISECTDTestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_922d994f-2ede-46a7-b4d8-646bc2bda159_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_15c48403-7916-414e-9155-d068c0bcb798_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_380c5de6-0919-462a-998e-51784dea38ab_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_541c24b7-1b52-432a-acb7-1d3d133bb293_terseLabel_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember" xlink:href="exdx-20210930.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LaboratoryEquipmentMember" xlink:to="lab_exdx_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_82146a44-0d03-4ff9-9e91-a3289fbb6405_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_7f62e5a6-f730-4ead-8380-3421d60d7d1b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationJan192026Member_6009e452-cad6-4c1b-a67e-96f28a7d7bbe_terseLabel_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration January 19, 2026</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_label_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Jan 19, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Jan 19, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member" xlink:href="exdx-20210930.xsd#exdx_ExpirationJan192026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationJan192026Member" xlink:to="lab_exdx_ExpirationJan192026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_02e17b40-9f58-4035-bdfa-08fc9ee0c054_terseLabel_en-US" xlink:label="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised (in shares)</link:label>
    <link:label id="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_label_en-US" xlink:label="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number Of Warrants Exercised</link:label>
    <link:label id="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number Of Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:href="exdx-20210930.xsd#exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:to="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_9a63c93a-7473-46b1-a448-4434d589b980_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_daa5d6c4-fc69-4f4f-9698-2f2348cf54a8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_df1237c9-eaff-4824-8b0e-66d834cc8ad8_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_2b803475-965b-4ebb-8226-b6978946e362_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_f5315a01-07f2-43be-b1fc-45be27c40ead_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_05f769e8-35ac-4ce7-99de-17e3abf664ec_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_25b812c7-ab30-4dca-8d09-9d3f6a39e36e_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan repayment</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_d942da7f-34d2-4107-9051-cd84643c0599_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_9a0161c7-0dc9-4e1f-a59d-f65457d7352c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_e526ad32-4f55-485b-bac2-860cca20a5f3_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_509ed791-878c-4169-835f-c1cc5a8bac79_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, annual reduction in prepayment penalty percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_label_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage, Annual Reduction</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage, Annual Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:to="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_8c442983-4cfe-4b8b-8110-89c638ac38cb_terseLabel_en-US" xlink:label="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares exchanged for warrants (in shares)</link:label>
    <link:label id="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_label_en-US" xlink:label="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Agreement, Number Of Shares Exchanged For Warrants</link:label>
    <link:label id="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_documentation_en-US" xlink:label="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Agreement, Number Of Shares Exchanged For Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:href="exdx-20210930.xsd#exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:to="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_e09eaf19-102f-4a1e-a799-a2eab8eec408_terseLabel_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical study activity</link:label>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_label_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Clinical Study, Current</link:label>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Clinical Study, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:href="exdx-20210930.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:to="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_4cd17b22-982d-4231-9ab6-87cd36ffc0a2_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3ad0255b-cb2a-4c30-a724-0ec822b430c1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_95d5b655-311d-4e04-8367-48b0c70e28d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, June 30, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_39763632-ad04-45b2-9f7c-e5f987acce5c_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan covenant, increase to interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:to="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2bcc1255-1bbf-438c-875f-857a42d1e1cd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2020, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7c837148-c92f-4689-babe-abff67cfb39e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, June 30, 2021, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_2ad4b40d-b97c-40b4-8a78-c306aca89644_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5fb36021-2437-4fd1-942b-854c9bf19d21_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_d9873da8-5e17-4a7e-81ad-7043d93c026b_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_e71a010e-dc19-4d8e-a2cd-fb51dfa15d3c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings-non-current portion, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_NoExpirationMember_86737ce6-6fd7-4948-8d53-886c46e71e9c_terseLabel_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No expiration</link:label>
    <link:label id="lab_exdx_NoExpirationMember_label_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No expiration [Member]</link:label>
    <link:label id="lab_exdx_NoExpirationMember_documentation_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember" xlink:href="exdx-20210930.xsd#exdx_NoExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_NoExpirationMember" xlink:to="lab_exdx_NoExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExchangingStockholdersMember_496e50c9-fb44-45e9-8129-f3969a2a3af2_terseLabel_en-US" xlink:label="lab_exdx_ExchangingStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchanging Stockholders</link:label>
    <link:label id="lab_exdx_ExchangingStockholdersMember_label_en-US" xlink:label="lab_exdx_ExchangingStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchanging Stockholders [Member]</link:label>
    <link:label id="lab_exdx_ExchangingStockholdersMember_documentation_en-US" xlink:label="lab_exdx_ExchangingStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchanging Stockholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangingStockholdersMember" xlink:href="exdx-20210930.xsd#exdx_ExchangingStockholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExchangingStockholdersMember" xlink:to="lab_exdx_ExchangingStockholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ae759a08-d5db-4d60-a11b-dbd065198a13_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClientMember_165d2fac-3da3-40eb-b011-b50fb0f4d190_terseLabel_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client</link:label>
    <link:label id="lab_exdx_ClientMember_label_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client [Member]</link:label>
    <link:label id="lab_exdx_ClientMember_documentation_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember" xlink:href="exdx-20210930.xsd#exdx_ClientMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClientMember" xlink:to="lab_exdx_ClientMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_b7ba6b92-12c1-4d7e-8fff-1a05195d6cdc_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling Costs</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_38ac4202-8358-4fe7-889c-e13e10b9ac6b_terseLabel_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, income tax benefit</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_label_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_documentation_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:href="exdx-20210930.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:to="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_678954c7-5940-4889-8cc6-48256c5063f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b9c0c803-a3b5-4a0d-82ea-36964f88f277_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5a0f5650-0b19-454e-8433-112c94270f8f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_323e4170-16db-4158-b4da-0de7765fa0fe_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_3c7fbeb9-43f7-4323-8ffd-2075eb20ceba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_7ddbfead-186e-4348-85e2-77ce9d75f5f5_terseLabel_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in purchase commitments</link:label>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_label_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Annual Increase In Commitment, Percentage</link:label>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_documentation_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Annual Increase In Commitment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:href="exdx-20210930.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:to="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_bb7c4fd9-a9cf-40b7-ace5-41f1de3247c1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_8ef8fef5-915b-4fcc-ae95-4a4db536e2d6_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1fdfcd19-0490-4754-a7f6-03f4ddf96d5c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_71584ac0-1c05-45b4-b4fa-880bf394a283_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a9b3041-d721-49d6-b761-a8641c8254f0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0bf11761-b045-4464-a52e-aade25669215_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OperatingLeaseMonthlyBaseRent_a7dd8053-60a9-46d8-95ba-ba43628a1321_terseLabel_en-US" xlink:label="lab_exdx_OperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease monthly base rent</link:label>
    <link:label id="lab_exdx_OperatingLeaseMonthlyBaseRent_label_en-US" xlink:label="lab_exdx_OperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Base Rent</link:label>
    <link:label id="lab_exdx_OperatingLeaseMonthlyBaseRent_documentation_en-US" xlink:label="lab_exdx_OperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRent" xlink:href="exdx-20210930.xsd#exdx_OperatingLeaseMonthlyBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OperatingLeaseMonthlyBaseRent" xlink:to="lab_exdx_OperatingLeaseMonthlyBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c55120ca-feb4-4eee-ab7c-5f9d07b55f79_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredOfferingCostsReclassifiedToEquity_dad26e0e-eb6e-4848-a923-1bbdfab3870f_terseLabel_en-US" xlink:label="lab_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs reclassified to equity</link:label>
    <link:label id="lab_exdx_DeferredOfferingCostsReclassifiedToEquity_label_en-US" xlink:label="lab_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Reclassified to Equity</link:label>
    <link:label id="lab_exdx_DeferredOfferingCostsReclassifiedToEquity_documentation_en-US" xlink:label="lab_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Reclassified to Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:href="exdx-20210930.xsd#exdx_DeferredOfferingCostsReclassifiedToEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:to="lab_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_061a33bb-c046-4fb7-bc00-3f6d26b4e58a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_f02c4fee-89b0-4af6-8886-4eb3155d4c46_totalLabel_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_label_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_documentation_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:href="exdx-20210930.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:to="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_8fff0aef-bda5-4d2c-8205-8cff9d4bb1b0_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b0134a56-0a61-4485-a773-5597ef2b64eb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_65621b7d-2fcd-4550-acf0-49f1746eb408_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_39603970-ca42-4795-b025-3998a744b48e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_7affa92e-54f2-4694-b916-4ace3c82cbc8_terseLabel_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration fee</link:label>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_label_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Annual Collaboration Fee</link:label>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_documentation_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Annual Collaboration Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:href="exdx-20210930.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:to="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract" xlink:href="exdx-20210930.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OtherFinancialInformationAbstract" xlink:to="lab_exdx_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_247d330d-f1c3-4868-a11f-af13a8ef862f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_30aac2cf-594b-45a1-ba8b-5281583bc6e8_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payment on capital lease obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fed7e0ad-b680-45dc-b9e0-3044e306b9a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_73b4bf96-4f0c-4323-acfc-46a5a7adb49a_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_3062e280-9a4a-4682-b33e-ebe17a70b662_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, due in year one</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c4722419-b2d0-46eb-898d-a7a7eb4fd4c5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used to compute net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_df521b38-468d-4cc6-b05a-4ca72345845e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_ab557205-b48d-4d57-a869-b12f9e8262e2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_da5f48cd-a688-4b45-901c-507d2126478e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_36a5f445-39f1-4e74-a24f-a53b2e9a2085_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0e8546ba-55e6-48fa-af58-95ced0449642_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_df730aad-dbe6-4f18-a55a-f87d86dce8cf_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OperatingLeaseTermOfContract_398cdc02-ac74-4a65-b473-070b2c05a12f_terseLabel_en-US" xlink:label="lab_exdx_OperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_exdx_OperatingLeaseTermOfContract_label_en-US" xlink:label="lab_exdx_OperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Term of Contract</link:label>
    <link:label id="lab_exdx_OperatingLeaseTermOfContract_documentation_en-US" xlink:label="lab_exdx_OperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseTermOfContract" xlink:href="exdx-20210930.xsd#exdx_OperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OperatingLeaseTermOfContract" xlink:to="lab_exdx_OperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b2253271-45b4-4dac-a85d-2a740763e327_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8fe3bfba-2259-4884-ab35-1da1fef2251c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_10ea0c46-0da5-4c15-97eb-7000e0edaf35_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_99775ca3-a096-4700-85bf-ec0e87b6936c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, June 30, 2021 (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_d5a8ce05-1536-4b75-b056-d7247ad1d940_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2181d37f-9be8-430d-84eb-bd182c39a6d1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8f406f01-7d49-4a71-a376-d3fb0a65f3be_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e3e6957b-7dd7-4620-85dc-fbe69c51b78e_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_478260f2-cfc3-4fa5-9642-13554691df33_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_ee414305-5d1f-4b91-b31a-0121fc95962b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses table</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d93714f3-3220-41b9-a2db-3165039b7d39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards released, Weighted-Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCustomerMember_8ff8bf3c-2478-454b-858c-a395dd09fc4e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherCustomerMember_label_en-US" xlink:label="lab_us-gaap_OtherCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCustomerMember" xlink:to="lab_us-gaap_OtherCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6f0cf04a-7573-44da-91b5-19e30dcea316_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e5bf46f2-9f12-46d1-98de-397e32c1798e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_45b678ea-161e-4528-affc-13fddd6479d0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_ea4bd172-42b6-4e19-9180-51a1b31471cf_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_8f0415f0-ecec-41ac-b6c4-42a569778078_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a7d5c661-3b6d-41e1-a973-672411514bbe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e4b835a0-ff44-46bc-81c6-6eb93fbd41a2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b55a3a8c-965a-479e-ab6b-0e082437f1da_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationApr12026Member_4dbf1070-50ea-4baf-89ad-4e214ce2a86b_terseLabel_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration April 1, 2026</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_label_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Apr 1, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Apr 1, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member" xlink:href="exdx-20210930.xsd#exdx_ExpirationApr12026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationApr12026Member" xlink:to="lab_exdx_ExpirationApr12026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_4cfef172-5b3f-4b38-b0bb-e7c4caeff9cd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d1badfb3-4ff0-477f-8d45-124f77892012_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_7aa6fa2c-3f8f-4773-a248-efc02b80d39f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic&#160;testing&#160;supplies</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_782852dc-ce0a-466e-a004-2b45b93fc2b5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock issued under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e86796de-b8a5-4418-8468-c864fc21863c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_bcc055fc-544d-4b3a-8e41-47d646ea35fa_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_de9d63a2-62b8-4afc-b7cc-f92ac375047d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted, Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0682fc4f-3760-469d-9e30-49579e7b23a0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3e4cf7e4-1ce9-426c-a612-4a63edaf47fa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuanceCosts_9290374d-e3ed-4dc1-9074-02a54b472007_verboseLabel_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_exdx_StockIssuanceCosts_8707d752-1fc7-4330-abc7-145c6a6b2157_terseLabel_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated offering expenses for aggregate expenses</link:label>
    <link:label id="lab_exdx_StockIssuanceCosts_label_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:label id="lab_exdx_StockIssuanceCosts_documentation_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts" xlink:href="exdx-20210930.xsd#exdx_StockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuanceCosts" xlink:to="lab_exdx_StockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_a9c1456c-7c89-4167-9552-759b6224cc53_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_95a034da-507b-4edd-871c-819a8b09fb01_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_8a482bea-5d05-4206-9110-963097e0aa00_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_8e62b6ae-2d0d-48e4-bdfd-c966b212a821_terseLabel_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of common stock warrants</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_label_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Net</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_documentation_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:href="exdx-20210930.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:to="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_86690cac-e17e-48c2-98db-5fd4021f44f5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0115d536-5993-47fc-9511-16c81a6f09f0_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_9624555e-0983-4d6a-8254-4f94a8283c47_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_55ce2612-a060-48b5-92e8-fb1226b4113d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_066c15e2-f23c-4e37-93e7-4b097ca93d7a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_6b593542-0dbd-41b3-9a63-7f91fbebc03a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions, Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_43849f44-5138-4c52-8b23-37d4f9631fde_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0d152e55-bd5a-4a64-a289-f2b30ae476f6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>exdx-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:c5a0a3fb-3fff-4206-b83d-31088152a01e,g:78c7fea5-b4e3-40b0-a9a0-b197701560e9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/Cover" xlink:type="simple" xlink:href="exdx-20210930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_870a7502-7529-4139-b080-5b41686e4e44" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_DocumentType_870a7502-7529-4139-b080-5b41686e4e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_93313481-c37e-4eb9-adc4-2b823b34d16d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_DocumentQuarterlyReport_93313481-c37e-4eb9-adc4-2b823b34d16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fbad76db-0bf7-4fd0-8fa5-f0d3c25a8ffa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_DocumentPeriodEndDate_fbad76db-0bf7-4fd0-8fa5-f0d3c25a8ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e1eb50dc-7bb7-442b-9532-fd74db4f6f04" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_DocumentTransitionReport_e1eb50dc-7bb7-442b-9532-fd74db4f6f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b5bb8f74-8db0-42a1-8649-a0f380131a7f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntityFileNumber_b5bb8f74-8db0-42a1-8649-a0f380131a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6e3257ab-7ceb-4faa-bad6-ba724ac763dd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntityRegistrantName_6e3257ab-7ceb-4faa-bad6-ba724ac763dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a70d072a-877a-4d80-b9e5-cd101a1c99e8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a70d072a-877a-4d80-b9e5-cd101a1c99e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_18901660-7dce-4c1f-9029-6ab15ded8ba6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntityTaxIdentificationNumber_18901660-7dce-4c1f-9029-6ab15ded8ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_950af8bd-c49a-4412-9068-afb10c71d4e3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntityAddressAddressLine1_950af8bd-c49a-4412-9068-afb10c71d4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f333aa70-528c-4ebe-ac3b-1c881466001e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntityAddressCityOrTown_f333aa70-528c-4ebe-ac3b-1c881466001e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a9d0694b-7d7d-4633-ada9-c2043f8a29ac" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntityAddressStateOrProvince_a9d0694b-7d7d-4633-ada9-c2043f8a29ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6af5e478-fb9c-4b12-83ba-4ec5cfe878de" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntityAddressPostalZipCode_6af5e478-fb9c-4b12-83ba-4ec5cfe878de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f8e397bb-de62-40ab-8970-004e87fb5565" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_CityAreaCode_f8e397bb-de62-40ab-8970-004e87fb5565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_441859dd-85e6-43e9-afe9-b60f2f382b8b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_LocalPhoneNumber_441859dd-85e6-43e9-afe9-b60f2f382b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4cccb98c-c1c4-45ca-a963-b7d7f70eeb80" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_Security12bTitle_4cccb98c-c1c4-45ca-a963-b7d7f70eeb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7e1c0240-656c-4455-96a9-453e019abd7f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_TradingSymbol_7e1c0240-656c-4455-96a9-453e019abd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_bdc8adfe-3ad3-487b-a6af-445f785d6d89" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_SecurityExchangeName_bdc8adfe-3ad3-487b-a6af-445f785d6d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d09208ce-6d6e-45f8-a763-040b58f904ed" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntityCurrentReportingStatus_d09208ce-6d6e-45f8-a763-040b58f904ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0763ffbe-0b43-4d29-8c7c-8b8805fa69bb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntityInteractiveDataCurrent_0763ffbe-0b43-4d29-8c7c-8b8805fa69bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0f90b7cf-4253-4fb8-8236-7100f9b26f66" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntityFilerCategory_0f90b7cf-4253-4fb8-8236-7100f9b26f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_61fd6745-09dd-4efd-9390-a494e7d236aa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntitySmallBusiness_61fd6745-09dd-4efd-9390-a494e7d236aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_21afaaec-6abe-44a2-ad69-805cb1e3a62d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntityEmergingGrowthCompany_21afaaec-6abe-44a2-ad69-805cb1e3a62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_e481ad70-9080-479b-aa8b-e63597694fef" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntityExTransitionPeriod_e481ad70-9080-479b-aa8b-e63597694fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3e04e6c1-7396-4c29-bb2c-e9f279166c8f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntityShellCompany_3e04e6c1-7396-4c29-bb2c-e9f279166c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_25fdc6ae-6578-4088-a112-2cf20792d479" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_25fdc6ae-6578-4088-a112-2cf20792d479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b939948a-f039-4eb4-973b-534f35247ae0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_EntityCentralIndexKey_b939948a-f039-4eb4-973b-534f35247ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_3ab64ecd-7b97-4c67-bbc5-df34f7015d67" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_CurrentFiscalYearEndDate_3ab64ecd-7b97-4c67-bbc5-df34f7015d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c98c4df9-e572-4ecc-b610-48f3b47e359e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_DocumentFiscalYearFocus_c98c4df9-e572-4ecc-b610-48f3b47e359e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9c4b3d15-32d9-4d2c-bc0b-f53d36e390bb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9c4b3d15-32d9-4d2c-bc0b-f53d36e390bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_01f0ff77-b39c-4cf5-ad97-7321632574af" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ca91a399-eff5-43e7-a468-302ec223ac5e" xlink:to="loc_dei_AmendmentFlag_01f0ff77-b39c-4cf5-ad97-7321632574af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="exdx-20210930.xsd#CondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_02311e2b-2221-4e11-9493-593d75a1cf21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_01df069a-b748-4a1a-8f8b-0d2bde5afb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_02311e2b-2221-4e11-9493-593d75a1cf21" xlink:to="loc_us-gaap_AssetsAbstract_01df069a-b748-4a1a-8f8b-0d2bde5afb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1ab46d38-f859-437b-8f2f-8033c5e7f5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_01df069a-b748-4a1a-8f8b-0d2bde5afb49" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1ab46d38-f859-437b-8f2f-8033c5e7f5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7481e5e8-db57-46ea-b3ea-3b658f8e5852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ab46d38-f859-437b-8f2f-8033c5e7f5f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7481e5e8-db57-46ea-b3ea-3b658f8e5852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3d4489c5-b74b-4f15-ab32-423911966f40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ab46d38-f859-437b-8f2f-8033c5e7f5f2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3d4489c5-b74b-4f15-ab32-423911966f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_55b019ce-2817-4eca-b3af-a187fa9bff78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ab46d38-f859-437b-8f2f-8033c5e7f5f2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_55b019ce-2817-4eca-b3af-a187fa9bff78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3b241e99-a8ce-4d90-a2c7-ac86eb5286a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1ab46d38-f859-437b-8f2f-8033c5e7f5f2" xlink:to="loc_us-gaap_AssetsCurrent_3b241e99-a8ce-4d90-a2c7-ac86eb5286a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_78ac2d2e-dd51-4e28-ab6e-e3e6ad268668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_01df069a-b748-4a1a-8f8b-0d2bde5afb49" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_78ac2d2e-dd51-4e28-ab6e-e3e6ad268668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_63230069-ca33-4e59-86b0-5bb3c543dd86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_01df069a-b748-4a1a-8f8b-0d2bde5afb49" xlink:to="loc_us-gaap_Goodwill_63230069-ca33-4e59-86b0-5bb3c543dd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ba27dd76-b7b4-4cbc-8015-cb6c00e3b53e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_01df069a-b748-4a1a-8f8b-0d2bde5afb49" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ba27dd76-b7b4-4cbc-8015-cb6c00e3b53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ed38c032-1a25-4029-b0ac-0cb4728e6659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_01df069a-b748-4a1a-8f8b-0d2bde5afb49" xlink:to="loc_us-gaap_Assets_ed38c032-1a25-4029-b0ac-0cb4728e6659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c09be6a4-4c1a-4dfb-94b0-a9201be7b74b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_02311e2b-2221-4e11-9493-593d75a1cf21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c09be6a4-4c1a-4dfb-94b0-a9201be7b74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5e7f554a-a24c-4dbc-a5ed-8800f641dd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c09be6a4-4c1a-4dfb-94b0-a9201be7b74b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5e7f554a-a24c-4dbc-a5ed-8800f641dd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6a64ca07-9125-4965-9036-0ed002aa5650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e7f554a-a24c-4dbc-a5ed-8800f641dd8e" xlink:to="loc_us-gaap_AccountsPayableCurrent_6a64ca07-9125-4965-9036-0ed002aa5650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b4b8574f-0eb3-47b1-b53e-d08209ed1ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e7f554a-a24c-4dbc-a5ed-8800f641dd8e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b4b8574f-0eb3-47b1-b53e-d08209ed1ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_84128aa6-3e76-4a5d-a862-2df8c9c21276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e7f554a-a24c-4dbc-a5ed-8800f641dd8e" xlink:to="loc_us-gaap_LiabilitiesCurrent_84128aa6-3e76-4a5d-a862-2df8c9c21276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_bf49855e-0e80-424e-a79b-835ce3fec477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c09be6a4-4c1a-4dfb-94b0-a9201be7b74b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_bf49855e-0e80-424e-a79b-835ce3fec477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3a9b2f34-a618-4fd9-b53e-4007c520802e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c09be6a4-4c1a-4dfb-94b0-a9201be7b74b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3a9b2f34-a618-4fd9-b53e-4007c520802e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b324cc46-f97f-41ef-91e9-64a2c4019813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c09be6a4-4c1a-4dfb-94b0-a9201be7b74b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b324cc46-f97f-41ef-91e9-64a2c4019813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_59b8bc2a-ca5d-4262-8816-ae3534f002af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c09be6a4-4c1a-4dfb-94b0-a9201be7b74b" xlink:to="loc_us-gaap_Liabilities_59b8bc2a-ca5d-4262-8816-ae3534f002af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_034bd75d-84b5-43e1-aa9a-84bf9b63a4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c09be6a4-4c1a-4dfb-94b0-a9201be7b74b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_034bd75d-84b5-43e1-aa9a-84bf9b63a4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a5565216-7c79-4f69-8a15-4e56c315c34b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c09be6a4-4c1a-4dfb-94b0-a9201be7b74b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a5565216-7c79-4f69-8a15-4e56c315c34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_09ccb835-2b9d-474f-b94a-4df3cdf003c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a5565216-7c79-4f69-8a15-4e56c315c34b" xlink:to="loc_us-gaap_PreferredStockValue_09ccb835-2b9d-474f-b94a-4df3cdf003c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_09a8581e-f599-400f-ad57-0d38ef7d72e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a5565216-7c79-4f69-8a15-4e56c315c34b" xlink:to="loc_us-gaap_CommonStockValue_09a8581e-f599-400f-ad57-0d38ef7d72e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2a96db2f-ff7f-4008-af9f-4b054c286b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a5565216-7c79-4f69-8a15-4e56c315c34b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2a96db2f-ff7f-4008-af9f-4b054c286b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_792c47ce-defd-4484-b2b0-c4a3165b0250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a5565216-7c79-4f69-8a15-4e56c315c34b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_792c47ce-defd-4484-b2b0-c4a3165b0250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_31b7cc4a-de3a-49ca-86e2-69f38a4fd492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a5565216-7c79-4f69-8a15-4e56c315c34b" xlink:to="loc_us-gaap_StockholdersEquity_31b7cc4a-de3a-49ca-86e2-69f38a4fd492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c3e096c5-2ab8-4d2b-9529-ce693aaacd47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c09be6a4-4c1a-4dfb-94b0-a9201be7b74b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c3e096c5-2ab8-4d2b-9529-ce693aaacd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exdx-20210930.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_740f94a4-0544-4a9a-8bdb-c0ff1dee4733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f955f403-caff-4a90-8dc4-f783db4820e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_740f94a4-0544-4a9a-8bdb-c0ff1dee4733" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f955f403-caff-4a90-8dc4-f783db4820e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a665fb1c-5b8a-4a30-8daa-24a597bddf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f955f403-caff-4a90-8dc4-f783db4820e7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a665fb1c-5b8a-4a30-8daa-24a597bddf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9954732d-80ab-4717-b82e-02accaff03f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f955f403-caff-4a90-8dc4-f783db4820e7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9954732d-80ab-4717-b82e-02accaff03f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_00b1871b-0c6d-4e50-9720-474dd50c403c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f955f403-caff-4a90-8dc4-f783db4820e7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_00b1871b-0c6d-4e50-9720-474dd50c403c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9c0dc0a9-bb0d-4621-9700-e45a8900dc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f955f403-caff-4a90-8dc4-f783db4820e7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9c0dc0a9-bb0d-4621-9700-e45a8900dc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9f737c67-8dea-4044-b77c-80125c45d8de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_740f94a4-0544-4a9a-8bdb-c0ff1dee4733" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9f737c67-8dea-4044-b77c-80125c45d8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c34f6c4e-c24f-4750-a931-074d1ac9fe4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9f737c67-8dea-4044-b77c-80125c45d8de" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c34f6c4e-c24f-4750-a931-074d1ac9fe4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_79b43f95-99d3-428f-ba6f-2fdbd3f74ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9f737c67-8dea-4044-b77c-80125c45d8de" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_79b43f95-99d3-428f-ba6f-2fdbd3f74ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_de522ae1-fa37-4e8d-8099-872776eb34a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9f737c67-8dea-4044-b77c-80125c45d8de" xlink:to="loc_us-gaap_CommonStockSharesIssued_de522ae1-fa37-4e8d-8099-872776eb34a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e164497a-85df-4b25-a39f-f07a5ea76b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9f737c67-8dea-4044-b77c-80125c45d8de" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e164497a-85df-4b25-a39f-f07a5ea76b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="simple" xlink:href="exdx-20210930.xsd#UnauditedCondensedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f1d5d6cb-69ca-4283-b547-65b3e8af3dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f1368d53-c13b-42ce-841f-ce6df2e5fc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d5d6cb-69ca-4283-b547-65b3e8af3dec" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f1368d53-c13b-42ce-841f-ce6df2e5fc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_33b47d63-0fe5-4fbe-b2c0-7e2050ec2af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d5d6cb-69ca-4283-b547-65b3e8af3dec" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_33b47d63-0fe5-4fbe-b2c0-7e2050ec2af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d44fd991-a1dd-43f0-b835-d8d79953991f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_33b47d63-0fe5-4fbe-b2c0-7e2050ec2af5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d44fd991-a1dd-43f0-b835-d8d79953991f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_85eaa413-4b00-4359-baac-cd80abfa44eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_33b47d63-0fe5-4fbe-b2c0-7e2050ec2af5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_85eaa413-4b00-4359-baac-cd80abfa44eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8782d107-3ae4-4b21-84bf-ad87a3a8338f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_33b47d63-0fe5-4fbe-b2c0-7e2050ec2af5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8782d107-3ae4-4b21-84bf-ad87a3a8338f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9a79303f-dc10-4eba-8339-f647b4bf2ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_33b47d63-0fe5-4fbe-b2c0-7e2050ec2af5" xlink:to="loc_us-gaap_CostsAndExpenses_9a79303f-dc10-4eba-8339-f647b4bf2ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2aedc1b1-fadd-496d-a065-215512893f92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d5d6cb-69ca-4283-b547-65b3e8af3dec" xlink:to="loc_us-gaap_OperatingIncomeLoss_2aedc1b1-fadd-496d-a065-215512893f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_25c6292e-56e8-40bb-89fe-2fa6d1a5e542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d5d6cb-69ca-4283-b547-65b3e8af3dec" xlink:to="loc_us-gaap_InterestExpense_25c6292e-56e8-40bb-89fe-2fa6d1a5e542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4e408da6-cbe7-494b-93c5-580d1f764b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d5d6cb-69ca-4283-b547-65b3e8af3dec" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4e408da6-cbe7-494b-93c5-580d1f764b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_cfc5c2af-efb0-4453-b55b-aa03fec51e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d5d6cb-69ca-4283-b547-65b3e8af3dec" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_cfc5c2af-efb0-4453-b55b-aa03fec51e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_904e6d2d-9506-4c8f-af26-3bb16bc2e708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d5d6cb-69ca-4283-b547-65b3e8af3dec" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_904e6d2d-9506-4c8f-af26-3bb16bc2e708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3ec05578-a80f-457d-8f2f-65a584285ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d5d6cb-69ca-4283-b547-65b3e8af3dec" xlink:to="loc_us-gaap_NetIncomeLoss_3ec05578-a80f-457d-8f2f-65a584285ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9a8f7814-15cf-42f7-acdf-3359dcf49f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d5d6cb-69ca-4283-b547-65b3e8af3dec" xlink:to="loc_us-gaap_EarningsPerShareBasic_9a8f7814-15cf-42f7-acdf-3359dcf49f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3bc30ee9-11a3-4751-92a7-a3376330810f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d5d6cb-69ca-4283-b547-65b3e8af3dec" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3bc30ee9-11a3-4751-92a7-a3376330810f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4ae9fb7a-7d77-4a3c-978c-547096c1c459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d5d6cb-69ca-4283-b547-65b3e8af3dec" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4ae9fb7a-7d77-4a3c-978c-547096c1c459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b5f0ca31-56ff-4b1b-9652-4bd43fafa002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1d5d6cb-69ca-4283-b547-65b3e8af3dec" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b5f0ca31-56ff-4b1b-9652-4bd43fafa002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exdx-20210930.xsd#UnauditedCondensedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2c7e2410-1c5a-49e0-a949-7f6679b56f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f9dd8afe-5236-4c76-9b13-dd031a4ccb52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2c7e2410-1c5a-49e0-a949-7f6679b56f18" xlink:to="loc_us-gaap_StatementTable_f9dd8afe-5236-4c76-9b13-dd031a4ccb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6e830ec5-d1f1-49e5-ac03-b517b2d1c3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f9dd8afe-5236-4c76-9b13-dd031a4ccb52" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6e830ec5-d1f1-49e5-ac03-b517b2d1c3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_57c8cbb5-9ea4-459f-9b45-38f4e83d45b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6e830ec5-d1f1-49e5-ac03-b517b2d1c3ec" xlink:to="loc_us-gaap_EquityComponentDomain_57c8cbb5-9ea4-459f-9b45-38f4e83d45b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6b95ea29-ac03-41d7-8f1d-2db603ae63cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57c8cbb5-9ea4-459f-9b45-38f4e83d45b7" xlink:to="loc_us-gaap_CommonStockMember_6b95ea29-ac03-41d7-8f1d-2db603ae63cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_54bed112-5bc4-4e5e-ae7c-e1bfc95110d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57c8cbb5-9ea4-459f-9b45-38f4e83d45b7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_54bed112-5bc4-4e5e-ae7c-e1bfc95110d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_44ab31d0-09b3-435d-8aae-9023dbb271dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57c8cbb5-9ea4-459f-9b45-38f4e83d45b7" xlink:to="loc_us-gaap_RetainedEarningsMember_44ab31d0-09b3-435d-8aae-9023dbb271dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bafd2280-2a7f-4eb3-b590-bdc0a898b0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f9dd8afe-5236-4c76-9b13-dd031a4ccb52" xlink:to="loc_us-gaap_StatementLineItems_bafd2280-2a7f-4eb3-b590-bdc0a898b0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bafd2280-2a7f-4eb3-b590-bdc0a898b0fa" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_39d3be9a-d0ae-47fe-a451-234c2c14d51c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_39d3be9a-d0ae-47fe-a451-234c2c14d51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_38af790a-bd90-47d2-bed8-597e3ed86a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockholdersEquity_38af790a-bd90-47d2-bed8-597e3ed86a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_257c1a43-020f-4fa0-8975-2e97069a63e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_257c1a43-020f-4fa0-8975-2e97069a63e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_389b84ad-0226-4134-9a19-f2f55d0fd301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_389b84ad-0226-4134-9a19-f2f55d0fd301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_cf6c631c-8b69-47a5-9b28-911e5af79da0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_cf6c631c-8b69-47a5-9b28-911e5af79da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_6a55f856-507b-4d7b-a0cd-9b51887fcb44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_6a55f856-507b-4d7b-a0cd-9b51887fcb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c906a8c5-2238-4411-9c4c-deca0590d9da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c906a8c5-2238-4411-9c4c-deca0590d9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_67ceda77-90fe-4584-84eb-aa26592d65b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_67ceda77-90fe-4584-84eb-aa26592d65b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9579bef4-2d1f-4771-beb7-f9c48674c2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9579bef4-2d1f-4771-beb7-f9c48674c2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1060ab03-d500-481f-9b54-8115c13c360a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1060ab03-d500-481f-9b54-8115c13c360a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_f87aa881-fd75-4bec-8a17-d0a166aefa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_f87aa881-fd75-4bec-8a17-d0a166aefa8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9d127b99-4555-45ca-a0a0-4110340534b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9d127b99-4555-45ca-a0a0-4110340534b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_61deed17-7998-4292-bb97-16f4dca719b3" xlink:href="exdx-20210930.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_61deed17-7998-4292-bb97-16f4dca719b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_86e6cc81-a0b3-46de-9e02-5bcb186ab5c2" xlink:href="exdx-20210930.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_86e6cc81-a0b3-46de-9e02-5bcb186ab5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fb06233a-3a9b-47b2-9c7f-de9a77671574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_NetIncomeLoss_fb06233a-3a9b-47b2-9c7f-de9a77671574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_982fdaa1-0e5c-43cf-b140-30ba7d9c95b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_982fdaa1-0e5c-43cf-b140-30ba7d9c95b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f95a8360-5c0a-441b-ae13-a59a1e6a3632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_78e56fd0-b468-43c2-885c-8406f0e0da9e" xlink:to="loc_us-gaap_StockholdersEquity_f95a8360-5c0a-441b-ae13-a59a1e6a3632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="exdx-20210930.xsd#UnauditedCondensedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c855deb6-d5be-4a92-894c-0eaff8f26579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts_e86fa40c-65b9-44a7-9269-a76e9bdfa200" xlink:href="exdx-20210930.xsd#exdx_StockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c855deb6-d5be-4a92-894c-0eaff8f26579" xlink:to="loc_exdx_StockIssuanceCosts_e86fa40c-65b9-44a7-9269-a76e9bdfa200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20210930.xsd#UnauditedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_275a57d1-123b-45c4-861d-7051710bcd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8ab4bf37-fe75-4072-ba19-e26fe4b36c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_275a57d1-123b-45c4-861d-7051710bcd7f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8ab4bf37-fe75-4072-ba19-e26fe4b36c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4a0f5105-0c66-4f4e-a918-cc04df4cb77c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8ab4bf37-fe75-4072-ba19-e26fe4b36c9b" xlink:to="loc_us-gaap_NetIncomeLoss_4a0f5105-0c66-4f4e-a918-cc04df4cb77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_411e5e45-840f-4301-9cae-bb82aa4475cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8ab4bf37-fe75-4072-ba19-e26fe4b36c9b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_411e5e45-840f-4301-9cae-bb82aa4475cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_e6d04a46-30c5-4f37-b44f-d5035aca4ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_411e5e45-840f-4301-9cae-bb82aa4475cd" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_e6d04a46-30c5-4f37-b44f-d5035aca4ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_5924a714-acf5-4594-b87e-d4124af5501a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_411e5e45-840f-4301-9cae-bb82aa4475cd" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_5924a714-acf5-4594-b87e-d4124af5501a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_d1de1405-8c10-415a-bb1e-66e0aba690d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_411e5e45-840f-4301-9cae-bb82aa4475cd" xlink:to="loc_us-gaap_PaidInKindInterest_d1de1405-8c10-415a-bb1e-66e0aba690d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_774c4917-9b42-41bd-a610-aea2d7758f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_411e5e45-840f-4301-9cae-bb82aa4475cd" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_774c4917-9b42-41bd-a610-aea2d7758f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e3ff2bde-634c-44e3-b371-f2671cc4083d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_411e5e45-840f-4301-9cae-bb82aa4475cd" xlink:to="loc_us-gaap_ShareBasedCompensation_e3ff2bde-634c-44e3-b371-f2671cc4083d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cce49ff4-3f0c-4e6f-8a90-a5e1779724d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_411e5e45-840f-4301-9cae-bb82aa4475cd" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cce49ff4-3f0c-4e6f-8a90-a5e1779724d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d560bc6e-20cc-4fae-ab76-f06204f2ec07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cce49ff4-3f0c-4e6f-8a90-a5e1779724d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d560bc6e-20cc-4fae-ab76-f06204f2ec07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_4a30fdc9-273f-4ae5-a59f-5cbaa69af803" xlink:href="exdx-20210930.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cce49ff4-3f0c-4e6f-8a90-a5e1779724d0" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_4a30fdc9-273f-4ae5-a59f-5cbaa69af803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_28db2de8-7e93-4499-a7cb-de267a67efb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cce49ff4-3f0c-4e6f-8a90-a5e1779724d0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_28db2de8-7e93-4499-a7cb-de267a67efb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8bceaca-14ee-4943-a23f-e41b7c3d3036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cce49ff4-3f0c-4e6f-8a90-a5e1779724d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8bceaca-14ee-4943-a23f-e41b7c3d3036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_6167d71b-01e9-45a8-9c01-df3854240b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cce49ff4-3f0c-4e6f-8a90-a5e1779724d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_6167d71b-01e9-45a8-9c01-df3854240b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d303fc05-ea38-4092-9031-6fc99f21f6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8ab4bf37-fe75-4072-ba19-e26fe4b36c9b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d303fc05-ea38-4092-9031-6fc99f21f6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_a97e2d0f-e2f3-46b7-bff5-773433147ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_275a57d1-123b-45c4-861d-7051710bcd7f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_a97e2d0f-e2f3-46b7-bff5-773433147ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cb30915b-e3f7-4988-b23f-a7cb69432209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_a97e2d0f-e2f3-46b7-bff5-773433147ae7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cb30915b-e3f7-4988-b23f-a7cb69432209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_410aeec8-b6aa-4610-b17e-08b9d10a12f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_a97e2d0f-e2f3-46b7-bff5-773433147ae7" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_410aeec8-b6aa-4610-b17e-08b9d10a12f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_14758e23-54cc-490c-8768-a80fc45996bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_a97e2d0f-e2f3-46b7-bff5-773433147ae7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_14758e23-54cc-490c-8768-a80fc45996bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2885c71b-ea7b-4a47-9534-073b9d07c666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_275a57d1-123b-45c4-861d-7051710bcd7f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2885c71b-ea7b-4a47-9534-073b9d07c666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e00aaa93-02a6-4490-afa6-753ec94e98a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2885c71b-ea7b-4a47-9534-073b9d07c666" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e00aaa93-02a6-4490-afa6-753ec94e98a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_e4d659ba-9556-4e5f-b110-a9f566f2a4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2885c71b-ea7b-4a47-9534-073b9d07c666" xlink:to="loc_us-gaap_ProceedsFromStockPlans_e4d659ba-9556-4e5f-b110-a9f566f2a4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_ea3bd0f5-14c8-4922-9d28-0035045ad95f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2885c71b-ea7b-4a47-9534-073b9d07c666" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_ea3bd0f5-14c8-4922-9d28-0035045ad95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_86c816de-8a9d-4d76-b665-6760e939a5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2885c71b-ea7b-4a47-9534-073b9d07c666" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_86c816de-8a9d-4d76-b665-6760e939a5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromBankDebt_b8672efe-bb41-417c-950b-3efe7b027be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromBankDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2885c71b-ea7b-4a47-9534-073b9d07c666" xlink:to="loc_us-gaap_ProceedsFromBankDebt_b8672efe-bb41-417c-950b-3efe7b027be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfBankDebt_eca55110-12be-43fa-92b4-960806f3d569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2885c71b-ea7b-4a47-9534-073b9d07c666" xlink:to="loc_us-gaap_RepaymentsOfBankDebt_eca55110-12be-43fa-92b4-960806f3d569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_29cabfc6-b5b0-4834-b7ad-f96dad7913cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2885c71b-ea7b-4a47-9534-073b9d07c666" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_29cabfc6-b5b0-4834-b7ad-f96dad7913cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_18f4ec08-0f8e-46f7-95ad-28599476d829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2885c71b-ea7b-4a47-9534-073b9d07c666" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_18f4ec08-0f8e-46f7-95ad-28599476d829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_384bc601-37d1-48fa-9006-e6ad200dcaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2885c71b-ea7b-4a47-9534-073b9d07c666" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_384bc601-37d1-48fa-9006-e6ad200dcaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e7fb8026-7c8f-4401-96f7-0661b4650032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_275a57d1-123b-45c4-861d-7051710bcd7f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e7fb8026-7c8f-4401-96f7-0661b4650032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63e9ca55-f761-4763-8b3c-a11ec151e949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_275a57d1-123b-45c4-861d-7051710bcd7f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63e9ca55-f761-4763-8b3c-a11ec151e949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d3600963-9407-444e-a710-cb5f74f99fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_275a57d1-123b-45c4-861d-7051710bcd7f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d3600963-9407-444e-a710-cb5f74f99fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0f97a98a-c69f-4a11-83d8-fe3600573251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_275a57d1-123b-45c4-861d-7051710bcd7f" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_0f97a98a-c69f-4a11-83d8-fe3600573251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_286095e9-1611-4bd3-b65b-119580559b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0f97a98a-c69f-4a11-83d8-fe3600573251" xlink:to="loc_us-gaap_InterestPaidNet_286095e9-1611-4bd3-b65b-119580559b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_9c24e298-f164-437a-bebc-9fa047e64141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_275a57d1-123b-45c4-861d-7051710bcd7f" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_9c24e298-f164-437a-bebc-9fa047e64141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderCapitalLease_9aebca8d-e5fe-4bf2-ba65-e28cd993ab7e" xlink:href="exdx-20210930.xsd#exdx_EquipmentPurchasedUnderCapitalLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_9c24e298-f164-437a-bebc-9fa047e64141" xlink:to="loc_exdx_EquipmentPurchasedUnderCapitalLease_9aebca8d-e5fe-4bf2-ba65-e28cd993ab7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_887a4b22-5897-476c-ae31-0fadd397fcb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_9c24e298-f164-437a-bebc-9fa047e64141" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_887a4b22-5897-476c-ae31-0fadd397fcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsReclassifiedToEquity_ce260c8e-ef8c-4999-b065-6cab2e937925" xlink:href="exdx-20210930.xsd#exdx_DeferredOfferingCostsReclassifiedToEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_9c24e298-f164-437a-bebc-9fa047e64141" xlink:to="loc_exdx_DeferredOfferingCostsReclassifiedToEquity_ce260c8e-ef8c-4999-b065-6cab2e937925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Organization" xlink:type="simple" xlink:href="exdx-20210930.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d081eb1-e7a4-4209-8680-e0795470984b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_02a77de4-f28b-4c0b-bea6-d243225e25fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d081eb1-e7a4-4209-8680-e0795470984b" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_02a77de4-f28b-4c0b-bea6-d243225e25fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_244a87de-5c17-4bc3-993e-2990a6e18f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4c9a38b3-68ef-4f6e-b05a-b4cda9b5f899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_244a87de-5c17-4bc3-993e-2990a6e18f80" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4c9a38b3-68ef-4f6e-b05a-b4cda9b5f899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dde07791-1701-4585-a7af-a60cf31154b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_244a87de-5c17-4bc3-993e-2990a6e18f80" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dde07791-1701-4585-a7af-a60cf31154b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exdx-20210930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fa25cb96-5295-473c-8862-702e9679ed70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6ad11542-8cf2-446c-94b1-567dc77599b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa25cb96-5295-473c-8862-702e9679ed70" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6ad11542-8cf2-446c-94b1-567dc77599b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exdx-20210930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f27d5653-158e-4328-8e54-026dabf7ccfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_ad37179e-bcc6-45cd-bc1d-187d9d963ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f27d5653-158e-4328-8e54-026dabf7ccfa" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_ad37179e-bcc6-45cd-bc1d-187d9d963ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_55ad654a-7b3f-491c-b755-af8695427e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f27d5653-158e-4328-8e54-026dabf7ccfa" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_55ad654a-7b3f-491c-b755-af8695427e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_df46a124-89c0-40fd-92bb-04ed095d2418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f27d5653-158e-4328-8e54-026dabf7ccfa" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_df46a124-89c0-40fd-92bb-04ed095d2418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_b97c4be1-d6de-41ca-a187-4db1fd0a8df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f27d5653-158e-4328-8e54-026dabf7ccfa" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_b97c4be1-d6de-41ca-a187-4db1fd0a8df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_16df3d1b-9b50-4bd3-8cca-00e1166c8fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f27d5653-158e-4328-8e54-026dabf7ccfa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_16df3d1b-9b50-4bd3-8cca-00e1166c8fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_14a64384-ec5a-4701-b0e0-ef9a3fee05b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f27d5653-158e-4328-8e54-026dabf7ccfa" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_14a64384-ec5a-4701-b0e0-ef9a3fee05b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_e894987d-1b63-4fc0-8239-360e305ab8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f27d5653-158e-4328-8e54-026dabf7ccfa" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_e894987d-1b63-4fc0-8239-360e305ab8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_8d7c6b25-4718-463c-ac24-8e3aa67be56e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f27d5653-158e-4328-8e54-026dabf7ccfa" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_8d7c6b25-4718-463c-ac24-8e3aa67be56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_4bac7af6-3c7f-40bb-80a5-f8426712d006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f27d5653-158e-4328-8e54-026dabf7ccfa" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_4bac7af6-3c7f-40bb-80a5-f8426712d006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_d80236c4-07f9-40ea-9034-b974618e7f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f27d5653-158e-4328-8e54-026dabf7ccfa" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_d80236c4-07f9-40ea-9034-b974618e7f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ad98485d-91be-4945-8981-83d6ffc0775a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f27d5653-158e-4328-8e54-026dabf7ccfa" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ad98485d-91be-4945-8981-83d6ffc0775a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f5dcc12a-34d1-4e3c-9f2e-f8a5d3c3ee88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f27d5653-158e-4328-8e54-026dabf7ccfa" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f5dcc12a-34d1-4e3c-9f2e-f8a5d3c3ee88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exdx-20210930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2b9b9f28-218a-448b-a082-8601a3c3ab00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_b0dca3f0-f946-48b1-a6b3-cb5b70e74152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b9b9f28-218a-448b-a082-8601a3c3ab00" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_b0dca3f0-f946-48b1-a6b3-cb5b70e74152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_404b8c5a-a4c4-4c67-b942-b882d871e0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b9b9f28-218a-448b-a082-8601a3c3ab00" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_404b8c5a-a4c4-4c67-b942-b882d871e0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_7b23318d-f2a3-44f6-a2f7-9e2ded18506f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b9b9f28-218a-448b-a082-8601a3c3ab00" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_7b23318d-f2a3-44f6-a2f7-9e2ded18506f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b5501f33-fccc-4f28-843f-d4688f19742e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b9b9f28-218a-448b-a082-8601a3c3ab00" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b5501f33-fccc-4f28-843f-d4688f19742e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c81beb08-ea6f-4911-899d-2e9dcc00b333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b9b9f28-218a-448b-a082-8601a3c3ab00" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c81beb08-ea6f-4911-899d-2e9dcc00b333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_caed7f5e-273b-45b7-91d2-21f96fa0ed16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7734d9c0-736c-459e-b8c9-097346eba6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_caed7f5e-273b-45b7-91d2-21f96fa0ed16" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7734d9c0-736c-459e-b8c9-097346eba6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_82cab900-786f-466a-b1bb-e19c300ead2d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7734d9c0-736c-459e-b8c9-097346eba6ac" xlink:to="loc_srt_MajorCustomersAxis_82cab900-786f-466a-b1bb-e19c300ead2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cccfb6fe-1b38-494f-bd78-aba3cdcd049e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_82cab900-786f-466a-b1bb-e19c300ead2d" xlink:to="loc_srt_NameOfMajorCustomerDomain_cccfb6fe-1b38-494f-bd78-aba3cdcd049e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_d13c8e6b-829b-43b2-9ed5-c5827ffa5626" xlink:href="exdx-20210930.xsd#exdx_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cccfb6fe-1b38-494f-bd78-aba3cdcd049e" xlink:to="loc_exdx_MedicareMember_d13c8e6b-829b-43b2-9ed5-c5827ffa5626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_4816073b-f73b-4f7b-b474-72b544778faa" xlink:href="exdx-20210930.xsd#exdx_MedicareAdvantageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cccfb6fe-1b38-494f-bd78-aba3cdcd049e" xlink:to="loc_exdx_MedicareAdvantageMember_4816073b-f73b-4f7b-b474-72b544778faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember_4e5c1f02-8a43-41ac-ae4e-e32f0ee391c5" xlink:href="exdx-20210930.xsd#exdx_BlueShieldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cccfb6fe-1b38-494f-bd78-aba3cdcd049e" xlink:to="loc_exdx_BlueShieldMember_4e5c1f02-8a43-41ac-ae4e-e32f0ee391c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember_e747bdbf-ec30-43af-a4d4-83d3eea4f812" xlink:href="exdx-20210930.xsd#exdx_UnitedHealthcareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cccfb6fe-1b38-494f-bd78-aba3cdcd049e" xlink:to="loc_exdx_UnitedHealthcareMember_e747bdbf-ec30-43af-a4d4-83d3eea4f812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_891439f5-a942-4b7f-8e3e-bb44a1017db5" xlink:href="exdx-20210930.xsd#exdx_JanssenSIMPONIMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cccfb6fe-1b38-494f-bd78-aba3cdcd049e" xlink:to="loc_exdx_JanssenSIMPONIMember_891439f5-a942-4b7f-8e3e-bb44a1017db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6827423f-d61e-405a-b8de-7d34b2c85ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7734d9c0-736c-459e-b8c9-097346eba6ac" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6827423f-d61e-405a-b8de-7d34b2c85ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4072e005-91bb-4c3b-be4e-efd3c1f50c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6827423f-d61e-405a-b8de-7d34b2c85ed6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4072e005-91bb-4c3b-be4e-efd3c1f50c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_b390e7ee-d78f-468d-b06f-3da3761176e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4072e005-91bb-4c3b-be4e-efd3c1f50c11" xlink:to="loc_us-gaap_SalesRevenueNetMember_b390e7ee-d78f-468d-b06f-3da3761176e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember_d7f689d4-260d-4955-a158-463e189d7268" xlink:href="exdx-20210930.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4072e005-91bb-4c3b-be4e-efd3c1f50c11" xlink:to="loc_exdx_ReceivableBenchmarkMember_d7f689d4-260d-4955-a158-463e189d7268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b405a57e-826d-4323-ac88-c5b69495fae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7734d9c0-736c-459e-b8c9-097346eba6ac" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b405a57e-826d-4323-ac88-c5b69495fae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_40149e33-f655-4d89-ac1a-48192a5f7153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b405a57e-826d-4323-ac88-c5b69495fae8" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_40149e33-f655-4d89-ac1a-48192a5f7153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_00835638-c7b8-42d0-bbe8-e1672493a157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_40149e33-f655-4d89-ac1a-48192a5f7153" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_00835638-c7b8-42d0-bbe8-e1672493a157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_90836f4d-d1a0-4f64-bf7e-1727e8c36a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7734d9c0-736c-459e-b8c9-097346eba6ac" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_90836f4d-d1a0-4f64-bf7e-1727e8c36a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_42c08e0a-a8d3-484d-b7e1-c19e3bf316f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_90836f4d-d1a0-4f64-bf7e-1727e8c36a0d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_42c08e0a-a8d3-484d-b7e1-c19e3bf316f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b183bdac-1d5d-4fec-a84a-12936dcab474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b183bdac-1d5d-4fec-a84a-12936dcab474" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cf32e51f-f244-4c39-8b1e-6619449b150a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cf32e51f-f244-4c39-8b1e-6619449b150a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7e083b20-ecca-474d-9fb7-45c5583a0f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cf32e51f-f244-4c39-8b1e-6619449b150a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7e083b20-ecca-474d-9fb7-45c5583a0f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_f4b5850b-7d44-4bcb-8e55-7beddfb74bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7e083b20-ecca-474d-9fb7-45c5583a0f8a" xlink:to="loc_us-gaap_SalesRevenueNetMember_f4b5850b-7d44-4bcb-8e55-7beddfb74bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f2e771f7-bb2d-4be7-9b29-87d1da190ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f2e771f7-bb2d-4be7-9b29-87d1da190ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_be0043bb-6a12-48cb-85b5-6f0399beb121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f2e771f7-bb2d-4be7-9b29-87d1da190ae7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_be0043bb-6a12-48cb-85b5-6f0399beb121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_edca614d-ab35-4297-b2bb-19014ad4d3de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_be0043bb-6a12-48cb-85b5-6f0399beb121" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_edca614d-ab35-4297-b2bb-19014ad4d3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_bcd9c764-cb01-4b4c-9878-248afd4ab7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_be0043bb-6a12-48cb-85b5-6f0399beb121" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_bcd9c764-cb01-4b4c-9878-248afd4ab7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_96796673-7238-4549-9a17-2b50082837c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_srt_ProductOrServiceAxis_96796673-7238-4549-9a17-2b50082837c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cf80bffe-21c2-4eae-a3be-b2c9b9f57dd6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_96796673-7238-4549-9a17-2b50082837c9" xlink:to="loc_srt_ProductsAndServicesDomain_cf80bffe-21c2-4eae-a3be-b2c9b9f57dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_6e1772dc-928c-47a9-af03-8c4a3e24a67b" xlink:href="exdx-20210930.xsd#exdx_AVISECTDTestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cf80bffe-21c2-4eae-a3be-b2c9b9f57dd6" xlink:to="loc_exdx_AVISECTDTestMember_6e1772dc-928c-47a9-af03-8c4a3e24a67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_f0b84e06-2bf7-48ec-a0d8-0e70f9ff337d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cf80bffe-21c2-4eae-a3be-b2c9b9f57dd6" xlink:to="loc_us-gaap_ShippingAndHandlingMember_f0b84e06-2bf7-48ec-a0d8-0e70f9ff337d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ff963b38-8cd0-46f9-80c0-f4513be91c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ff963b38-8cd0-46f9-80c0-f4513be91c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fe24cf0a-31f7-491b-98e9-6d6d051be5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ff963b38-8cd0-46f9-80c0-f4513be91c22" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fe24cf0a-31f7-491b-98e9-6d6d051be5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_e1cfaf2f-8f15-4dd6-9fe2-c0adb6aa165a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fe24cf0a-31f7-491b-98e9-6d6d051be5b6" xlink:to="loc_us-gaap_OtherAssetsMember_e1cfaf2f-8f15-4dd6-9fe2-c0adb6aa165a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_79f883ef-3d8a-42f2-843a-c9eb6c9584dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_srt_RangeAxis_79f883ef-3d8a-42f2-843a-c9eb6c9584dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_853649fa-dd5f-4966-a4c5-48bd567ceaad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_79f883ef-3d8a-42f2-843a-c9eb6c9584dd" xlink:to="loc_srt_RangeMember_853649fa-dd5f-4966-a4c5-48bd567ceaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f7db2829-8f1e-49c8-b92d-05205a6cf23d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_853649fa-dd5f-4966-a4c5-48bd567ceaad" xlink:to="loc_srt_MinimumMember_f7db2829-8f1e-49c8-b92d-05205a6cf23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_535722f0-b8ff-4633-9323-57b6376d92c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_853649fa-dd5f-4966-a4c5-48bd567ceaad" xlink:to="loc_srt_MaximumMember_535722f0-b8ff-4633-9323-57b6376d92c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_19bf6004-d3f5-463b-9e7d-848f19421572" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_srt_CounterpartyNameAxis_19bf6004-d3f5-463b-9e7d-848f19421572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31fed9da-58f0-46a9-b9bb-0d96a8b7e514" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_19bf6004-d3f5-463b-9e7d-848f19421572" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31fed9da-58f0-46a9-b9bb-0d96a8b7e514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_f7b203bf-5c14-4922-a907-87df2b98f006" xlink:href="exdx-20210930.xsd#exdx_JanssenSIMPONIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31fed9da-58f0-46a9-b9bb-0d96a8b7e514" xlink:to="loc_exdx_JanssenSIMPONIMember_f7b203bf-5c14-4922-a907-87df2b98f006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_07b9848b-b209-4f8e-9bea-ec481dc40297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_us-gaap_AwardTypeAxis_07b9848b-b209-4f8e-9bea-ec481dc40297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70373a10-6655-46a6-8a11-83c45cce468d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_07b9848b-b209-4f8e-9bea-ec481dc40297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70373a10-6655-46a6-8a11-83c45cce468d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7dc9dc85-e3b3-45d0-a955-99375b5a963f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70373a10-6655-46a6-8a11-83c45cce468d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7dc9dc85-e3b3-45d0-a955-99375b5a963f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c133e8d9-16fe-44e3-9100-431502c1adc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c133e8d9-16fe-44e3-9100-431502c1adc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e447815c-24c6-492a-b9bc-2f591bb94d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c133e8d9-16fe-44e3-9100-431502c1adc4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e447815c-24c6-492a-b9bc-2f591bb94d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenPromotionAgreementMember_e0d2fd04-7900-4923-8edf-e232fa8f1e36" xlink:href="exdx-20210930.xsd#exdx_JanssenPromotionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e447815c-24c6-492a-b9bc-2f591bb94d4a" xlink:to="loc_exdx_JanssenPromotionAgreementMember_e0d2fd04-7900-4923-8edf-e232fa8f1e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_3b9530a5-aa76-4d20-92fb-532c34f10d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_3b9530a5-aa76-4d20-92fb-532c34f10d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_ea804dce-ec03-4ec1-b57d-7e546da3ec8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_3b9530a5-aa76-4d20-92fb-532c34f10d40" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_ea804dce-ec03-4ec1-b57d-7e546da3ec8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TwoMajorSuppliersMember_c8d2951e-449a-41d6-aa7c-97ddba377c3a" xlink:href="exdx-20210930.xsd#exdx_TwoMajorSuppliersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_ea804dce-ec03-4ec1-b57d-7e546da3ec8d" xlink:to="loc_exdx_TwoMajorSuppliersMember_c8d2951e-449a-41d6-aa7c-97ddba377c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac9bc259-0a14-4394-ac44-aa3a52b97eca" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ae19ec31-dc9b-4a7b-83f0-0e4dec2d76c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ae19ec31-dc9b-4a7b-83f0-0e4dec2d76c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_b112478b-9c28-4034-88a9-a5ea7bf6d2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_RestrictedCash_b112478b-9c28-4034-88a9-a5ea7bf6d2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription_bd289c6b-6899-4345-b87b-83822c87c7fa" xlink:href="exdx-20210930.xsd#exdx_JointVentureQuarterlyPromotionFeePerPrescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription_bd289c6b-6899-4345-b87b-83822c87c7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFee_77637d54-8dd9-4d56-84eb-f2cb40a9982a" xlink:href="exdx-20210930.xsd#exdx_JointVentureQuarterlyPromotionFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFee_77637d54-8dd9-4d56-84eb-f2cb40a9982a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_cf5419dc-ba97-43e8-959d-03565973c6de" xlink:href="exdx-20210930.xsd#exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_cf5419dc-ba97-43e8-959d-03565973c6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureTerminationConsiderationReceivable_0f7f2d65-ee48-4124-980e-c04b0dc2ffd8" xlink:href="exdx-20210930.xsd#exdx_JointVentureTerminationConsiderationReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_exdx_JointVentureTerminationConsiderationReceivable_0f7f2d65-ee48-4124-980e-c04b0dc2ffd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_16cdbe67-4072-4b9e-b354-a6d03edad9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_16cdbe67-4072-4b9e-b354-a6d03edad9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_821105cc-8d7a-431c-8cd1-b6b01af13d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_AdvertisingExpense_821105cc-8d7a-431c-8cd1-b6b01af13d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_2994a203-235f-43cc-b1f3-6e9395982a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_CostOfRevenue_2994a203-235f-43cc-b1f3-6e9395982a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_673b369b-0f5a-44f5-933d-7a18b916665d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_673b369b-0f5a-44f5-933d-7a18b916665d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_82d2bece-1cf4-42ef-ae7a-c25fc4b68a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_82d2bece-1cf4-42ef-ae7a-c25fc4b68a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_98399e2e-a3c3-44c5-a319-8d70c367f939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_us-gaap_NumberOfOperatingSegments_98399e2e-a3c3-44c5-a319-8d70c367f939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments_9b70b05b-53b8-4595-bb1f-55daea8399bf" xlink:href="exdx-20210930.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2e8bc716-4135-4e14-9be7-0ab23dd3d653" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments_9b70b05b-53b8-4595-bb1f-55daea8399bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_25b0fc83-3409-4496-b419-1242551741ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2234f24a-99b8-4cfd-95c1-2317c329d5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25b0fc83-3409-4496-b419-1242551741ce" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2234f24a-99b8-4cfd-95c1-2317c329d5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ea17c1a9-41f6-421a-b081-a5b45bac2f2b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2234f24a-99b8-4cfd-95c1-2317c329d5e6" xlink:to="loc_srt_MajorCustomersAxis_ea17c1a9-41f6-421a-b081-a5b45bac2f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2e7947a7-d841-4221-b969-0b03904ae830" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ea17c1a9-41f6-421a-b081-a5b45bac2f2b" xlink:to="loc_srt_NameOfMajorCustomerDomain_2e7947a7-d841-4221-b969-0b03904ae830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember_6f1c81b2-1d6a-4123-80be-4265205e1021" xlink:href="exdx-20210930.xsd#exdx_HealthcareInsurersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2e7947a7-d841-4221-b969-0b03904ae830" xlink:to="loc_exdx_HealthcareInsurersMember_6f1c81b2-1d6a-4123-80be-4265205e1021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member_d19e10e3-b72c-46c1-9234-02dc3dfdd1ab" xlink:href="exdx-20210930.xsd#exdx_Government1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2e7947a7-d841-4221-b969-0b03904ae830" xlink:to="loc_exdx_Government1Member_d19e10e3-b72c-46c1-9234-02dc3dfdd1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_e2f1bef1-2759-47de-a2e4-e0137e6c3642" xlink:href="exdx-20210930.xsd#exdx_ClientMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2e7947a7-d841-4221-b969-0b03904ae830" xlink:to="loc_exdx_ClientMember_e2f1bef1-2759-47de-a2e4-e0137e6c3642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember_9270e737-d0cc-4e8f-9b86-e55792fc7144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCustomerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2e7947a7-d841-4221-b969-0b03904ae830" xlink:to="loc_us-gaap_OtherCustomerMember_9270e737-d0cc-4e8f-9b86-e55792fc7144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_1899c6e1-7c62-4ee5-835c-29d405e8449f" xlink:href="exdx-20210930.xsd#exdx_JanssenSIMPONIMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2e7947a7-d841-4221-b969-0b03904ae830" xlink:to="loc_exdx_JanssenSIMPONIMember_1899c6e1-7c62-4ee5-835c-29d405e8449f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_1f4cbf1b-956d-48f4-8ff2-906978153e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2234f24a-99b8-4cfd-95c1-2317c329d5e6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_1f4cbf1b-956d-48f4-8ff2-906978153e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e91038c4-d430-49b2-9c2e-88ba03a5c135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1f4cbf1b-956d-48f4-8ff2-906978153e73" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e91038c4-d430-49b2-9c2e-88ba03a5c135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_05b43b53-7dae-44e2-99b6-190c029ef91b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0f6fe0d7-31d3-487a-a8f6-449abcac9ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05b43b53-7dae-44e2-99b6-190c029ef91b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0f6fe0d7-31d3-487a-a8f6-449abcac9ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_43ab424a-4639-48b6-b433-6c5d17fa9231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05b43b53-7dae-44e2-99b6-190c029ef91b" xlink:to="loc_us-gaap_RestrictedCash_43ab424a-4639-48b6-b433-6c5d17fa9231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b640ffd0-8e25-47d2-9e88-5113b3398494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05b43b53-7dae-44e2-99b6-190c029ef91b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b640ffd0-8e25-47d2-9e88-5113b3398494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_65335aa4-2654-4432-bdfb-c7d218ca1ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_98ba5668-3cad-4f51-952c-dc7b8b47c1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_65335aa4-2654-4432-bdfb-c7d218ca1ea5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_98ba5668-3cad-4f51-952c-dc7b8b47c1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d95047c9-8591-4510-a273-7be5082402f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_98ba5668-3cad-4f51-952c-dc7b8b47c1b9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d95047c9-8591-4510-a273-7be5082402f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5e7b78-7f44-42e6-b739-c6ef36701a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d95047c9-8591-4510-a273-7be5082402f4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5e7b78-7f44-42e6-b739-c6ef36701a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1e6ac931-9226-4784-88c4-792a06faaa5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5e7b78-7f44-42e6-b739-c6ef36701a4e" xlink:to="loc_us-gaap_WarrantMember_1e6ac931-9226-4784-88c4-792a06faaa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_c1234dfd-b62b-406e-8f0f-29cb1f94b35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5e7b78-7f44-42e6-b739-c6ef36701a4e" xlink:to="loc_us-gaap_StockOptionMember_c1234dfd-b62b-406e-8f0f-29cb1f94b35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_eb835ada-ec82-426d-a179-ec24ceb430c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5e7b78-7f44-42e6-b739-c6ef36701a4e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_eb835ada-ec82-426d-a179-ec24ceb430c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4c5d70cc-973f-4bb4-af5f-27067ab6e31b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e5e7b78-7f44-42e6-b739-c6ef36701a4e" xlink:to="loc_us-gaap_EmployeeStockMember_4c5d70cc-973f-4bb4-af5f-27067ab6e31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f95ef240-bf84-447f-9031-e8004bcb1ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_98ba5668-3cad-4f51-952c-dc7b8b47c1b9" xlink:to="loc_us-gaap_ClassOfStockLineItems_f95ef240-bf84-447f-9031-e8004bcb1ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_53de83a2-e5af-45d9-9f7c-566377404490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f95ef240-bf84-447f-9031-e8004bcb1ef0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_53de83a2-e5af-45d9-9f7c-566377404490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="exdx-20210930.xsd#OtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_6f5208dc-1478-4cbc-8067-34f51e748afb" xlink:href="exdx-20210930.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_7805418f-01bc-4967-89e1-611aa7af13c7" xlink:href="exdx-20210930.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_6f5208dc-1478-4cbc-8067-34f51e748afb" xlink:to="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_7805418f-01bc-4967-89e1-611aa7af13c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="exdx-20210930.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_c98f2087-448a-497d-a4e6-8de421263c49" xlink:href="exdx-20210930.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_e4f56fc0-d121-4294-bc59-4c090105d460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c98f2087-448a-497d-a4e6-8de421263c49" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_e4f56fc0-d121-4294-bc59-4c090105d460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_39a02f86-04e8-4a28-9d4a-d89994b6d6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c98f2087-448a-497d-a4e6-8de421263c49" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_39a02f86-04e8-4a28-9d4a-d89994b6d6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3ca72d5d-d167-43c3-b21f-5f7968372025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c98f2087-448a-497d-a4e6-8de421263c49" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3ca72d5d-d167-43c3-b21f-5f7968372025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#OtherFinancialInformationPrepaidexpensesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_33872977-5586-4d61-ae6c-dc7a54f3a8b9" xlink:href="exdx-20210930.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_1e6d8aa5-58de-4626-80db-adc0488a50d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_33872977-5586-4d61-ae6c-dc7a54f3a8b9" xlink:to="loc_us-gaap_OtherAssetsCurrent_1e6d8aa5-58de-4626-80db-adc0488a50d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties_d92e33dc-b006-4286-b7b4-2933ad4dc5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_33872977-5586-4d61-ae6c-dc7a54f3a8b9" xlink:to="loc_us-gaap_PrepaidRoyalties_d92e33dc-b006-4286-b7b4-2933ad4dc5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_4c73c883-9420-47a0-915e-09b01c5e3f41" xlink:href="exdx-20210930.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_33872977-5586-4d61-ae6c-dc7a54f3a8b9" xlink:to="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_4c73c883-9420-47a0-915e-09b01c5e3f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_6f76bd36-741c-431b-8643-1a6c8c9a42e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_33872977-5586-4d61-ae6c-dc7a54f3a8b9" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_6f76bd36-741c-431b-8643-1a6c8c9a42e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1cb8ddda-8888-4ba7-9c8b-a68ba67692e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_33872977-5586-4d61-ae6c-dc7a54f3a8b9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1cb8ddda-8888-4ba7-9c8b-a68ba67692e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#OtherFinancialInformationPropertyandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_5fb402bd-d308-4ec3-a89d-199cf0e6c36c" xlink:href="exdx-20210930.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb68c779-504a-4a16-8ca2-a91c3d98e76f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_5fb402bd-d308-4ec3-a89d-199cf0e6c36c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb68c779-504a-4a16-8ca2-a91c3d98e76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5cacb97-df16-425a-a077-1316a0a3617d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb68c779-504a-4a16-8ca2-a91c3d98e76f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5cacb97-df16-425a-a077-1316a0a3617d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31b38fd5-b894-451b-b1ed-707307b8ffde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5cacb97-df16-425a-a077-1316a0a3617d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31b38fd5-b894-451b-b1ed-707307b8ffde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2b82a6e8-5c50-4602-8761-d30eba36523f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31b38fd5-b894-451b-b1ed-707307b8ffde" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2b82a6e8-5c50-4602-8761-d30eba36523f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_4de4199b-aa88-4242-8eb5-e3dfd92e8dff" xlink:href="exdx-20210930.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31b38fd5-b894-451b-b1ed-707307b8ffde" xlink:to="loc_exdx_LaboratoryEquipmentMember_4de4199b-aa88-4242-8eb5-e3dfd92e8dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_ffc6cca4-0769-48d1-9b76-2ebe2263cc1a" xlink:href="exdx-20210930.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31b38fd5-b894-451b-b1ed-707307b8ffde" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_ffc6cca4-0769-48d1-9b76-2ebe2263cc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_b11c91a6-7466-4a92-9207-8658823e030b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31b38fd5-b894-451b-b1ed-707307b8ffde" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_b11c91a6-7466-4a92-9207-8658823e030b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_299d228b-2009-4c0c-b2da-5403d792622f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31b38fd5-b894-451b-b1ed-707307b8ffde" xlink:to="loc_us-gaap_ConstructionInProgressMember_299d228b-2009-4c0c-b2da-5403d792622f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ccef2d2-3366-418a-8557-347f0efbe385" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb68c779-504a-4a16-8ca2-a91c3d98e76f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ccef2d2-3366-418a-8557-347f0efbe385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6a85c685-a934-48d8-8d57-47a31dd0caca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ccef2d2-3366-418a-8557-347f0efbe385" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6a85c685-a934-48d8-8d57-47a31dd0caca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9db5be3d-3ee4-4991-bdc5-4ba3fbce88ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ccef2d2-3366-418a-8557-347f0efbe385" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9db5be3d-3ee4-4991-bdc5-4ba3fbce88ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_466751b9-7745-4ce9-a154-75d0adaf64a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0ccef2d2-3366-418a-8557-347f0efbe385" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_466751b9-7745-4ce9-a154-75d0adaf64a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_00d0657f-3ffe-43c4-90c6-c288a21c9e6d" xlink:href="exdx-20210930.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e60628fd-9200-44b1-95dc-7a97cf91c7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_00d0657f-3ffe-43c4-90c6-c288a21c9e6d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e60628fd-9200-44b1-95dc-7a97cf91c7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4845b1e9-1385-4141-89f2-933136c3c77b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e60628fd-9200-44b1-95dc-7a97cf91c7f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4845b1e9-1385-4141-89f2-933136c3c77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab0fa7bb-c7a0-4dbb-b1a1-49063f568255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4845b1e9-1385-4141-89f2-933136c3c77b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab0fa7bb-c7a0-4dbb-b1a1-49063f568255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AssetsUnderCapitalLeaseMember_95120de8-5861-449d-932f-a866a7c106bd" xlink:href="exdx-20210930.xsd#exdx_AssetsUnderCapitalLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab0fa7bb-c7a0-4dbb-b1a1-49063f568255" xlink:to="loc_exdx_AssetsUnderCapitalLeaseMember_95120de8-5861-449d-932f-a866a7c106bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fded27f4-9a8b-4beb-b902-60c7d9a79747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e60628fd-9200-44b1-95dc-7a97cf91c7f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fded27f4-9a8b-4beb-b902-60c7d9a79747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1d540dcb-c768-48e3-bc8c-02c0297cd368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fded27f4-9a8b-4beb-b902-60c7d9a79747" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1d540dcb-c768-48e3-bc8c-02c0297cd368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_66a79c33-9e8e-4bcc-a34b-9e252638eb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fded27f4-9a8b-4beb-b902-60c7d9a79747" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_66a79c33-9e8e-4bcc-a34b-9e252638eb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_214a4667-13a9-49af-8dc0-552f2652dc38" xlink:href="exdx-20210930.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_1dbc65df-f4ca-4172-a170-b63a9bdb315b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_214a4667-13a9-49af-8dc0-552f2652dc38" xlink:to="loc_us-gaap_AccruedSalariesCurrent_1dbc65df-f4ca-4172-a170-b63a9bdb315b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_b737137e-3b4f-43a3-be65-0124cba2bbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_214a4667-13a9-49af-8dc0-552f2652dc38" xlink:to="loc_us-gaap_InterestPayableCurrent_b737137e-3b4f-43a3-be65-0124cba2bbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_6ec4c27c-9d29-4506-bd17-b65295447ded" xlink:href="exdx-20210930.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_214a4667-13a9-49af-8dc0-552f2652dc38" xlink:to="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_6ec4c27c-9d29-4506-bd17-b65295447ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_a799cb3d-9e8f-4ef4-a836-fa47ae844eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_214a4667-13a9-49af-8dc0-552f2652dc38" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_a799cb3d-9e8f-4ef4-a836-fa47ae844eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_eb2da376-2be6-4d96-a9d3-dbd15e56d211" xlink:href="exdx-20210930.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_214a4667-13a9-49af-8dc0-552f2652dc38" xlink:to="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_eb2da376-2be6-4d96-a9d3-dbd15e56d211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_af17517f-9101-4b10-b130-3380a934fa80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_214a4667-13a9-49af-8dc0-552f2652dc38" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_af17517f-9101-4b10-b130-3380a934fa80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_19270535-231a-4627-b016-6c98967e381a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_214a4667-13a9-49af-8dc0-552f2652dc38" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_19270535-231a-4627-b016-6c98967e381a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ca52e281-44fc-4c34-8075-99e3774f1ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_214a4667-13a9-49af-8dc0-552f2652dc38" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ca52e281-44fc-4c34-8075-99e3774f1ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Borrowings" xlink:type="simple" xlink:href="exdx-20210930.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8e0bbf6b-ff93-4bca-8233-bb925a798c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_0c973f0f-ee14-42d5-a8ca-2e544bcbb557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8e0bbf6b-ff93-4bca-8233-bb925a798c05" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_0c973f0f-ee14-42d5-a8ca-2e544bcbb557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsTables" xlink:type="simple" xlink:href="exdx-20210930.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d3e8261e-bf69-4b22-b623-fdf0a49df125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_f2ffc62b-0179-45f5-a6db-beaba83a5e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d3e8261e-bf69-4b22-b623-fdf0a49df125" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_f2ffc62b-0179-45f5-a6db-beaba83a5e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6d6394b4-dd68-4994-9df6-23e8d11d3fca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ccd63bcc-15a1-43c5-a777-f2d256e7374e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6d6394b4-dd68-4994-9df6-23e8d11d3fca" xlink:to="loc_us-gaap_DebtInstrumentTable_ccd63bcc-15a1-43c5-a777-f2d256e7374e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_86457941-c8b3-415b-a603-6430ef8f4711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ccd63bcc-15a1-43c5-a777-f2d256e7374e" xlink:to="loc_us-gaap_DebtInstrumentAxis_86457941-c8b3-415b-a603-6430ef8f4711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_60e45613-46f1-4080-8e0d-1416da09a031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_86457941-c8b3-415b-a603-6430ef8f4711" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_60e45613-46f1-4080-8e0d-1416da09a031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_eabe977c-f713-4913-b103-332811fe940d" xlink:href="exdx-20210930.xsd#exdx_Term2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_60e45613-46f1-4080-8e0d-1416da09a031" xlink:to="loc_exdx_Term2017Member_eabe977c-f713-4913-b103-332811fe940d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ebf31c6c-ac1a-4288-975b-b997c592bfae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ccd63bcc-15a1-43c5-a777-f2d256e7374e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ebf31c6c-ac1a-4288-975b-b997c592bfae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f891fed8-9fef-4775-9f72-af5e3e45e6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ebf31c6c-ac1a-4288-975b-b997c592bfae" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f891fed8-9fef-4775-9f72-af5e3e45e6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_29ff0ffe-152e-4936-a9f8-0c24eebe9b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f891fed8-9fef-4775-9f72-af5e3e45e6b3" xlink:to="loc_us-gaap_LoansPayableMember_29ff0ffe-152e-4936-a9f8-0c24eebe9b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_0a1bbbeb-3abe-4506-9d39-ab74bd3ead68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f891fed8-9fef-4775-9f72-af5e3e45e6b3" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_0a1bbbeb-3abe-4506-9d39-ab74bd3ead68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_da2b25f1-d51b-489d-9740-190e529f6dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ccd63bcc-15a1-43c5-a777-f2d256e7374e" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_da2b25f1-d51b-489d-9740-190e529f6dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_9fec9f25-a753-4e68-97ea-8406f02180e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_da2b25f1-d51b-489d-9740-190e529f6dff" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_9fec9f25-a753-4e68-97ea-8406f02180e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_bd3eae22-e20d-462d-ae05-9c8df48272ea" xlink:href="exdx-20210930.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_9fec9f25-a753-4e68-97ea-8406f02180e9" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_bd3eae22-e20d-462d-ae05-9c8df48272ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CapitalRoyaltyPartnersIILPMember_2d8c084e-f36a-4031-b42b-aba019b900b3" xlink:href="exdx-20210930.xsd#exdx_CapitalRoyaltyPartnersIILPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_9fec9f25-a753-4e68-97ea-8406f02180e9" xlink:to="loc_exdx_CapitalRoyaltyPartnersIILPMember_2d8c084e-f36a-4031-b42b-aba019b900b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ccd63bcc-15a1-43c5-a777-f2d256e7374e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_88b4b019-7603-4cd1-8fa7-6436acea052f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_88b4b019-7603-4cd1-8fa7-6436acea052f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d40d176d-129e-40c5-bac7-d4b12676892f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d40d176d-129e-40c5-bac7-d4b12676892f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_03e48cb1-be9f-4e36-9d38-d2b26d29d96e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_03e48cb1-be9f-4e36-9d38-d2b26d29d96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_ceee34a4-78bd-49d6-94ed-0c3b93b6ebb1" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_ceee34a4-78bd-49d6-94ed-0c3b93b6ebb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_afbb76bf-7d6f-42ba-80b9-75faa90ebd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_afbb76bf-7d6f-42ba-80b9-75faa90ebd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c8944b30-0c32-46ef-bc71-7f475594ecca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_us-gaap_DebtInstrumentTerm_c8944b30-0c32-46ef-bc71-7f475594ecca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_c58bf897-0826-436e-8643-dd3b8a5f6d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_c58bf897-0826-436e-8643-dd3b8a5f6d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_515c2c46-d79d-4304-9489-88a5917436cb" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_515c2c46-d79d-4304-9489-88a5917436cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_379ce648-5c25-47a1-b4e8-13068b84642e" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_379ce648-5c25-47a1-b4e8-13068b84642e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_ab896484-c0a4-411f-9ce9-28f97cd5a96b" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_ab896484-c0a4-411f-9ce9-28f97cd5a96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_d75640f9-6fd3-4fcc-9c1f-818bf5bc279c" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_d75640f9-6fd3-4fcc-9c1f-818bf5bc279c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_c925f783-17db-4886-8f02-fa07d0e99045" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7e3b258a-bd96-4023-8a0b-858041b4c3ff" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_c925f783-17db-4886-8f02-fa07d0e99045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#BorrowingsFutureminimumpaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4df91ed0-9bc0-475a-a0c1-374af7b9bad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_c38ff8a5-baa6-4b4b-94a5-1aaccbae986a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4df91ed0-9bc0-475a-a0c1-374af7b9bad9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_c38ff8a5-baa6-4b4b-94a5-1aaccbae986a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_aacd8e2f-1b00-4dd4-851a-29c9e8bf0b76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4df91ed0-9bc0-475a-a0c1-374af7b9bad9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_aacd8e2f-1b00-4dd4-851a-29c9e8bf0b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_457c13b3-c160-418a-ba3b-8ce0da8eb2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4df91ed0-9bc0-475a-a0c1-374af7b9bad9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_457c13b3-c160-418a-ba3b-8ce0da8eb2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_683b6873-bbc3-4d5f-bf52-79c032bef154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4df91ed0-9bc0-475a-a0c1-374af7b9bad9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_683b6873-bbc3-4d5f-bf52-79c032bef154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_bfdd0fa3-fed1-4936-b03b-0365de32aa87" xlink:href="exdx-20210930.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4df91ed0-9bc0-475a-a0c1-374af7b9bad9" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_bfdd0fa3-fed1-4936-b03b-0365de32aa87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6d592d59-6ae2-49e2-9124-fa1981c72dad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4df91ed0-9bc0-475a-a0c1-374af7b9bad9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6d592d59-6ae2-49e2-9124-fa1981c72dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_8d23f71b-5290-4e3d-981b-bc749973e3bc" xlink:href="exdx-20210930.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4df91ed0-9bc0-475a-a0c1-374af7b9bad9" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_8d23f71b-5290-4e3d-981b-bc749973e3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c8639cee-edae-41d9-9733-d766ca735aae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4df91ed0-9bc0-475a-a0c1-374af7b9bad9" xlink:to="loc_us-gaap_LongTermDebt_c8639cee-edae-41d9-9733-d766ca735aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="exdx-20210930.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ce9224b-c86e-4931-92b5-9e2250ccb1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c63a4781-1bdb-425b-a864-6bdd1e3db47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ce9224b-c86e-4931-92b5-9e2250ccb1f8" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c63a4781-1bdb-425b-a864-6bdd1e3db47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5a02bf31-0bdc-455a-8653-e19f57b2bb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b423ba9b-0a1c-465d-95d2-1612e37b0283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5a02bf31-0bdc-455a-8653-e19f57b2bb4f" xlink:to="loc_us-gaap_LossContingenciesTable_b423ba9b-0a1c-465d-95d2-1612e37b0283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_8ec7b515-c756-4989-9549-b88cbbcb9eee" xlink:href="exdx-20210930.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b423ba9b-0a1c-465d-95d2-1612e37b0283" xlink:to="loc_exdx_RentalPropertyByTypeAxis_8ec7b515-c756-4989-9549-b88cbbcb9eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_b3d3e129-c9aa-4722-9baf-75977abc6bf9" xlink:href="exdx-20210930.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeAxis_8ec7b515-c756-4989-9549-b88cbbcb9eee" xlink:to="loc_exdx_RentalPropertyByTypeDomain_b3d3e129-c9aa-4722-9baf-75977abc6bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_4e302a89-5eb7-4e11-a8e5-06a309cb0897" xlink:href="exdx-20210930.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_b3d3e129-c9aa-4722-9baf-75977abc6bf9" xlink:to="loc_exdx_OfficeAndLaboratoryMember_4e302a89-5eb7-4e11-a8e5-06a309cb0897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_1cfba06f-2b20-4310-b9c5-fd6fe6e4fc5b" xlink:href="exdx-20210930.xsd#exdx_OfficeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_b3d3e129-c9aa-4722-9baf-75977abc6bf9" xlink:to="loc_exdx_OfficeMember_1cfba06f-2b20-4310-b9c5-fd6fe6e4fc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_05121020-43f2-42ad-b418-bfc607c6af48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b423ba9b-0a1c-465d-95d2-1612e37b0283" xlink:to="loc_srt_CounterpartyNameAxis_05121020-43f2-42ad-b418-bfc607c6af48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e9718fa-022f-4511-843f-5d1fcd4e8c61" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_05121020-43f2-42ad-b418-bfc607c6af48" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e9718fa-022f-4511-843f-5d1fcd4e8c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember_37ba91a0-760a-4ef7-8800-954f65946914" xlink:href="exdx-20210930.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e9718fa-022f-4511-843f-5d1fcd4e8c61" xlink:to="loc_exdx_PrometheusLaboratoriesIncMember_37ba91a0-760a-4ef7-8800-954f65946914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_88b6e59b-d5da-4b15-9521-8aa180be37e2" xlink:href="exdx-20210930.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e9718fa-022f-4511-843f-5d1fcd4e8c61" xlink:to="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_88b6e59b-d5da-4b15-9521-8aa180be37e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a4987be7-8169-481c-aa02-0652599fe7d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b423ba9b-0a1c-465d-95d2-1612e37b0283" xlink:to="loc_srt_RangeAxis_a4987be7-8169-481c-aa02-0652599fe7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dff8b943-f9a0-433f-b222-258e01802245" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a4987be7-8169-481c-aa02-0652599fe7d2" xlink:to="loc_srt_RangeMember_dff8b943-f9a0-433f-b222-258e01802245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7b659172-1db6-403e-b8b3-9e2382134fc4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dff8b943-f9a0-433f-b222-258e01802245" xlink:to="loc_srt_MinimumMember_7b659172-1db6-403e-b8b3-9e2382134fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8d9ba9f5-2d66-41a9-a175-5b2d51aa3076" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dff8b943-f9a0-433f-b222-258e01802245" xlink:to="loc_srt_MaximumMember_8d9ba9f5-2d66-41a9-a175-5b2d51aa3076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_27c6e949-2b4b-4e45-9f1f-2c9c76918ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b423ba9b-0a1c-465d-95d2-1612e37b0283" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_27c6e949-2b4b-4e45-9f1f-2c9c76918ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_acbf0c2a-0da4-424e-a695-dc159740e693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_27c6e949-2b4b-4e45-9f1f-2c9c76918ea7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_acbf0c2a-0da4-424e-a695-dc159740e693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_77d43753-2f7b-4260-bd1d-779503e268c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_acbf0c2a-0da4-424e-a695-dc159740e693" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_77d43753-2f7b-4260-bd1d-779503e268c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_eae13816-9713-4905-881a-b82773a884c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b423ba9b-0a1c-465d-95d2-1612e37b0283" xlink:to="loc_us-gaap_TypeOfArrangementAxis_eae13816-9713-4905-881a-b82773a884c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_56afb8d8-e9c0-4d5e-bd97-6200b896617c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_eae13816-9713-4905-881a-b82773a884c5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_56afb8d8-e9c0-4d5e-bd97-6200b896617c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember_6df78149-ecae-4e06-bdaa-aa18c860c0ef" xlink:href="exdx-20210930.xsd#exdx_AHNCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_56afb8d8-e9c0-4d5e-bd97-6200b896617c" xlink:to="loc_exdx_AHNCollaborationMember_6df78149-ecae-4e06-bdaa-aa18c860c0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b423ba9b-0a1c-465d-95d2-1612e37b0283" xlink:to="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeasesRenewalTerm_1c5bbcb0-3559-4868-b011-ee90c086a791" xlink:href="exdx-20210930.xsd#exdx_OperatingLeasesRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_OperatingLeasesRenewalTerm_1c5bbcb0-3559-4868-b011-ee90c086a791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRent_125c0b1d-9a2f-4d88-a684-d74b8398e74d" xlink:href="exdx-20210930.xsd#exdx_OperatingLeaseMonthlyBaseRent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_OperatingLeaseMonthlyBaseRent_125c0b1d-9a2f-4d88-a684-d74b8398e74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_b9051362-eea6-444b-809e-ed04b456a632" xlink:href="exdx-20210930.xsd#exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_b9051362-eea6-444b-809e-ed04b456a632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_373c1341-410c-4a70-acee-bebbd4d30ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_us-gaap_LeaseAndRentalExpense_373c1341-410c-4a70-acee-bebbd4d30ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_127f9e1a-5648-4ca3-a463-8fb1727dae30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_127f9e1a-5648-4ca3-a463-8fb1727dae30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_2b38ab45-f0e4-40e1-8188-7bba4841ac7d" xlink:href="exdx-20210930.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_2b38ab45-f0e4-40e1-8188-7bba4841ac7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_3bff6fcd-0504-4073-86a2-27e9ed55e8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_3bff6fcd-0504-4073-86a2-27e9ed55e8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment_687e611d-2496-47a2-8622-9565531176b0" xlink:href="exdx-20210930.xsd#exdx_AdvancePayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_AdvancePayment_687e611d-2496-47a2-8622-9565531176b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementInitialLicenseFee_92f69d5f-1f60-405e-8d1c-7993c85e7ad6" xlink:href="exdx-20210930.xsd#exdx_LicenseAgreementInitialLicenseFee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_LicenseAgreementInitialLicenseFee_92f69d5f-1f60-405e-8d1c-7993c85e7ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_a9a9feb6-a47e-4de6-b8b9-ba71234dc1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_a9a9feb6-a47e-4de6-b8b9-ba71234dc1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_0af9f3f9-8277-451d-bc01-43d00061110a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_0af9f3f9-8277-451d-bc01-43d00061110a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_03f12c43-5097-4351-8a25-7cd3c12b6d3e" xlink:href="exdx-20210930.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_03f12c43-5097-4351-8a25-7cd3c12b6d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee_a3b17320-0365-4c88-aa4e-26eb187db921" xlink:href="exdx-20210930.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_CollaborationAgreementAnnualCollaborationFee_a3b17320-0365-4c88-aa4e-26eb187db921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses_e1f7ed15-3cab-4456-852d-b5d031436c59" xlink:href="exdx-20210930.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6967793d-0eff-486a-a491-2dd5036c1dc8" xlink:to="loc_exdx_CollaborationAgreementCollaborationExpenses_e1f7ed15-3cab-4456-852d-b5d031436c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exdx-20210930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5765e22c-518e-4744-b19c-1a32b015d257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_40e9ed61-6009-4ddc-87b4-1e664f424887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5765e22c-518e-4744-b19c-1a32b015d257" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_40e9ed61-6009-4ddc-87b4-1e664f424887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exdx-20210930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4cec2ef4-3e0b-4e4a-81b8-0acf8035107f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_75aed715-b115-4fff-a44e-2f7264b20746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4cec2ef4-3e0b-4e4a-81b8-0acf8035107f" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_75aed715-b115-4fff-a44e-2f7264b20746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9d2ff7ab-b199-4812-b22e-8e59832eb975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_588d7eed-9809-4cd2-a05d-11134c049196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9d2ff7ab-b199-4812-b22e-8e59832eb975" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_588d7eed-9809-4cd2-a05d-11134c049196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2d820ec6-9377-4761-86b4-2a8d883ece10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_588d7eed-9809-4cd2-a05d-11134c049196" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2d820ec6-9377-4761-86b4-2a8d883ece10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e634d8d-9a4a-41c5-90d4-5976178504c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2d820ec6-9377-4761-86b4-2a8d883ece10" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e634d8d-9a4a-41c5-90d4-5976178504c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a20f4128-4cd1-4c3b-8460-0a41d9d7ad11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e634d8d-9a4a-41c5-90d4-5976178504c2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a20f4128-4cd1-4c3b-8460-0a41d9d7ad11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c590bc2-835a-4faa-b69f-da5b0aea1eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_588d7eed-9809-4cd2-a05d-11134c049196" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c590bc2-835a-4faa-b69f-da5b0aea1eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3ac55c0-2326-43c9-b32f-5078e274371d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c590bc2-835a-4faa-b69f-da5b0aea1eb5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3ac55c0-2326-43c9-b32f-5078e274371d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6f55780f-fd79-4eef-bd98-08fa150a9b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3ac55c0-2326-43c9-b32f-5078e274371d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6f55780f-fd79-4eef-bd98-08fa150a9b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_01079582-6810-447a-a502-ed1463dbc2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3ac55c0-2326-43c9-b32f-5078e274371d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_01079582-6810-447a-a502-ed1463dbc2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_030c220b-e2a6-416d-aaf0-fb06320eee37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3ac55c0-2326-43c9-b32f-5078e274371d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_030c220b-e2a6-416d-aaf0-fb06320eee37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e84ef1d0-f776-4ddb-a3cb-7e23b61f04aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_588d7eed-9809-4cd2-a05d-11134c049196" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e84ef1d0-f776-4ddb-a3cb-7e23b61f04aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6797349b-f323-43d4-a4c0-4873374551c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e84ef1d0-f776-4ddb-a3cb-7e23b61f04aa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6797349b-f323-43d4-a4c0-4873374551c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_49de0eae-c91d-4286-aeb9-3442854e04d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6797349b-f323-43d4-a4c0-4873374551c9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_49de0eae-c91d-4286-aeb9-3442854e04d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ea308942-d3c9-43fc-9709-b99ef2a3fa43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_588d7eed-9809-4cd2-a05d-11134c049196" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ea308942-d3c9-43fc-9709-b99ef2a3fa43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_6f37e406-6b8e-4a75-8df7-3a250a1507d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ea308942-d3c9-43fc-9709-b99ef2a3fa43" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_6f37e406-6b8e-4a75-8df7-3a250a1507d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_31e6d7bf-6854-4eea-a084-2df152671dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6f37e406-6b8e-4a75-8df7-3a250a1507d5" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_31e6d7bf-6854-4eea-a084-2df152671dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquity" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fab3528c-75e8-47f8-adb0-f033302e16c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4a190641-329a-4f26-8048-83ae1abaf3af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fab3528c-75e8-47f8-adb0-f033302e16c1" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4a190641-329a-4f26-8048-83ae1abaf3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_337faa4d-eafc-4c27-98fd-23a4ba56ca41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_bdecbf25-5c8d-41cc-998b-7c2ce63bd2af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_337faa4d-eafc-4c27-98fd-23a4ba56ca41" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_bdecbf25-5c8d-41cc-998b-7c2ce63bd2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a847d7e7-2d39-4b07-be45-99f83fed6e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_18f86550-20c6-4882-af9e-2ca59df99674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a847d7e7-2d39-4b07-be45-99f83fed6e2d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_18f86550-20c6-4882-af9e-2ca59df99674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c52c8558-015f-41f3-9751-8b2e11e1b027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_18f86550-20c6-4882-af9e-2ca59df99674" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c52c8558-015f-41f3-9751-8b2e11e1b027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5f6e57f1-9949-4392-9b1c-8371c287c2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c52c8558-015f-41f3-9751-8b2e11e1b027" xlink:to="loc_us-gaap_EquityComponentDomain_5f6e57f1-9949-4392-9b1c-8371c287c2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bf04410c-eb0d-47d6-8bba-690b0c50bfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5f6e57f1-9949-4392-9b1c-8371c287c2c6" xlink:to="loc_us-gaap_CommonStockMember_bf04410c-eb0d-47d6-8bba-690b0c50bfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d0ad0c00-81e9-4676-ad49-4cbf08e90c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_18f86550-20c6-4882-af9e-2ca59df99674" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d0ad0c00-81e9-4676-ad49-4cbf08e90c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f117f18d-56cf-4f5f-bc0d-0e6bac3ccf97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d0ad0c00-81e9-4676-ad49-4cbf08e90c5b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f117f18d-56cf-4f5f-bc0d-0e6bac3ccf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_045f0f4e-7ab6-4a80-aedd-85677c99cac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f117f18d-56cf-4f5f-bc0d-0e6bac3ccf97" xlink:to="loc_us-gaap_IPOMember_045f0f4e-7ab6-4a80-aedd-85677c99cac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a173bc5c-64ab-4ce2-8271-641b58348637" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_18f86550-20c6-4882-af9e-2ca59df99674" xlink:to="loc_srt_CounterpartyNameAxis_a173bc5c-64ab-4ce2-8271-641b58348637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_789072d0-ec92-4b49-8e3e-091298a875dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a173bc5c-64ab-4ce2-8271-641b58348637" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_789072d0-ec92-4b49-8e3e-091298a875dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangingStockholdersMember_9debaeff-1104-428e-99cf-b75a8fe33ad2" xlink:href="exdx-20210930.xsd#exdx_ExchangingStockholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_789072d0-ec92-4b49-8e3e-091298a875dc" xlink:to="loc_exdx_ExchangingStockholdersMember_9debaeff-1104-428e-99cf-b75a8fe33ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_18f86550-20c6-4882-af9e-2ca59df99674" xlink:to="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_849c6fed-e744-4812-ac73-6cb85eaeacca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_849c6fed-e744-4812-ac73-6cb85eaeacca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_388c07be-2439-4e9a-8d1e-b32fc415aee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_388c07be-2439-4e9a-8d1e-b32fc415aee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_db9a993b-a908-4bb7-87db-2ea5098891d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_db9a993b-a908-4bb7-87db-2ea5098891d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts_afa71229-b7a1-4c26-9699-5bdbc15cbf83" xlink:href="exdx-20210930.xsd#exdx_StockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_exdx_StockIssuanceCosts_afa71229-b7a1-4c26-9699-5bdbc15cbf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_c24408e9-2c15-4a23-89cd-91b2b84f741a" xlink:href="exdx-20210930.xsd#exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_c24408e9-2c15-4a23-89cd-91b2b84f741a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f3b4a907-df23-434b-92b8-e7f626ad8951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f3b4a907-df23-434b-92b8-e7f626ad8951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a4dd2f8b-0e49-417a-a86b-6ed7501960a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a4dd2f8b-0e49-417a-a86b-6ed7501960a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_c1a75656-0e9a-466c-bf7b-7cf85da4d2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_c1a75656-0e9a-466c-bf7b-7cf85da4d2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_e4c41378-6b18-4164-ad94-057013541851" xlink:href="exdx-20210930.xsd#exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce896a95-840c-4d92-a6d4-2ada23c9913e" xlink:to="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_e4c41378-6b18-4164-ad94-057013541851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8c723ff6-1dc6-4a77-b417-da7f83836bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_04173147-209d-42b0-a6b4-32393bea607b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8c723ff6-1dc6-4a77-b417-da7f83836bcd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_04173147-209d-42b0-a6b4-32393bea607b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_72faed2f-3677-41c8-8211-f8616272aad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_04173147-209d-42b0-a6b4-32393bea607b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_72faed2f-3677-41c8-8211-f8616272aad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d6c5d9d1-0ad4-40f9-98ec-158ea8a91bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_72faed2f-3677-41c8-8211-f8616272aad4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d6c5d9d1-0ad4-40f9-98ec-158ea8a91bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_83b089ae-cb03-41c7-b5be-9e1dff117bf6" xlink:href="exdx-20210930.xsd#exdx_ExpirationJan192026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d6c5d9d1-0ad4-40f9-98ec-158ea8a91bd4" xlink:to="loc_exdx_ExpirationJan192026Member_83b089ae-cb03-41c7-b5be-9e1dff117bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_bc3be0e1-b61a-4f82-be35-838066c37d45" xlink:href="exdx-20210930.xsd#exdx_ExpirationMar312026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d6c5d9d1-0ad4-40f9-98ec-158ea8a91bd4" xlink:to="loc_exdx_ExpirationMar312026Member_bc3be0e1-b61a-4f82-be35-838066c37d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_514b20a7-6f8a-414d-a614-781aea88e301" xlink:href="exdx-20210930.xsd#exdx_ExpirationApr12026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d6c5d9d1-0ad4-40f9-98ec-158ea8a91bd4" xlink:to="loc_exdx_ExpirationApr12026Member_514b20a7-6f8a-414d-a614-781aea88e301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member_0a854a94-0239-4fdb-950a-766840a3af00" xlink:href="exdx-20210930.xsd#exdx_ExpirationSep72024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d6c5d9d1-0ad4-40f9-98ec-158ea8a91bd4" xlink:to="loc_exdx_ExpirationSep72024Member_0a854a94-0239-4fdb-950a-766840a3af00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_78780efe-9957-46d9-8b86-7dad39113719" xlink:href="exdx-20210930.xsd#exdx_ExpirationDec72025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d6c5d9d1-0ad4-40f9-98ec-158ea8a91bd4" xlink:to="loc_exdx_ExpirationDec72025Member_78780efe-9957-46d9-8b86-7dad39113719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember_83ac126f-92ca-4e9f-8460-a96bdb6195f8" xlink:href="exdx-20210930.xsd#exdx_NoExpirationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d6c5d9d1-0ad4-40f9-98ec-158ea8a91bd4" xlink:to="loc_exdx_NoExpirationMember_83ac126f-92ca-4e9f-8460-a96bdb6195f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3ccb8c04-a38d-490c-bd2e-36452fece7be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_04173147-209d-42b0-a6b4-32393bea607b" xlink:to="loc_us-gaap_ClassOfStockLineItems_3ccb8c04-a38d-490c-bd2e-36452fece7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_11163fbf-c609-4122-b842-3e49c81dac4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ccb8c04-a38d-490c-bd2e-36452fece7be" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_11163fbf-c609-4122-b842-3e49c81dac4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_396d5107-ef28-4261-b94c-f0c4c4f1a970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ccb8c04-a38d-490c-bd2e-36452fece7be" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_396d5107-ef28-4261-b94c-f0c4c4f1a970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_2939531d-cec0-4c4c-9220-776bb8cbaae4" xlink:href="exdx-20210930.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3ccb8c04-a38d-490c-bd2e-36452fece7be" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_2939531d-cec0-4c4c-9220-776bb8cbaae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlan" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockOptionPlan"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82bf7c79-6f60-45e7-8bb3-9db8bddcdfb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7c868a5f-f9c3-4d1b-8098-d4b59155d250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82bf7c79-6f60-45e7-8bb3-9db8bddcdfb8" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7c868a5f-f9c3-4d1b-8098-d4b59155d250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockOptionPlanTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d79d070-051c-436f-bbd4-21b4e42c5944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_84c90293-3c38-4bf9-95d5-a0e03ccce5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d79d070-051c-436f-bbd4-21b4e42c5944" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_84c90293-3c38-4bf9-95d5-a0e03ccce5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f054c1cf-761a-41cf-bdc6-e7219ea69218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d79d070-051c-436f-bbd4-21b4e42c5944" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f054c1cf-761a-41cf-bdc6-e7219ea69218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a16e0aaa-c1cf-43d6-9606-964ee757df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d79d070-051c-436f-bbd4-21b4e42c5944" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a16e0aaa-c1cf-43d6-9606-964ee757df0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_b21f453b-5b18-4aa5-a347-be1278972b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d79d070-051c-436f-bbd4-21b4e42c5944" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_b21f453b-5b18-4aa5-a347-be1278972b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8b5e4c6c-a315-4532-92ca-f1f07bfe6a07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d79d070-051c-436f-bbd4-21b4e42c5944" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8b5e4c6c-a315-4532-92ca-f1f07bfe6a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockOptionPlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1fb9bb2-60b4-4229-8ec3-f25a73743d69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae6d39c7-0e62-4728-9fec-2c7505ebbdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1fb9bb2-60b4-4229-8ec3-f25a73743d69" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae6d39c7-0e62-4728-9fec-2c7505ebbdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_237b8002-ca0e-4f86-bf0a-68223295b7db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae6d39c7-0e62-4728-9fec-2c7505ebbdc3" xlink:to="loc_us-gaap_PlanNameAxis_237b8002-ca0e-4f86-bf0a-68223295b7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_71e4d9be-2be7-402b-b95c-f1ad92448fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_237b8002-ca0e-4f86-bf0a-68223295b7db" xlink:to="loc_us-gaap_PlanNameDomain_71e4d9be-2be7-402b-b95c-f1ad92448fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_bd60e7de-dcd7-45c7-bfbc-a43eda3b9019" xlink:href="exdx-20210930.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_71e4d9be-2be7-402b-b95c-f1ad92448fb6" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_bd60e7de-dcd7-45c7-bfbc-a43eda3b9019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_98f5579f-a20c-4302-9307-2236f065f199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae6d39c7-0e62-4728-9fec-2c7505ebbdc3" xlink:to="loc_us-gaap_AwardTypeAxis_98f5579f-a20c-4302-9307-2236f065f199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_058a0fe5-3781-47e6-9282-4c06f845ba73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_98f5579f-a20c-4302-9307-2236f065f199" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_058a0fe5-3781-47e6-9282-4c06f845ba73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7a0ec08d-498f-415a-83a2-0325d6049067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_058a0fe5-3781-47e6-9282-4c06f845ba73" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7a0ec08d-498f-415a-83a2-0325d6049067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_734dafa1-7b76-4779-a125-97fe87203dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_058a0fe5-3781-47e6-9282-4c06f845ba73" xlink:to="loc_us-gaap_EmployeeStockMember_734dafa1-7b76-4779-a125-97fe87203dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_365af2f0-cfe4-4b9b-ac7e-5cf9244a7c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_058a0fe5-3781-47e6-9282-4c06f845ba73" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_365af2f0-cfe4-4b9b-ac7e-5cf9244a7c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32064ecf-95a1-4a12-9ec8-c211f95f3df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae6d39c7-0e62-4728-9fec-2c7505ebbdc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32064ecf-95a1-4a12-9ec8-c211f95f3df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3ac3d834-006c-4fd2-93c0-5a3679b0cc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32064ecf-95a1-4a12-9ec8-c211f95f3df3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3ac3d834-006c-4fd2-93c0-5a3679b0cc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eb44b018-bc38-4160-a9ff-c87238b0323a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32064ecf-95a1-4a12-9ec8-c211f95f3df3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eb44b018-bc38-4160-a9ff-c87238b0323a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7693cae0-aada-4c45-a20d-72c336ff4180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32064ecf-95a1-4a12-9ec8-c211f95f3df3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7693cae0-aada-4c45-a20d-72c336ff4180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_614ac0e4-eb77-452c-b302-6498ba5b92da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32064ecf-95a1-4a12-9ec8-c211f95f3df3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_614ac0e4-eb77-452c-b302-6498ba5b92da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_99f7208c-626d-4f41-8a6d-aa8c70ab8208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32064ecf-95a1-4a12-9ec8-c211f95f3df3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_99f7208c-626d-4f41-8a6d-aa8c70ab8208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7cd924b7-01d7-47e8-9ebb-61914e04126e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32064ecf-95a1-4a12-9ec8-c211f95f3df3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7cd924b7-01d7-47e8-9ebb-61914e04126e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a565e939-a6a5-4390-9f1c-292b774bc2be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa5ec25a-c580-4e7e-be9e-228d00a8599b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a565e939-a6a5-4390-9f1c-292b774bc2be" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa5ec25a-c580-4e7e-be9e-228d00a8599b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_daeb9b0d-2536-418b-a035-39a748961abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa5ec25a-c580-4e7e-be9e-228d00a8599b" xlink:to="loc_us-gaap_AwardTypeAxis_daeb9b0d-2536-418b-a035-39a748961abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d3cbed0-63c8-49ae-9731-7d5cdc1b992f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_daeb9b0d-2536-418b-a035-39a748961abe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d3cbed0-63c8-49ae-9731-7d5cdc1b992f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c591f449-203e-4472-9dd3-1dcf38dd4ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d3cbed0-63c8-49ae-9731-7d5cdc1b992f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c591f449-203e-4472-9dd3-1dcf38dd4ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa5ec25a-c580-4e7e-be9e-228d00a8599b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98f81a77-68bc-4f4f-8980-44283d45cef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98f81a77-68bc-4f4f-8980-44283d45cef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_38edc834-5fe9-4ed0-bf24-1c336f2810d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98f81a77-68bc-4f4f-8980-44283d45cef8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_38edc834-5fe9-4ed0-bf24-1c336f2810d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0136e218-28e7-455e-b5cd-bb341c07a622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98f81a77-68bc-4f4f-8980-44283d45cef8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0136e218-28e7-455e-b5cd-bb341c07a622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3e42f98-c2ad-4ac1-9087-13b60b16c6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98f81a77-68bc-4f4f-8980-44283d45cef8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3e42f98-c2ad-4ac1-9087-13b60b16c6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9e53eac0-cbc2-469a-a6a1-08363016d27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98f81a77-68bc-4f4f-8980-44283d45cef8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9e53eac0-cbc2-469a-a6a1-08363016d27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0a566a7e-b82d-4458-ac20-517340e3ee05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98f81a77-68bc-4f4f-8980-44283d45cef8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0a566a7e-b82d-4458-ac20-517340e3ee05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b1c2ff2d-117b-404e-9289-edc1f5592d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98f81a77-68bc-4f4f-8980-44283d45cef8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b1c2ff2d-117b-404e-9289-edc1f5592d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ba02b0ac-91a8-44d5-844e-afefa3dd1dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ba02b0ac-91a8-44d5-844e-afefa3dd1dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_78f39dd1-f396-4291-8921-a984695e2f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_78f39dd1-f396-4291-8921-a984695e2f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c70a5032-05ed-48dc-b072-26ab916b4d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c70a5032-05ed-48dc-b072-26ab916b4d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10c1b9cc-12ac-4296-b72a-e2305b7ccded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c70a5032-05ed-48dc-b072-26ab916b4d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10c1b9cc-12ac-4296-b72a-e2305b7ccded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_67908d07-c187-4865-9f1c-386a87a0df17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c70a5032-05ed-48dc-b072-26ab916b4d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_67908d07-c187-4865-9f1c-386a87a0df17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_51de9182-27c5-41de-9977-1db7b0519530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c70a5032-05ed-48dc-b072-26ab916b4d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_51de9182-27c5-41de-9977-1db7b0519530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1351f6a8-0173-466b-bcd3-67688cb8d165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c70a5032-05ed-48dc-b072-26ab916b4d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1351f6a8-0173-466b-bcd3-67688cb8d165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_7dfca1cf-0ec9-4759-a07d-c3cf4a3dcd14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c70a5032-05ed-48dc-b072-26ab916b4d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_7dfca1cf-0ec9-4759-a07d-c3cf4a3dcd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9eb46a26-de34-41ad-bba6-4903a21db6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c70a5032-05ed-48dc-b072-26ab916b4d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9eb46a26-de34-41ad-bba6-4903a21db6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ec1d03ea-fcf8-4c89-9f5a-8b32a3052a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ec1d03ea-fcf8-4c89-9f5a-8b32a3052a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_816d8bf3-95b0-43f2-948a-437062b994dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_816d8bf3-95b0-43f2-948a-437062b994dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62ab11df-9096-4fa9-99f8-5a9f12c35546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4dc67e1c-553a-4e43-9fa5-8a5f080fbcde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62ab11df-9096-4fa9-99f8-5a9f12c35546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5273fa25-7103-4779-952a-927ea2a8c628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62ab11df-9096-4fa9-99f8-5a9f12c35546" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5273fa25-7103-4779-952a-927ea2a8c628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ea8ef93a-b84c-45d8-8795-c63321e4a76d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62ab11df-9096-4fa9-99f8-5a9f12c35546" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ea8ef93a-b84c-45d8-8795-c63321e4a76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_381dc009-c466-42a0-98ec-8dce2cd29cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62ab11df-9096-4fa9-99f8-5a9f12c35546" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_381dc009-c466-42a0-98ec-8dce2cd29cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_688e8e9c-bf68-4fc8-8f53-35c006f445e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62ab11df-9096-4fa9-99f8-5a9f12c35546" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_688e8e9c-bf68-4fc8-8f53-35c006f445e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_021cf214-82eb-4434-8344-e4e94d5e1b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62ab11df-9096-4fa9-99f8-5a9f12c35546" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_021cf214-82eb-4434-8344-e4e94d5e1b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e8c4eb48-6d5d-4664-a748-ee436f3c695c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_62ab11df-9096-4fa9-99f8-5a9f12c35546" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e8c4eb48-6d5d-4664-a748-ee436f3c695c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockOptionPlanRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a181ef11-65cd-47fc-af2e-b43f5ca1d935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c657893a-8b8c-4280-af26-95009bb10a36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a181ef11-65cd-47fc-af2e-b43f5ca1d935" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c657893a-8b8c-4280-af26-95009bb10a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac3e48b7-74b6-41d1-bb8f-bb5553cdb112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c657893a-8b8c-4280-af26-95009bb10a36" xlink:to="loc_us-gaap_AwardTypeAxis_ac3e48b7-74b6-41d1-bb8f-bb5553cdb112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b1b0d90-3a55-4041-abfb-b578975e3f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ac3e48b7-74b6-41d1-bb8f-bb5553cdb112" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b1b0d90-3a55-4041-abfb-b578975e3f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dccf5935-b5ea-4524-830f-b6662c006893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b1b0d90-3a55-4041-abfb-b578975e3f37" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dccf5935-b5ea-4524-830f-b6662c006893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988630cf-ec74-40b7-b0c9-5c2d0011311d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c657893a-8b8c-4280-af26-95009bb10a36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988630cf-ec74-40b7-b0c9-5c2d0011311d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30b6cba9-1dbf-4099-87d1-37be8513483c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988630cf-ec74-40b7-b0c9-5c2d0011311d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30b6cba9-1dbf-4099-87d1-37be8513483c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b6a63dc5-38ea-4758-89f1-d2476778374a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30b6cba9-1dbf-4099-87d1-37be8513483c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b6a63dc5-38ea-4758-89f1-d2476778374a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_755d31b7-1851-43af-afc5-5a07178b0339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30b6cba9-1dbf-4099-87d1-37be8513483c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_755d31b7-1851-43af-afc5-5a07178b0339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cec6c454-b70c-4da7-9d38-b010d86e9848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30b6cba9-1dbf-4099-87d1-37be8513483c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cec6c454-b70c-4da7-9d38-b010d86e9848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e0aac164-605f-4cfa-808b-4217d4277692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30b6cba9-1dbf-4099-87d1-37be8513483c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e0aac164-605f-4cfa-808b-4217d4277692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16cb0902-48c8-4035-9af1-5893209d14e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30b6cba9-1dbf-4099-87d1-37be8513483c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16cb0902-48c8-4035-9af1-5893209d14e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77a036a7-4ce1-4649-a57d-572b22b9ee98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988630cf-ec74-40b7-b0c9-5c2d0011311d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77a036a7-4ce1-4649-a57d-572b22b9ee98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2a1cac45-4e21-479d-8cad-3569bbbad09d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77a036a7-4ce1-4649-a57d-572b22b9ee98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2a1cac45-4e21-479d-8cad-3569bbbad09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_caa49e16-9741-45e8-8144-2fee5205bf82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77a036a7-4ce1-4649-a57d-572b22b9ee98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_caa49e16-9741-45e8-8144-2fee5205bf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2e302711-6098-4758-b987-c3a53c4390c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77a036a7-4ce1-4649-a57d-572b22b9ee98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2e302711-6098-4758-b987-c3a53c4390c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e0190633-24dd-444c-99f5-b70dd3ef841c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77a036a7-4ce1-4649-a57d-572b22b9ee98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e0190633-24dd-444c-99f5-b70dd3ef841c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8fd009cd-46af-43c5-bd5e-e299b7873c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_77a036a7-4ce1-4649-a57d-572b22b9ee98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8fd009cd-46af-43c5-bd5e-e299b7873c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_e2c148f2-b722-44e8-a1be-51bcb3a30809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988630cf-ec74-40b7-b0c9-5c2d0011311d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_e2c148f2-b722-44e8-a1be-51bcb3a30809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_41e7bd35-ab1c-4459-877a-4a0b9beb39c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_e2c148f2-b722-44e8-a1be-51bcb3a30809" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_41e7bd35-ab1c-4459-877a-4a0b9beb39c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockOptionPlanFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b9d3aa1-819f-4d02-b103-4c2369d8e521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd7b555a-9773-42ac-8db9-d69059449b44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b9d3aa1-819f-4d02-b103-4c2369d8e521" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd7b555a-9773-42ac-8db9-d69059449b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f865953e-c90c-4705-9474-9e35ad6b89af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd7b555a-9773-42ac-8db9-d69059449b44" xlink:to="loc_us-gaap_AwardTypeAxis_f865953e-c90c-4705-9474-9e35ad6b89af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc69128a-69d8-4584-ace5-83185bfe2ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f865953e-c90c-4705-9474-9e35ad6b89af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc69128a-69d8-4584-ace5-83185bfe2ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1b43555e-62b5-4948-9620-7d82e973980f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc69128a-69d8-4584-ace5-83185bfe2ef7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1b43555e-62b5-4948-9620-7d82e973980f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_ca4a58df-cba5-4ad2-838f-614c634e98d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc69128a-69d8-4584-ace5-83185bfe2ef7" xlink:to="loc_us-gaap_EmployeeStockMember_ca4a58df-cba5-4ad2-838f-614c634e98d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f3220c5-62c3-4ffc-abd7-983b82c869cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd7b555a-9773-42ac-8db9-d69059449b44" xlink:to="loc_srt_RangeAxis_2f3220c5-62c3-4ffc-abd7-983b82c869cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1cce5a0b-1320-4c60-9b86-fc9edf3d106d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2f3220c5-62c3-4ffc-abd7-983b82c869cb" xlink:to="loc_srt_RangeMember_1cce5a0b-1320-4c60-9b86-fc9edf3d106d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5c9a6ffc-8400-430e-954f-5b74b2335d77" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1cce5a0b-1320-4c60-9b86-fc9edf3d106d" xlink:to="loc_srt_MinimumMember_5c9a6ffc-8400-430e-954f-5b74b2335d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c7a7be88-191c-4c6d-82b8-c10bfd019dbd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1cce5a0b-1320-4c60-9b86-fc9edf3d106d" xlink:to="loc_srt_MaximumMember_c7a7be88-191c-4c6d-82b8-c10bfd019dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd7b555a-9773-42ac-8db9-d69059449b44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9d51814b-44f5-423c-91af-1df0f973bfca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9d51814b-44f5-423c-91af-1df0f973bfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_559883e5-95ff-4232-b0f6-b7d96fbf63bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_559883e5-95ff-4232-b0f6-b7d96fbf63bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c6e2089b-d473-4e7e-9794-34a41b1528d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c6e2089b-d473-4e7e-9794-34a41b1528d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9eb090f4-1fad-4f8b-94ed-1489b824d66d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9eb090f4-1fad-4f8b-94ed-1489b824d66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_36bc0d8c-a960-475c-bbe6-92545c9e97ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_36bc0d8c-a960-475c-bbe6-92545c9e97ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_94539eaf-02b6-483a-b13e-4ed982143ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_94539eaf-02b6-483a-b13e-4ed982143ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2b585fbd-fff1-4f04-a542-0f3b12c2500e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2b585fbd-fff1-4f04-a542-0f3b12c2500e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_06a6ea7a-c03b-4255-af7f-b4745031748a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db475a9b-2f1f-45a7-a38a-9a8930f8e77d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_06a6ea7a-c03b-4255-af7f-b4745031748a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4d83f84-c161-4fdb-b3ec-d93634249e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22b58aa8-0f76-4529-9e26-5c121cf5f6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4d83f84-c161-4fdb-b3ec-d93634249e95" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22b58aa8-0f76-4529-9e26-5c121cf5f6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6eb6fc6e-fa32-494f-be3c-55fae283def7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22b58aa8-0f76-4529-9e26-5c121cf5f6dc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6eb6fc6e-fa32-494f-be3c-55fae283def7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4d7fe41d-c77d-4151-90a6-968dc75849cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6eb6fc6e-fa32-494f-be3c-55fae283def7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4d7fe41d-c77d-4151-90a6-968dc75849cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_b8eea58a-c7ca-4bf6-a812-dbf3815b88fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d7fe41d-c77d-4151-90a6-968dc75849cc" xlink:to="loc_us-gaap_CostOfSalesMember_b8eea58a-c7ca-4bf6-a812-dbf3815b88fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b0639086-3778-4668-a3bb-0d94d468428a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d7fe41d-c77d-4151-90a6-968dc75849cc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b0639086-3778-4668-a3bb-0d94d468428a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ff519cb1-ec7f-405a-bdda-f3324a58e4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d7fe41d-c77d-4151-90a6-968dc75849cc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ff519cb1-ec7f-405a-bdda-f3324a58e4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aaaf9a17-fe6a-4b72-8270-932744dfdabe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22b58aa8-0f76-4529-9e26-5c121cf5f6dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aaaf9a17-fe6a-4b72-8270-932744dfdabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6dcb39e0-cbbd-4f17-b267-1823eb0c3423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aaaf9a17-fe6a-4b72-8270-932744dfdabe" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6dcb39e0-cbbd-4f17-b267-1823eb0c3423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19" xlink:type="simple" xlink:href="exdx-20210930.xsd#Covid19"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Covid19" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReorganizationsAbstract_66cca453-2253-4ec7-b0e1-f21e87f2cb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReorganizationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_e4fbcc3f-7ee5-41d3-848a-b8d698a22394" xlink:href="exdx-20210930.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReorganizationsAbstract_66cca453-2253-4ec7-b0e1-f21e87f2cb0c" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_e4fbcc3f-7ee5-41d3-848a-b8d698a22394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19Details" xlink:type="simple" xlink:href="exdx-20210930.xsd#Covid19Details"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Covid19Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReorganizationsAbstract_8bb37f43-60b6-4e24-9eb6-6db8072a59e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReorganizationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a97ea2a-1625-44c6-8a08-5e4fd455ee69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReorganizationsAbstract_8bb37f43-60b6-4e24-9eb6-6db8072a59e3" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a97ea2a-1625-44c6-8a08-5e4fd455ee69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d64a2ea9-3beb-4b40-91b3-98cf690db326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a97ea2a-1625-44c6-8a08-5e4fd455ee69" xlink:to="loc_us-gaap_DebtInstrumentAxis_d64a2ea9-3beb-4b40-91b3-98cf690db326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c982ac70-1780-4213-bef8-b454fb3b2aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d64a2ea9-3beb-4b40-91b3-98cf690db326" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c982ac70-1780-4213-bef8-b454fb3b2aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PaycheckProtectionProgramCARESActMember_2aa02972-a29c-4d82-8ac5-f0b99cc06c68" xlink:href="exdx-20210930.xsd#exdx_PaycheckProtectionProgramCARESActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c982ac70-1780-4213-bef8-b454fb3b2aa5" xlink:to="loc_exdx_PaycheckProtectionProgramCARESActMember_2aa02972-a29c-4d82-8ac5-f0b99cc06c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0dcbc47e-7584-4b1e-90ae-52dd9a1db7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a97ea2a-1625-44c6-8a08-5e4fd455ee69" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_0dcbc47e-7584-4b1e-90ae-52dd9a1db7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_4f409665-f7fc-4f27-b89d-aa43a6400a7f" xlink:href="exdx-20210930.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0dcbc47e-7584-4b1e-90ae-52dd9a1db7a0" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_4f409665-f7fc-4f27-b89d-aa43a6400a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_73a996a0-1634-4035-88e4-82a3f5249111" xlink:href="exdx-20210930.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0dcbc47e-7584-4b1e-90ae-52dd9a1db7a0" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_73a996a0-1634-4035-88e4-82a3f5249111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ProceedsFromGovernmentAssistance_6a268d4f-34c5-4172-8aff-5c0b262839b4" xlink:href="exdx-20210930.xsd#exdx_ProceedsFromGovernmentAssistance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0dcbc47e-7584-4b1e-90ae-52dd9a1db7a0" xlink:to="loc_exdx_ProceedsFromGovernmentAssistance_6a268d4f-34c5-4172-8aff-5c0b262839b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromBankDebt_2e031e13-9dbc-4928-a652-0c3735acd403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromBankDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0dcbc47e-7584-4b1e-90ae-52dd9a1db7a0" xlink:to="loc_us-gaap_ProceedsFromBankDebt_2e031e13-9dbc-4928-a652-0c3735acd403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SubsequentEvents" xlink:type="simple" xlink:href="exdx-20210930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3978f144-fc9b-40ed-8897-bc06de1ff84d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_71f56ac7-2570-4cc2-b923-4fb735027719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3978f144-fc9b-40ed-8897-bc06de1ff84d" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_71f56ac7-2570-4cc2-b923-4fb735027719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SubsequentEventsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210930.xsd#SubsequentEventsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3e0b4a1e-87ef-4de3-ac39-96f46d24b4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_7ea06a22-a19e-4c84-b1d1-3070d813325b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3e0b4a1e-87ef-4de3-ac39-96f46d24b4dd" xlink:to="loc_us-gaap_SubsequentEventTable_7ea06a22-a19e-4c84-b1d1-3070d813325b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fafc7d6f-8552-4843-b01d-5c4e8055d9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7ea06a22-a19e-4c84-b1d1-3070d813325b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fafc7d6f-8552-4843-b01d-5c4e8055d9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c0bcb11d-8cde-40c2-b549-b6232764d24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fafc7d6f-8552-4843-b01d-5c4e8055d9d3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c0bcb11d-8cde-40c2-b549-b6232764d24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_eaf9a632-3161-45c4-a50e-9f3508e90b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c0bcb11d-8cde-40c2-b549-b6232764d24f" xlink:to="loc_us-gaap_SubsequentEventMember_eaf9a632-3161-45c4-a50e-9f3508e90b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_164aca2b-1861-4857-8fc0-6b6f99c696bf" xlink:href="exdx-20210930.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7ea06a22-a19e-4c84-b1d1-3070d813325b" xlink:to="loc_exdx_RentalPropertyByTypeAxis_164aca2b-1861-4857-8fc0-6b6f99c696bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_a6ef0905-64cc-49c7-91f9-c9e5113856ad" xlink:href="exdx-20210930.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeAxis_164aca2b-1861-4857-8fc0-6b6f99c696bf" xlink:to="loc_exdx_RentalPropertyByTypeDomain_a6ef0905-64cc-49c7-91f9-c9e5113856ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeSpaceMember_73fb365a-7292-47bb-bbbc-65eae71ea8fe" xlink:href="exdx-20210930.xsd#exdx_OfficeSpaceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_a6ef0905-64cc-49c7-91f9-c9e5113856ad" xlink:to="loc_exdx_OfficeSpaceMember_73fb365a-7292-47bb-bbbc-65eae71ea8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HeadquartersMember_e2e7e8dc-e71b-4c63-ba4b-1bfe70935506" xlink:href="exdx-20210930.xsd#exdx_HeadquartersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_a6ef0905-64cc-49c7-91f9-c9e5113856ad" xlink:to="loc_exdx_HeadquartersMember_e2e7e8dc-e71b-4c63-ba4b-1bfe70935506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_36246533-c897-480e-8a05-34a5c4aa1cc9" xlink:href="exdx-20210930.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_a6ef0905-64cc-49c7-91f9-c9e5113856ad" xlink:to="loc_exdx_OfficeAndLaboratoryMember_36246533-c897-480e-8a05-34a5c4aa1cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_096e0d5a-d42c-47aa-871d-7a24f90de274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7ea06a22-a19e-4c84-b1d1-3070d813325b" xlink:to="loc_us-gaap_DebtInstrumentAxis_096e0d5a-d42c-47aa-871d-7a24f90de274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5e8c09c9-6c7b-402f-b35b-baaf2195d125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_096e0d5a-d42c-47aa-871d-7a24f90de274" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5e8c09c9-6c7b-402f-b35b-baaf2195d125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_65ae085e-2293-4289-af26-b665c727c5fd" xlink:href="exdx-20210930.xsd#exdx_Term2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5e8c09c9-6c7b-402f-b35b-baaf2195d125" xlink:to="loc_exdx_Term2017Member_65ae085e-2293-4289-af26-b665c727c5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_c47e073c-137c-41c2-b462-72e123121994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7ea06a22-a19e-4c84-b1d1-3070d813325b" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_c47e073c-137c-41c2-b462-72e123121994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_58e0a72a-c748-433a-b666-5777b8b8b337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_c47e073c-137c-41c2-b462-72e123121994" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_58e0a72a-c748-433a-b666-5777b8b8b337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_50f446b8-d00c-485d-9973-f90ae57299fb" xlink:href="exdx-20210930.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_58e0a72a-c748-433a-b666-5777b8b8b337" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_50f446b8-d00c-485d-9973-f90ae57299fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_65fb7bb0-a093-4e3a-bca7-729f62eb8d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7ea06a22-a19e-4c84-b1d1-3070d813325b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_65fb7bb0-a093-4e3a-bca7-729f62eb8d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8aa27766-6991-499b-996a-e4ca30fcb105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_65fb7bb0-a093-4e3a-bca7-729f62eb8d90" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8aa27766-6991-499b-996a-e4ca30fcb105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_ac3bec8a-b2a6-4a25-9e35-8fe64938d6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8aa27766-6991-499b-996a-e4ca30fcb105" xlink:to="loc_us-gaap_LoansPayableMember_ac3bec8a-b2a6-4a25-9e35-8fe64938d6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_9a452613-7b45-4193-9b36-5e68691b16d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7ea06a22-a19e-4c84-b1d1-3070d813325b" xlink:to="loc_us-gaap_SubsequentEventLineItems_9a452613-7b45-4193-9b36-5e68691b16d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRent_7e013e33-8eef-4867-a17c-8635895681be" xlink:href="exdx-20210930.xsd#exdx_OperatingLeaseMonthlyBaseRent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9a452613-7b45-4193-9b36-5e68691b16d0" xlink:to="loc_exdx_OperatingLeaseMonthlyBaseRent_7e013e33-8eef-4867-a17c-8635895681be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseTermOfContract_3fe8983a-70af-46f6-824d-e5fe36ff3dcc" xlink:href="exdx-20210930.xsd#exdx_OperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9a452613-7b45-4193-9b36-5e68691b16d0" xlink:to="loc_exdx_OperatingLeaseTermOfContract_3fe8983a-70af-46f6-824d-e5fe36ff3dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRentFirstIncrease_88337e7d-6f6a-4187-b4eb-bd904c5a8316" xlink:href="exdx-20210930.xsd#exdx_OperatingLeaseMonthlyBaseRentFirstIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9a452613-7b45-4193-9b36-5e68691b16d0" xlink:to="loc_exdx_OperatingLeaseMonthlyBaseRentFirstIncrease_88337e7d-6f6a-4187-b4eb-bd904c5a8316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a15dedc0-1785-44db-9ea4-fa93faf9ea3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9a452613-7b45-4193-9b36-5e68691b16d0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a15dedc0-1785-44db-9ea4-fa93faf9ea3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_03c3967a-007d-4a81-896b-93c268f7b870" xlink:href="exdx-20210930.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9a452613-7b45-4193-9b36-5e68691b16d0" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_03c3967a-007d-4a81-896b-93c268f7b870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "1 8H# 2(  A$! Q$!_\0
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M&K]!J93POD--+&RYZCZ:W]4ELO7Y,^@AF7$6=5&\*N2'R2]&WN_3YGS9I?\
MP<I_\%';#Q7=>(;JV^'][9W"XBT&Z\,2K:6W&,HT=PDY]?GE;D^G%>Q? /\
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MG_"-Z]?:/'JEK8_\(WJ5YYEH\LL2R;[6VE09>"5=I8,-N2,$$^^5^#?_  =
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M+VRG5F6>>%0FVV<$AB<E>""2/L[_ (.NCE_@+C^[XH_]Q-?G3^PC^PC\7O\
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M4UZVMYNW8^1XLR^%;!_68KWX;VZIZ6?I>_WGE/\ P:_$_P##?WBS_LD.H?\
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MN($3Q37L=TDN&*O:KM )#I_1![&MN-LSG"K#+Z+M&*3:6E^R]$E?MKY&7".
MC.G+&U%>3;2O^+]6].^@M%%%?GY]R&>:Y7XQ_!SX:?M _#'6O@Y\8O!]GKWA
MO7[-K;5-+O%)25,@A@00T<B,%=)$(>-T5T9652.JH&?6G&4H24D[-:IKH1.$
M:D7&2NF?RM?MU_L<^/\ ]@_]I;7OV=/'M]_:']F^7<Z-KT>GRV\.L:?,NZ&Y
MC60?[T<@5G1)H9HQ(_EEC[#_ ,$%.?\ @K'\*/\ >US_ -,-_7W'_P '2_P&
M\/WOPD^&G[3EL;.WU32_$DWA>\6/3$^T7]O=6\MW#ON 0VRW:SGV1$,,WLC
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MH$%I-JWC'5M/\G[19Z;!M5C$)6 +R3206ZL%D,9N!(8W2-UK^ESX0?"'X;?
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M /"@U3_Y74?\0O\ ^W[_ -%8^$?_ (4&J?\ RNK]Y/PHQ[5\O_KAGG\R_P#
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MX->?^3"?&'_97M0_]-6EU^DE?FW_ ,&O/_)A/C#_ +*]J'_IJTNOTDKP<_\
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MZNG>$_$VL*=OB2$K^X@GN.GVT$&(-)M-P?*&Z6>1M_U/_P %,O\ @F/\*O\
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MK>*,/!YL[1EHT!G&U%S'N:?[*_X)B_\ !,?2/V7])M_C-\9+&WOOB+?6Y\F
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MG]E4T?*_+3T6AT^VI:KF6F^JT.SS35('%?)?[ ?_  4;\&?M'GXV2_$GXY>
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MK,X6-7+$JJLQP. I)X!H+EB\+"RE-*[:5VM6G;OWT]3O#GM16/J_CGP7X?\
M$FD^$-=\6Z;9ZMKGG_V+IMU?)'<7_DH'F\F-B&EV(0S;0=H.3@5@_#_]H[X
M_%?7)/#/PQ^-GA/Q%J$<#3R6.B>(;:ZE6($ R%8G9@H+*"V, L/44!+&86-1
M0E.*E>R5U=NR=K=[-?>CMJ***#H/S1_9_N_^"A7Q-_;/_:F_:8_8HT;X.6NF
MZM\3X?!.K67Q0U+59)DNO#EDEHMQ"+&$+Y<PG\PJS%@?D_AWO<_:1\ ?M?\
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M6PIWH&0X#DCSNIXM6IF6%SZM7AA95%.,(QDG!15G)N_-)26LM;1=TE:YY/\
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M)GPQ^-NF^(H)/"?PI^/SVOA_QW>7PGO'\$M?S:<[O(1N"OYBPM%&JJ888B$
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M\;X(-:=CGCD.(I2K4'3E)2M&,KP:Y>5+5RO)-.[>C;?O6=V>,ZQX+UG]I/\
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(H4444&<C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>exdx-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:exdx="http://www.exagen.com/20210930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exdx-20210930.xsd" xlink:type="simple"/>
    <context id="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i69bdb0e5056143559edb4f8abb0e6740_I20211105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2021-11-05</instant>
        </period>
    </context>
    <context id="i59ce805f96954e73a2aeb07fd95e73f9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie450365559dd46d89f2259410ea12471_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic947e90b872445479ee484e60712b752_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i865bea50ee1b455a84dfb11e33cf1313_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if523e9aa9c344c3aaa54d52f9293169d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i48d05d3781344ed6a035b262079c317a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i756e9691fbec4232a2a72550fe8827ce_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icddde24d5cf540848e569816d215bdc0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i927670c99ebc4fbaa921ca365127a3f9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0e0649178e5d45f48148b103ef4c2322_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iee067a33f24240b1b6a20b3e1806aff9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9320aadf1dce47e1bed19914403ec55e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if1bfa77cf666454cbdeda15eeedec294_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i11196ddd025a40529a27602303c8e198_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7ed996c7387441b79438aa8ee8022cbe_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i15af72fdfd9b40338bca87d9c7bc45b0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i145dd851fc06416792a8abd9ca0753ca_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0e86c5941f4241c8af84064215a7e2f5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8b6ff882bf31482d857ec6f5683bb78c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifbabc350d04d47b6b9d32913973c1fe7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib539fa002ab647c5846c0e3443ff5e82_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idf76918b1cb142d5a91a6c2666125f62_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2f30bb32e1574d1a9d2b765357dbe0bb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2c81cecd619e41fc8c3d99db6c936c40_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id7323a0eecec4c4ea71dc4cce1203339_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie9a730a0e88a4555abc24b44790a742b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9b0855316b0749f19d0440817fc74aba_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i38cae9d0228d4b1f8bfa2f60e4501c49_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5e627efdf666421e923aa8ef9d7b1607_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia0083052ba474d728b64eb6f8a434e04_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1613835ee0c640bca59673be80f4f805_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i926f7d0db6594babacd270a64a40aa1c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7e5abb84f7e7474bb50314ab8d17a743_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6c3746cf4a004a759993958c2357d3f8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4389a97a55544668bcf3bf8164728b95_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib3af59f4ffa848f3b05b4d67819e988c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id832ab757594443da2a42bdc495255a8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iee14b6a111af4fb7b7d7e961b7df5732_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie69e6ffa9ddd45f28e8ec1e038f2bb90_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibcbd85df5b8d470087005bf4782dd47b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i4b61faa063d54a29ac1703f1598a4fe4_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia15f05a146964743a0c788d2aded9cd2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i151e4ee09dca43adb7ec755e1cbaea6a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1d3b0ea347dd4649be1e8b2d457be919_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i891b142b8c174aee9f36273d0c239eda_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9cf656e94ec9450e9b8db4d75b446d2a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icff8ea4afd2e46bca741e9b8f9cd26d0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id38324ce009649c99841caeaeeee19c9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic20ea53b78964d2eb61a34f2189b8a76_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i737254d4d9d1414da6159fa82388a520_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i67c6964d373248dabdf6084b560f6710_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia257328b72b043bdad0caeccbdd70e27_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifb83497be17d4a9bbbde5ed69cb45bc3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i597e2d4f562748d496c7e6c7f253459c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5c6b787c0885415b85652bbc5e484066_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3af039dd0a6148ce8a2372743552eacf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1482dea3ca984bc698a8c00feba5b0fa_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id2256d5cb9fa4792ae30bcc04579ae40_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i532b378bfbdf4cd2ac330f10eff25f42_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i471234789a8b480e9e42bf570277a680_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i06dd18b2d2b343c5a26465304ea780b8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i53c032eb6d0b41fb85a0f9de89ed5b66_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1391ad143fa64151bce6d46f029b004f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3e3015ebd247430c8146f56ddd283df1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7f9ec400fb2f4a7c83cf5e1252a8e58a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0a4923ef3b1c4f67843da57220a877ba_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i382b42bc67f14a9790ebce32e9cde082_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie1b6e104b9dc4b7b9d1a57af719a5906_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibc633231ef254f659288a9bd53f5fed1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0e7b412022ff4e3881bf05b1500b0b9c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8e464ebc33994daf93b13d1aacd0c6b1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib10bc762d1904afc912369ca9320983f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id7da4f398eb84cc8b9c54e850f5e3930_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1641e7630f2d462fa941ca0b1795bd39_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if553089e6f8e49f48b85aaa4c21bacc6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i05c71c56629c42628c1e160c2c7fab30_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i902bd1d2194847388e05b8182f07579d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iac2947a35f6742c3829e243519fdfaff_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iabaa81a5a2494069ab337806bdab2015_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2d91998ff2db475f802cdcc0275405f9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5b61d7a18e7e4264848ef8479c9fd3dc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6c77f758beca4e84a48c2c0f4e371cde_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3ba9e492d61a4b95bb9150e34f4662f5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7c3ac17784114e34ab6fe76435aa264d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2bb26b0130c94f85a59a9057df4cadf4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3c0ae534cbe04b29aefafcd8deda24a7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5eaf63e0a6474648a8bbe8a5cf999092_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1ca0f5525e5e4b3685ab76f896c7eb7b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iac1adb571402442b9b60c2ec86d410e8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i89043fe0d8d347c681da5ba35f7a67d0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic59266bd338a4b6aaf33bc9b4f62065e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idab63119e003452c826621bb5adad62e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i712be5f8ad6d44689ef58bcfe6a5f73d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaba8282bb0c74750a2f12b06a4d5062d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if283cd72fcc34fcbb5110f8be286419a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1c61873a8b5e47a0bc7654ef13e90434_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i52d956d84424450187b7bff38697c856_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7b978a372f504f7b8ec73f8e9f98c5af_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i607600e57bc24ec88574eed626560514_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifb722c1180814c33b2ae495db1c4747d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie2d2aea57de8408b815a41b955b60d80_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i477e8dec7f57476099590b6983065827_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic49699145b6345228d52c3faecb8df97_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i2bd2168bca1e4040a9da3b4ab26b86cf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie23ea36541924557943e2430c72ae778_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i94231fb385924cf282805bc752ae2a94_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="idbf4e5e1265e49b0b09d773e4c783692_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i82e30d87f5d0467ebb7ed83b6b3c099f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id0b1bd5bd7b9482894c0d0ddb344acf9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib3d980d0bd964d458411201e56f11d8c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4f0d37e10e73443eb87f20a4a6c4f420_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6f41e1bfc70949dc928fce12adebe052_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:JanssenPromotionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icfc7b19c5d514b50b41cc32aa3d11d39_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic01c383878c04180a2854e8bd4bd7dbb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7580dedc91584d4f98d22c663e83c737_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3fbce269e861429686eecad63a7ac8d9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id46550cb6dd04983b799689bf77cb356_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i34ca585728074c7dbf14fb4257e9689b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if963174f2eb741b98f44a7603f0a3e37_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibc8a6c3b9a71449e81982ff6c411d4e5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5c552639d72a4d1586237a5c1c0e6160_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if8d669ae291047919c778bbafa987721_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icf6b4d792a8b4d7aba9272a67325b8b7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ica1cd48a7054411c9b4601c8284a7b57_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i90cc78dc6aae4cdcaf1d24b138a2cb0b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1e8e3ebf57ba4b84974afb49d0bb404e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idf4fcbdc1b4745a5b33f78a2ba491dc3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia1367b76ff734867a343920922f694fd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia703865d1c1e42238e72cf40c966acff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic41c409fd996414ca1c565c3fb9e700a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1a41951c3b0c4a48a5ed985502dfd9de_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i36ed70cc5c794512b4fad8285454fe80_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7bdcbd2fc6414ea79b1193e5620bf1a9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i489e0e440e7f4dcc98e8fdbfdd3625bb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4f11a04ba9ab4c488c85cd2feab5f19c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if9aeb5900bd34680b034242eb67e265a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7fe2dbff76584751aa65bc9192aca7f8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i91495a4d15cc42a9a43bf2c45f36cb29_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i062b3ce256a24e639baceecc90b79e9d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i009c796a34f14a8489e678bd5e7ba7e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i638a2a722ce94f7fbd4ee6222f3fec82_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id3c67b740ab54e61a5a9b343990c65fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icfa5972febc9459da204c8686e539242_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia4d4d2d813904871b8dc03c5d28b5913_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26a156c330594b2b9417a57e1bc8ad88_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i05e6cdd6406045d0a32cecdb01802bcc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i603ccc7a3961470db626807866947b63_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i55f4a3829c4446e58090abccb942038c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i597de8f2704546a48516c3951933870b_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="ie56e06d7b68849928e2fe39a26f73f85_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:CapitalRoyaltyPartnersIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i467bcd314d89428f837631f14432ed8c_D20181207-20181207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-07</startDate>
            <endDate>2018-12-07</endDate>
        </period>
    </context>
    <context id="i05b9273e32ae45169280d1693bd07c66_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i42432a2bad8448ddbefe4f6e51452afb_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i44af8d7a747943749fac22ffa3dd323f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i98f4b404a7a746b88f1807dade1827bc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iab6affb37170402fbe076933203ab105_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1ec99d0d3d254c33997d3054789d8af4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id4f3d87cb19a49f193d7d0107a085292_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if4d48a5110ed4d4291de9e8ecd5f4fe6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icd4718b3285d4a899f40931cbfe678bf_I20210823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-23</instant>
        </period>
    </context>
    <context id="ia8bc25f7d63f44cea35854b4039d0885_D20210823-20210823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="i43b31315848e4d43901c9f3183cbebb4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i05fc542a715f42e3aab293e27727085f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3f14904a63b24632b074d2bdb5d4c936_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i408f9d848a9e4b6884930325c910b9b3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia55722d9277e48b09ba4ff1dd33c2c09_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i29c2b0bce9e84c2a8890706b191065b5_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i8141bfc43efa4a6592ea1148f7f0529b_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:AlleghenyHealthNetworkResearchInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i21dbc0462f534175819f4c79dddf82df_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id0c459a6186e4f998b57dfa0fd36cc51_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9675b9781d014000845af2a6c5ce6ab4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic20a022810a34a0e8c547ff3a27e2eff_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3e41083069624d7b86843d65bcb1e246_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1907a197b9bf4ca081846376298c2dbc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id889a74f3c604c9e974adc011ac55e21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b2aebd9d89a4273b23eaddb67c7187b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic0afac1488f04780915c25495618223b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40bda80a1b244e9fb44a8c2c934a4459_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1d65917be864b4284e3dcea0b13a340_D20201110-20201110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-10</startDate>
            <endDate>2020-11-10</endDate>
        </period>
    </context>
    <context id="iba7d0acdfc0f4df5a66f2bb747bb7643_D20210325-20210325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="i0ad7af241ac04bb0b5bca5f52f3c3186_I20210325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="i1381f17c84bb46b99f0deedd39dd8927_D20210622-20210622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:ExchangingStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-22</startDate>
            <endDate>2021-06-22</endDate>
        </period>
    </context>
    <context id="i08bfaba48e6842479e60870fdf457e2f_I20210622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:ExchangingStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-22</instant>
        </period>
    </context>
    <context id="i383d4094819b45efbea334edd4261fee_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i055f44b2d2d645aaa59585abcbde2ce0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8744c39e0b4d471aa0dd059af498b3e8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i51655d8dd5cf4160a3e3c43d9ca5e140_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationSep72024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3ab1059999b0438cb0af5e2cefc99c04_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if1e027871f3d476fb7a00e85ba9c297c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ied9309b5ec844d98aad6b3f0e1ae47bb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1f87200751b54837b785f6f119eae03a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i813af130085e4bcfa2cc8e3c96aa96f8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iff8e60ce9c594c9aa9741f476323c52a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa5c746fe4b94017ad86dcc26492fd0a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i81f9417379b2400e818961f451bb1226_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i48504c2aaa3340f78e4733690a2c664b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idd19ac6d04c2437dabe28931d0bda370_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76d674daf6484d4dba8d57a883f437de_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibef4b05e619f40db9ce589f18c223874_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3d30161937ff49a0b250f9c9743eaad5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic949c32127e144a882f03102ba80d592_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iec9349a3150a4ff99322fb97e4697704_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia972fa811fe848438cbbf17df4213386_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5f5390aa51834b0b9c48b6a1ebb975d1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7535719e17e343dd934c82c15efb6c7a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i35982159cf8245aea8b27f18c2b7c347_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i64d9f93ee0074786a89f1f8599054033_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i812dfaa6798b45bf98314f6d3cb3caf2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaf397bbee62e4358a29c8fe357195adc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6c1776b0ca2349ccb5b02fae30a4d766_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i985d2c00754740a1a75159006860f2f5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i438f8b50be854314a57a86231478aeae_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4d8ea92229ac4b40bb2809f46bc58d7d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i68fba0d065ad49d59ebd33550ccf06b8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia119e096fc994ad881c098574fb63096_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4e7d648e35d44b77b7fd4855916a6275_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5f6449b025d641e0b0375cfa207f3273_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i63ee66c9d6104d338fa41906c77c9c58_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5c3796eb660a4650801221b114877277_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iefa8fc581abf42a49cbe113470783f21_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if68e692cf8c24949bdf0c1127a4fb582_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5dfd57d894e647a88470632fbe75162c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i035f9bfef7cb4a9193e6fb924522482a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i402a6e16113b408c83b914eaf5ca9d14_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i24ee58a4f9ca4e738b4bacc7d0c3ecff_D20200416-20200416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-16</startDate>
            <endDate>2020-04-16</endDate>
        </period>
    </context>
    <context id="i70e8b6ad8e4146a199fe29ee3340804a_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="ie9f93b64bd374d91a76b68cea11d1efa_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="id84bcf56412d40cbb17dc4a699c488f4_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:HeadquartersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i19fdfc2580cb4c58ba25b4bf22f281cb_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="ie47ef4f6de5046f08313d4c7118cd8d2_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="installment">
        <measure>exdx:installment</measure>
    </unit>
    <unit id="segment">
        <measure>exdx:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80L2ZyYWc6ODI1NTYwM2E4MmQ3NGI5OTkzYmViNTVjNzAwMmMxYmEvdGFibGU6NTQwYzEzYmVmZmJkNDJmYWJjNjkwZGRkNTYzMmE4NjIvdGFibGVyYW5nZTo1NDBjMTNiZWZmYmQ0MmZhYmM2OTBkZGQ1NjMyYTg2Ml8zLTEtMS0xLTE0MjUx_25f8d014-14f2-4390-8de7-40b968eea65a">0001274737</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80L2ZyYWc6ODI1NTYwM2E4MmQ3NGI5OTkzYmViNTVjNzAwMmMxYmEvdGFibGU6NTQwYzEzYmVmZmJkNDJmYWJjNjkwZGRkNTYzMmE4NjIvdGFibGVyYW5nZTo1NDBjMTNiZWZmYmQ0MmZhYmM2OTBkZGQ1NjMyYTg2Ml80LTEtMS0xLTE0MjUx_e9488f16-d60d-4c3b-bec0-95d3e17c83b6">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80L2ZyYWc6ODI1NTYwM2E4MmQ3NGI5OTkzYmViNTVjNzAwMmMxYmEvdGFibGU6NTQwYzEzYmVmZmJkNDJmYWJjNjkwZGRkNTYzMmE4NjIvdGFibGVyYW5nZTo1NDBjMTNiZWZmYmQ0MmZhYmM2OTBkZGQ1NjMyYTg2Ml81LTEtMS0xLTE0MjUx_1dcc752f-9c2f-465b-bcd7-b8dde51c57d3">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80L2ZyYWc6ODI1NTYwM2E4MmQ3NGI5OTkzYmViNTVjNzAwMmMxYmEvdGFibGU6NTQwYzEzYmVmZmJkNDJmYWJjNjkwZGRkNTYzMmE4NjIvdGFibGVyYW5nZTo1NDBjMTNiZWZmYmQ0MmZhYmM2OTBkZGQ1NjMyYTg2Ml82LTEtMS0xLTE0MjUx_61ee5c6c-9f95-4b8d-bdd5-6548f4dba3c6">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80L2ZyYWc6ODI1NTYwM2E4MmQ3NGI5OTkzYmViNTVjNzAwMmMxYmEvdGFibGU6NTQwYzEzYmVmZmJkNDJmYWJjNjkwZGRkNTYzMmE4NjIvdGFibGVyYW5nZTo1NDBjMTNiZWZmYmQ0MmZhYmM2OTBkZGQ1NjMyYTg2Ml83LTEtMS0xLTE0MjUx_eaef068a-aa5c-46a0-84e6-633f7d7dad97">false</dei:AmendmentFlag>
    <us-gaap:DebtInstrumentTerm
      contextRef="i42432a2bad8448ddbefe4f6e51452afb_D20191101-20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTExOQ_3937bf68-a790-4703-a448-0929f254939d">P24M</us-gaap:DebtInstrumentTerm>
    <dei:DocumentType
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGV4dHJlZ2lvbjo5OTFjZDhmMDg4ZDU0YTQyYmU2ODQzZTQzNjFiZTZiMF84NA_a1d09263-10ae-4d1b-b739-47a7535e9471">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6N2Y1NDkxZjNkMTlhNGM2MmJmNjkyNDUxMWY2YWZlNzEvdGFibGVyYW5nZTo3ZjU0OTFmM2QxOWE0YzYyYmY2OTI0NTExZjZhZmU3MV8wLTAtMS0xLTE0MjUx_17f99463-2e61-4876-adcc-4aa5ef3a2340">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6N2Y1NDkxZjNkMTlhNGM2MmJmNjkyNDUxMWY2YWZlNzEvdGFibGVyYW5nZTo3ZjU0OTFmM2QxOWE0YzYyYmY2OTI0NTExZjZhZmU3MV8xLTAtMS0xLTE0MjUxL3RleHRyZWdpb246MzE2YmUxMGJkYjdlNGFlM2JiMDQ0ZmYxMjg4MjM4MjBfMzY_be29d40f-906d-4dbf-96df-df0f00795702">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6N2Y1NDkxZjNkMTlhNGM2MmJmNjkyNDUxMWY2YWZlNzEvdGFibGVyYW5nZTo3ZjU0OTFmM2QxOWE0YzYyYmY2OTI0NTExZjZhZmU3MV8yLTAtMS0xLTE0MjUx_873698aa-0762-4a13-bae4-6f2407f987df">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGV4dHJlZ2lvbjo5OTFjZDhmMDg4ZDU0YTQyYmU2ODQzZTQzNjFiZTZiMF8xMjk_2867e8a4-288a-4f28-a6ea-5e675f24bfca">001-39049</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGV4dHJlZ2lvbjo5OTFjZDhmMDg4ZDU0YTQyYmU2ODQzZTQzNjFiZTZiMF8xMzM_4b665b00-1d30-489f-bb75-f117fdee8477">EXAGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NTZhODdmZjBiMjQ0NGQzODk2MzZmODIxYTc0NjU3YWEvdGFibGVyYW5nZTo1NmE4N2ZmMGIyNDQ0ZDM4OTYzNmY4MjFhNzQ2NTdhYV8wLTAtMS0xLTE0MjUx_5b173a8d-d74b-4dc4-9777-b7c05b452620">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NTZhODdmZjBiMjQ0NGQzODk2MzZmODIxYTc0NjU3YWEvdGFibGVyYW5nZTo1NmE4N2ZmMGIyNDQ0ZDM4OTYzNmY4MjFhNzQ2NTdhYV8wLTYtMS0xLTE0MjUx_75cd37b1-0eb0-4165-bcfe-48869341709c">20-0434866</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NTZhODdmZjBiMjQ0NGQzODk2MzZmODIxYTc0NjU3YWEvdGFibGVyYW5nZTo1NmE4N2ZmMGIyNDQ0ZDM4OTYzNmY4MjFhNzQ2NTdhYV8zLTEtMS0xLTE0MjUx_f1c7dd45-9a7a-494c-8df5-aaf0969c4435">1261 Liberty Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NTZhODdmZjBiMjQ0NGQzODk2MzZmODIxYTc0NjU3YWEvdGFibGVyYW5nZTo1NmE4N2ZmMGIyNDQ0ZDM4OTYzNmY4MjFhNzQ2NTdhYV80LTEtMS0xLTE0MjUx_103fc9d7-7163-48cc-83fc-7aa44f09bb87">Vista,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NTZhODdmZjBiMjQ0NGQzODk2MzZmODIxYTc0NjU3YWEvdGFibGVyYW5nZTo1NmE4N2ZmMGIyNDQ0ZDM4OTYzNmY4MjFhNzQ2NTdhYV80LTItMS0xLTE0MjUx_774708e7-93df-40ce-b92d-a1f21e6134df">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NTZhODdmZjBiMjQ0NGQzODk2MzZmODIxYTc0NjU3YWEvdGFibGVyYW5nZTo1NmE4N2ZmMGIyNDQ0ZDM4OTYzNmY4MjFhNzQ2NTdhYV80LTYtMS0xLTE0MjUx_b30ae0bf-bdcd-452c-ae9a-575c1eda254e">92081</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6MDQ2YjZmZGQ0OWQ1NDllNzlkMTdhNGM2ODUzY2JlYWMvdGFibGVyYW5nZTowNDZiNmZkZDQ5ZDU0OWU3OWQxN2E0YzY4NTNjYmVhY18wLTAtMS0xLTE0MjUx_7ad1754a-45e8-4b02-b22d-202b56359842">(760)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6MDQ2YjZmZGQ0OWQ1NDllNzlkMTdhNGM2ODUzY2JlYWMvdGFibGVyYW5nZTowNDZiNmZkZDQ5ZDU0OWU3OWQxN2E0YzY4NTNjYmVhY18wLTEtMS0xLTE0MjUx_427ba533-c13d-4f22-8729-fe1f30d9fbcd">560-1501</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6M2NkNDIzNDczOTc5NDEwYmEzMjdiYjg3NTFkZDdkNmEvdGFibGVyYW5nZTozY2Q0MjM0NzM5Nzk0MTBiYTMyN2JiODc1MWRkN2Q2YV8xLTAtMS0xLTE0MjUx_529e5a03-0f1a-46c3-85cb-1fad35eafe62">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6M2NkNDIzNDczOTc5NDEwYmEzMjdiYjg3NTFkZDdkNmEvdGFibGVyYW5nZTozY2Q0MjM0NzM5Nzk0MTBiYTMyN2JiODc1MWRkN2Q2YV8xLTItMS0xLTE0MjUx_8efb176f-8d1f-4603-b335-0fd653a4980e">XGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6M2NkNDIzNDczOTc5NDEwYmEzMjdiYjg3NTFkZDdkNmEvdGFibGVyYW5nZTozY2Q0MjM0NzM5Nzk0MTBiYTMyN2JiODc1MWRkN2Q2YV8xLTQtMS0xLTE0MjUx_8fe96600-7103-4393-8b60-ff413ed410a6">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGV4dHJlZ2lvbjo5OTFjZDhmMDg4ZDU0YTQyYmU2ODQzZTQzNjFiZTZiMF81OTk_1099dfa8-3204-4d1d-b0af-2daeca360181">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGV4dHJlZ2lvbjo5OTFjZDhmMDg4ZDU0YTQyYmU2ODQzZTQzNjFiZTZiMF85MDE_0da9ccd5-5e72-4a38-a1e0-e06f7481cd03">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NDlkZjQwNTFmNGE0NDM4OGI1ZTU2NTk3MjI5MDgxOGQvdGFibGVyYW5nZTo0OWRmNDA1MWY0YTQ0Mzg4YjVlNTY1OTcyMjkwODE4ZF8yLTAtMS0xLTE0MjUx_973b95bd-19fc-4ab8-8869-ac8344da4334">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NDlkZjQwNTFmNGE0NDM4OGI1ZTU2NTk3MjI5MDgxOGQvdGFibGVyYW5nZTo0OWRmNDA1MWY0YTQ0Mzg4YjVlNTY1OTcyMjkwODE4ZF8yLTQtMS0xLTE0MjUx_11dcadcc-bb3e-42f5-baff-ce1402b431dc">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGFibGU6NDlkZjQwNTFmNGE0NDM4OGI1ZTU2NTk3MjI5MDgxOGQvdGFibGVyYW5nZTo0OWRmNDA1MWY0YTQ0Mzg4YjVlNTY1OTcyMjkwODE4ZF80LTQtMS0xLTE0MjUx_6a7edb18-d237-4fa7-8173-f7220c842e7c">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGV4dHJlZ2lvbjo5OTFjZDhmMDg4ZDU0YTQyYmU2ODQzZTQzNjFiZTZiMF8xNTM0_2addd619-a4df-4522-afd3-e98a2597cc43">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGV4dHJlZ2lvbjo5OTFjZDhmMDg4ZDU0YTQyYmU2ODQzZTQzNjFiZTZiMF8xNjU0_d3c75589-16f8-4064-aab2-cb4ae8e089b1">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i69bdb0e5056143559edb4f8abb0e6740_I20211105"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xL2ZyYWc6OTkxY2Q4ZjA4OGQ1NGE0MmJlNjg0M2U0MzYxYmU2YjAvdGV4dHJlZ2lvbjo5OTFjZDhmMDg4ZDU0YTQyYmU2ODQzZTQzNjFiZTZiMF8xNzQx_77362cf3-a0ca-4346-9aca-ff8190d37a22"
      unitRef="shares">16164232</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfNC00LTEtMS0xNDI1MQ_ac085751-2424-4b87-8e14-64a81aff0f9a"
      unitRef="usd">106766000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfNC02LTEtMS0xNDI1MQ_26c75d73-e19b-496d-bc0d-7c77ad24f057"
      unitRef="usd">57448000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfNS00LTEtMS0xNDI1MQ_a963d561-0190-43ba-a4c8-6958e729a074"
      unitRef="usd">9210000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfNS02LTEtMS0xNDI1MQ_eefa8969-a96d-4900-b12d-19be55e2c06f"
      unitRef="usd">8910000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfNi00LTEtMS0xNDI1MQ_1ebcb142-2449-438c-a67d-33b140f12dcd"
      unitRef="usd">2405000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfNi02LTEtMS0xNDI1MQ_4ef10902-b20b-4076-ad68-408718aa1dfa"
      unitRef="usd">4159000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AssetsCurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfNy00LTEtMS0xNDI1MQ_d388ad6a-8c1d-4561-880d-00984c7a5d91"
      unitRef="usd">118381000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfNy02LTEtMS0xNDI1MQ_b62a8cea-99b1-4fc3-a30d-6a8a3792c92c"
      unitRef="usd">70517000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfOC00LTEtMS0xNDI1MQ_64d907fb-6fc4-4f01-92d4-c46ee8b80853"
      unitRef="usd">3446000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfOC02LTEtMS0xNDI1MQ_7b467475-5cc4-4b29-9113-ee056ad9ec73"
      unitRef="usd">2102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfOS00LTEtMS0xNDI1MQ_44d36bf3-dde5-4745-8287-32a56228e61a"
      unitRef="usd">5506000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfOS02LTEtMS0xNDI1MQ_300deb7b-fe76-40e1-a19e-c1586ae19194"
      unitRef="usd">5506000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTAtNC0xLTEtMTQyNTE_cfc9eaf4-2ed9-499d-8733-a22ed5101a49"
      unitRef="usd">439000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTAtNi0xLTEtMTQyNTE_c6bf5ce9-5cd5-4bfd-a4f1-d42a4b55c2d8"
      unitRef="usd">250000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTEtNC0xLTEtMTQyNTE_c6f0d374-8717-441d-ae5d-c18343a9468a"
      unitRef="usd">127772000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTEtNi0xLTEtMTQyNTE_083dd182-58d7-42e8-bca0-2e94e64d8f6c"
      unitRef="usd">78375000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTQtNC0xLTEtMTQyNTE_829c5753-6c7a-40ad-a50a-357b90e0933f"
      unitRef="usd">1512000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTQtNi0xLTEtMTQyNTE_98b3ba33-9d30-4dae-93b8-68c66e159580"
      unitRef="usd">3014000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTUtNC0xLTEtMTQyNTE_06f0efc4-a09e-4d20-8102-c537be3ec374"
      unitRef="usd">6584000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTUtNi0xLTEtMTQyNTE_3c5beacb-c7f2-42c2-ac85-46b362e419c9"
      unitRef="usd">5757000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTctNC0xLTEtMTQyNTE_24d4b065-03db-434b-b8e2-9df4e5270def"
      unitRef="usd">8096000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTctNi0xLTEtMTQyNTE_eb89c13d-2371-43a7-82ec-b6a31f27c6ad"
      unitRef="usd">8771000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTgtNC0xLTEtMTQyNTE_afd81ef4-7b51-4036-8589-3721b49c01d0"
      unitRef="usd">27288000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMTgtNi0xLTEtMTQyNTE_ab3f38a3-1a70-4e8f-a447-8b074e02296f"
      unitRef="usd">26659000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjAtNC0xLTEtMTQyNTE_50ed72f4-c00a-4b8a-9976-0e5ea6f77689"
      unitRef="usd">158000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjAtNi0xLTEtMTQyNTE_d0da781a-d755-413a-9ead-b4b30e4b60be"
      unitRef="usd">158000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjEtNC0xLTEtMTQyNTE_b86c5100-0b10-4b58-87f9-d4bb951b29b4"
      unitRef="usd">1427000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjEtNi0xLTEtMTQyNTE_455a39de-cfe6-40d6-84bb-5caf581dca87"
      unitRef="usd">948000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjItNC0xLTEtMTQyNTE_1f157c7c-c3f1-4213-905e-fad52f01ce77"
      unitRef="usd">36969000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjItNi0xLTEtMTQyNTE_8063524c-a1ad-4e2d-8bc3-3f50ad5213ad"
      unitRef="usd">36536000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjMtNC0xLTEtMTQyNTE_dacd07a3-80dd-4075-8a9c-e378119bdf11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjMtNi0xLTEtMTQyNTE_ee2ca786-6e03-4561-8dbc-3cbab1059764"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjo2Yjc1YjhmMzg5OTQ0NThiOGQ3ODNkOTE4MTg2ZGFiM18yMQ_336e6dc8-e9c2-434f-9b88-54d17ee8ab2e"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjo2Yjc1YjhmMzg5OTQ0NThiOGQ3ODNkOTE4MTg2ZGFiM18yMQ_7243d33f-efea-404b-8094-47f3999b2fe4"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjo2Yjc1YjhmMzg5OTQ0NThiOGQ3ODNkOTE4MTg2ZGFiM18zNQ_6b7e2d29-1f84-46e9-9fd1-ca5bdab8ca11"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjo2Yjc1YjhmMzg5OTQ0NThiOGQ3ODNkOTE4MTg2ZGFiM18zNQ_ec57eac6-1430-46a6-8561-2cd887de69a5"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjo2Yjc1YjhmMzg5OTQ0NThiOGQ3ODNkOTE4MTg2ZGFiM181Nw_5cad7353-6400-4379-b45e-90587725d342"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjo2Yjc1YjhmMzg5OTQ0NThiOGQ3ODNkOTE4MTg2ZGFiM181Nw_6665e0aa-9b58-48c9-b091-cdb5b47117c2"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjo2Yjc1YjhmMzg5OTQ0NThiOGQ3ODNkOTE4MTg2ZGFiM181Nw_b9843b48-b0ca-44df-af29-31b20e0cf9d0"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjo2Yjc1YjhmMzg5OTQ0NThiOGQ3ODNkOTE4MTg2ZGFiM181Nw_cdf33025-e623-4a8f-924a-090d7bf26124"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtNC0xLTEtMTQyNTE_15dc11bb-0c17-4a05-9c7e-71ee3bc2c7c1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjYtNi0xLTEtMTQyNTE_f0e6d436-a270-4647-b958-306fc4f83b98"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjowYmJkZmRhMjhmMzA0YmY0YTllYjE5ZjVjNWI3MGUwMV8xOA_ca48c59c-db86-47d0-93b1-57a6b0e04e28"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjowYmJkZmRhMjhmMzA0YmY0YTllYjE5ZjVjNWI3MGUwMV8xOA_f07a1fd5-1d39-4ef7-8acd-b1233825a8f5"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjowYmJkZmRhMjhmMzA0YmY0YTllYjE5ZjVjNWI3MGUwMV8zMg_6b5c49e9-f083-4f28-908c-030da3d909ee"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjowYmJkZmRhMjhmMzA0YmY0YTllYjE5ZjVjNWI3MGUwMV8zMg_ffdfcc19-32ce-41bb-939b-edcc34ea201f"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjowYmJkZmRhMjhmMzA0YmY0YTllYjE5ZjVjNWI3MGUwMV84Mg_22068120-c675-46ed-ac8c-b24ef4d94528"
      unitRef="shares">16164232</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjowYmJkZmRhMjhmMzA0YmY0YTllYjE5ZjVjNWI3MGUwMV84Mg_85cce2f7-1951-496a-908e-1d0bf47f4938"
      unitRef="shares">16164232</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjowYmJkZmRhMjhmMzA0YmY0YTllYjE5ZjVjNWI3MGUwMV84OQ_0447ca96-00ef-4016-a0dc-8e43ad833a79"
      unitRef="shares">12652308</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctMC0xLTEtMTQyNTEvdGV4dHJlZ2lvbjowYmJkZmRhMjhmMzA0YmY0YTllYjE5ZjVjNWI3MGUwMV84OQ_453c5299-5c4a-45d2-aabd-817fd498f70a"
      unitRef="shares">12652308</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctNC0xLTEtMTQyNTE_36792049-ca3a-40cd-bce8-544e8fe1fb34"
      unitRef="usd">16000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjctNi0xLTEtMTQyNTE_2ab0f817-82a0-4a91-b9b4-699285a05f81"
      unitRef="usd">13000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjgtNC0xLTEtMTQyNTE_cf009e95-3930-480a-8e09-aaa99018fc71"
      unitRef="usd">291874000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjgtNi0xLTEtMTQyNTE_d424eb58-4542-4cc5-b890-75be80e6570e"
      unitRef="usd">223115000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjktNC0xLTEtMTQyNTE_9f7c9d97-1442-43ed-96b0-7217a008c7c5"
      unitRef="usd">-201087000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMjktNi0xLTEtMTQyNTE_347b9115-e212-4063-8c31-f3ffd7966a23"
      unitRef="usd">-181289000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMzAtNC0xLTEtMTQyNTE_ea37a680-908a-46e9-97ef-d097a85c8fbc"
      unitRef="usd">90803000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMzAtNi0xLTEtMTQyNTE_8aaa8d9d-39e1-4d4e-924b-1fbadf512810"
      unitRef="usd">41839000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMzEtNC0xLTEtMTQyNTE_7a2410b9-5863-437e-b6f0-fd453a601196"
      unitRef="usd">127772000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xNi9mcmFnOjJhZWRkOTMwZGRjNzQ0NmZhZGZjNTMyODg2OTkwNjIzL3RhYmxlOjc5Yzc0Mzc3MDRlZDQ2MjFhOTAyOTFkMjM1NTUyMTQ5L3RhYmxlcmFuZ2U6NzljNzQzNzcwNGVkNDYyMWE5MDI5MWQyMzU1NTIxNDlfMzEtNi0xLTEtMTQyNTE_42d5c2bd-21d7-4618-b016-80db174efcb3"
      unitRef="usd">78375000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMy0yLTEtMS0xNDI1MQ_8fe5fbe7-ebd4-423f-8191-6d752fcb727f"
      unitRef="usd">12251000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMy00LTEtMS0xNDI1MQ_fb2f9796-28ab-4969-a7d4-46fab763672b"
      unitRef="usd">10775000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMy02LTEtMS0xNDI1MQ_3a081dfc-61fb-40c3-a57d-8f2d24b178ef"
      unitRef="usd">35610000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMy04LTEtMS0xNDI1MQ_5471217e-40e5-4702-9f48-b2b39554a8f9"
      unitRef="usd">29307000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNS0yLTEtMS0xNDI1MQ_127e2033-e116-4af5-b3c9-48b77f5b5393"
      unitRef="usd">5487000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNS00LTEtMS0xNDI1MQ_1377edc3-3a92-473b-95b5-059fef67b415"
      unitRef="usd">4341000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNS02LTEtMS0xNDI1MQ_d1963c8e-cb96-4bf7-84cd-36e728df9a78"
      unitRef="usd">15649000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNS04LTEtMS0xNDI1MQ_0fe37ca7-2a17-4def-aaa7-38bd4706495e"
      unitRef="usd">12224000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNi0yLTEtMS0xNDI1MQ_f3810b3c-8be9-4140-8eed-8a764f9ebc7c"
      unitRef="usd">11528000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNi00LTEtMS0xNDI1MQ_c0bb1d31-c77b-4a33-bd3c-4f385af0100c"
      unitRef="usd">9202000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNi02LTEtMS0xNDI1MQ_7f1c08a6-e3f3-408f-a5d2-c53e7289f091"
      unitRef="usd">32739000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNi04LTEtMS0xNDI1MQ_1fb1dc3a-3437-4a4c-839f-a299add75729"
      unitRef="usd">27104000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNy0yLTEtMS0xNDI1MQ_ff20fa1a-725b-461a-8fd9-ad2086706e3f"
      unitRef="usd">1740000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNy00LTEtMS0xNDI1MQ_b5c6e1d2-2d34-4c5b-b748-956062014d0f"
      unitRef="usd">1018000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNy02LTEtMS0xNDI1MQ_da5cdda6-9d1e-4c94-a087-5fca024fc594"
      unitRef="usd">5035000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfNy04LTEtMS0xNDI1MQ_e0410178-0f59-4e77-a94c-8a428592ac55"
      unitRef="usd">2403000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTAtMi0xLTEtMTQyNTE_ddb13e5f-7593-4910-9f29-1063d4629d74"
      unitRef="usd">18755000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTAtNC0xLTEtMTQyNTE_e7a18f87-2f57-467c-bf50-543e16a93ff6"
      unitRef="usd">14561000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTAtNi0xLTEtMTQyNTE_c1798386-a3b4-4b15-b06c-d0e9e7248fe5"
      unitRef="usd">53423000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTAtOC0xLTEtMTQyNTE_dc57ea97-def7-43e4-85c8-cf90bed9d832"
      unitRef="usd">41731000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTEtMi0xLTEtMTQyNTE_789ca620-896d-413f-93ed-5aa5ab296c63"
      unitRef="usd">-6504000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTEtNC0xLTEtMTQyNTE_76fa0cac-b5ac-499a-ae75-dc29345b1390"
      unitRef="usd">-3786000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTEtNi0xLTEtMTQyNTE_9a342ccd-7598-4791-a668-2b630083cbc6"
      unitRef="usd">-17813000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTEtOC0xLTEtMTQyNTE_0688b7ff-933b-4cde-94c1-846394d3af78"
      unitRef="usd">-12424000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTItMi0xLTEtMTQyNTE_2eea7cf1-ccfa-4198-b11b-85befdbcd005"
      unitRef="usd">678000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTItNC0xLTEtMTQyNTE_27c45d37-dead-4d67-b41e-1b9029fab080"
      unitRef="usd">647000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTItNi0xLTEtMTQyNTE_502fec30-7a2f-44c2-8a8f-67d44aeac9ed"
      unitRef="usd">1986000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTItOC0xLTEtMTQyNTE_afb52eea-499d-46d3-86d6-e880b3dd8979"
      unitRef="usd">1913000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTQtMi0xLTEtMTQyNTE_8a3264c2-5684-40d9-8b07-f7a8ac906742"
      unitRef="usd">3000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTQtNC0xLTEtMTQyNTE_52a536cf-5c3e-4185-9294-6606a4dca0d0"
      unitRef="usd">125000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTQtNi0xLTEtMTQyNTE_2fcfea87-b3c7-4c3f-9536-74affd90d134"
      unitRef="usd">1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTQtOC0xLTEtMTQyNTE_0e87ee3d-d43b-4a5a-ac0a-2adb8a85dcf8"
      unitRef="usd">985000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTUtMi0xLTEtMTQyNTE_8526f81c-8239-4ca3-8129-1e79a6cf5dd9"
      unitRef="usd">-7179000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTUtNC0xLTEtMTQyNTE_49e597f0-03b4-44d6-8ca8-2cef02dd64b6"
      unitRef="usd">-4308000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTUtNi0xLTEtMTQyNTE_10b5fb89-ccc4-47c6-a17c-db6dc970a418"
      unitRef="usd">-19798000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTUtOC0xLTEtMTQyNTE_b5869b8f-5c86-45b1-a310-4f46e277b737"
      unitRef="usd">-13352000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTYtMi0xLTEtMTQyNTE_a642e2ef-dd47-4625-bbca-28782dc367ce"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTYtNC0xLTEtMTQyNTE_13f78f47-101a-458e-b82c-056aa517a63f"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTYtNi0xLTEtMTQyNTE_3ab50c09-c042-4315-866f-1211b74bcadc"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTYtOC0xLTEtMTQyNTE_cb44d30c-bebc-4d1c-9cf4-8b4f9c26c3f5"
      unitRef="usd">-118000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTctMi0xLTEtMTQyNTE_301dd0a6-1a03-44f7-a37b-7680d3dd67f6"
      unitRef="usd">-7179000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTctNC0xLTEtMTQyNTE_27f1bb15-0920-4ec0-b567-79d200d04426"
      unitRef="usd">-4308000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTctNi0xLTEtMTQyNTE_c22402f3-f817-4b2d-910c-dd59e56576fa"
      unitRef="usd">-19798000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMTctOC0xLTEtMTQyNTE_c40e6c1c-0b15-41a1-ba1e-41636b7baaa5"
      unitRef="usd">-13234000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjEtMi0xLTEtMTQyNTE_7839615b-d747-4a19-bf24-0749929815e1"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjEtMi0xLTEtMTQyNTE_e48160ae-8289-4e95-9a2b-a496b48652d2"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjEtNC0xLTEtMTQyNTE_0102caae-a913-4636-ba79-2f8f0014a1be"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjEtNC0xLTEtMTQyNTE_dc9a916f-dbc4-481e-9b49-09b2dfe0a018"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjEtNi0xLTEtMTQyNTE_02487e91-5599-4ffc-9f1f-2ae255007a80"
      unitRef="usdPerShare">-1.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjEtNi0xLTEtMTQyNTE_34d3fbed-e0b6-4b3a-a4d4-fd6ad8bddc04"
      unitRef="usdPerShare">-1.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjEtOC0xLTEtMTQyNTE_3dfd6b21-7330-4266-8dc2-145bfbf12c72"
      unitRef="usdPerShare">-1.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjEtOC0xLTEtMTQyNTE_b248c5a5-c0a2-4baa-a687-dd7883e70541"
      unitRef="usdPerShare">-1.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjItMi0xLTEtMTQyNTE_466e4b57-deef-4bc3-a3e4-0cfd6f4ae7e9"
      unitRef="shares">16945591</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjItMi0xLTEtMTQyNTE_efb0d292-a7bd-4c89-ad70-7894cddfbab7"
      unitRef="shares">16945591</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjItNC0xLTEtMTQyNTE_5d7f854a-1466-4fd0-99fc-ec147da6f046"
      unitRef="shares">12644348</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjItNC0xLTEtMTQyNTE_8b46dd65-7fa0-4a15-8c18-dbaedc460af0"
      unitRef="shares">12644348</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjItNi0xLTEtMTQyNTE_47192f0a-5193-4ca1-b6ef-2b54a800fce2"
      unitRef="shares">15636150</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjItNi0xLTEtMTQyNTE_ffb24c15-0054-48e3-99e9-e18c4adb8265"
      unitRef="shares">15636150</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjItOC0xLTEtMTQyNTE_b989d1b9-3d5e-4cdd-9710-298ce8a4df32"
      unitRef="shares">12626259</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8xOS9mcmFnOjM1NDU3YTQxN2IzNDRkYTFiODBlODgyZWFjNzllZWI2L3RhYmxlOjNhZDZhNGRjMTk4MTQ2MTlhNDVmYjZjY2I2MmJhOTZmL3RhYmxlcmFuZ2U6M2FkNmE0ZGMxOTgxNDYxOWE0NWZiNmNjYjYyYmE5NmZfMjItOC0xLTEtMTQyNTE_bc35c7af-7dc2-4446-be6a-2f47cde3285e"
      unitRef="shares">12626259</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i865bea50ee1b455a84dfb11e33cf1313_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMi0yLTEtMS0xNDI1MQ_1579006c-6b57-4a97-8d80-0440f1407bbf"
      unitRef="shares">12652308</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i865bea50ee1b455a84dfb11e33cf1313_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMi00LTEtMS0xNDI1MQ_4a0d9897-289f-4c38-887d-a5f3b551979e"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if523e9aa9c344c3aaa54d52f9293169d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMi02LTEtMS0xNDI1MQ_792eb3bc-b7bb-40c1-b2e3-fdc80f3263d4"
      unitRef="usd">223115000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i48d05d3781344ed6a035b262079c317a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMi04LTEtMS0xNDI1MQ_8cbe0182-e7af-42ca-8fdc-4ccb37d0f389"
      unitRef="usd">-181289000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMi0xMC0xLTEtMTQyNTE_94a37217-3827-4295-ac70-9f24c0657bfe"
      unitRef="usd">41839000</us-gaap:StockholdersEquity>
    <exdx:StockIssuanceCosts
      contextRef="i756e9691fbec4232a2a72550fe8827ce_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMy0wLTEtMS0xNDI1MS90ZXh0cmVnaW9uOjQ3ZDRhNTIwMTBmODQ2Mjg5Y2M4OGFiMmRjNjkyODBkXzY3_b48ce234-fdac-49f0-b6a2-0086e7e0c833"
      unitRef="usd">4435000</exdx:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="icddde24d5cf540848e569816d215bdc0_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMy0yLTEtMS0xNDI1MQ_7dad7647-8330-4650-89b0-f8a65b5eadfc"
      unitRef="shares">4255000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icddde24d5cf540848e569816d215bdc0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMy00LTEtMS0xNDI1MQ_f8d49838-4ac9-46ce-aa91-5e1999862a64"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i927670c99ebc4fbaa921ca365127a3f9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMy02LTEtMS0xNDI1MQ_fec4fa69-ec16-4688-b893-2bde6ce6efb3"
      unitRef="usd">64705000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0e0649178e5d45f48148b103ef4c2322_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMy0xMC0xLTEtMTQyNTE_1f5fb73d-0a0a-42f9-ad12-c5b984e53bfb"
      unitRef="usd">64709000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icddde24d5cf540848e569816d215bdc0_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNC0yLTEtMS0xNDI1MQ_a9458bfb-7448-416b-a8c1-675c70f331e3"
      unitRef="shares">3381</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i927670c99ebc4fbaa921ca365127a3f9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNC02LTEtMS0xNDI1MQ_e99e9dde-4288-4ee4-b3c8-d2384de33b2c"
      unitRef="usd">44000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0e0649178e5d45f48148b103ef4c2322_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNC0xMC0xLTEtMTQyNTE_15ee2884-b253-4bad-8b73-598d7d8c2aba"
      unitRef="usd">44000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="icddde24d5cf540848e569816d215bdc0_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNS0yLTEtMS0xNDI1MQ_fc93bf2c-999c-4bcc-b396-c78d315e1fc2"
      unitRef="shares">14991</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i927670c99ebc4fbaa921ca365127a3f9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNS02LTEtMS0xNDI1MQ_af085094-5fb8-4ba9-be79-22915688a8e9"
      unitRef="usd">175000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0e0649178e5d45f48148b103ef4c2322_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNS0xMC0xLTEtMTQyNTE_f40c9dcc-dcf0-406d-89d7-dec1a9f74127"
      unitRef="usd">175000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i927670c99ebc4fbaa921ca365127a3f9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNi02LTEtMS0xNDI1MQ_11cf841f-5c2d-46d5-8a5c-b2bdefb61c58"
      unitRef="usd">912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0e0649178e5d45f48148b103ef4c2322_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNi0xMC0xLTEtMTQyNTE_8867d37a-e1de-4893-aa61-ff33af013081"
      unitRef="usd">912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="iee067a33f24240b1b6a20b3e1806aff9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNy04LTEtMS0xNDI1MQ_072cb8d0-861c-40e0-856f-3df0aa56a1a9"
      unitRef="usd">-6209000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0e0649178e5d45f48148b103ef4c2322_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfNy0xMC0xLTEtMTQyNTE_6c6912eb-19d4-4592-80db-19e54e1f5eb5"
      unitRef="usd">-6209000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9320aadf1dce47e1bed19914403ec55e_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOC0yLTEtMS0xNDI1MQ_aefe674a-390e-4489-a7fe-bf26f0c52e1e"
      unitRef="shares">16925680</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9320aadf1dce47e1bed19914403ec55e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOC00LTEtMS0xNDI1MQ_a144a6bf-7ece-4ae7-ad80-0e9a7f7b418c"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if1bfa77cf666454cbdeda15eeedec294_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOC02LTEtMS0xNDI1MQ_86955ce1-9270-484f-9706-2faf196c2345"
      unitRef="usd">288951000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i11196ddd025a40529a27602303c8e198_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOC04LTEtMS0xNDI1MQ_bcd0bd03-b57e-4f2c-8d39-556aa948de2f"
      unitRef="usd">-187498000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i756e9691fbec4232a2a72550fe8827ce_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOC0xMC0xLTEtMTQyNTE_840b1a41-c233-48a1-9e79-72f950ecf73c"
      unitRef="usd">101470000</us-gaap:StockholdersEquity>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i7ed996c7387441b79438aa8ee8022cbe_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOS0yLTEtMS0xNDI1MQ_ad9fee79-ab1b-47ea-8c21-5e2d057b72a3"
      unitRef="shares">804951</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i7ed996c7387441b79438aa8ee8022cbe_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOS00LTEtMS0xNDI1MQ_3fae5a7c-cbbb-4328-9219-7ab47b9eed64"
      unitRef="usd">1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i15af72fdfd9b40338bca87d9c7bc45b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOS02LTEtMS0xNDI1MQ_af0139db-aa23-4f69-8616-0d5670a3160a"
      unitRef="usd">12774000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i145dd851fc06416792a8abd9ca0753ca_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfOS0xMC0xLTEtMTQyNTE_2b280ab9-41a5-4004-8f4c-b86f51c7f712"
      unitRef="usd">12775000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i15af72fdfd9b40338bca87d9c7bc45b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTAtNi0xLTEtMTQyNTE_7c7a0880-7a2c-4966-82c4-7ceb8558f833"
      unitRef="usd">12775000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i145dd851fc06416792a8abd9ca0753ca_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTAtMTAtMS0xLTE0MjUx_454a376e-b861-4ac6-a45e-9e52eef9f037"
      unitRef="usd">12775000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7ed996c7387441b79438aa8ee8022cbe_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTEtMi0xLTEtMTQyNTE_15845c0e-f72a-406d-b771-7b07350ad624"
      unitRef="shares">6055</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i15af72fdfd9b40338bca87d9c7bc45b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTEtNi0xLTEtMTQyNTE_7fb74ad3-dbb0-41a5-a37d-8ef32ec87f81"
      unitRef="usd">35000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i145dd851fc06416792a8abd9ca0753ca_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTEtMTAtMS0xLTE0MjUx_4f391600-b0b4-4ab9-847a-8754e03a3bfd"
      unitRef="usd">35000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i15af72fdfd9b40338bca87d9c7bc45b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTItNi0xLTEtMTQyNTE_caf3ea38-05f4-4a65-8239-506d19b42dd2"
      unitRef="usd">1285000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i145dd851fc06416792a8abd9ca0753ca_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTItMTAtMS0xLTE0MjUx_cff0fbf3-7fdd-4eb2-aa65-6a57ff917eb1"
      unitRef="usd">1285000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i0e86c5941f4241c8af84064215a7e2f5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTMtOC0xLTEtMTQyNTE_db2e191c-3c07-4e80-ac3a-76577c06f87b"
      unitRef="usd">-6410000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i145dd851fc06416792a8abd9ca0753ca_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTMtMTAtMS0xLTE0MjUx_216ede40-8691-44ea-a248-9199e5db6293"
      unitRef="usd">-6410000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8b6ff882bf31482d857ec6f5683bb78c_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTQtMi0xLTEtMTQyNTE_335642bf-34aa-4d1a-a3f0-4bb805292d4f"
      unitRef="shares">16126784</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8b6ff882bf31482d857ec6f5683bb78c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTQtNC0xLTEtMTQyNTE_742c96e9-c47b-4d74-b46f-53d146deb9b7"
      unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifbabc350d04d47b6b9d32913973c1fe7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTQtNi0xLTEtMTQyNTE_5719242f-617e-464e-80f0-3d985b8dc266"
      unitRef="usd">290272000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib539fa002ab647c5846c0e3443ff5e82_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTQtOC0xLTEtMTQyNTE_248e0284-0080-4e8d-be36-b18adb97d971"
      unitRef="usd">-193908000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idf76918b1cb142d5a91a6c2666125f62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTQtMTAtMS0xLTE0MjUx_4a96082a-b2e9-4da7-968f-f9ba77d903b3"
      unitRef="usd">96380000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2f30bb32e1574d1a9d2b765357dbe0bb_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTUtMi0xLTEtMTQyNTE_101bce7e-5f8d-429d-aafd-8bee89ecc2be"
      unitRef="shares">1752</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2c81cecd619e41fc8c3d99db6c936c40_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTUtNi0xLTEtMTQyNTE_70032bc2-d98a-469c-af7a-551ba150960b"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTUtMTAtMS0xLTE0MjUx_2e5b175c-4bbf-420b-8a61-4e966f6b4bdd"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i2f30bb32e1574d1a9d2b765357dbe0bb_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTYtMi0xLTEtMTQ2NDU_d2d38cfc-4166-44e6-a4c1-7ef7636a5037"
      unitRef="shares">17977</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i2c81cecd619e41fc8c3d99db6c936c40_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTYtNi0xLTEtMTQ2NDU_8e94d0d2-39d8-40c0-ad85-a416a16fe043"
      unitRef="usd">215000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTYtMTAtMS0xLTE0NjQ1_6461dc19-e2d9-456f-b8c9-6f03c0467d22"
      unitRef="usd">215000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2c81cecd619e41fc8c3d99db6c936c40_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTYtNi0xLTEtMTQyNTE_5e0112f6-54a5-4a6a-aa4b-13ccc5386ab0"
      unitRef="usd">1354000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTYtMTAtMS0xLTE0MjUx_75979c66-54b2-4fb9-9c4c-1f7df2cde5e2"
      unitRef="usd">1354000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet
      contextRef="i2f30bb32e1574d1a9d2b765357dbe0bb_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTctMi0xLTEtMTQyNTE_f6b1d6ae-afb5-420c-a01b-b7b08c338424"
      unitRef="shares">17719</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="i2c81cecd619e41fc8c3d99db6c936c40_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTctNi0xLTEtMTQyNTE_9aeb957d-b716-451a-af92-bbce4fc4727e"
      unitRef="usd">32000</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTctMTAtMS0xLTE0MjUx_46b3f75a-4d6f-4d38-a08c-423c8d1c19eb"
      unitRef="usd">32000</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <us-gaap:NetIncomeLoss
      contextRef="id7323a0eecec4c4ea71dc4cce1203339_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTktOC0xLTEtMTQyNTE_c7d2f141-7bce-4ab1-9b02-e55150cb1600"
      unitRef="usd">-7179000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMTktMTAtMS0xLTE0MjUx_e2fa7fd0-9909-4d30-9e0a-ebdc5103bddb"
      unitRef="usd">-7179000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie9a730a0e88a4555abc24b44790a742b_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMjAtMi0xLTEtMTQyNTE_567a8a81-4754-4ef0-a137-14d959a43402"
      unitRef="shares">16164232</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie9a730a0e88a4555abc24b44790a742b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMjAtNC0xLTEtMTQyNTE_0d6b033b-8e0f-4e73-9baf-2ce3c043bf50"
      unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9b0855316b0749f19d0440817fc74aba_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMjAtNi0xLTEtMTQyNTE_5db77590-7486-4ab2-941c-92561f77d4ed"
      unitRef="usd">291874000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i38cae9d0228d4b1f8bfa2f60e4501c49_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMjAtOC0xLTEtMTQyNTE_aa545be4-fbc3-4ee0-a160-f53732d1c982"
      unitRef="usd">-201087000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjg3YmRhMDg3Njk1ZjRjNmFhMThiZjk2MGZlNjVjYWYyL3RhYmxlcmFuZ2U6ODdiZGEwODc2OTVmNGM2YWExOGJmOTYwZmU2NWNhZjJfMjAtMTAtMS0xLTE0MjUx_7ec1d4d2-3138-47cc-bace-bf207bc459e9"
      unitRef="usd">90803000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5e627efdf666421e923aa8ef9d7b1607_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMi0yLTEtMS0xNDI1MQ_c468c04b-9631-41eb-ab03-314ec0f9a4c3"
      unitRef="shares">12560990</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5e627efdf666421e923aa8ef9d7b1607_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMi00LTEtMS0xNDI1MQ_8997bed9-dc19-47bc-aba9-83be3bd52958"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia0083052ba474d728b64eb6f8a434e04_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMi02LTEtMS0xNDI1MQ_3d6411d3-a79a-4846-af24-d8212ef5b2e6"
      unitRef="usd">220248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1613835ee0c640bca59673be80f4f805_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMi04LTEtMS0xNDI1MQ_7b08244d-8055-41b4-8509-ab1f5744ee1a"
      unitRef="usd">-164602000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i926f7d0db6594babacd270a64a40aa1c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMi0xMC0xLTEtMTQyNTE_8ea6f080-1fb5-4061-8a3b-a28aa6eabc1c"
      unitRef="usd">55659000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7e5abb84f7e7474bb50314ab8d17a743_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMy0yLTEtMS0xNDI1MQ_8da6e422-ea9e-48c8-967d-02963008eda3"
      unitRef="shares">43700</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6c3746cf4a004a759993958c2357d3f8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMy02LTEtMS0xNDI1MQ_5b361b7d-459e-4bcc-97ea-634b37e6912c"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4389a97a55544668bcf3bf8164728b95_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMy0xMC0xLTEtMTQyNTE_8955754e-a216-4108-b7c8-5be95b8d1404"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6c3746cf4a004a759993958c2357d3f8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNC02LTEtMS0xNDI1MQ_05a5c9b5-c45f-4702-a439-3d9ba1f93040"
      unitRef="usd">431000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4389a97a55544668bcf3bf8164728b95_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNC0xMC0xLTEtMTQyNTE_0d4b42e8-747a-4d3f-95b2-9f3949779ec6"
      unitRef="usd">431000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet
      contextRef="i7e5abb84f7e7474bb50314ab8d17a743_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNS0yLTEtMS0xNDI1MQ_80302e02-e7f7-440c-99bb-9aab06bee872"
      unitRef="shares">22366</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="i4389a97a55544668bcf3bf8164728b95_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNS0xMC0xLTEtMTQyNTE_8c4ad7ae-d192-40c9-ab6f-a731f6df60d1"
      unitRef="usd">0</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <us-gaap:NetIncomeLoss
      contextRef="ib3af59f4ffa848f3b05b4d67819e988c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNi04LTEtMS0xNDI1MQ_9a7a295a-8740-4e0b-a9c1-82655b3a76ab"
      unitRef="usd">-5563000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4389a97a55544668bcf3bf8164728b95_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNi0xMC0xLTEtMTQyNTE_2e44a171-4e2c-46e4-bebd-00faed96b029"
      unitRef="usd">-5563000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id832ab757594443da2a42bdc495255a8_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNy0yLTEtMS0xNDI1MQ_b25a34aa-3577-495e-bdfc-548121dbc3bf"
      unitRef="shares">12627056</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id832ab757594443da2a42bdc495255a8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNy00LTEtMS0xNDI1MQ_145421c2-317e-40f7-9c31-b2f95c6b5dc0"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iee14b6a111af4fb7b7d7e961b7df5732_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNy02LTEtMS0xNDI1MQ_d124d4e5-ee8d-4261-822d-fe1f1cb8a6e7"
      unitRef="usd">220689000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie69e6ffa9ddd45f28e8ec1e038f2bb90_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNy04LTEtMS0xNDI1MQ_f0afd335-5a03-4c51-9144-63f47ebf8fec"
      unitRef="usd">-170165000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibcbd85df5b8d470087005bf4782dd47b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfNy0xMC0xLTEtMTQyNTE_0364f262-4edd-4d4a-bbbc-4c040480c6e9"
      unitRef="usd">50537000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4b61faa063d54a29ac1703f1598a4fe4_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfOC0yLTEtMS0xNDI1MQ_fadcb7a1-60f7-44f0-826a-381424cdc5db"
      unitRef="shares">3599</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia15f05a146964743a0c788d2aded9cd2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfOC02LTEtMS0xNDI1MQ_834db91b-2889-4338-887d-4e55bbdacc1a"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i151e4ee09dca43adb7ec755e1cbaea6a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfOC0xMC0xLTEtMTQyNTE_b8ba1f27-0f0e-48e9-aceb-788643d9c91d"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia15f05a146964743a0c788d2aded9cd2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfOS02LTEtMS0xNDI1MQ_bb6f2e90-cb8e-4c5e-9668-5cf235ee72c5"
      unitRef="usd">647000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i151e4ee09dca43adb7ec755e1cbaea6a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfOS0xMC0xLTEtMTQyNTE_fbca2ae4-e2b3-442b-992a-54e1d41e298f"
      unitRef="usd">647000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet
      contextRef="i4b61faa063d54a29ac1703f1598a4fe4_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTAtMi0xLTEtMTQyNTE_5b27adc8-b8f8-46d9-b568-9e364ea1bdff"
      unitRef="shares">9754</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="ia15f05a146964743a0c788d2aded9cd2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTAtNi0xLTEtMTQyNTE_84632be8-e765-43a6-b39c-ee5f8837a2d0"
      unitRef="usd">18000</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="i151e4ee09dca43adb7ec755e1cbaea6a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTAtMTAtMS0xLTE0MjUx_468b8839-605a-4201-95f3-0b6b26de8a10"
      unitRef="usd">18000</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <us-gaap:NetIncomeLoss
      contextRef="i1d3b0ea347dd4649be1e8b2d457be919_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTEtOC0xLTEtMTQyNTE_baad6397-5417-468b-90a4-4bceea8c3d64"
      unitRef="usd">-3363000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i151e4ee09dca43adb7ec755e1cbaea6a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTEtMTAtMS0xLTE0MjUx_092bf707-401e-415a-9508-7b83a1d83b43"
      unitRef="usd">-3363000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i891b142b8c174aee9f36273d0c239eda_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTItMi0xLTEtMTQyNTE_64562b6c-a80e-4ef3-9c18-757aa04b77c7"
      unitRef="shares">12640409</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i891b142b8c174aee9f36273d0c239eda_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTItNC0xLTEtMTQyNTE_a3cfd6ac-fd40-4c9d-ab6b-a23334f37cee"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9cf656e94ec9450e9b8db4d75b446d2a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTItNi0xLTEtMTQyNTE_591c8351-8315-449f-bcbd-6a10c97dd2d4"
      unitRef="usd">221356000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icff8ea4afd2e46bca741e9b8f9cd26d0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTItOC0xLTEtMTQyNTE_88511874-7bfb-4e24-a8f7-a5b2482dc75c"
      unitRef="usd">-173528000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id38324ce009649c99841caeaeeee19c9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTItMTAtMS0xLTE0MjUx_ab125a33-f6fe-4dd6-b629-6c7550d03a5a"
      unitRef="usd">47841000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic20ea53b78964d2eb61a34f2189b8a76_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTMtMi0xLTEtMTQyNTE_057db732-ac03-4e47-b630-fff7eaf7712c"
      unitRef="shares">55</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTMtMTAtMS0xLTE0MjUx_07046172-b923-4d47-90ae-760f2ea9df6b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic20ea53b78964d2eb61a34f2189b8a76_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTQtMi0xLTEtMTQyNTE_44f19778-7012-4391-abc8-a0be6a24426d"
      unitRef="shares">11649</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i737254d4d9d1414da6159fa82388a520_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTQtNi0xLTEtMTQyNTE_eec5b7dc-8ec8-4a0f-984e-e87c02069bac"
      unitRef="usd">142000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTQtMTAtMS0xLTE0MjUx_535a348f-5d1f-4f88-bf46-f39d0e50beec"
      unitRef="usd">142000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i737254d4d9d1414da6159fa82388a520_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTUtNi0xLTEtMTQyNTE_5d4a48f5-baf7-4ae5-bb3d-12a60dc9ec8b"
      unitRef="usd">799000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTUtMTAtMS0xLTE0MjUx_916522af-eebf-461c-8e19-edaaf072eec0"
      unitRef="usd">799000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i67c6964d373248dabdf6084b560f6710_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTYtOC0xLTEtMTQyNTE_850f542b-74c7-4327-a2e8-0d301d6daf5e"
      unitRef="usd">-4308000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTYtMTAtMS0xLTE0MjUx_8529d478-c0de-4a66-ac5e-0e063166f5c5"
      unitRef="usd">-4308000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia257328b72b043bdad0caeccbdd70e27_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTctMi0xLTEtMTQyNTE_4e222f1d-d808-4acf-9724-9cb4bb1eaeba"
      unitRef="shares">12652113</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia257328b72b043bdad0caeccbdd70e27_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTctNC0xLTEtMTQyNTE_00a69569-73e8-4a19-b4f1-78956497d20a"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifb83497be17d4a9bbbde5ed69cb45bc3_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTctNi0xLTEtMTQyNTE_9040d97a-c79f-4705-b490-061734b488df"
      unitRef="usd">222297000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i597e2d4f562748d496c7e6c7f253459c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTctOC0xLTEtMTQyNTE_bf7c300d-717c-4564-a0d2-cae7e8ca4494"
      unitRef="usd">-177836000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c6b787c0885415b85652bbc5e484066_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yMi9mcmFnOmRjZWZiZTNhOWZhNjQ2YWU5YzQ1Y2QyMDc5ZjRhMDE0L3RhYmxlOjkyZmIwMDNiYjRjZDRkYzQ4MTExNGIzNGU3MjYwZTU1L3RhYmxlcmFuZ2U6OTJmYjAwM2JiNGNkNGRjNDgxMTE0YjM0ZTcyNjBlNTVfMTctMTAtMS0xLTE0MjUx_910db57c-ad2a-44b6-9915-e50138302f92"
      unitRef="usd">44474000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNC02LTEtMS0xNDI1MQ_7bd1c223-5e7c-4c41-8ed3-5e052a570177"
      unitRef="usd">-19798000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNC04LTEtMS0xNDI1MQ_8846a210-13b7-4ee7-9592-f78b3933e227"
      unitRef="usd">-13234000</us-gaap:NetIncomeLoss>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNi02LTEtMS0xNDI1MQ_d598c22d-385c-45a3-9193-52fd43f8465a"
      unitRef="usd">656000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNi04LTEtMS0xNDI1MQ_0fa28731-8a7e-42cd-aea9-6686ec9973dc"
      unitRef="usd">392000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNy02LTEtMS0xNDI1MQ_11958e31-a506-4a04-85c0-35f9229537f5"
      unitRef="usd">226000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNy04LTEtMS0xNDI1MQ_9c3bb8fc-a7fa-4a5c-aed8-47c0c1a206d0"
      unitRef="usd">202000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:PaidInKindInterest
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfOC02LTEtMS0xNDI1MQ_6c5599cc-077d-4447-a089-616a4c267d6e"
      unitRef="usd">403000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfOC04LTEtMS0xNDI1MQ_8d146e74-f3bb-453b-9d13-c7fd293cce70"
      unitRef="usd">397000</us-gaap:PaidInKindInterest>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTAtNi0xLTEtMTQyNTE_df7adbe9-c1ab-41fd-8d80-a795ecac0af5"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTAtOC0xLTEtMTQyNTE_0ade7ffd-5df0-46f8-ae36-aad1f42d7ee1"
      unitRef="usd">-117000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTItNi0xLTEtMTQyNTE_8cbd4d77-390e-40c7-a161-fc24f17c17e9"
      unitRef="usd">3551000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTItOC0xLTEtMTQyNTE_9b647380-8d2f-4c4b-a096-fb4716b8addd"
      unitRef="usd">1877000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTQtNi0xLTEtMTQyNTE_20882d2b-17fc-4636-b37c-8c251eecf638"
      unitRef="usd">300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTQtOC0xLTEtMTQyNTE_478e2d00-842a-47c4-9888-6387d5e75a7e"
      unitRef="usd">3582000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTUtNi0xLTEtMTQyNTE_9193400a-d3ee-458c-acb3-3b7edd4d248a"
      unitRef="usd">-1754000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTUtOC0xLTEtMTQyNTE_28ba691d-8986-4a2e-9243-877df1b31826"
      unitRef="usd">-1627000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTYtNi0xLTEtMTQyNTE_cf6c12da-3f21-43a0-a705-346c3544a26c"
      unitRef="usd">167000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTYtOC0xLTEtMTQyNTE_92a8f624-a8a0-4482-a1ab-507eb4919875"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTctNi0xLTEtMTQyNTE_cb5a681d-b29c-4a84-9524-997bff70b844"
      unitRef="usd">-1085000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTctOC0xLTEtMTQyNTE_b89bbd54-145b-461b-a52a-cc5e4c5d887e"
      unitRef="usd">781000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTgtNi0xLTEtMTQyNTE_b301df98-e66f-4c30-a5db-769a1812b9eb"
      unitRef="usd">538000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMTgtOC0xLTEtMTQyNTE_8bcfd82f-c3e9-4857-960e-53416ab751c5"
      unitRef="usd">1472000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjAtNi0xLTEtMTQyNTE_3fb871ac-872d-452a-9a3a-5dcee45b6e24"
      unitRef="usd">-14222000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjAtOC0xLTEtMTQyNTE_d75f2909-6ed9-4d95-82cc-5aef97f611a5"
      unitRef="usd">-10185000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjItNi0xLTEtMTQyNTE_851a682d-d9c1-4e1a-8536-38ba5f61692b"
      unitRef="usd">1306000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjItOC0xLTEtMTQyNTE_da83b899-87ca-4e99-9dda-507f100cc139"
      unitRef="usd">450000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjMtNi0xLTEtMTczMTg_61cd6f11-2c5f-4c5b-86a1-a6d7a52bb817"
      unitRef="usd">50000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjMtOC0xLTEtMTczMTg_e2f0ab0f-1ebe-4569-987e-1c5e58b0961e"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjYtNi0xLTEtMTQyNTE_c9a012d6-efff-4c33-bff5-9600bea50fd8"
      unitRef="usd">-1356000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjYtOC0xLTEtMTQyNTE_d17315d4-ccb0-47b0-81a6-54962babc687"
      unitRef="usd">-450000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjgtNi0xLTEtMTQyNTE_a01603d5-6787-40b1-86b3-a825d022788c"
      unitRef="usd">80000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjgtOC0xLTEtMTQyNTE_b1948f21-7d1d-4f4a-802b-70cd3e9965d5"
      unitRef="usd">12000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjktNi0xLTEtMTQyNTE_5b55b8f6-5a0e-4dc8-836b-57446a1a1bd6"
      unitRef="usd">390000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMjktOC0xLTEtMTQyNTE_160e657b-0a69-41b7-bfdd-f43851e524f1"
      unitRef="usd">142000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzAtNi0xLTEtMTQyNTE_e3404931-bb99-4328-9195-a6e849dcbd9d"
      unitRef="usd">32000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzAtOC0xLTEtMTQyNTE_cda80da9-7f90-4ae7-88e2-fa158de42f0f"
      unitRef="usd">18000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzEtNi0xLTEtMTQyNTE_cf94458c-c746-4dfa-97d3-ab3e7468d9b1"
      unitRef="usd">343000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzEtOC0xLTEtMTQyNTE_e4b73ae3-a23c-47f9-9264-3a041ce0ecf5"
      unitRef="usd">187000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:ProceedsFromBankDebt
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzItNi0xLTEtMTQyNTE_12a09497-fdf0-42ac-af2b-5708f7b34290"
      unitRef="usd">0</us-gaap:ProceedsFromBankDebt>
    <us-gaap:ProceedsFromBankDebt
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzItOC0xLTEtMTQyNTE_76781f17-599a-4f86-9ec5-c60ac82497ef"
      unitRef="usd">2865000</us-gaap:ProceedsFromBankDebt>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzMtNi0xLTEtMTQyNTE_dd305cbc-e765-48ea-80e4-85ad3b92a854"
      unitRef="usd">0</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzMtOC0xLTEtMTQyNTE_10c91063-b2a4-46f7-ae03-6ab337db489c"
      unitRef="usd">2865000</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzUtNi0xLTEtMTQyNTE_0e71baec-139e-4cac-9f6e-aacb0ac0d2e0"
      unitRef="usd">69144000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzUtOC0xLTEtMTQyNTE_d0c30049-d6df-4477-b0f1-4d4ef4e40e95"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzYtNi0xLTEtMTQyNTE_9d16ac9e-7bd1-40e4-947c-435731d77492"
      unitRef="usd">4407000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfMzYtOC0xLTEtMTQyNTE_dc01a75b-86ed-4e5b-b5f2-ceff2c016fd9"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDItNi0xLTEtMTQyNTE_bdf97383-dee8-4a25-80be-81131f3d0963"
      unitRef="usd">64896000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDItOC0xLTEtMTQyNTE_bda14993-b78c-46f8-8a5a-6bd7844e3204"
      unitRef="usd">-15000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDMtNi0xLTEtMTQyNTE_b09ba1ae-a2a4-4c3f-9077-393c6048b39f"
      unitRef="usd">49318000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDMtOC0xLTEtMTQyNTE_0706caf5-4fe0-454e-9e41-eb4edbb79934"
      unitRef="usd">-10650000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDQtNi0xLTEtMTQyNTE_4a4a786d-d97a-436b-bd97-30901a6b8dd5"
      unitRef="usd">57548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i926f7d0db6594babacd270a64a40aa1c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDQtOC0xLTEtMTQyNTE_4c57a72b-38a7-4caa-8f7b-642759864645"
      unitRef="usd">72184000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDUtNi0xLTEtMTQyNTE_52c2c745-b5ee-431b-8f96-bb94a67e46aa"
      unitRef="usd">106866000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5c6b787c0885415b85652bbc5e484066_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDUtOC0xLTEtMTQyNTE_241c45db-8c80-4cbd-be37-d42a4be766c4"
      unitRef="usd">61534000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDctNi0xLTEtMTQyNTE_b3010cd4-1a19-40f2-95fe-9c08f16bfbe7"
      unitRef="usd">1362000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNDctOC0xLTEtMTQyNTE_f3434c9b-fb37-4168-b0bb-27aa8d12e233"
      unitRef="usd">1312000</us-gaap:InterestPaidNet>
    <exdx:EquipmentPurchasedUnderCapitalLease
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNTAtNi0xLTEtMTQyNTE_19fdecce-5826-4f7e-a1a5-8262c06c6ed0"
      unitRef="usd">1111000</exdx:EquipmentPurchasedUnderCapitalLease>
    <exdx:EquipmentPurchasedUnderCapitalLease
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNTAtOC0xLTEtMTQyNTE_b98ce3e8-270f-4566-8528-8dd3d89bec5d"
      unitRef="usd">123000</exdx:EquipmentPurchasedUnderCapitalLease>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNTItNi0xLTEtMTQyNTE_81979997-bc1a-4700-acc8-bbaf13029c4f"
      unitRef="usd">135000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNTItOC0xLTEtMTQyNTE_42f4c3fd-a384-46ff-a12c-ede29ce00daa"
      unitRef="usd">197000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <exdx:DeferredOfferingCostsReclassifiedToEquity
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNTYtNi0xLTEtMTQyNTE_f344f28b-d299-4266-bc2a-9f5c9a3c1d7f"
      unitRef="usd">28000</exdx:DeferredOfferingCostsReclassifiedToEquity>
    <exdx:DeferredOfferingCostsReclassifiedToEquity
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8yNS9mcmFnOjU4NTE4N2JkNjdmODQ3M2FhOGQzZjIyNDNiNGQ3NTUwL3RhYmxlOjdjNmIzYzU3ZTU0MzQ5OGViMWMyNWIyOGUzMTM5ZjFlL3RhYmxlcmFuZ2U6N2M2YjNjNTdlNTQzNDk4ZWIxYzI1YjI4ZTMxMzlmMWVfNTYtOC0xLTEtMTQyNTE_56412c01-cc95-4b7a-bfb6-d2b2847ea901"
      unitRef="usd">0</exdx:DeferredOfferingCostsReclassifiedToEquity>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zMS9mcmFnOmQwYzQ4MTdhYTJkOTQzNzRiY2JlOTg4OWM1ZTA1ZGRmL3RleHRyZWdpb246ZDBjNDgxN2FhMmQ5NDM3NGJjYmU5ODg5YzVlMDVkZGZfMjIwNQ_a95eb388-e70d-4531-a5ff-ebecbc1197b4">Organization&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exagen Inc. (the Company) is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At September&#160;30, 2021, the Company had cash and cash equivalents of $106.8 million and had an accumulated deficit of $201.1 million. Since inception, the Company has financed its operations primarily through a combination of equity financings of common stock and private placements of preferred securities, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zMS9mcmFnOmQwYzQ4MTdhYTJkOTQzNzRiY2JlOTg4OWM1ZTA1ZGRmL3RleHRyZWdpb246ZDBjNDgxN2FhMmQ5NDM3NGJjYmU5ODg5YzVlMDVkZGZfNjE4_c9b889b6-0872-4701-ab5f-25c70c2764a9"
      unitRef="usd">106800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zMS9mcmFnOmQwYzQ4MTdhYTJkOTQzNzRiY2JlOTg4OWM1ZTA1ZGRmL3RleHRyZWdpb246ZDBjNDgxN2FhMmQ5NDM3NGJjYmU5ODg5YzVlMDVkZGZfNjU1_57d183ba-c092-4b69-9e3d-8ba2fd897139"
      unitRef="usd">-201100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjExOTg_adccba18-1def-4505-9e26-8715b922fb95">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim condensed balance sheet as of September&#160;30, 2021, the condensed statements of operations and the condensed statements of stockholders' equity for the three and nine months ended September&#160;30, 2021 and 2020 and cash flows for the nine months ended September&#160;30, 2021 and 2020 and the related footnote disclosure are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all normal adjustments, necessary for the fair presentation of the Company's financial position as of September&#160;30, 2021 and its results of operations for the three and nine month periods presented. The results for the nine months ended September&#160;30, 2021 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. These unaudited condensed financial statements should be read in conjunction with the Company&#x2019;s audited financial statements for the year ended December 31, 2020, included in its Annual Report on Form 10-K filed with the SEC on March 16, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the fair value of financial instruments measured at fair value, the recoverability of its long-lived assets (including goodwill) and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended September&#160;30, 2021 and 2020, approximately 81% and 68%, respectively, of the Company's revenue was related to the AVISE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; CTD test. For the nine months ended September&#160;30, 2021 and 2020, approximately 81% and 71%, respectively, of the Company's revenue was related to the AVISE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; CTD test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is dependent on key suppliers for certain laboratory materials. For the three months ended September&#160;30, 2021 and 2020, approximately 95% and 98%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. For the nine months ended September&#160;30, 2021 and 2020, approximately 96% and 97%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Client(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes hospitals, other laboratories, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes patient self-pay&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company entered into an arrangement with a financial institution with which it has an existing banking relationship whereby, in exchange for the issuance of corporate credit cards, the Company agreed to obtain a $0.1 million certificate of deposit with this financial institution as collateral for the balances borrowed on these credit cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:16pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janssen Promotion Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, the Company entered into a co-promotion agreement (as amended from time to time, the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States. In August 2021, the Company and Janssen mutually agreed to terminate the Janssen Agreement effective on August 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Janssen Agreement, the Company was responsible for the costs associated with its sales force over the course of such co-promotion. Janssen was responsible for all other aspects of the commercialization of SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company was entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for that quarter over a predetermined baseline. For the first and second quarters of 2020, the tiered promotion fee ranged from $750 to $1,250 per prescription over a predetermined baseline. Due in part to COVID-19, in June 2020, the Janssen Agreement was amended to adjust the predetermined average baseline for the third and fourth quarters of 2020. The Janssen Agreement was further amended in June 2020 and December 2020 to adjust the predetermined average baseline for prescribed units for the quarters ending December 31, 2020 and March 31, 2021 and was subject to further adjustment under certain circumstances. In June 2021, the Janssen Agreement was again amended to proportionally increase the baseline for prescribed units for the quarter ended June 30, 2021 to reflect the addition of certain geographies to the sales territories covered by the Janssen Agreement. For the first and second quarters of 2021, the Company was entitled to an amended tiered promotion fee ranging from $500 to $1,000 per prescription based on the incremental increase in total prescribed units, and the Company was entitled to receive a promotion fee of at least $0.3&#160;million, but capped at 10% above the adjusted predetermined baseline. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the termination of the Janssen Agreement on August 31, 2021, the Company became entitled to receive an aggregate of $0.6 million in consideration. Pursuant to the terms of the termination, the Company is restricted from promoting any other biologic or Janus kinase inhibitor used for treatment of indications covered by the Janssen Agreement without first obtaining Janssen's written consent until May 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's obligations relating to sales and co-promotion services for SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were a series of single performance obligations since Janssen simultaneously received and consumed benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations was based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit since the Amended Janssen Agreement is cancelable. The Company recognized co-promotion revenue of approximately $0.4 million and $1.3 million during the three months ended September&#160;30, 2021 and 2020, respectively. The Company recognized co-promotion revenue of approximately $1.0 million and $3.4 million during the nine months ended September&#160;30, 2021 and 2020, respectively. The related expenses for marketing SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are included in selling, general and administrative expenses and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.6 million and $0.3 million for the three months ended September&#160;30, 2021 and 2020, respectively, and $1.3 million and $0.9 million for the nine months ended September&#160;30, 2021 and 2020, respectively, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $0.6 million and $0.4 million for the three months ended September&#160;30, 2021 and 2020, respectively, and $1.6 million and $1.1 million for the nine months ended September&#160;30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on the grant date and generally vest from the grant date in four equal annual installments subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company's common stock is determined by using the closing price of its common stock on the corresponding date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares in 2021 used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three and nine months ended September&#160;30, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,067,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,067,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,883,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,405,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,883,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,405,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Assistance Grant Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government assistance grants which are unconditional when received and intended to compensate for expenses incurred or replace lost revenue are recognized when those expenses are incurred or during the period that lost revenue is experienced, and the net amount is included in other income in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;Leases&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 842). The new topic supersedes Topic 840,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Topic 842&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases: Targeted Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to early adopt this ASU as of January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDg_60f2d053-4a82-4f52-a2fa-97fc2f0a0f1b">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjExOTU_d93a2d9e-f09b-4d04-97e7-cd299ce0b9e3">For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3af039dd0a6148ce8a2372743552eacf_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfMy0yLTEtMS0xNDI1MQ_03312126-a202-4ee9-94e3-518bdde0ff33"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1482dea3ca984bc698a8c00feba5b0fa_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfMy00LTEtMS0xNDI1MQ_17d04fc9-7ad1-4c32-8cf4-240c6492be3c"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id2256d5cb9fa4792ae30bcc04579ae40_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfMy02LTEtMS0xNDI1MQ_6dbbd7c5-2715-4a2e-a1ab-586921887c78"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i532b378bfbdf4cd2ac330f10eff25f42_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfMy04LTEtMS0xNDI1MQ_635584e9-ca31-4a1d-bc44-4ece38521197"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i471234789a8b480e9e42bf570277a680_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNC0yLTEtMS0xNDI1MQ_ce374ae4-8647-40ab-a0db-fba1836d7509"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i06dd18b2d2b343c5a26465304ea780b8_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNC00LTEtMS0xNDI1MQ_7151a08e-6045-4860-ad00-da7e5c7c9d3d"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i53c032eb6d0b41fb85a0f9de89ed5b66_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNC02LTEtMS0xNDI1MQ_c5895e7e-6b35-46e1-b0f9-b3d662c82af0"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1391ad143fa64151bce6d46f029b004f_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNC04LTEtMS0xNDI1MQ_1682b6c4-fe0d-4a37-af4e-10e7a0a7d6cd"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3e3015ebd247430c8146f56ddd283df1_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNS0yLTEtMS0xNDI1MQ_43d3d963-4e79-458e-a6dd-f3f98a6cddaa"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7f9ec400fb2f4a7c83cf5e1252a8e58a_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNS00LTEtMS0xNDI1MQ_22045694-cbd0-44bd-b8c2-44b8113c72e5"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0a4923ef3b1c4f67843da57220a877ba_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNS02LTEtMS0xNDI1MQ_21a3d045-35f0-4c6d-9fd2-c00307d9aac1"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i382b42bc67f14a9790ebce32e9cde082_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNS04LTEtMS0xNDI1MQ_42df5b98-6e2c-4b7a-95d8-7ae2ec9429f6"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie1b6e104b9dc4b7b9d1a57af719a5906_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNy00LTEtMS0xNDI1MQ_72fd32c1-9efd-4d1f-ba7c-0b79c4d7c792"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibc633231ef254f659288a9bd53f5fed1_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOmFlOGI2ZTBlYjlmZTRmZWFiMzUxOTdlNzVlOWU1ZGZkL3RhYmxlcmFuZ2U6YWU4YjZlMGViOWZlNGZlYWIzNTE5N2U3NWU5ZTVkZmRfNy04LTEtMS0xNDI1MQ_0e295459-7a30-46fb-99f6-133411136c55"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0e7b412022ff4e3881bf05b1500b0b9c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjNlZmJiOTk1ZDExMjQ2YzlhNDAwMWYzYjYzN2IxMjdjL3RhYmxlcmFuZ2U6M2VmYmI5OTVkMTEyNDZjOWE0MDAxZjNiNjM3YjEyN2NfMy00LTEtMS0xNDI1MQ_3e65c265-636a-4640-884c-7514958d5d5a"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8e464ebc33994daf93b13d1aacd0c6b1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjNlZmJiOTk1ZDExMjQ2YzlhNDAwMWYzYjYzN2IxMjdjL3RhYmxlcmFuZ2U6M2VmYmI5OTVkMTEyNDZjOWE0MDAxZjNiNjM3YjEyN2NfMy02LTEtMS0xNDI1MQ_c1d9b4f1-9bfb-4530-86d1-d7484a22c8e6"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib10bc762d1904afc912369ca9320983f_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjNlZmJiOTk1ZDExMjQ2YzlhNDAwMWYzYjYzN2IxMjdjL3RhYmxlcmFuZ2U6M2VmYmI5OTVkMTEyNDZjOWE0MDAxZjNiNjM3YjEyN2NfNC00LTEtMS0xNDI1MQ_d3d1ada0-cf88-4a78-939d-b3f6d4f104ee"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id7da4f398eb84cc8b9c54e850f5e3930_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjNlZmJiOTk1ZDExMjQ2YzlhNDAwMWYzYjYzN2IxMjdjL3RhYmxlcmFuZ2U6M2VmYmI5OTVkMTEyNDZjOWE0MDAxZjNiNjM3YjEyN2NfNS00LTEtMS0xNDI1MQ_a8bb28ee-b45a-4dbd-a3c7-fb34d5b757b4"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1641e7630f2d462fa941ca0b1795bd39_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjNlZmJiOTk1ZDExMjQ2YzlhNDAwMWYzYjYzN2IxMjdjL3RhYmxlcmFuZ2U6M2VmYmI5OTVkMTEyNDZjOWE0MDAxZjNiNjM3YjEyN2NfNS02LTEtMS0xNDI1MQ_ed08041b-361a-427d-a48d-9d7aef90f566"
      unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if553089e6f8e49f48b85aaa4c21bacc6_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMzM3Mg_58b81fb4-091d-48c2-9042-50c13fa87361"
      unitRef="number">0.81</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i05c71c56629c42628c1e160c2c7fab30_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMzM3OQ_e31bf86f-85f6-4dd6-a357-9b02b4d29ab8"
      unitRef="number">0.68</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i902bd1d2194847388e05b8182f07579d_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMzUxMA_eeedf216-a2c5-4c38-a750-20f98ba9bd12"
      unitRef="number">0.81</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iac2947a35f6742c3829e243519fdfaff_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMzUxNw_070f9503-3f5d-4214-b279-c61e9ee8b25d"
      unitRef="number">0.71</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iabaa81a5a2494069ab337806bdab2015_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTA5OTUxMTY0OTExMQ_47aa9b6d-aa89-415c-8953-7134b15a6892"
      unitRef="number">0.95</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2d91998ff2db475f802cdcc0275405f9_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTA5OTUxMTY0OTExOQ_60c64fec-562d-4630-8b71-40c5e9793033"
      unitRef="number">0.98</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5b61d7a18e7e4264848ef8479c9fd3dc_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTA5OTUxMTY0OTIzMQ_4656bedd-589c-4665-89e1-076eb5d9b691"
      unitRef="number">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6c77f758beca4e84a48c2c0f4e371cde_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTA5OTUxMTY0OTIzOQ_cba1d6b7-8a83-47bb-9bf6-059029cb6634"
      unitRef="number">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDk_71a17f84-fb93-422c-9542-31231b933b2a">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Client(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes hospitals, other laboratories, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes patient self-pay&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ba9e492d61a4b95bb9150e34f4662f5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfMy0yLTEtMS0xNDI1MQ_c7e7f378-7148-4a8d-850f-18eaf2d96618"
      unitRef="usd">6910000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c3ac17784114e34ab6fe76435aa264d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfMy00LTEtMS0xNDI1MQ_07aba1a3-ebb1-48b3-8550-f3b7ed6071e9"
      unitRef="usd">5749000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bb26b0130c94f85a59a9057df4cadf4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfMy02LTEtMS0xNDI1MQ_04ddefa0-5b63-4662-bcb1-f2a7d3f37187"
      unitRef="usd">20318000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c0ae534cbe04b29aefafcd8deda24a7_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfMy04LTEtMS0xNDI1MQ_ab8ed310-7f6b-4c7e-ad7a-3cab07405f45"
      unitRef="usd">15949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5eaf63e0a6474648a8bbe8a5cf999092_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNC0yLTEtMS0xNDI1MQ_b4a99878-f32b-4cb8-a2b8-ced5f10f509b"
      unitRef="usd">2330000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ca0f5525e5e4b3685ab76f896c7eb7b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNC00LTEtMS0xNDI1MQ_4163a0bc-eeb8-46db-8043-fae8b1217d5b"
      unitRef="usd">2184000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac1adb571402442b9b60c2ec86d410e8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNC02LTEtMS0xNDI1MQ_c32e06b4-8254-4df7-b39d-36b77a6b491d"
      unitRef="usd">6733000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89043fe0d8d347c681da5ba35f7a67d0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNC04LTEtMS0xNDI1MQ_7096f9bc-b3a2-4a9b-8a99-3ee5b665e8dd"
      unitRef="usd">6236000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic59266bd338a4b6aaf33bc9b4f62065e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNS0yLTEtMS0xNDI1MQ_2196b742-38aa-41da-a829-bef14bd9a6f3"
      unitRef="usd">2346000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idab63119e003452c826621bb5adad62e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNS00LTEtMS0xNDI1MQ_3ecc2ee9-1cce-4ba9-b200-e67c918f2f66"
      unitRef="usd">1260000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i712be5f8ad6d44689ef58bcfe6a5f73d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNS02LTEtMS0xNDI1MQ_7c67c75e-525e-4bd7-8709-121b247e506e"
      unitRef="usd">6738000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaba8282bb0c74750a2f12b06a4d5062d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNS04LTEtMS0xNDI1MQ_8897f53d-84fc-4a01-82ed-42038de0817b"
      unitRef="usd">3088000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if283cd72fcc34fcbb5110f8be286419a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNi0yLTEtMS0xNDI1MQ_0b81fe71-b5ed-4ce8-aa86-0462ffdc7176"
      unitRef="usd">265000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c61873a8b5e47a0bc7654ef13e90434_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNi00LTEtMS0xNDI1MQ_cd4f7120-3253-4d65-b2a7-52792aae04fa"
      unitRef="usd">235000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52d956d84424450187b7bff38697c856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNi02LTEtMS0xNDI1MQ_092321fd-10a5-49bd-a03b-2a142101ae9f"
      unitRef="usd">821000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b978a372f504f7b8ec73f8e9f98c5af_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNi04LTEtMS0xNDI1MQ_ca84699e-e59a-4742-8037-80ed0a26381e"
      unitRef="usd">636000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i607600e57bc24ec88574eed626560514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNy0yLTEtMS0xNDI1MQ_f1ae569f-ca2c-4f75-8d00-4bf2f6d5d3ac"
      unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb722c1180814c33b2ae495db1c4747d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNy00LTEtMS0xNDI1MQ_c54589d0-0b39-465c-b637-65a51f5a9ec5"
      unitRef="usd">1347000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2d2aea57de8408b815a41b955b60d80_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNy02LTEtMS0xNDI1MQ_4fb2d6f4-239c-4aa4-af2d-c467676495de"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i477e8dec7f57476099590b6983065827_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfNy04LTEtMS0xNDI1MQ_44fa22bf-ddc9-4e84-9e63-bf8c474df304"
      unitRef="usd">3398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfOC0yLTEtMS0xNDI1MQ_0b60576e-0686-4446-ac36-b5d96d892e07"
      unitRef="usd">12251000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfOC00LTEtMS0xNDI1MQ_864fb3cb-732b-4c93-822f-11790607035d"
      unitRef="usd">10775000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfOC02LTEtMS0xNDI1MQ_fb70b857-8880-49c4-8cad-eb123170f802"
      unitRef="usd">35610000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjczNGI0N2NmMmIxODQ0ZjM5OTU0MjkzODk4ZWI5YjBkL3RhYmxlcmFuZ2U6NzM0YjQ3Y2YyYjE4NDRmMzk5NTQyOTM4OThlYjliMGRfOC04LTEtMS0xNDI1MQ_8d7c63c3-b59a-4572-bb8d-1af4c1483b06"
      unitRef="usd">29307000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMTA_368043e7-3b0d-4afa-9a60-9102a06d8f7e">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDA_f554cae1-5724-412f-ae95-5d9c141bbc49">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCash
      contextRef="ic49699145b6345228d52c3faecb8df97_I20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfNjI4Mw_d3fe8da0-0c75-4e21-9dc2-9d67fb57433d"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDE_0f8642a6-7f38-4d28-8b0b-b657794e6ae6">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDE_f50178ea-0327-440a-8da5-d899c141e530">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjQ0ZGNlM2E4YzU1ZTRmZGE5ZmIyNGFjNjdmNjg4NzdjL3RhYmxlcmFuZ2U6NDRkY2UzYThjNTVlNGZkYTlmYjI0YWM2N2Y2ODg3N2NfMi00LTEtMS0xNDI1MQ_efa728ff-7c3d-44eb-a2e5-2d8e2358f763"
      unitRef="usd">106766000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjQ0ZGNlM2E4YzU1ZTRmZGE5ZmIyNGFjNjdmNjg4NzdjL3RhYmxlcmFuZ2U6NDRkY2UzYThjNTVlNGZkYTlmYjI0YWM2N2Y2ODg3N2NfMi02LTEtMS0xNDI1MQ_475649e3-5e9e-453b-b1ef-13788e9ccaf8"
      unitRef="usd">57448000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjQ0ZGNlM2E4YzU1ZTRmZGE5ZmIyNGFjNjdmNjg4NzdjL3RhYmxlcmFuZ2U6NDRkY2UzYThjNTVlNGZkYTlmYjI0YWM2N2Y2ODg3N2NfMy00LTEtMS0xNDI1MQ_cb68c9eb-51df-4d00-a8bd-206b092677e3"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjQ0ZGNlM2E4YzU1ZTRmZGE5ZmIyNGFjNjdmNjg4NzdjL3RhYmxlcmFuZ2U6NDRkY2UzYThjNTVlNGZkYTlmYjI0YWM2N2Y2ODg3N2NfMy02LTEtMS0xNDI1MQ_87f68823-b2ee-495a-ae71-2dd994076c73"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjQ0ZGNlM2E4YzU1ZTRmZGE5ZmIyNGFjNjdmNjg4NzdjL3RhYmxlcmFuZ2U6NDRkY2UzYThjNTVlNGZkYTlmYjI0YWM2N2Y2ODg3N2NfNC00LTEtMS0xNDI1MQ_a5a6292b-d57e-4fdd-b672-a13345d94584"
      unitRef="usd">106866000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjQ0ZGNlM2E4YzU1ZTRmZGE5ZmIyNGFjNjdmNjg4NzdjL3RhYmxlcmFuZ2U6NDRkY2UzYThjNTVlNGZkYTlmYjI0YWM2N2Y2ODg3N2NfNC02LTEtMS0xNDI1MQ_d4525aa7-5896-4493-a54b-e47e83a0876f"
      unitRef="usd">57548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjExOTY_cd725306-5a97-4992-84a5-f3c478d4dd1f">&lt;div style="margin-top:16pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i2bd2168bca1e4040a9da3b4ab26b86cf_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTAxNzE_cd53d6c6-882d-4118-849f-6c2fd9f1f7e6"
      unitRef="usd">750</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="ie23ea36541924557943e2430c72ae778_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTAxNzE_f315b38f-2c10-46d0-9de3-565f781bcb36"
      unitRef="usd">750</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i94231fb385924cf282805bc752ae2a94_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTAxNzc_4bbea50f-e7f8-4912-90de-888642a79742"
      unitRef="usd">1250</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="idbf4e5e1265e49b0b09d773e4c783692_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTAxNzc_92b78a90-829d-4b99-a6c1-877997778c33"
      unitRef="usd">1250</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i82e30d87f5d0467ebb7ed83b6b3c099f_I20210630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTEwMjg_940e4fff-0a0e-4edf-8989-3d57c13cf045"
      unitRef="usd">500</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="id0b1bd5bd7b9482894c0d0ddb344acf9_I20210331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTEwMjg_e9b2d36b-3d41-4884-b5ef-0833f53129c3"
      unitRef="usd">500</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="ib3d980d0bd964d458411201e56f11d8c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTEwMzQ_1aa491bd-877d-4c5a-a4c9-145ffd65c2d9"
      unitRef="usd">1000</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i4f0d37e10e73443eb87f20a4a6c4f420_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTEwMzQ_539e30b3-7301-4c9d-9783-9170aa278921"
      unitRef="usd">1000</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFee
      contextRef="i82e30d87f5d0467ebb7ed83b6b3c099f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTExODI_40fdf31b-ec47-4c32-b484-e07d6ef45c47"
      unitRef="usd">300000</exdx:JointVentureQuarterlyPromotionFee>
    <exdx:JointVentureQuarterlyPromotionFee
      contextRef="id0b1bd5bd7b9482894c0d0ddb344acf9_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTExODI_69b38540-654c-4db2-a808-fa46285f2ebc"
      unitRef="usd">300000</exdx:JointVentureQuarterlyPromotionFee>
    <exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline
      contextRef="idf76918b1cb142d5a91a6c2666125f62_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTEyMDA_213e44a3-3072-4841-952b-cc4ba7bafb71"
      unitRef="number">0.10</exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline>
    <exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline
      contextRef="i756e9691fbec4232a2a72550fe8827ce_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTEyMDA_ba931e00-371f-4401-a77f-5809673bede8"
      unitRef="number">0.10</exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline>
    <exdx:JointVentureTerminationConsiderationReceivable
      contextRef="i6f41e1bfc70949dc928fce12adebe052_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTEzNTQ_5515ce57-6f2c-4943-8bf8-763906e98594"
      unitRef="usd">600000</exdx:JointVentureTerminationConsiderationReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfc7b19c5d514b50b41cc32aa3d11d39_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTIyODM_4a970ad4-5de5-4df0-9785-6d5fdbb54a56"
      unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic01c383878c04180a2854e8bd4bd7dbb_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTIyOTg_6ee9f2ca-56d7-4a4d-bc21-bb64de53c1a2"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7580dedc91584d4f98d22c663e83c737_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTI0Mjc_49ac68d4-5860-4c0f-960f-e5111acc8e28"
      unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fbce269e861429686eecad63a7ac8d9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTI0NDI_026a87f4-101a-4dc9-b4a3-498feffc1083"
      unitRef="usd">3400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjExOTc_d9c74aa3-f513-4557-9126-c10b9ee90f86">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMTE_e4190ced-b479-4275-9204-ed9d955a2ae5">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.6 million and $0.3 million for the three months ended September&#160;30, 2021 and 2020, respectively, and $1.3 million and $0.9 million for the nine months ended September&#160;30, 2021 and 2020, respectively, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTMyMDI_5a22a67d-c918-40af-8d7e-8cff837bb5eb"
      unitRef="usd">600000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTMyMTc_fbb6e342-d0c1-424f-9e92-35c33310e82f"
      unitRef="usd">300000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTMyODY_d82ad4a5-6657-405b-9c64-958a024a480f"
      unitRef="usd">1300000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTMzMDE_35652ef2-9f10-4584-92e3-077f5fe6900f"
      unitRef="usd">900000</us-gaap:AdvertisingExpense>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDQ_ca3b34e2-8000-4947-b510-5f68a16c1817">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $0.6 million and $0.4 million for the three months ended September&#160;30, 2021 and 2020, respectively, and $1.6 million and $1.1 million for the nine months ended September&#160;30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:CostOfRevenue
      contextRef="id46550cb6dd04983b799689bf77cb356_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTM2Njg_d993a6ee-8729-4f26-828a-5645addd8eaf"
      unitRef="usd">600000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i34ca585728074c7dbf14fb4257e9689b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTM2NzU_62cf3242-ce29-4747-84c5-9f7bae9e0861"
      unitRef="usd">400000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="if963174f2eb741b98f44a7603f0a3e37_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTM3MzY_635969a5-f4a9-4909-aebe-f9886e54e5da"
      unitRef="usd">1600000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ibc8a6c3b9a71449e81982ff6c411d4e5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTM3NTE_7f7cc310-2459-433d-89dd-dd96c3c0616f"
      unitRef="usd">1100000</us-gaap:CostOfRevenue>
    <us-gaap:EmployeeStockOwnershipPlanESOPPolicy
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDU_5c71184d-f35c-4785-8d5f-0426bc6fc750">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on the grant date and generally vest from the grant date in four equal annual installments subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company's common stock is determined by using the closing price of its common stock on the corresponding date.&lt;/span&gt;&lt;/div&gt;</us-gaap:EmployeeStockOwnershipPlanESOPPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTQ4ODE_95fc6255-4bfc-4d8c-a9fc-5f8a33e61e7e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments
      contextRef="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjE5OTAyMzI3Nzk1OA_c2003199-26b0-4ece-8414-5746f6b9b911"
      unitRef="installment">4</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjExOTE_0805dfcc-97bb-4e62-bf70-6a4692ab5dfb">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDI_ee9115f3-470d-4916-8c6e-8761231aed7c">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares in 2021 used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three and nine months ended September&#160;30, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDY_807e7a5c-446e-43a5-8f91-90071ed87626">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,067,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,067,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,883,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,405,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,883,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,405,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5c552639d72a4d1586237a5c1c0e6160_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNC0yLTEtMS0xNDI1MQ_fb68b698-8e06-4045-861b-c968a51ef425"
      unitRef="shares">409108</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if8d669ae291047919c778bbafa987721_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNC00LTEtMS0xNDI1MQ_9ffff3ae-6a45-4d5e-ace5-bc0badddb63d"
      unitRef="shares">426827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icf6b4d792a8b4d7aba9272a67325b8b7_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNC02LTEtMS0xNDI1MQ_4c47de2e-a686-4990-a32e-ce1573f1df57"
      unitRef="shares">409108</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ica1cd48a7054411c9b4601c8284a7b57_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNC04LTEtMS0xNDI1MQ_1614a796-a16d-4d27-968b-d4ea4f392c88"
      unitRef="shares">426827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i90cc78dc6aae4cdcaf1d24b138a2cb0b_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNS0yLTEtMS0xNDI1MQ_27d5eaa9-92dc-4f15-8ce0-b87a03ae24b7"
      unitRef="shares">2067057</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1e8e3ebf57ba4b84974afb49d0bb404e_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNS00LTEtMS0xNDI1MQ_4a4705da-8f61-4278-a15b-cef454291a62"
      unitRef="shares">1975250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idf4fcbdc1b4745a5b33f78a2ba491dc3_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNS02LTEtMS0xNDI1MQ_544bc947-0b96-411d-b272-235fbe1c4285"
      unitRef="shares">2067057</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia1367b76ff734867a343920922f694fd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNS04LTEtMS0xNDI1MQ_ba6a4d13-7478-4b67-bbbb-dac6efc870b3"
      unitRef="shares">1975250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia703865d1c1e42238e72cf40c966acff_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNi0yLTEtMS0xNDI1MQ_f162b016-4d82-4e37-8a63-ad5de9bee0e2"
      unitRef="shares">403100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic41c409fd996414ca1c565c3fb9e700a_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNi00LTEtMS0xNDI1MQ_bfd180c7-c8c1-4737-ab51-ecfa5e453e70"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1a41951c3b0c4a48a5ed985502dfd9de_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNi02LTEtMS0xNDI1MQ_b627be07-7ca0-4dd5-a702-9bb49932ee7f"
      unitRef="shares">403100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i36ed70cc5c794512b4fad8285454fe80_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNi04LTEtMS0xNDI1MQ_340c1690-69cb-463d-92f0-3d22c7e16ca1"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7bdcbd2fc6414ea79b1193e5620bf1a9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNy0yLTEtMS0xNDI1MQ_b69df5b7-eb69-440c-a185-73dfb6a0efd3"
      unitRef="shares">4130</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i489e0e440e7f4dcc98e8fdbfdd3625bb_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNy00LTEtMS0xNDI1MQ_09dc0f0f-8e90-4e48-8536-fd98cbc10361"
      unitRef="shares">3144</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4f11a04ba9ab4c488c85cd2feab5f19c_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNy02LTEtMS0xNDI1MQ_8c63d88d-4308-44ee-aedc-a1883dccb67e"
      unitRef="shares">4130</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if9aeb5900bd34680b034242eb67e265a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfNy04LTEtMS0xNDI1MQ_f8f99982-ff97-4ef8-9f6a-8a2688101de1"
      unitRef="shares">3144</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfOC0yLTEtMS0xNDI1MQ_68c3c78d-0fe3-45ff-ae98-0e071f10ed5c"
      unitRef="shares">2883395</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfOC00LTEtMS0xNDI1MQ_fe1b672b-5a96-48f2-b131-c3db1b965ce3"
      unitRef="shares">2405221</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfOC02LTEtMS0xNDI1MQ_d527e85b-cb40-478f-8b52-b876b3632536"
      unitRef="shares">2883395</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RhYmxlOjdjNWM2ZGQ3ZDlmYjQ5OWRhZDU1OGRmMzY1MjM2NjcxL3RhYmxlcmFuZ2U6N2M1YzZkZDdkOWZiNDk5ZGFkNTU4ZGYzNjUyMzY2NzFfOC04LTEtMS0xNDI1MQ_48edd6c0-d095-4038-824e-f162fdd48236"
      unitRef="shares">2405221</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjEyMDc_72608a2b-09a4-4c11-91fc-c0ccccc156bb">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMTc5NDA_602d663c-2c5a-43c5-af42-79a4e9f0c343"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNC9mcmFnOjc1NmQ3NzY4NjU5YzQ3YzRhOTMyN2NhZGM1MGQxOGE5L3RleHRyZWdpb246NzU2ZDc3Njg2NTljNDdjNGE5MzI3Y2FkYzUwZDE4YTlfMjExOTI_fe4d438c-0e6a-4bb2-87ce-9642c5ca1e2c">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;Leases&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 842). The new topic supersedes Topic 840,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Topic 842&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases: Targeted Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to early adopt this ASU as of January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfNzc1_758713c0-3157-406c-b2fe-11d6d1f3005f">Other Financial Information&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid product royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid maintenance and insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for the three months ended September&#160;30, 2021 and 2020 was approximately $0.3 million and $0.1 million, and for the nine months ended September&#160;30, 2021 and 2020, was approximately $0.7 million and $0.4 million, respectively. At September&#160;30, 2021 and December 31, 2020, the gross book value of assets under capital lease was $2.5 million and $1.2 million, respectively, and is classified in "Laboratory equipment" in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued purchases of goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued clinical study activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capital lease obligations, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfNzc2_cedd683a-dd60-456f-a1f5-aded8f0faf44">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid product royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid maintenance and insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:OtherAssetsCurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfMS0yLTEtMS0xNDI1MQ_8fbb1f86-a2b4-42c8-b48f-a660ff52f7c9"
      unitRef="usd">1010000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfMS00LTEtMS0xNDI1MQ_cb519d08-7fdd-4154-9042-955c244537e2"
      unitRef="usd">1203000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidRoyalties
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfMi0yLTEtMS0xNDI1MQ_d00a6a5a-dae4-45c4-99cc-27bf6bd6543d"
      unitRef="usd">54000</us-gaap:PrepaidRoyalties>
    <us-gaap:PrepaidRoyalties
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfMi00LTEtMS0xNDI1MQ_e8c8852f-27fc-4bbf-b70f-a8b3190ad857"
      unitRef="usd">68000</us-gaap:PrepaidRoyalties>
    <exdx:PrepaidMaintenanceAndInsuranceContracts
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfMy0yLTEtMS0xNDI1MQ_68201592-2f8b-4f29-9972-0d30734ede69"
      unitRef="usd">1040000</exdx:PrepaidMaintenanceAndInsuranceContracts>
    <exdx:PrepaidMaintenanceAndInsuranceContracts
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfMy00LTEtMS0xNDI1MQ_04c5e7f1-3c67-466b-995b-8533b888a130"
      unitRef="usd">2229000</exdx:PrepaidMaintenanceAndInsuranceContracts>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfNC0yLTEtMS0xNDI1MQ_43a283e8-87f4-4694-aff5-04b9b3b341f8"
      unitRef="usd">301000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfNC00LTEtMS0xNDI1MQ_e14f963d-4983-4fbc-96fc-0549f05d8229"
      unitRef="usd">659000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfNS0yLTEtMS0xNDI1MQ_2ff8a6f5-e777-4e5c-9d2c-3cb61d7099b2"
      unitRef="usd">2405000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjFjZTdiN2IyOGQ1OTQ2MDA4NWI4ZDFlZTY1M2RkNTgxL3RhYmxlcmFuZ2U6MWNlN2I3YjI4ZDU5NDYwMDg1YjhkMWVlNjUzZGQ1ODFfNS00LTEtMS0xNDI1MQ_8cd36909-601f-492f-b66c-1f3064c938d2"
      unitRef="usd">4159000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfNzc3_7304438f-e98f-4455-8d1b-3db215a351ed">Property and equipment consist of the following (in thousands):&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7fe2dbff76584751aa65bc9192aca7f8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfMS0yLTEtMS0xNDI1MQ_74c37015-6562-49fd-b6c5-b83461d89408"
      unitRef="usd">83000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i91495a4d15cc42a9a43bf2c45f36cb29_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfMS00LTEtMS0xNDI1MQ_def4c23b-5466-44f4-803c-103e353392c5"
      unitRef="usd">64000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i062b3ce256a24e639baceecc90b79e9d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfMi0yLTEtMS0xNDI1MQ_9e181668-f5d4-497d-9c19-30f6f34b20a3"
      unitRef="usd">4100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i009c796a34f14a8489e678bd5e7ba7e7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfMi00LTEtMS0xNDI1MQ_dd24aaca-2090-4de5-97d2-4d52518205bc"
      unitRef="usd">2679000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i638a2a722ce94f7fbd4ee6222f3fec82_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfMy0yLTEtMS0xNDI1MQ_f4518df4-71cd-40dd-8f20-66e75e4a32ba"
      unitRef="usd">1106000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id3c67b740ab54e61a5a9b343990c65fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfMy00LTEtMS0xNDI1MQ_0e844e1e-2bf3-44f7-a9a4-7b93f3ad9c9a"
      unitRef="usd">927000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icfa5972febc9459da204c8686e539242_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfNC0yLTEtMS0xNDI1MQ_c2b7f0cb-2fd5-4e9b-8ece-47a1422a11e7"
      unitRef="usd">1141000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia4d4d2d813904871b8dc03c5d28b5913_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfNC00LTEtMS0xNDI1MQ_ba312a47-0eb1-4bc8-b049-949581ffdee2"
      unitRef="usd">1072000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i26a156c330594b2b9417a57e1bc8ad88_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfNS0yLTEtMS0xNDI1MQ_bb99aa83-aff0-42eb-b005-0ea807270b0f"
      unitRef="usd">613000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i05e6cdd6406045d0a32cecdb01802bcc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfNS00LTEtMS0xNDI1MQ_f8af1db8-1bd6-49ac-bcb8-8a043fcdf081"
      unitRef="usd">301000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfNi0yLTEtMS0xNDI1MQ_74493b23-4114-4a73-af2a-8278ebdcfcc2"
      unitRef="usd">7043000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfNi00LTEtMS0xNDI1MQ_e05d3a47-32ad-494b-b97f-f840531d2e3c"
      unitRef="usd">5043000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfNy0yLTEtMS0xNDI1MQ_0e36d12a-7b67-4bc9-af27-55169a751213"
      unitRef="usd">3597000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfNy00LTEtMS0xNDI1MQ_fcd1bb9a-ec6f-4598-ba80-3cfc478cba79"
      unitRef="usd">2941000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfOC0yLTEtMS0xNDI1MQ_cf6b97d1-2c2a-4ad1-b8eb-2cec84f00e0a"
      unitRef="usd">3446000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOjJjYWVlOWI3NDNmZjRjZGU5OGE1OTcxYjA5ZWM5OWQ0L3RhYmxlcmFuZ2U6MmNhZWU5Yjc0M2ZmNGNkZTk4YTU5NzFiMDllYzk5ZDRfOC00LTEtMS0xNDI1MQ_d96575e5-da16-4b89-afe7-4efeb13647bb"
      unitRef="usd">2102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfMzY1_a0568bc6-9ce7-4f53-98f3-ad002668ef52"
      unitRef="usd">300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfMTA5OTUxMTYyODU2OA_918243de-ef59-4587-81db-a54aaa5ab393"
      unitRef="usd">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfNDM3_8c164c6a-a216-47ee-b987-44bed9ac1bb6"
      unitRef="usd">700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfNDUy_d74e07a9-799a-494c-84ef-0bea1328a2ec"
      unitRef="usd">400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i603ccc7a3961470db626807866947b63_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfNTQ3_5ce027d7-c45c-48d3-a4e7-4d87c2e86cc4"
      unitRef="usd">2500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i55f4a3829c4446e58090abccb942038c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfNTYy_f5d2632b-7eb6-42ea-a563-644208b40e51"
      unitRef="usd">1200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RleHRyZWdpb246OTFhYmVmZWQwYmQ0NGQ1N2IxMDgyMmFhZjk1YWM1MjlfNzc4_a1a3eba5-c85c-492d-b434-4569c6bd867c">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued purchases of goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued clinical study activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capital lease obligations, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfMS0yLTEtMS0xNDI1MQ_8ab3e052-f01b-47bc-bd25-842b09d911b6"
      unitRef="usd">3793000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfMS00LTEtMS0xNDI1MQ_ac7b66db-2217-45d7-bfe5-c43dbcfc4420"
      unitRef="usd">3589000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfMy0yLTEtMS0xNDI1MQ_3096a76a-b499-4d10-87f0-fa0592792432"
      unitRef="usd">145000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfMy00LTEtMS0xNDI1MQ_0cb34d05-80cd-4e43-8dcd-e116f3189bf4"
      unitRef="usd">147000</us-gaap:InterestPayableCurrent>
    <exdx:AccruedPurchaseGoodsAndServicesCurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfNC0yLTEtMS0xNDI1MQ_8938c5c8-ce62-4b43-83b5-3c830ec38e10"
      unitRef="usd">765000</exdx:AccruedPurchaseGoodsAndServicesCurrent>
    <exdx:AccruedPurchaseGoodsAndServicesCurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfNC00LTEtMS0xNDI1MQ_6d9b8638-dee5-4882-97aa-ff08a474be05"
      unitRef="usd">311000</exdx:AccruedPurchaseGoodsAndServicesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfNS0yLTEtMS0xNDI1MQ_84f5086b-95de-4086-9cf6-4e3a9b8bd921"
      unitRef="usd">342000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfNS00LTEtMS0xNDI1MQ_58cc4173-64bf-4746-9212-40b46a91cbb5"
      unitRef="usd">221000</us-gaap:AccruedRoyaltiesCurrent>
    <exdx:AccruedLiabilitiesClinicalStudyCurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfNi0yLTEtMS0xNDI1MQ_9e9532ca-dfb5-4cb4-bcf7-fc879fe26460"
      unitRef="usd">337000</exdx:AccruedLiabilitiesClinicalStudyCurrent>
    <exdx:AccruedLiabilitiesClinicalStudyCurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfNi00LTEtMS0xNDI1MQ_0f173817-788e-44d5-be70-28cae3c60666"
      unitRef="usd">228000</exdx:AccruedLiabilitiesClinicalStudyCurrent>
    <us-gaap:CapitalLeaseObligationsCurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfNy0yLTEtMS0xNDI1MQ_41468c95-87ab-434d-9f91-f66be5797453"
      unitRef="usd">586000</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:CapitalLeaseObligationsCurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfNy00LTEtMS0xNDI1MQ_d2e763f6-f4af-41ec-8c1f-e81bb6eb5f06"
      unitRef="usd">308000</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfOC0yLTEtMS0xNDI1MQ_5272da8a-ec17-4b2c-8867-5d5cdf99431c"
      unitRef="usd">616000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfOC00LTEtMS0xNDI1MQ_43f11bcf-319a-4818-8a6c-2b5ef77fe3e4"
      unitRef="usd">953000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfOS0yLTEtMS0xNDI1MQ_10d7d22d-2732-49f6-b457-4d0d2060d41e"
      unitRef="usd">6584000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie450365559dd46d89f2259410ea12471_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV8zNy9mcmFnOjkxYWJlZmVkMGJkNDRkNTdiMTA4MjJhYWY5NWFjNTI5L3RhYmxlOmE5YWQ0ODhhNzQxODRkNmNiOGFhNTE0MzhjYzAwMzc4L3RhYmxlcmFuZ2U6YTlhZDQ4OGE3NDE4NGQ2Y2I4YWE1MTQzOGNjMDAzNzhfOS00LTEtMS0xNDI1MQ_7a5998ff-df77-4b2b-aa57-34241e738c6d"
      unitRef="usd">5757000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfNDkyNw_8979e66d-181d-49bc-90e7-94812cdff1dd">Borrowings&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus) and borrowed $20.0 million, $17.8 million of which was immediately used to repay the Company's existing loan with Capital Royalty Partners II L.P. and its affiliates. On December&#160;7, 2018, the Company borrowed an additional $5.0 million under the 2017 Term Loan. At September&#160;30, 2021, no additional amounts remain available to borrow under the 2017 Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the Company executed the First Amendment to the Loan and Security Agreement (the 2017 Loan Amendment). The interest rate on all borrowings under the 2017 Loan Amendment is 8.5%, of which 2.0% is paid in-kind in the form of additional term loans (PIK Loans) until December of 2022, after which interest accrues at an annual rate of 8.5%. The Company has estimated the effective interest rate of this loan to be approximately 10%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the 2017 Loan Amendment will be repaid in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTExOQ_3937bf68-a790-4703-a448-0929f254939d"&gt;twenty-four&lt;/span&gt; equal monthly installments commencing in December 2022. Upon repayment of the final installment under the 2017 Loan Amendment, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of the 2017 Loan Amendment using the effective interest method. For each of the three months ended September&#160;30, 2021 and 2020, the Company issued PIK Loans totaling $0.1 million. For each &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the nine months ended September&#160;30, 2021 and 2020, the Company issued PIK Loans totaling $0.4 million. In October 2021, the Company executed the Second Amendment to the Loan and Security Agreement (the Second Loan Amendment), discussed in Note 10 to these financial statements, below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2017 Loan Amendment requires a prepayment premium of 2% of the aggregate outstanding principal. The prepayment premium decreases by 1% on November 19, 2021 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2017 Loan Amendment is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the 2017 Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis. The consequences of failing to achieve the performance covenant may be cured if, within sixty days of failing to achieve the performance covenant, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The 2017 Loan Amendment requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2021, the Company was in compliance with all covenants of the 2017 Loan Amendment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon an event of default in any of the 2017 Loan Amendment covenants, the repayment of the 2017 Loan Amendment may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the 2017 Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the 2017 Loan Amendment due beyond twelve months of the balance sheet date as non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Future Minimum Payments on the Outstanding Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,829)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i597de8f2704546a48516c3951933870b_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTk3_d24e89d5-03cc-4cd7-b90b-5a1a2a8a5fbd"
      unitRef="usd">20000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ie56e06d7b68849928e2fe39a26f73f85_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMjAx_2ba7cb0f-9e15-491f-adf4-e72037d03fdb"
      unitRef="usd">17800000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i467bcd314d89428f837631f14432ed8c_D20181207-20181207"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMzg1_014aa446-f9a5-483f-a19b-4a762ceac07e"
      unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i05b9273e32ae45169280d1693bd07c66_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfNDIx_4d562fa9-b4bc-4b47-8543-b61355651e28"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfNjgx_9505889a-4ecd-42f5-be36-976d3f8f05e2"
      unitRef="number">0.085</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <exdx:DebtInstrumentStatedInterestRatePaidInKind
      contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfNjk0_9bef45ab-d77f-406e-a9b0-f54f9d225740"
      unitRef="number">0.020</exdx:DebtInstrumentStatedInterestRatePaidInKind>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfODM2_9505889a-4ecd-42f5-be36-976d3f8f05e2"
      unitRef="number">0.085</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfOTI3_b4ff9fb4-3b97-4d46-8f30-fc70caf2adf5"
      unitRef="number">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTI5Ng_92e05323-02ca-4045-a08f-d72b1ad8f169"
      unitRef="usd">1000000</us-gaap:DebtInstrumentFeeAmount>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="i44af8d7a747943749fac22ffa3dd323f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTUxMQ_963dab66-c210-457a-b6be-d82d91c63fe4"
      unitRef="usd">100000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="i98f4b404a7a746b88f1807dade1827bc_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTUxMQ_d3f681a0-c8ab-4a1d-8ff6-4539adbf2b74"
      unitRef="usd">100000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="iab6affb37170402fbe076933203ab105_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTYwNw_8c9c5dc8-f9d1-47a0-8c3e-ac23da1a9e23"
      unitRef="usd">400000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="i1ec99d0d3d254c33997d3054789d8af4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTYwNw_c5b80f73-9d0e-4930-a908-97fd06c0e7b9"
      unitRef="usd">400000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTY3MQ_77082d4e-c071-46cb-84fe-f5ca3b4279a8"
      unitRef="number">0.02</exdx:DebtInstrumentPrepaymentPremiumPercentage>
    <exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction
      contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTc1MA_282244c0-1f81-4cf1-a414-657757891a2b"
      unitRef="number">0.01</exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction>
    <exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance
      contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMjk3Mw_04aa74a0-1f2e-4048-a0d8-95af278332f4"
      unitRef="usd">2000000.0</exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance>
    <exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease
      contextRef="i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfNDM0NA_3012d540-c5f8-410d-b836-ea7afce0665a"
      unitRef="number">0.040</exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfNDkyOA_89071401-627c-4980-a712-97c79dbefe8f">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,829)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RhYmxlOjIzNzkwMjUzYmYxZjQyMTRhZGVjMDE1NjI2MjBiZGYyL3RhYmxlcmFuZ2U6MjM3OTAyNTNiZjFmNDIxNGFkZWMwMTU2MjYyMGJkZjJfMS0yLTEtMS0xNDI1MQ_ea057c2d-7fd1-425c-9069-c587bcef5cd4"
      unitRef="usd">446000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RhYmxlOjIzNzkwMjUzYmYxZjQyMTRhZGVjMDE1NjI2MjBiZGYyL3RhYmxlcmFuZ2U6MjM3OTAyNTNiZjFmNDIxNGFkZWMwMTU2MjYyMGJkZjJfMi0yLTEtMS0xNDI1MQ_60a868f5-2906-4264-ab74-18367463b0c7"
      unitRef="usd">2996000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RhYmxlOjIzNzkwMjUzYmYxZjQyMTRhZGVjMDE1NjI2MjBiZGYyL3RhYmxlcmFuZ2U6MjM3OTAyNTNiZjFmNDIxNGFkZWMwMTU2MjYyMGJkZjJfMy0yLTEtMS0xNDI1MQ_5acb039d-e772-45cb-9f0e-ce510b39ab3d"
      unitRef="usd">15619000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RhYmxlOjIzNzkwMjUzYmYxZjQyMTRhZGVjMDE1NjI2MjBiZGYyL3RhYmxlcmFuZ2U6MjM3OTAyNTNiZjFmNDIxNGFkZWMwMTU2MjYyMGJkZjJfNC0yLTEtMS0xNDI1MQ_f1954579-b591-4997-a01a-85e8a4cb6863"
      unitRef="usd">14280000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <exdx:LongTermDebtIncludingUndiscountedInterest
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RhYmxlOjIzNzkwMjUzYmYxZjQyMTRhZGVjMDE1NjI2MjBiZGYyL3RhYmxlcmFuZ2U6MjM3OTAyNTNiZjFmNDIxNGFkZWMwMTU2MjYyMGJkZjJfNi0yLTEtMS0xNDI1MQ_3b55ab89-2dc1-46e5-8623-ea6025b920c4"
      unitRef="usd">33341000</exdx:LongTermDebtIncludingUndiscountedInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RhYmxlOjIzNzkwMjUzYmYxZjQyMTRhZGVjMDE1NjI2MjBiZGYyL3RhYmxlcmFuZ2U6MjM3OTAyNTNiZjFmNDIxNGFkZWMwMTU2MjYyMGJkZjJfOC0yLTEtMS0xNDI1MQ_d45f4aa2-79ac-4acd-a6fa-ec614d88890d"
      unitRef="usd">224000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <exdx:LongTermDebtUndiscountedInterestAmount
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RhYmxlOjIzNzkwMjUzYmYxZjQyMTRhZGVjMDE1NjI2MjBiZGYyL3RhYmxlcmFuZ2U6MjM3OTAyNTNiZjFmNDIxNGFkZWMwMTU2MjYyMGJkZjJfOS0yLTEtMS0xNDI1MQ_5d9fe093-6b78-4523-af71-2b5107f6596d"
      unitRef="usd">5829000</exdx:LongTermDebtUndiscountedInterestAmount>
    <us-gaap:LongTermDebt
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RhYmxlOjIzNzkwMjUzYmYxZjQyMTRhZGVjMDE1NjI2MjBiZGYyL3RhYmxlcmFuZ2U6MjM3OTAyNTNiZjFmNDIxNGFkZWMwMTU2MjYyMGJkZjJfMTAtMi0xLTEtMTQyNTE_830a1547-3ff3-49b2-9270-873c58f63fc9"
      unitRef="usd">27288000</us-gaap:LongTermDebt>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfNDYxNQ_6242e679-43be-4a46-bfd4-fe5da42edd17">Commitments and Contingencies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the Company leases office and laboratory space in Vista, California, under leases that expire in January 2026, with an option to extend a portion of the lease for an additional 5-year period. In addition, the Company also leases additional office space in Vista, California, under a lease that expires in January 2026 with an option to extend the lease for an additional 5-year period. The Company's lease payments under each of these leases are subject to escalation clauses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective on August 23, 2021, the Company entered into a sub-lease agreement for an additional office space in Carlsbad, California. The sub-lease commenced in October 2021 and expires in April 2027. The sub-lease agreement provides for monthly base rent of $66,021 which began on October 1, 2021, and such amount shall increase by approximately 3% annually beginning October 1, 2022. The Company is entitled to base rent abatement for a specified period of time which began on November 1, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended September&#160;30, 2021 and 2020, rent expense was $0.2 million and $0.3 million, respectively. For the nine months ended September&#160;30, 2021 and 2020, rent expense was $0.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition-related liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition. The acquisition also included amounts that may be due under several licensing agreements. One such license agreement, the license agreement, dated September 13, 2007, between the Company and Prometheus Laboratories, Inc. (the Prometheus License), was terminated by mutual agreement on September 28, 2021. In consideration for terminating the Prometheus License, including with respect to the remaining potential milestone payments thereunder, the Company agreed to pay Prometheus Laboratories, Inc. a fee of approximately $0.1 million and acquired the intellectual property previously licensed to the Company pursuant to the Prometheus Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has ongoing royalty payment obligations of 2.5% on net sales of products which incorporate certain acquired technologies. Future royalties payable under these arrangements are limited to the lesser of (i) an aggregate of $1.2 million (including an upfront payment of $100,000) and (ii) the total royalties earned through January 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements as described above, individual license agreements generally provide for ongoing royalty payments ranging from 1.5% to 3.0% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when earned and recorded in costs of revenue in the accompanying condensed statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into an exclusive license agreement with Allegheny Health Network Research Institute, or AHN, to obtain an exclusive license to AHN's patent rights in certain inventions, pursuant to which the Company paid AHN an initial license fee of $0.4 million. In addition, under the terms of the exclusive license agreement, the Company is required to pay the greater of royalties in the low single digits on net sales of diagnostic tests using the assigned patents or a flat annual minimum royalty amount, pending approvals and commercialization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $4.1 million and $6.0 million for the years ended December 31, 2021 and 2022, respectively, with a 15% annual increase thereafter through the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into a master research collaboration agreement with AHN, pursuant to which the Company is required to pay AHN a collaboration fee of $0.4 million for each year during the initial term of the agreement. Collaboration expenses under the master research collaboration agreement were $0.1 and $0.2 for the three and nine months ended September&#160;30, 2021, respectively. Collaboration expenses under the AHN collaboration are included in research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payors and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <exdx:OperatingLeasesRenewalTerm
      contextRef="id4f3d87cb19a49f193d7d0107a085292_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMjM5_5279987c-6230-4e16-8048-d939d98af9f1">P5Y</exdx:OperatingLeasesRenewalTerm>
    <exdx:OperatingLeasesRenewalTerm
      contextRef="if4d48a5110ed4d4291de9e8ecd5f4fe6_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfNDM0_7cf66950-fd63-4e5d-8325-112db591dcba">P5Y</exdx:OperatingLeasesRenewalTerm>
    <exdx:OperatingLeaseMonthlyBaseRent
      contextRef="icd4718b3285d4a899f40931cbfe678bf_I20210823"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTA5OTUxMTYzMzc3Mw_2c8bbca0-a51d-408d-be25-269cef4b8e22"
      unitRef="usd">66021</exdx:OperatingLeaseMonthlyBaseRent>
    <exdx:OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent
      contextRef="ia8bc25f7d63f44cea35854b4039d0885_D20210823-20210823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTA5OTUxMTYzMzg0OQ_90f82875-c570-4019-b571-3b93c2e53eee"
      unitRef="number">0.03</exdx:OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent>
    <us-gaap:LeaseAndRentalExpense
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfNTk4_a15b231c-bed8-47ae-b074-b47bde40c0ec"
      unitRef="usd">200000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfNjEz_1dd8b8b3-e815-4ac7-bb87-5bd80f8a9bc8"
      unitRef="usd">300000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfNjk0_3965e58a-4d6c-4762-a695-90ef5d407b2c"
      unitRef="usd">500000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfNjk0_877be5f7-b088-42f1-a349-f6c90fc01f02"
      unitRef="usd">500000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i43b31315848e4d43901c9f3183cbebb4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTA5OTUxMTYzMzM3Mw_5025d63e-0b93-4da9-9819-33186220918f"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireProductiveAssets>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i05fc542a715f42e3aab293e27727085f_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTQyNQ_27b26041-df54-4a6d-aff7-bed0d18a35ca"
      unitRef="number">0.025</exdx:RoyaltyObligationPercentageOfSales>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="i3f14904a63b24632b074d2bdb5d4c936_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTYwMQ_31909ca4-40cf-45af-9743-4ced30e13eed"
      unitRef="usd">1200000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <exdx:AdvancePayment
      contextRef="i3f14904a63b24632b074d2bdb5d4c936_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTY0NQ_3990d832-16a5-43e3-8c2a-0ec2f2d36ef9"
      unitRef="usd">100000</exdx:AdvancePayment>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i408f9d848a9e4b6884930325c910b9b3_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTk3Nw_d0413e42-b75f-4033-bfc6-b7262dea4567"
      unitRef="number">0.015</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="ia55722d9277e48b09ba4ff1dd33c2c09_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTk4Mw_205a6c17-4393-48e3-bade-774c8fe18f8b"
      unitRef="number">0.030</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:LicenseAgreementInitialLicenseFee
      contextRef="i29c2b0bce9e84c2a8890706b191065b5_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMjQ3Mg_18d609e2-09fb-4750-ad61-676d2b12f89d"
      unitRef="usd">400000</exdx:LicenseAgreementInitialLicenseFee>
    <us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMjk0Ng_a54400e5-09c0-435e-a570-c7ca33a9e013"
      unitRef="usd">4100000</us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMjk2MQ_f348437d-6827-4751-82fc-8ed49c2a0284"
      unitRef="usd">6000000.0</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMzA0MQ_82c9f75b-24ec-40fa-b140-8ac9276c0c3e"
      unitRef="number">0.15</exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage>
    <exdx:CollaborationAgreementAnnualCollaborationFee
      contextRef="i8141bfc43efa4a6592ea1148f7f0529b_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMzMwNQ_8cb77c90-8a32-4ab9-91b9-ca7c61d1c49c"
      unitRef="usd">400000</exdx:CollaborationAgreementAnnualCollaborationFee>
    <exdx:CollaborationAgreementCollaborationExpenses
      contextRef="i21dbc0462f534175819f4c79dddf82df_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMzQ1MA_6244baff-7623-417e-9276-9ef617d87f65"
      unitRef="usd">100000</exdx:CollaborationAgreementCollaborationExpenses>
    <exdx:CollaborationAgreementCollaborationExpenses
      contextRef="id0c459a6186e4f998b57dfa0fd36cc51_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80My9mcmFnOjViODM1NGYwYTdjOTRiMTI5MDI1ZTllY2M3YzdkOGIxL3RleHRyZWdpb246NWI4MzU0ZjBhN2M5NGIxMjkwMjVlOWVjYzdjN2Q4YjFfMTA5OTUxMTYzMjY0NQ_46c185de-1576-402d-a4fb-c15b5ea3cdae"
      unitRef="usd">200000</exdx:CollaborationAgreementCollaborationExpenses>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RleHRyZWdpb246M2U4NTBkODJjMTI4NGQ4Y2E3ZWViYmFmNTQyZTMwYzlfMjk4_b148f8ce-5c60-4c83-be3f-3c0d18cb2631">Fair Value Measurements&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The fair value of the Company's money market funds is based on quoted market prices.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RleHRyZWdpb246M2U4NTBkODJjMTI4NGQ4Y2E3ZWViYmFmNTQyZTMwYzlfMjk5_7fc41366-034d-4fd4-8c0a-6c2a962a9389">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9675b9781d014000845af2a6c5ce6ab4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RhYmxlOjMwODQ5MTQ0MGNjYjRmNzliOGQ3ZGQ5OTgzYTVmNDkyL3RhYmxlcmFuZ2U6MzA4NDkxNDQwY2NiNGY3OWI4ZDdkZDk5ODNhNWY0OTJfMy0yLTEtMS0xNDI1MQ_3e39a9e2-76e4-412b-af82-500b3aebdacf"
      unitRef="usd">105679000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic20a022810a34a0e8c547ff3a27e2eff_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RhYmxlOjMwODQ5MTQ0MGNjYjRmNzliOGQ3ZGQ5OTgzYTVmNDkyL3RhYmxlcmFuZ2U6MzA4NDkxNDQwY2NiNGY3OWI4ZDdkZDk5ODNhNWY0OTJfMy00LTEtMS0xNDI1MQ_5de7bc5f-090d-4ba8-a309-0690c2e71462"
      unitRef="usd">105679000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3e41083069624d7b86843d65bcb1e246_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RhYmxlOjMwODQ5MTQ0MGNjYjRmNzliOGQ3ZGQ5OTgzYTVmNDkyL3RhYmxlcmFuZ2U6MzA4NDkxNDQwY2NiNGY3OWI4ZDdkZDk5ODNhNWY0OTJfMy02LTEtMS0xNDI1MQ_9e709af3-5da1-4491-b55a-0a9091fdc453"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1907a197b9bf4ca081846376298c2dbc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RhYmxlOjMwODQ5MTQ0MGNjYjRmNzliOGQ3ZGQ5OTgzYTVmNDkyL3RhYmxlcmFuZ2U6MzA4NDkxNDQwY2NiNGY3OWI4ZDdkZDk5ODNhNWY0OTJfMy04LTEtMS0xNDI1MQ_c26d9045-9f08-4a99-8f42-d6412aa6eba5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id889a74f3c604c9e974adc011ac55e21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RhYmxlOjExZDE3YjFlMjE0ZDQxMjA4Y2Q4MzUyOTA1N2NiMjU1L3RhYmxlcmFuZ2U6MTFkMTdiMWUyMTRkNDEyMDhjZDgzNTI5MDU3Y2IyNTVfMy0yLTEtMS0xNDI1MQ_f5390699-606c-4c91-baf1-76308e36345e"
      unitRef="usd">34507000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4b2aebd9d89a4273b23eaddb67c7187b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RhYmxlOjExZDE3YjFlMjE0ZDQxMjA4Y2Q4MzUyOTA1N2NiMjU1L3RhYmxlcmFuZ2U6MTFkMTdiMWUyMTRkNDEyMDhjZDgzNTI5MDU3Y2IyNTVfMy00LTEtMS0xNDI1MQ_623426f3-dd5e-4bae-80f9-a855f41f89ee"
      unitRef="usd">34507000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic0afac1488f04780915c25495618223b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RhYmxlOjExZDE3YjFlMjE0ZDQxMjA4Y2Q4MzUyOTA1N2NiMjU1L3RhYmxlcmFuZ2U6MTFkMTdiMWUyMTRkNDEyMDhjZDgzNTI5MDU3Y2IyNTVfMy02LTEtMS0xNDI1MQ_a0f5bcb7-051f-469f-8627-9b1af579600f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i40bda80a1b244e9fb44a8c2c934a4459_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80Ni9mcmFnOjNlODUwZDgyYzEyODRkOGNhN2VlYmJhZjU0MmUzMGM5L3RhYmxlOjExZDE3YjFlMjE0ZDQxMjA4Y2Q4MzUyOTA1N2NiMjU1L3RhYmxlcmFuZ2U6MTFkMTdiMWUyMTRkNDEyMDhjZDgzNTI5MDU3Y2IyNTVfMy04LTEtMS0xNDI1MQ_61d37b55-4c1b-4b30-993f-3253e7bed9ae"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfMjU5Ng_79ab03e1-e778-4480-9769-b548b61eaa01">Stockholders' Equity&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 10, 2020, the Company filed a registration statement on Form S-3 (the Shelf Registration Statement), covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units, which Shelf Registration Statement became effective on November 19, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 25, 2021, the Company completed a public offering of 4,255,000 shares of its common stock at a public offering price of $16.25 per share. Net proceeds from the offering were approximately $64.7 million, after deducting underwriting discounts and commissions and offering expenses of $4.4 million. The shares were registered pursuant to the Company's Shelf Registration Statement discussed above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exchange Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 22, 2021, the Company entered into an exchange agreement (the Exchange Agreement) with an Investor and its affiliates (the Exchanging Stockholders), pursuant to which the Company exchanged an aggregate of 804,951 shares of the Company's common stock owned by the Exchanging Stockholders for pre-funded warrants (the Exchange Warrants) to purchase an aggregate of 804,951 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.001 per share. The Exchange Warrants do not expire and are exercisable at any time except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than 4.99% of the Company's common stock, which percentage may change at the Exchanging Stockholder's election to any other percentage upon 61 days' notice to the Company. The Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants are classified as equity and the fair value of the Exchange Warrants was recorded as an increase to additional paid-in-capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. As of September&#160;30, 2021, none of the Exchange Warrants have been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Outstanding Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following equity classified warrants to purchase common stock were outstanding as of September&#160;30, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237,169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,086&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants (Exchange Warrants)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;804,951&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,214,059&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2021, warrants to purchase common stock were exercised resulting in the issuance of 17,719 shares of the Company's common stock and cash proceeds of an immaterial amount.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id1d65917be864b4284e3dcea0b13a340_D20201110-20201110"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfMjEz_e8e9a09f-a7b2-431b-8e67-71f0f7f5987f"
      unitRef="shares">150000000.0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iba7d0acdfc0f4df5a66f2bb747bb7643_D20210325-20210325"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfNDMx_7db56aa9-cef2-471c-8e8b-95b6fca776f7"
      unitRef="shares">4255000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i0ad7af241ac04bb0b5bca5f52f3c3186_I20210325"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfNDkx_2c1594cb-7845-4ed4-a9f1-a0da74f63bcd"
      unitRef="usdPerShare">16.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iba7d0acdfc0f4df5a66f2bb747bb7643_D20210325-20210325"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfNTU1_b3404ed0-fc11-44df-931c-ee38b7fe9d6f"
      unitRef="usd">64700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <exdx:StockIssuanceCosts
      contextRef="i0ad7af241ac04bb0b5bca5f52f3c3186_I20210325"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfNjQ3_bf3a1670-b3c1-4c32-b3b1-2519ed15579e"
      unitRef="usd">4400000</exdx:StockIssuanceCosts>
    <exdx:ExchangeAgreementNumberOfSharesExchangedForWarrants
      contextRef="i1381f17c84bb46b99f0deedd39dd8927_D20210622-20210622"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfOTkx_33ba4674-d995-45c6-8737-68c9a7629213"
      unitRef="shares">804951</exdx:ExchangeAgreementNumberOfSharesExchangedForWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i08bfaba48e6842479e60870fdf457e2f_I20210622"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfMTE0NA_84409b57-0d7a-48f1-9140-599c9a6389bc"
      unitRef="shares">804951</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i08bfaba48e6842479e60870fdf457e2f_I20210622"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfMTM4NQ_26fe0d63-c44b-4d80-9060-58029effb637"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="i1381f17c84bb46b99f0deedd39dd8927_D20210622-20210622"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfMTY0Ng_cf5ad683-a95a-4ded-b84a-74ac7e33e9a3"
      unitRef="number">0.0499</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <exdx:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfMjQzMA_c2afe735-67a7-4067-b9b5-d31970743a0b"
      unitRef="shares">0</exdx:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfMjU5Mw_3f18508d-d10c-49ca-b8bb-1f1a8ab14a9a">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following equity classified warrants to purchase common stock were outstanding as of September&#160;30, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237,169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,086&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants (Exchange Warrants)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;804,951&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,214,059&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2021, warrants to purchase common stock were exercised resulting in the issuance of 17,719 shares of the Company's common stock and cash proceeds of an immaterial amount.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i383d4094819b45efbea334edd4261fee_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfMS0xLTEtMS0xNDI1MQ_1fc1e605-3c6e-4bda-871c-2fd1b390bdc1"
      unitRef="shares">237169</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i383d4094819b45efbea334edd4261fee_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfMS0zLTEtMS0xNDI1MQ_2c379357-8c26-472c-ad50-2b09339295bb"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i055f44b2d2d645aaa59585abcbde2ce0_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfMi0xLTEtMS0xNDI1MQ_d515dca9-12c2-4438-a43a-701db8f7c100"
      unitRef="shares">67086</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i055f44b2d2d645aaa59585abcbde2ce0_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfMi0zLTEtMS0xNDI1MQ_69ecc69a-2f71-4e85-8fea-6c56aa368b1b"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i8744c39e0b4d471aa0dd059af498b3e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfMy0xLTEtMS0xNDI1MQ_27aef067-43e2-4816-b005-0e2948cffd2d"
      unitRef="shares">131</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i8744c39e0b4d471aa0dd059af498b3e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfMy0zLTEtMS0xNDI1MQ_0ef433ab-bf6b-4389-9a70-af4d88283124"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i51655d8dd5cf4160a3e3c43d9ca5e140_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfNC0xLTEtMS0xNDI1MQ_f17928dd-c50c-4a53-99e1-3ca5935f8a4c"
      unitRef="shares">83778</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i51655d8dd5cf4160a3e3c43d9ca5e140_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfNC0zLTEtMS0xNDI1MQ_c221ef6f-9de3-4573-af40-3f6248334850"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i3ab1059999b0438cb0af5e2cefc99c04_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfNS0xLTEtMS0xNDI1MQ_d558fcfb-f57b-4fd0-8b71-e87c6c14287f"
      unitRef="shares">20944</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i3ab1059999b0438cb0af5e2cefc99c04_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfNS0zLTEtMS0xNDI1MQ_776e5768-7bef-47ed-b04d-950f23598e6f"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if1e027871f3d476fb7a00e85ba9c297c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfNi0xLTEtMS0xNDI1MQ_b00409a7-95eb-4810-8091-61f871fe7274"
      unitRef="shares">804951</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if1e027871f3d476fb7a00e85ba9c297c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfNi0zLTEtMS0xNDI1MQ_e7a99d8a-e038-4a03-880f-d5a470a7837d"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i59ce805f96954e73a2aeb07fd95e73f9_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RhYmxlOjRjNWUwYTNjZTRiMDRmNzNiZWUwYzQ0Yjg2ZTQ2ZTA1L3RhYmxlcmFuZ2U6NGM1ZTBhM2NlNGIwNGY3M2JlZTBjNDRiODZlNDZlMDVfNy0xLTEtMS0xNDI1MQ_0ca454a3-0f18-4ea7-8ae2-c49b9a18df7b"
      unitRef="shares">1214059</us-gaap:ClassOfWarrantOrRightOutstanding>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80OS9mcmFnOjM3ZWZlNmJhNTY3NzRiYWJhOTEwOWM0MTFmOTkyMGJmL3RleHRyZWdpb246MzdlZmU2YmE1Njc3NGJhYmE5MTA5YzQxMWY5OTIwYmZfMTA5OTUxMTYzMDUwOQ_591d3357-635b-42c8-bf76-9c7daa5216e9"
      unitRef="shares">17719</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMjkwNw_0099e554-5398-4a23-be8e-0884b0cdf9db">Stock Option Plan&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Incentive Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally four years from the date of grant. As of September&#160;30, 2021, 1,139,831 shares of common stock remained available for future awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Board of Directors adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. As of September&#160;30, 2021, 327,516 shares of common stock remained available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;229,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(122,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,067,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,067,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable, September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;979,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.77&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. As of September&#160;30, 2021, total unrecognized compensation cost related to option awards was $7.7 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.2&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;422,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, all of the outstanding restricted stock units are unvested. As of September&#160;30, 2021, total unrecognized compensation cost related to restricted stock units was $5.9 million, which is expected to be recognized over a remaining weighted-average vesting period of 3.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83%-86%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47%-52%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8%-1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4%-1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.77&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.50-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.50-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45%-60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58%-83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%-1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense for the ESPP was immaterial for the three and nine months ended September&#160;30, 2021 and 2020. As of September&#160;30, 2021, total unrecognized compensation cost related to stock purchase rights granted under the ESPP was an immaterial amount, which is expected to be recognized over a remaining weighted-average vesting period of 0.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statement of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ied9309b5ec844d98aad6b3f0e1ae47bb_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfNTA0_12dc9aa7-a405-4d94-9978-5b7aaabde7ce">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ied9309b5ec844d98aad6b3f0e1ae47bb_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfNjM5_684653d4-168d-4ef7-a25c-d7af32f4dcba">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i1f87200751b54837b785f6f119eae03a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfNjc2_b4b76d72-0c6d-427e-955a-edc5c224120d"
      unitRef="shares">1139831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i813af130085e4bcfa2cc8e3c96aa96f8_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMTA2Mg_45dd8e81-1090-4b49-811a-0b4640b83100"
      unitRef="number">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i813af130085e4bcfa2cc8e3c96aa96f8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMTEwNw_5153f024-dfa3-4fff-9638-016814697f93"
      unitRef="shares">327516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMjkwMg_21c13f99-d92b-4cfc-87e1-3407c00e605c">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;229,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(122,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,067,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,067,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable, September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;979,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.77&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iff8e60ce9c594c9aa9741f476323c52a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfMS0yLTEtMS0xNDI1MQ_70309d9c-3123-4a5a-a0e2-e15eaf27bbd1"
      unitRef="shares">1975761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iff8e60ce9c594c9aa9741f476323c52a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfMS00LTEtMS0xNDI1MQ_f749066b-23a8-417b-830f-b4898e52d514"
      unitRef="usdPerShare">11.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ifa5c746fe4b94017ad86dcc26492fd0a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfMS02LTEtMS0xNDI1MQ_dd8cf806-1814-4bf2-84fb-c6c111b80fc7">P8Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="iff8e60ce9c594c9aa9741f476323c52a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfMS04LTEtMS0xNDI1MQ_7b96fa71-3ddf-48c4-ba68-864413ca7155"
      unitRef="usd">6750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfMi0yLTEtMS0xNDI1MQ_4cceae43-d878-46d8-adb1-aaffc7aaca5d"
      unitRef="shares">229850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfMi00LTEtMS0xNDI1MQ_837cf226-0508-4230-a747-3e320d60fe17"
      unitRef="usdPerShare">16.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfMy0yLTEtMS0xNDI1MQ_ddc6e94d-5446-4196-b22b-e59b204e23ad"
      unitRef="shares">11188</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfMy00LTEtMS0xNDI1MQ_a8c6f1cf-f0f3-475e-92a0-14f87ac20092"
      unitRef="usdPerShare">7.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNC0yLTEtMS0xNDI1MQ_96cd1343-b4e9-4570-9b3e-f269bcfbd7be"
      unitRef="shares">122435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNC00LTEtMS0xNDI1MQ_f3fa413b-6139-4075-92fe-0dc4d6365cac"
      unitRef="usdPerShare">14.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNS0yLTEtMS0xNDI1MQ_04d6b431-370d-4c8a-b645-a5477f06bcf1"
      unitRef="shares">4931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNS00LTEtMS0xNDI1MQ_1fdf5fec-350f-4369-80a4-9639fa10cc0b"
      unitRef="usdPerShare">21.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNi0yLTEtMS0xNDI1MQ_5c94e070-5012-491a-b364-bb5589176151"
      unitRef="shares">2067057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNi00LTEtMS0xNDI1MQ_b269b0c7-51aa-4782-a17a-95d7de03a89d"
      unitRef="usdPerShare">12.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNi02LTEtMS0xNDI1MQ_aaddd7ec-d8dc-4ab7-9aff-4be862a10f99">P8Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNi04LTEtMS0xNDI1MQ_32e1cee4-b565-4c96-91d1-d1a78bb445f3"
      unitRef="usd">6956000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNy0yLTEtMS0xNDI1MQ_e6b2c422-e20f-4886-badd-cebe576c58f2"
      unitRef="shares">2067057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNy00LTEtMS0xNDI1MQ_d944e6c0-fd94-4a34-a967-fe002e077c60"
      unitRef="usdPerShare">12.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNy02LTEtMS0xNDI1MQ_d20ab1ee-cf4a-47d4-a850-3b3ae447e555">P8Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfNy04LTEtMS0xNDI1MQ_807c25bf-d23d-4e93-88ae-e56d3b3ed117"
      unitRef="usd">6956000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfOC0yLTEtMS0xNDI1MQ_1abdb0a2-f214-40fc-80f1-b4a24c11ace6"
      unitRef="shares">979111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfOC00LTEtMS0xNDI1MQ_866f4aea-b346-4e14-83f9-dc5a64a59fe4"
      unitRef="usdPerShare">10.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfOC02LTEtMS0xNDI1MQ_abc8be65-c5a3-4fef-859e-dc160c1f3d68">P7Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmM1ZmNmNGYxMTMwZjQ3OTRiMDNmNWVjMzI2ODY2MDk1L3RhYmxlcmFuZ2U6YzVmY2Y0ZjExMzBmNDc5NGIwM2Y1ZWMzMjY4NjYwOTVfOC04LTEtMS0xNDI1MQ_48a543d6-ddf0-44b1-a869-2a489cb9dbcb"
      unitRef="usd">4794000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i48504c2aaa3340f78e4733690a2c664b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMTQ5Ng_88bb4f31-ae7d-4286-b95d-653bd62f6848"
      unitRef="usd">7700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMTU5NQ_0f3ab73c-54aa-459a-8b83-d57a2eb98bba">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMjkwMw_176d046f-a4ef-4ecb-a2a2-705c695568a0">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;422,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idd19ac6d04c2437dabe28931d0bda370_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfMS0yLTEtMS0xNDI1MQ_ac7a3939-994d-41a8-bca1-9eafa7e061e6"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="idd19ac6d04c2437dabe28931d0bda370_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfMS00LTEtMS0xNDI1MQ_e9e2f0a3-6cd4-4f76-b7cb-597b1fd53322"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="idd19ac6d04c2437dabe28931d0bda370_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfMS02LTEtMS0xNDI1MQ_ee9baf93-7bce-4d16-bec7-a1a95052ec69"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfMi0yLTEtMS0xNDI1MQ_e36c7d5f-297a-47c7-a0f9-abf7b3b25a7f"
      unitRef="shares">422150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfMi00LTEtMS0xNDI1MQ_107bf930-d11f-48eb-8b4b-32903a1ef2f4"
      unitRef="usdPerShare">16.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfMy0yLTEtMS0xNDI1MQ_29876498-9602-4f71-b942-7faf07609f6e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfMy00LTEtMS0xNDI1MQ_fa0b0c51-6923-401a-9029-edebca4f14dc"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfNC0yLTEtMS0xNDI1MQ_9e7266d6-32bf-4a46-8497-e52ce2cbf274"
      unitRef="shares">19050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfNC00LTEtMS0xNDI1MQ_acfdb6d0-231d-41c8-9833-f0b00b7dd526"
      unitRef="usdPerShare">16.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i76d674daf6484d4dba8d57a883f437de_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfNS0yLTEtMS0xNDI1MQ_c3969152-45ec-4e49-9712-83db6137f800"
      unitRef="shares">403100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i76d674daf6484d4dba8d57a883f437de_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfNS00LTEtMS0xNDI1MQ_8fb51480-df78-4784-bbd4-fb18fb4a87fe"
      unitRef="usdPerShare">16.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i76d674daf6484d4dba8d57a883f437de_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmQyZTZkODA4NGJkZjRiZDI4NzE0YWIzYWJiNzBmODk1L3RhYmxlcmFuZ2U6ZDJlNmQ4MDg0YmRmNGJkMjg3MTRhYjNhYmI3MGY4OTVfNS02LTEtMS0xNDI1MQ_58b25c55-b9f5-41b4-abf4-519593ec15a1"
      unitRef="usd">5482000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i76d674daf6484d4dba8d57a883f437de_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMTg2Ng_8ef5a067-740c-4394-ab8e-9e4d9d381fd8"
      unitRef="usd">5900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8b117632199f4f27b90a107da11c2bef_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMTk2NQ_15579023-a844-4799-a24b-af14f5eae96c">P3Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMjkwNA_2d8114a0-1954-430d-9ec0-9934c42853c7">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83%-86%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47%-52%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8%-1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4%-1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.77&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.50-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.50-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ibef4b05e619f40db9ce589f18c223874_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMi0yLTEtMS0xNDI1MS90ZXh0cmVnaW9uOjk2ZjIyZWY5NmMzMjQ5MjNiMTNhYzMyOWY0NzUwM2E4XzQ_d5b2f675-8397-448a-85c1-bdd2a085d8db"
      unitRef="number">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3d30161937ff49a0b250f9c9743eaad5_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMi00LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjY1NThjYTMwZDg0MjQ4MjNhYTI2MzIzNjNhMmEwMjIzXzQ_dd0af9ae-6fc7-4edd-a9ed-7fe165d3079a"
      unitRef="number">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMi02LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjVhMTdjNWEwMDdhMzQyNDhiN2IxZTZhNWJjZGQyMjI1XzQ_62b46931-8707-499b-831f-4074189d4422"
      unitRef="number">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMi02LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjVhMTdjNWEwMDdhMzQyNDhiN2IxZTZhNWJjZGQyMjI1Xzc_8a5313c1-bb13-493c-ac94-73f9a9b31d8a"
      unitRef="number">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ic949c32127e144a882f03102ba80d592_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMi04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjlmZmQ2ZWRmYmEyODRmZDliZDI4MjBjOTZlZTE0NjQxXzQ_1a8230c2-a400-48a3-bd43-28f7d9d35ba8"
      unitRef="number">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ic949c32127e144a882f03102ba80d592_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMi04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjlmZmQ2ZWRmYmEyODRmZDliZDI4MjBjOTZlZTE0NjQxXzc_b1c1958b-9cd0-4a98-97c7-6595e45dd35c"
      unitRef="number">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ibef4b05e619f40db9ce589f18c223874_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMy0yLTEtMS0xNDI1MS90ZXh0cmVnaW9uOjlhOTQwMjFiNTI1YTQyYjU5ZGVkY2QzOWRjOTQ5Nzk3XzQ_f982e5f7-e8ea-4b28-9b32-b1d1667b4d0b"
      unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3d30161937ff49a0b250f9c9743eaad5_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMy00LTEtMS0xNDI1MS90ZXh0cmVnaW9uOmZmMDU3ODFlYjQ3ZjQxMzE4ZTg3Y2NjMDdlNDY2ZTlkXzQ_3cc87f70-ad8c-4577-ab70-237f178917ef"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMy02LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjUzOGY3NTk0NTMyZjQ1M2U4NTUyN2I2NjU0NWVhNmM3XzQ_bffd7cfd-2632-4b87-b912-0ccc74866f6b"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMy02LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjUzOGY3NTk0NTMyZjQ1M2U4NTUyN2I2NjU0NWVhNmM3Xzc_db68adff-9eb7-4e3c-bfb0-e47a467222bc"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ic949c32127e144a882f03102ba80d592_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMy04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjk3OWE4YTQ1YzFlYzQwYmU4MTUzYmU2NDNmYzhjMmFhXzQ_cd8df384-c2c7-49aa-a5b2-aa88e2e71968"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ic949c32127e144a882f03102ba80d592_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfMy04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjk3OWE4YTQ1YzFlYzQwYmU4MTUzYmU2NDNmYzhjMmFhXzc_305ad745-136f-48dd-aefd-22b5695a5e52"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibef4b05e619f40db9ce589f18c223874_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNC0yLTEtMS0xNDI1MQ_ff5f67b3-2704-4512-969d-d77ec16cbf7d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3d30161937ff49a0b250f9c9743eaad5_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNC00LTEtMS0xNDI1MQ_94e01da8-888b-4254-9e71-f3c5aff18b85"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i81f9417379b2400e818961f451bb1226_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNC02LTEtMS0xNDI1MQ_91c3dee3-645e-4f53-8400-877272194423"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic949c32127e144a882f03102ba80d592_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNC04LTEtMS0xNDI1MQ_eb1737ae-736b-4c2a-b1e4-c7891584f98a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iec9349a3150a4ff99322fb97e4697704_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNS0yLTEtMS0xNDI1MS90ZXh0cmVnaW9uOjYwYTk0YTU0NjNmMzQ2YjVhYjM0NThlODk4OTUzMjUyXzQ_4033f021-bf44-4d73-a73c-51e8bd92f646">P5Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia972fa811fe848438cbbf17df4213386_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNS00LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjU4ZTRlNmFlZWYyZDQ2NzE5MDEzNDNiMjQxNTdmYzkzXzQ_cb46f2a3-b562-484e-86d7-a8e915a64ccf">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5f5390aa51834b0b9c48b6a1ebb975d1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNS02LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjVmMzE3ODAxYzBlMjRkNDFiN2JlOGZhZDE4MTQyOTE1XzQ_c04915ff-ade3-4ffa-9d13-133d3124fe34">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7535719e17e343dd934c82c15efb6c7a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNS02LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjVmMzE3ODAxYzBlMjRkNDFiN2JlOGZhZDE4MTQyOTE1Xzc_49592615-5b2a-4ac2-8e24-fbfdf79c2368">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i35982159cf8245aea8b27f18c2b7c347_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNS04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjFlODc4MDUxYjlkMTQ5ODRiYmRlNzYwMWJiYmEzMzBjXzQ_c3e91ab3-e4cc-483f-adb5-75a1f848b9c7">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i64d9f93ee0074786a89f1f8599054033_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOmZkZmZhNTE5MGYxNDRlM2U5NTc5MTNkNmVhMzMzY2M1L3RhYmxlcmFuZ2U6ZmRmZmE1MTkwZjE0NGUzZTk1NzkxM2Q2ZWEzMzNjYzVfNS04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOjFlODc4MDUxYjlkMTQ5ODRiYmRlNzYwMWJiYmEzMzBjXzc_60818d4c-a65c-4b9d-a318-6f96325a1ef6">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMjkwNQ_f3418029-fa1d-468e-a678-a4874f782a21">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45%-60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58%-83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%-1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i812dfaa6798b45bf98314f6d3cb3caf2_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMi0yLTEtMS0xNDI1MQ_03a4ee88-149b-45b1-91a8-6103eab1586f"
      unitRef="number">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iaf397bbee62e4358a29c8fe357195adc_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMi00LTEtMS0xNDI1MQ_5b8bab65-6fee-4bed-b4e2-14c50cc76215"
      unitRef="number">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMi02LTEtMS0xNDI1MS90ZXh0cmVnaW9uOmFlZWJkMjdhYmI2NTQ4YjJiMDNiZDA0ZTZiM2JhMzg5XzEwOTk1MTE2Mjc3ODM_4634afcc-25de-4829-8fd8-62a658c12d00"
      unitRef="number">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMi02LTEtMS0xNDI1MS90ZXh0cmVnaW9uOmFlZWJkMjdhYmI2NTQ4YjJiMDNiZDA0ZTZiM2JhMzg5XzEwOTk1MTE2Mjc3OTA_3fb8c08d-5c2d-4f99-88e0-0dadaa141921"
      unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMi04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOmFlZWM5M2ZkZGM2NzRjODE5NGMxOGY5YjVlM2RhZmE5XzEwOTk1MTE2Mjc3ODY_483ba132-1eaa-4d85-8738-af22413408db"
      unitRef="number">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMi04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOmFlZWM5M2ZkZGM2NzRjODE5NGMxOGY5YjVlM2RhZmE5XzEwOTk1MTE2Mjc3OTA_41c26cf7-11a7-475c-9a01-53f4cd3d2007"
      unitRef="number">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i812dfaa6798b45bf98314f6d3cb3caf2_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMy0yLTEtMS0xNDI1MQ_04708e47-e38d-4a8f-9502-3c85d90e7ad8"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iaf397bbee62e4358a29c8fe357195adc_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMy00LTEtMS0xNDI1MQ_1c13667e-544d-41b3-b4ce-36ca0eb4805f"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6c1776b0ca2349ccb5b02fae30a4d766_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMy02LTEtMS0xNDI1MQ_23368e46-2d23-4760-923c-102ea4678350"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMy04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOmQ3OGVmNjUxODg5OTQyN2ZhZGU1YTc0MWVlZTE1NWE1XzEwOTk1MTE2Mjc3ODQ_4668de22-c0a6-4d82-aba6-da98d59f9eaf"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfMy04LTEtMS0xNDI1MS90ZXh0cmVnaW9uOmQ3OGVmNjUxODg5OTQyN2ZhZGU1YTc0MWVlZTE1NWE1XzEwOTk1MTE2Mjc3OTI_2cef7aaf-5d70-48ae-9a5b-d1bfcf7990d6"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i812dfaa6798b45bf98314f6d3cb3caf2_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfNC0yLTEtMS0xNDI1MQ_9096ffb5-cb33-475e-8b4e-4bd05bb05505"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iaf397bbee62e4358a29c8fe357195adc_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfNC00LTEtMS0xNDI1MQ_e50e0947-3441-4f9b-bbe1-aa1777f348db"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6c1776b0ca2349ccb5b02fae30a4d766_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfNC02LTEtMS0xNDI1MQ_4f0b484d-e4e1-40d5-9e84-88707d28e8c4"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i985d2c00754740a1a75159006860f2f5_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfNC04LTEtMS0xNDI1MQ_606907f4-9719-47a1-ba35-cd0fcdf83407"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i812dfaa6798b45bf98314f6d3cb3caf2_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfNS0yLTEtMS0xNDI1MQ_1c53efbc-e3a9-4382-aebf-8f33e7872dcd">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iaf397bbee62e4358a29c8fe357195adc_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfNS00LTEtMS0xNDI1MQ_5bba8bf1-251a-4fc6-8674-2ba605a9b6ad">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6c1776b0ca2349ccb5b02fae30a4d766_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfNS02LTEtMS0xNDI1MQ_b45660f4-65d8-43f9-b5b3-cf91b8f4179d">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i985d2c00754740a1a75159006860f2f5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjk1OGNiNzg5ZTlkYzQ0Yjg5NjZhYjBlZWQ3Zjc1ZGE1L3RhYmxlcmFuZ2U6OTU4Y2I3ODllOWRjNDRiODk2NmFiMGVlZDdmNzVkYTVfNS04LTEtMS0xNDI1MQ_390dbdca-3013-4b6a-831a-99b4031f3f9c">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6c1776b0ca2349ccb5b02fae30a4d766_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMjY1NA_15f1de80-5278-48b2-9bdf-f781f8c2ec7a">P0Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RleHRyZWdpb246OWEwYWEwZDIxMGRlNDg4MTljODU2Y2Q3ZDc4NTcwZTFfMjkwNg_dd78a3cb-9aff-4e41-96ee-07a3d5b02ef0">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statement of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i438f8b50be854314a57a86231478aeae_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfMi0yLTEtMS0xNDI1MQ_f767645a-53ac-47d6-b247-28c54d92bce4"
      unitRef="usd">64000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4d8ea92229ac4b40bb2809f46bc58d7d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfMi00LTEtMS0xNDI1MQ_4cbbe704-b963-46a0-a24a-d26c01c9cf39"
      unitRef="usd">9000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i68fba0d065ad49d59ebd33550ccf06b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfMi02LTEtMS0xNDI1MQ_f208dc11-464b-47ec-84bc-6b2b0fdbe8c7"
      unitRef="usd">136000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia119e096fc994ad881c098574fb63096_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfMi04LTEtMS0xNDI1MQ_3f57e8d2-c89b-460d-812b-40cae8a39fa1"
      unitRef="usd">21000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4e7d648e35d44b77b7fd4855916a6275_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfMy0yLTEtMS0xNDI1MQ_7030b12e-f155-486c-b9dc-b7f2060ee2e2"
      unitRef="usd">1115000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5f6449b025d641e0b0375cfa207f3273_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfMy00LTEtMS0xNDI1MQ_bc877a8f-91f4-4fca-8722-fe8bfb6c47b6"
      unitRef="usd">710000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i63ee66c9d6104d338fa41906c77c9c58_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfMy02LTEtMS0xNDI1MQ_5ce5feba-1511-42f9-a4fc-3dda10057b5b"
      unitRef="usd">2955000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5c3796eb660a4650801221b114877277_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfMy04LTEtMS0xNDI1MQ_31bcf64e-6c8a-419e-8347-8e6f123c23f2"
      unitRef="usd">1696000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iefa8fc581abf42a49cbe113470783f21_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfNC0yLTEtMS0xNDI1MQ_bb23df56-bb46-41f6-97ea-9685c60b34ea"
      unitRef="usd">175000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if68e692cf8c24949bdf0c1127a4fb582_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfNC00LTEtMS0xNDI1MQ_2edcac08-8dcf-43f3-b0d0-523529057eb4"
      unitRef="usd">80000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5dfd57d894e647a88470632fbe75162c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfNC02LTEtMS0xNDI1MQ_6888c2d8-f2c5-4b14-96a4-8b84ea44fee9"
      unitRef="usd">460000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i035f9bfef7cb4a9193e6fb924522482a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfNC04LTEtMS0xNDI1MQ_77de442c-13ad-4c35-ad38-2caa8b022f13"
      unitRef="usd">160000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic947e90b872445479ee484e60712b752_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfNS0yLTEtMS0xNDI1MQ_69f76d48-3250-426c-a3f9-d5bf32d37be6"
      unitRef="usd">1354000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfNS00LTEtMS0xNDI1MQ_91f35e2e-ea25-4409-ad49-7731b136b744"
      unitRef="usd">799000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfNS02LTEtMS0xNDI1MQ_cf942af4-c49b-461a-b216-de99b34f1714"
      unitRef="usd">3551000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81Mi9mcmFnOjlhMGFhMGQyMTBkZTQ4ODE5Yzg1NmNkN2Q3ODU3MGUxL3RhYmxlOjIwMmNkMGY3YjgzZTQ2MDBhMDFmYjY1N2Y0Nzg3ZTU2L3RhYmxlcmFuZ2U6MjAyY2QwZjdiODNlNDYwMGEwMWZiNjU3ZjQ3ODdlNTZfNS04LTEtMS0xNDI1MQ_91236efa-cb27-42f6-b4a1-b81ef6538255"
      unitRef="usd">1877000</us-gaap:AllocatedShareBasedCompensationExpense>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81NS9mcmFnOmExNWU0YWRhYTI2MzQwYjJiZDE4MjI3MjUyNjk3OGYwL3RleHRyZWdpb246YTE1ZTRhZGFhMjYzNDBiMmJkMTgyMjcyNTI2OTc4ZjBfNDE0MA_93400baf-2cc5-4aa1-840d-c860ae8f9bec">COVID-19&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, due to the worldwide COVID-19 pandemic, the Company experienced a reduction in patient test volumes, delays in patient enrollment in ongoing and planned clinical studies, and delays in the procurement of its testing supplies. In response to the pandemic, the Company has curtailed non-essential employee travel, equipped employees with the ability to work remotely with the exception of clinical laboratory employees, and reduced marketing spend and employee headcount. The full extent to which the COVID-19 pandemic will directly or indirectly continue to impact the Company's business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, including, the success of ongoing vaccination efforts, the emergence and prevalence of variant strains of COVID-19, the institution or reinstitution of shutdowns, "stay-at-home-orders" and other public health measures as well as the related economic impact of these matters on local, regional and international markets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits net operating loss (NOL) carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. The CARES Act did not have a material impact on the Company's effective tax rate or income tax provision for the three months ended March 31, 2020. Under the Tax Cuts and Jobs Act (TCJA), NOLs generated post TCJA were allowed to be carried forward indefinitely but were only allowed to offset 80% of taxable income. As a result of the CARES Act and the change to permit NOLs generated in taxable years 2018, 2019 and 2020 to offset 100% of taxable income, the Company released valuation allowance against its deferred tax assets in the amount of $0.1 million. The release of valuation allowance resulted in a discrete tax benefit of $0.1&#160;million in the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2020, the Company received $0.7 million of funding under the CARES Act Provider Relief Fund, subject to the Company's agreement to comply with the Department of Health &amp;amp; Human Services' standard terms and conditions. The CARES Act Provider Relief Fund is a federal fund allocated for general distributions to Medicare facilities and providers impacted by the COVID-19 pandemic and is intended to support COVID-related expenses or lost revenue attributable to COVID-19. The funding received is considered a government grant, which is recognized when there is reasonable assurance that the grant will be received and that conditions attached to the grant have been met. During the three and nine months ended September&#160;30, 2020, the Company recognized $0 and $0.7 million, respectively, due to lost revenue attributable to COVID-19, which is reflected in other income, net, on its condensed statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April 16, 2020, the Company entered into a promissory note (the Note) with BOKF, NA dba Bank of Oklahoma (BofO), the lender, evidencing an unsecured loan pursuant to the U.S. Small Business Administration (SBA) Paycheck Protection Program (PPP) of the CARES Act of approximately $2.9 million (the PPP Loan). The Company applied for and received the PPP Loan pursuant to the then published PPP qualification and certification requirements. On April 23, 2020, the SBA, in consultation with the Department of Treasury, issued new guidance that created uncertainty regarding the qualification requirements for the PPP Loan (the New Guidance). In light of the New Guidance, on May 11, 2020, the Company paid off in full the principal and interest on the PPP Loan, resulting in the termination of the Note. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law. It provides additional COVID-19 focused relief and extends certain provisions of the CARES Act. At this time, the Company does not believe that the Consolidated Appropriations Act, 2021 has a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance
      contextRef="ibcbd85df5b8d470087005bf4782dd47b_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81NS9mcmFnOmExNWU0YWRhYTI2MzQwYjJiZDE4MjI3MjUyNjk3OGYwL3RleHRyZWdpb246YTE1ZTRhZGFhMjYzNDBiMmJkMTgyMjcyNTI2OTc4ZjBfMjAxNg_e9085e2f-be46-4386-8191-259cdab28cfd"
      unitRef="usd">100000</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit
      contextRef="i4389a97a55544668bcf3bf8164728b95_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81NS9mcmFnOmExNWU0YWRhYTI2MzQwYjJiZDE4MjI3MjUyNjk3OGYwL3RleHRyZWdpb246YTE1ZTRhZGFhMjYzNDBiMmJkMTgyMjcyNTI2OTc4ZjBfMjEwMQ_3c3d7ae4-e2de-402e-bc4e-3ceff9ac543d"
      unitRef="usd">100000</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit>
    <exdx:ProceedsFromGovernmentAssistance
      contextRef="i402a6e16113b408c83b914eaf5ca9d14_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81NS9mcmFnOmExNWU0YWRhYTI2MzQwYjJiZDE4MjI3MjUyNjk3OGYwL3RleHRyZWdpb246YTE1ZTRhZGFhMjYzNDBiMmJkMTgyMjcyNTI2OTc4ZjBfMjE3MQ_a8a1e751-19af-4071-8f13-d992ab52da08"
      unitRef="usd">700000</exdx:ProceedsFromGovernmentAssistance>
    <exdx:ProceedsFromGovernmentAssistance
      contextRef="iff1f83acce0e48d0868aba49fd1cd79d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81NS9mcmFnOmExNWU0YWRhYTI2MzQwYjJiZDE4MjI3MjUyNjk3OGYwL3RleHRyZWdpb246YTE1ZTRhZGFhMjYzNDBiMmJkMTgyMjcyNTI2OTc4ZjBfMjg3NA_47441ead-f9ae-4b99-97a1-f0feaecadbdd"
      unitRef="usd">0</exdx:ProceedsFromGovernmentAssistance>
    <exdx:ProceedsFromGovernmentAssistance
      contextRef="i07882f66dd744f50bfebdf5c98c90abd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81NS9mcmFnOmExNWU0YWRhYTI2MzQwYjJiZDE4MjI3MjUyNjk3OGYwL3RleHRyZWdpb246YTE1ZTRhZGFhMjYzNDBiMmJkMTgyMjcyNTI2OTc4ZjBfMTA5OTUxMTYzMTkzMw_15239885-a41d-4384-b4f0-912c3de12f47"
      unitRef="usd">700000</exdx:ProceedsFromGovernmentAssistance>
    <us-gaap:ProceedsFromBankDebt
      contextRef="i24ee58a4f9ca4e738b4bacc7d0c3ecff_D20200416-20200416"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81NS9mcmFnOmExNWU0YWRhYTI2MzQwYjJiZDE4MjI3MjUyNjk3OGYwL3RleHRyZWdpb246YTE1ZTRhZGFhMjYzNDBiMmJkMTgyMjcyNTI2OTc4ZjBfMzI5OA_bb2379e1-5786-4455-970c-f4d107adf29f"
      unitRef="usd">2900000</us-gaap:ProceedsFromBankDebt>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzI3NDg3NzkwNjk3Nzc_42f545c8-5d8a-4581-813a-63aadef8b3fa">Subsequent Events&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Company entered into a lease amendment relating to its existing office space located adjacent to the Company's headquarters. The lease amendment extends the term of such lease from January 2026 to April 2027. The lease amendment provides that the base monthly rent for the leased space shall be $22,470 for the 12-month period beginning February 2026 and $23,594 for the period beginning February 2027 through April 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Company entered into a fifth addendum to the lease relating to its headquarters. The fifth addendum extends to the term of such lease from January 2026 to April 2027. The fifth addendum provides that the base monthly rent for the leased space shall be $20,084 for the period between February 2026 and April 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Company entered into a first addendum to the lease related to its office and laboratory space in the building attached to the Company's existing headquarters. The first addendum extends the term of such lease from January 2026 to April 2027. The first addendum provides that the base monthly rent for the leased space shall be $14,751 for the period between February 2026 and April 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Company and Innovatus entered into the Second Loan Amendment to the 2017 Term Loan, which became effective on November 1, 2021. The Second Loan Amendment amends the 2017 Term Loan by, among other things, (i) decreasing the interest rate on all borrowings to 8.0%, of which 2.0% will be paid-in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until December 2024; after which interest will accrue at an annual rate of 8.0%; (ii) extending the interest-only period through December 2024 and the maturity date to November 19, 2026; and (iii) changing the specified level of revenue, as measured quarterly on a rolling twelve-month basis, commencing with the quarter ending December 31, 2022, the Company must achieve to satisfy the related financial covenant in the 2017 Loan Amendment, subject to exceptions based on achievement of performance milestones and the ability to cure any default thereof with the issuance of equity securities or subordinated indebtedness.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <exdx:OperatingLeaseMonthlyBaseRent
      contextRef="i70e8b6ad8e4146a199fe29ee3340804a_I20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzEwOTk1MTE2Mjg3MjA_be4833e3-d29c-450c-846f-0522a01743c2"
      unitRef="usd">22470</exdx:OperatingLeaseMonthlyBaseRent>
    <exdx:OperatingLeaseTermOfContract
      contextRef="ie9f93b64bd374d91a76b68cea11d1efa_D20211001-20211031"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzE1OTQyOTE4NjA0NjY0_2eb9c580-1f89-4bc7-bd65-6861e36f9c2c">P12M</exdx:OperatingLeaseTermOfContract>
    <exdx:OperatingLeaseMonthlyBaseRentFirstIncrease
      contextRef="i70e8b6ad8e4146a199fe29ee3340804a_I20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzEwOTk1MTE2Mjg4MDU_52fc0412-3455-4770-9ae0-2a5513b3bf4c"
      unitRef="usd">23594</exdx:OperatingLeaseMonthlyBaseRentFirstIncrease>
    <exdx:OperatingLeaseMonthlyBaseRent
      contextRef="id84bcf56412d40cbb17dc4a699c488f4_I20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzEwOTk1MTE2MjkyMDI_49d08647-b387-4674-b3a9-3b81196319ba"
      unitRef="usd">20084</exdx:OperatingLeaseMonthlyBaseRent>
    <exdx:OperatingLeaseMonthlyBaseRent
      contextRef="i19fdfc2580cb4c58ba25b4bf22f281cb_I20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzEwOTk1MTE2Mjk0NzE_c7bd93be-0896-4a3e-9a8c-760d044429cc"
      unitRef="usd">14751</exdx:OperatingLeaseMonthlyBaseRent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie47ef4f6de5046f08313d4c7118cd8d2_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzEwOTk1MTE2MzAzMTc_aa544711-78f8-43d4-b9ac-bd25b9f31153"
      unitRef="number">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <exdx:DebtInstrumentStatedInterestRatePaidInKind
      contextRef="ie47ef4f6de5046f08313d4c7118cd8d2_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzEwOTk1MTE2MzAzMzE_66ed7b50-9f2b-4de2-9df8-52bf33b69a0f"
      unitRef="number">0.020</exdx:DebtInstrumentStatedInterestRatePaidInKind>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie47ef4f6de5046f08313d4c7118cd8d2_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV81ODIvZnJhZzpjMThhNGZiYjRmMjI0NzA1YWNmYzI4NjQzZDFjOWE1ZS90ZXh0cmVnaW9uOmMxOGE0ZmJiNGYyMjQ3MDVhY2ZjMjg2NDNkMWM5YTVlXzEwOTk1MTE2MzA1MTM_aa544711-78f8-43d4-b9ac-bd25b9f31153"
      unitRef="number">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140199013086360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 05, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXAGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-0434866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1261 Liberty Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vista,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">560-1501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,164,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001274737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198926925464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 106,766<span></span>
</td>
<td class="nump">$ 57,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">9,210<span></span>
</td>
<td class="nump">8,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,405<span></span>
</td>
<td class="nump">4,159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">118,381<span></span>
</td>
<td class="nump">70,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,446<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,506<span></span>
</td>
<td class="nump">5,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">127,772<span></span>
</td>
<td class="nump">78,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,512<span></span>
</td>
<td class="nump">3,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">6,584<span></span>
</td>
<td class="nump">5,757<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,096<span></span>
</td>
<td class="nump">8,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="nump">27,288<span></span>
</td>
<td class="nump">26,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">948<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">36,969<span></span>
</td>
<td class="nump">36,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at September&#160;30, 2021 and December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized at September&#160;30, 2021 and December 31, 2020; 16,164,232 and 12,652,308 shares issued and outstanding at September&#160;30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">291,874<span></span>
</td>
<td class="nump">223,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(201,087)<span></span>
</td>
<td class="num">(181,289)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">90,803<span></span>
</td>
<td class="nump">41,839<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 127,772<span></span>
</td>
<td class="nump">$ 78,375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140199013125944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">16,164,232<span></span>
</td>
<td class="nump">12,652,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">16,164,232<span></span>
</td>
<td class="nump">12,652,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198927494312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 12,251<span></span>
</td>
<td class="nump">$ 10,775<span></span>
</td>
<td class="nump">$ 35,610<span></span>
</td>
<td class="nump">$ 29,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of revenue</a></td>
<td class="nump">5,487<span></span>
</td>
<td class="nump">4,341<span></span>
</td>
<td class="nump">15,649<span></span>
</td>
<td class="nump">12,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">11,528<span></span>
</td>
<td class="nump">9,202<span></span>
</td>
<td class="nump">32,739<span></span>
</td>
<td class="nump">27,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1,740<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">5,035<span></span>
</td>
<td class="nump">2,403<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">18,755<span></span>
</td>
<td class="nump">14,561<span></span>
</td>
<td class="nump">53,423<span></span>
</td>
<td class="nump">41,731<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(6,504)<span></span>
</td>
<td class="num">(3,786)<span></span>
</td>
<td class="num">(17,813)<span></span>
</td>
<td class="num">(12,424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(678)<span></span>
</td>
<td class="num">(647)<span></span>
</td>
<td class="num">(1,986)<span></span>
</td>
<td class="num">(1,913)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">985<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">(7,179)<span></span>
</td>
<td class="num">(4,308)<span></span>
</td>
<td class="num">(19,798)<span></span>
</td>
<td class="num">(13,352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,179)<span></span>
</td>
<td class="num">$ (4,308)<span></span>
</td>
<td class="num">$ (19,798)<span></span>
</td>
<td class="num">$ (13,234)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (1.27)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (1.27)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used to compute net loss per share, basic (in shares)</a></td>
<td class="nump">16,945,591<span></span>
</td>
<td class="nump">12,644,348<span></span>
</td>
<td class="nump">15,636,150<span></span>
</td>
<td class="nump">12,626,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used to compute net loss per share, diluted (in shares)</a></td>
<td class="nump">16,945,591<span></span>
</td>
<td class="nump">12,644,348<span></span>
</td>
<td class="nump">15,636,150<span></span>
</td>
<td class="nump">12,626,259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140199012684712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,560,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 55,659<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 220,248<span></span>
</td>
<td class="num">$ (164,602)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Net exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet', window );">Net exercise of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,563)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,563)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,627,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">50,537<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">220,689<span></span>
</td>
<td class="num">(170,165)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,560,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">55,659<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">220,248<span></span>
</td>
<td class="num">(164,602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,652,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">44,474<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">222,297<span></span>
</td>
<td class="num">(177,836)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,627,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">50,537<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">220,689<span></span>
</td>
<td class="num">(170,165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Net exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet', window );">Net exercise of common stock warrants</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,363)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,363)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,640,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">47,841<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">221,356<span></span>
</td>
<td class="num">(173,528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under Employee Stock Purchase Plan</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,308)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,652,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 44,474<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">222,297<span></span>
</td>
<td class="num">(177,836)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">12,652,308<span></span>
</td>
<td class="nump">12,652,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 41,839<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">223,115<span></span>
</td>
<td class="num">(181,289)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock in public offering, net of issuance costs of $4,435 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock in public offering, net of issuance costs of $4,435</a></td>
<td class="nump">64,709<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">64,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under Employee Stock Purchase Plan</a></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,209)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,925,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 101,470<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">288,951<span></span>
</td>
<td class="num">(187,498)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">12,652,308<span></span>
</td>
<td class="nump">12,652,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 41,839<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">223,115<span></span>
</td>
<td class="num">(181,289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Net exercise of common stock warrants (in shares)</a></td>
<td class="nump">17,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="nump">16,164,232<span></span>
</td>
<td class="nump">16,164,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 90,803<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">291,874<span></span>
</td>
<td class="num">(201,087)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,925,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">101,470<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">288,951<span></span>
</td>
<td class="num">(187,498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock in exchange for common stock warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(804,951)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Retirement of common stock in exchange for common stock warrant</a></td>
<td class="num">(12,775)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(12,774)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrant in exchange for retirement of common stock</a></td>
<td class="nump">12,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,410)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,126,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">96,380<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">290,272<span></span>
</td>
<td class="num">(193,908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under Employee Stock Purchase Plan</a></td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Net exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet', window );">Net exercise of common stock warrants</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,179)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,179)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="nump">16,164,232<span></span>
</td>
<td class="nump">16,164,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 90,803<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 291,874<span></span>
</td>
<td class="num">$ (201,087)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198925059336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 4,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198927257336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,798)<span></span>
</td>
<td class="num">$ (13,234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(3,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,754<span></span>
</td>
<td class="nump">1,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(167)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,085)<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,222)<span></span>
</td>
<td class="num">(10,185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,306)<span></span>
</td>
<td class="num">(450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Purchase of other assets</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,356)<span></span>
</td>
<td class="num">(450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from common stock issued under Employee Stock Purchase Plan</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common stock warrants</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Principal payment on capital lease obligations</a></td>
<td class="num">(343)<span></span>
</td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromBankDebt', window );">Proceeds from Paycheck Protection Program loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Repayment of Paycheck Protection Program loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,865)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock in public offering, gross</a></td>
<td class="nump">69,144<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs related to public offering</a></td>
<td class="num">(4,407)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">64,896<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">49,318<span></span>
</td>
<td class="num">(10,650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">57,548<span></span>
</td>
<td class="nump">72,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">106,866<span></span>
</td>
<td class="nump">61,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest expense</a></td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">1,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_EquipmentPurchasedUnderCapitalLease', window );">Equipment purchased under capital lease obligations</a></td>
<td class="nump">1,111<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Costs incurred, but not paid, in connection with capital expenditures</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DeferredOfferingCostsReclassifiedToEquity', window );">Deferred offering costs reclassified to equity</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredOfferingCostsReclassifiedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Reclassified to Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredOfferingCostsReclassifiedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_EquipmentPurchasedUnderCapitalLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equipment Purchased Under Capital Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_EquipmentPurchasedUnderCapitalLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Expense and Current Other Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198923800120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exagen Inc. (the Company) is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At September&#160;30, 2021, the Company had cash and cash equivalents of $106.8 million and had an accumulated deficit of $201.1 million. Since inception, the Company has financed its operations primarily through a combination of equity financings of common stock and private placements of preferred securities, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198925074120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed balance sheet as of September&#160;30, 2021, the condensed statements of operations and the condensed statements of stockholders' equity for the three and nine months ended September&#160;30, 2021 and 2020 and cash flows for the nine months ended September&#160;30, 2021 and 2020 and the related footnote disclosure are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all normal adjustments, necessary for the fair presentation of the Company's financial position as of September&#160;30, 2021 and its results of operations for the three and nine month periods presented. The results for the nine months ended September&#160;30, 2021 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. These unaudited condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements for the year ended December 31, 2020, included in its Annual Report on Form 10-K filed with the SEC on March 16, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the fair value of financial instruments measured at fair value, the recoverability of its long-lived assets (including goodwill) and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2021 and 2020, approximately 81% and 68%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test. For the nine months ended September&#160;30, 2021 and 2020, approximately 81% and 71%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on key suppliers for certain laboratory materials. For the three months ended September&#160;30, 2021 and 2020, approximately 95% and 98%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. For the nine months ended September&#160;30, 2021 and 2020, approximately 96% and 97%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.771%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,910&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,749&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,949&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,738&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,088&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into an arrangement with a financial institution with which it has an existing banking relationship whereby, in exchange for the issuance of corporate credit cards, the Company agreed to obtain a $0.1 million certificate of deposit with this financial institution as collateral for the balances borrowed on these credit cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,866&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janssen Promotion Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into a co-promotion agreement (as amended from time to time, the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. In August 2021, the Company and Janssen mutually agreed to terminate the Janssen Agreement effective on August 31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Janssen Agreement, the Company was responsible for the costs associated with its sales force over the course of such co-promotion. Janssen was responsible for all other aspects of the commercialization of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company was entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for that quarter over a predetermined baseline. For the first and second quarters of 2020, the tiered promotion fee ranged from $750 to $1,250 per prescription over a predetermined baseline. Due in part to COVID-19, in June 2020, the Janssen Agreement was amended to adjust the predetermined average baseline for the third and fourth quarters of 2020. The Janssen Agreement was further amended in June 2020 and December 2020 to adjust the predetermined average baseline for prescribed units for the quarters ending December 31, 2020 and March 31, 2021 and was subject to further adjustment under certain circumstances. In June 2021, the Janssen Agreement was again amended to proportionally increase the baseline for prescribed units for the quarter ended June 30, 2021 to reflect the addition of certain geographies to the sales territories covered by the Janssen Agreement. For the first and second quarters of 2021, the Company was entitled to an amended tiered promotion fee ranging from $500 to $1,000 per prescription based on the incremental increase in total prescribed units, and the Company was entitled to receive a promotion fee of at least $0.3&#160;million, but capped at 10% above the adjusted predetermined baseline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the termination of the Janssen Agreement on August 31, 2021, the Company became entitled to receive an aggregate of $0.6 million in consideration. Pursuant to the terms of the termination, the Company is restricted from promoting any other biologic or Janus kinase inhibitor used for treatment of indications covered by the Janssen Agreement without first obtaining Janssen's written consent until May 31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's obligations relating to sales and co-promotion services for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were a series of single performance obligations since Janssen simultaneously received and consumed benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations was based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit since the Amended Janssen Agreement is cancelable. The Company recognized co-promotion revenue of approximately $0.4 million and $1.3 million during the three months ended September&#160;30, 2021 and 2020, respectively. The Company recognized co-promotion revenue of approximately $1.0 million and $3.4 million during the nine months ended September&#160;30, 2021 and 2020, respectively. The related expenses for marketing SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are included in selling, general and administrative expenses and are expensed as incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.6 million and $0.3 million for the three months ended September&#160;30, 2021 and 2020, respectively, and $1.3 million and $0.9 million for the nine months ended September&#160;30, 2021 and 2020, respectively, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $0.6 million and $0.4 million for the three months ended September&#160;30, 2021 and 2020, respectively, and $1.6 million and $1.1 million for the nine months ended September&#160;30, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on the grant date and generally vest from the grant date in four equal annual installments subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's common stock is determined by using the closing price of its common stock on the corresponding date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares in 2021 used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three and nine months ended September&#160;30, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.671%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,067,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,067,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,883,395&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,883,395&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Assistance Grant Income</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance grants which are unconditional when received and intended to compensate for expenses incurred or replace lost revenue are recognized when those expenses are incurred or during the period that lost revenue is experienced, and the net amount is included in other income in the accompanying condensed statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Leases&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: Targeted Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to early adopt this ASU as of January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its condensed financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198923792232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock', window );">Other Financial Information</a></td>
<td class="text">Other Financial Information<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,405&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,043&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,043&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,597)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,446&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the three months ended September&#160;30, 2021 and 2020 was approximately $0.3 million and $0.1 million, and for the nine months ended September&#160;30, 2021 and 2020, was approximately $0.7 million and $0.4 million, respectively. At September&#160;30, 2021 and December 31, 2020, the gross book value of assets under capital lease was $2.5 million and $1.2 million, respectively, and is classified in "Laboratory equipment" in the table above.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Other Current Liabilities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,757&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198923675352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Term Loan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus) and borrowed $20.0 million, $17.8 million of which was immediately used to repay the Company's existing loan with Capital Royalty Partners II L.P. and its affiliates. On December&#160;7, 2018, the Company borrowed an additional $5.0 million under the 2017 Term Loan. At September&#160;30, 2021, no additional amounts remain available to borrow under the 2017 Term Loan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company executed the First Amendment to the Loan and Security Agreement (the 2017 Loan Amendment). The interest rate on all borrowings under the 2017 Loan Amendment is 8.5%, of which 2.0% is paid in-kind in the form of additional term loans (PIK Loans) until December of 2022, after which interest accrues at an annual rate of 8.5%. The Company has estimated the effective interest rate of this loan to be approximately 10%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the 2017 Loan Amendment will be repaid in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3NGJjMjUxMjlkZjRlZjE5NTRiZGVmNGU5ZDQ2YzhhL3NlYzo3NzRiYzI1MTI5ZGY0ZWYxOTU0YmRlZjRlOWQ0NmM4YV80MC9mcmFnOmNkY2UxYzdlNDIyYTRiZWZhN2QyN2Q3ZTIyNzcwNzMyL3RleHRyZWdpb246Y2RjZTFjN2U0MjJhNGJlZmE3ZDI3ZDdlMjI3NzA3MzJfMTExOQ_3937bf68-a790-4703-a448-0929f254939d">twenty-four</span> equal monthly installments commencing in December 2022. Upon repayment of the final installment under the 2017 Loan Amendment, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of the 2017 Loan Amendment using the effective interest method. For each of the three months ended September&#160;30, 2021 and 2020, the Company issued PIK Loans totaling $0.1 million. For each </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the nine months ended September&#160;30, 2021 and 2020, the Company issued PIK Loans totaling $0.4 million. In October 2021, the Company executed the Second Amendment to the Loan and Security Agreement (the Second Loan Amendment), discussed in Note 10 to these financial statements, below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Loan Amendment requires a prepayment premium of 2% of the aggregate outstanding principal. The prepayment premium decreases by 1% on November 19, 2021 and 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Loan Amendment is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the 2017 Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis. The consequences of failing to achieve the performance covenant may be cured if, within sixty days of failing to achieve the performance covenant, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The 2017 Loan Amendment requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021, the Company was in compliance with all covenants of the 2017 Loan Amendment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an event of default in any of the 2017 Loan Amendment covenants, the repayment of the 2017 Loan Amendment may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the 2017 Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the 2017 Loan Amendment due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Minimum Payments on the Outstanding Borrowings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,288&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198923481592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company leases office and laboratory space in Vista, California, under leases that expire in January 2026, with an option to extend a portion of the lease for an additional 5-year period. In addition, the Company also leases additional office space in Vista, California, under a lease that expires in January 2026 with an option to extend the lease for an additional 5-year period. The Company's lease payments under each of these leases are subject to escalation clauses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective on August 23, 2021, the Company entered into a sub-lease agreement for an additional office space in Carlsbad, California. The sub-lease commenced in October 2021 and expires in April 2027. The sub-lease agreement provides for monthly base rent of $66,021 which began on October 1, 2021, and such amount shall increase by approximately 3% annually beginning October 1, 2022. The Company is entitled to base rent abatement for a specified period of time which began on November 1, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2021 and 2020, rent expense was $0.2 million and $0.3 million, respectively. For the nine months ended September&#160;30, 2021 and 2020, rent expense was $0.5 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related liabilities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition. The acquisition also included amounts that may be due under several licensing agreements. One such license agreement, the license agreement, dated September 13, 2007, between the Company and Prometheus Laboratories, Inc. (the Prometheus License), was terminated by mutual agreement on September 28, 2021. In consideration for terminating the Prometheus License, including with respect to the remaining potential milestone payments thereunder, the Company agreed to pay Prometheus Laboratories, Inc. a fee of approximately $0.1 million and acquired the intellectual property previously licensed to the Company pursuant to the Prometheus Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has ongoing royalty payment obligations of 2.5% on net sales of products which incorporate certain acquired technologies. Future royalties payable under these arrangements are limited to the lesser of (i) an aggregate of $1.2 million (including an upfront payment of $100,000) and (ii) the total royalties earned through January 1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements as described above, individual license agreements generally provide for ongoing royalty payments ranging from 1.5% to 3.0% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when earned and recorded in costs of revenue in the accompanying condensed statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into an exclusive license agreement with Allegheny Health Network Research Institute, or AHN, to obtain an exclusive license to AHN's patent rights in certain inventions, pursuant to which the Company paid AHN an initial license fee of $0.4 million. In addition, under the terms of the exclusive license agreement, the Company is required to pay the greater of royalties in the low single digits on net sales of diagnostic tests using the assigned patents or a flat annual minimum royalty amount, pending approvals and commercialization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supply Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $4.1 million and $6.0 million for the years ended December 31, 2021 and 2022, respectively, with a 15% annual increase thereafter through the year ended December 31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Obligations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a master research collaboration agreement with AHN, pursuant to which the Company is required to pay AHN a collaboration fee of $0.4 million for each year during the initial term of the agreement. Collaboration expenses under the master research collaboration agreement were $0.1 and $0.2 for the three and nine months ended September&#160;30, 2021, respectively. Collaboration expenses under the AHN collaboration are included in research and development expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payors and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198925667624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>The fair value of the Company's money market funds is based on quoted market prices.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198923704392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2020, the Company filed a registration statement on Form S-3 (the Shelf Registration Statement), covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units, which Shelf Registration Statement became effective on November 19, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, the Company completed a public offering of 4,255,000 shares of its common stock at a public offering price of $16.25 per share. Net proceeds from the offering were approximately $64.7 million, after deducting underwriting discounts and commissions and offering expenses of $4.4 million. The shares were registered pursuant to the Company's Shelf Registration Statement discussed above. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2021, the Company entered into an exchange agreement (the Exchange Agreement) with an Investor and its affiliates (the Exchanging Stockholders), pursuant to which the Company exchanged an aggregate of 804,951 shares of the Company's common stock owned by the Exchanging Stockholders for pre-funded warrants (the Exchange Warrants) to purchase an aggregate of 804,951 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.001 per share. The Exchange Warrants do not expire and are exercisable at any time except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than 4.99% of the Company's common stock, which percentage may change at the Exchanging Stockholder's election to any other percentage upon 61 days' notice to the Company. The Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants are classified as equity and the fair value of the Exchange Warrants was recorded as an increase to additional paid-in-capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. As of September&#160;30, 2021, none of the Exchange Warrants have been exercised.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Warrants</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following equity classified warrants to purchase common stock were outstanding as of September&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237,169</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,086</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants (Exchange Warrants)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,951</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214,059</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, warrants to purchase common stock were exercised resulting in the issuance of 17,719 shares of the Company's common stock and cash proceeds of an immaterial amount.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198925071832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Option Plan</a></td>
<td class="text">Stock Option Plan<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Incentive Award Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally four years from the date of grant. As of September&#160;30, 2021, 1,139,831 shares of common stock remained available for future awards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Board of Directors adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. As of September&#160;30, 2021, 327,516 shares of common stock remained available for issuance under the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company's 2019 Plan is set forth below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(122,435)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,931)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,067,057&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,067,057&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">979,111&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.77</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. As of September&#160;30, 2021, total unrecognized compensation cost related to option awards was $7.7 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.2&#160;years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">422,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403,100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, all of the outstanding restricted stock units are unvested. As of September&#160;30, 2021, total unrecognized compensation cost related to restricted stock units was $5.9 million, which is expected to be recognized over a remaining weighted-average vesting period of 3.5 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83%-86%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47%-52%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8%-1.1%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4%-1.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.77</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.50-6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.50-6.08</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45%-60%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58%-83%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%-1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for the ESPP was immaterial for the three and nine months ended September&#160;30, 2021 and 2020. As of September&#160;30, 2021, total unrecognized compensation cost related to stock purchase rights granted under the ESPP was an immaterial amount, which is expected to be recognized over a remaining weighted-average vesting period of 0.4 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,877&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198923442376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Covid-19<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReorganizationsAbstract', window );"><strong>Reorganizations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock', window );">Covid-19</a></td>
<td class="text">COVID-19<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, due to the worldwide COVID-19 pandemic, the Company experienced a reduction in patient test volumes, delays in patient enrollment in ongoing and planned clinical studies, and delays in the procurement of its testing supplies. In response to the pandemic, the Company has curtailed non-essential employee travel, equipped employees with the ability to work remotely with the exception of clinical laboratory employees, and reduced marketing spend and employee headcount. The full extent to which the COVID-19 pandemic will directly or indirectly continue to impact the Company's business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, including, the success of ongoing vaccination efforts, the emergence and prevalence of variant strains of COVID-19, the institution or reinstitution of shutdowns, "stay-at-home-orders" and other public health measures as well as the related economic impact of these matters on local, regional and international markets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits net operating loss (NOL) carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. The CARES Act did not have a material impact on the Company's effective tax rate or income tax provision for the three months ended March 31, 2020. Under the Tax Cuts and Jobs Act (TCJA), NOLs generated post TCJA were allowed to be carried forward indefinitely but were only allowed to offset 80% of taxable income. As a result of the CARES Act and the change to permit NOLs generated in taxable years 2018, 2019 and 2020 to offset 100% of taxable income, the Company released valuation allowance against its deferred tax assets in the amount of $0.1 million. The release of valuation allowance resulted in a discrete tax benefit of $0.1&#160;million in the first quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, the Company received $0.7 million of funding under the CARES Act Provider Relief Fund, subject to the Company's agreement to comply with the Department of Health &amp; Human Services' standard terms and conditions. The CARES Act Provider Relief Fund is a federal fund allocated for general distributions to Medicare facilities and providers impacted by the COVID-19 pandemic and is intended to support COVID-related expenses or lost revenue attributable to COVID-19. The funding received is considered a government grant, which is recognized when there is reasonable assurance that the grant will be received and that conditions attached to the grant have been met. During the three and nine months ended September&#160;30, 2020, the Company recognized $0 and $0.7 million, respectively, due to lost revenue attributable to COVID-19, which is reflected in other income, net, on its condensed statements of operations.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 16, 2020, the Company entered into a promissory note (the Note) with BOKF, NA dba Bank of Oklahoma (BofO), the lender, evidencing an unsecured loan pursuant to the U.S. Small Business Administration (SBA) Paycheck Protection Program (PPP) of the CARES Act of approximately $2.9 million (the PPP Loan). The Company applied for and received the PPP Loan pursuant to the then published PPP qualification and certification requirements. On April 23, 2020, the SBA, in consultation with the Department of Treasury, issued new guidance that created uncertainty regarding the qualification requirements for the PPP Loan (the New Guidance). In light of the New Guidance, on May 11, 2020, the Company paid off in full the principal and interest on the PPP Loan, resulting in the termination of the Note. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law. It provides additional COVID-19 focused relief and extends certain provisions of the CARES Act. At this time, the Company does not believe that the Consolidated Appropriations Act, 2021 has a material impact on its financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReorganizationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReorganizationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198923672136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into a lease amendment relating to its existing office space located adjacent to the Company's headquarters. The lease amendment extends the term of such lease from January 2026 to April 2027. The lease amendment provides that the base monthly rent for the leased space shall be $22,470 for the 12-month period beginning February 2026 and $23,594 for the period beginning February 2027 through April 2027.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into a fifth addendum to the lease relating to its headquarters. The fifth addendum extends to the term of such lease from January 2026 to April 2027. The fifth addendum provides that the base monthly rent for the leased space shall be $20,084 for the period between February 2026 and April 2027.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into a first addendum to the lease related to its office and laboratory space in the building attached to the Company's existing headquarters. The first addendum extends the term of such lease from January 2026 to April 2027. The first addendum provides that the base monthly rent for the leased space shall be $14,751 for the period between February 2026 and April 2027.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company and Innovatus entered into the Second Loan Amendment to the 2017 Term Loan, which became effective on November 1, 2021. The Second Loan Amendment amends the 2017 Term Loan by, among other things, (i) decreasing the interest rate on all borrowings to 8.0%, of which 2.0% will be paid-in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until December 2024; after which interest will accrue at an annual rate of 8.0%; (ii) extending the interest-only period through December 2024 and the maturity date to November 19, 2026; and (iii) changing the specified level of revenue, as measured quarterly on a rolling twelve-month basis, commencing with the quarter ending December 31, 2022, the Company must achieve to satisfy the related financial covenant in the 2017 Loan Amendment, subject to exceptions based on achievement of performance milestones and the ability to cure any default thereof with the issuance of equity securities or subordinated indebtedness.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198927504456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risk and Uncertainties</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:16pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Marketing Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.6 million and $0.3 million for the three months ended September&#160;30, 2021 and 2020, respectively, and $1.3 million and $0.9 million for the nine months ended September&#160;30, 2021 and 2020, respectively, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $0.6 million and $0.4 million for the three months ended September&#160;30, 2021 and 2020, respectively, and $1.6 million and $1.1 million for the nine months ended September&#160;30, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on the grant date and generally vest from the grant date in four equal annual installments subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's common stock is determined by using the closing price of its common stock on the corresponding date.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares in 2021 used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three and nine months ended September&#160;30, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted, Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Leases&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: Targeted Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to early adopt this ASU as of January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its condensed financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198923763128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</a></td>
<td class="text">For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.771%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,910&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,749&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,949&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,738&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,088&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash and Cash Equivalents</a></td>
<td class="text">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,866&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,866&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.671%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,067,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,067,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,883,395&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,883,395&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198925127304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid expenses table</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,405&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment</a></td>
<td class="text">Property and equipment consist of the following (in thousands):<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,043&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,043&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,597)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,446&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued and other current liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,757&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198923491624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,288&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198923438584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198923486536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following equity classified warrants to purchase common stock were outstanding as of September&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237,169</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,086</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants (Exchange Warrants)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,951</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214,059</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, warrants to purchase common stock were exercised resulting in the issuance of 17,719 shares of the Company's common stock and cash proceeds of an immaterial amount.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198931257656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company's 2019 Plan is set forth below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(122,435)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,931)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,067,057&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,067,057&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">979,111&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.77</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">422,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403,100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions, Stock Options</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83%-86%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47%-52%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8%-1.1%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4%-1.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.77</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.50-6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.50-6.08</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions, Employee Stock Purchase Plan</a></td>
<td class="text">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45%-60%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58%-83%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%-1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Non-cash Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,877&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198925373688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 106,766<span></span>
</td>
<td class="nump">$ 57,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 201,087<span></span>
</td>
<td class="nump">$ 181,289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198927240568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue by Major Payers (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareMember', window );">Medicare | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember', window );">Medicare Advantage | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_BlueShieldMember', window );">Blue Shield | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_BlueShieldMember', window );">Blue Shield | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_UnitedHealthcareMember', window );">United Healthcare | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI) | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI) | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_BlueShieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_BlueShieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=exdx_ReceivableBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=exdx_ReceivableBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_UnitedHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_UnitedHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140199013202936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>installment</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline', window );">Joint venture quarterly promotion fee cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">12,251,000<span></span>
</td>
<td class="nump">$ 10,775,000<span></span>
</td>
<td class="nump">35,610,000<span></span>
</td>
<td class="nump">$ 29,307,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exdx_JanssenPromotionAgreementMember', window );">Janssen Promotion Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureTerminationConsiderationReceivable', window );">Termination of agreement</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments', window );">Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Period, Number Of Annual Installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeePerPrescription', window );">Joint venture, quarterly promotion fee per prescription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFee', window );">Joint venture, quarterly promotion fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeePerPrescription', window );">Joint venture, quarterly promotion fee per prescription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Product Concentration Risk | AVISE CTD Test</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Supplier Concentration Risk | Two Major Suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_JointVentureQuarterlyPromotionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture, Quarterly Promotion Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_JointVentureQuarterlyPromotionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_JointVentureQuarterlyPromotionFeePerPrescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture, Quarterly Promotion Fee Per Prescription</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_JointVentureQuarterlyPromotionFeePerPrescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_JointVentureTerminationConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture, Termination, Consideration Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_JointVentureTerminationConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Period, Number Of Annual Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exdx_JanssenPromotionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exdx_JanssenPromotionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_JanssenSIMPONIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_JanssenSIMPONIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exdx_AVISECTDTestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exdx_AVISECTDTestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=exdx_TwoMajorSuppliersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=exdx_TwoMajorSuppliersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198927187224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 12,251<span></span>
</td>
<td class="nump">$ 10,775<span></span>
</td>
<td class="nump">$ 35,610<span></span>
</td>
<td class="nump">$ 29,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_HealthcareInsurersMember', window );">Healthcare insurers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">6,910<span></span>
</td>
<td class="nump">5,749<span></span>
</td>
<td class="nump">20,318<span></span>
</td>
<td class="nump">15,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_Government1Member', window );">Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">2,330<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">6,733<span></span>
</td>
<td class="nump">6,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_ClientMember', window );">Client</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">2,346<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">6,738<span></span>
</td>
<td class="nump">3,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="nump">821<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 1,347<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 3,398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_HealthcareInsurersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_HealthcareInsurersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_Government1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_Government1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_ClientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_ClientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=us-gaap_OtherCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140199037043976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 106,766<span></span>
</td>
<td class="nump">$ 57,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">$ 106,866<span></span>
</td>
<td class="nump">$ 57,548<span></span>
</td>
<td class="nump">$ 61,534<span></span>
</td>
<td class="nump">$ 72,184<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198927684488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">2,883,395<span></span>
</td>
<td class="nump">2,405,221<span></span>
</td>
<td class="nump">2,883,395<span></span>
</td>
<td class="nump">2,405,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">409,108<span></span>
</td>
<td class="nump">426,827<span></span>
</td>
<td class="nump">409,108<span></span>
</td>
<td class="nump">426,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">2,067,057<span></span>
</td>
<td class="nump">1,975,250<span></span>
</td>
<td class="nump">2,067,057<span></span>
</td>
<td class="nump">1,975,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">403,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">403,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">4,130<span></span>
</td>
<td class="nump">3,144<span></span>
</td>
<td class="nump">4,130<span></span>
</td>
<td class="nump">3,144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198930448616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Prepaid expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Diagnostic&#160;testing&#160;supplies</a></td>
<td class="nump">$ 1,010<span></span>
</td>
<td class="nump">$ 1,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRoyalties', window );">Prepaid product royalties</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PrepaidMaintenanceAndInsuranceContracts', window );">Prepaid maintenance and insurance contracts</a></td>
<td class="nump">1,040<span></span>
</td>
<td class="nump">2,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid and other current assets</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">$ 2,405<span></span>
</td>
<td class="nump">$ 4,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidMaintenanceAndInsuranceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Maintenance and Insurance Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidMaintenanceAndInsuranceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198927397720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Property and equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 7,043<span></span>
</td>
<td class="nump">$ 5,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(3,597)<span></span>
</td>
<td class="num">(2,941)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,446<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture&#160;and&#160;fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="nump">2,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,106<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,141<span></span>
</td>
<td class="nump">1,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">$ 301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140199013169928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_AssetsUnderCapitalLeaseMember', window );">Assets under capital lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_AssetsUnderCapitalLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_AssetsUnderCapitalLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198927076952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Accrued and other current liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</a></td>
<td class="nump">$ 3,793<span></span>
</td>
<td class="nump">$ 3,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AccruedPurchaseGoodsAndServicesCurrent', window );">Accrued purchases of goods and services</a></td>
<td class="nump">765<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AccruedLiabilitiesClinicalStudyCurrent', window );">Accrued clinical study activity</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligations, current portion</a></td>
<td class="nump">586<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 6,584<span></span>
</td>
<td class="nump">$ 5,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedLiabilitiesClinicalStudyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Clinical Study, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedLiabilitiesClinicalStudyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedPurchaseGoodsAndServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Purchase, Goods and Services, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedPurchaseGoodsAndServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406127&amp;loc=d3e45023-112735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198926348520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 07, 2018</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loan payable | Capital Royalty Partners II LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Loan repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Loan payable | Innovatus Life Sciences Lending Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Term loan borrowings</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Term loan, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentStatedInterestRatePaidInKind', window );">Term loan, paid in-kind, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Term loan, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Term loan, fee incurred upon payment of final installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentPrepaymentPremiumPercentage', window );">Term loan, prepayment premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction', window );">Term loan, annual reduction in prepayment penalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance', window );">Term loan covenant, minimum unrestricted cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease', window );">Term loan covenant, increase to interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Paid in-kind note | Innovatus Life Sciences Lending Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentPaidInKindLoansIssued', window );">Term loan, paid in-kind loans issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPaidInKindLoansIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Paid In Kind Loans Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPaidInKindLoansIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPrepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPrepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium Percentage, Annual Reduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentStatedInterestRatePaidInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Stated Interest Rate, Paid In-Kind</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentStatedInterestRatePaidInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=exdx_CapitalRoyaltyPartnersIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=exdx_CapitalRoyaltyPartnersIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_Term2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140199015951336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Future minimum payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2021 (remaining)</a></td>
<td class="nump">$ 446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">2,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">15,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">14,280<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_LongTermDebtIncludingUndiscountedInterest', window );">Total</a></td>
<td class="nump">33,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_LongTermDebtUndiscountedInterestAmount', window );">Interest</a></td>
<td class="num">(5,829)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="nump">$ 27,288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtIncludingUndiscountedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Including Undiscounted Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtIncludingUndiscountedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtUndiscountedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Undiscounted Interest Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtUndiscountedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198927762008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 23, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating lease, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear', window );">Purchase obligation, to be paid remainder of fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase obligation, due in year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage', window );">Annual increase in purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember', window );">AHN Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CollaborationAgreementCollaborationExpenses', window );">Collaboration agreement, collaboration expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_LicenseAgreementInitialLicenseFee', window );">Initial license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember', window );">Prometheus Laboratories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Future minimum royalty commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdvancePayment', window );">Advance royalties payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember', window );">Prometheus Laboratories | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember', window );">Allegheny Health Network Research Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CollaborationAgreementAnnualCollaborationFee', window );">Collaboration fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember', window );">Office and Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OperatingLeasesRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeMember', window );">Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OperatingLeasesRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OperatingLeaseMonthlyBaseRent', window );">Operating lease monthly base rent</a></td>
<td class="nump">$ 66,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent', window );">Operating lease annual increase in base rent payment percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdvancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdvancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CollaborationAgreementAnnualCollaborationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Annual Collaboration Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CollaborationAgreementAnnualCollaborationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CollaborationAgreementCollaborationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Collaboration Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CollaborationAgreementCollaborationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LicenseAgreementInitialLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Initial License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LicenseAgreementInitialLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Annual Increase In Base Rent Payment, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OperatingLeaseMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Base Rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OperatingLeaseMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Annual Increase In Commitment, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RoyaltyObligationPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Percentage of Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RoyaltyObligationPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RentalPropertyByTypeAxis=exdx_OfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198927991512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - Money market funds, included in cash and cash equivalents - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">$ 105,679<span></span>
</td>
<td class="nump">$ 34,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">105,679<span></span>
</td>
<td class="nump">34,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198927536296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 22, 2021</div></th>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Nov. 10, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuanceCosts', window );">Estimated offering expenses for aggregate expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Number of warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_ExchangingStockholdersMember', window );">Exchanging Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants', window );">Number of shares exchanged for warrants (in shares)</a></td>
<td class="nump">804,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common shares to be called upon exercise of warrants (in shares)</a></td>
<td class="nump">804,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Sale of stock, percentage of ownership after transaction</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued in public offering, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from public offering, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuanceCosts', window );">Estimated offering expenses for aggregate expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange Agreement, Number Of Shares Exchanged For Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_ExchangingStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_ExchangingStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198925597288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">1,214,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Net exercise of common stock warrants (in shares)</a></td>
<td class="nump">17,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member', window );">Warrant expiration January 19, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">237,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member', window );">Warrant expiration March 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">67,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member', window );">Warrant expiration April 1, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member', window );">Warrant expiration September 7, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">83,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member', window );">Warrant expiration December 7, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">20,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember', window );">No expiration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">804,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140199013040648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock options, unrecognized compensation cost | $</a></td>
<td class="nump">$ 7.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares that remain available for future awards (in shares) | shares</a></td>
<td class="nump">327,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee payroll deduction percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock options, unrecognized compensation cost | $</a></td>
<td class="nump">$ 5.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member', window );">2019 Incentive Award Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares that remain available for future awards (in shares) | shares</a></td>
<td class="nump">1,139,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198927079512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock Option Activity (Details) - Stock options<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, December 31, 2020 (in shares) | shares</a></td>
<td class="nump">1,975,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">229,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(11,188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(122,435)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(4,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, June 30, 2021 (in shares) | shares</a></td>
<td class="nump">2,067,057<span></span>
</td>
<td class="nump">1,975,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, June 30, 2021 (in shares) | shares</a></td>
<td class="nump">2,067,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options exercisable, June 30, 2021 (in Shares) | shares</a></td>
<td class="nump">979,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, December 31, 2020, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">16.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">7.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">14.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">21.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, June 30, 2021, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">12.20<span></span>
</td>
<td class="nump">$ 11.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, June 30, 2021, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">12.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options exercised, June 30, 2021, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 1 month 20 days<span></span>
</td>
<td class="text">8 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 6,956<span></span>
</td>
<td class="nump">$ 6,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value | $</a></td>
<td class="nump">6,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options exercisable, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 4,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198926673192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Restricted Stock Units (Details) - Restricted stock units - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, December 31, 2020 (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="nump">422,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Awards released (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Awards canceled (in shares)</a></td>
<td class="num">(19,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, September &#160;30, 2021 (in shares)</a></td>
<td class="nump">403,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, December&#160;31, 2020 (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awards granted, Weighted-Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">16.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Awards released, Weighted-Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Awards canceled, Weighted-Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">16.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, September 30, 2021 (in dollars per share)</a></td>
<td class="nump">$ 16.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 5,482<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198925847928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 9 months 7 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198927672696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,354<span></span>
</td>
<td class="nump">$ 799<span></span>
</td>
<td class="nump">$ 3,551<span></span>
</td>
<td class="nump">$ 1,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="nump">2,955<span></span>
</td>
<td class="nump">1,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140198926976552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Covid-19 (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance', window );">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit', window );">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ProceedsFromGovernmentAssistance', window );">Proceeds from government assistance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromBankDebt', window );">Proceeds from Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_PaycheckProtectionProgramCARESActMember', window );">Paycheck Protection Program, CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromBankDebt', window );">Proceeds from Paycheck Protection Program loan</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ProceedsFromGovernmentAssistance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Government Assistance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ProceedsFromGovernmentAssistance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_PaycheckProtectionProgramCARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_PaycheckProtectionProgramCARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140199029022376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Innovatus Life Sciences Lending Fund | Loan payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentStatedInterestRatePaidInKind', window );">Term loan, paid in-kind, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2017 Term loan | Innovatus Life Sciences Lending Fund | Loan payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentStatedInterestRatePaidInKind', window );">Term loan, paid in-kind, interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OperatingLeaseMonthlyBaseRent', window );">Operating lease monthly base rent</a></td>
<td class="nump">$ 22,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OperatingLeaseMonthlyBaseRentFirstIncrease', window );">Operating lease, monthly base rent after first increase</a></td>
<td class="nump">$ 23,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Headquarters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OperatingLeaseMonthlyBaseRent', window );">Operating lease monthly base rent</a></td>
<td class="nump">20,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Office and Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OperatingLeaseMonthlyBaseRent', window );">Operating lease monthly base rent</a></td>
<td class="nump">$ 14,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentStatedInterestRatePaidInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Stated Interest Rate, Paid In-Kind</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentStatedInterestRatePaidInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OperatingLeaseMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Base Rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OperatingLeaseMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OperatingLeaseMonthlyBaseRentFirstIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Base Rent, First Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OperatingLeaseMonthlyBaseRentFirstIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Term of Contract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_Term2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RentalPropertyByTypeAxis=exdx_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RentalPropertyByTypeAxis=exdx_HeadquartersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RentalPropertyByTypeAxis=exdx_HeadquartersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $^*:E,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !/BFI3W7=/9^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:@,A$(9?I7C?G=5 *++QTM)3 H4&6GH3G232U16=LINWK[M--I3V 0I>G/G]
MYANP-5&:/N%SZB,F<ICO1M^%+$W<L!-1E #9G-#K7)=$*,U#G[RF<DU'B-I\
MZ".":)HU>"1M-6F8@%5<B$RUUDB34%.?+GAK%GS\3-T,LP:P0X^!,O": U/3
MQ'@>NQ9N@ E&F'S^+J!=B'/U3^S< 79)CMDMJ6$8ZF$UY\H.'-YVVY=YW<J%
M3#H8+*^RDW2.N&'7R:^KA\?]$U.B$;SBY31[(22_EWS]/KG^\+L)^]ZZ@_O'
MQE=!U<*O?Z&^ %!+ P04    " !/BFI3F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M $^*:E.%+C,61P4  /(5   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9A;<YLX%,>?NY]"X]F'=B8.('Q).HYG'')I9EO7C;.][,X^R"#;3$%BA;#C
M;[]'8(.3P0=V^F)S.W]^.A+_(VFTE>IGNN9<D^<X$NE59ZUU\MZR4G_-8Y:>
MRX0+N+.4*F8:3M7*2A/%69 'Q9%%;7M@Q2P4G?$HOS93XY',=!0*/E,DS>*8
MJ=TUC^3VJN-T#A<>P]5:FPO6>)2P%9]S_6<R4W!FE2I!&'.1AE(0Q9=7G8GS
MWG-=$Y _\37DV_3HF)BF+*3\:4X>@JN.;8AXQ'UM)!C\;;C'H\@H <>_>]%.
M^4X3>'Q\4+_+&P^-6;"4>S+Z%@9Z?=6YZ)" +UD6Z4>Y_<#W#>H;/5]&:?Y+
MML6S?=HA?I9J&>^#@2 .1?'/GO>). KH.2<"Z#Z O@IP>B<"W'U GCFK(,N;
M=<,T&X^4W!)EG@8U<Y#G)H^&UH3"=.-<*[@;0IP>>W+#%>F2=,T43T>6!DUS
MQ_+W\==%/#T1?TD^2:'7*;D5 0]>QEO 4@+1 ] U107G/#DGKGU&J$V=&AX/
M#Y_*S3FQ^W7A+W#<,C]NKN>B^?E[LDBU@B'W#R+9*R5[N63OA.2-]#/X$#1Y
MVB6\+N-XN&-WOR 4_9*BWX[B2\:4YBK:D4>>2*7KB' IK3*.$ U*HD$[HAE7
MH0S,B"(PIFM3A"L=QM!O;]XT#(-AR39LV6>*@87E#G0Z7;C6DD4IEJ^+DND"
MU;D5.M0[<A=&G$RS>,%5'0NN8=M.U[VT>Y<(SV7)<]F&YY&O0O.Q0+*F+*[M
MO0:=[Y/[VREYF'KG")5C5PYGM^%Z$+Y4T&/,=-X9F6L86D0JXLE,:+6#_Z 6
MMD']YA:#/+)AIPWD$WLF#P$,M' 9^CDITK4-DM3NVCVW=S$88(2T(J1M""=!
M (4B/3L<D(_P'/DLZG.'2SITX$ \- ^$O[$=QED9MN/^+T[/G$$_/\FMJ&7$
MY;["8&9G&%GE^P[NW*_)RB$X4W(3"K\^A;BF-\'0JF+@X!;^&FTFH=41^2M,
M3G\7N.(EM2\PYW6JLN#@;IYWX 3FJ*=1<(&WPX']#D.IJH"#6_='Z4-69FLI
M,,MM$.D/[*[3M]'D5#7 P0W\*=1@_W))'/IV\8[,N9\IR%<M%J[DR3@&NYEK
MZ?\\(PE39,.BC)/?[7.H$B2!:5 ^2<2PJU+AX!X/930(Q8K,=_%"1K6TN,#W
M^RDVV:R* \7M^Y P<OOLKYE8\9-%JT%H.IG?3+")&:UJ 6U5"[Q,*3/E*.89
M>;; ,++:27J#XH_74_N79%4-H*UJP(. "6.Q #,S-'9 K27#%1O(*M>GK5S?
M3(:@I(.OKJ2J_0H:=*92=)GOPS(3)@H\* 0QPLK]:2OWG\<LBLAUEL+MM+XO
M<9V&V3:M/)^V\OS;F*N5&5WWH*#78+)QPD1][GYI'4 KQZ>X81_(GH^GV\6J
MH!8+5VN:;]/*_BGNW(<N7'/H0BQ/O[8 H)7[TU9+@)?6/<^7\N1SIJ&&B]QF
MWX9BO\)_5\/K[=_2S]]B-GXV8V?@#'K4I2-K4T=8&3UMM2CPP!T4E,X'$?!G
M\@>O3QLN94,9HL/>T!UBZ_K*^5W<L _V>A>FIJC_X%#QL"5G@URWZ]"NBVXY
M5 7 Q>VZ7&T>L]W!Q5J_:!!KV@BIS-_%K?HUU7Z9?IH+E_OB8E1'^S.X84\
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M6D#3O* !BDHSZ[" =6+A1.T-\(1![/=1#Z6"*!BI$:CE"#1-$L>5[!12!P/
M9?][=$E%$1I!VA(%FF:*6RZT#BN>Y&7!B\LWR"47ID.T=0WP+4B9K!/%;$1*
M-PHP*2O;["1<CGPU#B:)<!SW/7.(A>$8F:"63= TG=S3+=7>I$"1EY-[X."4
M8 !T6N@89DLH:)I1#D6Q&_Q36(=\@7P<]<$.I99CO0]J605-T\HAL4\!''*'
M%R[#?B5WB@7>",>@EF30-,O<\3QGRM#R(5L37BB=X+1(-%[P[D^N* C>.X%/
M&C;3X+4L24)O9GK<DU0\T]D:.+OQ'S=TW)>W3(;A)%,\*IY\V_$LI4+^8AL4
M]3I%%;CE((Q.]93U]R3-&G-P :\@1)HY!-"]>D4_  3G$-H_('=$F+ZS4CLN
MV+\TU:6$OSTUI4/;X0+HH5@JO4EZ?P!10(\YBN8;*G[^"87PP]O 8[=1SS#V
MU<@<<]C!VH=N3O7[[4F1X]ATQJ%I&C4II^?IT<!@.!&9_^VX#G0X1Z$_QQZV
M$@C/PP#//1CW(FQ9\P="/-=3CBRI/2;(7IT!=S0'?>IRR7@C(6\; WRB,4A3
M9BA*ER,SZESJ^3HA)=/ER0ESR/-XB>*HWP^XY+"'T$@'A]N. )\<&ZN\RHBB
MACZW+&'.>0$/6?X20P3C?GEW":(8X7B$-G';$>#ICN!0XJ6CCC@!#\E["6/H
M]>&ZYL78&P/;<CP^9V3L\)'-X[/!A\.#!%=;[Y!SM?6+SA&2.;_[@X@G5DB0
MT:W6@U>1=E\<CL0.-XJ7]E1IPY7BN;W<4:)1&P']?LLU5]4WYJ"J.9A<_P=0
M2P,$%     @ 3XIJ4^P-5=RT @  =@D  !@   !X;"]W;W)K<VAE971S+W-H
M965T,RYX;6RMEEUOFS 4AO^*A7;12ELPD)"T2I#65--V,2EJM.W:A9-@U=C,
M-DFW7S_;$ 9M/KA(+H)MSOOZ.<<&,]\+^:)R (U>"\;5PLNU+N]]7Z4Y%$2-
M1 G<W-D(61!MNG+KJU("R9RH8'Z(<>P7A'(OF;NQE4SFHM*,<EA)I*JB(/+/
M S"Q7WB!=QAXHMM<VP$_F9=D"VO0/\J5-#V_=<EH 5Q1P9&$S<+['-PO R=P
M$3\I[%6GC6PJST*\V,ZW;.%A2P0,4FTMB+GL8 F,62?#\;LQ]=HYK;#;/KA_
M<<F;9)Z)@J5@OVBF\X4W\U &&U(Q_23V7Z%):&+]4L&4^T?[.G8R]E!:*2V*
M1FP("LKK*WEM"M$1!*<$82,(APJB1A"Y1&LRE]8CT2292[%'TD8;-]MPM7%J
MDPWE=AG76IJ[U.ATLA0\,XL"&7H@C/ 4T-IZ*72S(A*XSD'3E+!;] E]0#Y2
MN1E5<U^;J:V!GS;3/-33A">F64,Y0A'^B$(<!D?DR_/R1TB-/'!RW)?[)N$V
MZ[#-.G1^T0F_E=DK(*7)VA0X?3GC&+6.D7,<GW(D$NT(JP#=4(XRP1B1"I4@
MZY+='BM9[3AUCO9QVR5XA+$ISZY;F4M1/=QQBSL^B[MVZXA(I7,AZ5]3"(M=
MK^Y1UMINTJ$(</U[@SL@L$<\:8DG0XBI4M5EVLD[B+>8YR)Z?''+%P_A,V]*
MI0G/*-]>@HPO0IZ+Z$%.6\CIV7V_%$5AWIV7-OVLM9M=?=//!FWZ2U$]W+L6
M]^ZZF_[N7?U#?'S7#XGL,0?X_PL:7V_C-UZ]QR\.XG$8A6^(CT6&\22,\.P$
M<>=(":[\*#2&0["/1![']CN'HOTB^4[DEG*%&&R,%(^FQD/6AWS=T:)TY^2S
MT.;4=<W<?!B!M 'F_D8(?>C8H[?]U$K^ 5!+ P04    " !/BFI3@^IL^2,%
M   $%0  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;*U8;6^C.!#^*U:T
M'W:E;L$VA%"ED=HDIZMT>UNUV]L/I_M @I.@!9RSG;;W[V\,E*1FH+T756K
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MUXC!*)#OT3AV]:C&+_7C]U(Q& 4X+)C9VWZC?A,TIZF?TZ?$8-2F98S,4''
MJ"]3XY0.G\FY8C *9&<<FYY@-FC6/YG6B&1^1!Y_#H; $VH;7(C'F/'(X7N9
M)A<[Z83N"#73KL8>DD.DO*'A5B$[<].*V3DBCJ*8&9GZ#+!3Z!8T=D0O3+.3
M7>XJ"1S),.@N"1B$'6/9;X9F*'O9O1.'=(!\0! &F%E!& /V2*$@#+#S!F%,
MLY3]C-LG!]=/7G^G=,IL7*I< [GZ1A.3G9^?=D7[MX%BX5Q:&GWL4IDG[&<
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MZF+3OE_YN:CK8MU^7,E$^<;&0/U]613U\Y?FE<W]2\ W_P=02P,$%     @
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MC1V)D*BOZ]DG4B.62WWTYYJ!46:VW(+[J+J9?:G)/>!4 DV&]$)Q@BRS8N=
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MC0'T.ZX1]E^P0+B@_=O_ U!+ P04    " !/BFI3OC$$RZD$  "3"P  &0
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M- HAB9+X#%[:>YMZO/3_>PM_W2Z,U71+_CZC*.L595Y1]C%A/0OFZO+&U*S
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M%R^T]2!-).<<TO,%9>%FM5Y-*X4L=0I*7(PC2E7DR@6,/"EY.'UIB[HE%YE
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MIEO8H^2\0FFXDJ"QF ;S>+P8.G_O<,]Q8_9D<)4LE7IPE\_Y-(@<(12868?
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M&X*MXT^^&I/C#7A?6N2Y>V %PX?(L_\!4$L#!!0    ( $^*:E-.#^7;^ 0
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M8W+9=A?U!&H@X8R9EJS4FX[M?B0;:>&STOKH T.^APX)G:]MB5S*_Q2-9('
M_*G6^1_8'O;^I;7T'ZO5L\@Y[XFB];P4S PXFD&3K"4_5!/ _S\[\YNJ=R(0
MR[$"IE7?6R K6P1T=B^L)C/?B142\/8"FT!\#[.9^.LFUC9$WB?$GW 0]7.
M.HU!ZD(VGY'KP?\TK;#:#0=% X,!:9:$'P45TO2ZI<A"'AR=VYF2"3T@*C(5
MV?0C5L1]8^J8]6W3 .Z$*<P/PG5M$UN\7?*4Y$1'UYY%= YF8UWQ9P=@>B_
M2?!."B*RATP0N+)BJ&V;Z'$P,@./$:L%7=Z.[ :#_2!;C)![V&:/Q;FG79Q[
M>CR7X62!_JI?AO$%LO\ 'F%$)"5Z?RCT_56T6=XIKB2X]IR*4'90[J8E0 A
M6M3(&X(X;--"O"Q8#D :.J5BB6)(11&/U$UX)G+7&0@@F8BJ9-P UG+B3-HW
MWI.TR<CO!5M*G,C*@IA, (L^I  SBD&]HHXIYUFGG&='!?@!!E)#YQ],9F$3
MQ/LA+7PWD0,9W[UXZ^(T2!A"002!1B3<.5LI#]%P\D9!%QOGY!YRR-LL"@R&
M# B"^Q4EJ;3"%TXWR(LXX[NQ)=R''K O@C8&PC.F.5"8$HD^BD6'3 ;2TTW0
M=I +:--M30O%V-)ND"@+8]@F=-1L=QZ!4.)VP<+P*1Q_@I3 ZI+4'9?>&EV&
M;496 /IK& O8TJ6'#5B)NWOB.R@3<(3Q%;_$KCV2(<FAG8GP15\VIHYI+0$U
MAC7D$ 1[!%Z-WC'H1"#SIEM"..4(;U)!H7>#@02?'!1.C<[@F9K>6W?6%1*4
MC/<;E:3:(=_>V!OC:EZ69X!"KX/W2.1X/.U0OA3Y&0H0)/F#"<7,S"9J:WU3
M! AN$L,.,DL*)X!93NQ#-CN32J6!2=!\;\KU%$1&)@ !Q\V0G6E 9KV!?!KC
MN)N">@NAJ2PVNJ\_. ^LFM*$(1+G*$6P-ZZ;1EJ)P-O@>^:*%:NR,QEQ? #8
M9D,PE5S%]1XV4]>R;Q(,PDHIN+&7TL;B+4/*]0\3$AV?"/UI\J%J="6E6R17
M&WE**0OMV,=<9XTDT_#WE/OM38Q.H,A"*T:T<:8^S/'-76.2+TF^&_V?RC-1
M;30[9S."4.(A$N9B(FTI+0KA2M62P<MC_XAV<;\N):RW)96)PX#X1YMOV!")
M8%J(Y/UQ5)EP'D>& <?.M<L3?PFT^QBSA71A?92R(7>CR"ZU2\<=B0#6"8E.
MQ"78O)PIJE7KO*3-36IKT%PQ[#6@RY+S0'1)TD-E,4;"'C$OE0H9]14863"-
M;,#E)$/)["3F182*U1D9?&&Y7)%"A0>DU8#/&0:BQFD=LS0D%.V[9V@2DQ3I
MYZ$,%U4TW#EP)O*3? =)$W(L3D)8\L.20S8#?^L-K/6\D3K:$YZD9"9LK:RI
M" &AN,(2(X7?]_?NM?C4QMFVH337.+%#01A%R 8AY,CV<MH$,C.73PD4=[WV
M)AUH[<'4Y![L1$P22"*4)Y"(#+X9F?#8M^NA/[/+1""$7&K"* Z\R(GKC@!,
M%$R3H!)015.$KK/ WDLOBUHZQNRJHL4#H,U3^TC"EN!3IOIH3C-?S)$>[3B*
M1]JTI9J[<BB%+8<?V"1UKD8^&)/@R*BMV:!6PVY"V#7L4=$^23H%8GT"I!%.
MK_NXM.=YU,L:(M.QE.IYEU(]_THVY VEY;S6SY2 VX;,^%!>]6.4($-.-;RW
M"!8AI:=N.#P?#(^E":.',^PAM9<>!$I <G2![%@/PD_;OHSCAA?7Y1.2JK=U
M;<II*FXB+3^)DTEE0+OL\U2T1>K# -WA' 9/*'F&VCA&=]%YQR56R4&:=$(P
MSOKW@9\<VC%A! UJF]0.HC2%IT&6;!\^@*FH>(*BC&=3M@&3S@=<NP3Y;4@U
MVA%C>-$9PXNC*KS,L5(H(C@A>^%TDKZQ#@_9Q+]$\ '3T'NSJF[6-]@&<-(&
MBEH/$A'MW!I*T?I:!:#PM_GLJ:K(]0F ,0</'G4/4J4\JI0,'3&HI6F"J5:
MPW1*P-/Q83[AA-5DDL]+*O>WQ8!L7.?%O750N/UKRPC\Q:8)099A4)LD&)1!
M.76?/#?O;SJ)=H&5\A"&<!$<V&!Y<^4G@9.Z6DT$I*-&N)CW!T7SHU:SW!9-
MD_3V=_PICYK@CU.+?SM8X3[-</@V#=^7I=@0UVJ2Z_Z8O&(5!'LE(_ZJ,3[^
M]QCCWCJ+V>*O-,:C-C$X/%P<UR+#M+3HWPQ@^J!!_!BI4<K<E1S^8%20)G=9
MCL*'OD5FS:FD0;YB=R8B>5Y0PD+)SB@IV"#W"E/NR/298=\P\8S[L3DGO9JN
M9!TF$F1ULO!IZ]NNNWB3"FX>>28Y)?DY'1Y/22;#O'+04*,$A#8%,^UM-/66
MO&KK^\7]Q7SQ0OT2]ZQ8ONHZSE#7)?+<TU^6U]=GRM'B7DX6J//)APN2#!/%
MJU)#F,ML:TOCI^^!W^#Z]&KY_BPRP[DT-[0L*M54O+!X8'+#,S5JS.O/J SD
MI)%B3%O%#3FST;&44'7+-LRI%269=[S=>-A(B'B#JI[*+PB*FG9(FUG:9 !K
M4]!!DA_7 W)6LDO%!DD7.SBX 8(4ZQHK1TRT$AUO=/7*,$T)]Y2T=S1FJXKJ
M$)+]9%!66&HET9G(X"'WG&F;=-HT71."%#4><KW?]WAN^9Z!R:<:=@BY[A%@
M(!.!WE+!I<NL+0?5#1^Z<46W+O!02ANA_,"ZTL]A>_7#)G(6DW"N7P;]\BC2
M8L^O/LV66,9Q7WBG=@6=QU(9N%Y3V1"[#IQ_@PX[H7#%-1+ +4ZA3?UI'!+)
M>/J5H($Z@+4AW\Q-5FH*'-R'*O*.A(_1@VH;U< !&!500GB;(@7VB@S8<&6_
M;LF.#GDBEV^N;PZ+9[9U$?:<:(@IL<O;:8$.>Z3W5F1?,9T#=,:%$\&*U&][
MPPH*%JVC1C&G%G4;#P4P32)?=X(?BS1; DEX?;H+T=+N(KIQ%CA@<MS-*.#*
MAE1PBV"MR?] D>#9KW>'9>6E2(^0>$C.1R0REO-J=TRPM-0A<7+-2GU+]F4^
M5#P6%2_ZJ'CQE9L75>/,EJXN :I^L_YP@O2]1-3X44F/QJ?!.C98V+$$%KF3
MO2+A4-_+D&-SCUOEK1.L%=>>Q)XB/1-#&C2VY4EM:WL+BX.[((I$/**K%4 B
M:;[#K?C47BY(K#G=TNGP,+O//8R8C]6=(;^;=.$[H0WU-8EE&34VA7U:MQ$/
MO*X,5Q[<IHL-:^IST*BC^NTO"BT>'54-=4%9(=?8UI*,_:!^OY<(774HLHY7
M;N2P*P$=X3THJ-/]AJ$QB\.R)0S '@[!J)=\HB/Z+:16DJO<BS2CJ,RSQ-%M
M&[B#R5XD9L5=:=;B3/U<E.U0"3^P,:B[_7_<%H/$\&QMN,.4?,=D[V#*%&*<
MFPHI;HRLIX!4JGZ[L/M01.\9B@*&.W,JGRXW1'EPJIC%9%9DW$W@HLAWWP'.
M+)KN2,'<&9<5<JL!KC1=MUP_((ER?,A$1];P9VR,&F32_;\>7/SB!<GY'I09
MZ7=THM;1[B28DM$]T4]&2>X#L6.HD@>SWW=\!8[8O.3T4+)>&LBOZ:LT39,E
M'XTYX!=B[,^[*7N>J;>CHH^(?6=9Q@ H'=?!P4C*2.X90V<$R=L?-H.AC"(\
MLF7X03.X.:14;S(ZF::.3G>3B YBTX"C.-K?AUP<OZ&X-')(\H%A&DP>A-'O
MI*%^ESJ>FHCR3DQ1[KQPTJO]L"5,$;(>1D:]@MQB$>--HSD)IMLYCIK=P[L5
M?8N;SO>Z&VA\NM3?L8BXDVT+TW49""D-_ _OIU01.;D"\WGX8E@209L<=%/_
M,;4%Z&*(][&B3-WJ<6)V0Q>9.1P..QSQIJ749O*ZRQ**>L+W).V^)(^JO;^S
MN#A^U_"#(:<<73%V2"U:<"[J^H<-ZK^![)<Y<(""O\R @<8GP[G+>'9V.,?Z
M:SE1;SDSHB*%( #_3SCAU3V!9DR +8\RXSR907^Q]M FU)4EG#I]>[F\.AO<
M>^I."%.[>F7[EG1D+BZ0]*X[.*.NCUB^5%ODX7*%[E,'G+^B#L<B+JC?42Y<
M)5-8TJ.V\6"6SW$!FQ?J]-??KY;TY&R4ER&JR04N(SEI=XN%W*LR;D-\;V N
M8:NR0R4$569\75\ CN[<2:@*@J*<D@K5&'S)T[A#P*DF%RBD#SQUYH;CSD U
MOA/R$,B7\1AG,7]VNCI+(DL[)!'QI1M6PRTGSD""%FX7DU+4TEIDXY*51H7W
MZXWNM.U@3[T>;@ODN_28LVC='6MT=.N]B-3C#]\Z9A&[[D+ N(\I5XIRB:8S
M1$/UUJQ<2_?]H<BGL@$RM<3R09/\U' I>7JY_'3&\Z;SBXGZS7#CZ?2C;1!\
MGC^^.!-EDOP#/_,MG?482D/2H'DW;Y).BYQ\9]T":Q'Z=O$@IB+HC5='-<+I
M!AO=Z#K>=.-\+O4#B>&2"*6;<D1!'@PNS'6WB'7)AWKRLQ?),6*OJK^$R;+\
M;'8CF)?00(2E_>RHVF)/9^G^VI8LV><')+O\Q&^F"\C@#9R73BF9YKN*CE1-
M=^#="52E3IH<N5)QK>E.,80!?^C&4[,#M18J=Q(\]:OI*E/78).;$=&L23DB
MEF2<HH>>NT72T$_JHW8;OH<RXC Q1?56W!M6C2S2)2F*<C%'A;+2N3)E<3JD
MTU@=#S9BH3>CON0@M4(T!4>3[N)QUU9-MCR"G<Z%9 US:(6^E"2BTA!(QP"]
M1_4' F++8[@4(8*W35OD;$#<&6M7)?35;[>0!-=U"4EB866 @'SQ3Z_AY.IG
MX 7G=HLG$Y9^M*':](GA 1NZF$_G3Y(6<E/2X3BWFY-LP&;4)WDJ,X/2?1H9
MI2Q(KEY9[-S3^>;.:/=5]BX6R64)H*IOW=7%Q4Q=^B,A@.)4:F%$?2?P'4>7
MO>@ GNEN FVZLY@8\W[5-6/<(C'0NU1%5A_X3G;%3FC(^8.SZ61D&&2&S=&N
MS54'[B22I\6U#[E5NDNBLK9JRWB*)ZU.FIG%QR;GO=/E&I(M6S+O4>Q>9Y^I
M'N02C5HQI"QJ]^:%_%8F7NT4; QR0YM_<<"$^-;,2(1<-3C'M^VX'B)'&%PM
MDCT 4)!2)GS:[_(-?G.1<MQ8]/:1L)>W_39G^Z8$C[RCLRZJWQY$V1?3!2+4
M4MK<N\3?@";Y!&I#BT3NH[Z#.?2QJW-N9RI+][H2E-+/>6)9&NN_=&(;?Q@1
M[YI>+M^H9X_G9,SQRJ5-'?=8",B11@Q)TIXDU!X*G-30W97B6AYV45 U/N)@
MP!/?ZZ>.?$3+H.\&Q<)D%"IA<X:/5FG0,$"F*QD@3[4C(3H?1PTO[ D,$&9,
M@Y6#,FK!2)MB#QTF0^/\"T!U"%B'X*@_G[!T&C@:_36@FH\M/6758^9@SV-T
MB:@X N"\R+^2TGV#3QPJM<X'O_,D-.5?LQ(EF+7\Y+-[VOUB]E)^)]H/EY_;
MOM<$QAXNO\;4^>P9*B4GOV"5+\CA^%>C*QN"K?@CW78QC@;@_=K:D+[0 MWO
MB%__'U!+ P04    " !/BFI3-0%'5KX%  #T#P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6SM5]MRVS80_94=M4GM#&/Q)HER;,_8CM.X4R<:RVD>
M.GV R)6(,0@P &C'?]\%*-%2+&O<Z?2M+R0N>SG8/< "1_=*WYH2T<+W2DAS
MW"NMK0_[?9.76#%SH&J4-#-7NF*6NGK1-[5&5GBE2O3C,!SV*\9E[^3(CTWT
MR9%JK. 2)QI,4U5,/YRA4/?'O:BW&KCFB]*Z@?[)4<T6.$7[I9YHZO4[*P6O
M4!JN)&B<'_=.H\.SS,E[@3\XWINU-KB5S)2Z=9W+XK@7.D H,+?. J/?'9ZC
M$,X0P?BVM-GK7#K%]?;*^@>_=EK+C!D\5^(K+VQYW,MZ4."<-<)>J_N/N%S/
MP-G+E3#^"_=+V; '>6.LJI;*A*#BLOVS[\LXO$0A7BK$'G?KR*-\SRP[.=+J
M'K23)FNNX9?JM0D<ERXI4ZMIEI.>/9FVR0 UARE?2#[G.9,63O-<-=)RN8")
M$CSG:. M[-VPF4"S?]2WY-H9Z.=+-V>MF_@9-V.X4M*6!BYD@<6F?I\@=[CC
M%>ZS>*?!*=8'D(0!Q&$<[;"7='%(O+WD&7O;%OSGZ<Q83;SY:X>#M'.0>@?I
M<X!I.Q6-0!?I<R5SE&3:$Y,&KKFY#6#VX!OP@5PJ#4P6&SF9L ?4VT*_VS&1
M%Y#E)9@U6S5[6'IH.88ZH"UVA[)!8 88U*@=1-J7#I]5EHE' 5)C;;P,#>;(
M[QPOGE?<*JR]PEP).A?,(5POC=^4&G&#+?")5K0YXI+N/N%:ZPH+6AM9C<;P
MBH;HT[8B^G23I\4=:]%%B9-PDX^M,T$(IB5'44 4N]'-SV],&H,2]J:75Y//
MGR[A]4_1*'T'^_"FM?*FE7L#OZ,Q8$LF(0I?':SVDZ%E=A$@"ENL9J@['L-[
MFFU'HJ!=U0:BT0KG%\DMA>$C,F'+=M%#[_9Y@%XO&6P!MX/<@X[<@YT<>\\-
M6RPT+AX9W:9S&UUWF[HI<4D*MQ>MCQ27N6@*=)B1-D]5,_GPBUGQT3@>%8\(
M*#"TDYXR''*:6R@Z[/:X)%.J,31M]@^W<6XS.4\9N"5Y/_!Q&8'#]2QQ:1J-
MVL#/, S&44C_03!*Q_2/PR"),FI$@V!,([^J.]22RI^%.$@2LAQ$64IJHR2A
M;YP,X5QPFMZ+]IU$.H0HB(>AE\@@"<(L@\\4,+T7D\!P #%E/R-T0U)]GB=I
M&)*A)!W1-Z1V$B3C#&XV#@ "&0?Q('*-,!B-!M1(!L'0+R@>!TDX @?K<I6W
M4IF:DP43@'*00+"9HN-/:3IG T";'X"#V2G41"2W="K?\[>42MC%TF''TN&+
MC^!KI*.=YXXLY\R4GBB^<?&MH?TIR+G91MZ='MP-ZM#4+,?C'EV1#.H[[)TX
MLP&1CXSCHW'O43^B\/->2;JN9RCZD]/3W6V&7!'UI*%98XG*E3=#:_&J<W>,
M.A'#C?5'[\9&^I'R+SI\NL@\ >\23T0;#AV#1T&:9NL1]>*1(U(8+D6SE>B
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MPY7>'FN6^GT#81+T><&YVCMFA887,_D/4$L#!!0    ( $^*:E.(7(4FTP,
M )P2   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;+58VV[C-A#]%4)
M@5V@C43*ESBP#<0W;(JZ-6)L^U#T@9;&$AN)=$DZW@#]^%*72$ZJ2^RU7VR1
MXCE#SAS.B!P>A'Q2(8!&W^*(JY$5:KV[LVWEA1!3=2-VP,V;K9 QU:8I UOM
M)% _!<6131RG9\>4<6L\3/M6<CP4>QTQ#BN)U#Z.J7R90"0.(PM;KQV/+ AU
MTF&/ASL:P!KTU]U*FI9=L/@L!JZ8X$C"=F3=X[L%<1- .N)W!@=U](R2I6R$
M>$H:#_[(<I(9002>3BBH^7N&*411PF3F\4].:A4V$^#Q\RO[(EV\6<R&*IB*
MZ _FZW!DW5K(ARW=1_I1'+Y OJ!NPN>)2*6_Z)"/=2SD[946<0XV,X@9S_[I
MM]P11P##4PT@.8"\!W1J &X.<#]JH9,#.A^UT,T!W?> 7@V@EP-ZJ>\S9Z6>
MGE%-QT,I#D@FHPU;\I"&*T4;!S.>*&NMI7G+#$Z/UYFBD-BB-0LXVS*/<HWN
M/4_LN68\0"L1,8^!0C^A1W@&O@>T>4%+^K>0:$5?0"KT:0::LDA]-F.FZ9Q!
MHJG@'G M::J@1Z:>AK8V,T[LVEX^NTDV.U(S.Q<M!=>A0G/N@U^!GS7C!VWX
M13,>DP8"V[BZ\#=Y]?>$-#*N87>#7.='1!R"*R8T_3C<J?+']UF??Y_U13-\
M!IZ!XRKX&U^ZA7;=E*]3P[<$WZA5 OJW4.8$N!<:03\UT'<*^DY*[]9-ERD:
M!!*"3,%FA[Q:^?,7,Q0]:(C57PV&NH6A;N,Z5B"3G9)8T$+3R&3LU$[5?FEF
MPH,;Q_FA2E;-..+4X&9GVINWV,/_Q[UQ7:]P7>]C$KCWGTW>,K7P1#'T"T/]
MZXKAMC!T>S$Q-#-AMTX,+;B*X&1B.-/>_'1[;UPW*%PW:"2:1"8<ZY!!Y)^H
M NR4Y=*YK@[P467&%U-""Q4F=5(X%S@[%S@_ _C6@:1T(#E!#_DGC3(!\X ]
MTTT$35;*(H3=*RNB+$BX<RE%S%JH<+\F/HLV8-MNQ679P\U5X"MG&GST!6BD
MP[R0GQBELD[@WI6C5%8*W+]<E)JI<*_-V659P<U9]F?*E0*./JT?EJO??GWX
M?&J*++,P'ES7U:3,QL2YE*NG+53UU:L-V):P2)GQ27/NJXK1:1N"E,F1D"M'
MJ<R0I/D[_90-T4)5^VVR: &ZW;HHV4>'9W-N#=)K#H52KV=GD:*WN$JY3R\0
MWO5/\-T45_3/\-T\NR@IZ;-[FR65 >,*1; UIIR;OLF7,KL*R1I:[-*C^T9H
M<ZA.'T.@/LAD@'F_%4*_-A(#Q874^#]02P,$%     @ 3XIJ4ZB3>MXB!@
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M*<H2L.09C2F1X!<PIQ(GB2 )-B)KS@O9$[8CX&9.%*:9O-6H;ZLYN/EP"SX
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MB0@-@.]+SM5FHAW4EZ_1'U!+ P04    " !/BFI3FJ#VQ1T#  !D"0  &0
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MH>(U^AIR3#L/_+"&'WZ,*!O5A$9^;[I\!+.FIO(8>@G+"5VD#+"AP+(PA6)
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MO/#\XC)_D6R=W?W-F90LR1Y7E(24ZP[J]P5C<O^B!RBOCT?_ %!+ P04
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MO<LKC*<L'P/E0HO<WJ?G0N/MW'[&^(!BTA#@^4((O5X8!?63;/0_4$L#!!0
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MK$SC-*(G:1I<36QZ8)N]3"Q((Y3H!JB\%@X_R*163@GU]G3A0[2!I74![AF
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MR@;0]Z4D@47'WJOE4W#T$U!+ P04    " !/BFI3_+@?T80#  !-#0  &0
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M'):42S(>R45Y4YHZF*F%-"FYZ$R!NWW)4M*/+TC@Z"8J8REY.'W_<Z',];O
MW4\^G)ST'LZN=^VG#7!&0B_IY0&DY[T>3@P@1AX?1KZ/&Z.^.HAZ#W-#'+:9
M'X]R)3<%B(@SV,BT9,$C%2F94,&GFH-73DLN5LX\ ,-,":4#8RMOI?3!4C\Y
MN.]FT!0M3\FETDUL%\']G;;+=X#U# 1R(3J! ^(,XU%%C6%:WMA)L[@QOH""
M=GR_JJS"0M-5?W!)-@[-S0:9*ITQW87ID[5I/!(L!SF:%W.X&U6% !JC2CO(
M."V4I(V&M4<[L+0S)L0=/#$_\F?<RWRKICVHJ.R&5E [=#1N OS;;(Y[F_9U
MO$'%'Y7YO+#;D<T<>H7=:I;S93-?YIT C+V/L].J$JM/@A>R9&[S!P<<C^C:
M+Y@KS9]L-&B5F34P38)'I@V?;5M^:5K=LZ59M],RQS4/CE#SW\USP2335&R+
MMKW_EK/\:L71U;^2W/Q7V17LU=@>@V]=Y.4QB(R/0>01]&24O$F-87LT;IV_
MST[?SAK 6TY*OL/[E-@$#:8++@R7[6S.LXS)%X>PI3=T:E^&G_';]1G+Z4*8
M^PY,R6;\C65\42;=JEM(1+MJ,_X*V^O'W2N6C<5EQI8LF[1374R;86 '-FI[
M@<,N<M-<?@3S<9@? 0R+@RG ?)P7%N=_VL\0W8_#,&U#+S)$?8:HC_/R(9/F
M@\7Q^R3V\N\T2:(HCK&,3B9>!1,L;W$,7S\;I@T\L#@0Z<]RC5<;[Y#]?8#5
M=%^'8#O%.Q';*9YK0/QY X\D\5<;BP,>6!6PWH'X_CC04WZ?*(*J8MJP)QA'
MD@1#H!?]/1K'2'9B^/CK@STE490D?@0POX(HPA!X&G$$4P :,"2*FG-PYSP*
MU^=4N/F%:/P;4$L#!!0    ( $^*:E.7BKL<P    !,"   +    7W)E;',O
M+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +
M&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P
M6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,
M-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4
M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 3XIJ4ZV#8DG< P  <A\   \
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MMUVIKYI7ZU?&Z]?='W\#4$L#!!0    ( $^*:E.Y(]HWL@$  %0<   :
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $^*:E.%+C,61P4  /(5   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !/BFI3#BO4O6@%  "D%   &               @(&*#0  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 3XIJ4^P-5=RT @  =@D
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M965T-RYX;6Q02P$"% ,4    " !/BFI380W"=[0%  #1#   &
M    @(&W+@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M3XIJ4U=/6TZ+'@  K%T  !@              ("!H30  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( $^*:E.^,03+J00  ),+   9
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M970Q-"YX;6Q02P$"% ,4    " !/BFI3Z(+A@L4'  #M%0  &0
M    @($3=@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M $^*:E,,;B]O_P@  )04   9              " @0]^  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ 3XIJ4TX/Y=OX!   ^@P  !D
M             ("!18<  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " !/BFI397Y9_UT4  !3/   &0              @(%TC   >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( $^*:E,U 4=6O@4
M /0/   9              " @0BA  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ 3XIJ4S][Z>HL!   C H  !D              ("!
M_:8  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !/BFI3
M5<*VK.L"   9!@  &0              @(%@JP  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( $^*:E.BY:]UWP(  'T&   9
M      " @8*N  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ 3XIJ4P(SK%L^ P  : <  !D              ("!F+$  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !/BFI3Y@9- Z$%  "9#P
M&0              @($-M0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( $^*:E,S6*ZH30(  #T%   9              " @>6Z  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 3XIJ4XA<A2;3
M P  G!(  !D              ("!:;T  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " !/BFI3J)-ZWB(&  !^'@  &0
M@(%SP0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $^*
M:E/ZGLY'K ,  ,H.   9              " @<S'  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ 3XIJ4T"!5'.3 @  -P<  !D
M         ("!K\L  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    " !/BFI3PV@8&W\#   ^#@  &0              @(%YS@  >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( $^*:E.4DYB?J (  %$'
M   9              " @2_2  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ 3XIJ4ZZN43N& P  5@T  !D              ("!#M4
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !/BFI3+AYQ
MG?4"  "("0  &0              @('+V   >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( $^*:E.:H/;%'0,  &0)   9
M  " @??;  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M3XIJ4_OP%CP2!   ,Q   !D              ("!2]\  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " !/BFI3<&O\N*L"   U!P  &0
M            @(&4XP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( $^*:E,\=,EW, 4  'X8   9              " @7;F  !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 3XIJ4[X.^5V7 @
MWP@  !D              ("!W>L  'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " !/BFI31.TRGP@$  !E#@  &0              @(&K
M[@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( $^*:E,M
M+N+2Y ,  .@2   9              " @>KR  !X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ 3XIJ4V>10Q?1 P  5 X  !D
M     ("!!?<  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $^*:E-<Q)CZ!0,  !8*   9              "
M@98, 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 3XIJ
M4_RX']&$ P  30T  !D              ("!T@\! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " !/BFI3A].KD1L#   N$@  #0
M        @ &-$P$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( $^*:E.7BKL<
MP    !,"   +              "  =,6 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( $^*:E.M@V))W ,  '(?   /              "  ;P7 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " !/BFI3N2/:-[(!  !4'   &@
M    @ '%&P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" !/BFI39>&9M;<!  !E'   $P              @ &O'0$ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     -P W /@.  "7'P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>236</ContextCount>
  <ElementCount>339</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Unaudited Condensed Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedStatementsofOperations</Role>
      <ShortName>Unaudited Condensed Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Unaudited Condensed Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity</Role>
      <ShortName>Unaudited Condensed Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Unaudited Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedStatementsofCashFlows</Role>
      <ShortName>Unaudited Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2117104 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Stock Option Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlan</Role>
      <ShortName>Stock Option Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137109 - Disclosure - Covid-19</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Covid19</Role>
      <ShortName>Covid-19</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies - (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies - (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Other Financial Information - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/OtherFinancialInformation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - Borrowings - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Borrowings</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2324304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockholdersEquity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Stock Option Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanTables</Role>
      <ShortName>Stock Option Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockOptionPlan</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OrganizationDetails</Role>
      <ShortName>Organization - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Organization</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Other Financial Information - Prepaid expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails</Role>
      <ShortName>Other Financial Information - Prepaid expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Other Financial Information - Property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails</Role>
      <ShortName>Other Financial Information - Property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Other Financial Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails</Role>
      <ShortName>Other Financial Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Other Financial Information - Accrued and other current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails</Role>
      <ShortName>Other Financial Information - Accrued and other current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Borrowings - Future minimum payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails</Role>
      <ShortName>Borrowings - Future minimum payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - Commitment and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockholdersEquityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Stock Option Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanNarrativeDetails</Role>
      <ShortName>Stock Option Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails</Role>
      <ShortName>Stock Option Plan - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails</Role>
      <ShortName>Stock Option Plan - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails</Role>
      <ShortName>Stock Option Plan - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Option Plan - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Covid-19 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Covid19Details</Role>
      <ShortName>Covid-19 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Covid19</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="exdx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Subsequent Events - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SubsequentEventsNarrativeDetails</Role>
      <ShortName>Subsequent Events - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="exdx-20210930.htm">exdx-20210930.htm</File>
    <File>ex101-subleaseagreement819.htm</File>
    <File>ex102-amend2to1221libertyw.htm</File>
    <File>ex103-fifthaddendumtolease.htm</File>
    <File>ex104-firstaddendumtolease.htm</File>
    <File>ex105-secondamendmentloana.htm</File>
    <File>ex106-letteragreementippur.htm</File>
    <File>exdx-20210930.xsd</File>
    <File>exdx-20210930_cal.xml</File>
    <File>exdx-20210930_def.xml</File>
    <File>exdx-20210930_lab.xml</File>
    <File>exdx-20210930_pre.xml</File>
    <File>xgn311-93021.htm</File>
    <File>xgn312-93021.htm</File>
    <File>xgn321-93021.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exdx-20210930.htm": {
   "axisCustom": 1,
   "axisStandard": 25,
   "contextCount": 236,
   "dts": {
    "calculationLink": {
     "local": [
      "exdx-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exdx-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "exdx-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exdx-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exdx-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "exdx-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 452,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 6
   },
   "keyCustom": 40,
   "keyStandard": 299,
   "memberCustom": 34,
   "memberStandard": 33,
   "nsprefix": "exdx",
   "nsuri": "http://www.exagen.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.exagen.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Other Financial Information",
     "role": "http://www.exagen.com/role/OtherFinancialInformation",
     "shortName": "Other Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117104 - Disclosure - Borrowings",
     "role": "http://www.exagen.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - Commitment and Contingencies",
     "role": "http://www.exagen.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123106 - Disclosure - Fair Value Measurements",
     "role": "http://www.exagen.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Stockholders' Equity",
     "role": "http://www.exagen.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Stock Option Plan",
     "role": "http://www.exagen.com/role/StockOptionPlan",
     "shortName": "Stock Option Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137109 - Disclosure - Covid-19",
     "role": "http://www.exagen.com/role/Covid19",
     "shortName": "Covid-19",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Subsequent Events",
     "role": "http://www.exagen.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies - (Policies)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies - (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies - (Tables)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Balance Sheets",
     "role": "http://www.exagen.com/role/CondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Other Financial Information - (Tables)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationTables",
     "shortName": "Other Financial Information - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - Borrowings - (Tables)",
     "role": "http://www.exagen.com/role/BorrowingsTables",
     "shortName": "Borrowings - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exagen.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.exagen.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Stock Option Plan (Tables)",
     "role": "http://www.exagen.com/role/StockOptionPlanTables",
     "shortName": "Stock Option Plan (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization - (Details)",
     "role": "http://www.exagen.com/role/OrganizationDetails",
     "shortName": "Organization - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i3af039dd0a6148ce8a2372743552eacf_D20210701-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue by Major Payers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i3af039dd0a6148ce8a2372743552eacf_D20210701-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "idf76918b1cb142d5a91a6c2666125f62_I20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "ic947e90b872445479ee484e60712b752_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
     "shortName": "Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i3ba9e492d61a4b95bb9150e34f4662f5_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails",
     "shortName": "Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "role": "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "ic947e90b872445479ee484e60712b752_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "ic947e90b872445479ee484e60712b752_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Other Financial Information - Prepaid expenses (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails",
     "shortName": "Other Financial Information - Prepaid expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Other Financial Information - Property and equipment (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails",
     "shortName": "Other Financial Information - Property and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "ic947e90b872445479ee484e60712b752_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Other Financial Information - Narrative (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
     "shortName": "Other Financial Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "ic947e90b872445479ee484e60712b752_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Other Financial Information - Accrued and other current liabilities (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails",
     "shortName": "Other Financial Information - Accrued and other current liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "ie56e06d7b68849928e2fe39a26f73f85_D20170901-20170930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Borrowings - Narrative (Details)",
     "role": "http://www.exagen.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "ie56e06d7b68849928e2fe39a26f73f85_D20170901-20170930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Borrowings - Future minimum payments (Details)",
     "role": "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails",
     "shortName": "Borrowings - Future minimum payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "ic947e90b872445479ee484e60712b752_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - Commitment and Contingencies - Narrative (Details)",
     "role": "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
     "shortName": "Commitment and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "ic947e90b872445479ee484e60712b752_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i9675b9781d014000845af2a6c5ce6ab4_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exagen.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i9675b9781d014000845af2a6c5ce6ab4_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i756e9691fbec4232a2a72550fe8827ce_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "exdx:StockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "exdx:ClassOfWarrantOrRightNumberOfWarrantsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "ic947e90b872445479ee484e60712b752_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Unaudited Condensed Statements of Operations",
     "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations",
     "shortName": "Unaudited Condensed Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "ic947e90b872445479ee484e60712b752_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.exagen.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i59ce805f96954e73a2aeb07fd95e73f9_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i48504c2aaa3340f78e4733690a2c664b_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Stock Option Plan - Narrative (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
     "shortName": "Stock Option Plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i48504c2aaa3340f78e4733690a2c664b_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "iff8e60ce9c594c9aa9741f476323c52a_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Stock Option Plan - Stock Option Activity (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
     "shortName": "Stock Option Plan - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i81f9417379b2400e818961f451bb1226_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "idd19ac6d04c2437dabe28931d0bda370_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
     "shortName": "Stock Option Plan - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "idd19ac6d04c2437dabe28931d0bda370_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
     "shortName": "Stock Option Plan - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "ic947e90b872445479ee484e60712b752_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
     "shortName": "Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "ic947e90b872445479ee484e60712b752_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "ibcbd85df5b8d470087005bf4782dd47b_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Covid-19 (Details)",
     "role": "http://www.exagen.com/role/Covid19Details",
     "shortName": "Covid-19 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "ibcbd85df5b8d470087005bf4782dd47b_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i9b8a1702a09245e28f4b13ccccf0e5b2_I20191130",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Subsequent Events - Narrative (Details)",
     "role": "http://www.exagen.com/role/SubsequentEventsNarrativeDetails",
     "shortName": "Subsequent Events - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "ie47ef4f6de5046f08313d4c7118cd8d2_I20211031",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i5e627efdf666421e923aa8ef9d7b1607_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Unaudited Condensed Statements of Stockholders' Equity",
     "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity",
     "shortName": "Unaudited Condensed Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i7e5abb84f7e7474bb50314ab8d17a743_D20200101-20200331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i756e9691fbec4232a2a72550fe8827ce_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "exdx:StockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical",
     "shortName": "Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Unaudited Statements of Cash Flows",
     "role": "http://www.exagen.com/role/UnauditedStatementsofCashFlows",
     "shortName": "Unaudited Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://www.exagen.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210930.htm",
      "contextRef": "i2bf90ec6640b4f868fd90d3589671e15_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 70,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exdx_AHNCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AHN Collaboration",
        "label": "AHN Collaboration [Member]",
        "terseLabel": "AHN Collaboration"
       }
      }
     },
     "localname": "AHNCollaborationMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_AVISECTDTestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVISE CTD Test",
        "label": "AVISE CTD Test [Member]",
        "terseLabel": "AVISE CTD Test"
       }
      }
     },
     "localname": "AVISECTDTestMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_AccruedLiabilitiesClinicalStudyCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities, Clinical Study, Current",
        "label": "Accrued Liabilities, Clinical Study, Current",
        "terseLabel": "Accrued clinical study activity"
       }
      }
     },
     "localname": "AccruedLiabilitiesClinicalStudyCurrent",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AccruedPurchaseGoodsAndServicesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Purchase, Goods and Services, Current",
        "label": "Accrued Purchase, Goods and Services, Current",
        "terseLabel": "Accrued purchases of goods and services"
       }
      }
     },
     "localname": "AccruedPurchaseGoodsAndServicesCurrent",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdvancePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance Payment",
        "label": "Advance Payment",
        "terseLabel": "Advance royalties payment"
       }
      }
     },
     "localname": "AdvancePayment",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AlleghenyHealthNetworkResearchInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allegheny Health Network Research Institute",
        "label": "Allegheny Health Network Research Institute [Member]",
        "terseLabel": "Allegheny Health Network Research Institute"
       }
      }
     },
     "localname": "AlleghenyHealthNetworkResearchInstituteMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_AssetsUnderCapitalLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets Under Capital Lease",
        "label": "Assets Under Capital Lease [Member]",
        "terseLabel": "Assets under capital lease"
       }
      }
     },
     "localname": "AssetsUnderCapitalLeaseMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_BlueShieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Blue Shield",
        "label": "Blue Shield [Member]",
        "verboseLabel": "Blue Shield"
       }
      }
     },
     "localname": "BlueShieldMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_CapitalRoyaltyPartnersIILPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Royalty Partners II LP",
        "label": "Capital Royalty Partners II LP [Member]",
        "terseLabel": "Capital Royalty Partners II LP"
       }
      }
     },
     "localname": "CapitalRoyaltyPartnersIILPMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number Of Warrants Exercised",
        "label": "Class of Warrant or Right, Number Of Warrants Exercised",
        "terseLabel": "Number of warrants exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_ClientMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Client",
        "label": "Client [Member]",
        "terseLabel": "Client"
       }
      }
     },
     "localname": "ClientMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_CollaborationAgreementAnnualCollaborationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Annual Collaboration Fee",
        "label": "Collaboration Agreement, Annual Collaboration Fee",
        "terseLabel": "Collaboration fee"
       }
      }
     },
     "localname": "CollaborationAgreementAnnualCollaborationFee",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_CollaborationAgreementCollaborationExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Collaboration Expenses",
        "label": "Collaboration Agreement, Collaboration Expenses",
        "terseLabel": "Collaboration agreement, collaboration expenses"
       }
      }
     },
     "localname": "CollaborationAgreementCollaborationExpenses",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment and Software",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit",
        "label": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit",
        "terseLabel": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, income tax benefit"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance",
        "label": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, valuation allowance"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure",
        "label": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure [Text Block]",
        "terseLabel": "Covid-19"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/Covid19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance",
        "label": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance",
        "terseLabel": "Term loan covenant, minimum unrestricted cash balance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)",
        "label": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)",
        "terseLabel": "Term loan covenant, increase to interest rate"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentPaidInKindLoansIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Paid In Kind Loans Issued",
        "label": "Debt Instrument, Paid In Kind Loans Issued",
        "terseLabel": "Term loan, paid in-kind loans issued"
       }
      }
     },
     "localname": "DebtInstrumentPaidInKindLoansIssued",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentPrepaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Premium Percentage",
        "label": "Debt Instrument, Prepayment Premium Percentage",
        "terseLabel": "Term loan, prepayment premium percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentage",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Premium Percentage, Annual Reduction",
        "label": "Debt Instrument, Prepayment Premium Percentage, Annual Reduction",
        "terseLabel": "Term loan, annual reduction in prepayment penalty percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentageAnnualReduction",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentStatedInterestRatePaidInKind": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Stated Interest Rate, Paid In-Kind",
        "label": "Debt Instrument, Stated Interest Rate, Paid In-Kind",
        "terseLabel": "Term loan, paid in-kind, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentStatedInterestRatePaidInKind",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DeferredOfferingCostsReclassifiedToEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs Reclassified to Equity",
        "label": "Deferred Offering Costs Reclassified to Equity",
        "terseLabel": "Deferred offering costs reclassified to equity"
       }
      }
     },
     "localname": "DeferredOfferingCostsReclassifiedToEquity",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_EquipmentPurchasedUnderCapitalLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment Purchased Under Capital Lease",
        "label": "Equipment Purchased Under Capital Lease",
        "terseLabel": "Equipment purchased under capital lease obligations"
       }
      }
     },
     "localname": "EquipmentPurchasedUnderCapitalLease",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Agreement, Number Of Shares Exchanged For Warrants",
        "label": "Exchange Agreement, Number Of Shares Exchanged For Warrants",
        "terseLabel": "Number of shares exchanged for warrants (in shares)"
       }
      }
     },
     "localname": "ExchangeAgreementNumberOfSharesExchangedForWarrants",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_ExchangingStockholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchanging Stockholders",
        "label": "Exchanging Stockholders [Member]",
        "terseLabel": "Exchanging Stockholders"
       }
      }
     },
     "localname": "ExchangingStockholdersMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationApr12026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Apr 1, 2026",
        "label": "Expiration Apr 1, 2026 [Member]",
        "terseLabel": "Warrant expiration April 1, 2026"
       }
      }
     },
     "localname": "ExpirationApr12026Member",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationDec72025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Dec 7, 2025",
        "label": "Expiration Dec 7, 2025 [Member]",
        "terseLabel": "Warrant expiration December 7, 2025"
       }
      }
     },
     "localname": "ExpirationDec72025Member",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationJan192026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Jan 19, 2026",
        "label": "Expiration Jan 19, 2026 [Member]",
        "terseLabel": "Warrant expiration January 19, 2026"
       }
      }
     },
     "localname": "ExpirationJan192026Member",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationMar312026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Mar 31, 2026",
        "label": "Expiration Mar 31, 2026 [Member]",
        "terseLabel": "Warrant expiration March 31, 2026"
       }
      }
     },
     "localname": "ExpirationMar312026Member",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationSep72024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Sep 7, 2024",
        "label": "Expiration Sep 7, 2024 [Member]",
        "terseLabel": "Warrant expiration September 7, 2024"
       }
      }
     },
     "localname": "ExpirationSep72024Member",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_Government1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government1",
        "label": "Government1 [Member]",
        "terseLabel": "Government"
       }
      }
     },
     "localname": "Government1Member",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_HeadquartersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Headquarters",
        "label": "Headquarters [Member]",
        "terseLabel": "Headquarters"
       }
      }
     },
     "localname": "HeadquartersMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_HealthcareInsurersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthcare Insurers",
        "label": "Healthcare Insurers [Member]",
        "terseLabel": "Healthcare insurers"
       }
      }
     },
     "localname": "HealthcareInsurersMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_IncentiveAwardPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Award Plan, 2019",
        "label": "Incentive Award Plan, 2019 [Member]",
        "terseLabel": "2019 Incentive Award Plan"
       }
      }
     },
     "localname": "IncentiveAwardPlan2019Member",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Prepaid Expense and Current Other Assets",
        "label": "Increase (Decrease) in Prepaid Expense and Current Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_InnovatusLifeSciencesLendingFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovatus Life Sciences Lending Fund",
        "label": "Innovatus Life Sciences Lending Fund [Member]",
        "terseLabel": "Innovatus Life Sciences Lending Fund"
       }
      }
     },
     "localname": "InnovatusLifeSciencesLendingFundMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_JanssenPromotionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Promotion Agreement",
        "label": "Janssen Promotion Agreement [Member]",
        "terseLabel": "Janssen Promotion Agreement"
       }
      }
     },
     "localname": "JanssenPromotionAgreementMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_JanssenSIMPONIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen (SIMPONI)",
        "label": "Janssen (SIMPONI) [Member]",
        "terseLabel": "Janssen (SIMPONI)"
       }
      }
     },
     "localname": "JanssenSIMPONIMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_JointVentureQuarterlyPromotionFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture, Quarterly Promotion Fee",
        "label": "Joint Venture, Quarterly Promotion Fee",
        "terseLabel": "Joint venture, quarterly promotion fee"
       }
      }
     },
     "localname": "JointVentureQuarterlyPromotionFee",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline",
        "label": "Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline",
        "terseLabel": "Joint venture quarterly promotion fee cap"
       }
      }
     },
     "localname": "JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_JointVentureQuarterlyPromotionFeePerPrescription": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture, Quarterly Promotion Fee Per Prescription",
        "label": "Joint Venture, Quarterly Promotion Fee Per Prescription",
        "terseLabel": "Joint venture, quarterly promotion fee per prescription"
       }
      }
     },
     "localname": "JointVentureQuarterlyPromotionFeePerPrescription",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_JointVentureTerminationConsiderationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture, Termination, Consideration Receivable",
        "label": "Joint Venture, Termination, Consideration Receivable",
        "terseLabel": "Termination of agreement"
       }
      }
     },
     "localname": "JointVentureTerminationConsiderationReceivable",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_LicenseAgreementInitialLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Initial License Fee",
        "label": "License Agreement, Initial License Fee",
        "terseLabel": "Initial license fee"
       }
      }
     },
     "localname": "LicenseAgreementInitialLicenseFee",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LongTermDebtIncludingUndiscountedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Including Undiscounted Interest",
        "label": "Long-term Debt, Including Undiscounted Interest",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtIncludingUndiscountedInterest",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LongTermDebtUndiscountedInterestAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Undiscounted Interest Amount",
        "label": "Long-term Debt, Undiscounted Interest Amount",
        "negatedLabel": "Interest"
       }
      }
     },
     "localname": "LongTermDebtUndiscountedInterestAmount",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_MedicareAdvantageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Advantage",
        "label": "Medicare Advantage [Member]",
        "verboseLabel": "Medicare Advantage"
       }
      }
     },
     "localname": "MedicareAdvantageMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_NoExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No expiration",
        "label": "No expiration [Member]",
        "terseLabel": "No expiration"
       }
      }
     },
     "localname": "NoExpirationMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_OfficeAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Laboratory",
        "label": "Office and Laboratory [Member]",
        "terseLabel": "Office and Laboratory"
       }
      }
     },
     "localname": "OfficeAndLaboratoryMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_OfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office",
        "label": "Office [Member]",
        "terseLabel": "Office"
       }
      }
     },
     "localname": "OfficeMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_OfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Space",
        "label": "Office Space [Member]",
        "terseLabel": "Office Space"
       }
      }
     },
     "localname": "OfficeSpaceMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Annual Increase In Base Rent Payment, Percent",
        "label": "Operating Lease, Annual Increase In Base Rent Payment, Percent",
        "terseLabel": "Operating lease annual increase in base rent payment percent"
       }
      }
     },
     "localname": "OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_OperatingLeaseMonthlyBaseRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Monthly Base Rent",
        "label": "Operating Lease, Monthly Base Rent",
        "terseLabel": "Operating lease monthly base rent"
       }
      }
     },
     "localname": "OperatingLeaseMonthlyBaseRent",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_OperatingLeaseMonthlyBaseRentFirstIncrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Monthly Base Rent, First Increase",
        "label": "Operating Lease, Monthly Base Rent, First Increase",
        "terseLabel": "Operating lease, monthly base rent after first increase"
       }
      }
     },
     "localname": "OperatingLeaseMonthlyBaseRentFirstIncrease",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_OperatingLeaseTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Term of Contract",
        "label": "Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "OperatingLeaseTermOfContract",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exdx_OperatingLeasesRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Renewal Term",
        "label": "Operating Leases, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "OperatingLeasesRenewalTerm",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exdx_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.exagen.com/20210930",
     "xbrltype": "stringItemType"
    },
    "exdx_PaycheckProtectionProgramCARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program, CARES Act",
        "label": "Paycheck Protection Program, CARES Act [Member]",
        "terseLabel": "Paycheck Protection Program, CARES Act"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCARESActMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities",
        "label": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]",
        "terseLabel": "Other Financial Information"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exdx_PrepaidMaintenanceAndInsuranceContracts": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Maintenance and Insurance Contracts",
        "label": "Prepaid Maintenance and Insurance Contracts",
        "terseLabel": "Prepaid maintenance and insurance contracts"
       }
      }
     },
     "localname": "PrepaidMaintenanceAndInsuranceContracts",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_ProceedsFromGovernmentAssistance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Government Assistance",
        "label": "Proceeds from Government Assistance",
        "terseLabel": "Proceeds from government assistance"
       }
      }
     },
     "localname": "ProceedsFromGovernmentAssistance",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_PrometheusLaboratoriesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prometheus Laboratories, Inc.",
        "label": "Prometheus Laboratories, Inc. [Member]",
        "terseLabel": "Prometheus Laboratories"
       }
      }
     },
     "localname": "PrometheusLaboratoriesIncMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Obligation, Annual Increase In Commitment, Percentage",
        "label": "Purchase Obligation, Annual Increase In Commitment, Percentage",
        "terseLabel": "Annual increase in purchase commitments"
       }
      }
     },
     "localname": "PurchaseObligationAnnualIncreaseInCommitmentPercentage",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_ReceivableBenchmarkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable Benchmark",
        "label": "Receivable Benchmark [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivableBenchmarkMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_RentalPropertyByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental Property, by Type",
        "label": "Rental Property, by Type [Axis]",
        "terseLabel": "Rental Property, by Type [Axis]"
       }
      }
     },
     "localname": "RentalPropertyByTypeAxis",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exdx_RentalPropertyByTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental Property, by Type",
        "label": "Rental Property, by Type [Domain]",
        "terseLabel": "Rental Property, by Type [Domain]"
       }
      }
     },
     "localname": "RentalPropertyByTypeDomain",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_RoyaltyObligationPercentageOfSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Obligation, Percentage of Sales",
        "label": "Royalty Obligation, Percentage of Sales",
        "terseLabel": "Royalty obligation, percent of net sales"
       }
      }
     },
     "localname": "RoyaltyObligationPercentageOfSales",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Period, Number Of Annual Installments",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Period, Number Of Annual Installments",
        "terseLabel": "Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Period, Number Of Annual Installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodNumberOfAnnualInstallments",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exdx_StockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs",
        "label": "Stock Issuance Costs",
        "terseLabel": "Estimated offering expenses for aggregate expenses",
        "verboseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "StockIssuanceCosts",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised, Net",
        "label": "Stock Issued During Period, Shares, Warrants Exercised, Net",
        "terseLabel": "Net exercise of common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercisedNet",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrants Exercised, Net",
        "label": "Stock Issued During Period, Value, Warrants Exercised, Net",
        "terseLabel": "Net exercise of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercisedNet",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_Term2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term 2017",
        "label": "Term 2017 [Member]",
        "terseLabel": "2017 Term loan"
       }
      }
     },
     "localname": "Term2017Member",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_TwoMajorSuppliersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Major Suppliers",
        "label": "Two Major Suppliers [Member]",
        "terseLabel": "Two Major Suppliers"
       }
      }
     },
     "localname": "TwoMajorSuppliersMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_UnitedHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United Healthcare",
        "label": "United Healthcare [Member]",
        "terseLabel": "United Healthcare"
       }
      }
     },
     "localname": "UnitedHealthcareMember",
     "nsuri": "http://www.exagen.com/20210930",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r50",
      "r52",
      "r97",
      "r98",
      "r241",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r167",
      "r303",
      "r306",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r240",
      "r278",
      "r321",
      "r322",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r483",
      "r517",
      "r522",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r240",
      "r278",
      "r321",
      "r322",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r483",
      "r517",
      "r522",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r167",
      "r303",
      "r306",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r165",
      "r303",
      "r304",
      "r485",
      "r515",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r165",
      "r303",
      "r304",
      "r485",
      "r515",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r240",
      "r278",
      "r312",
      "r321",
      "r322",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r483",
      "r517",
      "r522",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r240",
      "r278",
      "r312",
      "r321",
      "r322",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r483",
      "r517",
      "r522",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r51",
      "r52",
      "r97",
      "r98",
      "r241",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r449"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r7",
      "r24",
      "r168",
      "r169"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r39"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r39"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued\u00a0payroll\u00a0and\u00a0related\u00a0expenses"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r199"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r25",
      "r362",
      "r449"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r359",
      "r360",
      "r361",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r323",
      "r325",
      "r365",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r236",
      "r292",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of common stock warrant in exchange for retirement of common stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising and Marketing Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r325",
      "r351",
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r78",
      "r260",
      "r270",
      "r271",
      "r441"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r94",
      "r148",
      "r157",
      "r163",
      "r178",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r391",
      "r393",
      "r421",
      "r447",
      "r449",
      "r492",
      "r504"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r12",
      "r49",
      "r94",
      "r178",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r391",
      "r393",
      "r421",
      "r447",
      "r449"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r326",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Costs incurred, but not paid, in connection with capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r19",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer.",
        "label": "Capital Lease Obligations, Current",
        "terseLabel": "Capital lease obligations, current portion"
       }
      }
     },
     "localname": "CapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r32",
      "r80"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds, included in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r74",
      "r80",
      "r86"
     ],
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r430"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r300",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Class of warrant or right, exercise price of warrants or rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of common shares to be called upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants issued to purchase redeemable convertible preferred stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r45",
      "r212",
      "r496",
      "r510"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r219",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23",
      "r449"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized at September\u00a030, 2021 and December 31, 2020; 16,164,232 and 12,652,308 shares issued and outstanding at September\u00a030, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r138",
      "r139",
      "r167",
      "r418",
      "r419",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r138",
      "r139",
      "r167",
      "r418",
      "r419",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r138",
      "r139",
      "r167",
      "r418",
      "r419",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r134",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risk and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r138",
      "r139",
      "r167",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenue"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r138",
      "r139",
      "r167",
      "r418",
      "r419",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r63",
      "r485"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Costs of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r64",
      "r94",
      "r178",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r421"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Shipping and Handling Costs"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r136",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r254",
      "r261",
      "r262",
      "r264",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r93",
      "r99",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r268",
      "r269",
      "r270",
      "r271",
      "r442",
      "r493",
      "r494",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/Covid19Details",
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Term loan, fee incurred upon payment of final installment"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r41",
      "r267",
      "r440",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Term loan, effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Term loan, interest rate",
        "verboseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43",
      "r93",
      "r99",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r268",
      "r269",
      "r270",
      "r271",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/Covid19Details",
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r93",
      "r99",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r263",
      "r268",
      "r269",
      "r270",
      "r271",
      "r293",
      "r296",
      "r297",
      "r298",
      "r439",
      "r440",
      "r442",
      "r443",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r250",
      "r265",
      "r268",
      "r269",
      "r441"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid expenses table"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r78",
      "r95",
      "r377",
      "r383",
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r78",
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Option Plan"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r60",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r120",
      "r122",
      "r124",
      "r125",
      "r126",
      "r129",
      "r130",
      "r409",
      "r410",
      "r498",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r60",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r122",
      "r124",
      "r125",
      "r126",
      "r129",
      "r130",
      "r409",
      "r410",
      "r498",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock options, unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Stock options, cost not yet recognized, remaining weighted average vesting period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPolicy": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares.",
        "label": "Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r55",
      "r56",
      "r57",
      "r101",
      "r102",
      "r103",
      "r106",
      "r115",
      "r117",
      "r131",
      "r182",
      "r292",
      "r299",
      "r359",
      "r360",
      "r361",
      "r380",
      "r381",
      "r408",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r526",
      "r527",
      "r528",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r412",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r411",
      "r412",
      "r414",
      "r415",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r252",
      "r313",
      "r314",
      "r319",
      "r320",
      "r412",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r313",
      "r314",
      "r319",
      "r320",
      "r412",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r412",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r263",
      "r290",
      "r399",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture\u00a0and\u00a0fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r196",
      "r197",
      "r449",
      "r491"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r57",
      "r65"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r201",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r116",
      "r117",
      "r147",
      "r376",
      "r382",
      "r386",
      "r513"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r58",
      "r145",
      "r438",
      "r441",
      "r499"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r73",
      "r75",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest expense"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r39"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Operating lease, rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r94",
      "r158",
      "r178",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r392",
      "r393",
      "r394",
      "r421",
      "r447",
      "r448"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r94",
      "r178",
      "r421",
      "r449",
      "r495",
      "r508"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r94",
      "r178",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r392",
      "r393",
      "r394",
      "r421",
      "r447",
      "r448",
      "r449"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r37",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r37",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loan payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r21",
      "r251",
      "r266",
      "r268",
      "r269",
      "r494",
      "r505"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total borrowings, net of discounts and debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r99",
      "r222",
      "r256"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 4.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r99",
      "r222",
      "r256"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 3.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r99",
      "r222",
      "r256"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 2.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 1.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2021 (remaining)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Borrowings-non-current portion, net of discounts and debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r43",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds, included in cash and cash equivalents"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r76",
      "r79"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r53",
      "r54",
      "r57",
      "r59",
      "r79",
      "r94",
      "r105",
      "r110",
      "r111",
      "r112",
      "r113",
      "r116",
      "r117",
      "r123",
      "r148",
      "r156",
      "r159",
      "r162",
      "r164",
      "r178",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r410",
      "r421",
      "r497",
      "r511"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncement, Early Adoption [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r112",
      "r118",
      "r129",
      "r171",
      "r172",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r224",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r378",
      "r379",
      "r380",
      "r381",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r446",
      "r486",
      "r487",
      "r488",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncement, Early Adoption [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted, Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r148",
      "r156",
      "r159",
      "r162",
      "r164"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r100",
      "r119",
      "r141",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r39"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r48",
      "r449"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Diagnostic\u00a0testing\u00a0supplies"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r396",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCustomerMember": {
     "auth_ref": [
      "r514",
      "r516",
      "r518",
      "r519",
      "r523",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer classified as other.",
        "label": "Other Customer [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r8",
      "r11",
      "r195"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid and other current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentInKindPIKNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured.",
        "label": "Payment in Kind (PIK) Note [Member]",
        "terseLabel": "Paid in-kind note"
       }
      }
     },
     "localname": "PaymentInKindPIKNoteMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payment of issuance costs related to public offering"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedLabel": "Purchase of other assets"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r68",
      "r387",
      "r388",
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Payments to acquire intellectual property"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r326",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r22",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r22",
      "r449"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at September\u00a030, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r10",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRoyalties": {
     "auth_ref": [
      "r9",
      "r11",
      "r194",
      "r195"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Royalties",
        "terseLabel": "Prepaid product royalties"
       }
      }
     },
     "localname": "PrepaidRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromBankDebt": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from bank borrowing during the year.",
        "label": "Proceeds from Bank Debt",
        "terseLabel": "Proceeds from Paycheck Protection Program loan"
       }
      }
     },
     "localname": "ProceedsFromBankDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock in public offering, gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Term loan borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r69",
      "r354"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from common stock issued under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r34",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r198"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment",
        "verboseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r200",
      "r449",
      "r500",
      "r509"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year One",
        "terseLabel": "Purchase obligation, due in year one"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment.",
        "label": "Purchase Obligation, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Purchase obligation, to be paid remainder of fiscal year"
       }
      }
     },
     "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReorganizationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reorganizations [Abstract]"
       }
      }
     },
     "localname": "ReorganizationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfBankDebt": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to settle a bank borrowing during the year.",
        "label": "Repayments of Bank Debt",
        "negatedLabel": "Repayment of Paycheck Protection Program loan"
       }
      }
     },
     "localname": "RepaymentsOfBankDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).",
        "label": "Repayments of Long-term Capital Lease Obligations",
        "negatedLabel": "Principal payment on capital lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "terseLabel": "Loan repayment"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r371",
      "r484",
      "r542"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r86",
      "r490",
      "r506"
     ],
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r26",
      "r299",
      "r362",
      "r449",
      "r507",
      "r530",
      "r535"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r101",
      "r102",
      "r103",
      "r106",
      "r115",
      "r117",
      "r182",
      "r359",
      "r360",
      "r361",
      "r380",
      "r381",
      "r408",
      "r526",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r143",
      "r144",
      "r155",
      "r160",
      "r161",
      "r165",
      "r166",
      "r167",
      "r302",
      "r303",
      "r485"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the entity has committed to make for future royalty guarantees.",
        "label": "Royalty Guarantees, Commitments, Amount",
        "terseLabel": "Future minimum royalty commitment"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "verboseLabel": "Proceeds from public offering, net"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "terseLabel": "Sale of stock, percentage of ownership after transaction"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Shares issued in public offering, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r138",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r325",
      "r350",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Non-cash Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r34",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r16",
      "r86",
      "r490",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r326",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r330",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions, Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions, Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r46",
      "r91",
      "r132",
      "r133",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r285",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r300",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r135",
      "r138",
      "r139",
      "r140",
      "r418",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration of Risk, by Risk Factor and Significant Payer"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options, vesting period",
        "verboseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Awards canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awards canceled, Weighted-Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awards granted, Weighted-Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, September \u00a030, 2021 (in shares)",
        "periodStartLabel": "Outstanding, December 31, 2020 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, September 30, 2021 (in dollars per share)",
        "periodStartLabel": "Outstanding, December\u00a031, 2020 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Awards released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awards released, Weighted-Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee payroll deduction percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares that remain available for future awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r332",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, June 30, 2021 (in shares)",
        "periodStartLabel": "Outstanding, December 31, 2020 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, June 30, 2021, Weighted Average Exercise Price (in dollars per share)",
        "periodStartLabel": "Outstanding, December 31, 2020, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options exercisable, June 30, 2021 (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercised, June 30, 2021, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest, June 30, 2021 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, June 30, 2021, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r324",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by supplier.",
        "label": "Supplier [Axis]",
        "terseLabel": "Supplier [Axis]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.",
        "label": "Supplier [Domain]",
        "terseLabel": "Supplier [Domain]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock options, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r345",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShippingAndHandlingMember": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Packing and transport of product.",
        "label": "Shipping and Handling [Member]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r87",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r47",
      "r55",
      "r56",
      "r57",
      "r101",
      "r102",
      "r103",
      "r106",
      "r115",
      "r117",
      "r131",
      "r182",
      "r292",
      "r299",
      "r359",
      "r360",
      "r361",
      "r380",
      "r381",
      "r408",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r526",
      "r527",
      "r528",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r131",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r22",
      "r23",
      "r292",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "verboseLabel": "Issuance of stock under Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r292",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of stock in public offering, net of issuance costs of $4,435 (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r23",
      "r292",
      "r299",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r22",
      "r23",
      "r292",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r292",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of stock in public offering, net of issuance costs of $4,435"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r47",
      "r292",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r22",
      "r23",
      "r292",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Retirement of common stock in exchange for common stock warrant (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r22",
      "r23",
      "r292",
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Retirement of common stock in exchange for common stock warrant"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r27",
      "r28",
      "r94",
      "r170",
      "r178",
      "r421",
      "r449"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r277",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r299",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r437",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r437",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r437",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r437",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r450",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash items:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]",
        "terseLabel": "Supplier Concentration Risk"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r263",
      "r290",
      "r399",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r121",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average number of shares used to compute net loss per share, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r120",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of shares used to compute net loss per share, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406127&loc=d3e45023-112735"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124505477&loc=SL117422543-158416"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782768-158439"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=122147696&loc=SL65671395-207642"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=SL117422267-158473"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r543": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r544": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r545": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r546": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r547": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r548": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r549": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r550": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r551": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r552": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r553": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r554": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r555": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r556": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(5)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0001274737-21-000115-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001274737-21-000115-xbrl.zip
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M;Y/X*H@G__U3W!^K[:=;VWO327_GZ>YHO-=76]/)3C2-=B9;D[W)__9AD+_
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MA],9P>H>H20F63<)!HL\3H*=$)3\_@O:A@A4^@G\ M+.N^M-G(-0'."O9#S
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MRH'Q[KUBA@ER)0QFV372>U@WY\G>2;+L,@!R5"!BY"1;68G'!9F]V$7F>W/
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M.D#;ZA#IRCK"^RL7B?EXCO1XN(KR>V4]X/V5B\>\.Z'$B.#DU^'IZA'BRGK
M^RL7BSD^H=2(X&!X\'&?$WE.P<0Y!WG]9DV8CV8;^RL7F]D?G'T<')W_OB;"
M1[-EVRL7FP$S&^R5PV.*R;!5,SP[/_GP87@4' W/SX>G*ZA&KFSL<'OE(C7
M("FOY^3XC*GS%,GS=#5#B-M;*TN8*Q>U.1B^&7P\.M=$^7YXL(H6]_;*QA&W
M5RZ.<WQROI)1F^V530+?7KFHS?#]X3$9VR<855R3XJ/9N.V5B]7\_Q\/A^?!
M\/A_3GY?R;CA"M/BRH5D3C\>2<'@Z?#MQR.V9]84^6CV;WOEPC/#XU\/3T\H
MHV)PM'J4N++AZNV5B\^\.<34L\/!47!V/C@?OO= G%:&(%<V<KV]<G&9UZ<G
M_UA%M_?JTN#.RH5EWA^>[0^/C@;'PY./:TI\//NVLW(!F ^#TW^L(L#)]LH&
M 7=6+M:"N=^#MZM7);.SLO&^G96+KE"-#/IM!D='OP<G[P_/SX>KE^>]PA2Y
M<K&6_>'I^>#P.#@]?/ON_ P3(X:GOPX/@O.3U:U#6&'Z7+D #)5O!?LG[]\/
MC_?)KT/=^ ;[^\,/YUAMB!4S*PLPNL*4NG+A&0M00;P4.>C_?#S]/3@_/5Q!
MY_C.RN;T[*Q<F :!I$Y7$F"TC0I_H68(?W]@K4#NH0M&^Y+%7Z,127^K_]/?
M'UTGDGOK*=#5#)G ^7OWUJH<!Q<,H_$LR-54Y2H=*VQ"5<[B(CA24:&",@NB
M=!ED4_A2!=,L2;)KX Y!48W^4..R"(I9E"3!"#O2IT695VJ"]\2I;E"OZ,9)
M5$8P,?AS @_)X;NHU,\P;SS#IEA9&CC.SZ_6X_*Q]UK9V?XFS5:PW^CS%U_]
ML;M/>\ \OF:SE3M*V3);W%<B-Y(Z'1-]=JB%^&<(W*_?).9[K$8[4QDL\C@)
M=L)@>ZN]C*LFDON[?!SOH>&.=^FJ4.-Q-"=JU(W5?EQ*_)!4\^"=BI)R-HYR
M%;S-LVI!#?-"%!A1L \C!)&4QE&0Q/,8)5021Z,XB<LEMF.$B2_7%/S=]^TX
M@W&H8#"9Y*HHO@LMMZWC>I>_Z2YO1)O!ASQ&C3 +P+XJ8*]!!?R1&18HB<&P
M%YQ%:? ^RL=9$;Q.KB:],#@K50_DZ5: ?,O^' ;[@V!O>^O9'OTP*$M>ON X
MNE+ S-Y%E_%\S<"^/VF/-H,WQEY:TS:IA259@Q]R-8]A.7IKLKPWS?!M%>4@
M3K-\+5!7<7MMZ_ ?E]NTM)(/@R@X4$ETC:: J/LH-1L:?XA-YX-Z_W:\M.,I
M3:,!6[OC#8WN[FNN]_V/1<.:6!\0."!YEEU>9]G$'A D6/]K^_V8 N]98']_
M$P-IC^,H"3Y$>9FJO*"+21'M[[P(]C,D?=!<<Z5*>K2"R2=P--Y'11&-9U6A
M2C@:6_V]_JYHKRHMM984_*/*R^#_*C#.Q[,P.(AS-0:)A=LW '6*GO@^2J,+
M-8>[UL?J^^=FR"'ZN0A.0:4KRRBUIXRW<.6/5L?*9./+4?:IR5U6@C#OM?7Y
M_6WJR16R(O@;O17K'5[!'?X-1(RDE[U[E#NK<Q_N)9(<?/VX[3IE@WR"W2D;
MCRKY8AUN7X?;OU)U;14G.-(?V7P[GZE@).L0)-F8LFNB,MCN/]\-SJ+D,AA<
MJ;12Y+;8C_*D&$63T EXKOVO]U (F6<+&,OR1R=<?8#)SX9! 1!<2;"0U0FR
M-+B>@=6//Y'C0%\>%Y;4TPDGI\$UN3D)!7Z/M\1S>-H5N0;L/7BIRM)>\";+
M \Q<6U0Y* F*/'55"@+)R> ))5HA8^)4MS@=)]5$X<UX#^DB\&#0,U20P*O#
M &^EMX9!CK,F?Q.(8CJ'>H9AX(XO#!91?HGSFT9C]"+&JJ#+V6,81+ Z<-$D
M!ZT'A7H([YO I^323!??78RC!3Z$EPX.^3R(\,FE3N"#-V+*'5WO,0Q,U4&V
M@6L*'YY[_"/H8B!T.0\Q60:7:78-0RWH\E]A6E$:!:>PK6L^<Q]\AF-L#X7/
MW'=F;E>>&IR(3_$<3@(0\/9N^'3K*7"B5!35?U7HX9\JA0?H2XR;[ST?V*JQ
M0N:)AQT863X)-G;RR68P33)VG)8.[WT,,VIRE[,*6>W.UA;^$;D;^!CF4\QP
M&J,EYU/3KH"Q Q,KRV@\ WZ, @JSKHM[S KG(SU18\S@1O.9)"->]=/?AY]F
M\2@NO\C6?SBS&-QGRGTO.'>R(&P*_1R$?)4##50EZ #_1DF.ZL^#7V@PQT[>
M#^"=H Y$P'* S<A44+D)!L=GA\'_?;;;ZS_I[^T]JV7WKW6"[Z<3J!R#-$!@
M'W_L]/2W*E4YF!O9=!J/0;_52OR%][W6K*/)/$[CHLS)Z1C .Z_@5]#!)= ?
MP"]P 9Q6=A)R8G$ZX7!I[M@H%=H4"NMM@,.C ( %PA.RT!MCK1#03!)8*U1#
MCJ)K4K3_G=%+LGQ"85<<@8PPS>P+ I0H;-2L]>[O?\;.82M_D,AGMW$/]!QG
M) =*>#2(-I!33+NI-NCW0:_#>C.2$%0\@R2N4O8)E$&_3ZNXNQ=\Z+WOX1T?
MP#*&8QG@:+6*._RTB%FXTS/6!'\/^"'UC?R1!<LYUSHJ+G","R)2E"UD>VW$
MF\&@NJ@*(&\NC=(,?".&GTKO9B>WXK<LO\2'G54CU+'*&/3%I1RB1:+@C@TP
M%XH*Y0JPGP+=1<%$36%X$ZZNI"-7?^*1*G%@QO* 9VCE_@ $%.6NP9#(%;;9
MD_H+T5;'63J-\WGW:0815%1XO4@Z'AA8T9B\+H6>.[MD[6331W=NUR7F-Z/B
MK>.5ZWCE.E[I(G @8UR+RIM$)2B(JEP&&WM;F_##LG#0!KJD3+=0"MH7O%TL
MX;-!/-]-+#VBA>_ [/=UY@=CK#Q,S]8Y4N<8Q@LF/M,K!]>,;@?*'%"KN-8?
M@Z^./B^?3+,J+V?!QHNGW\05^KSWXBXNVJ:.!,3P\LG3WG938HY #V7O;3F[
M3_?M)CE^2.^&P2GT>09SN&OV&';?8ZH=7+(7K%VT]^8^0GD&%MH'E:,*#SKR
MCZPD@%Z[]?0O83!2FF))<B&W;41ILPQ72V2Y6V9J9#U<D-3OP^OEUGIX% UB
MS+O(4KA^"08U*@MH4^,]HZ6QT$.#9 0O,C=0LD6Q0)WB2K$;^0^P_.F0.3<'
MTSR;LYL,APG_]H)#8[*K*[P<'<AQJ>94^ ([APP39D*'%W-(XHG *L4I&^T&
MO@D^P#:.*W9ONZ^]CDM$?:(!TDV9E^Q"J2]IT$*.]"(<$=Y%/@<:F@EB]?N]
MW1>M6\;I,JV[%K1O&0^L9=>:]TF.#I?<V:T*;M^GS]N;Q^:I6 &>^!HI^3SZ
M]'"26>[+7J)%$  U1_E8*O@/NA.QY!1_(N?@'+32$>;53:HQ'P2\*9IG54KY
M8'B&HQ$P!B3[1^>!6P&ZAMT,AI_&NE3N1Z7K%A$C7%UH%2B7;"XD:GL"D'S]
M$S"I<BUR, I'\A.6%VC?<I UG=\3_SX!^0QZ .S/\--"I0\H,_&^F'ES1=HY
M.](Q,O<UZ=Y#Q6=SC]8<^_,X=LL2NES9_(S7>@?A5@:_/A#WT$-)C6$3P- Z
M4.2Z^Y'/P5__M-=_]5__]5_P[\ZC+13^YA#+W_#&=;"=?&3K8/LZV+X.MGL1
M3LIB^J&5-)W)-0CP?VZ] 2M:_.MK^O6T2A35$0:GZ@)]Q< 4"_HE<"_>IV\<
M!_19&2_TY>Z%!W1A>[J9>]V0QZ;5R8ZKWM!57I"J>=%;NN@-5CR"*CHL8.$7
M*@GV<3NF,58ZNE>_HZL% G'ILBQWJ[[=YG2]\;N5O26)UMCU60F2N*!RT%%V
MI2B!T.GAP/6T*36#F 3S:**<JE(=;+B;;[S_@'2@%6!U& /ZD=D<V9"G'"2;
M4$%W+4!V%R-Q;TV37Y,F:SOP(Y,G,EKVB6 H^5]5G'-_G!$RT)B",I+!QOG6
M)O+HYZF9>"Y7^92S*"7O"=Z"2QP**@&L24B1W:PJ&9B4A'/8X67!(W-WK_B:
M<W]]K_B/?C[.C<^P" I5HM^OG$G)0L &X4@EV748+)**=,S(UL65T2>#Y_$9
M7> >O?GYM/=\[_E7MQ-WX,;=[I^_^+']WO/=NQG+7WZRVQL3WA=9WU1W_A[N
MG4D[DWS^&:?^:Z;2/A#7U4WK9+CC9WD-'\C$?OK[!LA;S@G=;$FE7._TBNUT
M6W9:&-Q( U^;V=UK%]:.8HLG07_[/V-Q#W"NW5&?U9[=2A%L?P>(<_OI#[1]
MJSV[E2+.[5T@SIUG/]#VK?;L5HHX=YX#<3Y]\0-MWVK/;J6(\^D>$.>SK1]H
M^U9[=BM%G,_Z0)S/UP;1JLQNI8CS.1I$+]8&T:K,[COF>/(:Q>D$UN?ESK-[
MJVP_SDH,?1(*J4X3GV:YNL@H+.JM5;"!O_[U3SM/7]D,@H$NAL/$]CB;T,^;
M#-9JKYI4M@06DV"P^YT/ Q#$\[F:Q(PI[=?;=[_,%M N<LZY"1#O8**1[M)J
M/F(4,<)&H1!95/(+J6(XS0*N%N8'W?*V$0*$P3<3KH7%$D$$CE08-$[1=V>R
MLK(1T#G#A6"/[FC9*$'V("YU- ^7"6-SC&99BUMS9D9PJ)NZ(UA95"5P6QV"
M'P:ZS 3GWPG]I=S/D>#GJUP##M:+E@E]'T=-98ZU)1$T?V>KN&980Q&.J*@!
M5G6*.!DP*-AT>:6:3K&*6'<NJ%*8-!#"OV$U%_@!EFK#;![BAM(XD&(#N9+7
M,QKG6<$X(G$:$R5A5&B3JC-A<':PC#DRBW!8,$.:#[Q,=TXW,Y9U;)G<2(VS
MN:)MP7'#/N)"]C[KI*^3LN]NB:Q(4O:W7;OVS(CMWE__U'^V]:KYW_-WP^##
MZ?#]X=GPS)#N?6ROS6X-$F13A3V%W#E8^)K\2#@"%H:@6N#AAZL</ *+D<@]
M-5+FL86?8QEZ* DU'''J1JR([Q"Z V$O$.O)IC;-B#"""2P"V.VX*F"[J6^K
MFB^2;*DD+>@JAF.8X?>F;3$_E#DY"3ZLY$K+N$QT7Y4R"QF%TNU:0H^S74VP
M0MVL'9:H-S 6@(D5<'XU'Q: BV_ J1X0R>_T@DZ:'YZ^OV=:[Z(R7:Y*Q7@H
MS;5>Q. :=I]C%.R<LY/Y**:!@3"MIXO#_8ADK46<CYLJDMZ\@.4=: 4HMK$3
M-[]*B-X.JP#A2.<2Y2Y\.XGF6+W(DMSH'-[3(A+V,%NL6ER4K'9YL'.Y&BL$
M!H\("&Q*CUT&8]"J8E 2+J(XA8%;61ZCX!_#J*E9KCFIW8>_N39UY-;'TC/B
MX%Z[+JPT!WG:*33W3XX/#L\/3XZ#DS>!*T&#P?%!\/KCX='!X?';WCV2#O"8
M(1\NH& 2,-? :N# +;"/-# )X!<EFRI4'0^/RZ-\R4:0S8W-=>+@9P(==\I7
ME]?AJ4W98H3;XX(^T7&E3]=X!,W7Y@2;9%QD/]=13O4F>*JG<9EB)WKD%@+:
MGXW'U8(- YDY30G88ZQ :8A+@52*+G)%$A?X$")*"R^:P;#00(!19@LT0ZH4
MZW1A>NI3A%A(>NUD9#7$I3 @#&K#4?%Q5.B1HGV(P\$<%^%*N9X+"G2!DKF,
M4Q]5"E\MVH"\DU4C>$_]1=B_P#,S)QE9E0OJD,:+1S(!+.SH4M5_\SJ]E71K
M?2!U<"F8T )W%[\OHCEK1-;FI:U(QTO-]!%>&QY%I40HM0SJED>"WXG#/!2'
MBU5H?;ARL-N0T I0A5E JA1[P3#%N@!K:*)G1#YL2+_[=; /BF@">Y;C0H<@
MRN%UY+Z9QO"$ M2!]#)1.5/2(JGF(SP2Q;(HU;S@UAS24Q I0/B!=Y[ANXLL
MFQ!!X;7V1$1&WK8W)S#C)X*915>*K7&4_VD)5)%1EKUT)LRIE"Y'[L4-0R:D
M(L6$=>L E!D-A_J!I!,]AB+^A/"<S[X)6UYI=$YVPLDRHFY*.X>L/<^JBQGY
M=,A+8LRB$+1-XBKS+">WC\&U@ZW*5$&Z(&UX!/LZEVXOP+>G50(T.K4@QA';
M?&6@_E5%B=Y6OF>B3 <VU]W#NBPP>.>UNE@$JT862224Z.!?^ ]H@>&3^WS0
MOXYSNN9;_GH$&]^8@.F)+^,23L[X#@..>^I>+<"0Z%\:GY+,:P%U0;,'_<C(
M_]BFGVDO<C! 'SB:.YNA2Z'% K2)&&TUE+XD)9B^1;/Q>#=A[BY9L->;(QG&
M30#-\-G95?5)C2OF[\!<)\"C@'$M?;>*8RN*AK(IVI+CQZBC@]YI0 U)PI(K
M;A$$Y$(A/Z#?  2859RP]BNC]Q<&EDZ/*926B#(6<MX0;XA<)<RA_\+J/$3]
MV+%MLM2;!%K.?(&"#6RZ'!4I>A8V%AG'"K4C&"4P4SHR9@57V\S:[32SWI\<
MG[\[^CTX'1Z?W[._1H@N-@V7VLBP'@G1)8DD/1,RKJ+)%?DHV!4S4AA-X[!:
MG%O8<^IG5H^ M?LX"C2_*LR3=VN]-.Y^OQYJ\_TP!-&*,15\R014<47GB&"G
MQF5U%Y!8.3%741YKKRR+Y_;[ND9YV*4EFI4D;K/D%;*AK\;217;=UO&4&XEZ
M=QU/^>*UHR/I'GCMM]7A:SZS_U$ ^F.:D,/".&^,A8Q2+4ZI6>+M3*D>6O[Z
MK.G;G%Y9XOKPO\%"MRP+B%XKTK7#22+DI)7-J2V]-HKQ5];48EZ];#H%3D?*
M0A)=HTD#[U*ZI05L;8QC/$,?'.DU@[E"\[RN/I\J[&%)NP+K0/ZKJ.C@H0&;
MO*1/2-Z O>7.X2%XXG4>HQIJ&L%$8^P3#>K2!?IYM,&>4.N7:$E[#3/0:0O\
MZJ*:U_,5I)],A*XY,QP8 .C 54X*#]N$Z(K$P)F&5Z][$M6G"!,%#.8RQ_'-
M]@%S18T+P>5C;#F*1BGY\:7A2"\X8P<:OD_T[S 8H3\QIR0(+O(GY3!$<D)H
M2NT 00$,KR55=0;<2/J%\F+(-S(@@8J.Y]@UE C13%I@HW7[-CH8F,-P08(5
M=C''L,P$/9+C#'13;:!J1/9>,"!% +Y/EF3DDL<N+<#X2>K[8=-(S)[0_GOA
M%M$').I20[7'J!#<%OJW8-:*<TK@Y#J+8$WU*49Q%@QJ&6SL_F73N )P9I0Z
M03M)^3;1Q#HUEWJ+\1KO.,93&B^=4SLX30 1NJQA:14LH=%&R(;!!^'F)7RK
MIF/87F(-W+3'VDAX+DXC:03(')<M">D"N$GU\RT3Q!K%* 66$^+Z&\-G!N(#
M!Y73P3%M@V&I@4,XR5,'DF]R2HV$;+H4D@M?8<?&KG&>^EQ%:7WH,/)%-4KB
M8L8VYL,,9>'L?L,IG,'1!=[V/UF5 [^_5X6_I4W!N98ZZ/7$@ $S0R)FCP$8
MWSX<"C T<_%=FB860 7Q7*QJ-HF1%]4"K\P61R;P"]=Z+-? G/2"6[+TP)QT
MCZ;AE!$0?F$R&QS'/AX^[UW:$R>VLO+DH_8*TT'8V)5&8[[#0$M./+FI?FIL
M,B@P7H%K#$R;XB/"7SCX8#!>*&LB347>B0%DW V.(Z^\5@F.I;^M'9?2/-=-
MWEH@LS/+A;Q!.SKLALH8>.N!]ZL%RV+O(KWK+L_46V@S"&'DL.MEA8<RN([(
MY6!\I4Z665N0Q>>4',+GI_I=-=0G8$.Q""NC:S#SIZ250B@15P%&?('A)E$G
MZ3@V20F>@YM[<7.<L$TT&,T.E)_$43.;0LI7$S;0,^>K>OP<TR"JX8M&/LMB
MT''3W'BSS2!ER<F.7].Y0>AE,RCB.64WJ*PJM%_*;-E=O&"K[;EYUIU5-OCG
MO:>3-6A2B)!\=#6S@J(53Y!Q3#%"U*<^\\@_-)F9OA+6L*"0%_!WN$%S],+:
M:#?VO*EGJ@$ORE),YXITU,R-AFH5_P4#]S [TCV().ZLVS'T8 Q6IRLQLLL@
M@ZRY$KVC>IW1*<ZUS4(V$4@:<E!RVY^24*R (^BT&^0[PKJ-#!'E3)9:8H/,
MF_RV$@0VSK%_2L_56<N,E<5ZC?2C094&E9F"Y  -(Q1AQ1*!LM\PJRY15^BQ
MHMP_KV41+#Z^] (Y9XHW10GGU2UE^\PMV76J\F(6+T(*,I' 1-\5V=2YA!^]
MV+[6P3V3"D::C2G'FV9-PCMO$:W(3N(%0C")>[D(ZF,'+H_A5Y0OYJ*>/-?N
MK%@N-,VI L:)H5W*Z<!AXV#@.D7797-@A^-H@;$1N"0;7U)TB^P:U+6!H:?%
M% / 3F L#"[B*?Q7F6?&*3#IF 5@*9V#]EX90@V#678-.R^<6"B-C$L?8A[V
MDF"F,#SQ:8Q^#5@!'B;J&+*G2#9:/[EA-]&^CE6%NT-WP+,+S(5C23LEN0"Z
MP@P=\9S,@AI<R*0N<Z/)6-,UF@17$6RLFFO:XR[@,&33$M6(<DYJ=\,X:Z?C
MS15[:Z?CER.[,:]T#&6MECG:?D/J>:&IAMC3_+E"+2X7GT$1(7@Q4'RH$RWX
M#S@7J(9.D-3IBRFPCO$,S["<:.MMH"]25N2$,U@W$^6+@;!-\%\]A)*E%[M/
M4%0XC0*CLLSC457J+%1M-N$[>52N,HT6PX*YV!1,23BK.6J$\2?\P/)#<JZ!
M]]-B&*G';'P2U--<=!>9^CO)5D)-#UC,Q,^:(E,F3@.;BF*>!APMRYW\J!Z&
M<S%%C>*^#O2D:S;"&F1YJI;%SRS]2.N,BU&5%_S&D)Z0EW"!G>(U9\4IN2NT
MLHGMJ1)U%V'/,*MX@FPURVM-S<XUC\3YC$K)UL#,C6G%^36N@!J1H5" 6,AY
MJRVR<;WAVI(=-K+K[-_34)H,F$R#76T]^GFG'AV<?!B>#LX/C]\&PW]^&![?
M?Y'&U]2J.UL!/00E^XL5WXXF5#=IP<U;1"5N:_'EZ,>8]L"Z!RO+EH.03RGL
M8!3L *73++R &1),?Z1@AE/7?4.#!\*)+DB^9'I$88 )6,(*0F%]])%EAFC0
MF!0:&P709'K +U;C%9AI4/BR<<QE>)*&"%JEDK?AVL:)@.^B5\VD7]#/-JW1
M37:<JS$L,GYV6**D-MZ*\,M^.>T9AK'"2LSU3!SOELVS13].,09)Y=-4?X=U
MY3]@*,##T=<@<K4()5J.BR0KBB0U)FF\B$SJ9:Z>%#"I!:W=5%?*7NJ?)Z#5
M<TZ-JY5K!X=^&?-UE7+5$&>Q8!90"MH_QNTP=13713_Y(LI!$T/C88HY-7%$
M'NV+Y3P%2ZF:\ZM L524;]D8O/%\+O 7>"#?D,"7!=HC^HLBS:[1*Y6!_.%O
MJE)*F_A/HC[VS"!!RUT5>GN$O N00KFYGO4720,7]3ZU-Z"&(RO"UVL7GC$Z
M^)2P0PH7$ 4\ZQ,)W)6BKC11XR3*A5(PV@ 4AYH\A6R(*?#3B*+A(IF[NA!2
M=$))RG;O@TL.,6>+K"Q2%ZJY?,]E+'.\-#)>)SPV4SQ=F#>;JFF,AQ[3<%7^
M<^%?'IOG+N2YNFHUS[2=K8.?K!>VY'P3TR>E"0O5,&!E5"5C*L/IG, QB;%*
ME_]V*,-21'Y7D]IMU=S"6\DYK2?_Y0;V%[V;'X6!1D6ZLY0J%[;V("V;66XN
M[S."3E<L$(?2VI,PE<A+:G.%7IRZC,A1%H'?@_3"VW5T/A?S6@L>8)L*!N#'
MK_8H0F=2]<5T)V[#+O0-JYJ6K?UR-\.Z&YRSC.#RK%72\0:B4#1E83!#S">*
MC&?*CB@!&9N8]N-62>UZ[G56)1,GL=Q(/*SKX%7A\F^=9,S+\N2F9>FUDH(]
MS[X2#+*&,MG).:T3.6FY8!+X;R\XL!X2=E<W(AB%[^]N#][ZN9]PL/7>*5:J
MT'_2VGZ\??U8%?O!$ID/IR'7)=4;)?J@$TVZ#S9,2$B^E=(B5N2P0A/,4J2F
MW^%'#NRB*RR%<8L 8$X3%\$M:<%L*UU'12.'N$.9E-).:\!*_ K?[:>XBVV?
M=3V)*:O*,:F!:%+S);TPW2J]P"/0$^CMM25AMRYZ!3'#B ^(2=_E#(TL3;@8
MM,C 4,?%9:2'SU_#7K"?I7 <"H66"V411*G_#&8?F':<QT"N5*.T=N[=C'BT
M=NY]\=K=X1@#61OF5#L\'.6'(Z'R6RB_BQ?X?&"B,%HJPNI1\8(Z'X 3178#
M3J2%#_Q8TNV63)&6#6M&G+15#$IR:314T<<6QETZU6Y@4C>*NJZ/]A-F8(@O
MQB33F=0MAJF =\:+R$D&@6MUIAQ<?9%G%9D3%!(R%TFZC0GPC/(,["$-2B!A
M/DJ>C2D$IJU G1+("B+2EJ-;7X"%D<,S48F:J8@+$JV[VW@M<:DF,99V=+BM
M;4B1&[\9T[;%3'"7S!TD'EJ5)'+5-$;3RDG[<(9M%C1..Y_F>H$\KX]U37#J
M+ $[&%^VCA-+F>6GTJ0*N2 5N8KGY'FBQ[M&:(8=JYW &_NTZ$17N;'-,9,J
MOQ)N,ZW0@V^"F4Z\TG@*&I:F*?7#12OS:@R/0-I(Q!=67W9=.6LF6#-YG&=<
MP]E )QM2(1\$=!JE:'@I]#Q.DRS+V276_6)3KDON!B%IXP#9%.-?(,#(/I\Z
M#@S/%PH&%+DWE9=_%;9M4:EK;J5QN+6FC'Y)EI/-/J?4:,NVS0/,2-"B(F9N
MOB'+2OQF/,(J-6,D>!!LR\4I==;)85/BB,SE69&[*O#U ITOF,C%O$.?,."Q
M,:P'99_ZK$=O\)KENRP?_YQ'G^)Y-4<^D%,NG? *:UWO8]H7]FO"56Z1$AN2
M$RMYLNQ"WY0D>TF$=K02D[NB_3 =RH5?:]#6K]YJ+#9K.]C]"^7@^C<BOPW&
MU;QBG9R*)Q9XUKA6( :3X(TN+= Z#37" H/PMNG;;)6V(DZWW"$KG !7247'
M=LWYW,6%!NAC]FM<.F,>A7NT>\%KQ, @IA\G2:5=;G1:3"Z[>.$0LV*1,&_0
MKRTZ3$SCD[GS4(Q^T/1?AO;@AG5?;NCZ2*T>X.9Z4%8H,EC,AW>S[J]1"Y <
M#';_K7:8\$5GF/!TN']RO']X=#A 4)I><*_ ,P-,28KB!"6UJU$XQ;;DE#)9
MT#DG+FDA7:_X,0G #2!+JYP*3 1G -GT6M<WJH$KL>\<04UBPU[!'!6$R9:7
M>\FIO>"$_ 28W0\7$-MHN#M%(&L?'7G0(S>7 <PDKC[V9DV>4JZY;/,NZK:2
MMO[)Y"^S#_'0RZ:FW .]PA-'?V[U]&$>@N2M&5^A5P5J2S$:TY48J3=;U$)A
M!W305.-UL:OF4RFU*4:SH,>VYY&92A%3:30&7;5PD4A0^TV$Q[L^TK(%S0R=
M[%0TEX\9*LW-RI]B356AH\?THZBNM3"OE8N-X9%P*V9NSH/GG_<BT*0"3_"8
MB$+F0)48_+?671"M32S>YC;3]MM&J([0],FF(W%;!S3&JCW1'ZQP6-N-_NXF
MF.)@3"'!4-8_A^)P32ST$#\:9,(5NM3%1(]U5B4*^3R)R5)DJ%B3;'E[#O7:
MZT9B816\;@]%7?;. X6-2/4AX=%(9!TMG4 [EDV"R:%K7=R#8XN[3C&[]1K+
M+. :#@+H8X7@1&!L!L^VI(2&J\VX)@]?X,*J>)*C2VJ$G/5";ZQQH7R"_XH*
M#E=U*.!TEIE1C+@ UN)T4\P??]LH-DWA*4<)/1AJC?4C3%6+QRCPUB*T@2D+
M,0U&=QGJ)+40F JE\L!KQ[@]"J/>G2XK, E(#Y#ZW58E-W,PNP7\;.(65OW&
M.Q.Y8D+BH,BA*,?(;M*"=T-/M#:]FB0BS#5:,KT=T15H!<:\MJO!CP$)H6*R
M))R=G&'.=(95KHS?QE)$?S$5AB]N#%:\<Z- &'O8V2Q4VVA=+I!76\;ODS92
M'RXDEPR8B#.I-2S\::,D/_6SR=8*]YC<+SO^@? 7+5=2,F96S\<HE>4K+8BY
MZ^36:.V,0Z4IH&O$MQT2%Z7882 .WKDA;8>4F;K%<Z)?UPL^+K):;+])8G:=
M96><REZ'XAK#(N"_,KM0-*C8R[(CE@'B4#@?YQ%P['VDRFNETO;UL2\Q1$N4
MU38*D\S =F;'NKKIH?^J4,MAW" GAP%&!CJ;JN=!F%'=43FOX<J*E_&4G65(
M]ZBTHMK54 #KJJ[#/([B2X7J+>FQWV 5+N#LE=JS</M"> 1 Z $T^7H9MS\]
MLGI:YC:@JCETZXF^1BG!+O-$)TI1"3RV\"$$P';AMPLA7G,@2YK21">EQ:@,
MQ)(OY>7GB$D8N,#!7(ZG&)?)W(O9S%2LRT1:N+!-7LZX0[+RP!P9&F59PA-4
M6K9+TU&67>J0 _,D-]E3BD?X_CFFP6"!.0;:@_T/ \SVF'.%N"1QF(PM3@JB
MP2)-$#24V)N1 ?R\RY1;X4/U9.L<$0&KR/#Q4TFXZJ4>*K!&4;TLUWM'9TFI
M^ IKE:7MR2VV7OY&E893[;&A?"7)6[<Q<%N$3#D#I@X7DV,]BYIT'TK.J0.$
MN&>&RG11!<FNTR#K8)4W";_5]F#M=7JP#H_//IX.CO>'J[( ':VM!YN=);,N
MV>O4:G'7Z]0C&SY#.YR:I_@8%U37R'YDK001S9)]6OA%*!QK(?Q.S'PV+G6)
MP6C@O%J,W3LM-B_/YB2;0*9^$:5/K_:NQIV[NF^\3<%;B2 ?Q=$H3KAZ46\G
ML4URUG-H76<C_KD?PM#Q_Q32(.\7.6;"X,_;YB<=FXXN@.U?:$3$4$.YR9;!
M-*LI,IX<28%0!#)L4H0RD3^6WE/EN\(4ST]L[+JP[PJT"IR@:]YV*ZJC#CD>
M4"V^&R4;H06\&663F  #_JCRI>Y:P9:,[C"0,]8!$J^0'"71UD&XG5(S/24J
M1&F;%MBY291>JE+D$;/I1.]8:"O&G(%%$\+MI<&82RF>N6X%]&T.W-XJN+SN
MC5EU<ZO?=.7 ?GOE0.3 L0B*%:?8>!5\1L)@OKG44YIS;2'Y]2&2D@S0VC1N
M+)4RF=XYMM,.22;&I]''D_KI%-7(^=LIY;[@.H["4UA1H&GH>[D.*S<XL8!]
MTM%(2T3;%XA@PQ99$H.T,Q ]%/$<\E!QW2QO;V/FN\)9*:X=C<>DL8>U[_7$
M6=$WO\GR?".V\K#HLYM 7^MPPZ""@6:PUJI5GFJK!>$=P%HZ6\Y'61+T-S%/
M,GWB?[NW&<R0HKG^F:'F24 @"F*6Y]FU<_&+S>!* :5C'%W3E96Q(76 <DA7
MT^!-Y(/6&Q:[8400(=TDEX$0G\S4;E *QDD4SVG&=Y"9:=T30B:TTZB*BFZQ
MM\"D^!%H[:J3U"15%9;UXQRD2))$W9I;9+?,[M*.JTGI:CP;7K8,PCXLTTC4
MBSR>(T"+K_2QMF$4+_L$O.5&3=/)8?.()*Q32'@7'4DK072)J_TXE'>C'@7G
ML(UI,LOSSGCKFKN08*![<Y\5US$"_/M*F8RRU2;A;@HV&8QVY8P8YJX[V&DK
M+BZYIACH:#%;%E0L:W,]C8.LB96@,V 7]CU2'(-P"]0';R)[ZB0,66Y9@[)
MEZ#'(&FP#!M+";5<L2R?6X9**10V*3DTSRY"'YG!.0TPUH62=BB8K6E6B,I@
M4VR_<4'%GIEYJH<CT>B50]"YV!O)M,[Q5*):9#[+Z\TD'(<DN7M]H AT.'*N
M$X*3P:$2G^]-.@O-*'*1_PPV6I5X2;06UH(]<HSUMS#UF:M]D%[?XIIAM;B3
MQX9.<CM2ALB/(VL0 K-L$25$\K%-M<><6INZZS@0=0T^JQ2AYQ7'GR4O7M6
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M_7VY4;S3G!(4)Q2XV/H$%!3S8)W O,EK>4/4RU<Q/;O::7QH6J[G?K,23OS
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MV3?/Z=FO'CSA1OW1XB2EG\7"4GQ?2N( /&%LOT/K5JN/@>LAUY3/!4[N#@1
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MSZ;J /UIQ\^V]VH5 _PNI1LA)\==)M+,PG<9WSM"<+)LK")\D[5M80%6K)"
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MV;XAN2).#[]!,#>_X'TYX84?(&? 6#LH>(?^./!RJ83_199<K?TV!-E4YM
M5GI/S4CELGH';*O BP0)AV&C,2A+K+5+30M1[W(#T9+"?)TS'O DCFO/)S73
M&P63EI<X"%CY=)8\T9V5=O6 I]'H93O8*J94UF+-^PG_J"^SEA]E1;M0!1D^
MZ:,+:\X0,0:SR=Y,!HFS,H#_@H 631Z$'N &Y,8'[,%+U8?%^>K+L3N9F=P#
M/WLPQK[6XTXTO8VO$60*P9(D5^PH()GHO^EN7>D-M9*HP9%V0E3EN5\?4EQ=
M,,6RGZR)Z WWR#P.*-H'H&QR1]4 2I'=>/V/.ZH95\4ZFDY.I]'^QP\?IL?[
M2%N'+MID?W_ZZ6QB?A5]?!=].IE^.#R=WK>@SD1!.:-&VA'BP:9#6:T6^T-4
M5A9T460M_,G!5)"DZSEGN7$&7KU\SEE^]>!A$=L#_ASA&G0,< "]$\6%EJK4
M+B''B+B^HI.H[KS;<496^@<#*"[K1O=@2?0@<1#=V2#5<A>P ZO(&P-Z])'K
MLA?L5061*G( /2*=0'U2]L';MH^KG7;$?H\+G_T\.?S[] 2,-.:E(!OU/Y]/
M_AF=G1S>NS*.>9:S]]-H^@]((T:?IB>408Q^_&<T^?3IZ'!_\N/1-#J:_!S;
M#!I*N)F/3\P7\-7@"H<GD&W[--T_@U]P_LU<?$)O"=?#=S:#,#G^9[1_-#G\
M$$>3?4A=QN;P^K@_G1X<'O\4?3PQ)]WGX[/I"7X&OC@]-#<XB3Y-3L[,4_TT
M.3P^/<.G_HB__WB,E_PP,0]^<AI-3@Y/\4*?S^!NYGJ'](&?)^:^'X^/S3.:
M%_S97-1<Y/ TPN,UQ@N>3%F6[OWA)_CRP"O'\#.>O^;*]*L_GT:?S0%M_OUQ
M?__S)W,BXWO"!>54AC_^^/GP"%]QZ_!X_^@S_FC' KYP>$Q#=!(=3#Y,?L(K
MXN0<O_MX0@>_C)^Y[/3@G]'GXP,S 'B1SR<G^/>3Z-WGL\\G.&>G,3+=?CZ;
MFI^4Z%YLQN& 'LJ\'++B3D^W'_G^'%>J.IGNXS#<-\2D5[4'F7O$D_6JQ>VM
MR-1L"MB"^83O5WU**EWZ$$KFEV5U760IE%\@M*];.OF6V;*JS2>Z90!!IIS!
M' L_YS9W]+ORZW\#SM>?_OAV]Z\64HFI09?:!Y_+?.#57Y\]V,T>[.YC\&!'
MA_,;M)C#\V".37-('D]/3Z.?S3D[_?@N'L*K(]+,(K%_!>, 0]QD40,&\P70
MV"2K)ON+_/#7-&]61;+^2U[B$^.7_NI?\8UYO2MH%)PG!<\ 3@;]F1?!V^]V
MWKZ!U_R_6S,=;2HWYB6R@TODO]JT_S?CZ;W=_6[TSR]W=D?_MNFR;W9>O?[M
MK_K=S@^O7OWF5WW]W<Z;EV]N==G_PN&M Q.W^X:F'(F*FE52_O<?7OW!;>T4
M3I&_O(QV\5-RC_O]*+_(3=_96WV!;^GM7V2+_H*L5O>TK<EGQ6JIW:&_8M2^
M>W@C(%Y]?PR>%^LW-E6?CCY_B-Y/)T=G[_<G)JCYZ>3CYT\F%#W:AU;U?>C.
MK.HRW]"U_D37^(\G'S_^[>>/'P^B_1^C0SMB!\:9O$Y0%^8VX_6?6$;?IK/S
MX]JS!K__(]#@.13 7[ & I\RH2'F&QK\;W1L_"TS<>^3RWP9P?\"Y_2)K7.:
M-U!9J"ZOH;,:UCM*#R)&P:Q[\+?'0O_^?V^S1^*[71(@Y:<@^?H!6X[^XSOL
M/N;A.%EF-!-Z??X6QO=7??2;'S=9O_X"WJ]VR&3?;:']QU:P6\<?0((8LAF/
M>"V?0=,03<O^NX\/:PT_GZZ_[G3]&Q"1_7^9\2GG%Y'WOX%C]I8+_MY#@V]^
MQ[G30X__UQB7AS+6M"OOW\!-'"?4*>:MJ_JK0H '-^[?IJ$$GI%OV52^?O'J
MQ>X/T>C_QHWDD\FI_!9/\M6!V+V:%3_G<.@\V*_-.SROF<>_9GKQ._*8G&1)
M$4V)!6UR?@ZR-"A.=K3S:>=7Q_.:LO(WC^2?U^RW>N)_H\O['9"F_?3ICBOQ
MQGSNW2YGZ11AA?^4E<"/&WVB?1(]^X//@?-SX/RMFICGV/DY=GZVE8\X=OXO
MQ#@]PP7'X()[XW!!>(<\_>\_Y+OS;._UR[VWBW3WU>LWL_G;W>SE(GV5+))7
MZ<OT;?J_N[NO_O"D08;W,)_#0.WI/]X?_GAX%DU^F\=_P".A&P@>&&9X=$'?
M>5_N/>_+;V,URK[\\<GORY//1]-3; E2/37W.RJ@NEBV?WGUW;UY7U[SRB+)
MVXM%!]V1U8RH,8@19KG2<C"N-^*D*YBYX$21$/=ZA9'T2UBV(55A[  2H4"S
M89W,F5FFFWG_!L[V:IVA>&0^!W8W^!&Y DJ2320*TUATT86JPO%\^(S*R#=$
M%!!$(.%ZV9ML\!O M[IQ3&XQ'#U&4&'_Q,8>^PW-XMR5@(]<@O8+"[8B70J_
MWBT91^NL60')'-**6')_H2LJJW) 2U$4OH?G=;;V:&IH0<!MF%4.28GFI#I7
ML>1!XTMWV7?0?*HCO#^8;7-O>=CC4EA;G5CSONTU]+\&,HJ9IXIS\\K=8E$-
MI&QB4@WS(ZI^*:I54KD<NI$E$P6:[;NU4HQ9A(=K6\:YH7LM<\B<1-0:U?R2
MN)B0!88$ LSS  >.8W&&3^$JFE5%2TRSP#&(Q$#074?$53U^"^G#JV;0XPSK
M0 E8#3;F!:2\LRRAQ0DTTK(*\9&)WHHY@8C@RVHMVGYK<[7K*MK:VR8^H^N<
M6K29K3+@\Y6MZO0_A&5+#01>IW^C:-DUS#O,W=P^G2[TNVL"%WP=$LO+&@A<
M>X_SN_8$WO_:'6=!G12%9:/29BL.)JNNJF6#Q#?%K/HB-%=YD;7R)]&VMJWZ
MPY-%Q#=^3VC(R\D\37-[-2L-1@^I1 ZRW_CIM<8&-I6A]H];THXX<)6L^P\C
M&\ELFB*9"UU4 ;\USQD1&1MN+B%O@NVV!>)NJZRD-8ID2/8K^2)D*LI!UP$(
MGY-Z;2G<2"@5=^T \_;O8Y!B:Y$\XQ,/M06+E]- +[#YDPC+D 1TVB&;:XNS
MJV4M>NZ!<+"946C@'?GS/2ZJ&7ILU35,80KB)>@HM,*.H2C<B+F1V(E0V9BU
M-C"6I;\B(:+/5_;$#,HX%^S$4MK!BL957D6KSMC@N>+JLT;B$HBED- O]6>!
M^2T72%=I_+K"+-ES)%9$74WZ,9CI)S8)XQ2TPP2OCOX/"11A'"^S;!6QH@GS
M("'#)@WR%V-J>"X#IY:Y\-#J$%]I0AHO<W-2FS<S&YD4GY>@: 1[:<9?;1PA
M ++<2UA$[@!&4O:X;SI2JV V:GR2D#X2;MIDP$LOS)"I4-S!2R%)7Y$EEBS/
ML8-!\(:"-@NA:>6%1B]D7ME2CXGSXMC;0""I'7J/6%["%TKG< S#;(X*]%.Y
MUVD#@D%ZQJ;B%XKENN$GD(([174*\GSHM?B5[)O0NX7O$TMX8'TO8'=$]F[W
M:":FR]'&XEU!F;BBH9C/U5ZT'[=77"!'=E<RY:U5V#41,'&NTO=!4&V%\9'0
M@N=S*S8(?TR 7.\JKSH0MF:ZV!3%7WF&OLWTY.V2D0\GK7A/QBX97&7D37I.
MA<O("-DA,"X3 _*,-)L+H@HA$G=:.["E4 -)\@#G26VY:L%C(!YID!RIA5$5
MB#7 M?7#_87*V&"<CW>&5%%YE9#.][*:&9\TKXSMX)/17#$GSBJEOX3$LT0X
M>8-!AXV!Q,G#6U&QG4(PGY>=I$DP-0#JY^:14:@-K FYF9JZ5NP%<(6R!)7Y
M8\ML7^8Z1;[(Y->4X7A:1_$&WD3?7^U+(H%[.:_SV0A5JQ@?7%A ]XQTK8[K
MF/A:9=A9L!J(7T 6Z LRP%"\XRA=22_MW3OS?S_\=<JT<C-,(K:.?=AML4/1
M?S"W1F/LW1(.'V;TT3%[CQ"4CY9(T42#.8?8@^5MS 7Q^.;P11[04\9H*H[O
M=Z+3P9$@$KI&),#SA3X97=RD<@'( EZBL%)#<FB-E;QH33AXB0>G.8! UU0'
M7C0"Q1IYZ,T, G&1FT,5JF!F9""1N4""<^(*M_9(N)V](7>#3:'8'-6[T=>F
M+Z6HV56)OE)/F2M69WW.Q'B4M5:9R]H)09GQ6597[*D(9;'$L_AH=GJL+X\6
M N;'OJ-EE56B76AI2=_$9FCY)3 N_07T^>PU9U5=9BKE]+3,RCB=WS'H0!>7
M:V^_UVP\5LG\$DZV&!=TD<-/'J/S,JLA5Y!2WIM'6AL S/L1 ?/ $6>.)N-_
M@2)UM\*%6UV7EAW8D>MS"(<Y'D]X0 7TK*'%0E;$"QW;?Y,B#9R/?%664>7\
MN!]^*#D#S@2N1\3%@@R)\%BJ_6I< %^E8>_UH"Z#J%[09BLS\IR[UBS\?Y-<
MA>CPB).A:>UC\*(3(2D?> 8OJ[D"-G_RS('9LRLXZR-$R(YLG&]"P"HL0-@4
MD2;";H2PFHX?^E)=S<VUD6R<(CKM!]"#MB@DS+4<9[2\V7=>#(K8A@'D$]O'
M0WK/EF^:9 1[)G! )R%(=W@G_,JL*:8D;[2 AMOW+%8T6S.M/676R<CK\V6<
M9STD,[=F&248<>G9B W-1X(UTD&7Q*T/Z[K +@%CHZ0WDL[Q=)M@$<4#6"KX
M^B)IFRJ#M'#:X0(T1BF#'0OG=6QK=K'9EN<@1QQ;Z8H5.M<H@:#=[41I[>D<
MA=1W58SOJK6JR(LB(%[95]LDJ*) _%XC*P1'\I0GSM!O7JY:4KCTLLK.^8F4
M]\/Y&3Q%>SG1OH_))3QREI!&/>-H0 EO!!-..73C5+4YBV<  ST,&_JCM' ]
MH91%,H<#'TK-+F$NH0/?2H:8*J=Q8/G9R[I%$NEIV0\(<L&'O4Z*2S-H,,LH
M6H,".'C2HDB$TL=QAA@3[2!SPT(Y=7Z5.7T<7_@F$/DD5YUMAJMU*S.RM.<:
M'VE2&2>)V7HH:2L.15Y+N1V4.92$+"P[>D.EWN->5KV,YVSX0T PA IL1YWA
M*\E*5+O\G)M,. J'KP1["?QMQ'R R>-B@[>U)*B&[87E!+16:2\DYTH#Q-K@
M<G ^\!K%IZG"X,16?NG2\V58,%%*L)GY0 [RU)9H&^/R& I 8'G A3*6I6M9
MKL(JWQC3,[+/K;PTS!E(B<L&%<D5L^JJ:["V,65DS8A>P,(A6NWGW-MCSKTY
M%G6["%&4K>[(WPW6^LP!EIPRO).@7R)A?9HEA15[)*G&&B PQL?VQ=PD=1U+
M"IG\5+X!;.ZL/$_.64\9C D=053)A;^; "<[)U4JD@0Q)@*>US'5FUN.H)U4
MX.I*%7@A5IQVP2V-S?''L^B\4F3'8(*>MO<[3GI]=F%+#L37[T93PM($XJR4
MUAEJ/.'()B3WB5/(Y:%JL8!0S$H;C85^4SV-4JOIV5DX,!A2AL?;=55?4J@+
M_R339[QD.)3M64;2T&F'RX\7*XG(8!R+)4PZ4C'X\F$13VM)_'![,!6+/$*L
M;*8\)X]]GD RG<"1DL :5H;B8\WA-E1V8%Z),XQVRLESUYY^#"\29>@@;?[4
M\7!OQZ4F%#_\!F;XN(]3 =<,$RDHJ>@C0X?DG,BB0^Q4B0!7DF+#6"-AMI./
MLJ:%\U*0+V']87?:L'KC$]N.NR\WFF@?*@4B>QFXW%!52L!-OTZ:BVA671>>
M".,*HK:V"Z(*#!XV! WH7,+?Z?PV?S#&-ZNMQP'Q"'FT984Y%*A2LQ;.W,\5
MJ R!RE'7D*P4-1@,-E0V&@41P?\S>QXBC6JUXJP,YV?,XN@*7&LV+WJ55X4"
MKT$Y!'-SO12V2KL8EPCM&/G_6?](BG4LSYF;_*FEOW?O@+FMS#075<+(Z**J
M>NJJ)( ':GT<!1LSDQ>4M9G7V34EI<Q?,.SCR IYYED#%:@3Q ]8%80W(PN$
M'D*R1@'(>2!D*4L=BC(2( I.[B:\;K3(ZZ8UBX!*VX*HI&5++XGOW%.^:]C]
MX;W6K<#:_? R6E7&(0&5P*L,O_G4%M0X$';J\&;FB&<$R_P"S@Z,G=$'M75P
MR,-U0:#B0YE<AM#8J>"*5%/CB[/523$-OR([XLPAXW?8N;5?LL:%TZY@$Z5*
M1Q*K[-FD+A+IX<;;6^FW/+$5,HYL'/16JIHP=)PW+WM[WT=WP=&4U<;FE^9X
M.4_ I:7E0%.>EXLB62XQUTF93^.^M%0K+KH\I84#$+*DB$6BF+ ;9DK1#DC"
M%LQ.D*_M';-<'21)7M*+Q2@:E@-\/LA%/[6E,(ZO'%P*7S\/GJ*NG10/HG"G
M/>O#V,7Q*E7D Y>[R(HT=@]&RR#-BF2=W7&J'U]PLSL.Z!F:^YB,0(5 SV4N
MS2?HM:&%6(& ;PGUC [S4&7U!8",8 *X:L3^ZZ =B=6583T!D-TW-'0_C(1Y
M/Y/'2,AX+*UX\V_.$^/R@A< =Q/=QH2[ZW0@3&MUO+WM.?'[B!._9OZ]OD6P
M2;2*8!V450Y+OZ("#:*'9JS03(>37G%6Z5G[RQ3$MT$O98M!T06AHVW\WOZN
M I[?C"':" $JJBZ%Y&)RB0%Y"_6PO*$)6%U4975>)ZL+:(!*TKQ2H(P4/J?]
MR)ZYL,B4&1:!R1@T@+J1M.> NCE ;>'I3<B+[0&K9'Y7N< G-KWCN?$?\_EZ
M7H#Q7U8MQJA59;90T%C0KE<X$U>9.?%MUH&/_!ZFLZAFU/:L<#K]I*G]N)U:
MU8Q#FY-OIZLL4A5.S,I;-\#81,A(.%12P?SG_L&V$\E;NIX/!$=0JC]IO2P^
M?=2LY?GEDTO0C2?,CP'>46$1WZDD5Q15D,_ )1!8-"*4'/H7D!FA;WOSKO-U
M&/>:R<%\V$)#"&,&LJ;GO( DO2=@FSAP,1"' QJ>A1/IC&[ 2'V&0@H8#K.0
M_AP5R0S8K:IZ_<(&+@[I!/'W,I_7U35DS\P?RT:\:[%SWFLN"-1,:3W@QT20
M89UA;_T<?*4,C&L"-? VFE]4<\CX$>I.A+=GD&<D@(*4S"7(8HQ>WE"%$O1)
MT=<CB!\T85(U"\.\+ 5$ J(<^ YSP- 6R37B(5+R!J%<2D"/0<X%2I"FE?D+
MF )&-F'GG=NPVAT<]0!=/I</Z"<?&8S7/8XKOZ*!3O-:^>Z8!ZQJW>@\YL'+
MCC//VRV2.:'GFJ3(;-B/71?_ZJJ:,''U'*"HC7A74+A\8C9R;[R(X2/QV6)
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MBI&!C<)^S@WL,DGY&!,Z13A/UR_P#,0SS&;,;'B_P,J-:^=K(@GWB<+&6)T
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MS:Q(;>M+[)"3["U;\C=JZ0>:M,Z,4#7+BRS@K) L*MM7/[?TQ/,\K\8Q$>\
M2K\A)>V?DMBG#H"%?$4Y3NLL,;NX@T\J4JZ5\&LI+&8O&4UT">YI!*9!>6\I
M^V<VGXA^ <8#_8< TG^S0GQXU ZU)Z#.0%[/NR5W<[IS7-_=9=/E"9RB(8=,
MKD ")*6<:V0OHZHU4%#5M9R\C@8L(+(OA_(.9(INJJY8DB2@.8';VE,2SZ&D
MS+@XD-;)->&"8>3XS7H UZ=FSVZLN6+4KT>>UU73(WXU1\N<L2U<VZ[JI>!H
M<'4HVAC0LLE(OC%?0HL!R5OY<FE/;3+&*V?C!7"00ZO*%\V2.JH<TBA)JU7
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M)(>S2:1%?'QK2WN5%$#!)-D/27PP/UOO,N(IT2*#M^7!E(--9#SP>6]X.7^
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M52CWSXHV._@'7 GABS!JQC6+XSNA5P7+@8U<33\TGNUP*Y.!=]BC2, [FFI
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M![#15D6O=E^_(K,$B= EL/F,Q]H-=-BAN\AN)[(<:/) Z$4G*A-"WEJ6)J^
M9HR 8ML]N;OPP^/;V?,'MK-9GL?8YH.L:>MN[NGRW,].'^(%44V]KNY(1Y&#
M\S0:\S#*/N'.6[0EA(6SPY"Z8? X*95/<6<? G)HY#N\>K7U>MNZ#^(XH,O0
M9H-. D*,GD_,]('MJQ.VZ 369VC9?9^@#LP Q$*( T4]]E75--3GHKW)QO/O
M>C@YV_1@X0>8:-G .#X$CK_#7C+;Y\WNSA[2\,HQ&@?;TQQVV7(E6=@Z,[[
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MW'UUEQU*3/F"#T'\+Z=3"427L,5@M+!X%RD=_P@UY#^E56FQ7PAC6:V*-75
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MSN28"072HQK9T+PE3)XI:YRNNEF!S"%:M]-L9$JS ,V[M]MMW@Q=!F16T%A
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M]0.ZPBC3Z&:4\35W%<6)NMP4-<J;@&"P=V#:\=2X;#AH][JURI*XIPK+(VJ
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M.ZTMT<*!PRH)_2]\G.Z'-H&:&ZW&14\1719:QVDU';+[".(*:C&LJ)$:J3!
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MR YKZJS,.#F,TXQUXCHV.+"."P^6,4<_,4**30,E]9=ALG^,21R8ADX!69_
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M8+#RS]3J@SI'TKT\I+IU,A*C?(?>B(A3?,P$P$XL)5.!3<:ZM&W<D(7L(,2
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MB)A"KB^T[MRL%BY:3E4"B,'?EMU@AT/A=#'-!0(#-]8[K>76K)=@L*74ARF
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M?%^VUTMC4IU7@<>*7D5/L\L4UC7TN)0*+SQ$9XG9H1IBBUZ<4)=,7)1J?IH
MRE?!6_56C1NU@Q4-<.5<1AS%CS'>$898TV_"EE8U""^'),+D@U*\0:ZUS2I/
MM0_L 7)V73X>%(JIC$E5Y@9/%/^&OGL*XJ4^;IC-N/819RMT9!TJT0I>*$:J
M+*=2 V=J5OB^A@EB.5UL*9"-UE(O8>B[FG)E>XY:#F@4;5(A2 Q8EZ>K/RTR
M,OTDW&=Y#/\G!S/:2YB=6I1:[:O!$6O4"!)=.>T#;TLEW>683&4+KRR<[9'8
M,AWA^A6J5\V6&,N@;<1FMH'A'Q@87IO+<M.@ VO%G*=" +8>1;\.3Z"Q/XM&
M%KD)FI$D0HK5RE354J>^3.^H ;W0C:*1OBWU&B*EVD.I)]K;-!ROHY0 &L &
M2-$K6'4MD5U+:F'9Z,M#: 7'X,.4TOFNAS]WD+>D/<CU[>N-0K=:D%G="VQ[
M=%<3DE/?U#ZJ]J_>.BPU$OMJQ5H(L 2^YRK>;1R^JF?L>K!E.'$(PYB65K90
MIQ$>AD+8-$":SW$QBI(D2*.L6JTZV,!0%.QVMT$SD%KS11TZ"Q'&8H;8HCBC
M9,FH#%V0#JIRDN72X6SAERY]C,7YL4CPA!5<VF H%GF[QDSA,,-!'W=-U5?1
M[9'*V0_1  ']%%9(=LO3^(]0B&9>D3VB6"8(4+<%<9%YXV"$ 6_T *WFI"6V
M12@/=2Z7+#J=SI5[**X!?(#!!UX:-DAJZ=">8*' 3S3$)5%FX?Y3-X+U=+R2
MK&!,46%[6&Q?3I:#"4_5#99SS<.5<3VC*G"4"]:>@40[[5_IF"\7V%]3[X'=
MS("=5HD%W6D/M+$$L&)3B=KF&3&A++/N5!:9A=6(FT"$<]BMU R\M"(Z7GBD
M,WZI2E!9 "O^TMP&NX-EJ5./"X;R5,0@QW "9^'8]^C83[(R4Y#@@9/U=XHA
M8@YTZ*0;^AFH-V*XG(/D<1W:[EN>M#ZGIG07R=R%\FFTNBQCECHQ';,OU;3B
M,(B5LV#0/[O5!0N%5$EE8VS.>$KIR***$FI?,ID(C2QYM]XF7YN-4BHCE?T@
M-JD%\*3_V :"TM0%"O4K-_U81>;.);.&; ZYSC*R'H+U*]GXH;1CP!-=,!0.
M>UEK>>L@BDR/XW&=DFYTH0NGB.O.2';#. TEVR]EI36GHJ6_3X30[7($#V9$
M*%"2"R:HKT(7-0N";0-_SAVP2A(?> X^@ (JA'=?1X4# 1/K<D-^NX$9BVKU
MZTL@I]Q3<C:I: 1DJ1MSY6(I$&^\6-D.Q>KLW ;PEDU=_Y(1)='U9E$</1?*
MVE""%A0S6H-BX!A$8H5 [+1U,!Q0J$X 9:14"X%= =N2+"NR2J"852W_8Y?9
M;J"+NT$ JR;D]K#3^LMM ZR80<^DA#(88T%R+0)MUQS8G<FZ9O)>R,:/0^RZ
M41:64)72A(GP8%+1Q':^=?BWF;H_SMJ^V@/)^: B0JX)VVU@Q!:CV&/T!#&+
M!.8^DRC!+P^)+_B&^&WQ=Y\1Q'TTJ8JH%-.&^N'I=BI,7QPC>;*#'*>C>):P
M,VOBQ]3C0:EWIYFL63+78MW50)-_K_*X"&,'EP4+)TS[%58W1?3\ML^>4\@%
M?K#8>L5H"^-B1N$$06[!N2UEM?YLVW^52FC]<$5W%T;!W^;9592O;FP.E)/5
M;!S;25XL[0FJ0EU_!);.>" X>*SE67]3 ,G&N6M79BB!2D6GT)IY;K#VV#7.
M;N.%ANOF.F'74F9=T0&:Y7N_9Z#O$BXN+C!DP@4ZJ@%,T+,RJQ@=/TDT7!:.
M:CXE"!0#01YR%;).N?MVXRGRV$Z#2P5?''V;"9BQR:6K!'KQA%+G7& 6%T,D
MZ1([4>DB?A%F^Y(@GG*]C9$.:^T1#AVE_PFGXVWX_BF.P*J>-A*FOM1 2]>Y
M@[;MRYJ,-#;32DM?>*,;JZCRZUC:A=S2Z"++L'Z^JT)Z)86I2SUH:RIM;+?K
MT;'W]>CB>'!^[GW].#@;G+RO622HBG3B99ET7,.56Z\4\?[!#QG72Q+]6P?6
M/!N=0WU39K/?GCWOX82OL0AV%"0B,D-8<IY-'JXRRXW%G;C;Z[G3S%B^>KKR
MC>39OBL!^7+AAKU7NVL2;WC9:M"]/3LY^?O7DY-WWN%;[\CW/GTZ7*49[7?;
MP&NZK.WS"+QWH.YN,&:F,*T,1(ATYOQX*V6CENSMG!C6/0^<N>SJ)LM"$LD4
MDR^$.6N)YF;/U)-_EA$2_PY2LC&+\,):!&Q*.$>L@,^$/;P]%$L<BL.L1\>A
M6S@V:I+?YSQLY)11^C]CSR:ZU]_O!*R+[71?Y;6_UYZE6='TY!2NI]'_K[_\
MZ?G+-P7]^^]57GJ?>][_PV[#T>1?M7\>]EU2F[SO]4UMZCD5X"'RT:.]8):Q
M_[<.P -V -9(J=JFC;%LOO3.>]X99C4'!27P^I>7F'8LL0WX4^]T202==1>-
M;FM'475,XMG#LG.V1OX=C?S&47B/V*H?3K=F_X.8,IZ'#\(O=<J'?FOVK]4-
M98<H-L;\KYO C\GZ5_\LY07\^ MHPQXTH@[$E:F1UWMOSDV+E*X3)0R])&&<
M=TQPPR</[J)=5KWFVS*![U8FL ZG9+7749^HA:3JFLH/L*32N9HV:3H7@^/^
M\858OH]Z8T^3:NI]I(+<$5K!'_*LFK&E#\:Q5<+::1ZOU_IM[$9LCJ%W'%SC
M\?\87,73>]IX:[/JQ\$T6N=U?TAK?506Z[S4A^]/ZCF+[[C86P5W_N7M]MI5
MBS'XAF3)WE$ZZOEV$ HD<R;"N5;KL[$+O3G7ZN<@OP)%_Y\H 0<TVG1EKR_6
MVKR^R[%?U<WE'9Z<K+V__;=A%L[A_R;E-/F?_P]02P,$%     @ 3XIJ4W&7
M6;.L"@  (G8  !X   !E>#$P,BUA;65N9#)T;S$R,C%L:6)E<G1Y=RYH=&WM
M76MSVCH:_KZ_0H?NMLV,,;YQ3S-#"9W3G;3)).QV]M..L 76J;%868307[^O
M)'.'E-*$ '%GDH)E2>_E>2]6PI/S/RZOF^W_W+10*/H1NOG7QZO/393+%PK?
MW&:A<-F^1'^VOUPAS[1LU.8X3JB@+,91H=#ZFD.Y4(A!K5 8C4;FR#49[Q7:
MMP6YE%>(&$N(&8@@=W$NK\!W@H.+OYW_D<^C2^8/^R06R.<$"Q*@84+C'OH6
MD.0[RN?3NYIL,.:T%PKD6(Z-OC'^G=YC/2ZHB,C%9)WS@GY_7E";G'=8,+XX
M#^@]HL&''*T4<<4-*E;)[V OZ%1QM=LM>Z5.8!6#CN]Z_[5!R +<KN<D8AR1
M#[D^C?,AD?O7W-) U$<T$&'-MJQ_Y-1]%^==%@O8C,-D_5*OL;*2( \BCR/:
MBVM*GYR>.AGV6<1X[8VE_M7E2+Z+^S0:U]XU.,71.R,!R^<3PFE7#R?T!ZG9
M#@BEWHZTE&68'=&83*2V'2EJZR&D'2J0;9G.HISSNF+> W4%&]1<TRW"P@,<
M!."3?$2ZL%*Q:KK.W%6N-YA<GE/0!W<0KJ_0.(!WM;Q=*IFPYE[5OFLUK[]>
MHL:7UM=+^&JCZT_HJM6X:VUC \NL3L5=X^"Y20MF*EIF9<5(KO=4FE>6%/?6
M*MX.:8+NB,_B #4@. (5:*R+K@A."(+!/@X(8C&Z]@7K$(YLVU 19J .$2-"
M8G1%X;H8HW_31& #8=0$YW89CRE&$>U3&;(#S$5,>!+2@8'>OWWC>O4KDB2,
MJY=G!AJ%D $0V(+#9;DOA(Z%;B!_$-CT&QX;J!7!RG^QV$#-!JJ"#!9L!G*W
M'G /Q+BDN!>S1% _,=#GV#?G-R)DNA$5(>*D2SB)?8($0[8#^6*BA-KI#LOE
M2(]-MJJX4D"$>YR D GJLBABH^3MFV*EOAU$BEM"9&Z2[2Q'5J4LUUD*E\I^
M$6.;$]F?8<MUT;F47&Q3QHBV00# Y5@6F=H0S,'EU-S%+?&IP%'RG(*NMPW:
M,IQ6,2A"DH)*EK8N]D6BL,TZ?Q%?T'NR/=9686,[[LOC!N_;'6MQD[O0:4<9
M5R<&I&H0Y"@:@R,P&G$JA$QKRF6!ZC@:P]XP@:I8E+G/]@R9 \"8X& 8_$0Z
M?(CY&*G,:%>,V15'35")"OS9U_=?$I_T(=NXEAY,TY2$@-I39RH0!W(.]4.4
M2AS)L4""1<MMS.N0#G8YZZ?W&VC 29\F)$$1\Y46L*+<I$DASP$FTWS=9,-8
M7YA/>],4;B"?]?LLCL;H>\Q&L=1D-6-.UDJSI9P$[1\D8T SK(P' \X>:!_$
M@'7LJE&T/)3\#VP$L"=$2!-4',>JWZ0RJ[=V_<P\8L1W#@3Q;? Y(+PO'3$%
M&<!W0*'6RM+^3QPKM+JZM)>.V>C^BQN]7)D8738]%$P,#RI@:AFY*@7,.2&-
MR%GF!X\,(.'_1K(_A![!.?@>H263=P(795"T(3CV+3$T"R_1GJS+!$F(HPBZ
M^5E%ZZH"*;OQ] D>#6!#%LAYT)"C]_89&A.LJZ@(95/\WCU#4"5$F.@B)$=P
M%S9;*H].R4")['>P4")L$D?+HF(FEI7+CX;0.#4&G$8H+9SE'?/4(42(>_ 1
M\E'ZXHOT*%3L6]G&WODA"881>8&^&BEI^JDT7$HC,2I!XP^Y>B]A,@6P0M44
MUQL>V 3N1&0B?X=Q4#T/:D1XD)#:Y$4]H,D@PN,:C95<:E(]Q5>'"<'Z-8FF
M>^B%J(^C]&!#&58/IT=!%<>LE"OR-$C XY\()ANG!T6F.B@JB&!US*V85;>T
M<=@R[8UCCRUK>V:U4G[R91VH@,7-4W>6MFI6G>V,4% &UD8&-R8#''_(N;DE
M3^LX& " 640#))%;3X=4VE@<2:.GY@P>D+WV#&L) -KWSY-25N);G3+**C9-
MB*F-7I'Z*D/<JN/=O=M +K31 NN/=K79]FF@QJR:3VWU+#V(6J8FCV"HOX5<
M[QM]!I;[ 6F[_;EQMG0Z_CM.3,^=3PCD;2;FW;< ]3VGO4<QOX_.0!EDJ;FT
M93?*AKUP^9G66<X*3V45"QVL;?[^N,X_4ZR^_(.HE]?(KAJPJFE9;]_8):O^
M6_K)H5_4,\/.$6.G6LV DP%GMZ2S/79^K^78"5=9W8?ROJGNNUG=/XT0+&5U
M/\-.5O<SX.Q-(\<RBEG=/S"8+=5]=U/=][*Z?QHAZ&1U/\-.5O<SX.POZ=B&
MG=7] X/94MWW-M7]8E;W3R$$+:.2U?T,.UG=SX"SS[I?SNK^@<%LJ>X7-]7]
M4E;W3R,$O:SN9]C)ZGX&G/TE'<=PL[I_8#!;_M#(IKI?SNK^:82@5\[2=X:=
M'33*8)/!YKE3SL%6_?0#:.LE.^V6H#QM"18_%/JX)Y_)8,<;NH\:Y!CCVC6*
M56_+N/X=Y9^L8&20/'%(;EME,C1F:#RF!/E275%!?0;_&%D?O(-G?4BYIJY'
M*5D?:C+.)0,9BU^ (67_%"EM14.B;)"2DDQ9M CG+"9LF$1CR6=%L.0,PPE*
MF:M^D04Q);@R%2>+KXT\V3G&?<45I]D+%]>]NMEF;9BG5UY:,22<=,:3_4@P
MZ:'94,P86(Z85J5X% %&"/HJ'=(,<=Q[$3J5"30(>9=H<&BR%%])I!E\-M-J
M+N /E!RD>DJVGG26O''C?4<,L-+! TS1^1$NT\%+,& J:,VH+_MX+!EX$BCE
MD&T@]8@Y7C0:HX!V%0NF 'S,Y$YYI?0\+(9<SNG!#)_U.U2NE,)5$4(#SB0A
M=$10,&&*AIL"13T8(WE?NJ&I^3E7I",/Q!_*;"BW#4A$[Q4?9"HM>4BC @J"
M.0BZ"/*I9J F$211* K4GQ-4$#^,P<2],7I/S!Z$RSV@7W)/W\$]<G("&3O"
M_&?3SS3!8S+TPXG]YF9PZ?Q@QG%TCV6C)2=(W:=F'DNR+3E;RBLY*/5Z:@A"
M'Q0+\A/"RYD0BO]+VFT(,0NU[X@#MGSP =N""% 4K[%D/IYPQ;Y$Z+8>? *-
M.< D(8I@2X2:H? Q4EM#(45W2NR>2DZ]9!VA&[11&!8;QCJ:@I37#76', A[
M^413>"EK; ;<(H6VO36O\J[SYCG=(184@TZ-DPA+CZVPO,\>G]1SDS6;@COP
M* 1)YE>)X?7WD,_TZ)%\!_+>][RBUZOA:(3'2>Z9R.C7FVW/S&F6Z16]79C3
M/,\LE9RGYR)S3*>\>7C79=VJ62Y5GH+B[.#/\J]:=W?7MXLLIYN9GB;J6%*9
MW%:W'K3FK=:JYD?OT>7'U%?FU[GGGI/R:V/^&>XJ/6NXF9TUO#(W-] EU/Z1
MY"UOSAYH3\KC'\<J.Z$_<1_',;KA;* B^PN. >*R]S-68?YDGE^X]=A-^1D>
M91M#$3*NZ T;O>WH*9_(;$LMK)WV;L^RY2MRZB0^WK[QRO5$?4<?.3P6X5B>
M+\A3M?B59<5U)OD$CX_#& N&;ED,7[Z/=Z"K/,9?5%D& \I#$B4)#9X\^H_8
M2&O@8<S,)'_T 7AJMJY/JK1>8D%TI-B6BA+;5?])YM)7EC)63>&L-\4.Q>SG
M8?&T9>X7]]L2Q<]3B@\6$.MJR!?,OT,?^H-$ N[?)17LV]$':]Y%4QJH>;U3
M:GT6>Z[_+9.#-^FOI;"-O[5RW"?3!?W74]7?<;WX/U!+ P04    " !/BFI3
M5/."3<,%  !X(P  '@   &5X,3 S+69I9G1H861D96YD=6UT;VQE87-E+FAT
M;>5:;5/;.!#^?K]B+]RUO1GBUP3R5F:,8ZAO0L(D9C@^W2BV$FOJ6!Y9(>1^
M_:WEA+8DM)3C6@@,$^QHM=Y]GI7T2+CS:W?@!E?G'L1REL#YQ7'/=Z%2U?5+
MV]7U;M"%#\%9#VJ:84(@2)HSR7A*$EWW^A6HQ%)F+5U?+!;:PM:XF.K!4"]<
MU?2$\YQJD8PJ1YWB&_RD)#KZI?-KM0I='LYG-)40"DHDC6">LW0*EQ'-/T*U
MNK)R>;84;!I+L S+A$LN/K)K4K9+)A-ZM/;3T<O[CJX>TAGS:'G4B=@UL.A]
MA=%#,VQ:5FT2$KM&2(,8S4;S@!Y8AV;3)%'M;]O&*'6T+SOE<IG0]Y492ZLQ
M+0)H'5J9;"]8)..6:1B_5Y3=46?"4XE/$]BYO"Q];'B2]$962<*F:4LE5"F[
MKIM#GG#1VC/43[MHJ4[(C"7+UMN S6@.?;J (9^1].U^CB14<RK8I#3,V3^T
M99H8GKI=K.)%/PE+Z3I^TRJ"]FYB-F823$.SOXSXV[%N2?,6@A^=QXE_$GP
MI]OU^MV+,P@&, J<?M<9=L'';T;!T'=Z;_9JAVUW<';F#5V\A;.+7N!7 Z_O
M] /H><[(@RKTO0"Z3N!UX4^G?^$,K\"T]['<3 N.KP!]PK$77'I>'X:G(S@?
M#LZ]8>![HWUP1NAD-!H,E97WEW.*1EW?.>T/1H'OHH7?=[5;.\_;AQ,T#CYX
MZ,8[\T<>-@Q<]6PG -,Z,*'G'Z/[*[ATKO9A=.$':',,;_;L1AO<?7"=GH\^
M^KZCW4/$SR&IMI6D'LUS+H"D$127E,)L+N<D299 I@)O)0>"@S<"&5-(*,DI
MD!PF/$GX(G^S5V^TGU66VTJQK09+1$,N2#$QMN9I1$5A53DZ)T(R?- [4S/_
M^%HZ/X,8A#]&L,.8I%.J&& "4J1#\97'2!/$5%"D0\"8@J 3*D1AR0N2O!LR
MI2GX:8@53J!+$[(@:.URD:V@>.G<88V2+ 93L^%=0,7L65$8X(CIJ1%3A 8+
MAG0A2Y@0CJ>2I6)0I?@T[R9C98+0Q:46^ 2<3+ $;*.8Z*S#'2&J;L"[82$I
M1F%,HWE"GQ5AQP57*KQR;(W_ZUPGR3BAZRS&7" B54PF(5E.6^N+=L3R+"'+
M%DM52*I3>T;$%)7-F$O)9ZTZQG]-<:H*2;):]A7>9?,GS:,9I>Z1&(Z,UD]>
M-6NJ29?19ENMH=7,YKW-AF;>V_95MTW-;MS?]7.WN@JY#!N1R3.2OJ_8E3O@
M)72"9&5($$]8!$5)M%=-DF=W6S(21:A86U9V T4%?"::"D=W$2W!_/&JS_CZ
MZ"DFA/RVN%8X/@HB43[O=<%W.ZB_@/!AY;8:?=L1VX5:W)@'U?1Q0L=B3L02
M3+7X'* $OV<U^F8U/A;!G2C5[>C^9AG[1J.FU2S(J( 9=H@W:U-7R\#/7O"5
MQQ:3"%OX@ 74P463HZ81(%'QY$JFACR-U'E$7JB:0O#0&Y;+XB2A%$?E6BOH
MC+ 4\'<RQUM4M&$I<^ED0D/YO/92VS>\0<PPY2A"=3>?K=(B<RPTHFH/MU2T
MD'D4T"SE$N]H."_.5<;+]>8+]9^2\I@^A1/!(K*$02CY&"$UZVKPF2\!"N=T
MZ!5;9MQT.Z[KG>/^>;?U4TT[M.TGUT\'6LVVGEZ5U;6Z77\*5?8\I]UM"@$W
MU.H<Z,LJO'_Y6F=F%'E5'F3Z4D#PO$T0=HAG=00H>$;5P<[KI?I[3G\^*X%U
MF&M?=87)DR'W6-,76:#;]=_Q4HT_4$??N?J$48@1P6C&[DC!':W8AP,S1$4T
MY&%('K%[>^'[A&UPG HZ_3_*9#<0>\7%4AP2E>5B&JI4S*;Z4VP87N^,$A3_
M;RYA<;W!TU;%TRYZNUJ%UO8J?#9BXSMY?C9QO]3H-HZU[@2K7N'(>/D&2TN@
M:)7LFFZ\U/&)/K6]-SYU(6/D<"XWNWSC/9#59_E.BGH[YNA?4$L#!!0    (
M $^*:E-ZD#/*MP4  &<C   >    97@Q,#0M9FER<W1A9&1E;F1U;71O;&5A
M<V4N:'1MY5IM4]LX$/Y^OV*;WK6]&>*7O %)RHR3".J9D#"V&8Y/-XJM))HZ
MED=6"+E??VLY@9:$EG)<"X%A@A6M5KO/KJ1GA=MO>L-N<'E&8*IF,9R==_IN
M%TIET[RH=DVS%_3@4W#:AYIAV1!(FF1<<9'0V#3)H 2EJ5)ITS07BX6QJ!I"
M3LS ,W-5-3,6(F-&I*+243O_!C\9C8Y^:[\IEZ$GPOF,)0I"R:AB$<PSGDS@
M(F+99RB75U)=D2XEGTP55*R*#1="?N97M.A77,7L:*VG;1;MMJDG:8]$M#QJ
M1_P*>/2QQ.D!H[16L:-1K58;5^H'C9%M'S0.&M7P\+!AAW]7JVBEB?+%H$PM
M8_:Q-.-)><IR YK[E52U%CQ2TZ9M67^4M-Q1>RP2A;-)'%P\%CHV-"EVK<HT
MYI.DJ1TJ%4/7W:&(A6R^M?1/*^\IC^F,Q\OF^X#/6 8#M@!/S&CR?B_#()0S
M)OFX$,SX/ZQIVVB>;BY6]J*>F"=L;;]=R8TFUU,^X@ILRZA];?'W;=WBY@T$
M/]N/8]?S W!Z/3+HG9]", 0_< 8]Q^N!B]_X@><Z_7=O:_NM[O#TE'A=;,+I
M>3]PRP$9.(, ^L3Q"91A0 +H.0'IP3'I>.>.=PF5_;T\WRSH7 (JA0X)+@@9
M@'?BPYDW/"->X!)_#QP?M?C^T--2Y"_G!(5ZKG,R&/J!VT4)=] U;N0(V8-C
M% X^$51#3EV?8,>PJR=W K K#1OZ;@?57\*%<[D'_KD;$'#VH.OT71PZ<!WC
MG@#\FN#4M@:GS[),2*!)!/DC8S";JSF-XR70B<2F$D!QT4:@I@QB1C,&-(.Q
MB&.QR-Z]K1^TGI67VU*PI1=)Q$(A:;XA-N=)Q&0N53HZHU)QG.B#;=A_?LN=
M7Q$8A'^*8(=3FDR8C@"7D& X=+RR*88)1@PD&S,I<P&1QX9<TPE+P$U"S&<*
M/1;3!94,-VB9KA!XZ2'#U*3I%&RC"A\")F?/*G(!+I2^7BBY:;#@1930(5Q&
M193RM93@;.0ZY86#T,.3%<08G%3R&*J6WM;V=R10=0L^>#F#\,,IB^8Q>U8!
MZ^2QTN;=+*G_ML4I.HK9VHN1D(A(&9V):9JQYOJA%?$LC>FRR1-MDA[4FE$Y
M02(S$DJ)6;..]E\QW*%"&J].>8UWT7U+<0RKH#D*S5'1>N95MZ&[3!5M]M4.
MC)I]>&^W9=CW]GU3[:%1/;A_Z)=J36UR838BDZ4T^5BJENZ %[,Q!BO% (F8
M1Y"G1&O5I41ZMR>E480$M5E)KR'/@"\X4J[H+J(%F#^?Y%G?7CWYAI#=)-<*
MQT=!)(OY7A=\-XOZ*P@?EFZKU;<=L5W(Q8U]4&\?QVPDYU0NP=:'3P,9]SVG
MT7>S\;$([D2J;D?W=[NVMU^WC$854B9AA@.FF[EIZF/@5Q_X6F.3*X0M?, !
MZN"A*9#32%#(>#+-3D.11/KZ(<M934YXV#7/5'YQ4)"CXJR5;$9Y O@[GF-S
M+&18L%LV'K-0/:\2:GM]&TPYNAQ%R.[FLY5;=(Z)1G7N827%<IK'@(\A$0I;
M+)SGURBCY;KF0OZ'1=B(H?L,CB6/Z!*&H1(CA-2NZ\5GOP0HG!./Y 4REMA.
MMTO.L%K>;?Y4,_:KU2?G3PVC5JT\/2NK&_5J_2E8V?/<=K<Q!*RC]:W/UUEX
M__&U]LS*_2H]2/2E@$#()@@[%&=]X2=%RO1]SNL-]8_<_GR1 FLSU[KJ&I,G
M0^ZQHB\R0;?SO\Y2KS_0-]V9_@0_1(O G_$[5'!',_;AP'C(B#P1AO01U=L+
MKQ.VP7$BV>3_2)/=0.P5)TM^252DBVWI5+$/]9^\8'B].TJ0_WNY@*5+AD^;
M%4][Z.UJ%E:V9^&S(1L_&.=G8_=+M6[C6NN.L?J-C504+ZPT)9)6Q:_8QCL<
MM^'3Y;UU.X2.,(9SM3GD.Z]]K#Z+5U#TRS!'_P)02P,$%     @ 3XIJ4V$;
MJ*LG%0  MJ$  !X   !E>#$P-2US96-O;F1A;65N9&UE;G1L;V%N82YH=&WM
M/6M3VTBVW_=7])+=6:@2QC;FG4F5 T[6>QG#@K.9^;35EMIV3_3P2BV,\^OO
M.:=;+]L"DA L U,S#$92J_N\WW[[U[.+T_X?EQTV5I[++C^]/^^>LHWMG9W/
MNZ<[.V?],_;/_F_GK%6K-U@_Y'XDE0Q\[N[L='H;;&.LU.1X9V<ZG=:FN[4@
M'.WTKW9PJ=:.&P21J#G*V7CW%O\"/P5WWOWE[5^WM]E98,>>\!6S0\&5<%@<
M27_$/CLB^L*VM\U=I\%D%LK16+%FO=E@GX/PB[SA^KJ2RA7ODG7>[NC/;W?H
M)6\'@3-[]]:1-TPZOV[(^J ^&![L\:;3XJW#@\'A;J-5'S:X.#PX.&PY>__=
MW85=[L#]^J%(S5SQZX8G_>VQP T<'S0GZF0J'34^;M3K?]^@^]Z]'0:^@K>%
M\+#^5:^QL)(2MVJ;NW+D'].!-O2CR64[<(/P^$V=_CG!*]M#[DEW=OR/OO1$
MQ'IBRJX"C_O_L") PG8D0CG4-T;RJX ]P?;HX]3L%]9QI2^2_3>:N.G.[5@.
MI&*->FVON./[][KDF,L?L@$?(ES1":\[IQ>],];^K=,[@__ZK'_!SB_:/=:&
MO\+%3U?=_A^L_?&JT\'+WWR>!T!!^@X\<;R[/_GY:&XM!4)_+".6;'*-L+ *
M6+%-A=#ZY<UALUD_6270VJ-0""W,5@<.@D/C9(L!3(CN039+7P5,#(?"5O)&
M,!ZQ8,AZP8WP!B)D#8NDL\4&,\9]AW$O $G>[?4N_M/N?[IFY]T/'79]VNWT
M3COP"2BBV_O(/GP"2NA:[/S28IR="9=/>2B8*SV)ZF#"0^6+,!K+"2 H& DU
MAE=-I1HSJ2(6Q;8MHB@((_W** )&C:PJ8+'K^\$-5W%4!2Q:B"QXJ0LZ-N0N
MXR/4N9O21PB.F<TGW)9J9K&'@I@M/EH!F)]F)VR/*L)  -.Q8.<"E & T)41
MDG7@LVM[+)S8%:Q1:^ MH0!F"D(6X.]3&0%_$?7/]$7@O&$8>$S!'@%+^O^;
M@@,*>!5 KP]8 8 3E2*I:RGE5H,R#?XK !^4!0"ASN_MCYT>B.?36D'PVD$X
M"4*.QCW;'/[RIG5P\H5^\N21LV[[8^_BNM\]O;;H^2VV60$(OP_",)A6@@2W
M:@N&X3J9SE>=TVZ_?7Z][C9QB755^^5-8[]^LOASE90SK[FL1&-H;DV(FXTY
M&%X%>TR-.7C/(E0<5/)YP'UZX%K8<0AJF:7&)'/(O]9&V[68*&VU':#5UCA@
MFW !%57$0:]X?+9$VPQ )7FX*\=B7N#(H<3?HG@R<>D-J-="%HI(X9NTWJN
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MMHFZT'%TY&IY"/*%J<3E6$=8E:%]":)7;04%S,7R)9,5RV\0?I?@40+:T3\
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M_<%.W^\/MO>&PP'O[0[;V]O=CACT@T[OCUX/J&Q!>_>0L;-0_+H5R;@Q%DC
MP5XWL8=3&=CQ0:?=_OL6M7MS-%2QA=$T/.R^NCX6>K+BQC9X*$?Q 4UHRSV:
MW_95J/3!BS;]'>*=QI!',IP=_'("3PVT_,4SP/R&$5H.70,C_R<..AT@BWY.
M,SKA^5#&(J>[T]T!8L]NQG(@+>NTF[MU2NE#1B/&0PN,BOA(_-%N?DU&6\QH
M?_Z*HS;K>K>7W!Q&7(^ 2P-EK8H.=H":B=!6^CS,IDLS=[=S_NUUDINM&@$K
MV%C<NWL^;2_ETX5(K(@&0K/NOD=*MX*@AR86-?"C;K*/\EJP*Y#=6.@')N>S
M5I$ .E+#/O"!TMPJ+85A[V._R1Z8MOYVI\U.N-8J!"?']34[U4V/7:32"G;\
MP,1=\)B=2C%2'CLY9OUN9Z.U[E1PS5#U,JWS5LEV.;$UARCC 'SW06\W^7D.
M<?DL+L<2U%18"Z9^/-)"4##2(M'"P#?#8&J,%S<&PDZ%B-E:'7_U\L5^M]L^
M+!O1A<[A:\;C@)W=@">-ZTW=M:*9%B.N PR$.+SAH6!JR'QPJ%S&3,96A*'P
M;<I#EFB5P/49-JA0I47(+76@&%Y35HL;"+#X P@.0=\-49.,N8ZXKV!X >X:
M+AHV3#5*E$$0]K4<0%2&4?/0<<Q>(5$9X1\O_\T^*VV'T*6J31,&!J9"Y,11
M\8E0^B(V56["/Z&I=V@\F%&KA$/4 -I4S$HGW.FA$V[O>4@=AV<#>*I&1G6*
M'[*!"GG6Z )YB^$0N"<G KL#OF%' 3X)WT-N0/D@8'&;:@$"#]6T-M19\? I
M/))WW7R,RE_3ET+CD4E3<)'<J3^WR)\9X]J)44UCD APBH,+I1S&8Y1S>8Z]
M)%,#%X? ?;KDA^@JLB?\D,N(S$H+"YX.)&] FST&"<2U@,=2 SUENN(QDPYR
MO5&ZHI@3D$OB.?-0J?9!L4$:6O+0>$"#'Z;.?(#!<"%6H.X>"R3H'H\,]F_P
MN@_*C_]C,S:4(3:R8 HTR%3:,9B7$#?0&#N;0MII8+A0A+.:@4%S4R& O0+!
MA4Y)0J?5F>YDFAFP8V.$+=R"Y]B,'$;"X#[H)5D6=(E2J)E?F'<"(V>^) 45
MTC30>D-PADE6EG5L3 K&-N#8'Y@</&R*YW(R5\^G0F-A"%4OE,MKG79Y3-SX
M8.ELJ'3-3XRPS8]-<XF;+CVO5[T\!DZ#=J"<)U*E!N:7CTN42E!9O$\7X=+,
MJ3R)A BI2 D(Q09V+'5 ?FSV*+U"QFSD#,[0U5TP-XW"!QTQJ3\N)<JQ#*R)
M%;TW<(><.QH(>7>[+,XV64U">)FXB'./8CF<Y8+G(XA[QO$_5*"4:,P<*Q*#
M;B'S*5Q+*AY5:LG;L '4E$ K?H_G B2J:V?O\!OFL9SRQRC8I;QVSM=B13_$
M)(X;#'[@&E4\0:\/_  ?P-0$+4\5)E1)9,J^$G#$H#8"7+^**LSVEC&^,*,\
M6<BM*<\F5@204(*Q>X7,X;:(H?8?P Q\)S$@W4CP%"12?.R='$*"=#D&^\;V
M7YH7378*+HUK\&U_VVE[P&^7'$"X^0J.+J<'$Q@W!O092*<BE# LU>;W,)G
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M8%QR4UP[;[4*QJN$UH4CR\?0A:'S!3 71 A:T.@32J=2&6:U=8FYEBC!O5T
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MDN3S9RZCP7D"DD7!@2JAJ8G@E0DA1,U"E3J#?NLXVHT_&B]Z[?88T"UI1_!
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M5*@?ZSPYL_>_QURUO-LYF/>=Z]V:9-Z= U4_&N_>+3+O$&@]6*9ON7-B6J;
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M=+U&U" )PZ@3GA@7+0$&E)@8 S&H%20;G=<^$QWK2MY<1->V>>T5T&T.&U1
MWP>@YT,(GCK'@F#$:^T(H!#$A8QOR$B7F++I2<L$RVX6:,7SCN%YO2&$BN?[
MP/-\.$$GYJE!1:)(@@ UV1,I*V.]%"6>8!.U;&]?\*Y>V8C*"NBV 'J]X80*
MZ/L ]'QH@:5\/GN!1(#0^8"&;'L+FU'-K<T:K*7FI?Q&=QEMTW*S'2\T>!5'
M$8?^>!)2"/&O>#(X*[-EEHLGU&!I>^()%Q+.O/;LJWPKJ=V!U)J=8REQFI A
MT5RZ,C /23$^"0:>O4I-5;9>]O995\,.%CT_<!BON^FJPGAE,)X/'CCI5639
MN^!!  &?L>PT&&*EHHI3!H%.8$S9TL' "N.6P7C=G4D5QBN#<:,$ :4/ 16Q
M@<4,8PL$J=%$)H^40_+20BD%I&('FR0?.(S7W;Y38;PR&,]'"B*%+"9M"$W2
M$HA:$[0E7(# C;0<O2Q+/;NP_"ZJ]=4@K&[M7'WG=>^L(MCX.Q_$]LI!HWEM
MTU4WUP[RVL6C?OV=.Z7,<':XC^KIOD@;[M&3\<'<DHD0'!-1)J*E%00LH\0F
M;@FC2@10W&8+KBSZ[6JYM)F^$#RV*.?WH/"^_BZ?BO<E\-[8+:N1F93=<)YD
M62JC/7'902,21&0*K4BIK.6"KE1+=_=4O.\ WM??$53QO@S>Y\YWS[0UPBB"
MP@$!QR1Q5'D2:+0QFVQEVN+>OA1=X/>^2[KB?0OPOO[FH8KW)?#^<NY\#U[J
MB%;G!Y[R^2XBD+(QGOC,XBX&&XS@DV726FS'^;Z;,Z[_/1B-.FDX.+T(7UQ>
M&;6A/,3VT]S?UANW&.6[S#\M1'A?1BV]Z/O!:2QZ4#EO(<Y[WHAA:&,]*DY)
MMDD# 282L2(&(A$E.FZ55V)O7W7E%;6,?U\T.]$.ZZ;"_HZP7T'XHL)^,[!O
M;!A7":E'3YS,_X"U2#!J28+G5H!T3%BZMR^ZVJ@*^P<.^Q5$,2KL-P3[N=/>
MH@#N?2@9"T.RX<8(*F4(=TI0:H1WOD0P==>P9D2CXOYAX7X%T8R*^\W@?CZR
M094Q3J=BVPM'P(=(+'A&#"AA(0A,DY%&O M73$-I&>YW<XSPB[)M+HZ^M"MM
MN@YC%PEM!6&+;ZGJ0FBU7/(N-/6B$8S@,:+VB1'O$Q)@V49QC#EBI(LI.!\H
ME7O[2C=[%V[/4;5%NFVP7$%8H<)RE;"<#Q9P[4$&4?(B& @$I8D#%@ESEG*;
MT%%#,RRA.9:XPG)[8;G>XH6*V24Q.W>42LI3]((2C3P1 ,^)09.(T@$ (WH;
M0VD$M$L%^"IJVX;:]98@5-0NA]IY/QV3D\4(+A'Y?-*J((A109%H#'4B!&.U
MG:!VJ?#<^H:*M*^M8_?>N9M%'B_'QW'8Z4U"@-U./XXW7>&Q+8?%)N,A$Z$=
M#OJ#;T.X]72XR^GP:R,\8E!P52PYJ0P0H,$2XZ@F2:/)!AU5&OC>?IM:22M.
M6](V4G%ZCSB=CY=(CE(HGXCT(A)@1A+++1"EJ$(('FF@)=M29S?L&E)7$#.I
M2+U/I,XG'))/$8TNB]8T 5^J'S-TB09,$]$Q43HX*TYW#*<KB))4G-XC3AOU
M"]'H&$4@ 4K] DHDZ"D2CL$9-#+X9/;VK6G3B;J;=0J3Y@L7TV 89]YY9XP?
MZ]R(K:MDN$MIUM>*K"?C\;#GSL?H3N+1X!<<QOZXLMQ"+/=;T[^77"7#/#%<
MV&R-H""&E7D245O,_H0,P>[MZR[3S4'Q"T=_VU&<N0X&V%42V% [1B6!E9+
M?/  ;)16)TKHI.D<@B+&HR'<QT1Y" J<FFR0I2NH@KHU9G:!!W:2!#;4G%%)
M8+4D,&<),.ID<L82[WTF >T50:8]"4X%;S5%8*5>VW:UO4\6J!2P#12PH3Z-
M2@$KI8#YD(>31EEG2A+!*%):,@D*1@DD4)%K[;30F0)$5\CF'KB64<!NEBB\
M^!+^Z+C8CZE7:Q1:6:-PF=-2[V,,Y',<#JZFLR/\.(O9_C@5:>6QA7CL32.H
M@0IXY#&1$* ,S>.2..>1<*,-#UXH[>/>_O_\E^&,_]"B\&V%;TM*%RI\UPG?
M^7 $$TF;E)&;S4?,9HB)Q!GN"94*43*-JNR%JO#=3?BNN >DPO?>X3MW^@IT
MDGIJB:? "0@FB5$J$<89<QKR01Q\A>^NPG>5D8&*U_O Z[S7[QU $-03%YTG
MD*TD8GT"8C+]6L^5%TEFK[]5V]MVL]#A,(X[)X/1O10VW&/\\JHGMWZ.^N_[
MB3\MH)FMC-1NJ&PCJW*=I7-'BO:-@(:@+ 2*BC"D@N1S51,4VA&M3#:-0U"Z
M; %X2%4:E<X>)IUMJ "ETMDR=-8<[I&8*ZL-J.640/24.*DTR?++(@L4@*^A
MWJ1-=%8SS2TK-JF 7PKP\UM-. ?*DR#),$W \4 LRQYG"-)&J609#5QK2RKB
M-UE;4A&_#.(;026@47GF"2WG/#!DQ&'9*\Z44$X[1)234A(NEIG^V892DO:-
MY]B]=U81;/R=500;?^=NUK1=1+T[9W'8&1WC,'8[#D<]W\%^Z(3>R?DXAL[?
M#@?CV.&-HV$5*;OO?>[2\2+R&1(&Y^XD[F@T:<%;WC9;\Y<X?%U4;+51<GYM
MTO(Y#OOY88TN_NZ/1;&_6)>T6I??MR[?7[5!2EC%I"/91<C^)#)+7.) J 9K
MN35,1G9SUGK3>O!L2FM5$Y;4A"P>IBA&8KBQ!**5Q")W!,$J!T9)'OC>/GT$
MS8+UE2X=N(DD-UR04D^WAWZZ+9DTJ:?;_7+:?'J$,LH]9DY#RP0!)11QJ"WA
MR21*63[N7+S3Z;8V/:BGVVHT(7B;=4 E$ESIR30L$NO $FH=#RE2I*4GDSZZ
M(H963[=ZNCV,TVW)#&%EM7MGM3F;G7(PV<MB1$J;;?:4/+'Y9"(<(Y<RGS]8
M=GNT61.JG;,*/1 01'(QD$B=(N $9K<M $E!83 N!$_+),1'O+GDI9YN]71[
M&*?;DMGPRFGWRVGS>6\1,GLYSH@6@A+@2A$3/"<,I$LN,>XUO]/9MC8]J%;.
M:C3!92O'2Y3$4^3Y=,-\NBFC21:@,2)J*H&5TXTV!XBV_G3;S?:;WR?_D>T1
MS->![V*G?W[JXK S2-.TY*AS/HJA,Q[D>SX]RR I.T+N.W6Y^C*RJ2CG]:(\
MSV6LB98<L=<RZU2"JTWWT(4*S"[4Z\E4NPXGRO4RS?AVPKVCE^?CT3CK3G[4
ME8 7(N#F9E=0*H*3985D3)F O2 H(A#J\Q&= &,6_38J3$-3JN6V"G6)R='
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M# ,./G@9W-Z^Z$J[JF&--4]:ZT\>J&P664C 9*(2&2BK0(- ZK4Q@6.(P?K
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M7<7Q#N#8^J2DBA:BMR!IM,X$!T%+!Z "OP''=93-6D$^7WMDF3=",F($DP3
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M:;L1=.8X04E66QTQ:<UXMF1D<]!N+6%H(8!K>4F5395-E<TNR68!3RLEEHS
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M@PE@E=<Q_R]Q*4!:?SU%UK&#&^'*QL*2I+V@-!#-M">0C4>"-'"2#7T=C4<
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M8>5SFBV]P!UA.GD"2BCBA/;$E.FT,?JDA,E6/J7MZ-ZMYGU;PL\+V/<5R/<
MY'EK'[2)/-!L[4-9VJ@]$&N,(1F_.LBH)>HX<==-LXYTFQOQVVHB_3*,9]@+
M%R6B4SM_,#Z.PXX_'PYC:;N9. #5WM^M-&![1S#%C^'C%60\T]19GO!)/SR=
MZN?+HJQ/)CI:V7DA=OZM86:5_N6L+DB"B)& -)Z@=X((IV,($#@8++$8+9?>
MJ%N3_2U#^9KG'%64KPWE\S88-PZ598$8:TKS'8_$<A#$:!T2<X(9K@K*%5\Z
MXMJ^7IZV&F(3!5_&UJKQJ=:R<,OB4Q-5.QST9P9^9=4[L.J;ANWDD_*,!R0B
M<49 8*F2I)((4%Y(R#2K?&95M4S%50U1[9[1=+M"YXKB^T%Q(QO-T23%@:#)
M  8PG& I?9941P?9/S)Z=07/-4RU<";O##^5.&R-1NV6G[H%$\&O3P_\,M7)
MRKT+<:]O6E!.HC+9+W7<^NR7&B!69BJV5KN4-'4&H/BEU,AV5*W7P%-+;*B*
MU/M%ZKR5Y(QU+D@@#*0CH)@C*#D2[V4$+X,Q)8NGS=(EMS5^M("%-#R/X8K\
MW:6JO1I8>K">ZGKJGHH*_ONKOCWIAXF;^O)B@ONEURH)+T3"[QKFDA.4A60-
MB4J5PFE!,PD'1[2RR SCSD:WMR]%<Z5*[7O8;BRWH"ZJ OW^@#YO;1GG4\@"
M)UY$2\!(3:RBD4@!3*'3DGE9_"+06S2JN-TVPFZ\<\>;5 YOLRBF1@IO%UBX
M=N_KUAR@6Q!#S!I;]LK^,AS\U0LQ_/CIMU$9@?'EU'SR16WKH;G(H?F^.;E&
M)&<T0T^,YH% B4Y8%$ADR/H.TJG(2S 1NIPO4VF\$'JV*,[XL.A@<SO^*AW<
M#QW,V]!!R\0MM43%D&WH8"4QW'LB,2:KDV(,BPU-NVP5R87[I8-M7UA]NX7K
MO?Y?<;22K7^[%L!<[;VN_SMV<[?E+^=#?XREA6:0.F?#XHN,/TW"\?%_SWMG
M9>EE]45V*\FY9H]C <OB%_PTV;)Z-'CBL_8-XR\SA?SE!/OC)_WP_$(GJV6Q
MD&5QQ0 BR5"9[&,$ZQF!R) 8*101QJ',AH6RW)7HG*#-93:U:F%[ 7T/\]HK
M9N\)LPUO (UPQEIBM,>,V?R3#0%+E6?*FN ]$W9O'^0RXP3:5[K04H.IV$N#
MVOVRLXG-C7:_-$AUDJ;,S!K.BU<9:]G\'0CUX)(1Y/-WOOM#,1]48EDJ7I9:
M!.F(4<@(JJ!1<N<,TWO[2_%IK4+8[2J$ZWM?*H;O!<-?C:(IAB-/66PT$19=
M:?Y7V2@R.A+F993&4:M8W,+6EW:?\[OQSBJ"C;^SBF#C[WQHY39796AJB+OF
MU]M>;O/B0F]K?OV.QN,5TP\L4L:#(EFY)\7H@KB49"E4I2ZBI"F8211<KB *
M7JMMMIH-[F^K5 7\O0&^$4)G6C 9@'CO* &=_S$,%9%@%7?HO#)Z12'T6DVS
M?#5-ZO6Q[VLU3;LJ86HUS?5S:0?Y,L-,>^/'./2]::IH5!9Y=09GA4NJN[%C
M"?B-IHIF*O=3UKC)MKB74QU[/E.^4&V&A6R&9L=J=A$4%4$2I8TF66Z,&.4$
M0<-EH)QGN]#O[9NFR5!GRVXW5E=?*U.QNF*L-D9\, NF3#+4@04""9 8RAW1
MU <1K54RE(+YI3M.:YG,0I:0'YR>#OHS(Z@W&I61'_F.XK#S_/3L9/ IQLX$
M#YTOU36E>JP:^@\V2W__9E)1L!I/68QO_VS81M))Z4Q21&+98QJ\(48H1V0^
M,14R9"ZHO7UAES:.:AU-RQ!Z_\911>A=$#IO$664126U(Q25)<"<)BZ%0!((
M(UF49=]PZ2C>HB$<.Q<<^L8\^H##(?;KZJ('['C>J_7S^U2_+GS.RK +,>SG
MYLR&*(""%8PX9S/#"FZ(95825-& #=X%&[(-U":?L\:'6F\"59@N"=-Y0\@'
M-#2@)3J3*P&,FA@3>58=)DV(P!--V1!:>NY@#0U]UP[J]7WO#$_*6/Q2(M_)
M,/-XUAOG7YW$26^5RQ>&=\^5U2!0:_EUHWU5K^),Y48OT[\'_7='<7CZ=*IY
M_RZ*]_*KWE6^78AOGU^Q6<C"9!>CUZ (A(3$ZB (.A'S;TRP+CN> D3MKMHA
MR*[<)JJ0O3_(SIM($9P6&#-&N? $LJ%$+%= !%)@/F8J3B5[9EJR#.PAA(E^
MP4_^.);,V' PCE/XY1_?#?&T<S*X8XZL1HE:R[6;F\US0R?K);?T1^S_^2RZ
M.LQC,:YM#N!A'*D%JTD**;NC'#W!Q$OFC)JDG0!NZ<KZ5FOHJ&787>\L_ K@
M%0!XWEC22AN6F";26B2%@(F-7A*O*'K#,[1CVMOG7:.:HSEK2&FUR/OB))1L
MVKV83#6BM NTNS:3Z;+76AGW3HQ[T#"90A!4>N=)U$H2,+$4=T8@1F(0KNS
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M"0Z/[22WA6D>+L>XUP[Q.^:!%^2U4(%HYBSRV  /.&F0B2P@[2Q-01M%&/
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M(,[[9!UEZ[.L7*<V/%^8)N6*>8_?O/>=@%Z>>?"'YX\?_=C:)N69=BG;8/C
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MN2/)2522X40#ES19PXFWV!%EA O,]!Z56P2'38]*#%AC3AQBD@ X4 7@P'5
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M<(H&H'J"^EP/W\%L6I5H/ /)+3);["$+$'9B0:$$D^8D&V 9W;(6VXJT]?"
M-AVSW3] ,P,->S@];L$N-DT6Y+Q);=E^L(@%5*<M0DYAB,UT;N^LF41+#+A
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M**]OM<(Y:\4%2P..T0!TO,+ 79[R0N\LX2PK7+Z>B% #@,>,*^^K)E.\:;,
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MC"G-(6#9P(RW:LV7F<V4G3E'&B JY$W>=-&L^YQS$S4<@QM<)2_ @B><O&;
MNN2ZAV9C)9D8$'V4C2GXT_4>]*(QV9G%LGLPQ+/V;97URNFL<KRQ/7_UM^P:
MG@?&<89P?G  ?_/&B$RWO"?VVI?^&^FIM2%T.=.T.O>4,Q52<NNH(%3[R$,D
M6G +2\Z#]KQPRAPS^6R]NH\?4Q1R(U9W^B L;+?U0/LRX8O_\MO?X.B9TK]H
M"B+V>OX@">X?M8'<RX'GWX.4+!Q>_0T1YA"N> %QY45:,O@9(&T V/O75*,V
M9O_F:KQ_\^G+T8<_NQ_/__G4?O7GI\[^VT^=0U^V#_=X^^S/TZ,/1Z+SX>59
M!YZYN']S</CR].C\G_./']Y<'IW#LU^](1WZ^DM[_^2J??[R]./9)W+TH4U@
M_+'SU9%C*90DS&'$B)"(X\(A2V. :,P7GD2&L8B+FS=*%9P7%!?1)28&JTUA
MK;1,1A>9(<7BYDU>H)D-@M?36'XY7;M0-+*<X_OVM\^/-A!.0*ML($9PC>'*
M=&0+5(QZHUB4F[RYU A[Z\6D_ =PK)[.1N!;M<3_R&*;_<8R_=&OAM4?YB*_
MS=?@F\&.-;(>V/XDE?.$U8P>NU0%J9A!\#^,N"@B,B0*9'SP*N)H(N<_<<_S
M1K]K+(1A5@CKR*<)2\;Y/I"T5$$W3OG$?@J&DC7_I;;W(QB&KW[][>Y&ZI8[
M(?16+S:?_\T5F]/]G5PB"B/IFHLJ_#;^X;^^K"X@^O^M[.7GY9O^VZQ.LRF4
M=D$6#PJGO9_ZX^D&R2ZN-TF:<\K--S<?[^:/%NI=Z\^*8I<(<NW'>/>NGPEV
M_9?>=.=-@R5\5W#VF 9;W/:Q*XX2C*4#T#?<\BSZFD?.?WR%_^H*[!O>Y-KC
M$K=ZZ7IO]"%?6W[+E\5UH2&$%CGV8+B.(I[<%$RB+U;'4?@6,W '#=BX;@SZ
M5GJQ7YJ3'KA I:LU9!BJE"BI?ZE&*5D0'H0:XY:''^YRJ.BA$>=V,_N_'H:5
M=HV#'#_L5:\M<1U5?J&\56@7%$1CNM""!\D,-<%B"?Z[@-^B/GZ]JJH5L;7.
M3,UX[DV ,2EG98_3;V\.0+T\^PC7@(]^=0"^^L'A&]K>W^.=#Z_YQ_V7W8^'
M1Z1-TW-.E@Y M3]TNG ?.SI+U[X7G?VC2_#SR='9Z:?VAW^ZG;/W7S^F9^Z_
MC.UEAE(5K240:"%#+4><.H4L5^#^%P6.4= HG4X41A!R/0J.YBV(;4'L[B 6
MN,"L$$)H[WGAE8Z4"LT)#H90+DD&,4PH(UL0^XD@MMB/PEE!M,<*@;GQB!/!
MD<:<(BV$2XV/F R9<95B]HA![.&CMQ_LHHXS-Q>#OA^Y86O0OS+=X>W<TC4.
MO__\L^H;Y&S-0U&S F_'$[\%HG6 :)DBS6-L"B,,\B: -R4< )%V#E%I8V%]
M(3CSSYZ+-7L1/ARD/&TMNKNUWVK1?6K1HCD/RBD%H0>H373IQ%9$5F*(291E
M1&/CE9#/GA=J4[3HZ225QA;[W.2:MUS/4)=05*-!_BTI6%J.+>OJ)EG]6T0G
ML]4+[>GR[O7\Z_'B_C%>VRW K0-PRT0DA0*S(C1%-"J+>*0:W 1)$?8,2\:#
M#T6==.%;FK5_FQ(_:(IAJ\0/I\1+Y"+< >Q&@I@K).)%84&)A4T,(\PJI0P!
M''Y.=RC5&Z_$_[K40EV$=-&X*]=5A&SS##\HSY"78[XT<IOZ7!^%.LO]OCFL
MB6)!(24C!Q32')D8!<+<:LLLXR2J9\\97K-UW3;EL&G6?ZM0#Z-02\D'P@'N
MF$=<*P:^N75(%]$A++B.6'@%]OS9\T*L:=0WRG8_\NS#=YCSA]H(7MW*$]_4
MS?,);!;?QZP\;KS_(54Q\W9@OL!]:Q7N8!66RV1HC,H4X%<%*1//E "KX*F#
MV,\6Q$NLM:5-G^ ?T2-X+15Z'*4T6P3=(NA/*\G9(NB](^BB7ZV<9X7&&A68
M1'"N:42V*!Q*A_@*[C13GF9JSG4]ZT>'H-<Z[+?NRK[ZN-4U)VPW]>A@?08V
M._.3 [ ;V2CA@<\K7GL:^ F?2&3'DF'.F8HH:/@/YT(@Y8E%S%M*A&&"!+]X
ME)9P01@5CED<N)>%X0%C9SEW,5*M\.()QCD9#.-I7^.8X$V'@[>-'1<;.]*%
M"=K QHZW.XQ]S<W?%+_M,=+M,=)-&>SV&.GV&.GV&.E3/D9Z.[UX.1I ;#X:
MA%I!P/.I?X@05:<&J-L3I'>8U'_%X:OO).!;SO3(&*BW,<I"*"X%,:80UFFB
MJ7%&1G7[0PW7!%2O!OWJWU+V].?9T8=_X'FO66>_<P[//OL(XSEX]8(<'+HO
M1V=[XN.'MDC?MY3'.>^<?OSP7AR=.=RF'^$].I\^'G[B1X?O1>?KR[*]WX5W
M^03O]G;5@5')'9.8"%2(@J+$\HQLX02RBO&">*4Y5L^>J\=\T&H+6%O N@U@
M:<*U,-P3X1RG1AO.;*2.B\@*9ZF^_?F1+6#='V M)IY3VT)'F440]!2(\\B1
MPLPA@EE@@C%-G7CVO%CS3-9& =8C*M^\G1+^96 :S; _N)KFY?YMQ9KW#D>X
MH):Y0$5A* \%TR"C(3BGL94Z:']/M09;K+HOK%H^/ZH#4:0H%(K"<W"NI$?:
M$8T8CD5DW%)L6-XDPVL>#-G6<SZ0SF'MI"X,XY%PH[C2H9#*>A&D-3+(>]J=
MWNK<_>G<DG_@*3<082**-4;<!X% [R"T\8(*HBB&(#25]A1R6_+YPQV!U$I[
ME%IM3[?GTF9=U8_#2S,(VT.F]XYH!5.&&DFI"YI'&:WG(124TLAB<(INO8@-
M0[3EXZ61 VYYB',D<1YQ[#U2D6)4%$&*P VCUJ3CI007&W\R;:N^ZZFO3Z<1
MK>386 %! #'":,LXTQJ[0D2[S4G\# U=.CL:%.>!!$1M9"DG(5%*'R%I-8O,
M>.TT:*BF<N/U\]^7>DA\1Z?]KD]<&TO$:MM Z!K<<=$(+6D,UFDNM#<4<Z<*
M503!-.5;MV'#0&G%45)'K8S8642C%X@';9$*+B N#>&4&D*"S&X#WQXFW0B=
M,]QS3[TB3&.N)+'*.\R<\%19H0G;)A\V3N<6'0%K&*&&2X2#)8C;U'X7<XTT
MUT*1&'VH.U=B23=%YYY2\J%7#0>C6@_+7NI3>3((U;:UU?U#&2T,$85C# O-
M+;6:$VF$# 0TPGBUK?WX"6BU7/MAK=;&*)9:3&#$:;" 5E@ >!D%""6QQ?'9
M\X+<5_''-JVP*?J)12B<]P7'!>;"8\.H"\Y;3!2FUKEM6N%GZ.>B-Q&5B<1;
MA8CU!>+:.&0=_*H,YBPZ'[$B=V@&LTTK?+^N'?:'F>9UU8FC^TTN?-]QZ<<'
M33^HQ<(6M^X+MY;+'B3GFEG*$">$(VYD\C"H08I*%:QWT3F(@N0.H-B:R/5S
M3OANM?5G'^??:NO]:>M2ARPL/$LY"T9-:I/%(0K0,J*H.!:,>!J8>_9</!IM
M?<"$1JVS>N.\D;]"5?W6,LZ-SD<U7;L/%P-0IOHX:_).S'D?1OBUH4'>)CQN
M,ZV_;)K;LC==X?V9!8:?NR']D C'9];Y6MS<0N8ZD+E<D8$#*SP!CT;:U"O8
M.IT<'(F$((4V4A!*& 1F.T(O[_C^NCE1V5;)UU3R'^+M;)7\YRCY4O;%>6*M
M-BBX(B(NM$+6*(P8Q"]<*F>-U*F05*_8/]T@)?_7I5Y6MWG9:?7"]V1>YGW6
MQ]J][CN/_SW2)G7_LAQ4)VRQ>QWL/EA1^Q(+B&$]0=2!E\8-_&15L"CM<B@>
M,0[8) >-\W5+9C>T"=T6UK:PMAGNZQ;6[@_6ELXVZ4)($03RAA00=ZH4=X;4
MP#@&2UC!I;7))25XS?*B386U;_?67&K+MU&])O=O2L.U0MV?-FE7;DTX/!V$
MT#J'IYY6K=#SP;<F#9WJY1MW=<K/2LK:NC15RUQ<#/I?0!F'H7O5^E_KE/GJ
MU! /6R43KS*7.@2N>"BP)-1*09M^EW*NW^4,-(A%[;]-Q#I!@>)QHL"=.V&V
MOQZ18X-%H:PK$/B8H+E1,*159,AXC&E1J! %??8<[RXGVUL@EMVQ(*VSRC&2
MJ)B!4!/#\GJL"F6L2;U>B/-2^[S*>+S*>+O*W[?*AWL"QO*E?7AT=;#_GA[L
M'6NB*&<^(%A<C;A0$BGB+3*"&V.$L4RSM.;+B83QFN_D11\#10^ 9CV<V/E.
MH+A38]RM"-VU9>Y^FQTK1PKN"H,,3<9>AH"L!LGAW :OC2/6%DEHEE/,=P8*
M+)6BL2B\EQR0"5MP*WP43BNGL;%CH"!;H+B?57Y_=0PS'; T&DFM3=I]=0@,
M<$38@E/.J#(TN+3*R_ULIM P"-5%<*G1</=JM[4WO!$-EOHC[F1(.4E;Z2W;
M[W]J?3;=44CMDFL:'A 8G[AYS$7J!M[JI@-5&4W6D:P",^><-$P7A$OL;4$+
M!>)6%."!V()=DU%9$JA;E@(\.5$Z?,..!=AW*KU$C@N'P-"#4\&3C^&5=#2H
MPCD.T<'N,J7)G0%#B,@-4U0[SGD1A,())YRSFE/,U'5UI-MEO>VR'ET=1^%I
MP:A%,M@B56F#11 %0P6'.5:6XR#(L^=D=SGD6XT0M2M15BW7!04O8QD2X7?K
MV:HF3<]:N4<ZA":YSS1<\3GL7MO5_[K6Y-<P&6Q"_^SU!_,@] E[S@U&H:9"
MJ[E.&YJ2UE^EL66W')8SO5G'/<L?D,7@G3L-?M0-![$9VLPX#I,L/&$V WYL
MB&'!&H&<2DBKJ4>6,PZ>?:%=8;TJI%MD)]B4E,2LJ,VS[G6G2[P&:<(&*O6V
M*?ZV*?ZV*?ZV*?ZV*?Y3;XI_._JZQB36ZG%AK@9@(A;ZXV<FG_$E3=Y^LYKE
M;\1&[<.R)V[:!NWCI)=MI/V=Z9H!N'K_*C[$\Q?B")YUL']ZVOGZYLM!NN>\
M4QZ\>GG:.7R!VU]/SXZ^[EVVP8E?W)H].NR>PKCYP:L7K+/_@D,00(_H:W[T
MX06,^\W7@U>=L_;^WM?.U]-5??25L2Q@05'$Q"(NK4/64X$4IQ9KKPE)V5JV
M(_6#M])_V"W9I]1-_T?#V;\)RWY4K?06R[X;RQ;+3(R3MBB\1902B;CP$MD8
M!'*<>9NJGSG%^7B#NF=NUTWOLK_JEG_?E6L[^3'_\SB<_%:9(K)0W:96_)MO
M>J?S,2MFZ^><C]D@]W4>U5\W2_2WN4I)N2VJWP'5EP^M,:P+(PN#+-<:<4\P
M4C)B$!4L-)6:<I9ZD_'E[<$U,7TU'#RH"[K5RX=QQ;9Z>?]ZN=0\V%G&/890
M$:?VWH$SI#S\% @I(B-*V\B37GYW\^ 'U\LGES%L78P&[M14H4H;92?]OJ]J
M/H,P^%RZATD0/JXSN!OG8X0O_LLX;/R[6;U7:>'V>OY=LVQ;8%L?V%8T(%::
M*2><0BXD:DF;@(U9@9A3# ?'5" 01LKBNQV.[4'Y#5/2[W4XMDKZ8$JZZ'T4
M7EM5,(5\" )QI2C2TA@4(U:&2VX#%L^>,_*O[#'XR%,9@_Z5Z<Y5AFUCIDWQ
M,Q8RU&_'2[6%K3O UHKMMG0\0146:>$#XO CTBX6$#XQ X!FO::I-2I?]QSD
M-IFQZ8IY7\F,K6+>BV(N^A-".<>)3.7I-B)P($ Q*0'W'UM>&$V<M>!/4/K=
M_L0VFW'O_H2#C](HX$M'_JJ5UN5S.;S:9C$VSKN8#9!F*O/_:!;P75J_+:#=
M =!6<3AKP:@SR$<+ 9*S'%D7)8I.21T#+7B1-L/9YG.[;97TYV4QMDIZKTJZ
MM(<2P>501"*I%(0#W MD@\2(*F<"<P4NBB)Y'6KCE?3I9#'^F#M0W+<PAGP>
MO-J9G$BZ2*?$[]BO>!M%_8CT1K.(F67S8+J$6UB[ ZPMEVQPP@OEM$!*&HLX
MXQ[IJ F*16&#D%IRP9X]%^J[>9^W68X-T\_[RG)L]?,^]7.I'QL-LF"Q0)&;
MB#@)#BE'(@HJ-6<)5D2<BO[Q=[L=VV3'O2EA?;S>-"F/[HKC]=L(:M.\C+QF
M*R*I+8JMC6(KFN4**JDW*C4Z3^7^E@**J4(BX87S46O.B$LTD-_M96PS'!NF
MG_?E96SU\S[U<]'+X"P28EU$C*0688HD!LC"(6I%B%+&P )_]ER+S:=I?3K)
MC5MU67F(O,:W[GODG<#O^T3F_<_*X[8(/_($^M92?)^E6*Z*(=A+3ZE'5#**
MN(;(U'*1.@!B3W&!/82HX,GM"+7<3O)N$>FF-@[?XN86-Q^')[W%S1^/FXL>
MMC1":Q4C\N!/IPC8(F, -QFG@)B2*5?X1($JQ7T=PMI4W/PVX4+N\?<_<]TG
M5]$P3%H!7M/\LY93*;EU5!"J?>0A$G ZK _PHP8M<LH<<_QLJ;G@C>U$O[?7
MZ%H=%E<W\^STAZ'%=UL/W*)S/]CA?EFY;K\:#3:E'R=N_]$@P'GGTQ%]_^7H
MJ^^"EET=I>=_^'C:H6^NX%_V\?#U5>>KN^Q\;5\M]N,\HF_//AX".M#W.*$%
MC!>0Y 7[N/\:_O7=]MEK&-,>:W_],W;V/UUU+H^5ECH4A4=$D41B;!V"^95(
M0[A,G8^1^ :R042#WTN ZZ0,$;-HM+1<,6,I^$A".HBR&7':+W;P_+T_&.0F
MF-6R_,^*VX(NU.OQ[2^;'YQ23 (882M=D>G4,0B'!PWQBGGXY(<V%,W/6=7-
M=G4W3C!TLG48!N>MO_JFMZSZ/V;0-P[Q=6_:)+V5QEMW0?^C?PY#N&J%+\&-
M$H^R:0W3>W3A/5KF9!!"ZHK<^B5=._^6O[8NR^%IZW6OU_]LAJ.J]5<90^N=
M*T//!?@M]!)BMUZ"*6B]WFG]]7?KE\FUO^8T@<WB%=9LP*VE#RI2B;G@A>%*
MD,(Q+8AF3('T)!PA$NN,(^F'Y0;KZW$[N1!\]7+0/W]=52,#[W80_^KW3M(\
M)$#:E%;=/QR'VH>?V+&G/"CM!4K=[A%WJ7&.QA8)0R"05D9$ZY-Z[.(;>G6O
ML_Q!% $77MI"*:XU58'&P+2A181H78G[7?ZWX<)<)06HMHM>+_K9WI=C:HUT
M%D>DP6Z#Z2$1&?!F4) 4,^D!\[U]]IS(W>5=X$G?_7YL79Z6[C3S*I3GY\&7
M-4?+J ) &/9;@S3ULQ#UORL J;(:)E#)Z)3A9UQ359]JN&K];0;#7AA4K=>O
M6W_M_KU;MWX?5BT3(X00\!W5;NN@-R&%J)U9F7J$$C4/B1-X2D@([F=Z ?BF
M=:25%](ZSPB'^(A3%<'$%8Q$PCFCP2N7I17L-99H_,,6K!Y$;K^>D&-,N#&<
M%RAJDTY^,I!;HBWB1A;4!>.P!*='W(!5#3/(LC&\B81DI[4.(8VPFDH6&#40
M89,"$ Y[^!^S'H-C5'R#=NAUY^6\R,3R2_#H:QCTOT-:\!.3%GCVEV/N14'!
M>T46(K9TF%\B)3A#MB!,B$*00-6SY[W^LK#,@(4YAU 8T&<0SDT),/+9E-W<
MJQT0KL:7ZT5J4]W(3O_SQ(O4UWB1Z8\ORT$U;.V!^?39AX173G_^*WN6O<3@
MY4:#$C![;X6;F:^:W/OK;NL0/AEW,FL- ,=;B;VEVVVF,04IBU,Y_XQ$ '*M
M(@*RPALMZ**VRH +00W6E M8[L@M2:P^+N(@+$TI+J()6:&"RX'KZUX%054:
MR+BIT%MXB7?#U&3Y[S!(?;/-29BH'*)/3>?.3KX<:X&%4FG/-Z3.0#2FJG96
M("T+#]Y=Q+ *SYZK%80^_]F9NA0_>)7SJ8?Y):Z7=7:A_S8E_/Y_RYY_RDO\
M"1]K&R(7QB(O940<%P$9;3&*@D?M*14R9<#H"B/\GZ3!%S"/@ /H4]GS8ZJ>
M9.\R>]<4=R<Q;-7ZY>_7_S=# 42=@,5E=TH(!O> $:4[X!S"#8WT3$"FKI@#
MSW&8/<!>;P0/KI$G;I%D<\7L8+]-OP=):ELS-FFG$)_ %&<*R=JNA1AK9JE%
M>Y288T!$<W"2['M8H)_\$3)#;R\Q+\;OL14:$)K#U^S8\AAUM!PQJ],>,H0*
M*C+ )B>Q,Y%"E"L@L%T!3>#_+W1;36#E1R%[.A=U^\":P#3QD8UZW5!5\ZY3
M%Q:C2G*3XMX$<V@*<_4C:\'LCX;5T-3)M8M!V7/E17(T$]7RXA#ZO6N=H<LR
MN4XAA]D945MS3B2XAPZ57]!IZ7WH_?9DQ*!]^.++P9MCIIFTL5#(2(T1ES@1
M"W*%0!5UI()KIOVSY\-+F,DK%/NC0>.K)QXY6(QFG6%68:6ZW9Q  N4^AQ]<
M6K9RFG_(!FBW]?X"UFHPSC9-2*C*9,MFGG*SASOOBY<IZOA_HW)0YU.25,TG
M,F+(F+5./N-NF+1F&F,>L5Z&L)>#J*>;NX Q=4Z.-0U8,,H03F>S.>8"&:PB
M^%'4$N-5)(5.K(C79R\2?H!43 \>)AFQ(4ED@HXPK+&C/P60,5\[1'P-87NH
M7:WK8&54I:==8R7/P_"T[W=;+_N#5C#@:C4/N@,+_**H5PGW)HX>R'O:N8&1
MK)6LXR8J+XWD4G,FN8[&41JC8=[#O,=;DX:O" BF[G\>X.L\X"<LT? >;XYU
MP;RQ18$<)8"R0AID"QN05]1KX@H64YGO.O"4\ @TPZ1%+*P"G5!8>N,#451:
MUR3/Y#<YN[<K>+L5!%>Z4,1@Y%0ZKFF(!X<I-:423!MO([62KZ9YOP&D)O P
MGP!;67$Q]E>:'!6GNS)1&%[TJVSE?LLL5@!"4^;"_\SO(S?U*'AZB[%5OSL:
M7G_+=:2OMTC W9("\G:I.,(6)FCFOZ>#*5?;24!V$,PGE*/<WTSWTEQ5S_YG
M/J4(ON;"'"Z^_O75)C<4 6S4IOZ-L]G8HAY\\/--$:"BB=$R"<X6QS3:@&6A
M&:.8&4OPZF*9+9#="<B.+E,UC=-.>*=0U)Z PP^0IAP+"#P L%'$Z$#96J:(
M!*>UQYYY"!<<8UI+S[#@4H'HF\@;9X)LG8E[6D$GK,)1,@2S'A! #49&8X6T
MC!X7#@=I=3)%RW7@-YBBU[W6@1OVFSB-W+#9\2[ \OL[['8T-R[L=^RT?%FY
M45755.6YP([@YJ%5'1E"+)D[EYEA?ERU [Y\MW^YF?M&A]<$#$V(6K5,ZV(:
M_\*/Y^7H_"<D6E>IVV1<?]?#VN;+LM:Q5$<L,3CK/""')>!FX2Q2/ 84A3/,
M<BJU4<^>+_<D_<\X]C,GH XG.7VZ*J]5I[Q62 8LWB!D'@+[8Q*K=Y:1O;QQ
M\#;X41[<4Q891]I[QU11RKG#B$0%(N,B0883C@HAI0#S2 Q-U4.K1&9F[SGM
M/,^Z8?1QP5Z9\H'=Q+ [ ._P*Z \B+$!6$];YB#]_6PJJK'-F":58=PCF_1D
M"&/K7N4=\$:5IG52!NQ&L@>@1-V1KS..P]!-&>:4GKP8]"_"8'A5*U<JC$JY
MN92J<3"]8%B&U4TYG@:RX7,SG#.(0XAN8$BQ3/4-YDN $:2JAV&J?$A4(:V)
M?J=%.TE)I5Y^HH,'=,M4@#)SQ_C8Z-7,D=*R5XT&]77P$I]+G[ !;AZV>OUA
M&4M7AQXP^ K"L_R'_/C!13]OT83/M:%,3XRC0:^L3EL&9BA9\54F-=>8P5B(
MP"T/45-Z<BR3 K>N@AFD""%? MC52IG?Z1!,-?8 *@>S/8&[]&4M"'#KST_Z
M:38 G1Q,11[5^&EI/NMWKDJ01OBNN>=OKK2O%J=K90;B_!)6!62_N@"LC65J
M40)_R%(]2.LU@L6&V3H'M!^E7#;,PP"T 00M37,K45?GG.-EZ'X.*(=N+6NJ
MLJK%&R:W@B^OBY+3\IFROKX_^>XT'E"(G**&RR;#!EF\2GLD+G]O&7?&XE"5
M7T L)P)Q^R>NB!6KV91\FJ6IWI=IQ(.D\/T!J$W>@/1@=NK*QUY(2%'7<,$U
M,.VI]#H[GC'57*=O< 8$/()3"/?5G[NKUDGHA4%^6 3=:24L&+>A@WE.%_:"
MKR?O1H]M:2TGJ@O27*MP6L@\1^=EKSP'L]TMX68_5NKQ#8E#"(QV0KA!Z=+(
M\L"MZ>;9^V&;%->:]S^:]?MC E3M^H7>SPSZ#QCS[_60GVXP=O:)M2^/,3=&
M<I-L/$W-ZKE"!GL(QH2)5"K&:&+X6E7D,8F]-A;@>LE=G4>WQA;MI'(_ ((:
MMQ-2G%0[M9J,83T#0S+O-2[56WW3(Q2@ZF=@I),.CW4H?''AHE'/>66[2D8O
MQ8D7_2HKR?B6L?D/O1/P/ULS"FG3_DS:>0:+:Q.BI.=F<^1 +^L$:.TWC :S
MN%3V$NX$G^]-Z5FX(+MAV4PMNA]C_V(G;SK"TL'<] "DFNWHZ86N*=ZNAGWW
M*3WWW'S*%OVTM&6]&_49U"N;XAJ0%K!H>D"E68(&E>"B;.K3V #0S*C;['CW
M77JS!.5S2S4H3T[" -[\E_+7.LTW.]7-$ZIQO=',+FTV87E[<K+)/]VBG8[N
M\C3T4C5 ^H*9;P"#F =4U6!=#F!6DX_DPB_5K_6;N/ZHZULIU(&%L-ULC]*N
M7$;)7"9?I9=+J]Y*929)QF'EP+6JQGMPR_,^%H.=&?!OU3)9+_E.^FWIMK$_
MEG:3:^.6*^MG&IFN>OG\SJNFU0:0PI!FM>IW/S=7?EYQ87[H23\G"=RIZ34R
M#=H*QC^-])=5=Z6<MSL-]=RN4-KTOF.%6>FS-*L]7<7^8&=60TUV#-)4E'V_
M4XO295EEA)@6<S03E>;3)I:\T*JUMUDJ$//SI6_:3/"[J<)]=N+SB8[>C%-?
M^RLI4KE-?+';VLBWSQ4:JW ER<\4!5=Y3).WKN=IJ<QCU3V-ZVF<"]W:6ZNC
MEBPG%S"Q+H/-? 7:N*@'\#LG1_QF)$?&WE.GWYLZ4+.5:*^;\>XW29VGFR/I
M[+=Q9^^884*]X!@Y$17B!'MD%2M0,-)$%W!1"//L.5]9)%O7N"8YF4AH58<P
MNZV];G)#3DYO)X,0/"_(8(/O8]R<M5@+[HD-W10)5=.[F\!\6B()_T\.#%AN
MFV793%#!3\HI4ZX[6:54A;(Z1,^5=SD^.DF5=;-C2*6;@Q"[C;%,FM,<Q[CA
MI5/-G@U7*2=?AY3CW<#FGG%04IT&",#R2$UZD1YJ^EW]-/!>\\SRR]$PF:\F
MD&G]W1QT')O]@YET[.PY\(5SWP]XW/\=6&\_ZH:#V ;GN(Z'YP\H'2:Y><I]
M  [VCI7&DG"8QH)*A[A6&!E)$J>AD]K;$(.*B^?Z-\6F[F6MNM:IB+6$CG,'
MTZV"\:'<Q0QGLB<[J=1P;C-AY0&AQ4!BD-4X]KO=_F4%?FA2@OX(7LY7O_YV
M]^8:MRSXH+>:KOG&*[D]R;2,)3=/R3GEBRK\-O[AO^/V)F4O/R_?]-]FS9O:
MEU3LL=@[,)6XU!]/ZT!V<5T+TK0N;+ZY^7@W?[30#*;^3-%=RMBU'^-=<L?/
M!+O^2V^Z\Z;!$KZKF+S58[_1Q_&;'5B_Z](5';7J8J2';"(EO]4-)@O(M,W$
M6)7G>@4]MB;;ZE:=L_)>U"_U,4\8Y:\/T5O[6_=M=D.VV\WC[1NRK?W2/[3?
MVNW>]B=T%I_UGZ9^U6RCB[_'F^]OLS3#[![$EWG3ZRB8P:9T7KNKOU5W7CM[
M_;7S]=,EC.WKT?G1EX]G;Z[:AV]/85QG[?T7I'/VFK;/?H=Q'ETM=EYKG[79
MP>'>5>>P4WX\>WF>#HMW7KW\]/%#^[)]^![N.[I*'> ^GOT9V\L=*X/!0CKJ
M$2P=09R*U+>IT!#I*6E=B,)Y#J$=OZ_>XP_>5NVQM3.^-9[3+0O3!J'8&@>(
MUH"XU[T.C.TP!_KM'.=O\6T=?%MFCRRP2=&^0!1@#?"MX,A8R1%1K)"\8!8[
M">JUH_4F<3C]:YU2]A".Z.,BD7@"()8<L\/+_A:[UL&N9?8Y89S%3'L4I*2(
M"V>1CC@@%P3!EFECF7_VG(B=@N@-HI[XUWI@?.N!/17P2D> M_"U!GQUEFFM
M<C=I(36R0D-HJ;5$!A.#E C*<&<+53" +[Y#U?+&X<;Z7JL:=#_$E??D M8H
MH3<.3@_3.<2?[0Q>FXS8(NV:2)O++&9A]O5X)^Q]+QT=2_O<TPYD6V1=!UF7
M@UIFA3!6:42]2\><@D"JH P%4V":.G9BQY\]9VR'\>6#*_><M]LDEW%3P>ZO
M4%6_/:CS>-=GW*>587+C)OX]H%.BL/\Z/JHPQJ*Z#W/39A;>O!INZ6=O.:>_
M_(1=HOD"OIE5W6_6LSGFN-?S^=)F8?](Z]H)6WNSCKU905#KN8C<&(JD-@YQ
MXSPR14Q\M47J):Z4QJFM/ET^S+ZT\?R($A";"FIC+VJ;C=@DP+J+D[S*-U[H
M+K=%K%L@UO*VMO Z!E@F5%BI$!?@')LH2:+L);"<A= UH9BBRYG3VV/6YNWX
M;*H'G,/]F=+'G7Q>-!U;:!2@RAY9]M$>WBV[9;#S6+DF'[:TZ=%Q33ZN3,JJ
MG/76&JRSD7:X-VR7^$NV"(<PGL,7QXIA0P27B,7($CL=19I*C)1D3JA8L.@T
M.+!RAZIEDJ#O2IC\1(+)AZ&-?,H=#OFJ1H-K,VJR":/F3VB+^+A(/,6#DWC^
MT3\_+^LCW7L]_T?6A9/4%SM4&\CM.6'W_:<\V&^3SJNCRZ-#?W8 ST_WM\'Y
M_7C8[1[1-@-H_G3PZO67Q3,]G0^O>?OK>_SQ['> Z[;HP#7MLP3+_\!W_7,&
M]YT!A/.CLY>QLW_TI?/FN*"<AD)JQ)D-$/[S MGH.8I!> ,?>4_D(GUF08O"
M%$$5E!!.B4GK4ACLJ<:BP&J)VW-F';(G.+<2=Z#[_/;WSX]7<*:(Y<)BP7B,
MA74%P]%C)4(1 MX0NL_5JO)7[CRVD<>4OW&D:O9X9+?NG]9/G6-JGH*NL:E/
M4G]PU8(1NWS,_I^R&IJ=UA^I^5!_T"O-3G.*JKD]=RD(7RY2=Q^X_$\#4@'W
MP]<5.\W![UZKGSM8I//PH-BI:9)I7:2$XOA(:*B?EH]NS3>IOPF-/(_,*^DL
MT89K0'[FI0?PD0:DB&JZ$HUF/,)$<O";'PVN<EG[3,K@H.Z*T#NI%_IMZ(5+
MTTW.X1/#(W #Q;&@4FN89E10AA$/I$ J=73QB05!*Q-AZB&T7\0,E#MDU=T1
M<B?-\:K.2R&XZOVQ+,VL>R.5WQ9#TXC.C!Q6BX)XO1S>5?0B]UP900@.'GZD
MFOB@@PK.B\AC6$W3MQ6]M4QA&Q]+%PN(^3"*OH P LP?4HP*1 CUJ<C%.VN^
M*7J'<TU,ZM4>%R(U0C3#1E"%B30"HLVT^TCFLUL;/-<U([AB,]MT3&A]TDGN
MO=')J()HAJTR -FU'W,^F/2NJ)Z=:<N39:U85,P_S*!;6>-G=;.>\^GS&NJ3
MNI?M;$/=;'5FE';O8E!VTR=R\1$K.OVDL8V95FRZ9M#T,UBG69CS7!)E&57"
M<Z.TCAR4E3@+2BR5C4UJ05$VFUK MT\_SRMTNQ[O[_ CJ/8&,6S^:,-RN"<.
M$H? X='7]E>7>H91IZQU!B. 58\XN(S(!M!U6F@'X9Q5@=)GSXMB)Q\H76P;
M5G.WV7"24'XJ9&0L]TG0JA%<TG1KJDY3/YIQHY3<??,[N+J,2B%HE(!2D7,7
M#(1$(E%1@(7$2HWC(I BM$J<%MNGS,M,W4!VW"/E=6\L/$W'AJ;3[ ;U3/FI
MLG2"#]X<:QP555(@)R2X+)BDFDA)$J\7<S0(%@*$0&Q%]Y2:YB_WV0($3T=Y
M%V2)SM/#E8DF8%@.NW4[KBD.&=MT**DQ=*:]96V7LKDIS\.BY$X[W-:BNZ'M
MD!))QYVY>_($C;F%4KNHM1!;<QDTMDI2S@67.@2N>"BP)-1*06]-\C))_-9*
MYI-.F>Z+>EB;T\'Q1_M=AY_XL2'"4K""@,!>)3J$@"R6'%DNK0\<.QQ<:J:_
MW-A[PI2=5GN=98V11,52MR ,ZPFH62A0(0CK/'%>:G]K]J7MLJY<UK,77X^)
M]\J"LX."(B*5E4AD08^0L%X!8AIMG4K+N@R,XV5-NIN0+/F7W:N:J^>NM"G?
MA0)WRD1NQ>7VXO()'S-=B""40=P7#E"@H,A -(9@XB-XRUA:ZM;:Q\-2*0H1
MG?>2\R@P.-G61^&T<AH;ZV]-BK)=M&L734EI [BB -A*)>);@@SC&L4"YC@Z
M3"*F2<>7B6\WKQ?OFFG9O6D36Y2WQ5(O\::+?+FA^=K7N9%I+]2ZD_-4N5'=
M]%7&&=+SX-/.8\N7YJ37KX:EJW)OW:JYYH^KBT%JS_M[V:]RI^^PTX*@83?%
MU11T:KE)YR(]Z*0=:M,EKVE+6G>\K+O1-E<TC=F3@(1JV.]!-'Z9NMDV_<]]
M1OG11=-*KF8UR$F 0=V]#]0S=\]-P7SBQ4@MB_OP45JQ9@[*:G82&JJ"F5G)
M><.Z_5?ZOF;(>91-[\S4R:].[U0PI@%\+X@1 $0F(!BG$ZK=UD$OU*%A_?%<
MZ]J<'US^L\\CG38Z(CF_@F6BX!E>AM";3W'"9/P]Z"?ZRS"J6G^-L^QE:IJ8
MER@S <U>4G_EKSMYG1+I9M/^'>+4\U$F<9AI2]N;&0E5X["AEJRJ]./FBRD.
M&3]JS-*Y_)VS/=7R4C0&?TQG,&EQU+KH#T.FH9B*P32OEKL;Y]E?2/>F84\D
M[N99,6.*VOG0?"U.3V89840HK@+WG&E,G(Z,*.9LL):O[2:,VR0>]C/:#,+?
MM02#/[27VVX_6>LS'X:W4TI'8"I\P0+"$'>#%V$TT@IB<08+4%"*-5%Q-3WD
M7!AAW!BG3L-J)I-$"_2Y[(\J$(]&7?U88,>2=S$:I#*WB2#/R-[>9C=>7J2C
M[_=JWI!!_\ITT\N/6[G.-.)>FSD+B^@$IT82$3D-S!A+-0M42BJQ$G%UC16;
MRUN]K0=T,!G'E 7I(+X#K:B><I;JS57GS3$%I[G G"#P>SF$8(5')B9O+7CL
MB3),.).8$9;=L\Q_E(HXD_7,"]P8SZI)(0%N3XAN)J9\HCK!G?9 2D\ 7B%L
MJSMKU@*4:$:6FM<G>S<8I%[K38G (!G"\W(X5:Q$80\7PT!^*7_-NP13+J_U
MDO L$JXQ3 9+L\IHRC5X:KV%*,-I5EQ3W[<$SHW\O1H9&/DPA&JVV&3#2,1_
MN/@=7::#C$1C[0Q('G81<6$BTI(#-KO@&0Z$@7%.).(W)'9^F?H'B;7E(@[Z
M-?O!^1VV7^ZX\FN4_^_YSZFVN;';3WC#Y0@#_#"ML5>,(E(8@3@+#"E'#<+!
MT4@]*T),)/(8[X A6R[4S^8X45C4N=]<8SX%D6 &O6RE![G'^'@'ODYD\\<2
M1?XU"1(F;L%FAHZ+;L'4\1EC_57V^4=5WJA-5!W3V!$NJE+P,U.7,<;U%=[\
M)%*$^*,Q#I.YJ4FC*C<H;0K$;/]SCB$R[<MH$G3-W5$S4*5=EC&+6^[9O-JM
M@6\',Y0^R'15ZWDU'*NH/7C_1@=N"Z42,2RCPFD"/JEEJ_%E<3]NZ]?<!"R?
M6.?RV(-/PP*GR$H!A@4SAFQT!?Q*"^J#X:*0R;"L\FM [M;<;A5"4NHU.*>!
M*XNU-3Q&XCUCCCI\S7F [:JNM:H\[<EC80I')%B*%, I,!?6^("DY$[% .&;
MLL^>LY4\%&MXJRN0:Y:+KF:]3'OW,UF;MQ.SDWNW.S=(O.N9:*FQ0\E6#4+B
MAJ@?D4\WS= *3FAWG*M1M.%B;,@F)A03Z98I3])FAH@ XVUS]<T:GTPGUAU5
MJ3IH"9?K=,\>!-<G,(M7K?\38()/6YTPO.P//K7> NR; :Q".A=>#D?#D%FB
M]OY/9R=I<-_6 <>JKX"/X;+$#&:&F4(PC;R:)29+1%^]AGUL-E"O964NC#>E
M3T]+WU0"2I0S)J9)%ZVUCZ0=.)W6I>H]#IY0.EHM<6$)&(A"V/$^DA@GB 0C
M-[ &-CFTB>/PNAY@\^>7X>GN3;3/WK#VR3%1OL Z4(1UM(A+@9'Q!4&%+,#M
M)S0J[5>SM,^1LD]+2:>,#BFU.6%IN4',%SDXE]+@Z6.X.#%T9;28 $V#%XE.
M,_F'$"[[\J2L*5/FH&[1S6J-JG'"U52)F395@615J,GW6K&;2>M2Z<F$[F+L
M!M6I;5"+T'#GIF3H9Y"^#'#3K'KY]><RPZ[I9K\;75R  SA1E4V%U9G4>MZU
MO@E<S7F]]UW5[[: K/V\SY"XN^!AR>$%&3NI68;'%C%M9E13PI-:(  /W>FX
MC')\9&--F+OC"<KE]'<SEJG35*>2&A:A<7;\YL[Q3P_[/N'.R;$1'*0L", ^
MA\&C$@&95)[FI#.,08"""4ND7M_(AF_&LN^/P@V]LY_@"M/4@)%QQ9GTJ%!4
M)NM&D*+1(14\!S_#8*KXL^?%#;2W]28=0$RJ8!^7TNP'U_"ID 72^_ERG/%Y
MFS6CJ;L)"9US?)8%9+%J=9J*G8993SB^^KJ'06 4=3I*81'EP4'4' VRA&.D
MC(/@MG#8L9 :#E];J#JM8,X;KODHZR0!-Y:C:\1(++@**\\F/^GCQ^+ZX\<_
MX23QRF.7C_D8Y1^)I"SO^J?7F4+'9J9;;QEBM\Y-E91P, Z7W=Q;+D;;*7J^
M.>!=$:'D\'?AP7>(?17AQ$;'68B&FT)H&@PA7$49L:#:KA?[SJWFQ*VOS<#<
M9T\Z#/[:ONP [CLKI=,)Z!E%W%B--('_."-=03QQX"[<' 9G1R$?6\L([T>#
M<80Y3HJD>'@<#D^9I5OS2M>4W\XR(]Y:?E/!UUJI%N*MP[R@$:"*2*&(CCR1
M5'H?%?7QUH7[-XC;W%^;>M G[)9^?4/:>ZF= +<F1B13SUJ8^I":L11(AU@0
MZ55JSW5-&<ZZ 8?'C@MM"J**P*/6R@KIHP&+Q KG!+EUO=5VC>]2=G66-WEY
MX8@2/B B8)4YIAX9'BUR1%@1#'/>A&M.;\2Y8SUI]6]=V;]X-.";0).LV *X
MY!X"34EG+C-M,*AN50;/[5^<SYP:^'G)^+4]G;GF&IOIW>1S'*FJH@O+ BY)
M]B=L2EV&JEKA\E2UQY/T/\E/G8^<V>6M*X;AT[POT/IL!F487M4;,*E4.<6
M=;%:NO$REQO5&SKPZ^S&<+-=G#:5PWFOC*6K[_OO3*EJ-;(7_= S]=W]% VU
M7/FY[.:MA6J87<O/B1/]/''Z[M2;R2?]SV'0.\^G!UJF69^=5CN76H,PPI?7
M/Y<I87O5']2/AT? Q;[57'-B>DWR-;EJG\MPF6F'DZ%.9;)9N5S(J=[DR:71
MY)VF\W'YKDE[+M/"O?&=Y6 03D9=4[-GU/.9OM'F\&Y<R%@.6F8XK'=/)J'?
M^!$&9J=.,@]/RT%ZB<$P5X#-'XH'?<I]=^;KOZ9+62:]_=3K7R9">&=R1<$P
MS6R_FSC>7=>4Y_/%U^?&IR? TE?#>7>VJ0G/:<,=D*]AZ]1\#ID*_BH,X=[0
MJ^_.@S;S=T]HY=-92QC$>:H)3M(_?RJSW@ZL4G.(IOZ_+H7(NXCG:;H&5;U7
MF%ZCFG+0YR]L>*<SR,#TC=+A]$N8T.E[C0\3SUWB3)J=E-6M^CUX&J@)K'0:
MH'\L./57.6QBL(T$J9=)9_.AV23Z\/]Y5&I$;Z9G0\*<_B@U?3BIJX5="#XS
M@3?*5%:3;>#^ #Y)]4K+X-=*&OPY:^&M<B:W[$M6/%NO#]BF- DK'KQ)V$M3
M#OXQW5&8M@2K-J4G6*<<.WB=[L'^^\N/^R=71U]?7!WLOP5GK@,.VS_=H_,_
M3S^>O<?M\_=?VZ_:8M'!:]/WO'/X^Z>#?1CGX6O>>07.''W!/G[XISPZ?WG>
M.7QS]?&P?7GTM9MRR_S8IK!<N8"$*S#B3C%D XN(N50U["PM4FP^WV'+1<8T
M*P*-7'#'J&%<>*%$@;$D+L3%CF!ITEMYUL'HF33G3>W;VKW OOW-\R-EP1$=
MK.&*46X,-L%"/&@,BT(R3XK)(<.'DK=W[C3X43<<Q(GDU:<Y]GK^K^D)LF9:
M_$'O;7"C00JY?S=561TFV_&$Y5,<R^@X846!,.,>\=2L3CEL4.&HT07\RY1>
ME+=-L2K)<8@0A^1&R:W<OK.5UCYY#,.Y7!QX2A%L1"\?8BLG] B--<D)D?-&
M1%K)CT@*]3DK5'+R4C%2+32I3419Y0S@V!V:7GI:@K,+0<]5JK2&#\%^)8_U
MU]_N#ORWS(K36TW7?'?69KK&N?[<834'=1=5^&W\PW_'?%ME+S\OW_3?9LV;
M#8*4$5]LF9WV >J/I\GR75PGS)O6W<TW-Q_OYH\6.L;6GPFVJ^3U'^-=<L?/
M!+O;4V\:K-[EM-B.]:F/E=%;/?4;K>S7I/G\\9W 5_=[ON%-KB?1(+=YZWI3
M\2'?6W[+F<[O/2TM&N?0YN9@NZPKF ?6Z.&]B4M^:Q;&V[SG$YBOOU+2MQ8D
MLIVVNTP;W4[;7::-K0/%MR6+^6D<,:M?MPYQ[\:3>%L>OEL\X]ZD;SO(?^<@
MUW.$-I61J=WOA92C'GP*:8LA;T+-;G8Z4]4;G?F'5/'SV73G#I^N[T&MF*%'
M2)#T+V(RTH445DM%/";P,*S2$7QJ"B=<*(SE]\)D] <(4.+6@/^]F(K1BISZ
MQM <W3%GV= <M2\/]M^(]N$;W'[5.3LZ>WO>^=HM#UZ]81]?O1$'AR=?CPYA
MC/N?EFF.ONYQ^/N7SOZ;RR/:*3NOCMC!A]?\X[[_]''_DSC8A^_^<(0/#O^,
M[:ME6NC M$FGF601..*$6F2BHDA@;)D)UAL7TVEZL5/(9=J[&VF.[H./:(L5
MCQHK',4&4ZH(-HP;')037,;(#)6!@B7=8L4F8P5>(L@,TCH1$=;8(VZ-0H9A
MC7"AL:-!$E[0+59LL>)N6,$")U@Q$*:"<B^M*A1GOA#661(HOV4?G5A^"1Y]
M#8/^]\/$SVZP\TA@@B[ A X2:Q,9$MX0Q+DFR IA$#8::Q*]XX*EU*JBA/YW
M"Q-;F%@+)HC&TA MK;:1.X,54;Q@LJ!:.>JMV\+$AL($7X )1PNO,1=(1ZP0
M-UHC%3E%OH HQ)@B6"-^(DRL8$)=7>Q1C($@U?;VAK]1GL_&W?N!OVUIPP9M
M:S^F+?CM6+>E#1NQ!_ZX2AL6SYKC;67#OWSO=%O9L*ULV%8V/()IVU8V_/RM
M[LW?C-^.\*%&N*UFV%8S_$O2B5XI;22/S!68.QVTY,8[3(AQ0@1*<CH1$[K0
M-V:[0WE33O'%EX_[+]C1V<MN^^P%AG' &/?X$7V36D)<'1SND0[ME#!VLI13
M/'SYJ7WHR_:']U?MP[>?.OLOKMK[IV?P_5\[N?7$>W9$7U]U#O]95<T0!=.X
MT!H5.-']N;3U8")!LF!8!58P+A)I+M\16&YW'K90L194<)NZ"GKM 3$XE<Q2
M%N#M;"&=)$K:+51L,E0L%C,4E'%:1(:\%R$5,P2D<-3(*"$B)U'IL(6*+53<
ML>X)FV@<X4I%S*7"F@A'!=>B((I2=DNHV&Y2_G"46*QE,#BF A2)L" 1\4)'
MI HJD;;$1"%U@7'<UC)L8>*.'@6VWBALB*6<!QTMYT8YZC3CAG.AMS"QH3"Q
M6,M0$,^D%0)"#F+!F6 8:9UZFU#!@K3!Z]2N[N?6,ER?KQGO_\.8PLW(LKWR
MKE=NE^"G7[FBHF>I+]!-_<-_9H.7U4V*OMUTZ'"^,4O32W?:"^9\*0>:>LE9
MD]BCX%O^WZB?V%*;SR\&J0?@[HI9:J#KYQ<\30NU;MG 3#][_B@;F,D';V#V
M;MAWGT[[71\&5?(>AE?IBZ<^PZ8TBSIX-W89VNSCAX_=#K@'G<.C^AD?_CP]
M.'QQ>?"AC<'$GQ\<?KIJO_KS?*E9U%??_7C^GAZ=OR"=>KS@'KP0J3/MT5=P
M(SX<B8/#UY='YQ\CO(?HG!Q+;2QF@: @I4*<*S#YLM#("JYL00*HXU([,^*"
MT[H@!?>6@Z-G#971%8QP'CW\:;&]U.P2_.]6O0AWZ&7V[:^='V8@P45#0J'
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M*=\!0Q] 3 :903+_P0<[;%6I]UMN(K@S;G5<]Q).TI'^EGD?;I+&W'D7)"Z
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MX=-M>PA_@[%\:1\>?6WOO[\\>',L-/$L'>4NF("8DCJ%;)0%TDYZ8P0E1="
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M(:+=9*H;BHENO>ZE[ER)$W,/[*AOYFT1-#; -WC=FWH :;M$[RQ@\>_]-'Z
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M$:= P+VW SZZ#PI_^LS(YR\,K%_-P,#=<IN%>]6A["]#V7_W*0^8GW@T!1K
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MD7Z6BSQ.4T]&]Y]L\7W6N74PY*L<>>F &]=4M"V!(4^]-,KS+"1P]&CZAHH
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M50> 8)N>R<!N18.:D.:LJ@;S8F2*!C 0H-F"^CO.^*[;'WL[GVU3LZTD]=.
M->FAW[,$U+QPL[<UF*-C%S+0&]RL$(=7F8XG&E0C!^.L=*]AFZ67O6D34:)Q
ML[KF3PL(@U%Q'Z +IW[[%4"&AG28JI-KB^/01%%8!KD"FZ7CF/J^YL$7DS&"
MK6 $5TU,H&2BBF$VFY3&UC&=6)>PIA,L(D1!4-LV\,2!NTR;I2>F?]QAIEAY
M-.$7:C8M1'O!V QE^JI,:VII(K?X$"2BD9J4I\6%-H&P['ELQ.=D@L=74PKN
M/M 1_D*CNDQN&0H'KU%JO(QBZ-8V*,[5H#@=CZ6-(&O #0<:8_X::[,0#"1]
M.L-*^6F)9'>Q/K.^!A>YG;9U3*M4<[(3;P F!%8'(3B,MK5MI]G,M#5?@?E7
MF@@W4/1__;^$4N_7(;_NZS_]7]U'Z#FV/S.;W/[4U@6V/P8CN4 O=[KPC6EM
M:W\J4!6V/S0*<F$=0!+#YHUA^ZJ[F)*LZBO<]Q*.:8"R_O,%G*@M@9P8-)-&
M5^ =8N0VQC0[KGVG"?;^V;M]5+9E39O\!HCDCKO#VDZ4\7:08!UOF>UN,#!0
M[IFR*# \&\^FCFC49:4Z:R:?3FQ<DR/Z0U6^B6@S7,=*;S,K^@VX#BM-E@H*
MO;6GL M$1RLT%XQ')^9?U?4M(53S@*/?.S8&'$9^;E$KJJI5:4,7MQP(QETF
MJNF#\9X)9FA_LRC/X6WJRFG7HHEMB\,+RWBUM)V>CDO$_2G%I,B,A'X+3^SM
M[O9[VHKUM_J.]M[#O7NO06Z.)^6FHS\DK,;QB&(B9D/3_M7N-<+3N'TO\-Q,
M&:YS("42\5B(F2EQAP?KR(Z5_YJ?0*VB-*[*;V&?M%PTKV7IR2F>NX7-CO9D
M\1QL.;F6++K.7NAVJ@&_ZB.AR;%>)XH]#0NB<7P0'^E"6@ 5</J+TGBR=[QP
MK1;1#BQTO%]II=H"5<+[M("5^O.<T;<P)>W]Q_W#.U[!<NYEY3$'I8JN\VCZ
M"V7:$]MX"A3#R-]8,1/SX!*;JM752F:90,9R#<F%+=<V@0RB:50B$;B(DV[&
MMCIA-M1ZUJ*\H0ZTAHIA":FT,<(K:T.<3L8C;,B>3<?%<#@;*312,0=:(N4K
M;'?6SRF&*+P-IUE(-EGPD]$8O5<M\R[04+BQBW(FC F^(7UJ^!&G,ZR98?NC
MS?J'0S5!&6WNP7LHZ<!T+L8:6<YDTS1*D366K"E6VK9\[0_]O?MAQQWD$YQ2
MM!G>XYB6Q(:06$B@?]T&%(6MQ1ML(#Q&S'Y]PM7>DZ9Z&1 08A2H2]W@7Z5Q
M\!BJ^)TV*G6S@YIB8O;WW\CO6V\1WD^<CF!])]>;O0.XYF2,_0XZ]Z=,;[P!
M,]-$64,"&.,7_FG)=8Y(72Q6*[ZE%-;'6S6(;0A$B_Z%\70TCH+ZW"1B35;5
M/RLX 4?;<[[&=3G5H 2#V05F:R?7L Z0L.-R5FHOZ,.?.Q8$\%3-\(L"2186
M#8=NKGB_93;#F0W.42]U#!A< >>^S-'T B'#)AEPMGDGP&T/WJ#D [@K"OH1
M@B!.T:B:.D$PWPT8]H%ZJC7#B8%+!KLG)@A.IGL31SI H7WJTKQ 9= ,Q]+$
MKIV78O(UK04O^"N.$X I'< 9^H=ZE5@!@F%0AR.QL#(D2FR,,NOO8W$ 1KA+
ME!\5L;QTG.)6.6T-6MAX>X:^UXFJ)Q%5QKK7 %556.MYQ(1ABH&.7,X?9;\[
MP'L=X.^'VWVK&,K;K(<Y78#.*U[A<EWE-3@LXV&I$5&%L0#0'.YIG%ST;M7T
M6F-T'FZ7C:A:^RAM8!9V: !BTLA]<V=ME=3F!S#P@(/KA"5WW1G?\XS1MZ*>
M3VVPWN!06">L**NH&7(@.*>PLXG_3WUM[/_3Q?ZKGUD6OR_6C5]!+,Z#8VC7
MVR#WZ#[](<CDD;+MTFWE@QZT1,QCKM.^QE4L)OK=*GA@5<'E&7N@$7"H0(*X
M;FO5;<F8^=281EAOH+U _9XH26S$PEI,MPNT&N*UMEQTX$[,8*4#<].+\=3\
M#DFWR!5!O" @_I$-.1OZ=]$PL&:6-!:OB!)%T_"A)A-\Q'4S^WP05/,[BFY]
M_2D'IUEH*T5'@3 M;C"M!3>05%48U*0*;3#*HF5S>3D67" T\PG\\(;7,3 ^
M*,<6:]5A>]F'OQGPS^,/0_CS?_!E>Q<#L:G-Q3<?_J??^QW\&4QB[X[$IG[6
M6WCYSVC4-:KQ-%PQ$(K=$U414-L,^[=EFB;N<HU/JCE1$X F/KUN:YN;Q>AV
M1*E18*P9W#3K^M5C74!"\BG7<0][$VOR%*-2-]2;BN@1!C4&%V@,3TR[X!6\
MXLAB-.N281?'QDR^IF<3XP%;"J,H<VP =&NB;WIY(W7A[.^6HK<$KY&D+X'O
MS,L:RC#G\C5'WK^==7[(@@%_U>!M5D&0.5'[&XX4X29H_'$,DN%?9>\_XU+7
MRO6KO[0,_X!50_#WAQFX2HB+L3T[UQX:(D>C]M 8UT-L$VA^.(\3_J=FC=<X
M5+D"D]C2+7F\C]QJN-&ZX16"AC&?4'$8;:+&%XAPIZ/G-OZY)#CDG-(+@U%3
MFCHGPT]@\8%@LHK2X?IISK8\97BRBIU.2JS<JP$?K!L-'#HGT2LL^O(:/D.]
MK9'S;;Y=78X'EUHLWJ4P5M9]M 52NJ3:&D2=]7D?Z].84S:U,!\!\3T= BDQ
M?X+$/9XN&_70@$6SJ#<:=::"^G2_^+/NU-DU/*33FE5)7&G2Z$FB=?SO?^YN
M]2L 3*M?D+\J^$QD"/./0E;(GN:W>Q_Z3A-BQJT)I3D>#-2):G VYFJFI\Z0
M-;_?>MNWF2KA\,G_1C@^L#H0,F<\&17<^K;U2\V]OY$$=<V>3NF?G!+K0^M\
MMF4M6!DL6*-%"S&>& @?S9:X!P[J<P!OIPMQ,@W.;G(@+LUB;+TI&>=$?VZO
MGDV46>6R 1TF%5;JFZTAI_2>GU5:LK!*HMGRD1Q=ZRH *$%!:X@D7=-J>DI.
M^2"WD,U^WW@_)]Q< =]KI624SCP;)G-<J)3.9Z$I>#K&?+UK>S,NF-,!RX[<
M7*D98^X!T6,><&O9@X6UM8_K6YBA"YMG-0PP5<:<KE^[=!RZ#.":5I5F=B=;
M7R]Q7/&1<-:-VKAE.V)KX[[P(K@M5>T([H(.I<ULT/[4,'C#L1 <WMP9'<Y>
M4-BSB#.'BOD!)<V;V:>#.3Y0VD,UQCD&=?5L#KQQUL0,!H.@>KHCRXOB0G/*
M7(S>&A&P%<TWM K>"-:\R,#-N>:#DP($W?NMOK91AED5#6QY#BMK"EAGJC,!
M'F("S(?92Q<]*(U=K3M33.X$2$68N1^Z1FYI1$D+-SL_I?$K_$5$4?.8("4W
M94ZZW,OD+*?CJ<FH10%VMTRT4XIQY+]&6#N%Y5#7SJU%Z[5Q\X9]JP</Z33<
M0)>-:6-$=\U863L$N]B$0IL>M(E8:8;HUZT(]N5QYLS)!%V#T@F4YIN)\>P"
MAVY5YK0.U:E3T,(ZYXHKPE=TH=SZ]^W=T 6T\.[P::UBJCHUJ4BC:FMN6%FE
MT&LL<>S4^;^9<G&%THRDL*.H<$S8>&)"O*ZJ4B^_%=LS)L1#JNVJ9>O'V34T
M0WDF\H$SQ4Q]$(K"*LEE;HD2KC%NS4'7V?P=",URZ6(7RW+T55>GL'\U36(%
M4M5%97@4-! X22;HHFLOKQM<L(8NT?NYJLIF[%3K VLN(YDJ2UXNGUW"A6(^
MQ5M']QO%CXCB>#W&$)OSUXN10W6O H0VBF7&<W%=U&<4UGQ0J $GW[ZIL_?[
MS>@2$.7\"TZT-7R)F?;LNE*%YA=P/YNCJ ?!:7K"/+TV$^Q+VABAB1]6Z #"
M(AHIN2SEJNT!VQA4W4'37&/3W#LU+ \W"L84>-K8F87&5;KX25VUHJ4K26<?
MBI$V#MTXP*NZ0F6L4]:S##G-AM<;WKF=)^?L$2=0Z@&!E3:J<Y;W2E,NB;9@
MW35( U<$X#(EIYIF37 5I9#&V3,+U67_>)SZKUJ?C9!)S)0!6 ,<H!EG@*EW
M?I=&-#>0NKE2B!F8=":[IM H- .!J.=O^G,S7S35P@)G>CX5CDC#P6BF,/@?
M?KJ9S$^(T8!0?K!)*_#;ITL%?51S-GQCHB(NKS6Z3543M$:XC:;PT^B\^L)J
M,H5N/ZUBW(U)%E,]VF%\A1K5T$P]J;%I0#><GK'FRK(< ]M-G3K.E"V(,L,"
MC6RZKHNI<-@%6@OU\M =N9B >S0I4%':4)WME3-N0C9U5;'8N;^0MC-ZRBZ[
MTA0V4ZH=(/- G+ZF)819FRN+UV&(W;<'&A"X.BL]$ U.AA=:,R%!7%C4:)<L
M5-4MEL!;A]XFJX'P1\;/T\;1%5KTML$"NXUMTV1AZZ#KM'!U=W=\?8.>?'*"
M?093U1@XLO#X>#.L!VGM5C,*G;U8;PQO;P?>C/5I:$IR2IP^7FTNKG.,PFXL
MSG7[\L*/X22-[?D//]JD(<9ES#TV>_MW;Z&9H3?_%A';C.^YB;:9H;6/[N:&
M6'%9K#Z6^QG6R.=>U.9_+-'@Y:GM*"\-P>K!G"]HI#RPW^>]TJB<VXT9JBNI
M]A;@2^!<YO&,1HU915H,[8X&)@EQ40!5V>E$;P>(48+,OO.?M_VZY*MS7.];
M.:';0+O=NL=NF?26"?AH<P$HE8  TR.>#6@$$NZ<N-,FT'BD*I,"Z;0WU*+I
MQ2W26_J&J[:T>GCZ"DH0C%&Z)IZJ=ZZ>8%Z-^D(CU48(YLWIUO!C@;A@:G1B
M?2XTC0W8D?5A&P.YG1,%?YU>EV" \CD=OZP V=@#Z+T[IVY)[TZ_G5#5TSOP
MXI/!.,,"(#-&4K6[D-Q(Y=[NW*1EO$C?HG8/\=,9F/*V"Q.LHVI8FAG97!J;
MSLR_=M.P"TWMQN/0%B:&7$V$1[=5SXVHKMU>!$HP8[ GU[H%8#PQB=JYL=0;
M/3.76IO,TTEAMKS:GMRV5Y<:N@6/5@_85@@UK0<&-7\%)M1IW1=9?^Z&MN..
M= 44S0(*VA50+.[*D.L*!@STC$5AAQ!R-W-'8F9#56%7=$M.BX$-KI[-)D7I
MFA2=?S30K7/ Z"/33V9'[9W,,+YW<<K-4 F"%U3CY*NJ.EVKKJ:SB:E6F!2Z
MN<O2-CYDHH9Z4'R1VS) G88RK5G.+RQ[/XTGVALJ<:SVW"K[-<9^??W/>"TV
M? ENO9%*R.II+[IH P._EP4&O>S0^E;\$,>N#*;<?;NI,?BU-,&'F(#SLBW2
MQ8WZ5;037#465DLPBT+1+A7FI;!?7&\_5NF"Q)WQ@=L7N!9K_F>NFQ-CJZ:A
MV!1H%8W:Q OM@YI(,M$"?*BC9_!^X#*B@&V-ZZX6Y,I]!\6P:':3PBNA<+,^
MF#X\JP(:?1 HHAM*PS2$]/6#T.^UTVNK4"X*7]V1.+%;557'78+00>%@\Z)C
M!Z!7H7JV$JF5!^FY>E)T/R>89=.W[@S#>YO19NOK#5]PW\-_ND.X$V*#ES:_
M8E*E&+&HTN Y'#18*BYY:^),>/CVX5B4T1W8/0_,V/$2EG*IO<[Y0"M.+#6?
M:YFK2,7I&E4+),%K&QLTPU'O%QR</UO-D(BJ:2'!= T['FG'AU]WK(X?JJ#H
M C-2_Y_U"3X@NML=X(H<8( '^)_Q%:83^JX"R-HPBT[)7&'UJ8(] 6-.=UF4
M2IV;&&>M^2NE;])FBHO3^295J2Z4;DW',,!\LWN50[=)X@H#H6\P(226Z^ +
M6'0(EU!TFEO/<S-(+YJFRA7ME0"-Y/(&_<4^%&W%N/9>[1.#EPF^(S=508C=
MT##^G ?:[U7-=E=5NL1D-VQ(8BX!TBP/O!6C:ZZ(YW0VE>.K417Z;@T0;X)H
M-/WPL2% 77(PTR,/)RXT#6:T[1 UQ9/@)TQF%U6+J180^)-K#"\4(X-(8X>T
M82^0K72LVG+ZC<(&%_QV7>EV.&)MM3K3KP'P8R<PFLH+\/=M-8.M[1U/G+ZS
MP(NMX@B[!+@&G#LDQ=NAA33RJ G*ZY_/594NYKA-2,5@#DU<5,'4'X 7-+#%
M9'5@8BX28O(\C;=T^6+#-,3TC&.68CY[4-62G*OKULFA?S[)>GGQ6<U!X+OL
MBU$.ZC/'E$J=O6P*]7J7G&!1(P31K.L%1B=CYS!BK3DZ-E4-73D%FM3\[LK&
M&P=@) W*"_T0@Z>DY9-M#40ZLF)"B\NY!)FIT<"NH%N6.QDCQJ4K8)LK:S";
M5.JQSOK-;+RGVCS#(,UF[.HWIF[&.#@:0J&2OE6E;C5<Q4&A+*E5])OO7V5*
M*^QR\]K]BOA=A;X1K_-O#1Y4S9!U3]T<OW")*<IQIC'.#*_:7OI&=1(ZFIBS
M-H\UXTXMR*N23OMC:0OPW/RZX1F9,EXA"KAJ#2"WX6?E>!E++(\?NFHA!8_'
M]\=7M?==^FIJ=()\"E^A]XW^[_3ZPGCR2QY0=TPT),RFS;*TL!2:=22&V@0*
MX8&);6A"0RV,':RS@8YG/&+7S"VK&\[=3I<>(2P?2@@=)#3N>2,&.QJ/")#X
MY$2AH@?; 5AQ6F,?ZIRE!$*RP0\]K]R.N^$NIJ"+^G5HLLTG-;\=ZDC-Q'6[
MX$68#C!D8^C8$8_^PA1,8>76X'HAK*K=?75K8!6W*-,M=J:2MLJW7A:3V3S.
MC@Y8F:(;+1,JYLA-*;*KV4!K5DT-SB4>4*NTM\2"6SV'MPY_NY'OIMO/W4BJ
MH17QYG,Y@^>;]E =7#'$/E*#:CD@T6V?'>R$ QLS=2HS.YD:?XQ6A&T1N@4E
MS^RR06(2' NN33'PL"BU86M4ZA0,+D,\%P:RN-]6I;#C)E0TPBHHBY-L6=*6
MQ+I\0XTDY[YPL%XOGM.YU5S#>A187W5VRW92N7H*-%AF:+<B4VM>*DL7C=2A
M=%.7IG7B_\V*"T32&8[+2J'4U%*!HC9$DTZ855Q075'!.-]5<=Y(P]CJ<(-H
MB MP1V;*(Z?:OCYU@#"+2[/59\UR&9=LJ-K2;EE&OQ$R1+%H[=%2IUWLLPNW
M.5K3_E3;H9H'A[P\-V#18,L,9/FSK=XJ-![7TM"SC@/55O=\2&]>B7I-0]((
M(XQH:!AO):MIQ3D^VMI/<WK(,#_'TZ\+RC3GH.:QI6#<P"_JQKXE:L*%I9V2
M<N7#%B,1A):&4C-KG(['@W*^H QL,&U9UC'*!<ST>2#91ESV=@)WLZZ5"YNB
M8\*;A*47ZB<Z)DVT;FK0G(/^MSBX)OC3^.G4"F2A=-)1UQJ;D)&%/\1AW5H'
M3FN?<NEJC><C"S@W!'493W1LV_YKKH*L=H[J^J[[ )3.0QR;QVG/%MU:*]\:
MW0YW.K<U=;=.HH499^Z!\M]H9UP$W&0T9R\Z2G'4:)*1MG .Z;;0(GB** -+
M$X_&[S+DJ;.%QA*_!(IU<\YM^:0%-K66@G**0%?]F*(GF[O0Q=G%J)Q7R4;9
M@?*:SIS&0A2]Q@=Y[7;VY_.>Q-@6&PVK93XC[>390EK8)1ML.EC,(\F6>GR
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M<,8/]FC@.QOI.BVP?.#:[29=4<#+CW.1L1<N<^Q7QGO37G<%-W=Y "L91/D
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M9Q9&C5F_:ME[KYYML9P5/JB!&9OTQH3I]&EN2<RS:VP23%&_M-5QOQ<X:;P
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M1/AD1H<#!@;:&-?@5HDA/)VF64 !94K/L(F%?R?)LDR!K5=VC0]]RG>N(V
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MA3V$ZO[:]^X/YOX(#>/'.)4#9.K!V.U[Y[<*R4<XF3U;3RUCM(S1Y(B.[F"
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M/+-CHY41999=H6EO@\5 GBJJ(;$1P@<Q$A[,"=ZOK_;*Z/!WJ!433F&3</R
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M@2"4@5<6,VD^R9SK2-VH! YR%9RH:@3+_+/K@AGBB>TA<@56(ONQ:W/&(;"
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ML,VHU3F'NY6GIW/.G\9&6IWSC139ZIS]UJ"-!Z>@:X8GV/B=SI99^ 6AQ,.
MYM%4-=";+S(-293.4],77O?D'T]#*CVQ K1O-FP/92/GI"V^W_HSK]OQ" ]P
M\++5&GO5&N$7#V1$7DYB1%_R52;EW!M+39G\93W)(M/(,<'"H]$DS3*1F6H?
MXW+A_!SZ<3&?XIBROV9IN:3!CFHLL'(\[N9PW$=3^&-]](!%T?_NTOIW#(*E
M+4?:OT3I<2M#KTB]7L^+HPF<Y^I&) HC05)>ER?TI\YE 2+!S[#$*"AQ\IH?
MG[XRP_0OX:[B\.2W,,$0QWN41TH*?9@6*<UM]#:(H??\<N=_HKSP6\G32IZ'
MDSQM^<G^)4__9!;-BCF<,HB7<E&D9+V(_XI_V4GP_()X'+?+G4WFSZ>_7N+T
M^&68Z;'WK>!I!<^#")ZVXF#_@F< @B<#$Z-9\,!?6L'3"IZG)GC:///^!<\0
MEP4>E:_$2YSZB;_9UWJ?^HF,MZ?)RBL+@(Y%S*^(;VH-PZ]5T+Y+DO3:1_2"
M]]$L="ZGA.<-/\%+L,'PG>N\_^@*XDB,U;M9*X9:,?2 8JA-/>Y?#(U.XK H
M$,13A$FT7)89BZ'W])?U$+*%<'*^P9JIE^N#9;,(X9<H?11>'9HY[Y)I*U-:
MF7)?939>.R!ASS+ERU72][R3<1^1;DF*U.:V?<RB9!HMP5EZ0]C:B&_W@;&U
MW K\SJ<R#AVO[Y]XB$MRZ@T#_A<#V@7I$D61_04%8P*OUA F?C;QDS _^? E
M#E<(8X)_Z76[O5;JM%+G_J1.F[PZ *G3VTKJO-5HLZW4::7.$4N=7L?[CU;L
M[%WL]#88.P3A^M$2%/_L7"*RJ9(77G_8=9V+W+D0H?*Q0:B,NR,E5#XR^JUR
MJBZF!!F+@9M/""Z[(#=+C?I ?ZN09[3BIQ4_#Q&^\3KO?KT\KN'JS5MY1\@[
MSO_^].D],%!>$"SBZW1:4FSU1 "JY?>!^GV0ACGA%/K+9>AG"BKV'1*;S[#=
MK_W"=PA<8!).?02=Q5$%])["O\H)BQCC* $.2L">4OT,LR#UOFW "0Z&"UN&
M/3PJ1X:]?/7S4V/8W_PO:9(N5LZ;+T68('"Z<SF=APM?<W#+.2WG?#/GO+IX
M_QUPSBL_GI8QV:[.^RCY/,$*\I:/#HF/3@D@\+_W"X]9\<3N :GQ?C$SQS4/
MYV# P)M.J 6);$$BOVN0R(/5E:CV7[]Y^QVH_=?A+$JB5NL?KM8_<C9Z?_'3
M=\!&[_U)&.<M"[4L]  L]/'3F^^ A3YF80XDU'J@+2,]#",]9,O-HVWCMSD.
M"8-E..C%.K,L7=@%EW_)G7^4?@;T$R,"^3+-"@?8B<; X(P49Y9F]/E_\:<<
MGM1LJCK[7575.?=S9X+UG)AA] M,4T:)G9]H6?(06')C4&A33*8I7&%]34[A
M!,G]Q=FH,U0G$0&E),6+D_Z(#O(>]KP6U%D#0*:@SG\X?_Y_WJC[<OV_:A,/
ML9;F --O\RBW4)I05<$O JR1#B@C.$.T9N*R99DMTYPJD'*5]S]7&7T]CXDR
M]!EW7MQ$\/&\G/P!'\=* /Q@'/F3*,:6#_JF7ZB'N?"Z#%&AXMB)"N!4M8I(
M@^/"#Y.5DX6S,,-V#_@+/!0+"&:,D$TU#5RUQ'TE6)4M"ZHOLK.18"04A<B=
M(PP^[I%^FN],IM9L(J)7,DT^G\[#H(SA".CHX5JES@0DX77(HC!=1$6]".P=
M2$YGU/6>^S\^'_Z(U_0IO%*1],N3OW= -B\CAN["4U7/,.^[B> .X0)G&N-;
M+O_RS2NG7,)CLO!?99C?<@EM!%@N>]#=' '&/43!?SV+SLX&DVEOZ/7&P6P0
MSKSQ<# )0OCG.!B,IN?^_WG=_K/#C1MO(<6_X3KN06)?PGO]H@2#?N<%;MC7
M8\H+NQ@+N1"9+\JH"T8SL24PJZ)\YGCC_L"5+UY%>4$S7M&8"A#B@FI! I8O
M&=MG\!I@_AR. OZ "J5 PPL$^TQ->R5!+1\ /1&6*,CI<7Y9S-,,-A>LRX8M
M#O1N?WS<O,7XO#,Z']PE;S'L=<Y[PWN/@P\ZH[,'2(>,.][X7J/KCV8=/[1G
M]'6^)<GZYG\O_OKF5^?=KZ\Z39YK355Z0]KQWGV1HUC=8Q88/P!EO 9;^(7N
MD6:SSQ-']SZFH!X( TQ6+PX[Q+'E/D[S4XQ8%"48$2D8A0G\;SKU[Q*.NE\6
M$5V'K@Y\U@$[.0H</(67AW^H!WF@AW]L&)5&'.:":NQ?S:-PMMZ\V![DUP_R
M^2W-GS\>G[YN->(Q$-U3THA_]Q? .Q>!?Q/M7]X<LR8\J(,\_.-BG;?6.ML>
MW4XZSYP?VA%6!]]F%;B6V=DJ\O>8D>"#"?K6=9;]WTD:K.#_YL4B_N__#U!+
M P04    " !/BFI3*:TI9;H/  "OH0  $0   &5X9'@M,C R,3 Y,S N>'-D
M[5UMDZ,V$OZ^OX+SE\M5Q6NP/:^ULRG/6^)DWFX\N\FWE S"UBU(7@$SX_OU
MUQ)@C#%">,8Y[NS4IL: NEOJI]7JEH3X]-.K[QG/F >$T;.6]=%L&9C:S"%T
M<M;Z\G3=/F[]]/G#AT]_:[?_.'^\,2Z9'?F8AL8%QRC$CO%"PJGQNX.#;X;+
MF6_\SO@W\HS:[<^2Z(+-YIQ,IJ'1-;O6ZE-^:A\@$_7<<;OGNFZ[WS4/V^/C
MGM/N6>;QL7701::%?YR<'AW;1RY&!^UQ'_?:?7-LMM$),MMCZ^3HR+0.#DU\
M(IF^!J>!/<4^,J!A-#A]#<Y:TS"<G78Z+R\O'U]Z'QF?=+JF:77^N+T9R:*M
MI*Q'Z+=<Z=<Q]]+RO8YX/$8!3HOC5^<U5QR_H@FF'VWF=T1CS9.>F985G(B"
M-Z%!B*B]X.V$O!W.9SA83P./.^*QD&.V3:O=M98E.>&";%G,02=^V#)0&'(R
MCD)\S;A_B5T4>4 2T>\1\HA+L -6X&&!<Z[ TN,0\0D.[Y"/@QFR<:4>/G\P
M# $.\6>,AP8M$+HH&,N*!CR49*)9/6A6#.<-LU$H;524#]*6%:@ZV L#<=7.
M>'Q\#9Q61[\&4=">(#3;H!;+E'%-DCOU:[-DK=;)R4GG59C?^GJLM2A9OBU^
MMJUN/;%EIJDO&Z[:*=U[U"'K>O7JD-*]L0YKNUN91511RNM LQKKNZ^F$E("
MT?J#.@(#;'^<L.>.@XDTY0KS7RTN?DB#S\M$E+)0THL[R;W9C%"7Q3?@E@#L
M-$7M$;NI4RNXYC5=0_XY1=SFS*OH1YT99S/,0X*#9;<N&4PY=L]:PKFW4^_U
MIX?&'Z$F:9&"@+SIB<<=(,'>3=:2E%:@?]8*   /Q[II<L-G'-=M.) $,'!(
MH/_GVV\CKV[[@<2.O/^/YCO8K=M\("&4;-!Z0?T$SPWBG+4N&,2D+4/<^_(X
M+(LNI,"X:,HKY995X[,)P1[\,]I9\-HV)-6GSFK9%2Y1@)U[^EG^7K7KA#@I
MHB!<,0AMNKPFUY(E-U/5*15*'4R!^!QY8E0>33$. UT-KZ55J-R2*N^"GD>@
M,+S0><+'2!@9,:>=A^$!<6C2%(<$*OD63/*,U ")+JL)D/%#CO$_=@BP+Q1%
M#H%$=Z&;A<("YMZ#,Y45U.Q)VMS4T/5,L[\"W8+S$H@9;X.Y1L9]#U^B\%'(
M[&]3YCF8!U??(Q+.WP/&-5S5</8A/*\-Y[*4OQNQG#VPI1!LX&+?)D(-^8%I
M'KX+Y'O7G(?E @73:X^]U'7(ZWFH03PTS:-2$//0"9:&Y+E# -WS":+DW[(6
M>G#D*!3*A_3$LN*0G@2VQX*(8[A8)M]1/5_B$!%/T_K7$:JTWC?AGU+K</E#
MPFF77-$H\GW$YS JD DE+GAB&@YLFT4T)'3RP#QB0\JM!XHF+W7OZ%DR^\KA
ME#"6(TG&VLAX&RGS/7(KVMX&@EI(=LU^M]CC])$4_3']O>^0JQ \H;'WOJ F
M'%60]LR#WELAC<7L 5U5_R-^QC3"X_DM^A?C#V@.D7*M$?'M8M3CYV'_+7X9
M"B>BC?'<D,*-6/I^U"T%ZPYQ,>_QC+=@" 7>:O2/^G+*;7/T%_+V>)=B MI%
MDPG'$UE;YB8]9@OH5TA2V\)Q7\[A;6X+>>F")O4->]LH0TRDX3;\C[]'Y!EY
M(CM'U(&&AYS8D+6+9ULPE#IBU59STI=3A9M;C:C*CX80:"S5QH#J&%E]XN=[
M,RK#<X3MB!.QBKH%8RDR5YJ$9?;E5.+F)I$)W$G([\,IYM>$(FH3Y VIR[A?
M9\JJE%R9H<-_Q5A \C(6S(PE;GM &*V3KE4Q469H%B1IA3!= <YNIF2E*G[@
M>(:(@U]G8A6CGH^LRU3M&WM].4-? \=$C)'*V;O$/ AR^] <P@41/<S$^L9[
MP5O.68UQ'V+INAC'LF34LY"V1WH9C\VR9GUV:DP/(-*MA^EN9\:E>H>(CT?8
M 4-GH@@$>F*QV"-H3+SZ >S;Q:AA/X1HMA[LB6#9DZ5H(Y%M+ G?29,X9YRS
M%PCU-;%=*J\.7(^LXL1%1KR3&JX3F!:HU)'H<:^8)F0L=C/PS-J_V2BEH%?[
MIY.^55BXR8&QVZ-0IHKK* 3M^,#:C_P9FLM],!MBI.2EQ*MK]JU"&I?#*^9M
M),R-E/M.HG?!?)^$HOTPF%XP.4V$J?ZJMX)>.:# D%*<T\R8R:$]QVZ/R<:K
M6C7XJ7N6R*WK8+;SOO$:$?X5>1&^Q4CH2_H9/=#6DZK[5,\J3@H+/H9D9"QS
MVG40Z@1O*@;*.*[;[Q6CYA) =C&D6ZO86JY-R4'MS [ZECXV.^B[-GU-HMZ+
M$."U#JWB=.V.O^=0U&&M36MEU&IG==1;L\J\]N6#W?-4195NN,&HFH_::QWW
M+3V0=CWT*FKZC4#IX7/2MXKK\FL[T:YB<C^3*S\>TEQJ7R52#B8]TRJN"TD.
M1LS"$#QV5^6UAY$"J7(,Z0$ Z\U_6?T[.X!DRGS#Z*%@HG1-D(U8Z^.L'#;[
M<2.GXZ7+@0U*V6@<T6*G!J_7MZK]VNJ]5,0>2$0?%_L<Y8,O(*?F/CY]?FHH
M^WVKL,R]#LI,0O)8RMACB>@BZQ\$0>3+VV_"4L5/C>5!OUM8NUZ'Y=+$PI*,
M/9:)1SQ'@7CAWA>[KV3UKN*-6&]VM56,U>@>]KO%5[;*G&Y;RC*6A1F)M)W$
M^8(]$\<ZT3[.2196!_='5G&#D*1L6R>[I]F::T Y&K7='_>[A1745,\[:<NC
M:!S@[Q$TX.I9?PFG0*6V[A.KN \J8V'$/'98Z9N^TE?!1=D5^F:_N^;EO150
M=BEI^M3)'^ 97^<.^11'?"8'"4L@Q>F"?PY^N;M@GH?&+#Z/ZA;[8W'8'QI#
ME(OL\*P5\@BWY.&D9ZVRTI2(F^(\PKBT/&'Y=(8Y8<Z3/&;0B7CR'D< ,(4D
MC,35SYQ%L[-67)R$V&\9\:F$BR.73QWF(T*'\$PPR@XP+;3D$=N8/(M:G&-J
M3WW$OZD;HR!H0GMRBAY,.);/<W>3."98;J&+O&#1Q%H\ZC0Z?C:.#Z:#!WA,
M0DU5Q'=\1J$_\KF&(J"&))8[PK.CKMGMJW$M+]\$6"_Q.!Q2J+<\_/(!$6=(
M?R/4N6&(!D-(0L2!WB5P:M&^ 4:;8V=[."9GWM')#8:0_);1<.K-S^69I#0L
M;7,%575KXZ.OP[^XL2M0B1=9YLDOGT3^ ^:V&%<F6!=L%8<:2JAIUK-8BD:#
M1U/$<2&O&\#P2R>RZ/D\*_(0-V7P@KCS%0?RC4M9V[M(]-1[=T!I)#:U0ZT]
M+]F>4Z*G[0M^=[>1W*$AGF"NTW-<E]A8[?7R99K@Z40'15[Z?L_Y7!0?O)*@
M?#PN*_\.K7'"4X= _<2G-88%*,2,'IUHM.G<B_!H2K#GJ-$HEFL"(K\RL+FO
M< L"YB?,?4*EP L&:G&2 TFSJ*BTQ]5EL[F/WFI<(>9ML?,+1EXXM<%!J!$M
M*]T$7,M?!4J:4NHTJ@FWY/RT>]P-HQ-A9&(X_$(=2/C$6_,8(I\0BT,2!KZX
M+K557?*&VN@-^'2(SA>A^U#DALA+;E_C\DZJ0=G4@/]7B&8AZQX-;Q_N[X;J
M;KF^;",Z92YP#6!TPR_($[:H&>OF2;;4#U.B]PQIXQCJ$3N1'=?GK1%N@6$3
M EX()>TIMK]!P!)B62_X->'(OQ@\7HT&=J@V7&WR)MCR+:1*U4/D:JDFU'PY
M5OEGA#AX?6\.FO:9D*1RH!J4#1TTLB %>A?4G@=JW,K+-P'!=6G!I22NDTBD
M%$UH4=[OR;.I%_'((UQD$SN:KE/-H@G.\H)Q1M$SX5$P(,XC]@B&5-NYLAEE
M/K&S4X]2[W>)7<PY=I[0ZP &^# 0J_1Q:.IY["7^!EKIK.<VA#5UIJG23\$X
M"B-J8',R4P[']1DUU/]=O=I31"<01RUO\:V:-%;1-,%KK)_+CT.CW#/5H%:/
M25,3A+SW$U^/@@PVO!-3$/[,(Z(&R\YP2*$'(K&[)/ZKZ54WX-L$5_NS^)@6
M%?<LM<FO*=@$.\^6;P8S;G7-[J'N<L]J^2:T)IZ6'8G/.NK,W^8*-J'^R1%<
MZ2HA#*-RSN@B/M@E'BW32$MLNPK%0)N>X@2_DS-A;K(#8)[P:WCN@8\M[89;
ME;E%I8:I% V]@N^ :_*,Y5*$:$77M$[4)J*F:8*UB*D*J-.1NAVKI9I0\YMX
MY&-\OK D=2,4!$UH#_0/&V,GN(;X+7/TT'=(^@'ATLY71=C4J&!(*7M&813<
M$!>/;()!9'"#J?A\^G5$*U9L=*F; "XD[,[W.$*O3NT+)9O0@D<V1UXXOQ][
M)#XR.YOLNW='R%/L:=$A;4(<MKSR )[;BX0EK5N"T%J[J.#0U.0TCFI@3,[<
MI4X8M):@"7;[$''($P.<65^Z82!. 88T.WA%8X_'INR:8-\B)XK _I8CKQ%S
MPY?*>6(=RB: G<YG#YQG)!6O-_U=*-Z$ML11,S@/B*/1C(3(B_=3J;=[JHF:
MT*Z%#:5=R2E4M[3W:=$V=CN=F)G#D!=!Q)*Z2LATP'-4K#M5D34!U20#O$5B
MCY38G2!&!+DX(7Z+PZQ$P\IC!&WZALY@)B:8A#H/$+]1"."&PYN'"L]:2=<$
M=-\^/P_F"E8,E^>88I>4AU#;$-58CZ#<*GM->!"F<<5FNVU76#0UYLPF!"^Q
M+?9_'^A.(*Z6;T1G\5 0W+N_BQ=9:'C/'\ED&J:[59.[P=4KA&TD4&P=K\OF
MO2/,9->7V(@;Z.PF%HLP\8[VRX@O=NG*5W4+M;W#Y0Z@/J/&=N^2ILC-S<%[
M*$7%:5O; '4-(N^81%9\[Z;CN*8W6R5JVHZJ=+TI6VRZC8_"_4*SKT&)3T:=
MQ_96<QE+GVU#@Z(\FJN)<CI()3O\DVQ9TS1TF6UQ0-!/O&5^:>.D;J4M7"W6
M4%17%U&'-+_\ ]%:LO C%X'BH*RTT1MR:ZS/3[8E9-MXTR$[]M7I8^>:\=1O
MEZ>[F_#Z;_O]9"TOS=!_9LP1"X(CS)^)#6%[#&9Y)] D;WXL>XMXK]9J>(&@
M"='L(O*(\_! ]5[7FJ(-]6$#S\.3*:;S>"<E!$POC'][Q %&8'=B*!8BJR;;
MZC%I IK)YOO%'K&%9]':LU].UH2VI1,!]R[\A3A!6N CMD4>15R"G2>6'K];
M&H9I<VCL^%-__F1Q(D/U/H_W8=Z0#1T74/LJP\^7:8*55^[YO$"S&7;BMZ26
M7L@80U(A@F2/T#?LH-=BWH2UKJ<7)C_P/HIFD$-5KKJ7%F\"Y(.OP]'5Q=/E
M$R1_%2/2FI*-:$%A?Q=T+$ILY(W"R)EKQH25Y,V/"6$@M4[JQ(0%@B; ><>6
M@E9E0]:5_$M;($_5">PI]M'G#_\!4$L#!!0    ( $^*:E,9YAY?[Q4  *_(
M   5    97AD>"TR,#(Q,#DS,%]C86PN>&ULW5U9<UNWDGZ_OT+C^SH=8U]2
M-[GEV,DMUSBQRTXF=YY86!HV*Q2I.:2\S*^?!A=9DBF+(@&+=E5B:Z'/Z49_
MZ W=C7_\\_WIY.0M#O/Q;/K# _X=>W""TS3+X^GK'Q[\\?LOX![\\\>__>T?
M_P'P[Y]>/CMY,DOGISA=G#P>,"PPG[P;+]Z<_)EQ_M=)&6:G)W_.AK_&;P/
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ME@."B@(?70*6HT@\JA)TGU/HW6D\N*<F?%BN^N^S1^E_S\<#+AUK>G$^K^_
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M.S6_'DKY,>1+.L+KNI;ZHH)N9O/N0/73:27S]W>S493:&,40L"0'RI<((=A
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MN]7>,76W_GG](X8Y_OBW_P=02P,$%     @ 3XIJ4WL]#-XB40  .*$# !4
M  !E>&1X+3(P,C$P.3,P7V1E9BYX;6SLO6MS6SF2)OQ]?D5M[==%%^Z7CNG9
MD%WE;L^X;+]V=??N)T8"2-B<HD@W2;GL_?5O@B)E74CI4#P@*5D1%2I)E,_)
MRP,@,Y&7?__?7TY'/WS&Z6PX&?_E1_$G_N,/.$Z3/!Q_^,N/?__M!?,__N__
M^+=_^_?_P=C_>?;NU0\_3]+9*8[G/SR?(LPQ__#'</[QAW]FG/W^0YE.3G_X
MYV3Z^_ S,/8?BW_T?/+IZW3XX>/\!\FEN/[I],_)  =5(E.E%*8EMRQZE9D2
MW'MA)'"!_^O#GYU/KB 8%C4JIGGD# )P%D5PC@MC.8;%0T?#\>]_KE\BS/ '
M8FX\6_SXEQ\_SN>?_OS33W_\\<>?OL3IZ$^3Z8>?).?JI]5?_[C\\R\W_OX/
MM?AK$4+X:?'IQ9_.ANO^D!XK?OH_O[YZGS[B*;#A>#:'<?KV GI]GE_\P\O4
MF)_./Z0_G0W_/%O\^U>3!/.%>NYDX8>-?U%_8JL_8_573$B2\I^^S/*/__%O
M/_QP+CF8INEDA.^P_+#\]N_O7MZD=#B>_Y2'IS\M_^8G&(V(XL43YE\_X5]^
MG U//XUP];N/4RP;J5^Q7(DRE9S_69_VT\XT?21"INDL(J/?XK@"O$<:USU]
M=YHOGL4R%C@;S7ND^.:S>Z5W<@K#/@5\X]$]4+MX$#O%TXC3/DF]\MQ+=*Z(
MO$YA?21^@0\X_E.:G/ZT(.[O8SC+0]I1GT_&F3C'_'Y.&VS=:V>3\GX^2;]_
MG(PR[=2__.ML./]Z-_WX)7]A==?E0?$%H5N_XQ(O!)KA>%CWH5?TX_)%E?*&
M7.&7.=(_RS_^,,Q_^7%HC"XJ@$)?O-:" T^0P:+FOL2BW&#KMU7V5@R.)NG*
MRT=UVYU<X&0$$4>+WP[.9NP#P*?!Q<-)(OB2OIT-(I0LI>=,@J/C#*-BT00Z
MIW+BX(./O,!-E,U6J"TPBPN<+5_Q4U7?3SB:SU:_62B4<;'<NO_G9EK.E7=_
M[EZ.$QWQ,_P9S___<GQ3@.\FH]&+R?0/F.:!\VALR<2KMIYIE23SWB3F-;>%
M(\\0UBRP'EC?DM"K<OD&ZY/I2D++_>*>&TJU@GK%R7RR/\6<@X/X^_&'R90>
M]Y<?^:XX>CXY/9V<D_C^(TQQ]N9L7NVA:F(.5,@J8@"6.2#39.,QT$8PJ722
M2>AL1&H"FMNHVC]"FJITTD@?-[$B=L7*3:X'RD-Q@0,M#5H?VF7)(F;/3'"H
MZ!L+UC7:4=<?AX\5%SO*_B8:9"]H>#F;G6'^^6Q*\'R+T^$DGZ/V-?ZQ^&@V
MD,8E 5HQ+CGMI87<0A^<81*#XS: 51C:(>1.^KX#U/2KHYM(4HV0] \8G>$W
M(I4/T6O(1*2T3 NE60 16)'%F,Q+5ESL$TA7R?LN<;2#AF["2/<"HW?XZ6R:
M/I(\\LDXO\/Y<+H.^X-4;+)*$/O1!MH\P; 0I6=!"#1U7\W VZ&I(Y7? :A:
MZ.LFMLQ^L+58#P,+QA1O+#/<1:8S?2%?.!.]1GCO2HI:'Q!:"R*?D'4?;=T$
MEMT56"?YO\]F\T4,Y+?)2<X++<#H+0SSR_%S^#2<P^B?,)W">'Z^_PY2X!9\
MHM-9*A*,%H*%I!/+F("3EYII*32!U]:D/FZ0M=7<3:BYI@;[XL,WGRH/LU^^
MX#0-:=T,K$N8P3D6./F:VGA-HD%:(2"M"3);$^W^C?>UM#YNL#76W4VT^99&
M_7J"@W$A8M%,9D%>B'."_-GH6*%%XJVK(0ZU=P/_"6L]:^XFU$+3C>V7TT^C
MR5<\I_SMTB)X.X+Q;""XY1"Y8MEPSK0GVNG4IV4BA$E")44?[W]WVTSP=PF[
M7K6X)BBZ<P3]MN6RD>Q!\0[ >\%*=H;IB"0D$*Y&=H6U@ 5\WOMFMY'<[Q)Y
M/6IP#>YVCL9WL3\7BZ?FE.3GD]-/.)XM4E7>(8EO-ISC>YQ^'B8\9_<=ILF'
M<[6>>T8A"^EB(&_;&&+0)"#/"&B)"<&5YD;IZ _F:.S"V>-&\U'A8@WP[WWQ
M4#,F;C\EEN[6-\OD-<X'5F3$3 O3A4"RE$&R&(-CPA:=$S@1XC6S\F9JQOU>
M_3AQM@<UK$'-O2\9;B-W@>>UU'J+-B7:W(%'Q;3-R )RR4Q,47@+T22Y"V@V
MOOG[PTP_2E@#F9TO%(@&$L[D%%]-9K-!B=Q*I8 I")&<G"A92*ZPC(&\;.N$
M<6W"NE?(>)SXV%WB:_2_<]#_UER,X&7) *0P).:(S<*BT)PI'L'ED(*);2Z0
MNN?&])+A48(!3SX4,XE##5I&!B@4 Q- H 5EE6SGJ-R2X;%#1N!O$$=(G.7L
MH2 S4EFFD[/D.!)G.7,E0*<432O.+M/1XXJ^E.C=/,]M!V&N2TWZX3QM]\]I
M-*'=_R\_SJ=G^.V7D_$<O\Q_&2U>^)<?9_BA?M,;'L[A54WAR;C:S2=?AK.!
M1:\X)L.R*(+I@(9!XE5"@G:B+)+"-LEOMY+5(UIN2<&_!3WW4/<FY.PL]@8Y
M;M=H^GEQ1G8B:G"M**!73*PEJT];8%-IPRU(V%U]DU:RWQLPC$L^Q6C(, 5-
MOG"HP4=MF/)%$]U9F]@F_W&/@+A2.W)X/&PC\@8XN&1^_;JPG <V!H,@PSEC
M6F3'?!&9R1PM5X!6I3:AW!ND[-\YZ$%%FQ.@[R'?!AGR&T)H2^*,CIB%6#BE
MQ"H:)//8)88B%O(!A."YS:7EK60]!B#T)_<&N\ [G!-_F'^!Z9C\KMF2*JTA
M*D&^+P\U8J%,9AX 6>!2Y1BE$[G-5K">GL< @QXDO3'Y_=]_NB88<HU^OU^!
MX/NSTU.8?IV4]\,/XV$9)AC/3U*:G(WG-=(U&0W3$&?O\#..SS!^_17^>S)]
M"U_)M_VY,CB:W:=B</>7[EQ"V#/?UVH*L5BC>(:<1-(F%\\5:I>+#EF@\S#8
M_?6[[0,_#V?PX<,4/RPN4-Z4Y9N^N=B!>U4CW&3_U"N28C6+Q2$33CKT25G@
M;7:$NRC;W0X:)UKAT_.;H^'L][?D3-(O"!YBH&7B'CDP\)E6IR?^HT/!D@BH
M8E$UZ-_()-I,U?YWPU[1<=-0ZDD!#6RF#8R?QPZ<4SJ'Q)E3-M73 %GT*=!.
M3A]8C&"A36#E-JKV%85K"HG>Q'[H"-UL.A\L]NKG9[/YY)2VZX4SZ66"&#BQ
MX&UAVEI@4<1(1E](BG.$+#MMIO3X2ZBAGZXC9OW[#Q5[ZT^MD][$VZ--7:EY
M#:?XIERA:6D[=B%JF]!;)]UO)&>_(;<^]#1I)>2](2"E5*(MM 7&FC8?=&$Q
M.\\@ GG^*7/=K77!,6I^0VQM;XK?1K8]*GR1#_ K9K+7I[CTZ+)0R:.-S,MZ
MVZOJ;2]FPY+QTI4"QDI[ET.TYKG[L_IZE/2D'S'U:-E=(>4D?X:%H;ERQKVP
MW*G(2OVBBXLL:J>9D]%H[9PO %NI[MH+'HT.=Q%<W\OO64WG_SC$45X1@R:)
MPB7SM11<"T@,4"-#)0M'5$$DTTF+UY_\X-6WDZAZ;+VP(.;OX]I#Z6\(H_G'
M2_L".NUBCH4A'06T+T!AH+-F7F6%"+IXT2UC;?WS'[P.>Q!;CZT/%B3])XQG
M,QR_?_GKVS>O7RX)\D%H%8IA$+1D.KK"/"HRZJ/6(+AP.79;A>N>_N"UN+/(
M&O0=N!&(>?;U&8[3QU.8_GY^!THGLY:JL&P%,LT-F6T^(W-9Z2B3-YC;5%'>
M1=FC<6B;J*)!SYR;]*VH6R4[=*"O::+)710>)N>D7[W>"9H>E-(D\^ ..C5W
M$CDW+%2G4"<R*>/"*BE9D;EB>!)M.N0<!C1WY*4<%C/;Z*)%JS8875Q[O<;Y
M\J",*G!T2'LT>19,6Y]9Y+8PE4$Y*X2S:)H 9"TY^[^/Z5=KU],:=Q9YW^[Z
M.TPX_%P/U0L^5T$$5ZP/9.9*RS/97X9L)V'($K,*!7W@I/6=C,R-KW@DRNU1
MCGLY$;[^1O]TL;O%NJ$9A\Q+2Z0IJ1@D[UDRT0:BM "VJ=Z\A:COP=Z\EP(:
M--6[05HE;+D2NI"V7ROS&W%'8V#>3Y%W 61'+>QC$[E$HN:"/'&E6+&UU#?[
MFH0IH'99"!),<<*TR6[<.T"V-R:;XV,;X;? Q3)D<X/$Y=G'N5?&*N+3Q5K0
M6RO^(GJ&PCJI@Z*#L$WJ^QV$'8'E<5\E7@='CQK8:%ON/0?R=2WUG0\_8_/$
MQQMOVE.VX^T<7DMQ! Y.%:.35Z)V4/ &? [.:51.Z"([ICC>>.>NI<]_7'K'
M=#*F;]/YJ(8WT^<?8?P!7XXO_\5PG(:DN%<7>4P2?4Q.+/K $O!1:!8B.L8A
M2I6SRK;1T;$SZ4TS(P%%P*0$RZE>WX*+S*O"&4>=,<GL;/H>,B/WBZ^M4B>W
MT5"#U,EW.)M/AZF.28'9QT$40FKG(PM)TA[/E6;> QTB!HFR8K-LY,9=I>-[
M0\@.6NC[GOX_)R3!?Q#?9U/\_\Y@.L?IZ"L)Y'12%? ":YN>MU.<I>EPT9=O
M$+/T(=G(K*]->I0VY- N4.RE3-XE=WW*S:8;Q"W?_+V I+U:^LX9N)/8@7-6
MN5S;YN5,U&5CS[N%%IG(OX$0O.P)-$\HN;?@>T] N(NZY_#I$^:3TRJ9;V?D
M29Q\QF<P0WHH#A(9KR+DQ"($1[@F!R28D!DGW\0$IY+-=]KSO5'S!*Z6ZNLQ
M>>(& [_A]'0X7EAD9)[-AO3X95.Z5?!]P(LKM6\Q0]1T"M.1S(+GR!+7D><D
M2\G=;BVV>^]WBZF>5=)@+,,RD/^")$@4DD&?YO\<SC^N B>_?$FCL]H7Z60V
M0_HO_P9?!L*F'-$2UKFKV4(UWJ]H_P6;N<(,.<16-;I;$_N]0&]?^FPRP.$S
M3N?#&5'URY?:2A,'7@K!34ITI#N@+;5.+4E9L&@C%U"$RCHV0=A-6KXW .VH
MC093%YY/9O.+&\>!#$&#Y(I)94KM&D?GKBB*60R*CEVR]42K6]E+9'QOJ+B_
M#EH,1JA-^YY=[[U[4OM??EA(Y-G7;W_R%K[67YW4SHHO8#A=-,NDW>_L=-6#
M_Q/6*,7/P\]T/(_S.YCCP#H5E0V1\6)JR[YB6% J,T>,Q2"LM:91;_'6K'UO
MP#TNK+08W7!?!A=?_H&S^44?64$[?9:1;%,F4M%,2RRU)PRP)$U).EH/K>8Y
M],C%$\3WA( 6LR!>GU51OREO/BU<I?&']^=U\+-!\"H$E,A )47K+!GZ3H1J
ME/"DK"MT]K2Y#MM$TO<&M'YTT^<DA_.NV/?%_Q7HKY@[&8_/8/1R/)O#:+3D
M+CH>N8G,J)HE8()AD>P=9DP&A,IZ+)VB)JTI_5X >7QJ[W-*PZZR/4_*A!0B
M;=J!!$DBU2J0/Y\T?0$%1L;@,+4YRG<B>U]-9 Z\D>Y-LX=N0].YE"05)='0
MZBJ26-%)T>$1!3)K1= Z1&$:69['6N&W1XQL6P*XC:X.4<75A;ZG$L =];IM
M.==]E'((\#CD7D7)&:9$[KS3F84279W29(Q7P(O?UT;T$$H FV)F&UWLK02P
MZ&B\X9&Y7#F.*3*/QC 7,6>BCG[3*$;R0$H M]):IQ+ ;43>(*'PMM*%(M$Y
M41RY!C+7&8:.S$!)B\!ED4$$#M@HA__XBL2.RF2YEX;VT;#@4FE#%]*>JLCN
MI<@MJH3NHX4]5Y%%Y%RK&)D%(9GV=0,TT3!;> U#8!1R3WT)CKB*K!4^MA%^
M US01IK/TGQ3"1/F!%;0&0NQQB%D(/XE$4O\"@U99W4]>; G:-Q.UQ'8)?=5
MX:29_!O8)N_//GT:#3=7N,640W)6LQ1)A3KJQ()WGDGMH60-T94VG9/N(.SQ
MX*-/#?3<$78)W3?3Y3CBQ389K O6.L6<K)W#C XLU*G;,AK.O?3*I4[W:)V:
MP:ZCX/LQ3WO108\IZY?HF9V,\Y*BV7(1="&J]S[1&\G9?Y_HW35U4^T]B;G-
MOK"&N%0\CZ4@DR+11HA0KW1I>45)\ _%N-RMT=XQZOZ63M%[4OTVTNV[".[D
M'R_?__+\MY]_P]DJK&)1."<SG4?2)Z9=+<>C X_YI$&AU&#=M2S;#??:-Y^]
MWS:9/4E\TI^X6EAZ'X>?/M7,[7'^&XPS_=F'57B,1Z^16T(F>3_:8V+ LV<<
M'2^A%*5<JVS%#20]9/7W*^\&#N$S& $9+N\_(LY?U;^N@ETXP"585=O!^I0Y
MT[:0[\L39T4;05P'DD&;<<R;*/I^++U>==.@P^XZNE;AKPZ4-0U";J;M,#'(
M?G38 1@[*&!/V\J*0CK=4N% FJL;7A"17%@,S&:;N1$136P31-@W-.Z(/NX=
M&5O(O0$BWLP_XK06BLU7,R-1I )%ECH^MO9BRI8%(I(E#CE: &%-F[O/&Z3L
M/W[4EYXF?0JY1SNS6E+OZM&X0+0+Q7N%M<VJ!Z9ED<QK!2P%C#8%XW6W.:R=
M',&+UWX_!L/]I=UC$? %$4OD=2&C]PC0)0+V'_.YIPJN*W$'^?4<VKE,CC?*
MZE" Y5S+](*U#&IJOO8Q&^L2 O2\AENJ\9;P3;]:W$9L/6OO5Y+4Z=GIRL]T
M.4I?;S!+;:\>DF<QR,RXD=R 346J'H<U7G[U?OWW>PM_TH?D>CY"?X4OEP@Q
MRC@I"V?1E]J\7"D6:GM3XZ)5SN8@4Z?TH([S-K\\:!7>6W(]K\+G]9C'Z2>8
MSK_6"3R+G46$6"SGFF553*6';#QTF;87PEC04A"YO6ER'07?EVVTLPYZ;%2Q
M #A^.INFCS##DP]37+!_G<2E,]"%R/Z-J*[D[=_$VEV3DWVIH6];K#.QY#=B
M#AF8\:7&#R#0>14CXSE8\-&A$9UZFCX$K-QBQQT(*MM(O_?>E.O&L147)5>Q
M,)/JIAFD9!"XJYELA?9,HI)W&^1Z^ EVC;1PYT2[;438X+)N46AZD9G(';V1
MS!]&- 6FB\=:*P@,D_8B)\UE:),D?H6,[\> V%T+#=H8W5FO/+NU3\."C7%^
M.X+QI473A:>FES<MN#K,M<\.8-FV(<>^--VB)JH%;XXKIT!P9A<C'BQ8YD$(
MYE72)B6L0[^^<_3><3-UY.#=1L$-0/NM%_G[^23]7@<9S]Z]__LJ:IM3R,D;
MABHJIDWF9"H0F2$H9Z*!8%5I@KY;R=K_!=?A-;^QA?RN:FM@X55VWY1+TCDO
MAQ5*H<^!B3J;66M4+ A>QV(+PV42D!L-IUA+SO=G\>VNE0;]"B\O(5HAKR=C
M^/:;W^B[&:1%?[DELKN0V]2HVY+@P]AK/:CZNKNP!STU.-VV)1NU=EZ8Q*1.
MMKK&4!UM^K&8.M<SZ*S;)'$<!:SN,*0.CZIMU-,H&G71 ?\B9K.BC6=9,M?,
MA<I]D(IYS(6A5+) O6Q36P6F-KUH_\9/4RVMB5;U(N(F6>8K ^^ODTE>B@)/
M/XTF7Q%7V=67Y$$FX;+^;;%05 Q&<3!T6#L22Y:<!5EJ"S69E"Z"9\T;>W+W
MH?O[,Y3VJ.>F36^[4;^B?15J[D#]GJ)F]Z'_,/;6/A&S(UA[4'?3T-F]N$#P
M7.>$#!,G?Q>38-&XS!P:;3,H3,V#9,<#UCNLN(>+U6VTW+?U]]L?DU_AOR?3
M%4D7?H[/,IB:2*4#,"VRK8))++B<(RCGDNHVV6S#"PX9ZFJOI$G/$MYH].U]
M#O'/PQE\(//UPR)0.%F-AV@^E?B.]^YI1O$VW%^?6*Q<E*7PXGC1O.H\1)X<
M6 A@?-$=)Q;?0<%NI]75AU_,_GAUT0!7%)UBJ:4.I@YM)[*9+T6RP&VHKI%"
MUV8\\5V4'6(D%@;!E4^:9:VJUQ9E'72*S/L(G*SQ))1I=(?P $9B]8JE/B9>
M;:.N!D[V!GF<>W52DHDA-; 0:MOQ5#))A4X8J00= S)D@VV*[6ZC:E]]N9LB
MI3>Q'[JK]GFV--D1*Y#/%F8K I$J() !4<ALE0)8Y%XP,%&;"$D6V6EJ6L=D
M\^OO/U00I3^U3GH3;\^9I/5"]4VY0M.%*7HW4;UG&V\D9__9Q;OJ:=)*R'M#
M@$07M /'LM>"B"-MQ6 #XY&KP#6@5YU"KL>H^5MRA?>B^&UDV[<W_C>$T?QC
M(D?UY7AV-OWF+-HBDA=DLI";6)W%>D/ ::O4TM;R)A3\>C/0#>[XIC?L-T.X
M)^E/^A9=CW;?@JB_3C[C=%R/?;&D)HM ;T3%HI.):4O'4J#CBG&9D\HE9P'=
M^B_=>/2#U^!NPNI[*3X?#2]=T$DR/[&0">$,;34N(P.)FB$7RJ%-RFK926N7
MG_K@%79O$35HN;UHJ;!B;$E2D(Z3:T",\43P05\8&826H3$NR)*<T&T2L]80
M\Y"5W9>,>^QJN;D(1/@0DD7!7+*U_1<:YE6]LP]9TV[OM0[=!K<=OHZFP9+=
M660;^U3M/1+]'M/9E-Z$L^;!YYNOVE.\^0X>KX682^#)96ZEI45'*O5*U0;'
MRH><,EC7,<1\\Z4[-KD?P6SVIBSR>;\%=4HP2$XZ9[%XS;1VM'%P)1AZSNNT
M#X&E3=;(6G)VSL<C">;AZ&P^_(S?Y'<>A\1\'J<\_70V7X8K?H'IF"0^>XO3
MQ;74R6G5P<"H3"L7).V>4&IZ<V"AN,2,M<JYQ:U!&YGT0OX!VGOOC*P;B7M[
MUV.+?*[T$?/9")>2>?9U(:?SV%CP$8@,SU2"S'0Q9%(;,JYS<M%'3;YT;#-1
M]Q:B]A5H[A\N?4GZT,'EGN#_[.OZ!RPB-3D83EP'YDT@F\4(3@Z"4W6@D^&>
M%"!+&VN\(5.'"G_WAKM^M[_>]-\B8WXM99>JEKK0U[8"XPX*#U0B>RR0Z 35
M'?5Y"-P9-.BB\\R5.NA.HF71J<#((RO*.BY MQGF<QB\W574^E#AMHT:&\#L
MGXO2A54P3J"%%%0-ETK+M"/#QM?4!Q<D<%L P+3)&[U"Q@$J.GK5TJ0O$;>P
M\>NY_^93%>=%99I4.I?,HI61:6Z1^<(+DX%LV!)T5(WZ]-X@Y9'I?3=1[[VT
M':.GU^=:^>]EO>7*#(0+]*/4":-6/+69"'!DI>U-,=&?"AK<A?RR2FJNI"U)
MTLED5T/TP:G"=(R:03$$6<>M@VA1B4YY0ENC8@TQCPP+NXI[X[5(CR'UQ=7-
MB^$8QFD(HY?C,IF>+DRHM],)^9WSKS#.^*^SX:<:1=@AGGZO]^P<3-^=NVN1
M=*EMX"D7P3EJ\IO!Y9QRLE$A>(]I<*\W[CP3=/'DVFQC?C+.OZP>_RV418##
M(K-D2EFR280',G6-8TJ[PK%$5+Y-1O+=M/4P$77]&_XZG<QF PO>).L-@Z!H
M_?KLF<_$N7:@1,X\0:,![;?3M?^=KF>4K!F,VI<:6G3@2^GL]&P$="S_C)^F
M2&MS,;$!:>=:B'V<3TXGT_GP_UU9JS>8&80<#<DA,X58.PF2NQAS;6<<0968
MT'M(;7SRGCAX=, [B&H;V.X;"7N-\X&VUAD1 W-.$T4) ]F-AGQ*DSF9D\5J
M:!,BOXVJ1P>EWE30P'3_%MC?2.5YE#]%ZY,CG\)P#4R#L,PGJ U/15(Y>'2V
M30.SKA3NZU*O,5B:*.18KOLVLO3LZT5?03!T:,?@&%G#-<':  /N'!-*6."@
MK&@T:+(#<8>_?NL3%%VWJ7LJ9Y^'625PZ5EW(;'IM5H'(@]SL]:[@KL":$?M
M' A(2D3E2S8L^J#K[4UD46!FCCO%79T8DMO<DQT,0'=<E1T#?K912@/<O#B;
MDJ#/IK4)Z8OAE_K=JNQ#1B_!HF<FF=I:GDOFG14L*XYDZELC&W5XW4S3$5G2
M]U7AI(G\^RZ[>05Q,JU_\/6"X55<-J,6(40&X#VM!TU48:S]9'/)0:+/I5MV
M^,97/!XE]RC*WHMS%CD .+V@J8X!GY3Y'S!=3:0J)=F40#/N;*BA*,%"=)9)
MC"BE52F);@UL[G[7(U-YS\)MX"6_0ICAQ\DHOSS]-)U\/F^>MR0M"I&" ,N<
MKLX>!,F"K$- K/%>*N2*M[GHNH6HQP.0OC708TG019;O9#PCYWG1P^EE#01^
MH$/IXE0*(4OI(RFQ=LE//+$HZ_P9S55V05HIVU@%MU'U^.#1FP[V46ZT\2[O
M=4WXJ5?&+2Y$;SR\W2WH[7Q<N_J,4$.@6BI(BM8NDJYR@@(EZJ@=Q\U7GS=>
MT_R^DQ"8I2N:!2 XZ8@$T4"&IJUU4 %<<+K-C*7V]YU=+CD&(M.:R2FRY"R9
M8+Y62B>?&)>ICOM(65G?A/\NU!W1KG8_Q-QH)=2W2AK<@-YU/VN)Q53'JJ)'
M8C\E!DK7X7K2D-E&]KM]NB;O 2H]JJ%%4]JNX6NTW$I?VR?)VI=<QUI*DA-S
M0$@N0217VJ02/L!+IEW@TD0A#^F227MMR+@,3"AOF!9:,!]JAS>EA+)))>?:
M.&V/X9)I*U#<XY)I&^4<Z&Z@"XE/ETR]*/@>EP3WT<ZA;BLC+^!B-=^ UE*.
MU>D%P73@5A5CO31[SJ!\ )=,K?&SC5+ZCC37#K+SV=_)09X^AT_#.8P6H:]5
M]QLC),_UDL-;41MYTR:L9&'@JXF7!+?Q6G+$AB#SK:\Y(O/XOEJ9-!'I/MJB
M/YM,IY,_:HUA'^&@6YZV<_RG*Z77 C[D@A0T18GDG58:O4V<EF]62@O0@@]N
M>>ZN,8XX?[D(%%XUI1VJ*(T'%G.P3//:L0]X9-YXKD7425V_I.LMK+&6H!X.
MGH289[5Z]>5L=@;C1%;=J\GXPV\X/:TO'7@?=>0B,&?K=(&4:0NEU<6L5A82
M C>-XM)WTW: UN$]X&+-.=.G#AJ$;M[AI_/QJK-K=&7-LW V,R$#$MO)L C)
ML4R6OK3.^M (&YLH>AR(Z$7>#<S4J[R^))]\BK/Y.YCC^WE-?W]++B1]0'O_
M@"O4/I&_%S$4IE%9%K+R+,LH;9:!A-(F):H[C8\#*XUTTN/5^,*RNDKF.6F7
MB7T+0_KYOX;C/*#-$)4&S9R/F6RV3&1JS(PG%8.*%F/LUE"X^SL?-A1:"KC!
M+?AFQ/Y2"J9JQ%T"+908G8V%N6P)M#)"[9%,)Z$I (%CS*Y-O=-69#YL +77
MS,;+\KY@5(_(0?)!ZZAX1;)DVF)A,3E1*Z>=,83QU*C4\B8MCQ$06\OXIM9-
MOUI_@:N^ALGX6'QPC/O:\T35OA=D';.<5?1@BLUJ']O$!4&/4?_WD_9-$-@>
M+8EOQ]JK"8QGU7_"/##"))FT9=D%.N$4UW3"^< \$1>$(X)3MU;V'5[VL#7=
M1*0W5>[Z5/ETY1[1=Z?#L]-+9Y)R(:'5-;5;FEK;3<:N1L^$XM9'KZV6=P;"
MMGOEXU-_3^*]"0*_'Q"<C,=G,'J'^3S);P#1!Z)9L\3)YM5"%!9J\:STI6:]
M& CV7IM!9PJ^)XCL(OR;B+GW9.XU1#^??,8QU/^??AH-:Y#M5]+#Z=GIW\?3
MBY9)SV'V\1F,ZJ>#[(S5O 1F2U9,E]HR)Q']7M#A9V*2M!CN@9MMZ7ATZ&FJ
MB#51K]T*=M;3_GHR_D;^94?IY3A-ZY71SWC^_T$*TA3G%1,N1Z:]M[4AFV0%
MN,L<0^#:[("BSH0\6ABU4<4:'/4</EV68:=L5<VR$Z9>4*ID&#CG6&T*8&P=
M7]*HQ>H:8O8V5;.]I[JU;(\E)>TJ'XL<!O*LC M:L.0C;7_"1 ;U&H@<+H[%
MD]\MQ!X@<M"9FKMJ]U:T;"WEYE<KE]K_=:&K:?[8)LH.DS2VJ^9N!<*.8M\G
M+"Q';:P@TFPA]'//F4>>F=#"9N !N-K'IG#@EMS[0L,VTNX[S:M&7247;M7
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M_39\D9 5&$2G8U8(N5&1]&::'@4(>A)YBQU@.,8WY?D4\W#^ M)P-)Q_/1\
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M!S'96+H=]_O6\(;<V?TK>!L)]I[>4,HPU6O4;\.D5S.D47$)Q)_!2!X("L'
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M(U2L)/KZ:=73H_C7'\KTX7$ENI_=%R(Y_=A54>P]5:&,%4HW5"C_<*ZQGZZ
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M7-2#(FC8L)B;X%EZT6Y2@VE-F#8;PK-TSU$:A>=!,:.UWZ_Y2CYFE59/]?+
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MP#NG$6&R XB&(U4WI&%I^ZJ"WE=U!MFPQ^K_>>3,MF[=]Y%9>ZQ.M99_>S2
M PXU_H-D92FR6TE_7L._*T0-OO7S"43DR($]@0'#/D1>XDFMB"AT8\9=S(F(
MJ'[(XX7&YC8"MW#!!B_8 #;8-;[$L,9.OT7>1AYU>B@;DOW[$G<&F^<6.9QH
M'WS(ZV>V=ZW)2>\V]*5G3+>CK&G-WN:P[CW?B=_8AW555B13]8B6GN=@CGP"
MB<N%JNTC(/$)@;%P?1%SA[N./VO7L1UCYC8R[$#K<<"9N5?7[LLR4\>N@:_
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MHA6'YP#5["O-&;'U'AA[$ML3N]B@GC1X\0Q14T0O'C8]A_#%,W1HQB^>NWO
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M@0#_C"*GIH9-(])Y_KBY0TX-.TD8<N:26\.+[H58[\QJ]O#H%R$F3!/!,J&
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M_#_O2853MT0]JW!#X#<B2C6?O;&.B&O%WJRDFJDBHREA'+!"F?$J11F@$)=
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MQ4EY<+7UU\E_X$K*Q60(S@_P4ZW->FM3$LF=V#ZLOZKU3R. 5:P[1EF>4J(
MUHH!I"D"!-FY?$8Y5WF&-7(2ITL-3$V#&HQ5H8\&IE?^@8M$]JM-"'IB.YGX
M,^,L'M?,[],(<V]''\S?7FK#Q8>/(@'73&N_]*O7!?'&^+%:F'LWM2O>I]56
M-5N>FX?U%SL5ZA0+306GO"BEH3.G !42 I8S9/ZJ2,XRE5*$;O#5<$<R-8GH
M>B0\[+:;K?DBYLOO[3G!X#JNOATTR,LC#NUC^X T5ORWUEG:&K(_J-F8#R2I
MC1FIQNM 9F/ZDGB@>4U/$W_2KOBA#'C@X(2N3VJ]??YLWM3M_;+R;GZRT[).
M<"K,E<(9*8 ]YC&3)TP!SU,),L2(^76.=>YU!.[0YM3$LH5L%A\6=#5[V,.^
MNR4JV*4#W"0R,*V1Q;!*Z?IQ_E/)Y)OY_=SJ6Y4S(T*<L <SH?.\7FUW[$2O
MKD2<R?3J?.LP*;))JMGFAVGHYUPJ^=OSWS<VAJ(Y0%I^OQ?;^<\J!=*;U7([
M7^[,[QX,IGHO;'\6BIFD4B,!)%090&:%!PA#')14,LHR#K50/FH5!M;4!*TJ
M(Z\7JW\UV99U:T["]O;\FY^2!>H_-[$;OU<BZZ$Q**DZI37)GGW\Q5J5S)=_
M3?:&)0?+[I*#;<G!N"@'XV'Y#JJR@:"-*L1AZ7RIU8&?/M3_V18W63^MZL=6
M+@%O;%V"]?.;E50S66J%A2(@8QP!5"*[)4<EX)*I0@LH"K>%N6-[4Q/@QC?X
M"/-=4J&V"[\&>6*A^[I/]_/>KZ\1V(PLG"&('.!][43/#0[9_<\?V4?;R=A3
MMVVWVV[=$;129R:D]C]V4OJ3+2KO2+MC<MAEHH76,)4(8)92@-(T!1SE$&"D
M(8<D%;KTJG7LU_S4Q*>[$U5-.NQZMOJA8\+0#4"G_O#=]0O-\HA;?1<)'FE;
MSX>Z2'MY3A!>:0//AY[+NW9>3QDZH?KZR!:+WW:;^5)M-C.J9<I+J4"FN 1(
MZ S07'"@:5I*)HS:2<^8LJ/G3TVSFG&^PIBT('VG1L<,NDZ%!O,RSM3'D9(!
MDYRSAM\PJ3E^WLB3F+/&G$Y:SE\V='==:;5>*UEMZG]FZX=U-0V2E1-$F^E[
M5@A4\!P5()-980N8IX"F&0;:_)I1007VV[)R:W9J'[C!F?RLO'U">/PZ4N^Z
MM1Z:T.A>#@W@^J#Q+K'DFM50C;IQJC*X:^_:D#OM/D0%WFQW:GKD_78?.DZW
MW+WN]I,H]4O^FMW_^Z<W]COCS1KM=U4%71>9*'*B.9"YH1KEB@$JN9E>()[C
ME&BH2J>4OSUM3$U\#,KD"*:;VO2QV"\M@;B)K",GM"1_U!@=3SG[^)$K4270
MJGX7FZ>CQJ;P&CE+JP,!M8[:"RMQ3&F>5M+8=^LH.NB O14]ETN'5T_8-(E*
M/ZEM\_;!PAB24@E(3@5 "FG LY*"7&6B-#,PA;67N_K95J:F<FT:W=_44OQX
M9&O/"/SS3#INY=S*3V2E.Z'FNM(-*H1PD8/@M0].6QJ]W,%%8\]5.+A\\;#O
M_D5!R<:7AF0H)U29%1;3%" &.>"E3D%!,V4F-I1D?K'J9UN9VG?_LO#I0%^E
M\XRZ??\W\Q1[+\6;(N_/OY>"H)__^99&_?Q[C7WY^?=?/.SS_Z(VRMQD=V7?
M&F%9K"IOI4Z@G3W[MN?<WU9F*:57Z\?WJW65RW73<;W#3&N8F;5/D=NZ2FE&
M <,I ZQ,,\XQYKGR\GT,@FIJ\M(:59UR=,SJQO+6SBK6,INHIK&MR@]46W>3
M$V68OG83LM%[,/K$9[S.\Y;,H&0'E=@PR$:5Y*!DOI3PL \?>D+V[E=5&JM*
M--+D^5=F:0?S3(&4:AOZ5R# BUP!:!9^NBPDEM@I W9?(U,3Y.9@Z-VOY(#T
M6G9]=T9=C\UNXVF<LS,OB@:<H%WFX(9CM#,/'?DL[;)9IP=J/=<.F]E]6(JU
M8AOU5M7__;"\%V*]4_+CG/'YHJZ2NY25N#1NC<OOG7^;E=)\^F8N![1B""",
M&>"$F34@%Y1BB@M2>.5OOA70U.2C05_-"%95T8ZV8.[B -IOAG9SG[E-SL;L
MB<@"U9J2_*4UYJ\VMTW;-QW053_5Q57V-G7_/=QT+!2]06=B-X,:=1(6BL*7
M\Z]@SQU80;1./?E1'67KWY?)UCC%*&,:J#++ 3(K9T R@H%,F:89U(HRZ%5$
MM+>YJ>EI@S99J.-J(V;=U KKTVKM?NKH2+J;9(:C,K(@MBQ62#LU0F+4+W<C
M)6QQT?XFQZTOZF3^28E1M[MN3$3[<;Y4'\R/FYDBLBRL3W=><&XK$Z> RYR!
MG.4TSRAF5))!:6?W34Q-2 XI4?^P&),*Y-"$L@<B'4_P;J(GLCAX,C,\,>R)
M\7'2P!Z:>9VDKR=F7DSQ>GKER/4_F[QXG1PF??GPOJP6"[U:VQMGNB@IRLL<
M<&USPV00 6:T!"B20DYQKCEV\J!^/1,F)U"W%X[<)_7LL'$]2>S@]-KCOW6.
M:COI=RFVFD_X-1JO"NG-/3F-8J3#S9A6@MAHW12L-.GM2 ;X$#>S_B^K9[;8
M/G]FZ^W2##0?/GS\W/B'H2+5RE;+,Z,L!D@5#'!:EN:O6DF:(B$Y=O8FOM;:
MU ;$=M': $Y:Q,F'#\G'SQY.M%=I[A]6@I,WTF+_/&]#O)"O$NCACQR2R)$\
MDP>^B'YNRJZ\]#HL7WW(>*[+KO8<.3$[WS1 ;-\JOCV4GGZS^JF6S/[W\6DQ
MMT6YFL*H?U^:5V=K1-Y(OPU)_8TM[+_.2II!B6 *2DPR@(SP IX5*<"8TJPD
M7%#NY/P8 ,O4A/J;6C\FBQ5;)J*QY"YYK"U(=AT3$F&CN'EMA(?\W-AS#NH^
M7G]$UGYK2'*PQ#H?U;8D!V/NDL:<I&M/'6+_V]B=XS%RC-=)(XTKL3O+;P *
M0V_O\'1C$^,-7F&X.!K: CW2/ZG[%_74E *__[Y6C3_9;FD&AB<SOCY_,B]H
MX\0I"D9EB;19:.2Y^4.8(2Y%#&2YSEDJ-#3_ZIKIW;G5J0UF792)A>GI5^M'
M>?_8%(W(V"L0?PZ]$L5[<W)S]GCW%D=+*>]-0C?/O/_-PTXFK.J]G6_$8F5K
M5G@FJCQ_\X3>\VH /R",L@7:3T+0;<H+38VZE=AO[LOMOBM7#W6%OI?2O":;
MZISN85WE@K1S54YXP3@L@%WN 40H!:RD): D3Q%4'/&4^KE#GV]H:D-BX^_;
M@.TD"&P!^SI&7^"W7Q5"LA99%X83-L!-NI^-&URE+SQX9'?I?O-.7::O7']C
M*;</RZ?==O/11FG 9N^3H+R >8D!I4(!)$0*F,@9X)Q(E:JBH)G727A/6U,3
MA@K;__U_947Z/^' &FUG"'6;' 2B*;(2'.JPW24UT+ND@IK "$'R#IS$J;5V
MIKW7J:YVV?"+]=1Z;@E<%^2W9QNN5=4"*Q@J89YSPVC)@"W^""C.2V#F%ZH4
M*5*9\ JC<&AS:N+A5!?$H^Z:#_UN$A.8U,A2TU,5)%"-M@&\C%,3I-/N-&J"
MG!+A7!/DS*T##KO^73'Y7SNSE#<?<NM+0 42UD7/:(]9O:0L!SP5!*@R+2A%
MG)5NJY<+SY^:O'01>AQGG"'.X?SH-CHB"T,7W)#3_S.4>)S:W$;-2"<Q3B^+
MWW'*9;M[CTC.W#;>L<=ES$='&3V7#9"J;_]:_<[^O]7ZZ^[I:3'OZ)40)"MS
M#+"4R.B5^8.53 +$:*DS(B@A[@?N%QJ9FF@9F$F%,]D#]?A0+S'I(& !^(FL
M8F>H&2)FESCR4+0 7(TD:SZODY^Z7>&@5^(NW3N>SEU!?R1VUZ[U/Y"M'O=F
MM]FN'LWCJO5(F68008EMF<@2H$)@0/,,F0D:U64I6:Z0<#UY/7W\U%2N!>==
M5OL,<_W:=CL?D57-E0JOX]'+%M]\#GKFT:,=>%XVJWNRV7/5X&1HV_5.;'?K
M^?+[F]7&KM9LQI[U3_5Q'P:824UTKG*04;/"0I(A0#6V.7-0 3.,"N17(\>E
MT:E]UD>8$PNZVM-I8-\0=NG4 VY;.J%YC2P/(2@=DCC,F:/0><&N-SQVVB]G
M*LYD]7*_=\"ZZ6^KGVJ]M+/(K)G#EF56RAP6(*]F$3C/ +'Y%W5:%L*&D1#I
MGGO^Y/%3DYL#0(_I_REI#HNCFZB(K! =;$.60Z=\>"R$;N)EI"50!V.@I<]%
MJWL7/:=WC;?<N8CX:*%S^:K7"4K_F[EPN_G0Y#W[VWJUV<Q(RK1FF()4VSTA
M@7/ F=! 0)W*7 KS?TX*%Q'CY&320E2R*@Q4%0/:>%8#BM&/;I.U5^Z=R,H=
M,E"[MM3F.*MMM;]9A:AG-D)73"K2^AS./U4H=0_1H6.E^YH:7*;QAUHL+!RV
M?)Y),WD5L#!"CVR2(IR6@-"<FY6U9F6*)=3:*?KY_..G)M2-TV %,6DP>M=H
M[-+7+[*WDQ)9'[WX&%*@\8S9M]1G[#YN[/*,9TPY4YWQW%7^'^I'P^WB\X_5
M4GW:U0Z0#,M":P7*-$L!TA !@B4#628+R'&&.73*)7;NX5/[2"M\204PJ1&Z
M?Z(GQ%W_0&^A(_+GZ<&$U\=YR>1!G^;)PT;[,"^9T?TL+UXS<,&UKZC\[O%I
ML7I6ZJM:_YP+=6&@7U0=87YZT%^46'U?SO^W&>>KP=QN5VT.%<<S6#*6I6;D
MM;,N!,U/K, (8(E3A3-=*.A7\"L6TJG)1;>6^:?5$E0!\%5)RG,3_W>_[,^.
MT13Q>]UQD3:%OAQQJ;9?@G5+?#0])YM:]542"VO777+_:,/J1BI7'ZD'(E6V
M#XUVW'5:;-)/5FO1&QSL[2Z4DIOWAJ(/F\W.1JL_: /E<;6LE&Y6EEJ4J4Z!
M0*F9'Z8< P8Q 0P)I!!E J=>N6:OMCBU4: %G-C7*-G^4,F\@6W'!5$!3S86
MN=W!>=KQQ5R8?]%J727>^]Z[E3.P4]S$/2C5D47ZF.4/'89KO/6X&]0+WHV;
MT#[P5UH=VP/>C80S_N^.-PZ3I2KR83,3L$QS*B!@A!" ; 9]CE,,*$.8VVIT
MDJG9=F53;SM]$/5CO01F__!XK_XWVT;"*FQ^0M'0Y*8&_L9'_N3O^RWV_J2/
M#0SZW3:/'O7C/#;GY1?XXE\'COZF/SKI3"ABNL!4  P+"%"&4D @DD!2S DB
MI-1^M2J.'S^Y<=W\;4B*F OD.0[)@RF)/?ZZL^$_UIXU.NS >MS$N*/H6?-.
MALSS5PTL.G,8::L%Q.9^M_VQ6MM%PHR0C&F(A*$*9P"A4@ B,@TTP50KH;CY
MKU?%F<MM3>V3KO$E; ]P^+EY'\-NGWH@WB)_]]W9]5W2$'A &K"PS'4ZPE:5
MZ6EOW)(RUPT_J2?C<,L-;CW\^JDQOW!J_ ^UL4FUE]+NF=DL=]]6]E=->FV[
M2_8B\?879>6N\J&LJZ#NV,)F',UFJ*"YS#$!4F%E=4H",P$AIC]I6;(<PHSX
M%;&9C&E3D\7&P$0=3#E3$&!O3M*Q)[$&#? XFD0_^#@J30+PA,:%D/Y--4%U
MBHB&(EM-V_[Z+GD7^J4<YATUJ?X/[U0U#?/&]\6:AMU]+ES30CBT+K$9QDS+
MG]E<?E+;6<XR#HN4 IZEI1W:S4\Y%P 7J$CS(I6,(;\RPT?/G]KX6J5S?C+8
M$KU:)_,&K!EN!QP(OZ32;0B[@:#(XTB+++'0K-J+Q4Y6>GXX9TW:B^XZ97SO
MQ7;^,W@5W[,T!2[*>]S&R#5VSQIX6C+W_&7^T="?URNY$UM;8+<YT-PT^V%*
MY2DT$WR 4S.S1X5"@"B-069KSV&"J?D?UZ#HBZU,30D:H-54IT$Z( 'U95+[
MU2 85?'/^OQ9\HJAOLK"S:'4EUL8+:+ZJI'=P.KK%P^.KU;FIA_FN6]M$KY5
ME0:K\:B9:5GD..4ER(04 ,G2+!6*'!DB-:8LYS3CTC.P^G)K4Q.#%FSUGLL#
MW'9BX'G8U\^TVSPA&'^1%>*(N@[2JTYV0\*EKS,2.DZZI\6Q Z2O&W\F,MKA
MIN$)YP]E-MIIRA>V555&8.L!)6S4Z7=;T8FE(N,*I%(R@#)1 IH:MBE'199K
M2$3I%%[BW_34=&9?P.GNL/8PDVC/A8</]1BBE!O64U1@@#C.;?5@!K)"$*19
MH<UD;V96G'SUNN1W(8RPPHG*N9N^Q^$QLMB?%%+:,VJ!-_G797+ 'K8\@Q]?
MP4LV.#8_>AD'/UK.E7;P?,* )!J?U\INNS1CCYW;/FQ_J/6;W7IMM\HJ%YF+
MJ5K-S_="K'=*?IPS/E]4>PT'_WE9EI@3B4&!M)FZ%BFT%0,Q@*)4-B$'0LPI
MQW-LH%,;C2K#DO?S)5N*.5N8CUFOUH_5SJ9'9HN8/=LOI5/JK^CK\,K*=E*]
MJ6;;=?\UEM8IJ#?_,^E-]_T_J[\V-B<=HY,_7$(F1OZNW3.D3.0M&"G72O2W
M(5 &EQ%ZI3<73,SVQ\LJ,P*+1_EIQFAOY$PW'_?9ZS2G!1>" @@I!PAERBQ#
M\Q283P[3#)>I@%XN=[=#FMJLX&9W@AL2$ ;H8 ]'DM&Z;>H.()'R&X8C>1JI
M:SZ^3F[$<#0&2TQS^N2!@C[_OISKN;"#B! V@'>^_/YYM9B+HXE@5I0I0;H
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M(KP(?Z*MAZ-WZ<K+,YUM!\\^F]2N@ROV/]6F@V>'1*Q)[=3\L-E6L[/?E".
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MJ/OOW]?J>Y6<<;N>+S=S44U 9KDH-5?<3 YR79H_8&Z=D*3IG1(K#E.A.)M
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M[%>5(BHM,I;GG .1H@(@S4O 19J"7!=F(.%(83).>)$G\*F-.!8JT 9K,F_
MMCG":KROF".LK_L=-U4GV*FQ-V3CY0>S!"26@:2EH$T/=N55>=WT8 []-HW
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M25_3&W8-[+J!8J<&:F=9]'YF^] 6K6JB9F7Q !=8A5R%B((T26. D*" 0)8
M2&0<"BZIW@]8;P.\B#HW,[,/I#=<(J^:VE.C\BS\#*V%R_WB S9_'_I@9W:@
M\-T^G^*^C[QHG"?L=5C<N[9^Q)W>5_4*>Z?SZ;?'L;2&NR"WM@:"3)A"6$6
M*!@!A 4$)!,2Q"25<<1A2@RE_/ @Y_,NYA;,?&_Z"'C#FWP0]V?+9'B&Y3#K
M?!M"GJWJ@7 >RDA<5MTQ1>%9-Q,S$UY2\YR0\&++<3/\Z,ZQV?6@A.$TDQ1
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MYIL+P":J]]8-G*,B;]=PZ"WP=O'+TQ5WNR;_46&WJXU=^*D?]%"^73_0?+5
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M>,2LJLMU=S.W:=]*69>7Y.N'![W-K&/'\YK>S36OW@7XAUF&VT'U;!V.\6S
M,C*ZLQ#]&#BU$A>ZFM12]*M[:BVNM+ZQ*F4=Y2@SG!(L)&"9J4.)8 8RA#/
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M)_\E\R]?39LGO8'Z(C])P]:O/S?%H\U-PI8N[V7Q !>A@$DDDP0P86K!48P
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MT \ C$>)V DGKG><#,?G+F#S";Z]R<2^:9F>1R>VFE#XP(6UG+F<R%1.HK#
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M$QZ[OH5K9T:1)D_:LA)<85I@(5L0 [,:9-)<!"_:&$X/TS1N5/)9\#600#J
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MX;A;[CHE8S_/-4',4>SN "XO<MZ\4,+L/4S)^WP)IU.RO282@LWD<;)2JE/
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M+DPI$W(J.A35YLGC7G)V@LS@H]%;0N9XKG=@^]S>Q*OI[(S4UT3%I#AB8$)
M;2UM! L2:"]*.:L4]X*W"18^0-!NSQR##U9_3OP<POH.$/0WG'[^0G2_^$J^
MP&>\F9!S+3_F_'AHP%"B ^:R<[52+K'@?&+$M%KH+I)N-&AG+S)W0]L/]?C?
M3DS]8G![HNZF:D53> (EF+&U-"4*<E"MD?15UJI  <[;A)CV)'0W'/Y060(M
M1?4C9M7=T_=D\.RZAWJKM,RR>VI?PS?*>*1'BTP.I1:<B61JSQZL=0XZ,%>L
M=2$2M$0;GWLG\H[O"[5=Y%.-ETQ*R)D.(3(C575SG64A"L5RYDJ 3BDV&BM_
MDXYN&ED,A(N[K:$.YGH'-^8E]><<>;DX.5W,-_V(OTU7$XN>3-!D6!9%5+X8
M<F)XU?+"19E%4HUR51\EJQ-$'2#OAZ!S-/,[0-*M/;Q:G,!T/C$N^12C80%K
M:RP3"K%'&Z9\T;2_K$UL4R!S+SF=(.=X<=]V(8_F?0< NE94\1>LUN#$QF 0
M9#AGA!;9,4\V)Y,Y6JX K4JY"7CND#(N< 80[\,%+ ?PN@.P/- O=KL9HR-F
M(20S,>G:EP(9H$L,12PI&"%X;C21[C&RQLV?'!Y$P\F@ T#=;A.[W876$)7(
MG/%01^NI.H\! %G@4N48I1.YC0JZGYYQ$Y>&A]  7.\ .Y<7.[G-^(:^7$TB
ME"REYTQ"[5M=YS)&$SB+M5V)#S[RTB8%Y2XMG;3@&-!</HS-'0#ES3PM$5;X
M"L__^V9^URG]L)C-?ETL?X=EGCB/Y'O2.8C:>CH'J4X8,HEYS6WAR#.$-BU?
M]B2T$[OZ0%S<31MH)J0.,/AH[;(*644,P#(G=:L='5301C"I=)))Z&Q$&X?_
MZ"+SEH\P[>"P3UWY/K(Y&&>GN)PN:@!WN6[6JY[TOPL<Z#"&VBHN2T:6HF<F
M.%3TA07;)B1P8&OQEL\JSX:L(^70%Y[.NWN\.EO2L7A_OL#FM/R&OV]^M)I(
M,DK)G%",RYJX4X S'YQA$H/C-H!5V.9Y>3?Z1J\_>%[<#2NO#N[0!W:UZ3ER
MM2GE0_0:,FU*DJTKE&8!1&!%%F,R+UGQ-A52.Y$W>EG#V!@\0EJ]0/ #GIXM
MTQ?B7WXQS^1,3Y?WG;-)*C99)8A=T092]4#.>I2>!2'0U%L@0YN90_M0.7IY
MQ/,"LH7L^LE6WFV+YW/B+!A3O+',<!>9SO0'\)1IFT9X[TJ*NDTN\QY$CEYE
MT1DX]Y=</]A\D?_OV>I\ZNZGQ0-![+_!<@GS];:/7 K<@J_C=Z0B?FHA6$@Z
ML8P)N D\TR%L])ZP)ZFC5W$\&T[;2K&7&_XATWGSPW>GF_9EK[_A,DWIJ$ZL
M2YC!.19X0::-U\1*K*51TIH@LS6Q38_ _6D=O71D;/-S*#GVB]3-'7'_!H-Q
M(6+13&91&PX[P2)&QPH=2&]=#6BU&EFU)ZFCUZN,C=.!I-@O3,\/XNN3T]GB
M.Y[O]/W6^'D_@_EJ(KCE$+EBV=3N/U[4!TY#1U((DX1*BG[\_%KU88+'KY$9
M&[.#BO1@Y'[%95P\@XI]<)^3XAV ]X*5[ S3$5,=>>KJ"X*P%K" ;Y.]<!"Y
MXU?;C(W; <79@;[=Q4+?G-18_<R:5H+SU4;>'Y"XO9JN<=OT[YP['S M/L\W
MGW+N?H8LI(MUMKPQQ ^3@-Q/H/,L!%>:&Z5CFW3^UCL;O]ZG*S?NV4 RXJ&I
MM3R/7V=;9_;*_OH-UQ-;)]1DT@$N!&*]#)+%&!P3MNB<P(D0;QG2=XN&#EMZ
M-XS^T(]8SR"33A&W.3KW;LY;M"G1'02\IN;9C"P@WV1Y1N$M1)/D,8![<.7=
M\/9#/UBUET@'5L'-#ALE<BN5 J8@U)F54;*07&$9 SAGG3"NESXFX@_Q]G0X
M^SO SJ/Y4<'+D@%(V$B\(*X4%H7F3/$(+H<43&SSR'E\[MH?XN%H,.$<F6ST
M>CY,D\%[4J9*,."5Y<PD#O4%(3) H1B8  (M**M:E=0>E+HF_A O/4<*8E X
MC=H1X+P!WA=<3Q/,;FZO37N FPN.T"O@D1T/WSC@X1&AR1N3,5J63<0Z(I30
M&W0B90:E^"*M<:W2"9^F;AC[GSX;-VVG)^AM <U3;>-!7K,&QX*T@8&S&&(N
M0"=D/PO_\K,[J1,82M3WV^V'<7+ *',;'77]H+Z$U9=?9XO?CYL =O\G#JEE
M=J!Y>#5RN=!5>PEGP+@LF)!U>)))FGDK,G/<""=X3-FU::+V&%4#^''U,]\O
M%U^GQ+]?OO^5M/F;^64C\A=I/?U*9PM7=<C4='Y&W[L:N7;)&P^U?[URK&"-
M:7,G6:QIERAM01V5;34*;!CZN]%HQZ'N'B_QN87;@7MYTS?6P(L1W#">K&6Z
M:&00A&<I<9V+3G5:9"^AB58 &P,'CP8L]A%*!XBZ\;I1GR;(Z)CAC2U]6NS(
MX4MNZIKYB]I4YZF0+\5K'AL@B]%+ *V=:=06H\5NQBW!Z@#?HT.DB_R&AV>]
MO4*BBDSU#23F^<7)8KF>_O?FKQ.TF6O0EBF>ZHP=DD#4NM2L#F4@@8;<:B;R
M >2.J\K'Q]G.X_V&$GD/%\ UVB_=SOGGBP%/=3#UXHQ$,C%!DG\H-(-4ZC-U
MT"QZARQK03\HQG#1*,5\1PK'5=3=H;>)8#L ['GBQ;]/Y_EB2M DBXQ"D\WE
M-\/'A 'BD$!F+7*(8 //;1Y6[M(R;N%L=R \4E@=P.W5=MF'9G4XIY,.PM66
M0I*V$S,#2QL#!)F=,[ZX-C6T3Q V;O5L=T <4HP=H/)BCL/-A+,)JE)DS'28
ME$Y,:U0L*B=8D=:)E#3WJE$Z[;WTC%LPVQT&!Q!:!]"[^[!ZR:]M-N354T5"
M'4K13!5..T-;F(= A\J@<"XXJ1O=R[O3.&[9;'<0;23<+F'[(IT;P,1WG'[=
M-'_+QO*8+!*N4JI=/I!!=)85;B7716+B;3K_[$)=;UVFAD'&DP \4DRCC@/=
MO+O>W=+[)9Z28;PU0<@9>WFVK#+83*M\L5KANL:1%2\Y!2:=HE,,M=MR[5QI
M4@0RDJ%XOEO>]$'+]]9W:E"L/9-4NAA$>P\KMR-1T_GNMAN3/D>9T3.'09$1
M$FH20(HL(UDA8!V61H79.Q+86T.J9U)^QPNK4Q1>:/7W\'VCTL''A)" "8U8
M)_$J!I*.&)(KYI+*BJOGPM\MTGIK0_7,U^XA NK5W%N>$1U3B-/9N<4\SYOS
M=<G1:S^;6&%==B(29+"69H$G*YK@DXOR1DO-HVJ3]G$LY;UUJ7H^O+82;P=P
MWOT9>%)/8DG<,(3:1(8'R0)7@MF20BA2%-NHL^3N-(Y[F7?PI-Y(G!U,^'U@
M9V_F7W&U!W,A.)29T_4B2RT9BX[%4@QS3FFEA': ;1SQ8>COI*/],R7=M11N
M![J7+*"+ZN_T7V?3)=+^:5/K[[7EP9INF5H)<%I_99*BXD&8R% 51T:2]RQ6
M(ZE:YY9,)BEY&]V[.XU=INLU1="=)\DFXNS"S[JSMXT!1!O,9Y6Q>!'%$!P0
M$^W& A#[!&=1.&3<QY#I9T*6-C6MN]'79<;=J! ]7HQ=P'-WUDZ(0<:C5,SH
M&N(-Y"%X9ST#STN=Z1QL?-:L^WMH[-**?4Z8-A)GOU;L91+5CLR5M8*T.ID(
MM?LL:,>"49IQI^B$<I>L;1/4&H;^<0'^W%9L2^'V8,4N%PDQKWXE1M_?+!$Y
M!X!01QR K5%ESJ#05\XH3$%C\&#:6 5/D=:ES=H4+[<-@D&%UR,:S[L>HL[6
MA C$&6/K2,;:A*%F885BK"T2=&SD/]U+3Y>&Z*BXVU],G8%MVZ#HXN#07D!%
MLG\,$YHL:1VD9"%+SX@.P[6!'$R;TM?'J.K2M!P+>$>)K /X?<#3K3_WKKQ=
MS#]_PN7)]BWD;7V[>!=GT\_GO)MXF[RH#;(\A%SG%5AR[JQAUEF.004PC8+W
M>Q Y[H-H!^!L)= N?/3K)^\7F/_]%<;U)'KK)%'$8M2":>$2<8M'INA[+G+I
M(K8W#2^H&?>!LP/\'2VBSI3BY1XP@:ESM\FKJZU-5"$+0T;-@N6>VZ*RL>VU
MWUXP:Y89W ',CA91=_KLHOG-NW*M%=Q$A@2Q)%+,)M96Z\2>Z""S$FR&[()0
MJ4VH\4G2QIV5TP$$AQ5>!VKO_>6)NJ<;DZCSZ!,G0[9X.ENV5$[17J0W(6AG
MLY=M7P_OHVK<,3@]8' HD?4S7VQWKDZ4US'9"ID:;=6^ZGO.+4,+F2C,">!9
MLXGNH7'< 3@=(+21.#MXAZG;JO]?G^2_P@PW92#$L6FJ'1KI!YO9?]>_<>TW
MS]M2W\T43+.SVO'U];?T!>:?\0.=K=>E( D!78F>2\M<\H5I72NGZI'FUHJH
MK:$=MNF>^KS['->!;_:NTS%8?O2C-*GCK:OESXJSI#><5<Q'E1@(@4D8@4&W
MN0:.(GO<2$&?0-]+E$=V)B8.+-<=H#<K2\84;31H[NBHUIYLQ&26HBE.EQ *
MM"F+;X_>9@&(3M&[CRA[:=-^=GHZV[ 29A>L?#,OB^4)W&CLRTMP$#RP9$.M
M+12">94]*UCW;)R2IDTGD1T)'#<:T0R/+<330:3AHM].[<!3A[!(;WDP&)BP
M1+F.6;%H361"!..Y,2'R-CKP%B$C]Z-M(>P[M4F'<[X#X-S'HM?GW[@Z<"%)
MC3(00X353"L'=;!J8J1^N79HM=#/IZMN4S=NR.I9%=51@AE[M-=EHOW%#,G\
MUSG)YOI3ZB0 40\^,S1UT'0LM<K*&H;2IQR"@NB>[.>^ZV+]J:;CQ+MHR.L.
M%-66]DV_ACQ=GY&\WIP7RN=?SM:_+=;_B1L=//'>@8Y2,N.#JQX/.3NH2+N0
MK9A5<"7='D$XF/F_&X4CEXNU EY308VMO"X:RKTK]-^+OIH?,,U@M9J6*>9/
MB^THH(32\N218?$U]ST$%GE- 4D0)0;E@C0[J;"=EQPY<;NI(FO#]\'0-.AH
MDW?+SS"_Z,U\@]+=!IG<^/<#C"UYF)Z!AI1<7^#E8KY:S*;YHLGR^VM$7YN/
M<S5!Y<K(RMP+C((AJ1.F)0]D9'G.D+M@M./!ZS8/^H.0?^RU^" 1O\!JNGI7
MKA/RR]EJ.L?5ZA6NTG)Z>M'.^KSU1YWL2?\X37'UB>3[RZR^MW,)SF74K$A/
M!FSBD<XM6)9E+8<T*$UY9MX.L:UQ+;_G1_WM&[H?S/2OB%_A&J:S@P9+W?<Q
M ZOE>ZGK2SMK#9[@P$P29.3%I!CY%LAD"!PL"E]\FZ:@76CG;8#[5EC[Q?HE
M+)??Z?2<CX37*8#R43'KL3!=+)+I4AMEZY0A1%-\:/?<]B1Y?PAMN0<*[WO!
M&%:&'7C3'ZKBF&-^#<LY[6%%"OWLY&Q6$X_(Y":-OI[D3'>)"X()1\C1QAL&
M#@H#,K.+$L+HV"8+_&G:QO6@QX?DP-(;,'-WT'OXX]G)"2R_+\K'Z><Y>7NI
M=NRX8WD<<C7O^,D#W-:'[&&@"_SN,I?@*R!-BL$R(X-AVJG$O+>2.4ZNLG4!
MLVMS*S],T]$/&8_Q]\HZM9 K^"7SJ4BFM4TL:#*CC74Y.6="B&U:3>U&W\@S
MF89!S)VGC.%%TZ?CL-MA;Z^XGE^!C:;(I,O&&L6$J1G92GKFT6C&I<T0BTNI
M-!I3U4R1D4F12%#G*<,?IJN_OR1L3]?UJPEDY00=-A93LO5!,=-7(C-!ED3(
MP2ILU+3A$:+Z55E[8./N,+AAA-"!J?\K3)<;'^4O"*NSY<8,W?#J^_F?5PK8
M&,C6:& NUG;G0206G2'#L7@;2#$[;%0<OS.)(P]]:X.U-@+J 'GW>\ZW-Y6+
MMB"D9CXDSC0ON=881L8U9AY,EEKX-CIM%_)&GO#62+L-+I@.T/8!O^+\#.M<
M'3)4JH1N;R@&EW1$P7(MT=<B 0-2VDSG*$KFX'-I8_L_2=K(X]O:H&Q8@72!
ML!42 ?7HO**]S1:;%)OM!)'SO4V$S45E$5F(AI^G__E$^^(<A; V^9);8>Q)
MXD8>T-8*9<,*I0.<O<A?<;F>KB[R'6X?&Z'!:N4UPV2 ?'$"0^3(&98 JB!R
MTZAOUA.$C3Q=K0V^AA1&!]@ZGW+]D6[\.SM!'W0@'X:):!73A2Y]+U5@RG)4
MW$#T)35R+A^B:=PBA&:^Y2 BZ !,KT].9XOOB.=-"G^?TP=_F9[6KG&O/[Y[
MOU6^/KMDHZQ!0^&9MK7X+%6K$A6 K8UJ+#:!U2[4C9L\W@A@@XNE ZC5&:I+
M_$*7^O0KGL_+O-]'UA&2@V*92HY\9$X.B^=@6/&Z3EB5F?,V77AWI7#<!@;-
M=%H#\70 NXL7UO>XW,SSO>,C>RZ53;5S0PFT':P=%FI7FN"T%1Y=D6V"%T\0
MMEM0EO]@*!M2&AV ZR-^KK[*!SQ=+"]Y=>?$0 Y>>Y-9$'$SBLTP'_RF0LT6
MLA"<,VV>.'8B;S>@_6CA_^$ETP'<?L/?K[%KN9C3E^D\*^7^_1634Q(2F-*U
M?0RJFK OD70UF*R20O1ME-N^E.X&PA_M7:"IO'[D!_1/=41EP^?S[><_V^/Y
M??MI_W0N8X@$#\^D\,"T]I$!]Y)YRP406B#R'RX'*'W!?$:\K%T#KSW@OBOU
MX?:7[_7/7VF=Q?):#+JVP5*%LQ*T9<0%P<!&55M,1,?1:6':=($Z@-ANG]KW
MP=*=N[:QT#JX>5]-5_#Y\Q(_7VSL_&5D<^ZON49<1U^#B*#)A-7).C)<M631
M>YF]$\AC&T-O)_*Z?7H_!GO#"Z8#M%T<J+J=6YUV;KWX7FW11:F4\)D5"77&
M.#GH(&M[2Y1T"0EON&V3^G$ L=T^R0^A!5L)K2M</K"QFZ<N&L-%48J55(>(
M5;YZK0K+VGI?!+GTLDW<>#\ZNWVZ'P:-@XNJ*R"^(-;EZ>RLCEG\B.ELN>F;
M^OI;[0.)N?:AKH'-LXMZCMOQIRL.)"\B1NX9@MUD9@GF0\A,8B"?C/.H5)NF
M$\/OI=LL@6$ /8K(?V1O>VL3Q>]_@?^[6+Z'[T32$56QQR_Z;'[YSCMO[ZPG
MP.R*02;=II-4I%M>9$E'H01;@--UW^95JYVS_ICM/:D#27--.W3*THUB:K:U
M3X'Q0#^P&,%"FUR$QZCJUOW>!QW[N$![B6'$BWVU7$\V9_3EV6J].*'/>_%M
MNIIXF2 &3M3[JJ&M!19%C Q%2(ISA"QW:H)('W\-0/2WV^"Y?_UQX3*<7!>#
M,7EDB/P&)V0 W-C#J\4)3.<3,EM+M 69B*K.F-.%Q>P\@TB&14Z9Z["3K[$3
M4AXD8QS #"'7Q=!,'KO?UU\PDU&PQ+_@2<3E) N5/-K(O RD8%64Y&1GPY+Q
MTI4"QDK[E.%SS^>.)_"!I+08AF6]2/M%_DJ&()F*VSUH+VP=R<'*YEXM+K*H
MG69.1J.U<[X ["7V6PN,$U-M+/]CF'@P$+[B,BZ&@,(OLS/\^&6*LWQ!/IHD
M"B<W$[1B6D#M4JB1H9*%(ZH@TF[]_&Y_\CAAS$;"/XIMXTO]K_/I&O._(<S6
M7Z[I,'3:Q1P+0[KR2(?5_ADZZYK@H1!!%R_D3K*___/'"1TV0L  +!S[&OA?
M,%^1"#Z^^<O[=[^]V6[ !Z%5*(9!??+1T96:(KL9O*E!<.'R[38X#V#@OD\?
M)];6" %'LZ^#T/"=NN]?OO^"\_3E!)9_WYC%EJP7+6MLVPID>M/BR6=D+BL=
M9?(&<ZOTXL<I&_=]=G!OLXE N@38Q6ZVQT]S)Y%S4Y,*:_M$5=LGUHNS9$4W
MJN%)M.FU_Q1EXX8SAL7!DR [0B@=@&Q36[0]@K_A>JN*HPH<'2(C;5X]>I]K
MA^3"5 ;EK!#.-AKK?2\YO<'I&(G??FPZFOUC6T(?,.'T:U7>EWRY<.M=L3Z0
M 2<MSV0=U.X3PFP*B%#0#YRT?B=SZ,$EQKW(F@!C0)YVH%WN4<6?Z)]NM'"L
MBM<X9%[:7/.=%8/D/4LFVD [*X"-FGD\3-2X^4+/:1D=)(8>$54W<GG>!#D<
M-;?$TKG0V0?:B@"FO0@23''"-!KG\3!1O=U=!PK^*4 =*(4> +5U:>]L::MQ
M.??*6')ODXND9V7FY)"B9RBLDSHH4K]MNG0\05AGP#H4 +>!-: T.@#7 QK]
M[72.;]9XLIH$VH\M.K,L@-=>T)K%0F=2..G0)V6AT?"]IR@;-U>QV4TXJ$ Z
M -B=<_(>E_4;\!G%1,O$/7)@X+.BXT>[B@X%2X*.9RQ*T$:?YSZ\1E67J0X'
MRO^I6_%08?S(.8"_P;(RX"LV3_R[L]*S9?L]OL?V*7Y1>!4S)":R(=.M8")4
M:6!"!F5S@OIH^H.E^#U2P?IN^?(+S#_CF_GUWYC.TY2@='XE0 HQ24-W (@Z
M-"QH,CDT_0$*C(S!86I3#W44V=TF">Z#KSU*D0<69(_7[^U0<RI*HA&%%:EK
M/9@*S$>!S%H1M Y1&-X&F(.\ 37#WC."9-]'HGTDUB4";P4A'9)%$R5G6-L8
MTL'-+)3H:C-J8[P"7OQS(?"'>B3:"P?[/A+M(Y0.0';_*T71T7C#(W.Y<BBF
M6!M6&.8BYDR[H>\TZC;S SX2[27QG1Z)]F%_!QAZ+!19)#HGBF,Q2K(W(CH6
MHJ0#Y[+(( (';!1C._(IH-G;4E<7Y$%RZA%RUX*4$3G7*D96^Y:3.UY/CXF&
MV<)5"!&CD,^4._$CO!7L)?@]W@KVD4('@**#F,_2^J'@-))K9 5I=HC*,"T#
M\:MVP2?^" U99Y7;E*$_3E=GL#I4_(MFLN@ 69O1Z-.'WSUBRB$YJUF*=49?
MU(D%[SR3VD/)&J(K;7()GR"LLPR,@; UI#1&+F3;'I-WRX^X_#I-Y^J\3F&S
MUBGF9,W;-3JP ,(Q&0WG7GKETDY=X7>J8;N/@G'S+)[?N!I$$GT@:?5BGK<[
M6%VD@1?/8RG(I$ATU!"0@8I("C?5-@S&Y=T2G?>!TUTRQJN0.UZR=V%R))O'
MS@I\\1]O/KY^^>G5)UQ=^*L6A7,RDZJ4/I$'#($!Z6+FDP:%4M=.XCNE ][]
M[-%%?ZRT%L.QK@=CYLOT])04)S'EWV">Z=<^7\0L>/0:N:530,Z$]O5A@6?/
M.#I>0BE*N3;I#@^2-%Y=Y;#0&9;W'8#H%Y@!W<H?OR"NW];?KB+9^*(E6%7K
MC7S*G&E;R WEB;.BC2 N!>)9FRZ<#U$T;JK,>)&B0234*=*V)[&0<DV% T&A
MGIE0YT)Y#,QFF[D1$4ULXW8]3-.XWOPP,M\!2 <(H ,HO5M_P>6+U0K7JXLX
MA$@%BBS,%U&3(;-E@3;%$H<<+8"PC5KRWR&E/^ <(N/%D P?V:/Z4)7SYO2X
M4+Q76"M\:K\Z663MB@@L!8PV!>-I'X-Y4)?+CMN^;QPO_#">]P"4BRIIHZP.
M!5C.IO82M+;V&C:ULW4VUB4$&!@J8_M8!XKLMM /X-_8?<JF\^G)V<F%_>YR
ME+X^NI1:M1J29S'(S+B1W(!-1:H!6Y1=7WIDT1\BN,407!Q;_/#M&N%&&2=E
MX2SZ4FM"E6*AUNP8%ZUR-@>9=GHCW[%#W;<]Q=_$11Y$_ =S<63QOZP7'RZ)
M2^OOM07'1@.*$(OE7+.LBJGTDZV$+I,:K,V3M12TO<%0<!\%XPYN'<=F.%H2
M8YL/>'JV3%]@A2\^+W'#KMM;VIKB9(%C#AF8\:5Z<1!(.]8Y[CE8\-&A$3LE
MEN]F7.Q*UGCWS_&27[06P]B1_GM;^107)5>Q,)/J20M2,@C<U7R10@>-=G5[
MLN;0G9#:F"-M)/AD9Z1]V-E!%.3%[[#,E[E#W,4Z^RXRVD-@NGAD(2(P3-J+
MG#27H4URWPTRQAT//5Z0]G!9= "D31O]7^BXY=IH'^>KK<"6E6$;[OWR_>IW
MWL/W^KW-CJ^V/<]UFO&UH^FX<@H$9W93GFS!,@^U([]*VJ2$M=U*HS>HX7<S
M<@G1X>"Z\VPULJ0[0/O5-)_--.[:)7'UX>-?MW> RRGDY U#%173)G.Z VA;
M(2AGHH%@59NQ2X^2-2[^QD?-HI4(.\!C9<^[<HV;YW4Q0BGT.3!1&S]JC>1!
M"U[[=0K#91) )[T)#N\E9R?\^3_>M7Z\;#H V/6#2N?PM\4<KK[SB;Y:0:JB
MO'S:T=IY81*3.MEJ!D,UJNFOQ=0.6T%GW>8M;4]"QU6* T#CM@W94$Z=N*]T
M>$\6&PE=.'87>^%9EDS.OJL##F@OBGG,A:%4LD -(JN]/-F'%AK9D&LIX7O<
MVT'8W8$&NS(N_G6QR%O6X<GI;/$=\2*KZQK_R!S9II9O#J6*P2@.AE2^(S9F
MR5F0)3*C9%*Z")YUF[G*Q]&]$U;#'^_2?49I_X#8OMCKUHQ&\%SGA.3^<3)V
M,0D6C<O,H=$V@\+4W,T^A.Y>')KV"#L2W$>(>^P[_]/OBTTW^XLM7-QJ1*(,
MICX+ZP!,BVPK(Q,++N<(RKFD=IOA\L "/Q:VCA'P8F!N=Z .#[UVWEZV%I/H
M8W*"#J:H)8E(]T^HE;0<HE0YJVP;M2<]FO3=@,O_>#?^\PJ] Y0_VL(.4 1,
M2K"<ZIPN<)%Y53CCJ#,FF9UM%/KIMY_@,P-DGX:#^TBK ^3=G&4_B4)(\C$C
M"TEZIKG2S/M:]V20=E)LEHVZ@]^DX\?L C(,NHZ0R-@6WO]:3.?K_R ^G2WQ
M?Y_!DCYV]OTRZ/ K(AV4]R3,M)R>UN],8I8^)!N9]2'0):$-BWYS8KR4R;OD
MRFZFW[XK_YB5T,<!K+V(NL??Q#FK7#9TAG*FW61CF=<869$I:@XA>#D0X'[,
M\K3G0-A>0N@>4B_A]!3SBY/*R2L[X$5<?-UX??2A.$G%:!%R8A&"HS.$G@43
M,N/*6!.<2O9VAYI#4;<#-3]F^<ES '-H4?:$W4^X/)G.-V(F\W4U)2F?FZ^7
M,V\FO+@BB7L,49.E068'"YXC2UQ'GI,L)>\V.&B_=7_,U.:!\3BP>+IP+#:-
M$W\ECM..-@V._S9=?[F8-/'Z6YJ=Y5HQOUHA_2]_@F\385..:.E<<5='4=81
M XKN";"9*\R00VP3O#Z V!\SLW$H%Z6M;#N [XO\%9?KZ8IV\?I;S7'"B9="
M<),2F2T.Z@M^JE77@D4;N8 B5-:Q"3KOTO)CYM\, [XC)=,!MEXN5NO+&1@3
M&8(&R163JE98*=I&%$4QBT&1:4&VL&@UD.T:&3_FX_)0\;Q#Y=$!F)Y,QGPH
M%_-7F"[_ V9G2%KZ[&3C[*_J@:J1IU?3KV2"S/,'6./$.A65#9'Q8NATZ6)8
M4"HS1XR(05AKS4B9V\=N[0=]8!D&]7T!YT<^29L__@-7&R'A<KK(@JZD+",9
M[TRDHIF66!@@74Y)FI)TM!X:3: 8<A>[G8\_Z"O/:' X^"B071070[V[G]5L
M@7?EW>G&$YU__HB?-YR?!*]"0%F;HR5%ISH9^DJ$:GOQI*PK=$VV>4]_B*3=
M8/H'?2X:1E!CAZH./FPWSMD%+U[,YV<P>S-?K6$VVS(C.AZYJ4E9=8*E"89%
M,NN8,1D0*J?BK3J>!X);K2G=#<Q_Q*>IKC#P(\\"O#EM<7'AV32?#/C$NL\V
M)W"?_;>?&BA-Y"5YQ92N]9DZ6!8UJ6$AM31&."U2F_$$[:8&/CHG5DJEB]3
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MBGO)&?=F:^4B'L_Y#N!SI)-RWM]N8E1&KT R-%#J5+3 0G&)$6N5<YIK'=K
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MQ-$!N,X[7=P]-Q=>0Y".&V685*(.E)9T67-AF4W!!^M0^=O%0(.V9WN(KIW
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MZY1IE>K].UT/&7*66)SJ;<3RH/R_^%WU%^ (FN'Y17N!/;(K5S)COE[>,J&
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M#7$GDS"NV.@LV\F#[?[.KG9U!O!@C:3=_I[:YHOZ1YWJ]+__U_\'4$L#!!0
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M&3$T'PEC(96QA.)-;S=865["MYD9LV+MBX5XZPWBCX;XX 8>WFT=-(+](U.
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MML@@@+TB_H1OL>C1).J-J<S=@8T(XU$$J8$8 S;,&HD_EW0;!"!_N5[U.\[
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M!/H P?+4( #;#% V Y3- .7K!BBKS!4>![IPBW\WLO_X=/PO4$L! A0#%
M  @ 3XIJ4Z#AJ%.+5 $ ,X(( !X              ( !     &5X,3 Q+7-U
M8FQE87-E86=R965M96YT.#$Y+FAT;5!+ 0(4 Q0    ( $^*:E-QEUFSK H
M ")V   >              "  <=4 0!E>#$P,BUA;65N9#)T;S$R,C%L:6)E
M<G1Y=RYH=&U02P$"% ,4    " !/BFI35/."3<,%  !X(P  '@
M    @ &O7P$ 97@Q,#,M9FEF=&AA9&1E;F1U;71O;&5A<V4N:'1M4$L! A0#
M%     @ 3XIJ4WJ0,\JW!0  9R,  !X              ( !KF4! &5X,3 T
M+69I<G-T861D96YD=6UT;VQE87-E+FAT;5!+ 0(4 Q0    ( $^*:E-A&ZBK
M)Q4  +:A   >              "  :%K 0!E>#$P-2US96-O;F1A;65N9&UE
M;G1L;V%N82YH=&U02P$"% ,4    " !/BFI32(I"6U<0  "97@  '@
M        @ $$@0$ 97@Q,#8M;&5T=&5R86=R965M96YT:7!P=7(N:'1M4$L!
M A0#%     @ 3XIJ4PWUYT.GW0$ /W 3 !$              ( !EY$! &5X
M9'@M,C R,3 Y,S N:'1M4$L! A0#%     @ 3XIJ4RFM*66Z#P  KZ$  !$
M             ( !;6\# &5X9'@M,C R,3 Y,S N>'-D4$L! A0#%     @
M3XIJ4QGF'E_O%0  K\@  !4              ( !5G\# &5X9'@M,C R,3 Y
M,S!?8V%L+GAM;%!+ 0(4 Q0    ( $^*:E-[/0S>(E$  #BA P 5
M      "  7B5 P!E>&1X+3(P,C$P.3,P7V1E9BYX;6Q02P$"% ,4    " !/
MBFI3 ;(ERLK/   /W@@ %0              @ '-Y@, 97AD>"TR,#(Q,#DS
M,%]L86(N>&UL4$L! A0#%     @ 3XIJ4U1\B9;4>P  P[(% !4
M     ( !RK8$ &5X9'@M,C R,3 Y,S!?<')E+GAM;%!+ 0(4 Q0    ( $^*
M:E-FU$9KDP@  "4O   0              "  =$R!0!X9VXS,3$M.3,P,C$N
M:'1M4$L! A0#%     @ 3XIJ4R-*C[-_"   ^"X  !               ( !
MDCL% 'AG;C,Q,BTY,S R,2YH=&U02P$"% ,4    " !/BFI36-SS*TD&  !3
M)0  $               @ $_1 4 >&=N,S(Q+3DS,#(Q+FAT;5!+!08
..#P /  P$  "V2@4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
